

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number  
**WO 2004/094671 A2**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68

(21) International Application Number:  
PCT/US2004/012788

(22) International Filing Date: 22 April 2004 (22.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/464,586 22 April 2003 (22.04.2003) US  
60/464,588 22 April 2003 (22.04.2003) US

(71) Applicants (for all designated States except US): COLEY PHARMACEUTICAL GmbH [DE/DE]; Elisabeth-Selbert-Strasse 9, D-40764 Langenfeld (DE). COLEY PHARMACEUTICAL GROUP, INC. [US/US]; 93 Worcester Street, Suite 101, Wellesley, MA 02481 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VOLLMER, Jörg [DE/DE]; Kohlrauschweg 24, D-40591 Duesseldorf (DE).

JURK, Marion [DE/DE]; Klosterstr. 4, D-41540 Dornagel (DE). LIPFORD, Grayson, B. [GB/US]; 38 Bates Road, Watertown, MA 02472 (US). SCHETTER, Christian [DE/DE]; Oerkhaushof 35, D-40723 Hilden (DE). FORSBACH, Alexandra [DE/DE]; Raiffeisenstrasse N°1, D-40764 Rantingen (DE). KRIEG, Arthur, M. [US/US]; 173 Winding River Road, Wellesley, MA 02482 (US).


(74) Agent: TREVISAN, Maria, A.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT OF TLR LIGANDS



(57) Abstract: The invention provides in part novel screening methods and compositions for identifying and distinguishing between candidate immunomodulatory compounds. The invention further provides methods for assessing biological activity of composition containing a known TLR ligand. These latter methods can be used for quality assessment and selection of various lots of test compositions, including pharmaceutical products for clinical use.

BEST AVAILABLE COPY

WO 2004/094671 A2



GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT  
OF TLR LIGANDS**

**Background of the Invention**

5 Nucleic acids with immunostimulatory activity have been identified. The first recognized immunostimulatory motif was the CpG motif in which at least the C of the dinucleotide was unmethylated. It has been postulated that mammalian subjects recognize the unmethylated dinucleotide as being of bacterial origin, and thus mount a heightened immune response following exposure. The ensuing immune response includes both cell mediated and  
10 humoral aspects. Since the discovery of the CpG immunostimulatory motif, other immunostimulatory motifs have also been identified including the poly-T and T-rich motifs, the TG motif and the poly-G motif. In some instances, immunostimulation has also been observed in response to exposure to methylated CpG motifs and motif-less nucleic acids having phosphorothioate backbone linkages.

15 The responses induced by immunostimulatory nucleic acids are varied and can include production and secretion of cytokines, chemokines, and other growth factors. The nucleic acids can induce a heightened immune stimulation regardless of whether an antigen is also introduced to the subject. Identification of new motifs as well as of subtle differences between response profiles of different nucleic acids oftentimes can be laborious, and a high  
20 throughput system for screening nucleic acids for their ability to be immunostimulatory as well as to determine the profile of responses they induce would be useful.

**Summary of the Invention**

The invention provides in its broadest sense screening methods and tools for  
25 identification and discrimination of immunomodulatory molecules and assessment and standardization of samples containing known immunomodulatory molecules. The immunomodulatory molecules can be immunostimulatory or immunoinhibitory, and most preferably are Toll-like receptor (TLR) ligands.

In one aspect, the invention provides a screening method for identifying TLR agonists.  
30 The method comprises contacting a cell line endogenously expressing at least one TLR with a test compound and measuring a test level of TLR signaling activity, wherein a positive test level is indicative of a TLR agonist (i.e., an immunostimulatory compound). The positive test

- 2 -

level may be apparent without referring to a control. Preferably, however, it is determined relative to a control (i.e., the TLR signaling activity from a reference compound).

In some embodiments, the reference compound is a compound that induces no response (i.e., a zero response) or a minimal response. In this case, a test level that is greater  
5 than the reference level is indicative of a compound with TLR signaling activity. More preferably, the reference compound is a compound that induces a positive response (i.e., a non-zero response) and that is immunostimulatory. These reference compounds are referred to herein as negative and positive reference compounds, respectively. If the reference compound is immunostimulatory (i.e., a positive reference compound), a non-zero test level  
10 that is lower than the reference level is still indicative of an immunostimulatory test compound. In this latter embodiment, the test compound is less immunostimulatory than the reference compound (for that particular readout), but it is nonetheless immunostimulatory given the non-zero response induced. There may be one or more concurrent or consecutive assays with a negative reference compound, a positive reference compound, or both. The  
15 reference may also be a standard curve or data generated previously.

In a related aspect, the screening method involves exposing the same cell to a positive reference compound and a test compound in order to identify a test compound that inhibits the immunostimulatory response of the positive reference compound (i.e., a TLR antagonist or an immunoinhibitory compound).

20 In still a related aspect, the screening method involves exposing the same cells to a positive reference compound and a test compound in order to identify a test compound that enhances the immunostimulatory response of the positive reference compound (i.e., an enhancer).

In both of these latter aspects, the assay requires a co-incubation of the positive  
25 reference compound, the test compound and the cells. Separate assays with positive reference compound alone and optionally negative reference compound alone are usually also performed.

The positive reference compound is a known TLR ligand. Non-limiting examples include but are not limited to TLR3 ligands, TLR7 ligands, TLR8 ligands and TLR9 ligands.  
30 In some embodiments, the positive reference compound is an immunostimulatory nucleic acid. In some embodiments, the positive reference compound is a CpG nucleic acid, a poly-T nucleic acid, a T-rich nucleic acid or a poly-G nucleic acid. Another example of a positive



reference compound is a nucleic acid comprising a backbone that contains at least one phosphorothioate linkage.

It has been further discovered according to the invention that the RPMI 8226 cell line expresses TLR7 and responds to the imidazoquinoline compound R-848 (Resiquimod) which is known to signal through TLR7 and TLR8. Accordingly, the screening method can be performed using RPMI 8226, Raji or RAMOS cells and an imidazoquinoline compound such as R-848 or R-847 (Imiquimod) as the positive reference compound.

In one embodiment, the test compound is a nucleic acid such as but not limited to a DNA, an RNA and a DNA/RNA hybrid. The test compound may be a nucleic acid that does not comprise motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif. The test compound may be a nucleic acid that comprises a phosphorothioate backbone linkage. In another embodiment, the test compound is a non-nucleic acid small molecule. The non-nucleic acid small molecule may be derived from a molecular library. In other embodiments, the test compound comprises amino acids, carbohydrates such as polysaccharides. It may be a hormone or a lipid or contain moieties derived therefrom. In other embodiments, the test compounds are putative ligands for TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10 or TLR11.

In one embodiment, the cell is a RPMI 8226 cell, a Raji cell, a RAMOS cell, a THP-1 cells, a Nalm cell or a KG-1 cell and the TLR is TLR9. In another embodiment, the cell is a RPMI 8226 cell, a Raji cell or a RAMOS cell and the TLR is TLR7. In yet another embodiment, the cell is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

In another embodiment, the cell is an RPMI 8226 cell and the TLR is TLR7 or TLR9. In still another embodiment, the cell is a Raji cell and the TLR is TLR9, TLR7 or TLR3.

Depending upon the embodiment, the TLR signaling activity may be measured or detected in a number of ways. In one embodiment, the TLR signaling activity is measured by cytokine, chemokine, or growth factor secretion. The cytokine secretion may be selected from the group consisting of IL-6 secretion, IL-10 secretion, IL-12 secretion, IFN- $\alpha$  secretion and TNF- $\alpha$  secretion, but is not so limited. The chemokine secretion may be IP-10 secretion or IL-8 secretion, but is not so limited.

In another embodiment, the TLR signaling activity is measured by antibody secretion. The antibody secretion may be IgM secretion, but is not limited to this antibody subtype.

In another embodiment, the TLR signaling activity is measured by phosphorylation. The total level of phosphorylation in the cell or the level of phosphorylation of particular factors in the cell may be measured. These factors are preferably signaling factors and can be selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, Jun, c-fos, and subunits of NF- $\kappa$ B, but are not so limited.

In still a further embodiment, the TLR signaling activity is measured by cell surface marker expression. In one embodiment, the TLR signaling activity is measured by an increase in cell surface marker expression. Examples of cell surface markers to be analyzed include CD71, CD86, HLA-DR, CD80, HLA Class I, CD54 and CD69. In other embodiments, the TLR signaling activity is measured by a decrease in cell surface marker expression. Cell surface marker expression can be determined using flow cytometry. TLR signaling activity can also be measured by protein production (e.g., by Western blot).

In another embodiment, the TLR signaling activity is measured by gene expression. Gene expression profiles may be determined using Northern blot analysis or RT-PCR that uses mRNA or total RNA as a starting material. The gene expression of interest may be that of the chemokines and cytokines and cell surface molecules recited above. Gene expression analysis can be performed using microarray techniques.

In yet another embodiment, the TLR signaling activity is measured by cell proliferation. Cell proliferation assays can be measured in a number of ways including but not limited to  $^3$ H-thymidine incorporation.

In one embodiment, the cell is an RPMI 8226 cell and TLR signaling is indicated by expression of a marker such as CD71, CD86 and/or HLA-DR or by expression, production or secretion of a factor such as IL-8, IL-10, IP-10 and/or TNF- $\alpha$ . Preferably, in this latter embodiment, the RPMI 8226 cell is unmodified. In another embodiment, the cell is a Raji cell and the TLR signaling is indicated by IL-6 or IFN- $\alpha$ 2 expression, production or secretion. In yet another embodiment, the cell is a RAMOS cell and the TLR signaling is indicated by CD80 cell surface expression.

TLR signaling activity can be measured via a native readout or an artificial readout or both. A native readout is one that does not rely on introduction of a reporter construct into the cell of interest.

The cell line may be used in a modified or unmodified form. In one embodiment, the cell line is transfected with a reporter construct. The transfection may be transient or stable. The reporter construct generally comprises a promoter, a coding sequence and a

polyadenylation signal. The coding sequence may comprise a reporter sequence selected from the group consisting of an enzyme (e.g., luciferase, alkaline phosphatase,  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein (GFP, U.S. Patent No. 5,491,084), etc.), a surface-expressed molecule (e.g., CD25), a secreted molecule (e.g., IL-8, IL-12 p40, TNF- $\alpha$ , etc.), and other detectable protein sequences known to those of skill in the art. Preferably, the coding sequence encodes a protein, the level or activity of which can be quantified, with preferably a wide linear range.

In some embodiments, the promoter is a promoter that is responsive to TLR signaling pathways (i.e., a "TLR responsive promoter"). In some embodiments, the promoter contains a binding site for a transcription factor activated upon CpG nucleic acid exposure, such as for example NF- $\kappa$ B. In other embodiments, the promoter contains a binding site for a transcription factor that is activated by a positive reference compound other than CpG nucleic acids. The transcription factor binding site may be selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE, as well as others known to those of skill in the art.

In another embodiment, the promoter contains a functional promoter element from an IL-1 gene, an IL-6 gene, an IL-8 gene, an IL-10 gene, an IL-12 p40 gene, an IFN- $\alpha$ 1 gene, an IFN- $\alpha$ 4 gene, an IFN- $\beta$  gene, an IFN- $\gamma$  gene, a TNF- $\alpha$  gene, a TNF- $\beta$  gene, an IP-9 gene, an IP-10 gene, a RANTES gene, an ITAC gene, a MCP-1 gene, an IGFBP4 gene, a CD54 gene, a CD69 gene, a CD71 gene, a CD80 gene, a CD86 gene, a HLA-DR gene, and a HLA class I gene.

The TLR responsive promoter may be a TLR1 responsive promoter, a TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter, a TLR10 responsive promoter or a TLR11 responsive promoter.

In these latter embodiments, the cell line may be transfected with a reporter construct having a promoter derived from a particular cytokine, chemokine, or cell surface marker, and a unique reporter coding sequence conjugated thereto. In this way, the readout from a particular reporter construct is a surrogate readout for cytokine, chemokine, or cell surface marker readout. Measuring readout from the reporter coding sequences described herein is in

some instances easier than measuring cytokine or chemokine secretion, or upregulation of a cell surface marker.

In these latter embodiments, the cell line may be transfected with a number of reporter constructs each having a promoter derived from a particular cytokine, chemokine, or cell surface marker, and a unique distinguishable coding sequence conjugated thereto. In these  
5       embodiments, multiple readouts are possible from one screen. In other embodiments, multiple native readouts are also possible from one screen.

In a related embodiment, the cell may be further transfected with a nucleic acid that codes for a TLR polypeptide or a fragment thereof. Preferably, the TLR is one that is not  
10       endogenously expressed by the cell. As an example, if the cell is an RPMI 8226 cell which has been shown to express TLR7 and TLR9 according to the invention, then it may be modified to express TLRs other than these (e.g., TLR8) in some embodiments. In this aspect, the RPMI 8226 cell is responsive to TLR8 ligands. In preferred embodiments, the TLR is a human TLR (i.e., hTLR).

15       In another aspect, the invention provides an RPMI 8226 cell transfected with a TLR nucleic acid. In still another embodiment, the TLR nucleic acid is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR8, TLR10 and TLR11. The encoded TLRs nucleic acids can derive from human or non-human sources. Examples of non-human sources include, but are not limited to, murine, bovine, canine, feline, ovine,  
20       porcine, and equine species. Other species include chicken and fish, e.g., aquaculture species. The TLR nucleic acids can also include chimeric sequences consisting of domains originating from different species. In preferred embodiments, the TLR is a human TLR.

In still another aspect, the invention provides kits including the cells lines (e.g., the RPMI 8226 cell line), the reporter constructs and/or expression constructs described above,  
25       and instructions for use.

Other aspects of the invention provide methods for analyzing the biological activity of individual lots of material containing previously identified specific TLR ligands (i.e., specific compounds which are ligands for a particular TLR) intended for use as, or for use in the preparation of, pharmaceutical compositions. The methods permit a qualitative and,  
30       importantly, a quantitative assessment of biological activity of individual lots of TLR ligands, pre-formulation as well as post-formulation. Such methods are useful in the manufacture and validation of pharmaceutical compositions containing, as an active agent, at least one specific ligand of at least one specific TLR. The specific TLR can be any known TLR, including

without limitation TLR3, TLR7, TLR8 and TLR9. The specific TLR ligand is an isolated TLR ligand, either found in nature or synthetic (not found in nature), including in particular certain nucleic acid molecules and small molecules. Nucleic acid molecules that are specific TLR ligands include synthetic and naturally-occurring oligonucleotides having specific base  
5 sequence motifs. Furthermore, specific TLR ligands include both agonists and antagonists of specific TLR.

These methods are to be distinguished from test procedures and acceptance criteria for new drug substances and new drug products which are classified as chemical substances. Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the instant  
10 invention deal specifically with characterizing drug substances and drug products which are classified as oligonucleotides. Oligonucleotides are explicitly excluded in ICH Topic Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Step 4 – Consensus Guideline: 6 October 1999, § 1.3.

Further still, the methods of the instant invention are to be distinguished from test  
15 procedures and acceptance criteria for biotechnological/biological products. Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the invention deal specifically with characterizing biotechnological/biological products which are classified as DNA products. DNA products are explicitly excluded in ICH Harmonised Tripartite Guideline Specifications: Test Procedures and Acceptance Criteria for  
20 Biotechnological/Biological Products, Step 4 – 10 March 1999, § 1.3.

In one aspect, the invention provides a method for quality assessment of a test composition containing a known TLR ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule; measuring a  
25 test activity of a test composition comprising the known TLR ligand; and comparing the test activity to the reference activity. In one embodiment the method further involves the step of selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

In one embodiment, the reference composition is a first production lot of a  
30 pharmaceutical composition comprising the known TLR ligand, and the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for finished pharmaceutical products containing a known TLR ligand.

In another embodiment, the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and the test composition is a second in-process lot of a composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for raw materials and/or other in-process materials containing a known TLR ligand bound for use in a pharmaceutical product.

In one embodiment according to this aspect of the invention, measuring the reference activity involves contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and measuring the test activity involves contacting the test composition with the isolated cell expressing the TLR responsive to the known TLR ligand. Further, in one embodiment the isolated cell expressing the TLR responsive to the known TLR ligand includes an expression vector for the TLR responsive to the known TLR ligand. Such expression vector, and likewise for any expression vector according to the instant invention, can be introduced into the cell using any suitable method.

In one embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand. Such a cell can be naturally occurring or it can be a cell line, provided the cell does not include an expression vector introduced into the cell for the purpose of artificially inducing the cell to express or overexpress the TLR.

In one particular embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is Raji, RAMOS, Nalm, THP-1 or KG-1 and the TLR is TLR9. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226, Raji or RAMOS and the TLR is TLR7. In yet another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a HeLa cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

Further according to this aspect of the invention, in one embodiment measuring the reference activity and measuring the test activity each comprises measuring signaling activity mediated by a TLR responsive to the known TLR ligand. As described in greater detail elsewhere herein, TLR signaling involves a series of intracellular signaling events. These signaling events give rise to various downstream products, including certain transcription

- 9 -

factors (e.g., NF- $\kappa$ B and AP-1), cytokines, chemokines, etc., which can affect the activity of certain gene promoters. For example, in one embodiment the signaling activity is activity of a reporter gene or reporter construct under the control of a NF- $\kappa$ B response element.

In other embodiments, the signaling activity is activity of a reporter gene or reporter  
5 construct under the control of an interferon-stimulated response element (ISRE); an IFN- $\alpha$  promoter; an IFN- $\beta$  promoter; an IL-6 promoter; an IL-8 promoter; an IL-12 p40 promoter; a RANTES promoter; an IL-10 promoter or an IP-10 promoter.

In one embodiment, the known TLR ligand is an immunostimulatory nucleic acid. An immunostimulatory nucleic acid can include, without limitation, a CpG nucleic acid. In  
10 another embodiment, the known TLR ligand is an immunoinhibitory nucleic acid. When the known TLR ligand is a TLR antagonist (e.g., an immunoinhibitory oligonucleotide), the method according to this aspect of the invention can further involve measuring the reference activity of the reference composition and measuring the test activity of the test composition, each performed in the presence of a known immunostimulatory TLR ligand.

15 In various embodiments, the known TLR ligand is a ligand for a particular TLR. Thus in one embodiment the known TLR ligand is a TLR9 ligand. More specifically, in one embodiment the known TLR ligand is a CpG nucleic acid.

In one embodiment, the known TLR ligand is a TLR3 ligand. Such a ligand can include, for example, a double-stranded RNA or a homolog thereof.

20 In one embodiment, the known TLR ligand is a TLR7 ligand. In one embodiment the known TLR ligand is a TLR8 ligand.

The invention provides in another aspect a method for quality assessment of a test lot of a pharmaceutical product containing a known TLR9 ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference lot of a  
25 pharmaceutical product comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid molecule; measuring a test activity of a test lot of a pharmaceutical product comprising the known TLR9 ligand; comparing the test activity to the reference activity; and rejecting the test lot if the test activity falls outside of a predetermined range of variance about the reference activity.

30 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT GTC GTT-3' (SEQ ID NO:1).

- 10 -

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGA CGT TTT GTC GTT-3' (SEQ ID NO:139).

5 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT TTT CGA-3' (SEQ ID NO:140).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTC GTC GTT-3' (SEQ ID NO:141).

10 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3' (SEQ ID NO:142).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GGT CGT TTT-3' (SEQ ID NO:143).

15 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GTG CGT TTT T-3' (SEQ ID NO:144).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TCG GCG GCC GCC G-3' (SEQ ID NO:145).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TC\_G TTT TAC\_GGC GCC\_GTG CCG-3' (SEQ ID NO:146), wherein every internucleoside linkage is  
25 phosphorothioate except for those indicated by “\_”, which are phosphodiester.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

30

### **Brief Description of the Figures**



Fig. 1 is a bar graph showing cell surface expression of various markers by RPMI 8226 24 hours and 48 hours following stimulation with CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), LPS and IL-1.

Fig. 2 is a bar graph showing IL-8 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 3 is a bar graph showing IL-6 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 4 is a bar graph showing IP-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 5 is a bar graph showing IL-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 6 is a dose response curve showing fold induction of IL-8 production 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1) and non-CpG nucleic acid (SEQ ID NO: 2). The  $EC_{50}$  for CpG nucleic acid is 19 nM and the  $EC_{50}$  for non-CpG nucleic acid is 263 nM.

Fig. 7 is a bar graph showing NF- $\kappa$ B activation in RPMI 8226 transfected transiently with a NF- $\kappa$ B-luciferase reporter gene construct as a function of cell density and nucleic acid amount transfected, following exposure to CpG nucleic acid (SEQ ID NO: 1), LPS and TNF- $\alpha$ . NF- $\kappa$ B activation is measured by luciferase activity.

Fig. 8 is a bar graph showing RT-PCR results from RNA isolated from RPMI 8226 using gene specific primers for TLR7, TLR8 and TLR9 genes.

Fig. 9 is a dose response curve showing IP-10 production induced by SEQ ID NO: 1, and inhibition thereof in the presence of SEQ ID NO: 151, a immunoinhibitory nucleic acid.

Fig. 10 is a bar graph showing the results of a TLR9 RT-PCR analysis of a number of cell lines.

Fig. 11 is a bar graph showing the results of a TLR7 RT-PCR analysis of a number of cell lines.

Fig. 12 is a bar graph showing the results of a TLR3 RT-PCR analysis of a number of cell lines.

Fig. 13 is a bar graph showing the results of a TLR3, TLR7, TLR8 and TLR9 RT-PCR analysis of the Raji cell line.

Fig. 14 is a graph showing IL-6 production by the Raji cell line upon stimulation with various ODN (SEQ ID NO:1; SEQ ID NO:154; SEQ ID NO:158; SEQ ID NO:160; SEQ ID  
5 NO:159; SEQ ID NO:161).

Fig. 15 is a bar graph showing IL-6 production of the Raji cell line upon stimulation with poly I:C and R-848.

Fig. 16 is a bar graph showing IFN- $\alpha$ 2 production by the Raji cell line upon stimulation with CpG ODN (SEQ ID NO: 1), R-848 and poly I:C.

Fig. 17 is a bar graph showing CD80 expression (by flow cytometry) by the RAMOS  
10 cell line upon stimulation with CpG ODN (SEQ ID NO: 1) and non-CpG ODN (SEQ ID NO: 2).

Fig. 18A is a bar graph showing the induction of NF- $\kappa$ B by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-  
15 ODN, GpC-ODN, LPS, and medium.

Fig. 18B is a bar graph showing the amount of IL-8 produced by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-ODN, GpC-ODN, LPS, and medium.

Fig. 19 is a bar graph showing the induction of NF- $\kappa$ B-luc produced by stably  
20 transfected 293-mTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

Fig. 20 is a bar graph showing the induction of NF- $\kappa$ B-luc produced by stably transfected 293-hTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

Fig. 21 is a series of gel images depicting the results of reverse transcriptase-  
25 polymerase chain reaction (RT-PCR) assays for murine TLR9 (mTLR9), human TLR9 (hTLR9), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in untransfected control 293 cells, 293 cells transfected with mTLR9 (293-mTLR9), and 293 cells transfected with hTLR9 (293-hTLR9).

30

It is to be understood that the Figures are not required for enablement of the invention.

#### **Brief Description of Sequences**

SEQ ID NO:1 is the nucleotide sequence of an immunostimulatory nucleic acid (TLR9 ligand).

SEQ ID NO:2 is the nucleotide sequence of a non-CpG nucleic acid.

SEQ ID NO:3 is the nucleotide sequence of human TLR2 cDNA (U88878).

5 SEQ ID NO:4 is the amino acid sequence of human TLR2 protein (AAC34133).

SEQ ID NO:5 is the nucleotide sequence of murine TLR2 cDNA (AF165189).

SEQ ID NO:6 is the amino acid sequence of murine TLR2 protein (NP\_036035).

SEQ ID NO:7 is the nucleotide sequence of human TLR3 cDNA (NM\_003265).

SEQ ID NO:8 is the amino acid sequence of human TLR3 protein (NP\_003256).

10 SEQ ID NO:9 is the nucleotide sequence of murine TLR3 cDNA (AF355152).

SEQ ID NO:10 is the amino acid sequence of murine TLR3 protein (AAK26117).

SEQ ID NO:11 is the nucleotide sequence of human TLR4 cDNA (U88880).

SEQ ID NO:12 is the nucleotide sequence of human TLR4 cDNA transcript variant 4 (NM\_138557).

15 SEQ ID NO:13 is the nucleotide sequence of human TLR4 cDNA transcript variant 2 (NM\_138556).

SEQ ID NO:14 is the nucleotide sequence of human TLR4 cDNA transcript variant 1 (NM\_138554).

20 SEQ ID NO:15 is the nucleotide sequence of human TLR4 cDNA transcript variant 3 (NM\_003266).

SEQ ID NO:16 is the amino acid sequence of human TLR4 protein isoform A (NP\_612564).

SEQ ID NO:17 is the amino acid sequence of human TLR4 protein isoform B (NP\_612566).

25 SEQ ID NO:18 is the amino acid sequence of human TLR4 protein isoform C (NP\_003257).

SEQ ID NO:19 is the amino acid sequence of human TLR4 protein isoform D (NP\_612567).

SEQ ID NO:20 is the nucleotide sequence of murine TLR4 cDNA (NM\_021297).

30 SEQ ID NO:21 is the nucleotide sequence of murine TLR4 mRNA (AF185285).

SEQ ID NO:22 is the nucleotide sequence of murine TLR4 mRNA (AF110133).

SEQ ID NO:23 is the amino acid sequence of murine TLR4 protein (AAD29272).

SEQ ID NO:24 is the amino acid sequence of murine TLR4 protein (AAF04278).

- SEQ ID NO:25 is the nucleotide sequence of human TLR5 cDNA (AB060695).  
SEQ ID NO:26 is the amino acid sequence of human TLR5 protein (BAB43558).  
SEQ ID NO:27 is the amino acid sequence of human TLR5 protein (O60602).  
SEQ ID NO:28 is the amino acid sequence of human TLR5 protein (AAC34136).  
5 SEQ ID NO:29 is the nucleotide sequence of murine TLR5 cDNA (AF186107).  
SEQ ID NO:30 is the amino acid sequence of murine TLR5 protein (AAF65625).  
SEQ ID NO:31 is the nucleotide sequence of human TLR7 cDNA (AF240467).  
SEQ ID NO:32 is the nucleotide sequence of human TLR7 cDNA (AF245702).  
SEQ ID NO:33 is the nucleotide sequence of human TLR7 cDNA (NM\_016562).  
10 SEQ ID NO:34 is the amino acid sequence of human TLR7 protein (AAF60188).  
SEQ ID NO:35 is the amino acid sequence of human TLR7 protein (AAF78035).  
SEQ ID NO:36 is the amino acid sequence of human TLR7 protein (NP\_057646).  
SEQ ID NO:37 is the amino acid sequence of human TLR7 protein (Q9NYK1).  
SEQ ID NO:38 is the nucleotide sequence of murine TLR7 cDNA (AY035889).  
15 SEQ ID NO:39 is the nucleotide sequence of murine TLR7 splice variant  
(NM\_133211).  
SEQ ID NO:40 is the nucleotide sequence of murine TLR7 splice variant (AF334942).  
SEQ ID NO:41 is the amino acid sequence of murine TLR7 protein (AAK62676).  
SEQ ID NO:42 is the amino acid sequence of murine TLR7 protein (AAL73191).  
20 SEQ ID NO:43 is the amino acid sequence of murine TLR7 protein (AAL73192).  
SEQ ID NO:44 is the amino acid sequence of murine TLR7 protein (NP\_573474).  
SEQ ID NO:45 is the amino acid sequence of murine TLR7 protein (P58681).  
SEQ ID NO:46 is the nucleotide sequence of human TLR8 cDNA (AF245703).  
SEQ ID NO:47 is the nucleotide sequence of human TLR8 cDNA (AF246971).  
25 SEQ ID NO:48 is the nucleotide sequence of human TLR8 cDNA (NM\_138636).  
SEQ ID NO:49 is the nucleotide sequence of human TLR8 cDNA (NM\_016610).  
SEQ ID NO:50 is the amino acid sequence of human TLR8 protein (AAF78036).  
SEQ ID NO:51 is the amino acid sequence of human TLR8 protein (AAF64061).  
SEQ ID NO:52 is the amino acid sequence of human TLR8 protein (Q9NR97).  
30 SEQ ID NO:53 is the amino acid sequence of human TLR8 protein (NP\_619542).  
SEQ ID NO:54 is the amino acid sequence of human TLR8 protein (NP\_057694).  
SEQ ID NO:55 is the nucleotide sequence of murine TLR8 cDNA (AY035890).  
SEQ ID NO:56 is the nucleotide sequence of murine TLR8 cDNA (NM\_133212).

- SEQ ID NO:57 is the amino acid sequence of murine TLR8 protein (AAK62677).  
SEQ ID NO:58 is the amino acid sequence of murine TLR8 protein (NP\_573475).  
SEQ ID NO:59 is the amino acid sequence of murine TLR8 protein (P58682).  
SEQ ID NO:60 is the nucleotide sequence of human TLR9 cDNA (AF245704).  
5 SEQ ID NO:61 is the nucleotide sequence of human TLR9 cDNA (AB045180).  
SEQ ID NO:62 is the amino acid sequence of human TLR9 protein (AAF78037).  
SEQ ID NO:63 is the amino acid sequence of human TLR9 protein (AAF72189).  
SEQ ID NO:64 is the amino acid sequence of human TLR9 protein (AAG01734).  
SEQ ID NO:65 is the amino acid sequence of human TLR9 protein (AAG01735).  
10 SEQ ID NO:66 is the amino acid sequence of human TLR9 protein (AAG01736).  
SEQ ID NO:67 is the amino acid sequence of human TLR9 protein (BAB19259).  
SEQ ID NO:68 is the nucleotide sequence of murine TLR9 cDNA (AF348140).  
SEQ ID NO:69 is the nucleotide sequence of murine TLR9 cDNA (AB045181).  
SEQ ID NO:70 is the nucleotide sequence of murine TLR9 cDNA (AF314224).  
15 SEQ ID NO:71 is the nucleotide sequence of murine TLR9 cDNA (NM\_031178).  
SEQ ID NO:72 is the amino acid sequence of murine TLR9 protein (AAK29625).  
SEQ ID NO:73 is the amino acid sequence of murine TLR9 protein (AAK28488).  
SEQ ID NO:74 is the amino acid sequence of murine TLR9 protein (BAB19260).  
SEQ ID NO:75 is the amino acid sequence of murine TLR9 protein (NP\_112455).  
20 SEQ ID NO:76 is the nucleotide sequence of human TLR10 cDNA (AF296673).  
SEQ ID NO:77 is the amino acid sequence of human TLR10 protein (AAK26744).  
SEQ ID NO:78 is the nucleotide sequence of human TLR6 cDNA (AB020807).  
SEQ ID NO:79 is the nucleotide sequence of human TLR6 mRNA (NM\_006068).  
SEQ ID NO:80 is the amino acid sequence of human TLR6 protein (BAA78631).  
25 SEQ ID NO:81 is the amino acid sequence of human TLR6 protein (NP\_006059).  
SEQ ID NO:82 is the amino acid sequence of human TLR6 protein (Q9Y2C9).  
SEQ ID NO:83 is the nucleotide sequence of murine TLR6 cDNA (AB020808).  
SEQ ID NO:84 is the nucleotide sequence of murine TLR6 cDNA (NM\_011604).  
SEQ ID NO:85 is the nucleotide sequence of murine TLR6 cDNA (AF314636).  
30 SEQ ID NO:86 is the amino acid sequence of murine TLR6 protein (BAA78632).  
SEQ ID NO:87 is the amino acid sequence of murine TLR6 protein (AAG38563).  
SEQ ID NO:88 is the amino acid sequence of murine TLR6 protein (NP\_035734).  
SEQ ID NO:89 is the amino acid sequence of murine TLR6 protein (Q9EPW9).

SEQ ID NO:90 is the nucleotide sequence of a consensus sequence for NF- $\kappa$ B p50 subunit.

SEQ ID NO:91 is the nucleotide sequence of a consensus sequence for NF- $\kappa$ B p65 subunit.

5 SEQ ID NO:92 is the nucleotide sequence of an example of an NF- $\kappa$ B p65 subunit binding site.

SEQ ID NO:93 is the nucleotide sequence of an example of a murine CREB binding site.

10 SEQ ID NO:94 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:95 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:96 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:97 is the nucleotide sequence of an example of an ISRE.

15 SEQ ID NO:98 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:99 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:100 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:101 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:102 is the nucleotide sequence of an example of an ISRE.

20 SEQ ID NO:103 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:104 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:105 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:106 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:107 is the nucleotide sequence of an example of an NFAT binding site.

25 SEQ ID NO:108 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:109 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:110 is the nucleotide sequence of an example of a GAS.

SEQ ID NO:111 is the nucleotide sequence of a p53 binding site consensus sequence.

SEQ ID NO:112 is the nucleotide sequence of an example of a p53 binding site.

30 SEQ ID NO:113 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:114 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:115 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:116 is the nucleotide sequence of an example of a p53 binding site.

- 17 -

SEQ ID NO:117 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:118 is the nucleotide sequence of an example of a TARE (TNF- $\alpha$  response element).

SEQ ID NO:119 is the nucleotide sequence of an example of an SRF binding site.

5 SEQ ID NO:120 is the nucleotide sequence of an example of an SRF binding site.

SEQ ID NO:121 is the nucleotide sequence of the -620 to +50 promoter region of IFN- $\alpha$ 4.

SEQ ID NO:122 is the nucleotide sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1.

10 SEQ ID NO:123 is the nucleotide sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1 (point mutation, AL353732).

SEQ ID NO:124 is the nucleotide sequence of the -280 to +20 promoter region of IFN- $\beta$ .

15 SEQ ID NO:125 is the nucleotide sequence of the -397 to +5 promoter region of human RANTES (AB023652).

SEQ ID NO:126 is the nucleotide sequence of the -751 to +30 promoter region of human IL-12 p40.

SEQ ID NO:127 is the nucleotide sequence of the -250 to +30 promoter region of human IL-12 p40.

20 SEQ ID NO:128 is the nucleotide sequence of the -288 to +7 promoter region of human IL-6.

SEQ ID NO:129 is the nucleotide sequence of the IL-6 gene promoter from -1174 to +7 (M22111).

25 SEQ ID NO:130 is the nucleotide sequence of the -734 to +44 promoter region derived from human IL-8.

SEQ ID NO:131 is the nucleotide sequence of the -162 to 44 promoter region of human IL-8.

SEQ ID NO:132 is the nucleotide sequence of the -615 to +30 promoter region of human TNF- $\alpha$ .

30 SEQ ID NO:133 is the nucleotide sequence of a promoter region of human TNF- $\beta$ .

SEQ ID NO:134 is the nucleotide sequence of the -875 to +97 promoter region of human IP-10.

SEQ ID NO:135 is the nucleotide sequence of the -219 to +114 promoter region of human CXCL11 (IP-9).

SEQ ID NO:136 is the nucleotide sequence of the full length promoter region of human CXCL11 (IP-9).

5        SEQ ID NO:137 is the nucleotide sequence of the -289 to +217 promoter region of IGFBP4 (Insulin growth factor binding protein 4).

SEQ ID NO:138 is the nucleotide sequence of the full length promoter region of IGFBP4.

10        SEQ ID NO:139 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:140 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:141 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:142 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:143 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:144 is the nucleotide sequence of an immunostimulatory nucleic acid.  
15        SEQ ID NO:145 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:146 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:147 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

20        SEQ ID NO:148 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

SEQ ID NO:149 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

SEQ ID NO:150 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

25        SEQ ID NO:151 is the nucleotide sequence of an immunoinhibitory nucleic acid.

SEQ ID NO:152 is the nucleotide sequence of a sense primer for human TLR3.

SEQ ID NO:153 is the nucleotide sequence of an antisense primer for human TLR3.

SEQ ID NO:154 is the nucleotide sequence of a GpC nucleic acid.

SEQ ID NO:155 is the nucleotide sequence of a CpG ODN.

30        SEQ ID NO:156 is the nucleotide sequence of a GpC ODN.

SEQ ID NO:157 is the nucleotide sequence of a Me-CpG ODN.

SEQ ID NO:158 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:159 is the nucleotide sequence of a TLR9 ligand.



SEQ ID NO:160 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:161 is the nucleotide sequence of a TLR9 ligand.

### **Detailed Description of the Invention**

5 In its broadest sense, the invention relates to screening methods and tools to be used to identify and discriminate between newly discovered immunomodulatory molecules and to compare and standardize compositions of known immunomodulatory molecules. The immunomodulatory molecules are preferably TLR ligands.

Thus, the invention is based in part on the discovery that cell lines expressing  
10 endogenous TLR respond to TLR ligands in a manner similar to the response of peripheral blood mononuclear cells (PBMC). PBMC respond to immunomodulatory TLR ligands by modulating one or more parameters including gene expression, cell surface marker expression, cytokine and/or chemokine production and secretion, cell cycle status, phosphorylation status, and the like. TLR ligands can be categorized and distinguished based  
15 on the cellular changes they induce (i.e., their induction profiles). The ability of a TLR ligand to provide therapeutic or prophylactic benefit to a subject depends on its induction profile. The ability to screen new TLR ligands for a panel of response indicators or parameters allows for rapid discrimination and categorization of TLR ligands. Moreover, the similarity between the cell line responses and those observed after in vivo administration of the TLR ligand  
20 indicates that the cell lines are suitable predictors of in vivo activity. The use of in vitro propagated cell lines additionally overcomes the variability encountered when using freshly isolated PBMC.

The TLR ligands identified according to the invention therefore can be used therapeutically or prophylactically in a more patient- or disorder-specific manner. The  
25 invention allows for the tailoring of TLR ligands for particular patients or disorders.

The invention identifies a number of cell lines that can be used to identify TLR ligands based on endogenous TLR expression such as TLR3, TLR7 and TLR9 expression. As an example, the invention is premised in part on the discovery of TLR9 expression in a number of cell lines including RPMI 8226, Raji, RAMOS, THP-1, Nalm-6 and KG-1. Cell lines  
30 RPMI 8226, Raji and RAMOS have been determined to express TLR7 according to the invention. Cell lines KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell have been discovered to express TLR3 according to the invention.

It is further premised in part on the discovery that RPMI 8226 cells respond to the imidazoquinoline compound R-848. Consistent with this latter finding, it was also discovered that RPMI 8226 cells express TLR7.

The invention in other aspects provides for screening methods and tools for verifying and standardizing compositions containing known TLR ligands. These compositions may be for example commercial production lots to be used in a clinical setting. Accordingly, the invention provides methods for standardizing lots of known TLR ligands prior to distribution and use clinically. In this way, production processes can be observed and controlled and substandard production lots can be identified and eliminated prior to shipment.

The methods of the instant invention can be used at any step in the preparation and production of clinical material, i.e., pharmaceutical product. In particular, the methods will find use in characterizing or validating raw materials, in-process materials, finished product materials (e.g., pre-release materials), and post-production materials (e.g., post-release materials). The methods can also be used to validate existing process methods, as well as to validate new or changed process methods used in the production of the pharmaceutical product.

## 20 Screening Assays Generally

The screening assays provided herein may be used to identify immunomodulatory agents. Immunomodulatory agents are agents that either stimulate or inhibit immune responses in a subject. Accordingly, as used herein, immunomodulation embraces both immunostimulation and immunoinhibition.

The screening methods are used to identify TLR agonists and antagonists. The methods can also be used to identify compounds that enhance the immunostimulation induced by a TLR agonist. This latter set of compounds is referred to herein as "enhancers". A TLR agonist is a compound that stimulates TLR signaling activity. A TLR antagonist is a compound that inhibits TLR signaling activity. Agonists are generally referred to herein as immunostimulatory compounds because stimulation of TLR is associated with immune stimulation. Antagonists are generally referred to herein as immunoinhibitory compounds because inhibition of TLR is associated with immune inhibition. TLR antagonists include compounds that reduce (or eliminate completely) the immunostimulation induced by a TLR

- 21 -

agonist. In some embodiments, the agonists, antagonists and enhancers are TLR ligands (i.e., they bind to a TLR). In other embodiments, the test compounds with agonist, antagonist or enhancer activity may act downstream or upstream of the TLR-TLR ligand interaction.

An "immunostimulatory compound" as used herein refers to a natural or synthetic compound that characteristically induces a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunostimulatory compound is a natural or synthetic compound that induces a TLR-mediated response when contacted with a cell that naturally or artificially expresses a suitable functional TLR polypeptide. Depending on the aspect of the invention, the cell may be an experimental cell or a primary cell such as a PBMC.

Examples of immunostimulatory compounds include the following immunostimulatory nucleic acids, which are discussed in further detail below:

	5'-TCGTCGTTTTGTCGTTTTGTCGTT-3'	(SEQ ID NO:1)
	5'-TCGTCGTTTTGACGTTTTGTCGTT-3'	(SEQ ID NO:139)
15	5'-TCGTCGTTTTGTCGTTTTTTTCGA-3'	(SEQ ID NO:140)
	5'-TCGTCGTTTCGTCGTTTCGTCGTT-3'	(SEQ ID NO:141)
	5'-TCGTCGTTTCGTCGTTTTGTCGTT-3'	(SEQ ID NO:142)
	5'-TCGTCGTTTTTCGGTCGTTTT-3'	(SEQ ID NO:143)
	5'-TCGTCGTTTTTCGTGCGTTTT-3'	(SEQ ID NO:144)
20	5'-TCGTCGTTTTCGGCGGCCGCCG-3'	(SEQ ID NO:145)
	5'-TCGTC_GTTTTAC_GGCGCC_GTGCCG-3'	(SEQ ID NO:146)

Imidazoquinolines are immune response modifiers thought to induce expression of several cytokines including interferons (e.g., IFN- $\alpha$  and IFN- $\beta$ ), TNF- $\alpha$  and some interleukins (e.g., IL-1, IL-6 and IL-12) as well as chemokines (e.g., IP-10 and IL-8). Imidazoquinolines are capable of stimulating a Th1 immune response, as evidenced in part by their ability to induce increases in IgG2a levels. Imidazoquinoline agents reportedly are also capable of inhibiting production of Th2 cytokines such as IL-4, IL-5, and IL-13. Some of the cytokines induced by imidazoquinolines are produced by macrophages and dendritic cells. Some species of imidazoquinolines have been reported to increase NK cell lytic activity and to stimulate B cells proliferation and differentiation, thereby inducing antibody production and secretion. Imidazoquinoline mimics can also be tested using the screening methods.

An "immunoinhibitory compound" as used herein refers to a natural or synthetic compound that characteristically inhibits a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunoinhibitory compound is a natural or synthetic compound that inhibits a TLR-mediated response when contacted with a cell that naturally or artificially expresses a suitable functional TLR polypeptide.

In addition to the immunoinhibitory nucleic acids disclosed elsewhere herein, immunoinhibitory compounds and TLR antagonists encompass certain small molecules (chloroquine, quinacrine, 9-aminoacridines and 4-aminoquinolines, and derivatives thereof) described by Macfarlane and colleagues in U.S. Pat. 6,221,882; U.S. Pat. 6,399,630; U.S. Pat. 6,479,504; U.S. Pat. 6,521,637; and published U.S. Pat. application 2002/0151564, the contents of all of which are hereby incorporated by reference in their entirety.

The invention provides in part methods and tools that utilize cell lines, in modified or unmodified form, as surrogates for PBMC. Immunomodulation by TLR ligands can be assessed using one or preferably more parameters including but not limited to cytokine and chemokine secretion, upregulation of cell surface markers, changes in cell proliferation, phosphorylation changes, and the like. These parameters may be native readouts or artificial readouts as described herein.

The cellular response to immunostimulatory nucleic acids by the cell lines described herein (e.g., RPMI 8226, Raji, RAMOS, and the like) so resembles that of PBMC that these cells can be used to identify and differentiate between immunomodulatory compounds based on the extent of the induced response and the particular profile of that response. The invention provides a number of cell lines each with a particular endogenous TLR expression profile, as described herein.

The cell lines can be used to identify immunomodulatory compounds with particular response profiles. As an example, the cell lines can be used to identify molecules that are mimics to known TLR ligands. The cell lines can also be used to identify TLR ligands that trigger some but not necessarily all of the responses induced by known TLR ligands. For example, the cell line can be used to distinguish between compounds based on individual or group cytokine or chemokine secretion, or based on upregulation of one, a subset or all cell surface markers. As an example, in some therapeutic instances, it may be desirable to use a compound that induces the secretion of relatively high levels of chemokine such as IP-10, yet induces only relatively low levels of one or more other factors. The screening methods of the invention allow for the identification of such a compound with this type of induction profile.

It is to be understood that the screening method also can be used to determine effective amounts of known and newly identified immunomodulatory compounds. For example, the EC<sub>50</sub> value of a TLR ligand for the production of a particular cytokine or chemokine can be determined, thereby facilitating comparison between different nucleic acids.

5           Generally, these assays require the incubation of cells with a reference compound and a test compound, and an analysis of the readout. Depending on the embodiment, the same cells are exposed to the reference compound and the test compound. An example of this latter embodiment is a screening assay for compounds that enhance the immunostimulatory effects of a TLR agonist. Another example is a screening assay for compounds that inhibit the  
10 immunostimulatory effects of a TLR agonist. In both examples, the reference compound is a positive reference compound (i.e., it is itself immunostimulatory).

          In other embodiments, particularly those directed at identifying immunostimulatory compounds, separate aliquots from the same cell line (or from the same freshly harvested cell population) are exposed to either the reference compound or the test compound, and the  
15 readouts from each are measured and compared to the other. If the reference compound is a negative reference compound (i.e., it is inert and neither immunostimulatory nor immunoinhibitory), then any test level that is greater than the reference level is indicative of a test compound that has at least some immunostimulatory capacity. Generally, the negative reference compound is used to set background levels of immunostimulation or  
20 immunoinhibition observed in the absence of the test compound. If the reference compound is a positive reference compound (i.e., it is immunostimulatory), then it is possible to compare and contrast the induction profile of the test compound to that of the reference compound.

          In some instances, separate reference assays individually containing a positive and a negative reference compound are performed alongside the test assay. For example, if the test  
25 assay is a screen for an immunostimulatory TLR ligand, then reference assays can be a positive reference assay (in which the reference compound is immunostimulatory), a negative reference assay (in which the reference compounds is immunologically inert or neutral), or both. A test compound is defined as immunostimulatory if it induces a response greater than that of the negative reference compound. The level and profile of the immunostimulatory  
30 response can be compared to the level and profile induced by the positive reference compound. It is to be understood that a test compound that induces a level of immunostimulation less than that of the positive reference compound may still be considered immunostimulatory according to the invention. Modifications to these screening assays for a

desired readout will be apparent to those of ordinary skill in the art based on the teachings provided herein.

If the test assay is a screen for an immunoinhibitory TLR ligand, then the assay may generally involve co-incubation of the test compound and a positive reference compound.

5 The control assay may include co-incubation of the negative and positive reference compounds. As used herein, co-incubation embraces simultaneous or consecutive addition of the reference and test compounds. The test compound may be added before or after the positive reference compound. An immunoinhibitory test compound may be identified by a diminution of the immunostimulatory response induced by the positive reference compound  
10 when in the presence of the test compound. If the level of the response is less in the presence of the test compound, this indicates that the test compound is capable of interfering with the immunostimulatory effects of the positive reference compound. As an example, simultaneous or consecutive addition of a putative immunoinhibitory test compound can reduce the amount of cytokines or chemokines secreted by cells in response to the positive reference compound  
15 alone, indicating an inhibition of the immunostimulatory effects of the positive reference compound.

The reference immunoinhibitory compound can be used at one or more concentrations in conjunction with a selected or constant concentration of reference immunostimulatory compound. Under proper conditions, the immunostimulatory effect of the reference  
20 immunostimulatory compound will be less in the presence of the immunoinhibitory substance than in the absence of the immunoinhibitory substance. Furthermore, under proper conditions, the immunostimulatory effect of the reference immunostimulatory compound will decrease with increasing concentration of the immunoinhibitory substance.

The breadth of response by the cell line to immunomodulatory compounds, and its  
25 facile manipulation, allows for the identification of novel compounds. The cell line allows the rapid discovery of such compounds given that it lends itself to high throughput screening methods such as those provided herein. These methods and compositions are described in greater detail below. The invention therefore provides screening methods that utilize cell lines that either endogenous express TLRs such as the RPMI 8226 cell line as well as cell  
30 lines that have been modified to express TLRs. The invention further provides compositions that comprise such cell lines.

The verification and standardization methods of the invention generally involve assays in which an isolated cell expressing a functional TLR is contacted with each of two

compositions, each composition containing a known ligand for the TLR. One composition is a reference composition, and the assay using the reference composition yields a reference activity. The second composition is a test composition, and the assay using the test composition yields a test activity. The two contacting steps can be performed on separate cells that are alike, and typically will be performed on separate populations of cells that are alike. For example, the separate cells or the separate populations of cells can be drawn from a single population of cells. In typical usage according to this embodiment, the reference and test activities are measured essentially concurrently, although the use of historical reference activity is also contemplated by the methods of the invention. As an alternative, the two contacting steps can be performed on a single cell or on a single population of cells, usually in an essentially concurrent manner when it is desirable to have competition between reference and test compositions. In one embodiment the known TLR ligand is a nucleic acid molecule.

The assays of the invention are performed under specific conditions so that comparison can be made between reference and test activities or levels. The results of the comparison can be used as a basis upon which to accept or reject the test material as suitable for its intended use.

The biological characterization of the reference composition will generally entail a series of biological activity measurements of the reference composition using a single assay under defined conditions in order to define a range of inter-test variance. The range of inter-test variance so obtained using reference composition can be used to define an acceptable range of variance within which a subsequent test measurement must fall in order to satisfy quality standards. Such a range of acceptable variance can serve as a basis for developing predetermined range of variance about the reference activity, i.e., acceptance criteria for a particular test composition or test lot. For example, a particular reference composition can be assayed under defined conditions in a number of independent measurements and found to yield a result expressed as  $100 \pm 5$  units of activity. Under this same example, a subsequent test measurement of a test composition performed using the same assay and defined conditions is found to yield 97 units of activity. The activity of the test composition under this example thus yielded a result that falls within the normal range of inter-test variance observed for the reference composition. Accordingly, the test material under this example could be selected on the basis of the test activity falling within a predetermined range of variance about the reference activity. In short, the test material can be deemed acceptable

provided the test activity falls within a predetermined range of activity that is related to the activity of the reference material.

In one embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of the same particular TLR ligand. Such comparison is useful for quality control assessment of the test lot of material, also referred to  
5 herein as validation, e.g., product validation. Such comparison is also useful for process validation.

In another embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of a different TLR ligand. In a simple  
10 example, where a test TLR ligand (T) is expected to have little or no activity characteristic of reference TLR ligand (R), comparison can be made between T and R to confirm the lack of R-like activity possessed by T. In a more complex example, where a test TLR ligand (C) is capable of exerting two different effects, wherein each effect is characteristic of one of two different classes of TLR ligand and is best characterized by one of two different reference  
15 TLR ligands (A and B), the test TLR ligand (C) can be compared with either of the two reference TLR ligands (A or B). In this second example, test composition C could be found, for example, to possess 50 percent A-like activity compared with reference A and 70 percent B-like activity compared with reference B. Test composition C could thus independently meet or fail to meet predetermined standards for each of A-like activity and B-like activity.  
20 Such comparison is also useful for quality control assessment of the test lot of material, e.g., product validation. Of course test TLR ligand C can alternatively or additionally be compared against reference TLR ligand C, as described in the preceding paragraph.

To facilitate the methods of the invention, certain conditions for carrying out the assays are standardized and used for measurements of both reference activity and test activity.  
25 In this way direct comparison between reference activity and test activity can be made readily. Conditions that can be standardized and used in this manner can include, without limitation, readout, temperature, media characteristics, duration (time between introduction of reference composition or test composition and activity measurement), methods of sampling, etc. In some embodiments the methods of the invention can be at least partially automated in order to  
30 increase throughput and/or to reduce inter-test variability. For example, robotic devices and workstations with the capacity to dispense and/or sample fluids in a set or programmable fashion are now well known in the art and can be used in performing the methods of the instant invention.



- 27 -

In one embodiment a standard curve of reference composition activity is employed. Typically the standard curve is generated by selecting conditions including concentration of the reference composition such that the dose-response curve is essentially linear (and the slope is non-zero) over a range of concentrations that includes the effective concentration at which activity is 50 percent of maximum (EC50). In one embodiment the standard curve spans a range of concentrations defined by  $EC50 \pm 1 \log$  concentration, e.g.,  $1 \times 10^{-7} \text{ M} - 1 \times 10^{-5} \text{ M}$ , where EC50 is  $1 \times 10^{-6} \text{ M}$ . In another embodiment the standard curve spans a broader range of concentrations defined by  $EC50 \pm 2 \log$  concentration, e.g.,  $1 \times 10^{-8} \text{ M} - 1 \times 10^{-4} \text{ M}$ , where EC50 is  $1 \times 10^{-6} \text{ M}$ . In yet another embodiment the standard curve spans a narrower range of concentrations defined by  $EC50 \pm 0.5 \log$  concentration, e.g.,  $3.16 \times 10^{-7} \text{ M} - 3.16 \times 10^{-6} \text{ M}$ , where EC50 is  $1 \times 10^{-6} \text{ M}$ . The foregoing embodiments are intended to be exemplary and not limiting in any way. One of skill in the art will be able to select, for a given reference composition and without undue experimentation, an appropriate range of concentrations about some middle value in order to generate an essentially linear standard curve with a non-zero slope.

In one embodiment a non-linear standard curve of reference and test composition activity is employed. The standard curve can be generated by selecting conditions including concentrations of the reference composition such that the dose-response curve is sigmoidal and the EC50 value can be determined. Comparison of reference and test activity can be done by comparing, e.g., the EC50 values of both curves. Concentration range is chosen to yield a complete sigmoidal response, e.g., concentration should include  $EC50 \pm 3 \log$  concentration or  $EC50 \pm 4 \log$  concentration. In the case of testing an inhibitory compound the value determined would be the IC50, i.e., concentration where inhibition of the stimulatory signal is half-maximal.

The methods of the invention can be adapted to be automated or at least partially automated methods, as well as to parallel array or high throughput format methods. For example, the assays can be set up using multiwell plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery device suited to the geometry of the multiwell plate. Manual and robotic multiwell delivery devices suitable for use in a high throughput screening assay are known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are

known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully robotic systems are known in the art for applications such as generation and analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. Pat. Nos. 5,443,791 and 5,708,158.

### Cell lines

The screening methods may use experimental cells. As used herein, an experimental cell is a non-primary cell (i.e., it is not a cell that has been recently harvested from a subject). It excludes, for example, freshly harvested PBMCs. An experimental cell includes a cell from a cell line such as the RPMI 8226 cell line.

In certain embodiments, the cell naturally expresses a functional TLR. In one embodiment relating to the verification and standardization aspects of the invention, the cell may be a PBMC, preferably a PBMC freshly harvested from a subject.

Cells that would be suitable for identification of TLR agonists, antagonists or enhancers according to the invention may possess one or more particular attributes. These attributes include but are not limited to being of human origin, being an immortalized stable cell line, endogenously expressing at least one functional TLR or a combination of functional TLRs, having intact signaling mechanisms, having intact uptake mechanisms, being able to upregulate cytokines, chemokines or cell surface markers, deriving from normal human B cells or from myeloma or B cell leukemia, deriving from human plasmacytoid and myeloid dendritic cells, and readily activatable by TLR ligands such as TLR7 ligands, TLR8 ligands or TLR9 ligands such as CpG nucleic acids or nucleic acids having other immunostimulatory sequence motifs or small molecules such as imidazoquinoline compounds.

In some embodiments, the cell line is the Raji cell line which expresses TLR3, TLR7 and TLR9. This latter cell line secretes, for example, IL-6 and IFN- $\alpha$ 2 upon CpG nucleic acid exposure. In other embodiments, the cell line is RPMI 8226 which expresses TLR7 and TLR9. Upon CpG nucleic acid exposure, this cell line expresses, produces and/or secretes IL-8, IL-10, IP-10 and TNF- $\alpha$ . It also expresses at its cell surface CD86, HLA-DR and CD71. In yet other embodiments, the cell line is the RAMOS cell line which expresses TLR3, TLR7 and TLR9. This cell line at least induces CD80 cell surface expression in response to CpG nucleic acid exposure.

The cell lines have been observed to respond in a concentration dependent manner to TLR ligands such as but not limited to CpG nucleic acids and some non-CpG nucleic acids including T-rich nucleic acids, poly-T nucleic acids and poly-G nucleic acids. The highest responses have been observed using CpG nucleic acids.

5       The screening methods employ a variety of cell lines as shown in the Examples. These include A549 (human lung carcinoma, ATCC CCL-185), BeWo (human choriocarcinoma, ATCC CCL-98), HeLa (human cervix carcinoma, ATCC CCL-2), Hep-2 (human cervix carcinoma, ATCC CCL-23), KG-1 (human acute myeloid leukemia, ATCC CCL-246), MUTZ-3 (human acute myelomonocytic leukemia, German Collection of Cell  
10 lines and Microorganisms (DSZM) ACC-295), Nalm-6 (human B cell precursor leukemia, DSZM ACC-128), NK-92 (human Natural killer cell line, ATCC CRL-2407), NK-92 MI (IL-2 independent human Natural killer cell line, ATCC CRL-2408), Raji (human B lymphocyte Burkitt's lymphoma, ATCC CCL-86), RAMOS (B lymphocyte Burkitt's lymphoma, ATCC CRL-1596), RPMI 8226 (human B lymphocyte multiple myeloma, ATCC CCL-155), THP-1  
15 (human acute monocytic leukemia, ATCC TIB 202), U937 (human lymphoma, ATCC CRL-1593.2) and Jurkat (human T cell leukemia, ATCC TIB 152).

As shown in the Examples, each of the afore-mentioned cell lines has a particular endogenous TLR expression profile which dictates its suitability in a particular screening assay.

20       A cell that artificially expresses a functional TLR can be a cell that does not express the functional TLR but for a transfected TLR expression vector. For example, human 293 fibroblasts (ATCC CRL-1573) do not express TLR7, TLR8 or TLR9, and they express very little TLR3. As described in the examples below, such cells can be transiently or stably transfected with suitable expression vector (or vectors) so as to yield cells that do express  
25 TLR3, TLR7, TLR8, TLR9, or any combination thereof. Alternatively, a cell that artificially expresses a functional TLR can be a cell that expresses the functional TLR at a significantly higher level with the TLR expression vector than it does without the TLR expression vector. Transfected cells are considered modified cells, as used herein.

30       A cell that artificially expresses an expression or reporter construct is preferably stably transfected.

RPMI

The RPMI 8226 cell line is a human multiple myeloma cell line. The cell line was established from the peripheral blood of a 61 year old man at the time of diagnosis for multiple myeloma (IgG lambda type). RPMI 8226 was previously reported as responsive to CpG nucleic acids as evidenced by the production and secretion of IL-6 protein and production of IL-12p40 mRNA. (Takeshita et al. (2000), *Eur. J. Immunol.* 30, 108-116, and Takeshita et al. (2000) *Ibid.* 30, 1967-1976) Takeshita et al. however used the cell line solely to study promoter constructs in order to identify transcription factor binding sites important for CpG nucleic acid signaling. It is now known according to the invention that the cell line produces a number of other chemokines and cytokines including IL-8, IL-10 and IP-10. It has also been discovered according to the invention that the cell line responds to immunostimulatory nucleic acids by upregulating cell surface expression of particular markers. Many of these markers, including CD71, CD86 and HLA-DR, are similarly upregulated in PBMCs exposed to immunostimulatory nucleic acids. This has been observed using flow cytometric analysis of the cell line following CpG nucleic acid exposure. In other aspects of the invention, the cell line can be used in similar screening assays that involve secretion of IL-6, IL-12 and/or TNF- $\alpha$ .

It has recently been discovered that R-848 mediates its immunostimulatory effects via other TLR family members, namely TLR7 and TLR8. TLR7 has previously been found expressed on human B cells. It has now also been discovered according to the invention that RPMI 8226 expresses TLR9 as well as TLR7, thus making it a suitable cell line for identifying immunostimulatory nucleic acid and/or imidazoquinoline (e.g., R-848) mimics or other small molecules that also signal through TLR7 and/or TLR9. Incubation of RPMI 8226 cells with the imidazoquinoline R-848 (Resiquimod) induces for example IL-8, IL-10 and IP-10 production.

#### Known TLR Ligands

Ligands for many but not all of the TLRs have been described. For instance, it has been reported that TLR1 and TLR2 signals in response to peptidoglycan and lipopeptides. Yoshimura A et al. (1999) *J Immunol* 163:1-5; Brightbill HD et al. (1999) *Science* 285:732-6; Aliprantis AO et al. (1999) *Science* 285:736-9; Takeuchi O et al. (1999) *Immunity* 11:443-51; Underhill DM et al. (1999) *Nature* 401:811-5. TLR4 has been reported to signal in response to lipopolysaccharide (LPS). Hoshino K et al. (1999) *J Immunol* 162:3749-52; Poltorak A et al. (1998) *Science* 282:2085-8; Medzhitov R et al. (1997) *Nature* 388:394-7. Bacterial

flagellin has been reported to be a natural ligand for TLR5. Hayashi F et al. (2001) *Nature* 410:1099-1103. TLR6, in conjunction with TLR2, has been reported to signal in response to proteoglycan. Ozinsky A et al. (2000) *Proc Natl Acad Sci USA* 97:13766-71; Takeuchi O et al. (2001) *Int Immunol* 13:933-40.

5 TLR9 is a receptor for CpG DNA. Hemmi H et al. (2000) *Nature* 408:740-5. Other TLR9 ligands are described herein under "Immunostimulatory Nucleic Acids". Certain imidazoquinoline compounds having antiviral activity are ligands of TLR7 and TLR8. Imidazoquinolines are potent synthetic activators of immune cells with antiviral and antitumor properties. R-848 is a ligand for human TLR7 and TLR8. Jurk M et al. (2002) *Nat Immunol*  
10 3:499. Ligands of TLR3 include poly(I:C) and double-stranded RNA (dsRNA). Alexopoulou et al. (2001) *Nature* 413:732-738. For purposes of this invention, poly(I:C) and double-stranded RNA (dsRNA) are classified as oligonucleotide molecules. TLR3 may have a role in host defense against viruses.

#### 15 Reference and Test Compounds

A test and/or reference compound can be a nucleic acid such as an oligonucleotide or a polynucleotide, an oligopeptide, a polypeptide, a lipid such as a lipopolysaccharide, a carbohydrate such as an oligosaccharide or a polysaccharide, or a small molecule. Alternatively, these compounds may also comprise or be synthesized from elements such as  
20 amino acids, carbohydrates, hormones, lipids, organic molecules, and the like.

Small molecules in general include naturally occurring, synthetic, and semisynthetic organic and organometallic compounds with molecular weight less than about 2.5 kDa. Examples of small molecules include most drugs, subunits of polymeric materials, and analogs and derivatives thereof.

25 Some specific examples of small molecules include the imidazoquinolines. As used herein, an imidazoquinolines include imidazoquinoline amines (imidazoquinolinamines), imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2 bridged imidazoquinoline amines. These compounds have been described in U.S. Pat. Nos. 4,689,338; 4,929,624; 5,238,944; 5,266,575; 5,268,376; 5,346,905; 5,352,784; 5,389,640;  
30 5,395,937; 5,482,936; 5,494,916; 5,525,612; 6,039,969 and 6,110,929. Particular species of imidazoquinoline agents include resiquimod (R-848; S-28463; 4-amino-2 ethoxymethyl- $\alpha,\alpha$ -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol); and imiquimod (R-837; S-26308; 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinoline-4-amine). Further examples of specific small

molecules include 4-aminoquinoline and derivatives thereof, 9-aminoacridine and derivatives thereof, and additional compounds disclosed in U.S. Pat. Nos. 6,221,882; 6,399,630; 6,479,504; and 6,521,637; and published U.S. Pat. Application No. 2002/0151564 A1, the entire contents of which are hereby incorporated by reference.

5           The test and reference compounds may be formulated for pharmaceutical use or not. For example, a test compound not formulated for pharmaceutical use can be a compound (e.g., a lot or batch of the compound) under evaluation for possible use in preparing a pharmaceutical formulation of the compound.

10           A reference compound, as used herein, is a compound having a known activity in the presence of a TLR. The reference compound may stimulate TLR signaling (and is therefore regarded as a positive reference compound), or it may be inert in the presence of a TLR (and is therefore regarded as a negative reference compound). If it is a positive reference compound, it need not be the best known stimulator of TLR signaling (i.e., it is possible that other reference compounds and even test compounds will stimulate TLR signaling to a greater extent). The readout of the screening assay may simply be stated relative to the level of signaling that occurs in the presence of the reference compound. Preferably, the reference compound is analyzed prior to the screening assay in order to determine its level of activity on a TLR. In some aspects of the invention, the reference compound and the test compound will be assayed separately (i.e., in separate wells); in other aspects, the reference compound and the test compound will be assayed together (i.e., in the same well). These latter aspects are designed to measure the ability of a test compound to modulate the activity of the reference compound. The activity of the test compound and the reference compound combined (i.e., when assayed together in the same well) may be the same as that of the positive reference compound alone, indicating at a minimum that the test compound is not inhibitory; or it may be less than that of the positive reference compound, indicating at a minimum that it is inhibitory to the effect of the reference compound; or it may be additive or synergistic possibly indicating that the test compound is an enhancer. The effect of an enhance may be due to its ability to stimulate TLR signaling independently of the positive reference compound.

30           A "reference composition" as used herein refers to a composition that includes a reference compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A reference compound may be an immunostimulatory compound or it may be an immunoinhibitory compound.

As discussed further below, in some aspects of the invention the reference compositions include both finished products, e.g., finished pharmaceutical products, as well as raw materials and other in-process materials used for the preparation of such finished products, all of which contain a known TLR ligand. As used herein, a "production lot" shall refer to a batch or lot of a completed product prepared for release as clinical material, e.g., a pharmaceutical product. As used herein, an "in-process lot" shall refer to a batch or lot of unfinished product that is prepared in the course of making a production lot; an "in-process lot" shall also refer to a batch or lot of raw material provided for use in the production of a production lot.

10 In some aspects of the invention, the reference compositions of the invention are highly characterized in terms of their chemical, physical, and biological properties. A reference composition will be a specific composition previously determined to have a specific activity, or range of specific activity, of the particular known TLR ligand present in the composition. As used herein, "specific activity" refers to an amount of activity per unit mass  
15 or per unit volume of the reference composition as a whole, as determined using a defined assay under defined conditions. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR  
20 ligand at a determined concentration or activity.

At least the following parameters are typically very well defined for a given reference composition: chemical formula of the active ingredient TLR ligand (e.g., nucleobase sequence and type of backbone of a nucleic acid; structural formula of a small molecule); concentration; diluent composition; and purity. Such parameters as purity and concentration  
25 can be determined using any appropriate physicochemical method, e.g., optical spectroscopy including absorbance at one or more specified wavelengths; nuclear magnetic resonance (NMR) spectroscopy; mass spectrometry (MS), including matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS); melting point; specific gravity; chromatography including as appropriate high pressure liquid chromatography (HPLC), one-  
30 and two-dimensional polyacrylamide gel electrophoresis (PAGE), capillary electrophoresis, and the like; as well as other methods known to those of skill in the art.

Reference compositions can also be very well characterized in terms of their biological activity, independent of the methods of the invention, although the methods of the

- 34 -

invention generally include such characterization, at least in part. A reference composition can be very well characterized in terms of its biological activity by characterizing, both qualitatively and quantitatively, the response by sensitive cells to the reference composition under defined conditions. For example, a reference composition can be a specific CpG oligonucleotide such as SEQ ID NO:1 which in a specific assay and under specific conditions of temperature, concentration, duration of contact between the CpG oligonucleotide and a population of TLR9-expressing cells, and particular readout, reliably yields a specific result or range of results. Results can be expressed in any suitable manner, but can include results expressed on a per-cell basis, e.g., picograms of particular cytokine per cell per hour of contact with the reference composition. Reference compositions can be very well characterized in terms of their biological activity according to one or more parameters, for example, according to their capacity to induce each of a plurality of cytokines.

The methods of the invention also involve measurement of a test activity of a test composition containing a known TLR ligand. A "test composition" as used herein refers to a composition that includes a test compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A test compound can be an immunostimulatory compound or it can be an immunoinhibitory compound. In some aspects of the invention, the test compound is a known TLR ligand. Test compositions of the invention may comprise known TLR agonist or TLR antagonist compounds, generally but not necessarily nominally the same as the reference compositions against which comparison is to be made according to some aspects of the invention. Thus test compositions may encompass immunostimulatory compounds, immunoinhibitory compounds, known TLR ligands, finished pharmaceutical products, and raw materials and other in-process materials used for the preparation of such finished products.

Unlike a reference composition, a test composition is not characterized at all, or is only partially characterized, or is not as well characterized as the reference composition, in terms of its chemical, physical, or (most particularly) biological properties. The methods of the invention permit further characterization of the test composition by comparison with a reference composition. In some aspects, a test composition will be a specific composition previously determined to be a ligand of a specific TLR. In one embodiment the test composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the test composition is a representative sample of a particular lot or batch of



a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR ligand at a determined concentration or activity.

#### Immunostimulatory and Immunoinhibitory Nucleic Acids

5 Nucleic acids useful as reference compounds and as test compounds in the methods of the invention include single- and double-stranded natural and synthetic nucleic acids, including those with phosphodiester, stabilized, and chimeric backbones. Also encompassed are at least the following classes of nucleic acids, which are described in detail below: immunostimulatory CpG nucleic acids (CpG nucleic acids), including but not limited to types  
10 A, B, and C; immunostimulatory non-CpG nucleic acids, including without limitation methylated CpG nucleic acids, T-rich nucleic acids, TG-motif nucleic acids, CpI motif nucleic acids, and poly-G nucleic acids; and immunoinhibitory nucleic acids. Nucleic acids useful as reference compounds and as test compounds in the methods of the invention also include nucleic acids with modified backbones, including "soft" and "semi-soft" oligonucleotides as  
15 described herein. As will be appreciated from the descriptions below, certain of these various classes of nucleic acids can coexist in a given nucleic acid molecule.

A "nucleic acid" as used herein with respect to test compounds and reference compounds used in the methods of the invention, shall refer to any polymer of two or more individual nucleoside or nucleotide units. Typically individual nucleoside or nucleotide units  
20 will include any one or combination of deoxyribonucleosides, ribonucleosides, deoxyribonucleotides, and ribonucleotides. The individual nucleotide or nucleoside units of the nucleic acid can be naturally occurring or not naturally occurring. For example, the individual nucleotide units can include deoxyadenosine, deoxycytidine, deoxyguanosine, thymidine, and uracil. In addition to naturally occurring 2'-deoxy and 2'-hydroxyl forms,  
25 individual nucleosides also include synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g., as described in Uhlmann E et al. (1990) *Chem Rev* 90:543-84. The linkages between individual nucleotide or nucleoside units can be naturally occurring or not naturally occurring. For example, the linkages can be phosphodiester, phosphorothioate, phosphorodithioate, phosphoramidate, as well as peptide linkages and other  
30 covalent linkages, known in the art, suitable for joining adjacent nucleoside or nucleotide units. The linkages can also be mixed in a single polymer (e.g., a semi-soft backbone). The nucleic acid test compounds and nucleic acid reference compounds typically range in size from 3-4 units to a few tens of units, e.g., 18-40 units.

In some embodiments the nucleic acids are oligonucleotides made up of 2 to about 100 nucleotides, and more typically 4 to about 40 nucleotides. Oligonucleotides composed exclusively of deoxynucleotides are termed oligodeoxyribonucleotides or, equivalently, oligodeoxynucleotides (ODN).

5 A CpG nucleic acid is an immunostimulatory nucleic acid which contains a cytosine-guanine (CG) dinucleotide, the C residue of which is unmethylated. The effects of CpG nucleic acids on immune modulation have been described extensively in U.S. Pat. Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068; and published patent applications, such as PCT/US95/01570 (WO 96/02555); PCT/US98/04703 (WO 98/40100);  
10 and PCT/US99/09863 (WO 99/56755). The entire contents of each of these patents and published patent applications is hereby incorporated by reference. The entire immunostimulatory nucleic acid can be unmethylated or portions can be unmethylated, but at least the C of the 5'-CG-3' must be unmethylated. The CpG nucleic acid sequences of the invention include, without limitation, those broadly described above as well as those disclosed  
15 in U.S. Pat. Nos. 6,207,646 and 6,239,116.

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTGTCGTTTTGTCGTT-3' (SEQ ID NO:1).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTGACGTTTTGTCGTT-3' (SEQ ID NO:139).

20 In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTGTCGTTTTTTTCGA-3' (SEQ ID NO:140).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTCGTCGTTTCGTCGTT-3' (SEQ ID NO:141).

In one embodiment the CpG nucleic acid has a base sequence provided by  
25 5'-TCGTCGTTTTCGTCGTTTTGTCGTT-3' (SEQ ID NO:142).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTTCGGTCGTTTT-3' (SEQ ID NO:143).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTTCGTGCGTTTT-3' (SEQ ID NO:144).

30 In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTCGGCGGCCGCG-3' (SEQ ID NO:145).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTC\_GTTTTAC\_GGCGCC\_GTGCCG-3' (SEQ ID NO:146).

The oligonucleotides described by SEQ ID NOs: 1, 139-145 are fully stabilized phosphorothioate backbone ODN. The oligonucleotide of SEQ ID NO:146 has a chimeric backbone in which all internucleoside linkages are phosphorothioate except for those indicated by “\_”, which are phosphodiester.

5 CpG nucleic acids have been further classified by structure and function into at least the following three types, all of which are intended to be encompassed within the methods of the instant invention: Type B CpG nucleic acids such as SEQ ID NO:1 include the earliest described CpG nucleic acids and characteristically activate B cells but do not induce or only weakly induce expression of IFN- $\alpha$ . Type B nucleic acids are described in U.S. Patents  
10 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068. Type A CpG nucleic acids, described in published international application PCT/US00/26527 (WO 01/22990), incorporate a CpG motif, include a hybrid phosphodiester/phosphorothioate backbone, and characteristically induce plasmacytoid dendritic cells to express large amounts of IFN- $\alpha$  but do not activate or only weakly activate B cells. Type C oligonucleotides incorporate a CpG,  
15 include a chimeric backbone, include a GC-rich palindromic or nearly-palindromic region, and are capable of both activating B cells and inducing expression of IFN- $\alpha$ . These have been described, for example, in copending U.S. Pat. application Ser. No. 10/224,523, filed August 19, 2002. Exemplary sequences of A, B and C class nucleic acids are described in the afore-mentioned references, patents and patent applications, the entire contents of which are  
20 hereby incorporated by reference herein.

In other embodiments of the invention, a non-CpG nucleic acid is used. A non-CpG nucleic acid is an immunostimulatory nucleic acid which either does not have a CpG motif in its sequence, or has a CpG motif which contains a methylated C residue. In some instances, the non-CpG nucleic acid may still be immunostimulatory by virtue of its having other  
25 immunostimulatory motifs such as those described herein and known in the art. In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid. In some instances the non-CpG nucleic acid is still immunostimulatory despite methylation of the C of the CpG motif, even without having another non-CpG immunostimulatory motif described herein and known in the art.

30 In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGTTTTGTZGTTTTGTZGTT-3' (SEQ ID NO:147), wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGZTGTZTZZGZTTZTTZTTGZZ-3' (SEQ ID NO:148), wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having  
5 a base sequence provided by 5'-GZGTTTGZTZTTZTTZTTGZG-3' (SEQ ID NO:149),  
wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-GZZZAAGZTGGZATZZGTZA-3' (SEQ ID NO:150), wherein Z represents 5-methylcytosine.

10 Non-CpG nucleic acids include T-rich immunostimulatory nucleic acids. The T-rich immunostimulatory nucleic acids include those disclosed in published PCT patent application PCT/US00/26383 (WO 01/22972), the entire contents of which are incorporated herein by reference. In some embodiments, T-rich nucleic acids 24 bases in length are used. A T-rich nucleic acid is a nucleic acid which includes at least one poly T sequence and/or which has  
15 a nucleotide composition of greater than 25% T nucleotide residues. A nucleic acid having a poly-T sequence includes at least four Ts in a row, such as 5'-TTTT-3'. In some embodiments the T-rich nucleic acid includes more than one poly T sequence. In important embodiments, the T-rich nucleic acid may have 2, 3, 4, or more poly T sequences, such as SEQ ID NO:1.

Non-CpG nucleic acids also include poly-G immunostimulatory nucleic acids. A  
20 variety of references describe the immunostimulatory properties of poly-G nucleic acids. Pisetsky DS et al. (1993) *Mol Biol Reports* 18:217-221; Krieger M et al. (1994) *Ann Rev Biochem* 63:601-637; Macaya RF et al. (1993) *Proc Natl Acad Sci USA* 90:3745-3749; Wyatt JR et al. (1994) *Proc Natl Acad Sci USA* 91:1356-1360; Rando and Hogan, 1998, In *Applied Antisense Oligonucleotide Technology*, Krieg and Stein, eds., pp. 335-352; Kimura Y et al.  
25 (1994) *J Biochem (Tokyo)* 116:991-994.

The immunostimulatory nucleic acids of the invention can also be those which do not possess CpG, methylated CpG, T-rich, or poly-G motifs.

Exemplary immunostimulatory nucleic acid sequences include but are not limited to those immunostimulatory sequences described and listed in U.S. Non-Provisional Pat.  
30 Application No. 09/669,187, filed on September 25, 2000, and in corresponding published PCT patent application PCT/US00/26383 (WO 01/22972).

Immunoinhibitory nucleic acids have been described in Lenert P et al. (2001) *Antisense Nucleic Acid Drug Dev* 11:247-56 and in Stunz L et al. (2002) *Eur J Immunol*

- 39 -

32:1212-22. These inhibitory phosphorothioate ODN (S-ODN) differ from stimulatory S-ODN by having 2-3 G substitutions in the central motif. As inhibitory S-ODN did not directly interfere with the NF- $\kappa$ B DNA binding but prevented CpG-induced NF- $\kappa$ B nuclear translocation of p50, p65, and c-Rel and blocked p105, I $\kappa$ B $\alpha$ , and I $\kappa$ B $\beta$  degradation, Lenert et al. suggested that the putative target of immunoinhibitory ODN would lie upstream of inhibitory kinase (IKK) activation. Stunz et al. reported that replacing GCGTT or ACGTT with GCGGG or ACGGG converted a stimulatory 15-mer ODN into an inhibitory ODN. All inhibitory ODN had three consecutive G, and a fourth G increased inhibitory activity, but a deazaguanosine substitution to prevent planar stacking did not affect activity. Inhibitory ODN blocked apoptosis protection and cell-cycle entry induced by stimulatory ODN, but not that induced by lipopolysaccharide, anti-CD40 or anti-IgM+IL-4. ODN-driven up-regulation of cyclin D(2), c-Myc, c-Fos, c-Jun and Bcl(XL) and down-regulation of cyclin kinase inhibitor p27(kip1) were all blocked by inhibitory ODN. Stunz et al. also reported that interference with uptake of stimulatory ODN did not account for the inhibitory effects of the immunoinhibitory nucleic acids.

In one embodiment the immunoinhibitory nucleic acid has a base sequence provided by 5'-TCCTGGCGGGGAAGT-3' (SEQ ID NO:151).

Immunoinhibitory nucleic acids have also been described in U.S. Pat. No. 6,194,388, issued to Krieg et al. The immunoinhibitory oligonucleotides disclosed by Krieg et al. are oligonucleotides with GCG trinucleotides at or near the ends of the oligonucleotide and are represented by the formula 5' GCGX<sub>n</sub>GCG 3' in which X is a nucleotide and n is an integer between 0 and 50.

The nucleic acids used as either test or reference compounds can be double-stranded or single-stranded. They can be deoxyribonucleotide (DNA) or ribonucleotide (RNA) molecules. Generally, double-stranded molecules are more stable in vivo, while single-stranded molecules have increased immune activity. Thus in some the nucleic acid is single-stranded and in other embodiments the nucleic acid is double-stranded. In certain embodiments, while the nucleic acid is single-stranded, it is capable of forming secondary and tertiary structures (e.g., by folding back on itself, or by hybridizing with itself either throughout its entirety or at select segments along its length). Accordingly, while the primary structure of such a nucleic acid may be single-stranded, its higher order structures may be double- or triple-stranded.

For facilitating uptake into cells, the nucleic acids are preferably in the range of 6 to 100 bases in length. However, nucleic acids of any size equal to or greater than 6 nucleotides (even many kb long) are capable of inducing an immune response. Preferably the nucleic acid is in the range of between 8 and 100 and in some embodiments between 8 and 50 or 8 and 30 nucleotides in size.

The terms "nucleic acid" and "oligonucleotide" are used interchangeably to mean multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)). As used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms "nucleic acid" and "oligonucleotide" shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g., genomic or cDNA), but are preferably synthetic (e.g., produced by nucleic acid synthesis).

The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with substitutions or modifications, such as in the bases and/or sugars. For example, they include nucleic acids having backbone sugars that are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other than a phosphate group or hydroxy group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose or 2'-fluoroarabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have an amino acid backbone with nucleic acid bases). Other examples are described in more detail below.

The immunostimulatory and immunoinhibitory nucleic acids can encompass various chemical modifications and substitutions, in comparison to natural RNA and DNA, involving a phosphodiester internucleoside bridge, a  $\beta$ -D-ribose unit and/or a natural nucleoside base (adenine, guanine, cytosine, thymine, uracil). Examples of chemical modifications are known to the skilled person and are described, for example, in Uhlmann E et al. (1990) *Chem Rev* 90:543; "Protocols for Oligonucleotides and Analogs" Synthesis and Properties & Synthesis and Analytical Techniques, S. Agrawal, Ed, Humana Press, Totowa, USA 1993; Crooke ST et al. (1996) *Annu Rev Pharmacol Toxicol* 36:107-129; and Hunziker J et al. (1995) *Mod Synth*

*Methods* 7:331-417. An oligonucleotide according to the invention may have one or more modifications, wherein each modification is located at a particular phosphodiester internucleoside bridge and/or at a particular  $\beta$ -D-ribose unit and/or at a particular natural nucleoside base position in comparison to an oligonucleotide of the same sequence which is composed of natural DNA or RNA.

For example, the oligonucleotides may comprise one or more modifications and wherein each modification is independently selected from:

- a) the replacement of a phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside by a modified internucleoside bridge,
- 10 b) the replacement of phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge,
- c) the replacement of a sugar phosphate unit from the sugar phosphate backbone by another unit,
- d) the replacement of a  $\beta$ -D-ribose unit by a modified sugar unit, and
- 15 e) the replacement of a natural nucleoside base by a modified nucleoside base.

More detailed examples for the chemical modification of an oligonucleotide are as follows.

The oligonucleotides may include modified internucleotide linkages, such as those described in (a) or (b) above. These modified linkages may be partially resistant to degradation (e.g., are stabilized). A "stabilized oligonucleotide molecule" shall mean an oligonucleotide that is relatively resistant to *in vivo* degradation (e.g., via an exo- or endonuclease) resulting from such modifications. Oligonucleotides having phosphorothioate linkages, in some embodiments, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases.

25 A phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside can be replaced by a modified internucleoside bridge, wherein the modified internucleoside bridge is for example selected from phosphorothioate, phosphorodithioate,  $\text{NR}^1\text{R}^2$ -phosphoramidate, boranophosphate,  $\alpha$ -hydroxybenzyl phosphonate, phosphate-( $\text{C}_1$ - $\text{C}_{21}$ )-O-alkyl ester, phosphate-[( $\text{C}_6$ - $\text{C}_{12}$ )aryl-( $\text{C}_1$ - $\text{C}_{21}$ )-O-alkyl]ester, ( $\text{C}_1$ - $\text{C}_8$ )alkylphosphonate and/or ( $\text{C}_6$ - $\text{C}_{12}$ )arylphosphonate bridges, ( $\text{C}_7$ - $\text{C}_{12}$ )- $\alpha$ -hydroxymethyl-aryl (e.g., disclosed in WO 95/01363), wherein ( $\text{C}_6$ - $\text{C}_{12}$ )aryl, ( $\text{C}_6$ - $\text{C}_{20}$ )aryl and ( $\text{C}_6$ - $\text{C}_{14}$ )aryl are optionally substituted by halogen, alkyl, alkoxy, nitro, cyano, and where  $\text{R}^1$  and  $\text{R}^2$  are, independently of each other, hydrogen, ( $\text{C}_1$ - $\text{C}_{18}$ )-alkyl, ( $\text{C}_6$ - $\text{C}_{20}$ )-aryl, ( $\text{C}_6$ - $\text{C}_{14}$ )-aryl-( $\text{C}_1$ - $\text{C}_8$ )-alkyl, preferably hydrogen,

(C<sub>1</sub>-C<sub>8</sub>)-alkyl, preferably (C<sub>1</sub>-C<sub>4</sub>)-alkyl and/or methoxyethyl, or R<sup>1</sup> and R<sup>2</sup> form, together with the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain a further heteroatom from the group O, S and N.

The replacement of a phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge (dephospho bridges are described, for example, in Uhlmann E and Peyman A in "Methods in Molecular Biology", Vol. 20, "Protocols for Oligonucleotides and Analogs", S. Agrawal, Ed., Humana Press, Totowa, 1993, Chapter 16, pp. 355 ff), wherein a dephospho bridge is for example selected from the dephospho bridges formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethyl-hydrazo, dimethylenesulfone and/or silyl groups.

A sugar phosphate unit (i.e., a  $\beta$ -D-ribose and phosphodiester internucleoside bridge together forming a sugar phosphate unit) from the sugar phosphate backbone (i.e., a sugar phosphate backbone is composed of sugar phosphate units) can be replaced by another unit, wherein the other unit is for example suitable to build up a "morpholino-derivative" oligomer (as described, for example, in Stirchak EP et al. (1989) *Nucleic Acids Res* 17:6129-41), that is, e.g., the replacement by a morpholino-derivative unit; or to build up a polyamide nucleic acid ("PNA"; as described for example, in Nielsen PE et al. (1994) *Bioconjug Chem* 5:3-7), that is, e.g., the replacement by a PNA backbone unit, e.g., by 2-aminoethylglycine. The oligonucleotide may have other carbohydrate backbone modifications and replacements, such as peptide nucleic acids with phosphate groups (PHONA), locked nucleic acids (LNA), and oligonucleotides having backbone sections with alkyl linkers or amino linkers. The alkyl linker may be branched or unbranched, substituted or unsubstituted, and chirally pure or a racemic mixture.

A  $\beta$ -ribose unit or a  $\beta$ -D-2'-deoxyribose unit can be replaced by a modified sugar unit, wherein the modified sugar unit is for example selected from  $\beta$ -D-ribose,  $\alpha$ -D-2'-deoxyribose, L-2'-deoxyribose, 2'-F-2'-deoxyribose, 2'-F-arabinose, 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose, preferably 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose is 2'-O-methylribose, 2'-O-(C<sub>2</sub>-C<sub>6</sub>)alkenyl-ribose, 2'-[O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl]-ribose, 2'-NH<sub>2</sub>-2'-deoxyribose,  $\beta$ -D-xylo-furanose,  $\alpha$ -arabinofuranose, 2,4-dideoxy- $\beta$ -D-erythro-hexo-pyranose, and carbocyclic (described, for example, in Froehler J (1992) *Am Chem Soc* 114:8320) and/or open-chain sugar analogs (described, for example, in Vandendriessche et al. (1993) *Tetrahedron* 49:7223) and/or bicyclosugar analogs (described, for example, in Tarkov M et al. (1993) *Helv Chim Acta* 76:481).



In some embodiments the sugar is 2'-O-methylribose, particularly for one or both nucleotides linked by a phosphodiester or phosphodiester-like internucleoside linkage.

In some embodiments, the nucleic acids may be soft or semi-soft nucleic acids. A soft nucleic acid is an immunostimulatory nucleic acid having a partially stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages occur only within and immediately adjacent to at least one internal pyrimidine-purine dinucleotide (YZ). Preferably YZ is YG, a pyrimidine-guanosine (YG) dinucleotide. The at least one internal YZ dinucleotide itself has a phosphodiester or phosphodiester-like internucleotide linkage. A phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide can be 5', 3', or both 5' and 3' to the at least one internal YZ dinucleotide.

In particular, phosphodiester or phosphodiester-like internucleotide linkages involve "internal dinucleotides". An internal dinucleotide in general shall mean any pair of adjacent nucleotides connected by an internucleotide linkage, in which neither nucleotide in the pair of nucleotides is a terminal nucleotide, i.e., neither nucleotide in the pair of nucleotides is a nucleotide defining the 5' or 3' end of the nucleic acid. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 dinucleotides and only n-3 internal dinucleotides. Each internucleotide linkage in an internal dinucleotide is an internal internucleotide linkage. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 internucleotide linkages and only n-3 internal internucleotide linkages. The strategically placed phosphodiester or phosphodiester-like internucleotide linkages, therefore, refer to phosphodiester or phosphodiester-like internucleotide linkages positioned between any pair of nucleotides in the nucleic acid sequence. In some embodiments the phosphodiester or phosphodiester-like internucleotide linkages are not positioned between either pair of nucleotides closest to the 5' or 3' end.

Preferably a phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide is itself an internal internucleotide linkage. Thus for a sequence  $N_1$  YZ  $N_2$ , wherein  $N_1$  and  $N_2$  are each, independent of the other, any single nucleotide, the YZ dinucleotide has a phosphodiester or phosphodiester-like internucleotide linkage, and in addition (a)  $N_1$  and Y are linked by a phosphodiester or phosphodiester-like internucleotide linkage when  $N_1$  is an internal nucleotide, (b) Z and  $N_2$  are linked by a phosphodiester or phosphodiester-like internucleotide linkage when  $N_2$  is an internal nucleotide, or (c)  $N_1$  and Y are linked by a phosphodiester or

phosphodiester-like internucleotide linkage when  $N_1$  is an internal nucleotide and Z and  $N_2$  are linked by a phosphodiester or phosphodiester-like internucleotide linkage when  $N_2$  is an internal nucleotide.

Soft nucleic acids according to the instant invention are believed to be relatively  
5 susceptible to nuclease cleavage compared to completely stabilized nucleic acids. Without meaning to be bound to a particular theory or mechanism, it is believed that soft nucleic acids of the invention are cleavable to fragments with reduced or no immunostimulatory activity relative to full-length soft nucleic acids. Incorporation of at least one nuclease-sensitive  
internucleotide linkage, particularly near the middle of the nucleic acid, is believed to provide  
10 an "off switch" which alters the pharmacokinetics of the nucleic acid so as to reduce the duration of maximal immunostimulatory activity of the nucleic acid. This can be of particular value in tissues and in clinical applications in which it is desirable to avoid injury related to chronic local inflammation or immunostimulation, e.g., the kidney.

A semi-soft nucleic acid is an immunostimulatory nucleic acid having a partially  
15 stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages occur only within at least one internal pyrimidine-purine (YZ) dinucleotide. Semi-soft nucleic acids generally possess increased immunostimulatory potency relative to corresponding fully stabilized immunostimulatory nucleic acids. Due to the greater potency of semi-soft nucleic acids, semi-soft nucleic acids may be used, in some instances, at lower  
20 effective concentrations and have lower effective doses than conventional fully stabilized immunostimulatory nucleic acids in order to achieve a desired biological effect.

It is believed that the foregoing properties of semi-soft nucleic acids generally increase with increasing "dose" of phosphodiester or phosphodiester-like internucleotide linkages involving internal YZ dinucleotides. Thus it is believed, for example, that generally for a  
25 given nucleic acid sequence with five internal YZ dinucleotides, a nucleic acid with five internal phosphodiester or phosphodiester-like YZ internucleotide linkages is more immunostimulatory than a nucleic acid with four internal phosphodiester or phosphodiester-like YG internucleotide linkages, which in turn is more immunostimulatory than a nucleic acid with three internal phosphodiester or phosphodiester-like YZ internucleotide linkages,  
30 which in turn is more immunostimulatory than a nucleic acid with two internal phosphodiester or phosphodiester-like YZ internucleotide linkages, which in turn is more immunostimulatory than a nucleic acid with one internal phosphodiester or phosphodiester-like YZ internucleotide linkage. Importantly, inclusion of even one internal phosphodiester or

phosphodiester-like YZ internucleotide linkage is believed to be advantageous over no internal phosphodiester or phosphodiester-like YZ internucleotide linkage. In addition to the number of phosphodiester or phosphodiester-like internucleotide linkages, the position along the length of the nucleic acid can also affect potency.

5       The soft and semi-soft nucleic acids will generally include, in addition to the phosphodiester or phosphodiester-like internucleotide linkages at preferred internal positions, 5' and 3' ends that are resistant to degradation. Such degradation-resistant ends can involve any suitable modification that results in an increased resistance against exonuclease digestion over corresponding unmodified ends. For instance, the 5' and 3' ends can be stabilized by the  
10       inclusion thereof at least one phosphate modification of the backbone. In a preferred embodiment, the at least one phosphate modification of the backbone at each end is independently a phosphorothioate, phosphorodithioate, methylphosphonate, or methylphosphorothioate internucleotide linkage. In another embodiment, the degradation-resistant end includes one or more nucleotide units connected by peptide or amide linkages at  
15       the 3' end.

A phosphodiester internucleotide linkage is the type of linkage characteristic of nucleic acids found in nature. The phosphodiester internucleotide linkage includes a phosphorus atom flanked by two bridging oxygen atoms and bound also by two additional oxygen atoms, one charged and the other uncharged. Phosphodiester internucleotide linkage  
20       is particularly preferred when it is important to reduce the tissue half-life of the nucleic acid.

A phosphodiester-like internucleotide linkage is a phosphorus-containing bridging group that is chemically and/or diastereomerically similar to phosphodiester. Measures of similarity to phosphodiester include susceptibility to nuclease digestion and ability to activate RNAse H. Thus for example phosphodiester, but not phosphorothioate, nucleic acids are  
25       susceptible to nuclease digestion, while both phosphodiester and phosphorothioate nucleic acids activate RNAse H. In a preferred embodiment the phosphodiester-like internucleotide linkage is boranophosphate (or equivalently, boranophosphonate) linkage. U.S. Patent No. 5,177,198; U.S. Patent No. 5,859,231; U.S. Patent No. 6,160,109; U.S. Patent No. 6,207,819; Sergueev et al., (1998) *J Am Chem Soc* 120:9417-27. In another preferred embodiment the  
30       phosphodiester-like internucleotide linkage is diastereomerically pure Rp phosphorothioate. It is believed that diastereomerically pure Rp phosphorothioate is more susceptible to nuclease digestion and is better at activating RNAse H than mixed or diastereomerically pure Sp phosphorothioate. Stereoisomers of CpG nucleic acids are the subject of co-pending U.S.

patent application 09/361,575 filed July 27, 1999, and published PCT application PCT/US99/17100 (WO 00/06588). It is to be noted that for purposes of the instant invention, the term "phosphodiester-like internucleotide linkage" specifically excludes phosphorodithioate and methylphosphonate internucleotide linkages.

- 5 As described above the soft and semi-soft nucleic acids of the invention may have phosphodiester like linkages between C and G. One example of a phosphodiester-like linkage is a phosphorothioate linkage in an  $R_p$  conformation. Nucleic acid p-chirality can have apparently opposite effects on the immune activity of a CpG nucleic acid, depending upon the time point at which activity is measured. At an early time point of 40 minutes, the  $R_p$  but not
- 10 the  $S_p$  stereoisomer of phosphorothioate CpG nucleic acid induces JNK phosphorylation in mouse spleen cells. In contrast, when assayed at a late time point of 44 hr, the  $S_p$  but not the  $R_p$  stereoisomer is active in stimulating spleen cell proliferation. This difference in the kinetics and bioactivity of the  $R_p$  and  $S_p$  stereoisomers does not result from any difference in cell uptake, but rather most likely is due to two opposing biologic roles of the p-chirality.
- 15 First, the enhanced activity of the  $R_p$  stereoisomer compared to the  $S_p$  for stimulating immune cells at early time points indicates that the  $R_p$  may be more effective at interacting with the CpG receptor, TLR9, or inducing the downstream signaling pathways. On the other hand, the faster degradation of the  $R_p$  PS-nucleic acids compared to the  $S_p$  results in a much shorter duration of signaling, so that the  $S_p$  PS-nucleic acids appear to be more biologically
- 20 active when tested at later time points.

A surprisingly strong effect is achieved by the p-chirality at the CpG dinucleotide itself. In comparison to a stereo-random CpG nucleic acid the congener in which the single CpG dinucleotide was linked in  $R_p$  was slightly more active, while the congener containing an  $S_p$  linkage was nearly inactive for inducing spleen cell proliferation.

- 25 Nucleic acids also include substituted purines and pyrimidines such as C-5 propyne pyrimidine and 7-deaza-7-substituted purine modified bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, and thymine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

- 30 A modified base is any base which is chemically distinct from the naturally occurring bases typically found in DNA and RNA such as T, C, G, A, and U, but which share basic chemical structures with these naturally occurring bases. The modified nucleoside base may be, for example, selected from hypoxanthine, uracil, dihydrouracil, pseudouracil, 2-thiouracil,

- 47 -

4-thiouracil, 5-aminouracil, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine, 5-bromocytosine, N<sup>2</sup>-dimethylguanine, 2,4-diamino-purine, 8-azapurine, a substituted 7-deazapurine, preferably 7-deaza-7-substituted and/or 7-deaza-8-substituted purine, 5-hydroxymethylcytosine, N4-alkylcytosine, e.g., N4-ethylcytosine, 5-hydroxydeoxycytidine, 5-hydroxymethyldeoxycytidine, N4-alkyldeoxycytidine, e.g., N4-ethyldeoxycytidine, 6-thiodeoxyguanosine, and deoxyribonucleosides of nitropyrrole, C5-propynylpyrimidine, and diaminopurine e.g., 2,6-diaminopurine, inosine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, hypoxanthine or other modifications of a natural nucleoside bases. This list is meant to be exemplary and is not to be interpreted to be limiting.

Modified cytosines include but are not limited to 5-substituted cytosines (e.g., 5-methyl-cytosine, 5-fluoro-cytosine, 5-chloro-cytosine, 5-bromo-cytosine, 5-iodo-cytosine, 5-hydroxy-cytosine, 5-hydroxymethyl-cytosine, 5-difluoromethyl-cytosine, and unsubstituted or substituted 5-alkynyl-cytosine), 6-substituted cytosines, N4-substituted cytosines (e.g., N4-ethyl-cytosine), 5-aza-cytosine, 2-mercapto-cytosine, isocytosine, pseudo-isocytosine, cytosine analogs with condensed ring systems (e.g., N,N'-propylene cytosine or phenoxazine), and uracil and its derivatives (e.g., 5-fluoro-uracil, 5-bromo-uracil, 5-bromovinyl-uracil, 4-thio-uracil, 5-hydroxy-uracil, 5-propynyl-uracil). In another embodiment, the cytosine base is substituted by a universal base (e.g., 3-nitropyrrole, P-base), an aromatic ring system (e.g., fluorobenzene or difluorobenzene) or a hydrogen atom (dSpacer).

Modified guanines include but are not limited to 7-deazaguanine, 7-deaza-7-substituted guanine (such as 7-deaza-7-(C<sub>2</sub>-C<sub>6</sub>)alkynylguanine), 7-deaza-8-substituted guanine, hypoxanthine, N2-substituted guanines (e.g., N2-methyl-guanine), 5-amino-3-methyl-3H,6H-thiazolo[4,5-d]pyrimidine-2,7-dione, 2,6-diaminopurine, 2-aminopurine, purine, indole, adenine, substituted adenines (e.g., N6-methyl-adenine, 8-oxo-adenine) 8-substituted guanine (e.g., 8-hydroxyguanine and 8-bromoguanine), and 6-thioguanine. In another embodiment, the guanine base is substituted by a universal base (e.g., 4-methyl-indole, 5-nitro-indole, and K-base), an aromatic ring system (e.g., benzimidazole or dichloro-benzimidazole, 1-methyl-1H-[1,2,4]triazole-3-carboxylic acid amide) or a hydrogen atom (dSpacer).

For use in the instant invention, the oligonucleotide reference compounds and test compounds can be synthesized *de novo* using any of a number of procedures well known in the art, for example, the  $\beta$ -cyanoethyl phosphoramidite method (Beaucage SL et al. (1981) *Tetrahedron Lett* 22:1859), or the nucleoside H-phosphonate method (Garegg et al. (1986) *Tetrahedron Lett* 27:4051-4; Froehler BC et al. (1986) *Nucleic Acids Res* 14:5399-407; Garegg et al (1986) *Tetrahedron Lett* 27:4055-8; Gaffney et al. (1988) *Tetrahedron Lett* 29:2619-22). These chemistries can be performed by a variety of automated nucleic acid synthesizers available in the market. These oligonucleotides are referred to as synthetic oligonucleotides. An isolated oligonucleotide generally refers to an oligonucleotide which is separated from components which it is normally associated with in nature. As an example, an isolated oligonucleotide may be one which is separated from a cell, from a nucleus, from mitochondria or from chromatin.

Modified backbones such as phosphorothioates can be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Pat. No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (e.g., Uhlmann E et al. (1990) *Chem Rev* 90:544; Goodchild J (1990) *Bioconjugate Chem* 1:165).

#### TLR expression

The cell lines can be used in their native state without any modification. For example, in the case of the RPMI 8226 cell line, it can be used to identify compounds that signal through at least TLR9 and/or TLR7. In other instances, however, the cell line can be modified to express a TLR that it does not naturally express. In still other instances, the cell to be used in the screening method may express one or more endogenous TLR and yet still be manipulated to express an additional TLR different from those it endogenously expresses. The cell may also be manipulated in order to increase or decrease the level of TLR that it endogenously expresses. The cells may be stably or transiently transfected.

A cell that does not naturally express a protein or polypeptide, but is genetically manipulated to do so is referred to as ectopically expressing the protein or polypeptide.

The basic screening method remains the same regardless of which TLR is expressed by the cell. However, the reference compound and the readout may vary depending upon the TLR(s) expressed. In the most simple aspect, the screening method is used to identify a compound that signals through a TLR such as for example TLR9. In this case, the positive reference compound may be an immunostimulatory compound already known to act through TLR9 (e.g., CpG nucleic acid).

The methods of the invention involve, in part, contacting a functional TLR with a test composition. A functional TLR is a full-length TLR protein or a fragment thereof capable of inducing or inhibiting a signal in response to interaction with its ligand. Generally the functional TLR will include at least a TLR ligand-binding fragment of the extracellular domain of the full-length TLR and at least a fragment of a TIR domain capable of interacting with another Toll homology domain-containing polypeptide, e.g., MyD88. In various embodiments the functional TLR is a full-length TLR selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and TLR10.

To date, there are eleven TLRs known. Nucleic acid and amino acid sequences for ten currently known human TLRs are available from public databases such as GenBank.

Similarly, nucleic acid and amino acid sequences for various TLRs from numerous non-human species are also available from public databases including GenBank. For example, nucleic acid and amino acid sequences for human TLR9 (hTLR9) can be found as GenBank accession numbers AF245704 (coding region spanning nucleotides 145-3243) (SEQ ID NO: 60) and AAF78037 (SEQ ID NO: 62), respectively. Nucleic acid and amino acid sequences for murine TLR9 (mTLR9) can be found as GenBank accession numbers AF348140 (coding region spanning nucleotides 40-3138) (SEQ ID NO: 68) and AAK29625 (SEQ ID NO: 72), respectively.

Nucleic acid and amino acid sequences for human TLR8 (hTLR8) can be found as GenBank accession numbers AF245703 (coding region spanning nucleotides 49-3174) (SEQ ID NO: 46) and AAF78036 (SEQ ID NO: 50), respectively. Nucleic acid and amino acid sequences for murine TLR8 (mTLR8) can be found as GenBank accession numbers AY035890 (coding region spanning nucleotides 59-3157) (SEQ ID NO: 55) and AAK62677 (SEQ ID NO: 57), respectively.

Nucleic acid and amino acid sequences for human TLR7 (hTLR7) can be found as GenBank accession numbers AF240467 (coding region spanning nucleotides 135-3285) (SEQ ID NO: 31) and AAF60188 (SEQ ID NO: 34), respectively. Nucleic acid and amino acid

sequences for murine TLR7 (mTLR7) can be found as GenBank accession numbers AY035889 (coding region spanning nucleotides 49-3201) (SEQ ID NO: 38) and AAK62676 (SEQ ID NO: 41), respectively.

5 Nucleic acid and amino acid sequences for human TLR3 (hTLR3) can be found as GenBank accession numbers NM\_003265 (coding region spanning nucleotides 102-2816) (SEQ ID NO: 7) and NP\_003256 (SEQ ID NO: 8), respectively. Nucleic acid and amino acid sequences for murine TLR3 (hTLR3) can be found as GenBank accession numbers AF355152 (coding region spanning nucleotides 44-2761) (SEQ ID NO: 9) and AAK26117 (SEQ ID NO: 10), respectively.

10 Nucleic acid and amino acid sequences for human TLR1 (hTLR1) can be found as GenBank accession numbers NM\_003263 and NP\_003254, respectively. Nucleic acid and amino acid sequences for murine TLR1 (mTLR1) can be found as GenBank accession numbers NM\_030682 and NP\_109607, respectively.

The functional TLR also is not limited to native TLR polypeptides. As used herein, a  
15 native TLR is one that is naturally occurring. The TLR may be a non-native (or non-naturally occurring TLR). An example is a chimeric TLR having an extracellular domain and the cytoplasmic domain derived from TLRs from different species. Such chimeric TLR polypeptides can include, for example, a human TLR extracellular domain and a murine TLR cytoplasmic domain. In alternative embodiments, such chimeric TLR polypeptides can  
20 include chimerae created with different TLR splice variants or allotypes.

#### TLR Signaling Pathways

The screening methods provided by the invention measure TLR signaling activity. TLR signaling activity is activity that results from interaction of a TLR with a TLR ligand.  
25 TLR signaling can be measured in a number of ways including but not limited to interaction between a TLR and a protein or factor (such as an adaptor protein), interaction between downstream proteins or factors (such as an adaptor protein) with each other, activation of nuclear factors such as transcription factors or transcription complexes, up- or down-regulation of genes, phosphorylation or dephosphorylation of proteins or factors in the  
30 signaling cascade, expression, production and/or secretion of cytokines and/or chemokines, changes in cell cycle status, up- or down-regulation of cell surface marker expression, and the like. Those of ordinary skill in the art are familiar with assays for measuring these latter



- 51 -

events including but not limited to gel shift assays, immunoprecipitations, phosphorylation status analysis of proteins, Northern analysis, RT-PCR analysis, etc.

The following is an exemplary TLR signaling pathway or cascade. It is to be understood that this is meant to be illustrative and that different factors may be involved in the signaling of particular TLR. One TLR signaling pathway is known to use the cytoplasmic Toll/IL-1 receptor (TIR) homology domain, present in all TLRs. This domain interacts (e.g., binds to) and thereby transduces a signal to a similar domain on an adapter protein (e.g., MyD88). This type of interaction is referred to as a like:like interaction of TIR domains. This interaction is followed by an another interaction between the adapter protein and a kinase, through their respective "death domains". In the case of at least TLR4 signaling, the kinase then interacts with tumor necrosis factor (TNF) receptor-associated factor-6 (TRAF6). Medzhitov R et al., *Mol Cell* 2:253 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15 (1999). After TRAF6, two sequential kinase activation steps lead to phosphorylation of the inhibitory protein I kappa B and its dissociation from NF- $\kappa$ B. The first kinase is a mitogen-activated kinase kinase kinase (MAPKKK) known as NIK, for NF- $\kappa$ B-inducing kinase. The target of this kinase is another kinase made up of two chains, called I kappa B kinase  $\alpha$  (IKK  $\alpha$ ) and I kappa B kinase  $\beta$  (IKK  $\beta$ ), that together form a heterodimer of IKK $\alpha$ :IKK $\beta$ , which phosphorylates I kappa B. NF- $\kappa$ B translocates to the nucleus to activate genes with kappa B binding sites in their promoters and enhancers such as the genes encoding IL-6, IL-8, the p40 subunit of IL-12, and the costimulatory molecule CD86. The signaling mechanisms of TLRs are not limited to this pathway; other signaling pathways exist and can be used in the screening readouts of the methods provided herein.

The screening assays employ a number of readouts (or parameters). The readouts can be native readouts. A native readout is one that does not rely on introduction of a reporter construct into the cell of interest. The readouts can be artificial. An artificial readout is one that relies on introduction of a reporter construct into the cell of interest. Examples of both are provided herein. In still other embodiments, a given assay may measure one or more native readouts and one or more artificial readouts. Each readout whether native or artificial is related to signaling pathways that ensue after TLR engagement with a ligand.

Each cell line described herein will be associated with a particular set of native readouts which the invention seeks to determine in the screening assays provided. As an example, the response of the RPMI 8226 cell line to an immunomodulatory molecule can be assessed in terms of native readouts such as CD71 expression, CD86 expression, HLA-DR

expression, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion. RAMOS response can be assessed, inter alia, by CD80 cell surface expression. Raji response can be assessed, inter alia, by IL-6 secretion.

As described in greater detail herein, the cell line can be used in an unmodified form. In one respect, an unmodified cell line will naturally respond to a TLR ligand through a native readout system. For example, an RPMI 8226 cell exposed to an immunostimulatory TLR ligand may increase expression of IP-10 from the native gene locus. Alternatively, the cell line may be modified to contain a reporter construct that acts as a surrogate for the IP-10 gene locus. For example, the reporter construct may contain the TLR responsive promoter elements that are naturally found in the native IP-10 locus operably linked to a reporter coding sequence that encodes a gene product that is detectable and quantifiable. The structure and variability of suitable reporter constructs will be discussed in greater detail herein.

Readouts typically include the induction of a gene under control of a specific promoter such as a NF- $\kappa$ B promoter. The gene under the control of the NF- $\kappa$ B promoter can be a gene which naturally includes an NF- $\kappa$ B promoter or it can be a gene in a construct in which an NF- $\kappa$ B promoter has been inserted. Endogenous genes and transfected constructs which include the NF- $\kappa$ B promoter include but are not limited to IL-8, IL-12 p40, NF- $\kappa$ B-luc, IL-12 p40-luc, and TNF-luc.

Increases in cytokine levels can result from increased production, increased stability, increased secretion, or any combination of the foregoing, of the cytokine in response to the TLR-mediated signaling. Cytokines generally include, without limitation, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-11, IL-12, IL-13, IL-15, IL-18, IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , TNF- $\alpha$ , GM-CSF, G-CSF, M-CSF. Th1 cytokines include but are not limited to IL-2, IFN- $\gamma$ , and IL-12. Th2 cytokines include but are not limited to IL-4, IL-5, and IL-10.

Increases in chemokine levels can result from increased production, increased stability, increased secretion, or any combination of the foregoing, of the chemokine in response to the TLR-mediated signaling. Chemokines of particular significance in the invention include but are not limited to CCL5 (RANTES), CXCL9 (Mig), CXCL10 (IP-10), CXCL11 (I-TAC), IL-8, and MCP-1.

- 53 -

TLR signaling activity can also be measured by phosphorylation, such as total cellular phosphorylation or phosphorylation of specific factors such as but not limited to IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

5 TLR signaling activity can be measured by changes in gene expression. The expression of CD71, CD86, CD80, CD69, CD54, HLA-DR, HLA class I, IL-6, IL-8, IL-10, IP-9, IP-10, IFN- $\alpha$ , TNF- $\alpha$ , and the like can be assessed as a measure of TLR signaling activity. Gene expression analysis may be performed using microarray techniques.

TLR signaling activity can also be measured by cell proliferation status or changes thereto.

10 TLR signaling activity can also be measured by cell surface marker expression such as the cell surface expression of markers such as but not limited to CD71, CD86, HLA-DR, CD80, HLA class I, CD54 and CD69.

TLR signaling activity can also be measured by antibody secretion such as but not limited to IgM secretion.

15

#### Reporter and Expression Constructs

The cells can be manipulated by the introduction of expression and/or reporter constructs. The expression constructs preferably comprise a TLR coding sequence, as described above. The reporter constructs can be used as surrogate measures of native TLR  
20 signaling activity. These reporter constructs are intended to substitute for the "native" readouts capable with the cell line. In order to act as substitutes, the reporter constructs include a promoter element derived from a gene known to be modulated following TLR engagement with a TLR ligand. The reporter construct further includes a coding sequence linked to the promoter. The coding sequence is usually that of a reporter (i.e., a protein that is  
25 detectable or quantifiable).

The reporter construct generally includes a promoter, a coding sequence and a polyadenylation signal. These nucleic acids shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, in addition to  
30 promoter elements that are responsive to TLR signaling. The nucleic acid constructs may optionally include enhancer sequences or upstream activator sequences as desired.

The promoter in the reporter construct will include a TLR responsive promoter element, and will therefore be regarded as a TLR responsive promoter. As used herein, a

TLR responsive promoter is a promoter having an activity that is modulated (i.e., either activated or inhibited) by signaling through a TLR (e.g., by TLR interaction with its ligand). In order to be modulated by TLR signaling, the promoter contains sites that are bound by transcription factors modulated by TLR signaling. The factors may be activated or inhibited  
5 by TLR signaling. Activation of the transcription factor includes increases in the activity of the transcription factor per se, increases in its ability to interact with other factors or with DNA that serve to increase its activity, and increases in its transcription and translation (i.e., increased mRNA and protein levels of the transcription factor). Conversely, inhibition of the transcription factor includes decreases in the activity of the transcription factor per se,  
10 decreases in its ability to interact with other factors or with DNA that serve to decrease its activity, and decreases in its transcription and translation (i.e., decreased mRNA and protein levels of the transcription factor). The effect on the transcription factor is usually the downstream result of other interactions in the signaling pathway. The expression of coding sequences linked to such promoters will therefore be modulated by TLR signaling events, and  
15 it is the level of expression of these coding sequences that can be used as a readout of TLR signaling in the screening methods provided herein.

The TLR responsive promoter may comprise a transcription factor binding site selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an interferon-stimulated response element (ISRE), a GAS, an ATF2 binding site, an  
20 IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE, among others. These binding sites and their sequences are known in the art. Below is a exemplary list of these sequences.

W = A or T, R = A or G, Y = C or T

25 NF- $\kappa$ B Binding site:

Consensus p50 subunit  
5' GGGGATYCCC 3' (SEQ ID NO:90)

30 Consensus p65 subunit  
5' GGGRNTTCC 3' (SEQ ID NO:91)

Example of p65 subunit binding site  
35 5' AGT TGA GGG GAC TTT CCC AGG C 3' (SEQ ID NO:92)

CREB Binding site:  
5'AGA GAT TGC CTG ACG TCA GAG AGC TAG 3' (SEQ ID NO:93)

- 55 -

## AP-1 Binding site:

5'- CGC TTG ATG AGT CAG CCG GAA -3' (SEQ ID NO:94)

5'- CGC ATG AGT CAG ACA -3' (SEQ ID NO:95)

## 5 ISRE :

5'- TGCAGAAGTGAAACTGAGG-3' (SEQ ID NO:96)

5'- AGAACGAAACA-3' (SEQ ID NO:97)

5'- GAGAAGTGAAAGTGG-3' (SEQ ID NO:98)

5'- TAAGAACATGAAACTGAA-3' (SEQ ID NO:99)

10 5'- ATGAAACTGAAAGTA-3' (SEQ ID NO:100)

5'- TGAAAACCGAAAGCGC-3' (SEQ ID NO:101)

5'- AGAAATGGAAAGT-3' (SEQ ID NO:102)

## SRE

15 5'- TCACCCAC-3' (SEQ ID NO:103)

5'- CTCACCCAC-3' (SEQ ID NO:104)

5'- GCCACCCTAC-3' (SEQ ID NO:105)

## NFAT:

20 5'- TATGAAACAGTTTTTCC -3' (SEQ ID NO:106)

5'- AGGAAACTC -3' (SEQ ID NO:107)

5'- ARGARATTCC -3' (SEQ ID NO:108)

5'- CCAGTTGAGCCAGAGA -3' (SEQ ID NO:109)

## 25 GAS:

5'- CTTTCAGTTTCATATTACTCTAAATCCATT -3' (SEQ ID NO:110)

## p53 Binding Site :

## 30 p53 Consensus site:

5'- RRRCWWGYYY -3' (SEQ ID NO:111)

## Examples of p53 binding sites:

35 5'- AGGCATGCCT -3' (SEQ ID NO:112)

5'- GGGCTTGCCC -3' (SEQ ID NO:113)

5'- GGGCTTGCTT -3' (SEQ ID NO:114)

5'- GCCTGGACTTGCC -3' (SEQ ID NO:115)

5'- GGACATGCCCCGGGCATGTCC -3' (SEQ ID NO:116)

5'- GTAGCATTAGCCCAGACATGTCC -3' (SEQ ID NO:117)

40

TARE (TNF- $\alpha$  response element):

e.g. from the COL1A1 promoter

5'GAGGTATGCAGACAAGAGTCAGAGTTTCCCCTTGAA 3' (SEQ ID

NO:118)

45

## SRF

5'- CCWWWWWWGG -3' (SEQ ID NO:119)

5'- CCAAATAAGGC -3' (SEQ ID NO:120)

- 56 -

The TLR responsive promoter element can be derived from the promoter of a naturally occurring (i.e., an endogenous) gene that is activated or inhibited by TLR signaling (such as the IL-6 gene, the IL-8 gene, the IL-10 gene, the IL-12 p40 gene, the IP-9 gene, the IP-10 gene, the type 1 IFN gene, the IFN- $\alpha$ 4 gene, the IFN- $\beta$  gene, the TNF- $\alpha$  gene, the TNF- $\beta$  gene, the RANTES gene, the ITAC gene, the IGFBP4 gene, the CD54 gene, the CD69 gene, the CD71 gene, the CD80 gene, the CD86 gene, the HLA-DR gene, the HLA class I gene, and the like). The afore-mentioned genes are genes that are known to be activated in response to TLR interaction with its ligand.

Suitable promoter regions are described in the Examples. Briefly, the upstream (5') - 620 to +50 promoter region of IFN- $\alpha$ 4 or the upstream (5') -140 to +9 promoter region of IFN- $\alpha$ 1 can be used. In one embodiment, the IFN- $\alpha$ 4 sequence is cloned into the *Sma*I site of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') promoter region of IFN- $\alpha$ 4.

The promoter can also be the upstream (5') -280 to +20 promoter region of IFN- $\beta$ . The promoter can also be the upstream (5') -397 to +5 promoter region of RANTES. In one embodiment, the RANTES promoter sequence is cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') -397 to +5 promoter region of RANTES.

The promoter can also be the upstream truncated (-250 to +30) and full length (-860 to +30) promoter regions derived from human IL-12 p40 genomic DNA. In one embodiment, the truncated IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p $\beta$ gal-Basic (Promega) resulting in an expression vector that includes a  $\beta$  gal gene under the control of the upstream (5') -250 to +30 promoter region of human IL-12 p40. In another embodiment, the full length IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p $\beta$ gal-Basic (Promega) resulting in an expression vector that includes a  $\beta$  gal gene under the control of the upstream (5') -751 to +30 promoter region of human IL-12 p40. In another embodiment, the truncated -250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') -250 to +30 promoter region of human IL-12 p40. In yet another embodiment, the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the

- 57 -

pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') -751 to +30 promoter region of human IL-12 p40.

The promoter can also be the upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. The promoter can also be derived from the full-length promoter region of the IL-6 gene from -1174 to +7 (Accession No M22111, SEQ ID NO:129).

The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71.

The promoter can also be derived from the -615 to +30 promoter region of human TNF- $\alpha$ .

The promoter can also be derived from a promoter region of human TNF- $\beta$ .

The promoter can also be derived from the -875 to +97 promoter region of human IP-10.

The promoter can also be derived from the -219 to +114 promoter region of human CXCL11 (IP9). The promoter can also be derived from the full length (-934 to +114) promoter region of human CXCL11 (IP9).

The promoter can also be derived from the -289 to +217 promoter region of human IGFBP4 (Insulin growth factor binding protein 4). The promoter can also be derived from the full length (-836 to +217) promoter region of human IGFBP4.

The promoter response element generally will be present in multiple copies, e.g., as tandem repeats. For example, in one reporter construct, coding sequence for luciferase is under control of an upstream 6X tandem repeat of NF- $\kappa$ B response element. In another example, an ISRE-luciferase reporter construct useful in the invention is available from Stratagene (catalog no. 219092) and includes a 5x ISRE tandem repeat joined to a TATA box upstream of a luciferase reporter gene.

The reporter construct coding sequence is preferably any nucleotide sequence that codes for a protein capable of detection or quantification. The protein can be an enzyme (e.g., luciferase, alkaline phosphatase,  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein (GFP, U.S. Pat. No. 5,491,084), etc.), blue fluorescent protein (BFP, e.g., U.S. Pat. No. 6,486,382), etc.), a surface-expressed molecule (e.g., CD25, CD80, CD86), a secreted molecule (e.g., IL-1, IL-6, IL-8, IL-12 p40, TNF- $\alpha$ ), a hapten or antigen, and other detectable protein products known to those of skill in the art. For assays relying on enzyme activity

readout, substrate can be supplied as part of the assay, and detection can involve measurement of chemiluminescence, fluorescence, color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using flow cytometry (FACS) analysis or functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many of these and other suitable readout systems are well known in the art and are commercially available. Preferably, the coding sequence encodes a protein having a level or an activity that is quantifiable, preferably with a wide linear range.

5 The expression construct coding sequence is preferably a TLR coding sequence derived from the sequences listed herein. Preferably, the expression construct promoter is a constitutive promoter, although in some embodiments it may be inducible. Those of ordinary skill in the art are familiar with such promoters.

As used herein, a coding sequence and the regulatory sequences (such as promoters) are said to be operably linked when they are covalently linked in such a way as to place the expression or transcription and/or translation of the coding sequence under the influence or control of the regulatory sequence. Two DNA sequences are said to be operably linked if induction of a promoter in the 5' regulatory sequence results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a regulatory sequence would be operably linked to a coding sequence if the gene expression sequence were capable of effecting transcription of that coding sequence such that the resulting transcript is translated into the desired protein or polypeptide.

25 Methods for nucleic acid introduction into cells are known in the art.

The nucleic acid may be delivered to the cells alone or in association with a vector. In its broadest sense, a vector is any vehicle capable of facilitating the transfer of the nucleic acid to the cells so that the reporter can be expressed. The vector generally transports the nucleic acid to the cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antigen nucleic acid sequences. Viral vectors are a preferred type of vector and include, but are not limited



to, nucleic acid sequences from the following viruses: retrovirus, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, murine mammary tumor virus, and Rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. Most useful are those retroviruses that are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., Gene Transfer and Expression, A Laboratory Manual W.H. Freeman C.O., New York (1990) and Murray, E.J. Methods in Molecular Biology, vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

A preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication-deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, wild-type adeno-associated virus manifest some preference for integration sites into human cellular DNA, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression characteristic of retroviral infection. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

Recombinant adeno-associated viruses that lack the replicase protein apparently lack this integration sequence specificity.

Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al.,  
5 Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been found to be particularly advantageous for delivering genes to cells *in vivo* because of their inability to replicate within and integrate into a host genome. These plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid.  
10 Some commonly used plasmids include pBR322, pUC18, pUC19, pRc/CMV, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.

In general, the vectors useful in the invention are divided into two classes: biological  
15 vectors and chemical/physical vectors. Biological vectors and chemical/physical vectors are useful in the delivery and/or uptake of reporter constructs of the invention.

Most biological vectors are used for delivery of nucleic acids and thus would be most appropriate in the delivery of nucleic acids.

As used herein, a "chemical/physical vector" refers to a natural or synthetic molecule,  
20 other than those derived from bacteriological or viral sources, capable of delivering the reference and test compound.

A preferred chemical/physical vector of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a  
25 liposome. Liposomes are artificial membrane vessels which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vessels (LUV), which range in size from 0.2 - 4.0  $\mu\text{m}$  can encapsulate large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., *Trends Biochem. Sci.*, (1981) 6:77).

30 Liposomes may be targeted to a particular tissue by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to an immune cell include, but are not limited to, intact or fragments of molecules which interact with immune cell specific receptors and molecules,

- 61 -

such as antibodies, which interact with the cell surface markers of immune cells. Such ligands may easily be identified by binding assays well known to those of skill in the art. In still other embodiments, the liposome may be targeted to the cancer by coupling it to a one of the immunotherapeutic antibodies discussed earlier. Additionally, the vector may be coupled  
5 to a nuclear targeting peptide, which will direct the vector to the nucleus of the host cell.

Lipid formulations for transfection are commercially available from QIAGEN, for example, as EFFECTENE™ (a non-liposomal lipid with a special DNA condensing enhancer) and SUPERFECT™ (a novel acting dendrimeric technology).

Liposomes are commercially available from Gibco BRL, for example, as  
10 LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2, 3 dioleyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications. Liposomes also have been reviewed by Gregoriadis, G. in *Trends in Biotechnology*, (1985) 3:235-241. In some preferred  
15 embodiments, the method of choice for delivering DNA (for transfection) to the cells is electroporation, particularly where a stably transfected cell line is sought.

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting.

20

### Examples

#### **Example 1. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using Cells Stably Transfected with hTLR9 Expression Vector**

CpG ODN (SEQ ID NO:1) is currently in preclinical and clinical trials for a number of  
25 clinical applications. SEQ ID NO:1 has been discovered to induce signaling through TLR9. In order to assess different lots of clinical material, the methods of the invention are employed, using a highly characterized lot of SEQ ID NO:1 as a reference.

In a TLR9 assay, the CpG-non-responsive human embryonal kidney cell line HEK293 (e.g., ATCC CRL-1573) was stably transfected with a hTLR9 expression construct and found  
30 to express full-length human TLR9 constitutively. The cells also contained a genomic copy of a reporter construct with a 6x NF-κB binding site and a luciferase gene reporter cassette. Incubation of the cells with CpG ODN (SEQ ID NO:1) activates NF-κB driven expression of luciferase, while incubation with medium alone (negative control) does not. The cells are

- 62 -

then lysed and activity of the luciferase protein determined by its catalytic activity of luciferin oxidation which is measured in a luminometer. Results are expressed as fold induction above medium control.

Assay set-up includes a reference standard material which is highly pure and well characterized. The reference material is used to create a standard curve within a defined range where the dose-response curve is linear (e.g., in the range of the EC50 value for SEQ ID NO:1, 70-100 nM). The test material is dissolved for testing and assayed at a defined concentration. Activity of the test material is calculated using the standard curve of the reference material. Quality of the tested material is deemed acceptable if activity of the test material compared to activity of the reference material falls within predetermined limits.

**Example 2. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using RPMI 8226 Cells**

The assay of Example 1 is performed using RPMI 8226 cells (ATCC CCL-155) in place of the stably transfected HEK cells of Example 1. RPMI 8226 cells naturally express human TLR9. The cells are stably transfected with a 6x NF- $\kappa$ B-luciferase reporter construct. It is to be understood that the assay could also be carried out by measuring a native readout such as IL-10 secretion.

**Example 3. Expression Vectors for Human TLR3 (hTLR3) and Murine TLR3 (mTLR3)**

To create an expression vector for human TLR3, human TLR3 cDNA was amplified by the polymerase chain method (PCR) from a cDNA made from human 293 cells using the primers 5'-GAAACTCGAGCCACCATGAGACAGACTTTGCCTTGTATCTAC-3' (sense, SEQ ID NO:152) and 5'-GAAAGAATTCTTAATGTACAGAGTTTTTGGATCCAAG-3' (antisense, SEQ ID NO:153). The primers introduce *Xho*I and *Eco*RI restriction endonuclease sites at their 5' ends for use in subsequent cloning into the expression vector. The resulting amplification product fragment was cloned into pGEM-T Easy vector (Promega), isolated, cut with *Xho*I and *Eco*RI restriction endonucleases, ligated into an *Xho*I/*Eco*RI-digested pcDNA3.1 expression vector (Invitrogen). The insert was fully sequenced and translated into protein. The cDNA sequence corresponds to the published cDNA sequence for hTLR3, available as GenBank accession no. NM\_003265 (SEQ ID NO:7). The open reading frame codes for a protein 904 amino acids long, having the sequence corresponding to GenBank accession no. NP\_003256 (SEQ ID NO:8).

Corresponding nucleotide and amino acid sequences for murine TLR3 (mTLR3) are known. The nucleotide sequence of mTLR3 cDNA has been reported as GenBank accession no. AF355152 (SEQ ID NO:9), and the amino acid sequence of mTLR3 has been reported as GenBank accession no. AAK26117 (SEQ ID NO:10).

5

#### **Example 4. Reconstitution of TLR3 Signaling in 293 Fibroblasts**

Human TLR3 cDNA and murine TLR3 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *EcoRI* site. The resulting expression vectors mentioned above were transfected into  
10 CpG-DNA non-responsive human 293 fibroblast cells (ATCC, CRL-1573) using the calcium phosphate method. Utilizing a “gain of function” assay it was possible to reconstitute human TLR3 (hTLR3) and murine TLR3 (mTLR3) signaling in 293 fibroblast cells.

Since NF- $\kappa$ B activation is central to the IL-1/TLR signal transduction pathway (Medzhitov R et al. (1998) *Mol Cell* 2:253-8; Muzio M et al. (1998) *J Exp Med*  
15 187:2097-101), in a first set of experiments human 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an NF- $\kappa$ B-driven luciferase reporter construct.

Likewise, in a second set of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an IFN- $\alpha$ 4-driven luciferase reporter  
20 construct (described in Example 8 below).

In a third group of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and a RANTES-driven luciferase reporter construct (described in Example 14 below).

#### **25 Example 5. Reconstitution of TLR7 Signaling**

Methods for cloning murine and human TLR7 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated herein by reference. Human TLR7 cDNA and murine TLR7 cDNA in pT-Adv  
30 vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *EcoRI* site. Utilizing a “gain of function” assay it was possible to reconstitute human TLR7 (hTLR7) and murine TLR7 (mTLR7) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors

mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

#### **Example 6. Reconstitution of TLR8 Signaling**

5           Methods for cloning murine and human TLR8 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated by reference. Human TLR8 cDNA and murine TLR8 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from  
10   Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR8 (hTLR8) and murine TLR8 (mTLR8) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

15

#### **Example 7. Reconstitution of TLR9 Signaling in 293 Fibroblasts**

          Methods for cloning murine and human TLR9 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are  
20   incorporated by reference. Human TLR9 cDNA and murine TLR9 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors  
25   mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

          To generate stable clones expressing human TLR9, murine TLR9, or either TLR9 with the NF- $\kappa$ B-luc reporter plasmid, 293 cells were transfected in 10 cm plates ( $2 \times 10^6$  cells/plate) with 16  $\mu$ g of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH, Cölbe,  
30   Germany). Clones were tested for TLR9 expression by RT-PCR, for example as shown in Fig. 21. The clones were also screened for IL-8 production or NF- $\kappa$ B-luciferase activity after stimulation with ODN. Four different types of clones were generated.

- 65 -

293-hTLR9-luc: expressing human TLR9 and 6x NF- $\kappa$ B-luciferase reporter  
 293-mTLR9-luc: expressing murine TLR9 and 6x NF- $\kappa$ B-luciferase reporter  
 293-hTLR9: expressing human TLR9  
 293-mTLR9: expressing murine TLR9

5

Human 293 fibroblast cells were transiently transfected with hTLR9 and a 6x NF- $\kappa$ B-luciferase reporter plasmid (NF- $\kappa$ B-luc, kindly provided by Patrick Baeuerle, Munich, Germany) (Fig. 18A) or with hTLR9 alone (Fig. 18B). After stimulus with CpG-ODN (2 $\mu$ M, TCGTCGTTTTGTCGTTTTGTCGTT, SEQ ID NO:1), GpC-ODN (2 $\mu$ M, TGCTGCTTTTGTGCTTTTGTGCTT, SEQ ID NO:154), LPS (100 ng/ml) or media, NF- $\kappa$ B activation by luciferase readout (8h, Fig. 18A) or IL-8 production by ELISA (48h, Fig. 18B) was monitored. Results are representative of three independent experiments. Fig. 18 shows that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

Human 293 fibroblast cells were transiently transfected with mTLR9 and the NF- $\kappa$ B-luc construct. Similar data was obtained for IL-8 production (not shown). Thus expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG DNA stimulation similar to hTLR4 reconstitution of LPS responses.

Figs. 19 and 20 demonstrate the responsiveness of a stable 293-mTLR9-luc and 293-hTLR9-luc clones after stimulation with CpG-ODN (2 $\mu$ M, SEQ ID NO:1), GpC-ODN (2 $\mu$ M, SEQ ID NO:154), Me-CpG-ODN (2 $\mu$ M; TZGTZGTTTTGTZGTTTTGTZGTT, Z = 5-methylcytidine, SEQ ID NO:147), LPS (100 ng/ml) or media, as measured by monitoring NF- $\kappa$ B activation. Similar results were obtained utilizing IL-8 production with the stable clones. These results demonstrate that CpG-DNA non-responsive cell lines can be stably genetically complemented with TLR9 to become responsive to CpG DNA in a motif-specific manner.

#### Example 8. Method of Making IFN- $\alpha$ 4 Reporter Vector

A number of reporter vectors may be used in the practice of the invention. Some of the reporter vectors are commercially available, e.g., the luciferase reporter vectors pNF- $\kappa$ B-Luc (Stratagene) and pAP1-Luc (Stratagene). These two reporter vectors place the luciferase gene under control of an upstream (5') promoter region derived from genomic DNA for NF- $\kappa$ B or AP1, respectively. Other reporter vectors can be constructed following standard

- 66 -

methods using the desired promoter and a vector containing a suitable reporter, such as luciferase,  $\beta$ -galactosidase ( $\beta$ -gal), chloramphenicol acetyltransferase (CAT), and other reporters known by those skilled in the art. Following are some examples of reporter vectors constructed for use in the present invention.

5 IFN- $\alpha$ 4 is an immediate-early type 1 IFN. Sequence-specific PCR products for the -620 to +50 promoter region of IFN- $\alpha$ 4 were derived from genomic DNA of human 293 cells and cloned into the *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -620 to +50 promoter region of IFN- $\alpha$ 4. The sequence of the -620 to +50 promoter region of IFN- $\alpha$ 4 is provided as  
10 SEQ ID NO:121.

#### **Example 9. Method of Making IFN- $\alpha$ 1 Reporter Vector**

IFN- $\alpha$ 1 is a late type 1 IFN. Sequence-specific PCR products for the -140 to +9 promoter region of IFN- $\alpha$ 1 were derived from genomic DNA of human 293 cells and cloned  
15 into *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -140 to +9 promoter region of IFN- $\alpha$ 1. A sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1 is provided as SEQ ID NO:122.

#### **Example 10. Method of Making IFN- $\beta$ Reporter Vector**

20 IFN- $\beta$  is an immediate-early type 1 IFN. The -280 to +20 promoter region of IFN- $\beta$  was derived from the pUC $\beta$ 26 vector (Algarte M et al. (1999) *J Virol* 73:2694-702) by restriction at *Eco*RI and *Taq*I sites. The 300 bp restriction fragment was filled in by Klenow enzyme and cloned into *Nhe*I-digested and filled in pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -280  
25 to +20 promoter region of IFN- $\beta$ . A sequence of the -280 to +20 promoter region of IFN- $\beta$  is provided as SEQ ID NO:123.

#### **Example 11. Method of Making Human IL-6 Reporter Vectors**

Reporter constructs are made using the -285 to +7 promoter region derived from  
30 human IL-6 genomic DNA. (Takeshita et al. Eur. J. Immunol. 2000. 30: 108-116.) In one reporter construct the IL-6 promoter region is cloned as a *Kpn*I-*Xho*I insert into pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of



- 67 -

an upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. A sequence of the -288 to +7 promoter region of human IL-6 is provided as SEQ ID NO:128.

The promoter can also be derived from the full-length promoter region of the IL-6 gene from -1174 to +7 (GenBank Accession No M22111) as shown below as SEQ ID NO:129.

#### Example 12. Method of Making Human IL-8 Reporter Vectors

Reporter constructs have been made using a -546 to +44 and a truncated -133 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71. In each reporter construct the IL-8 promoter region was cloned as a *KpnI-XhoI* insert into pGL3-Basic Vector (Promega). One of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -546 to +44 promoter region derived from human IL-8 genomic DNA. Another of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -133 to +44 promoter region derived from human IL-8 genomic DNA.

The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71. A sequence of the -734 to +44 promoter region derived from human IL-8 is provided below as SEQ ID NO: 130.

#### Example 13. Method of Making Human IL-12 p40 Reporter Vectors

Reporter constructs have been made using truncated (-250 to +30, SEQ ID NO:127) and full length (-751 to +30, SEQ ID NO:126) promoter regions derived from human IL-12 p40 genomic DNA. (Takeshita et al. Eur. J. Immunol. 2000. 30: 108-116.) In one reporter construct the truncated IL-12 p40 promoter was cloned as a *KpnI-XhoI* insert into p $\beta$ gal-Basic (Promega). The resulting expression vector includes a  $\beta$  gal gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a second reporter construct the full length IL-12 p40 promoter was cloned as a *KpnI-XhoI* insert into p $\beta$ gal-Basic (Promega). The resulting expression vector includes a  $\beta$  gal gene under control of an upstream (5') -751 to +30 promoter region of human IL-12 p40. In a third reporter construct the truncated -250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a

- 68 -

fourth reporter construct the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -751 to +30 promoter region of human IL-12 p40. A sequence of the -751 to +30 promoter region of human IL-12 p40 is provided as SEQ ID NO:

5 126.

**Example 14. Method of Making RANTES Reporter Vector**

Transcription of the chemokine RANTES is believed to be regulated at least in part by IRF3 and by NF- $\kappa$ B. Lin R et al. (1999) *J Mol Cell Biol* 19(2):959-66; Genin P et al. (2000) *J Immunol* 164:5352-61. A 483 bp sequence-specific PCR product including the -397 to +5 promoter region of RANTES was derived from genomic DNA of human 293 cells, restricted with *Pst*I and cloned into pCAT-Basic Vector (Promega) using *Hind*III (filled in with Klenow) and *Pst*I sites (filled in). The -397 to +5 promoter region of RANTES was then isolated from the resulting RANTES/chloramphenicol acetyltransferase (CAT) reporter plasmid by restriction with *Bgl*II and *Sal*I, filled in with Klenow enzyme, and cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -397 to +5 promoter region of RANTES. Comparison of the insert sequence -397 to +5 of Genin P et al. (2000) *J Immunol* 164:5352-61 and GenBank accession no. AB023652 (SEQ ID NO:125) revealed two point deletions (at positions 105 and 273 of SEQ ID NO:125) which do not create new restriction sites. A sequence of the -397 to +5 promoter region of RANTES is provided as SEQ ID NO:125.

**Example 15. RT-PCR Analysis of Cell Lines for TLR Expression**

TLR expression was determined using total RNA of cells prepared by standard methods (QIAGEN). RNA was transcribed to cDNA using AMV Reverse Transcriptase (Roche). Quantitative PCR was performed with TLR-gene specific primer sets using a LightCycler Instrument (Roche). Controls for genomic DNA impurities were performed by a similar PCR method using RNA (but without reverse transcriptase).

A variety of cell lines was screened for their expression of TLR3, 7, 8 and 9. These cell lines are A549 (human lung carcinoma), BeWo (human choriocarcinoma), HeLa (human cervix carcinoma), Hep-2 (human cervix carcinoma), KG-1 (human acute myeloid leukemia), MUTZ-3 (human acute myelomonocytic leukemia), Nalm-6 (human B cell precursor

- 69 -

leukemia), NK-92 (human Natural killer cell line), NK-92 MI (human Natural killer cell line, IL-2 independent), Raji (human Burkitt's lymphoma, B lymphocyte), RAMOS (Burkitt's lymphoma, B lymphocyte), RPMI 8226 (human multiple myeloma, B lymphocyte), THP-1 (human acute monocytic leukemia), U937 (human lymphoma) and Jurkat (human T cell leukemia).

All B cell lines express, as determined by Real Time-PCR (RT-PCR), endogenous TLR9. In addition, all lines except NALM co-express TLR7. Nevertheless, none of the other cell lines appeared to express TLR7, whereas low TLR9 expression on the mRNA level was observed for KG-1 and THP-1. TLR3 appeared to be expressed in most of these cell lines, with the highest mRNA levels for example in the NK cell lines (e.g., NK-92).

Raji cells contain high levels of TLR9 mRNA and low levels of TLR3 and TLR7 mRNA suggesting high expression of TLR9 protein and lower levels of TLR3 and TLR7 protein.

These results indicate that the cell lines expressing TLR9 can be used to screen potential new TLR9 ligands (CpG ODN, etc.), cell lines expressing TLR7 to screen potential new TLR7 ligands (ORN (oligoribonucleotides), small molecules, etc.), and cell lines expressing both receptors may be used to screen for "hybrid" TLR7 and 9 agonists. In addition, cell lines lacking TLR8 expression (i.e., all cell lines tested) can be used to confirm the specificity of a TLR7 versus a TLR8 ligand (i.e., the latter should not be able to stimulate TLR7-expressing cells). In contrast, cell lines expressing TLR3 (e.g., Raji cells) may be used to screen for potential new TLR3 ligands (dsRNA, etc.).

#### **Example 16. Screening of Various Cell Lines for Responses to TLR Ligands**

Except where otherwise indicated, the following general methods were used. Cells were plated at  $5 \times 10^5$ /ml in 48 well plates in RPMI medium with 10% FBS. Stimulation was performed by addition of the oligonucleotides or other compounds diluted to the test concentrations in TE. Cells were incubated for 24 or 48h and the supernatants were taken to analyse for the presence of cytokines or chemokines.

The TLR ligands used are as follows:

TLR3: Poly I:C

TLR7, TLR8: R-848

TLR9:

T\*C\*C\*A\*G\*G\*A\*C\*T\*T\*C\*T\*C\*T\*C\*A\*G\*G\*T\*T (SEQ ID NO: 2);

- 70 -

T\*C\*G\*T\*C\*G\*T\*T\*T\*T\*G\*T\*C\*G\*T\*T\*T\*T\*G\*T\*C\*G\*T\*T (SEQ ID NO: 1);  
 T\*G\*C\*T\*G\*C\*T\*T\*T\*T\*G\*T\*G\*C\*T\*T\*T\*T\*G\*T\*G\*C\*T\*T (SEQ ID NO: 154);  
 T\*C\*G\*T\*C\*G\*T\*T\*T\*T\*C\*G\*G\*C\*G\*C\*G\*C\*G\*C\*C\*G (SEQ ID NO: 158);  
 G\*G\*G\_G\_A\_C\_G\_A\_C\_G\_T\_C\_G\_T\_G\_G\*G\*G\*G\*G\*G (SEQ ID NO: 159);  
 5 T\*G\*C\*T\*G\*C\*T\*T\*T\*T\*C\*G\*G\*C\*G\*G\*C\*C\*G\*C\*C\*G (SEQ ID NO: 160);  
 G\*G\*G\_G\_A\_G\_C\_A\_G\_C\_T\_G\_C\_T\_G\_G\*G\*G\*G\*G\*G (SEQ ID NO: 161).  
 \* phosphorothioate linkage; \_ phosphodiester linkage.

Increased expression of cell surface markers was determined using cells stimulated as  
 10 described above and then stained with different monoclonal antibody combinations specific  
 for the cell surface markers. Analysis of the cells was performed by flow cytometry.

Changes in reporter gene activity were determined using cells transfected with a  
 NF- $\kappa$ B reporter construct (Stratagene) and a  $\beta$ -galactosidase reporter control plasmid  
 (Invitrogen) using electroporation. For NF- $\kappa$ B analysis, a 5x NF- $\kappa$ B-Luciferase Vector  
 15 (Stratagene) was used. The amount of DNA transfected as well as cell concentration was  
 varied. Stimulation was performed 24h after transfection. Cells were stimulated with the  
 indicated amounts of ODN, R-848, LPS, TNF- $\alpha$ , or IL-1  $\beta$  for the indicated incubation times.  
 Cell extracts were prepared by lysing the cells in 100  $\mu$ l reporter lysis buffer (Promega) using  
 the freeze-thaw method. All data were normalized for  $\beta$ -galactosidase expression.  
 20 Stimulation indices were calculated in reference to luciferase activity of medium without  
 addition of ODN.

Stimulation of the Raji cell line with a TLR9 ligand (CpG ODN), a TLR3 ligand (poly  
 I:C) or a TLR7 ligand (R-848) results in the ligand-specific secretion of cytokines. Figs. 14  
 and 15 show IL-6 production of Raji cells upon stimulation with ODN, poly I:C or R-848.  
 25 Fig. 16 shows IFN- $\alpha$ 2 production of Raji cells upon stimulation with ODN, poly I:C or R-848.  
 In all assays, cells were incubated with Na-Butyrate for 48h before stimulation with TLR  
 ligands. CpG stimulation of the RAMOS cell lines can result in the CpG-specific up-  
 regulation of cell surface markers such as CD80, as shown in Fig. 17.

### 30 **Example 17. Inhibition of a Positive Reference Compound Response with an Inhibitory Test Compound**

Inhibition of CpG mediated chemokine production was determined using RPMI 8226  
 cells incubated with increasing amounts of SEQ ID NO:1 in the presence of an

- 71 -

immunoinhibitory ODN (SEQ ID NO: 151). IP-10 production was measured 24h later by ELISA (Fig. 9).

### Equivalents

5           The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described  
10   herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

          All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

15

We claim:

- 72 -

**Claims**

1. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising  
contacting an RPMI 8226 cell that expresses a TLR with a test compound and  
5 measuring a test level of TLR signaling activity,  
wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and  
wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-8 production, IL-8  
10 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.
2. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising  
15 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,  
wherein a test level that is positive is indicative of an immunostimulatory compound, and  
wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-  
20 1 cell.
3. The method of claim 1 or 2, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a reference TLR signaling activity.  
25
4. The method of claim 3, wherein the reference compound is a positive reference compound
5. The method of claim 4, wherein the positive reference compound is  
30 selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

- 73 -

6. The method of claim 3, wherein the reference compound is a negative reference compound.
7. The method of claim 6, wherein the negative reference compound is  
5 medium alone.
8. The method of claim 5, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.  
10
9. The method of claim 5, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.
10. The method of claim 1 or 2, wherein the test compound is a nucleic  
15 acid.
11. The method of claim 10, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.  
20
12. The method of claim 10, wherein the nucleic acid comprises a phosphorothioate backbone linkage.
13. The method of claim 10, wherein the nucleic acid is a DNA, an RNA or  
25 a DNA-RNA hybrid.
14. The method of claim 1 or 2, wherein the test compound is a non-nucleic acid small molecule.
15. The method of claim 1 or 2, wherein the test compound comprises an  
30 amino acid, a carbohydrate, a lipid, or a hormone.
16. The method of claim 15, wherein the carbohydrate is a polysaccharide.

17. The method of claim 1 or 2, wherein the test compound is derived from a molecular library.
- 5 18. The method of claim 1, wherein the cell is transfected with a nucleic acid.
19. The method of claim 18, wherein the nucleic acid encodes a TLR or a reporter construct.
- 10 20. The method of claim 2, wherein the cell is transfected with a nucleic acid.
21. The method of claim 20, wherein the nucleic acid encodes a TLR or a reporter construct.
- 15 22. The method of claim 19 or 21, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.
- 20 23. The method of claim 22, wherein the TLR is a human TLR.
24. The method of claim 19 or 21, wherein the reporter construct is selected from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.
- 25 25. The method of claim 19 or 21, wherein the reporter construct comprises a TLR responsive promoter.
- 30 26. The method of claim 25, wherein the TLR responsive promoter comprises a transcription factor binding site selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an



- 75 -

IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

27. The method of claim 25, wherein the TLR responsive promoter is a  
5 promoter region selected from the group consisting of an IL-1 promoter region, an IL-6  
promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter  
region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an  
IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter  
region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a  
10 MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69  
promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region,  
a HLA-DR promoter region, and a HLA class I promoter region.

28. The method of claim 18 or 20, wherein the cell is stably transfected.  
15

29. The method of claim 1 or 2, wherein the TLR signaling activity is  
measured by cytokine secretion or chemokine secretion.

30. The method of claim 1, wherein the TLR signaling activity is selected  
20 from the group consisting of IL-8 secretion, IL-10 secretion, IP-10 secretion and TNF- $\alpha$   
secretion.

31. The method of claim 2, wherein the TLR signaling activity is selected  
from the group consisting of IL-6 expression, IL-6 production, IL-6 secretion, IL-8  
25 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10  
secretion, IP-10 expression, IP-10 production, IP-10 secretion, IL-12 expression, IL-12  
production, IL-12 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.

32. The method of claim 2, wherein the TLR signaling activity is measured  
30 by phosphorylation.

33. The method of claim 32, wherein phosphorylation is total cellular  
phosphorylation.

34. The method of claim 32, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NFkB subunits, c-Jun and c-Fos.

5

35. The method of claim 1 or 2, wherein the TLR signaling activity is measured by gene expression.

36. The method of claim 1, wherein the TLR signaling activity is measured  
10 by gene expression selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression, IP-10 expression, and TNF- $\alpha$  expression.

37. The method of claim 35, wherein TLR signaling activity is measured  
15 by microarray techniques.

38. The method of claim 2, wherein the TLR signaling activity is measured by cell proliferation.

20 39. The method of claim 1 or 2, wherein TLR signaling activity is measured by cell surface marker expression.

40. The method of claim 1, wherein TLR signaling activity is measured by cell surface expression of CD71, CD86 or HLA-DR.

25

41. The method of claim 2, wherein TLR signaling activity is measured by CD71 cell surface expression, CD86 cell surface expression, HLA-DR cell surface expression, CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

30

42. The method of claim 2, wherein TLR signaling activity is measured by antibody secretion.

- 77 -

43. The method of claim 42, wherein the antibody secretion is IgM secretion.

44. A composition comprising  
an RPMI 8226 cell stably transfected with a nucleic acid encoding a TLR  
5 polypeptide, or a fragment thereof.

45. The composition of claim 44, further comprising a reporter construct  
comprising a promoter and a reporter sequence wherein the promoter is a TLR responsive  
promoter.

10

46. The composition of claim 45, wherein the TLR responsive promoter  
comprises a nucleic acid sequence selected from the group consisting of an NF- $\kappa$ B binding  
site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3  
binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding  
15 site, and a TARE.

47. The composition of claim 45, wherein the reporter sequence is selected  
from the group consisting of a luciferase sequence, a  $\beta$ -galactosidase sequence, a green  
fluorescent protein sequence, a secreted alkaline phosphatase sequence and a chloramphenicol  
20 transferase sequence.

48. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is a human TLR polypeptide or fragment thereof.

49. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6,  
TLR7, TLR8, TLR9 and TLR10.

50. The composition of claim 44, wherein the TLR polypeptide or fragment  
30 thereof is a human TLR polypeptide.

51. A screening method for identifying agonists of Toll-like receptor (TLR)  
signaling activity, comprising

- 78 -

contacting an cell that ectopically expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

5 wherein the cell that ectopically expresses a TLR is selected from the group consisting of RPMI 8226, RAMOS, Raji, Nalm, THP-1, KG-1 and 293 HEK.

52. The method of claim 51, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a  
10 reference TLR signaling activity.

53. The method of claim 52, wherein the reference compound is a positive reference compound.

15 54. The method of claim 53, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

20 55. The method of claim 54, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

25 56. The method of claim 54, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

57. The method of claim 52, wherein the reference compound is negative reference compound.

30 58. The method of claim 57, wherein the negative reference compound is medium alone.

59. The method of claim 51, wherein the test compound is a nucleic acid.

- 79 -

60. The method of claim 59, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.

5 61. The method of claim 59, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

62. The method of claim 59, wherein the nucleic acid is a DNA, an RNA, or a DNA-RNA hybrid.

10

63. The method of claim 51, wherein the test compound is a non-nucleic acid small molecule.

64. The method of claim 51, wherein the test compound comprises an  
15 amino acid, a carbohydrate, a lipid, or a hormone.

65. The method of claim 64, wherein the carbohydrate is a polysaccharide.

66. The method of claim 51, wherein the test compound is derived from a  
20 molecular library.

67. The method of claim 51, wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-6 expression, IL-6 production, IL-6 secretion, IL-8 expression, IL-8 production, IL-8 secretion,  
25 IL-10 expression, IL-10 production, IL-10 secretion, IL-12 expression, IL-12 production, IL-12 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.

68. The method of claim 51, wherein the TLR is selected from the group  
30 consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

69. The method of claim 51, wherein the TLR is a human TLR.

70. The method of claim 51, wherein the cell is transfected with a reporter construct.

71. The method of claim 70, wherein the reporter construct is selected from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

72. The method of claim 71, wherein the TLR signaling activity is measured by luciferase expression,  $\beta$ -galactosidase expression, chloramphenicol expression, acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.

73. The method of claim 71, wherein the reporter construct comprises a TLR responsive promoter.

74. The method of claim 25 or 73, wherein the TLR responsive promoter is a TLR1 responsive promoter, a TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a TLR10 responsive promoter.

75. The method of claim 73, wherein the TLR responsive promoter comprises a transcription factor binding site selected from the group consisting of an NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

76. The method of claim 73, wherein the TLR responsive promoter is a promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter

- 81 -

region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

5

77. The method of claim 51, wherein the cell is stably transfected with a TLR nucleic acid.

78. The method of claim 70, wherein the cell is stably transfected with the  
10 reporter construct.

79. The method of claim 51, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

80. The method of claim 79, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, TNF- $\alpha$  secretion, IL-10 secretion and IP-10 secretion.  
15

81. The method of claim 79, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-6 secretion and IL-12 secretion.  
20

82. The method of claim 51, wherein the TLR signaling activity is measured by phosphorylation.

83. The method of claim 82, wherein phosphorylation is total cellular phosphorylation.  
25

84. The method of claim 82, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.  
30

85. The method of claim 51, wherein the TLR signaling activity is measured by gene expression.

86. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-8 expression, IL-10 expression, IP-10 expression, CD71 expression, CD86 expression and HLA-DR expression.

5

87. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- $\alpha$  expression.

88. The method of claim 51, wherein the TLR signaling activity is  
10 measured by microarray techniques.

89. The method of claim 51, wherein the TLR signaling activity is measured by cell proliferation.

90. The method of claim 51, wherein the TLR signaling activity is  
15 measured by cell surface marker expression.

91. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface  
20 expression and HLA-DR cell surface expression.

92. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

25

93. The method of claim 51, wherein the TLR signaling activity is measured by antibody secretion.

94. The method of claim 93, wherein the antibody secretion is IgM  
30 secretion.

95. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising



contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

5 wherein a test level that is less than a reference level is indicative of test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell.

10 96. The method of claim 95, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an immunostimulatory imidazoquinoline compound.

15 97. The method of claim 96, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

98. The method of claim 96, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

20

99. The method of claim 95, wherein the test compound is a nucleic acid.

100. The method of claim 99, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a  
25 poly-G motif.

101. The method of claim 99, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

30 102. The method of claim 99, wherein the nucleic acid is a DNA, an RNA or a DNA-RNA hybrid.

- 84 -

103. The method of claim 95, wherein the test compound is a non-nucleic acid small molecule.

104. The method of claim 95, wherein the test compound comprises an  
5 amino acid, a carbohydrate, a lipid, or a hormone.

105. The method of claim 104, wherein the carbohydrate is a polysaccharide.

106. The method of claim 95, wherein the test compound is derived from a  
10 molecular library.

107. The method of claim 95, wherein the experimental cell is transfected with a nucleic acid.  
15

108. The method of claim 107, wherein the nucleic acid encodes a TLR or a reporter construct.

109. The method of claim 108, wherein the TLR is selected from the group  
20 consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

110. The method of claim 108, wherein the TLR is a human TLR.

111. The method of claim 108, wherein the reporter construct is selected  
25 from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

112. The method of claim 111, wherein the TLR signaling activity is  
30 selected from the group consisting of luciferase expression,  $\beta$ -galactosidase expression, chloramphenicol acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.

- 85 -

113. The method of claim 108, wherein the reporter construct comprises a TLR responsive promoter.

114. The method of claim 113, wherein the TLR responsive promoter  
5 comprises a transcription factor binding site selected from the group consisting of an NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

10 115. The method of claim 113, wherein the TLR responsive promoter is a promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter  
15 region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

20 116. The method of claim 113, wherein the TLR responsive promoter is selected from the group consisting of a TLR1 responsive promoter, TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a TLR10 responsive promoter.

25

117. The method of claim 107, wherein the cell is stably transfected with the nucleic acid.

118. The method of claim 95, wherein the TLR signaling activity is  
30 measured by cytokine secretion or chemokine secretion.

- 86 -

119. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-6 secretion, IL-12 secretion and TNF- $\alpha$  secretion.

5 120. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, IL-10 secretion and IP-10 secretion.

121. The method of claim 95, wherein the TLR signaling activity is  
10 measured by phosphorylation.

122. The method of claim 121, wherein phosphorylation is total cellular phosphorylation.

15 123. The method of claim 122, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

124. The method of claim 95, wherein the TLR signaling activity is  
20 measured by gene expression.

125. The method of claim 124, wherein the gene expression is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression and IP-10 expression.

25 126. The method of claim 124, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- $\alpha$  expression.

127. The method of claim 95, wherein the TLR signaling activity is  
30 measured by microarray techniques.

128. The method of claim 95, wherein the TLR signaling activity is measured by cell proliferation.

129. The method of claim 95, wherein the TLR signaling activity is measured by cell surface marker expression.

5 130. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface expression and HLA-DR MHC class II cell surface expression.

10 131. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

132. The method of claim 95, wherein the TLR signaling activity is measured by antibody secretion.

15 133. The method of claim 132, wherein the antibody secretion is IgM secretion.

20 134. The method of claim 95, wherein the cell is contacted to the positive reference compound and the test compound simultaneously.

135. The method of claim 95, wherein the cell is contacted to the positive reference compound prior to contact with the test compound.

25 136. The method of claim 95, wherein the cell is contacted to the test compound prior to contact with the positive reference compound.

30 137. A method for quality assessment of a test composition containing a known Toll like receptor (TLR) ligand, comprising:  
measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule;  
measuring a test activity of a test composition comprising the known TLR ligand; and  
comparing the test activity to the reference activity.

138. The method of claim 137, further comprising selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

5

139. The method of claim 1, wherein the reference composition is a first production lot of a pharmaceutical composition comprising the known TLR ligand, and wherein the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand.

10

140. The method of claim 137, wherein the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and wherein the test composition is a second in-process lot of a composition comprising the known TLR ligand.

15

141. The method of claim 137, wherein the measuring the reference activity comprises contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and wherein the measuring the test activity comprises contacting the test composition with the isolated cell expressing a TLR responsive to the known TLR ligand.

20

142. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand comprises an expression vector for the TLR responsive to the known TLR ligand.

25

143. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand.

30

144. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226.

- 89 -

145. The method of claim 137, wherein the measuring the reference activity and the measuring the test activity each comprise measuring signaling activity mediated by a TLR responsive to the known TLR ligand.

5 146. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of NF- $\kappa$ B response element.

147. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of interferon-stimulated response element (ISRE).

10

148. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IFN- $\alpha$  promoter.

149. The method of claim 145, wherein the signaling activity is activity of a  
15 reporter gene under control of an IFN- $\beta$  promoter.

150. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-6 promoter.

20 151. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-8 promoter.

152. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-12 p40 promoter.

25

153. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of a RANTES promoter.

154. The method of claim 137, wherein the known TLR ligand is a TLR9  
30 ligand.

155. The method of claim 137, wherein the known TLR ligand is a TLR3 ligand.

156. The method of claim 137, wherein the known TLR ligand is a TLR7 ligand.

5 157. The method of claim 137, wherein the known TLR ligand is a TLR8 ligand.

158. The method of claim 137, wherein the known TLR ligand is an immunostimulatory nucleic acid.

10

159. The method of claim 137, wherein the known TLR ligand is a CpG nucleic acid.

160. The method of claim 137, wherein the known TLR ligand is an immunoinhibitory nucleic acid.

15

161. A method for quality assessment of a test lot of a pharmaceutical product containing a known TLR9 ligand, comprising:

20 measuring a reference activity of a reference lot of a pharmaceutical product comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid molecule;

measuring a test activity of a test lot of a pharmaceutical product comprising the known TLR9 ligand;

comparing the test activity to the reference activity; and

25 rejecting the test lot if the test activity falls outside of a predetermined range of variance about the reference activity.

162. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID NO:1).

30



- 91 -

163. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTGACGTTTTGTCGTT-3' (SEQ ID NO:139).

5 164. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTGTCGTTTTTTTCGA-3' (SEQ ID NO:140).

10 165. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGTCGTTTCGTCGTT-3' (SEQ ID NO:141).

15 166. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGTCGTTTTGTCGTT-3' (SEQ ID NO:142).

20 167. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTTCGGTCGTTTT-3' (SEQ ID NO:143).

168. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTTCGTGCGTTTTT-3' (SEQ ID NO:144).

25 169. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTCGGCGGCCGCCG-3' (SEQ ID NO:145).

30 170. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTC\_GTTTTAC\_GGCGCC\_GTGCCG-3' (SEQ ID NO:146), wherein every internucleoside linkage is phosphorothioate except for those indicated by “\_”, which are phosphodiester.

- 92 -

171. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

5 wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-1 cell, and the TLR is TLR9.

10 172. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

15 wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

wherein the cell is a Raji cell or a RAMOS cell, and the TLR is TLR7.

173. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

20 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

25 wherein the cell is a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell, and the TLR is TLR3.

174. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

30 contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

- 93 -

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell, and the TLR is TLR9.

5

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

10

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell and a Raji cell, and the TLR is TLR7.

15

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

20

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

25

wherein the cell is selected from the group consisting of a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is TLR3.

176. A screening method for identifying an enhancer of a Toll-like receptor (TLR) agonist, comprising

30

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity, and

contacting a cell with the positive reference compound and a test compound and measuring a test level of TLR signaling activity,

wherein the positive reference compound is a TLR agonist, and a test level that is greater than the reference level is indicative of a test compound that is an enhancer of a TLR agonist.

5

177. The method of claim 176, wherein the positive reference compound is an immunostimulatory nucleic acid.

10

178. The method of claim 176, wherein the positive reference compound is an imidazoquinoline compound.

180. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, a RAMOS cell, a Jurkat cell, a HeLa cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is TLR3.

15

181. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, an RPMI 8226 cell, a RAMOS cell, and a THP-1 cell, and the TLR is TLR9.

20

182. The method of claim 176, wherein the cell is selected from the group consisting of a Raji cell, an RPMI 8226 cell and a RAMOS cell, and the TLR is TLR7.

25

183. The method of claim 1, wherein the TLR is TLR7 or TLR9.

184. The method of claim 172-175 or 176, wherein the cell is unmodified.

1/15




Fig. 1

2/15




Fig. 2

3/15




Fig. 3

4/15




Fig. 4



5/15





Fig. 5

6/15

**Fig. 6**





Fig. 7

8/15



**Fig. 8**

9/15




Fig. 9

10/15




Fig. 10




Fig. 11

11/15




Fig. 12

12/15




Fig. 13




Fig. 14



13/15




Fig. 15




Fig. 16




Fig. 17

14/15




Fig. 18A




Fig. 18B




Fig. 19





Fig. 20



## SEQUENCE LISTING

<110> COLEY PHARMACEUTICAL GmbH  
COLEY PHARMACEUTICAL GROUP INC.

<120> METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT OF TLR  
LIGANDS

<130> C1041.70024W000

<140> not yet assigned  
<141> 2004-04-22

<150> US 60/464,586  
<151> 2003-04-22

<150> US 60/464,588  
<151> 2003-04-22

<160> 161

<170> PatentIn version 3.2

<210> 1  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 1  
tcgctcgtttt gtcggtttgt cgtt 24

<210> 2  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 2  
tccaggactt ctctcagggt 20

<210> 3  
<211> 2600  
<212> DNA  
<213> Homo sapiens

<400> 3  
ggatccaaag gagacctata gtgactocca ggagctctta gtgaccaagt gaaggtagctt 60  
gtgggggtca ttgtgcccatt tgctctttca ctgctttcaa ctggtagttg tgggttgaag 120  
cactggacaa tgccacatac tttgtggatg gtgtgggtct tgggggtcat catcagcctc 180  
tccaaggaag aatcctccaa tcaggcttct ctgtcttctg accgcaatgg tatctgcaag 240

```

ggcagctcag gatctttaaa ctccattccc tcagggctca cagaagctgt aaaaagcctt 300
gacctgtcca acaacaggat cacctacatt agcaacagtg acctacagag gtgtgtgaac 360
ctccaggctc tgggtctgac atccaatgga attaacacaa tagaggaaga ttctttttct 420
tccctgggca gtcttgaaca tttagactta tcctataatt acttatctaa tttatcgtct 480
tcctggttca agcccccttc ttctttaaca ttcttaaact tactgggaaa tccttacaaa 540
accctagggg aaacatctct tttttctcat ctcaaaaaat tgcaaatcct gagagtggga 600
aatatggaca ccttcactaa gattcaaaga aaagattttg ctggacttac cttccttgag 660
gaacttgaga ttgatgcttc agatctacag agctatgagc caaaaagttt gaagtcaatt 720
cagaacgtaa gtcactgat ccttcatatg aagcagcata ttttactgct ggagattttt 780
gtagatgtta caagttccgt ggaatgtttg gaactgagag atactgattt ggacactttc 840
catttttcag aactatccac tggtgaaaca aattcattga ttaaaaagtt tacatttaga 900
aatgtgaaaa tcaccgatga aagtttggtt caggttatga aacttttgaa tcagatttct 960
ggattgttag aattagagtt tgatgactgt acccttaatg gagttggtaa ttttagagca 1020
tctgataatg acagagttat agatccaggt aaagtggaaa cgtaacaat ccggaggctg 1080
catattccaa ggttttactt attttatgat ctgagcactt tatattcact tacagaaaga 1140
gttaaaagaa tcacagtaga aaacagtaaa gtttttctgg ttccttggtt actttcacia 1200
catttaaaat cattagaata cttggatctc agtgaaaatt tgatggttga agaatacttg 1260
aaaaattcag cctgtgagga tgcttgccc tctctacaaa ctttaatttt aaggcaaaat 1320
catttgcat cattggaaaa aaccggagag actttgctca ctctgaaaaa cttgactaac 1380
attgatatca gtaagaatag ttttcattct atgcctgaaa cttgtcagtg gccagaaaag 1440
atgaaatatt tgaacttatc cagcacacga atacacagtg taacaggctg cattcccaag 1500
acactggaaa ttttagatgt tagcaacaac aatctcaatt tattttcttt gaatttgccg 1560
caactcaaag aactttatat ttccagaaat aagttgatga ctctaccaga tgctccctc 1620
ttacctatgt tactagtatt gaaaatcagt aggaatgcaa taactacgtt ttctaaggag 1680
caacttgact catttcacac actgaagact ttggaagctg gtggcaataa cttcatttgc 1740
tcctgtgaat tcctctcctt cactcaggag cagcaagcac tggccaaagt cttgattgat 1800
tggccagcaa attacctgtg tgactctcca tcccatgtgc gtggccagca gggttcaggat 1860
gtccgcctct cgggtgtcggg atgtcacagg acagcactgg tgtctggcat gtgctgtgct 1920
ctgttcctgc tgatcctgct cacgggggtc ctgtgccacc gtttccatgg cctgtggtat 1980
atgaaaatga tgtgggcctg gctccaggcc aaaaggaagc ccaggaaaag tcccagcagg 2040
aacatctgct atgatgcatt tgtttcttac agtgagcggg atgcctactg ggtggagaac 2100

```

cttatggtcc aggagctgga gaacttcaat ccccccttca agttgtgtct tcataagcgg 2160  
 gacttcattc ctggcaagtg gatcattgac aatatcattg actccattga aaagagccac 2220  
 aaaactgtct ttgtgctttc tgaaaacttt gtgaagagtg agtggtgcaa gtatgaactg 2280  
 gacttctccc atttccgtct ttttgaagag aacaatgatg ctgccattct cattcttctg 2340  
 gagcccattg agaaaaaagc cattccccag cgcttctgca agctgcgga gataatgaac 2400  
 accaagacct acctggagtg gcccatggac gaggctcagc gggaaggatt ttgggtaaat 2460  
 ctgagagctg cgataaagtc ctaggttccc atatttaaga ccagtctttg tctagttggg 2520  
 atctttatgt cactagttat agttaagttc attcagacat aattatataa aaactacgtg 2580  
 gatgtaccgt catttgagga 2600

<210> 4  
 <211> 784  
 <212> PRT  
 <213> Homo sapiens

<400> 4

Met Pro His Thr Leu Trp Met Val Trp Val Leu Gly Val Ile Ile Ser  
 1 5 10 15  
 Leu Ser Lys Glu Glu Ser Ser Asn Gln Ala Ser Leu Ser Cys Asp Arg  
 20 25 30  
 Asn Gly Ile Cys Lys Gly Ser Ser Gly Ser Leu Asn Ser Ile Pro Ser  
 35 40 45  
 Gly Leu Thr Glu Ala Val Lys Ser Leu Asp Leu Ser Asn Asn Arg Ile  
 50 55 60  
 Thr Tyr Ile Ser Asn Ser Asp Leu Gln Arg Cys Val Asn Leu Gln Ala  
 65 70 75 80  
 Leu Val Leu Thr Ser Asn Gly Ile Asn Thr Ile Glu Glu Asp Ser Phe  
 85 90 95  
 Ser Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Tyr Asn Tyr Leu  
 100 105 110  
 Ser Asn Leu Ser Ser Ser Trp Phe Lys Pro Leu Ser Ser Leu Thr Phe  
 115 120 125  
 Leu Asn Leu Leu Gly Asn Pro Tyr Lys Thr Leu Gly Glu Thr Ser Leu  
 130 135 140  
 Phe Ser His Leu Thr Lys Leu Gln Ile Leu Arg Val Gly Asn Met Asp  
 145 150 155 160  
 Thr Phe Thr Lys Ile Gln Arg Lys Asp Phe Ala Gly Leu Thr Phe Leu  
 165 170 175  
 Glu Glu Leu Glu Ile Asp Ala Ser Asp Leu Gln Ser Tyr Glu Pro Lys  
 180 185 190

Ser Leu Lys Ser Ile Gln Asn Val Ser His Leu Ile Leu His Met Lys  
 195 200 205  
 Gln His Ile Leu Leu Leu Glu Ile Phe Val Asp Val Thr Ser Ser Val  
 210 215 220  
 Glu Cys Leu Glu Leu Arg Asp Thr Asp Leu Asp Thr Phe His Phe Ser  
 225 230 235 240  
 Glu Leu Ser Thr Gly Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe  
 245 250 255  
 Arg Asn Val Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu  
 260 265 270  
 Leu Asn Gln Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr  
 275 280 285  
 Leu Asn Gly Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile  
 290 295 300  
 Asp Pro Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His Ile Pro  
 305 310 315 320  
 Arg Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Leu Tyr Ser Leu Thr Glu  
 325 330 335  
 Arg Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro  
 340 345 350  
 Cys Leu Leu Ser Gln His Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser  
 355 360 365  
 Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp  
 370 375 380  
 Ala Trp Pro Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala  
 385 390 395 400  
 Ser Leu Glu Lys Thr Gly Glu Thr Leu Leu Thr Leu Lys Asn Leu Thr  
 405 410 415  
 Asn Ile Asp Ile Ser Lys Asn Ser Phe His Ser Met Pro Glu Thr Cys  
 420 425 430  
 Gln Trp Pro Glu Lys Met Lys Tyr Leu Asn Leu Ser Ser Thr Arg Ile  
 435 440 445  
 His Ser Val Thr Gly Cys Ile Pro Lys Thr Leu Glu Ile Leu Asp Val  
 450 455 460  
 Ser Asn Asn Asn Leu Asn Leu Phe Ser Leu Asn Leu Pro Gln Leu Lys  
 465 470 475 480  
 Glu Leu Tyr Ile Ser Arg Asn Lys Leu Met Thr Leu Pro Asp Ala Ser  
 485 490 495  
 Leu Leu Pro Met Leu Leu Val Leu Lys Ile Ser Arg Asn Ala Ile Thr  
 500 505 510  
 Thr Phe Ser Lys Glu Gln Leu Asp Ser Phe His Thr Leu Lys Thr Leu

515                      520                      525  
 Glu Ala Gly Gly Asn Asn Phe Ile Cys Ser Cys Glu Phe Leu Ser Phe  
 530                      535                      540  
 Thr Gln Glu Gln Gln Ala Leu Ala Lys Val Leu Ile Asp Trp Pro Ala  
 545                      550                      555                      560  
 Asn Tyr Leu Cys Asp Ser Pro Ser His Val Arg Gly Gln Gln Val Gln  
 565                      570                      575  
 Asp Val Arg Leu Ser Val Ser Glu Cys His Arg Thr Ala Leu Val Ser  
 580                      585                      590  
 Gly Met Cys Cys Ala Leu Phe Leu Leu Ile Leu Leu Thr Gly Val Leu  
 595                      600                      605  
 Cys His Arg Phe His Gly Leu Trp Tyr Met Lys Met Met Trp Ala Trp  
 610                      615                      620  
 Leu Gln Ala Lys Arg Lys Pro Arg Lys Ala Pro Ser Arg Asn Ile Cys  
 625                      630                      635                      640  
 Tyr Asp Ala Phe Val Ser Tyr Ser Glu Arg Asp Ala Tyr Trp Val Glu  
 645                      650                      655  
 Asn Leu Met Val Gln Glu Leu Glu Asn Phe Asn Pro Pro Phe Lys Leu  
 660                      665                      670  
 Cys Leu His Lys Arg Asp Phe Ile Pro Gly Lys Trp Ile Ile Asp Asn  
 675                      680                      685  
 Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser  
 690                      695                      700  
 Glu Asn Phe Val Lys Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser  
 705                      710                      715                      720  
 His Phe Arg Leu Phe Glu Glu Asn Asn Asp Ala Ala Ile Leu Ile Leu  
 725                      730                      735  
 Leu Glu Pro Ile Glu Lys Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu  
 740                      745                      750  
 Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Met Asp Glu  
 755                      760                      765  
 Ala Gln Arg Glu Gly Phe Trp Val Asn Leu Arg Ala Ala Ile Lys Ser  
 770                      775                      780

&lt;210&gt; 5

&lt;211&gt; 2824

&lt;212&gt; DNA

&lt;213&gt; murine

&lt;400&gt; 5

gcccccatg gccatatggg caccggggag cggcggctgg aggactccta ggctcctggg 60  
 caggcgggtca catggcagaa gatgtgtccg caatcatagt ttctgatggg gaagggttga 120  
 cggcagtcctc tgcgacctag aagtggaaaa gatgtcgttc aaggaggtgc ggactgtttc 180



cttctgacca	ggatccttggt	tctgagtgt	ggggcttcac	ttctctgctt	ttcgttcatc	240
tctggagcat	ccgaattgca	tcaccgggtca	gaaaacaact	taccgaaacc	tcagacaaaag	300
cgtcaaattct	cagaggatgc	tacgagctct	ttggctcttc	tggatcttgg	tggccataac	360
agtctctctc	agcaaacgct	gttctgctca	ggagtctctg	tcattgtgatg	cttctgggggt	420
gtgtgatggc	cgctccaggt	ctttcacctc	tattccctcc	ggactcacag	cagccatgaa	480
aagccttgac	ctgtctttca	acaagatcac	ctacattggc	catggtgacc	tccgagcgtg	540
tgcgaacctc	caggttctga	ttttgaagtc	cagcagaatc	aatacaatag	agggagacgc	600
cttttattct	ctgggcagtc	ttgaacattt	ggatttgtct	gataatcacc	tatctagttt	660
atcttcctcc	tgggtcgggc	ccctttcctc	tttgaaatac	ttaaacttaa	tgggaaatcc	720
ttaccagaca	ctgggggtaa	catcgctttt	tcccaatctc	acaaatttac	aaaccctcag	780
gataggaaat	gtagagactt	tcagtgagat	aaggagaata	gattttgctg	ggctgacttc	840
tctcaatgaa	cttgaaatta	aggcattaag	tctccggaat	tatcagtccc	aaagtctaaa	900
gtcgatccgc	gacatccatc	acctgactct	tcacttaagc	gagtctgctt	tcctgctgga	960
gatttttgca	gatattctga	gttctgtgag	atatttagaa	ctaagagata	ctaacttggc	1020
caggttccag	ttttcaccac	tgcccgtaga	tgaagtcagc	tcaccgatga	agaagctggc	1080
attccgaggc	tcggttctca	ctgatgaaag	ctttaacgag	ctcctgaagc	tgttgcgtaa	1140
catcttgga	ctgtcggagg	tagagttcga	cgactgtacc	ctcaatgggc	tcggcgattt	1200
caaccctcgc	gagtcagacg	tagtgagcga	gctgggtaaa	gtagaaacag	tcactatccg	1260
gaggttgcat	atccccagct	tctatttggt	ttatgacctg	agtactgtct	attccctcct	1320
ggagaagggtg	aagcgaatca	cagtagagaa	cagcaaggtc	ttcctgggtc	cctgctcggt	1380
ctcccagcat	ttaaaatcat	tagaattctt	agacctcagc	gaaaatctga	tgggtgaaga	1440
atatttgaag	aactcagcct	gtaagggagc	ctggccttct	ctacaaacct	tagttttgag	1500
ccagaatcat	ttgagatcaa	tgcaaaaaac	aggagagatt	ttgctgactc	tgaaaaacct	1560
gacctccctt	gacatcagca	ggaacacttt	tcattccgatg	cccagacagct	gtcagtggcc	1620
agaaaagatg	cgcttcctga	atattgtccag	tacagggatc	cgggtggtaa	aaacgtgcat	1680
tcctcagacg	ctggagggtg	tggatgttag	taacaacaat	cttgactcat	tttctttgtt	1740
cttgccctcg	ctgcaagagc	tctatatattc	cagaaataag	ctgaaaacac	tcccagatgc	1800
ttcgttgttc	cctgtgttgc	tggatcatgaa	aatcagagag	aatgcagtaa	gtactttctc	1860
taaagaccaa	cttggttctt	ttcccaaact	ggagactctg	gaagcaggcg	acaaccactt	1920
tgtttgctcc	tgcgaactcc	tatcctttac	tatggagacg	ccagctctgg	ctcaaactct	1980
ggttgactgg	ccagacagct	acctgtgtga	ctctccgcct	cgctgcacg	gccacaggct	2040
tcaggatgcc	cggccctccg	tcttggaatg	tcaccaggct	gcactggtgt	ctggagtctg	2100

```

ctgtgccctt ctctgttga tcttgctcgt aggtgccctg tgccaccatt tccacgggct 2160
gtggtacctg agaatgatgt gggcgtggct ccaggccaag aggaagccca agaaagctcc 2220
ctgcaggggac gtttgctatg atgcctttgt ttctacagt gagcaggatt cccattgggt 2280
ggagaacctc atgggtccagc agctggagaa ctctgacctg ccctttaagc tgtgtctcca 2340
caagcgggac ttcgttccgg gcaaattgat cattgacaac atcatcgatt ccatcgaaaa 2400
gagccacaaa actgtgttcg tgctttctga gaacttcgta cggagcgagt ggtgcaagta 2460
cgaactggac ttctccact tcaggctctt tgacgagaac aacgacgcgg ccatccttgt 2520
tttgctggag cccattgaga ggaaagccat tcccagcgc ttctgcaaac tgcgcaagat 2580
aatgaacacc aagacctacc tggagtggcc cttggatgaa ggccagcagg aagtgttttg 2640
ggtaaatctg agaactgcaa taaagtccta gggtctccac ccagttcttg acttccttaa 2700
ctaaggtctt tgtgacacaa actgtaacaa agtttataag taacatagaa ttgtattatt 2760
gaggatatta actatgggtt ttgtottgaa tactgttata taaatatgtg acatcaggct 2820
ttag 2824

```

<210> 6  
 <211> 784  
 <212> PRT  
 <213> murine

<400> 6

```

Met Leu Arg Ala Leu Trp Leu Phe Trp Ile Leu Val Ala Ile Thr Val
1           5           10          15

Leu Phe Ser Lys Arg Cys Ser Ala Gln Glu Ser Leu Ser Cys Asp Ala
          20          25          30

Ser Gly Val Cys Asp Gly Arg Ser Arg Ser Phe Thr Ser Ile Pro Ser
          35          40          45

Gly Leu Thr Ala Ala Met Lys Ser Leu Asp Leu Ser Phe Asn Lys Ile
          50          55          60

Thr Tyr Ile Gly His Gly Asp Leu Arg Ala Cys Ala Asn Leu Gln Val
65          70          75          80

Leu Ile Leu Lys Ser Ser Arg Ile Asn Thr Ile Glu Gly Asp Ala Phe
          85          90          95

Tyr Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Asp Asn His Leu
          100         105         110

Ser Ser Leu Ser Ser Ser Trp Phe Gly Pro Leu Ser Ser Leu Lys Tyr
          115         120         125

Leu Asn Leu Met Gly Asn Pro Tyr Gln Thr Leu Gly Val Thr Ser Leu
          130         135         140

```

Phe Pro Asn Leu Thr Asn Leu Gln Thr Leu Arg Ile Gly Asn Val Glu  
 145 150 155 160  
 Thr Phe Ser Glu Ile Arg Arg Ile Asp Phe Ala Gly Leu Thr Ser Leu  
 165 170 175  
 Asn Glu Leu Glu Ile Lys Ala Leu Ser Leu Arg Asn Tyr Gln Ser Gln  
 180 185 190  
 Ser Leu Lys Ser Ile Arg Asp Ile His His Leu Thr Leu His Leu Ser  
 195 200 205  
 Glu Ser Ala Phe Leu Leu Glu Ile Phe Ala Asp Ile Leu Ser Ser Val  
 210 215 220  
 Arg Tyr Leu Glu Leu Arg Asp Thr Asn Leu Ala Arg Phe Gln Phe Ser  
 225 230 235 240  
 Pro Leu Pro Val Asp Glu Val Ser Ser Pro Met Lys Lys Leu Ala Phe  
 245 250 255  
 Arg Gly Ser Val Leu Thr Asp Glu Ser Phe Asn Glu Leu Leu Lys Leu  
 260 265 270  
 Leu Arg Tyr Ile Leu Glu Leu Ser Glu Val Glu Phe Asp Asp Cys Thr  
 275 280 285  
 Leu Asn Gly Leu Gly Asp Phe Asn Pro Ser Glu Ser Asp Val Val Ser  
 290 295 300  
 Glu Leu Gly Lys Val Glu Thr Val Thr Ile Arg Arg Leu His Ile Pro  
 305 310 315 320  
 Gln Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Val Tyr Ser Leu Leu Glu  
 325 330 335  
 Lys Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro  
 340 345 350  
 Cys Ser Phe Ser Gln His Leu Lys Ser Leu Glu Phe Leu Asp Leu Ser  
 355 360 365  
 Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Lys Gly  
 370 375 380  
 Ala Trp Pro Ser Leu Gln Thr Leu Val Leu Ser Gln Asn His Leu Arg  
 385 390 395 400  
 Ser Met Gln Lys Thr Gly Glu Ile Leu Leu Thr Leu Lys Asn Leu Thr  
 405 410 415  
 Ser Leu Asp Ile Ser Arg Asn Thr Phe His Pro Met Pro Asp Ser Cys  
 420 425 430  
 Gln Trp Pro Glu Lys Met Arg Phe Leu Asn Leu Ser Ser Thr Gly Ile  
 435 440 445  
 Arg Val Val Lys Thr Cys Ile Pro Gln Thr Leu Glu Val Leu Asp Val  
 450 455 460  
 Ser Asn Asn Asn Leu Asp Ser Phe Ser Leu Phe Leu Pro Arg Leu Gln

465                                      470                                      475                                      480  
 Glu Leu Tyr Ile Ser Arg Asn Lys Leu Lys Thr Leu Pro Asp Ala Ser  
    485                                      490                                      495  
  
 Leu Phe Pro Val Leu Leu Val Met Lys Ile Arg Glu Asn Ala Val Ser  
    500                                      505                                      510  
  
 Thr Phe Ser Lys Asp Gln Leu Gly Ser Phe Pro Lys Leu Glu Thr Leu  
    515                                      520                                      525  
  
 Glu Ala Gly Asp Asn His Phe Val Cys Ser Cys Glu Leu Leu Ser Phe  
    530                                      535                                      540  
  
 Thr Met Glu Thr Pro Ala Leu Ala Gln Ile Leu Val Asp Trp Pro Asp  
 545                                      550                                      555                                      560  
  
 Ser Tyr Leu Cys Asp Ser Pro Pro Arg Leu His Gly His Arg Leu Gln  
    565                                      570                                      575  
  
 Asp Ala Arg Pro Ser Val Leu Glu Cys His Gln Ala Ala Leu Val Ser  
    580                                      585                                      590  
  
 Gly Val Cys Cys Ala Leu Leu Leu Leu Ile Leu Leu Val Gly Ala Leu  
    595                                      600                                      605  
  
 Cys His His Phe His Gly Leu Trp Tyr Leu Arg Met Met Trp Ala Trp  
 610                                      615                                      620  
  
 Leu Gln Ala Lys Arg Lys Pro Lys Lys Ala Pro Cys Arg Asp Val Cys  
 625                                      630                                      635                                      640  
  
 Tyr Asp Ala Phe Val Ser Tyr Ser Glu Gln Asp Ser His Trp Val Glu  
    645                                      650                                      655  
  
 Asn Leu Met Val Gln Gln Leu Glu Asn Ser Asp Pro Pro Phe Lys Leu  
    660                                      665                                      670  
  
 Cys Leu His Lys Arg Asp Phe Val Pro Gly Lys Trp Ile Ile Asp Asn  
    675                                      680                                      685  
  
 Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser  
    690                                      695                                      700  
  
 Glu Asn Phe Val Arg Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser  
 705                                      710                                      715                                      720  
  
 His Phe Arg Leu Phe Asp Glu Asn Asn Asp Ala Ala Ile Leu Val Leu  
    725                                      730                                      735  
  
 Leu Glu Pro Ile Glu Arg Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu  
    740                                      745                                      750  
  
 Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Leu Asp Glu  
    755                                      760                                      765  
  
 Gly Gln Gln Glu Val Phe Trp Val Asn Leu Arg Thr Ala Ile Lys Ser  
    770                                      775                                      780

<210> 7  
 <211> 3029  
 <212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

gcggccgcgt cgacgaaatg tctggatttg gactaaagaa aaaaggaaag gctagcagtc 60

atccaacaga atcatgagac agactttgcc ttgtatctac ttttgggggg gccttttgcc 120

ctttgggatg ctgtgtgcat cctccaccac caagtgcact gttagccatg aagttgctga 180

ctgcagccac ctgaagttga ctcaggtacc cgatgatcta cccacaaaca taacagtgtt 240

gaaccttacc cataatcaac tcagaagatt accagccgcc aacttcacaa ggtatagcca 300

gctaactagc ttggatgtag gatttaacac catctcaaaa ctggagccag aattgtgcca 360

gaaacttccc atgttaaaag ttttgaacct ccagcacaat gagctatctc aactttctga 420

taaaaccttt gccttctgca cgaatttgac tgaactccat ctcattgtcca actcaatcca 480

gaaaattaaa aataatccct ttgtcaagca gaagaattta atcacattag atctgtctca 540

taatggcttg tcatctacaa aattaggaac tcagggttcag ctggaaaatc tccaagagct 600

tctattatca aacaataaaa ttcaagcgct aaaaagtga gaactggata tctttgccaa 660

ttcatcttta aaaaaattag agttgtcatc gaatcaaatt aaagagtttt ctccagggtg 720

ttttcacgca attggaagat tatttggcct ctttctgaac aatgtccagc tgggtcccag 780

ccttacagag aagctatgtt tggaattagc aaacacaagc attcggaatc tgtctctgag 840

taacagccag ctgtccacca ccagcaatac aactttcttg ggactaaagt ggacaaatct 900

cactatgctc gatctttcct acaacaactt aaatgtggtt ggtaacgatt cctttgcttg 960

gcttcacaaa ctagaatatt tcttcctaga gtataataat atacagcatt tgttttctca 1020

ctctttgcac gggcttttca atgtgaggta cctgaatttg aaacggtctt ttactaaaca 1080

aagtatttcc cttgcctcac tccccagat tgatgatttt tcttttcagt ggctaaaatg 1140

tttgagcac cttaacatgg aagataatga tattccaggc ataaaaagca atatgttcac 1200

aggattgata aacctgaaat acttaagtct atccaactcc tttacaagtt tgcgaacttt 1260

gacaaatgaa acatttgtat cacttgctca ttctccctta cacatactca acctaaccaa 1320

gaataaaatc tcaaaaatag agagtgatgc tttctcttgg ttggggccacc tagaagtact 1380

tgacctgggc cttaatgaaa ttgggcaaga actcacaggc caggaatgga gaggtctaga 1440

aaatattttc gaaatctatc tttcctacaa caagtacctg cagctgacta ggaactcctt 1500

tgcttgggtc ccaagccttc aacgactgat gctccgaagg gtggccctta aaaatgtgga 1560

tagctctcct tcaccattcc agcctcttcg taacttgacc attctggatc taagcaacaa 1620

caacatagcc aacataaatg atgacatgtt ggaggggtctt gagaaactag aaattctcga 1680

tttgagcat aacaacttag cacggctctg gaaacacgca aaccctgggtg gtcccattta 1740

tttcctaaag ggtctgtctc acctccacat ccttaacttg gagtccaacg gctttgacga 1800

```

gatccaggt gaggtcttca aggatattt tgaactaaag atcatcgatt taggattgaa 1860
taattttaa acacttccag catctgtctt taataatcag gtgtctctaa agtcattgaa 1920

ccttcagaag aatctcataa catccgttga gaagaagggt ttggggccag ctttcaggaa 1980

cctgactgag ttagatatgc gctttaatcc ctttgattgc acgtgtgaaa gtattgcctg 2040

gtttgttaat tggattaacg agaccatac caacatccct gagctgtcaa gccactacct 2100

ttgcaacact ccacctcact atcatgggtt cccagtgaga ctttttgata catcatcttg 2160

caaagacagt gcccccttg aactctttt catgatcaat accagtatcc tgttgatttt 2220

tatctttatt gtactttctc tccactttga gggctggagg atatctttt attggaatgt 2280

ttcagtacat cgagttcttg gtttcaaaga aatagacaga cagacagaac agtttgaata 2340

tgcagcatat ataattcatg cctataaaga taaggattgg gtctgggaac atttctcttc 2400

aatggaaaag gaagaccaat ctctcaaatt ttgtctggaa gaaagggact ttgaggcggg 2460

tgtttttgaa ctagaagcaa ttgttaacag catcaaaaga agcagaaaaa ttatttttgt 2520

tataacacac catctattaa aagaccatt atgcaaaaga ttcaaggtag atcatgcagt 2580

tcaacaagct attgaacaaa atctggattc cattatattg gttttccttg aggagattcc 2640

agattataaa ctgaaccatg cactctgttt gcgaagagga atgtttaaat ctactgcac 2700

cttgaactgg ccagttcaga aagaacggat aggtgccttt cgtcataaat tgcaagtagc 2760

acttgatcc aaaaactctg tacattaaat ttatttaaatt attcaattag caaaggagaa 2820

actttctcaa tttaaaaagt tctatggcaa atttaagttt tccataaagg tgttataatt 2880

tgtttattca tttttgtaa tgattatatt ctatcacaat tacatctctt ctaggaaaa 2940

gtgtctcctt atttcaggcc tatttttgac aattgactta attttaccba aaataaaaca 3000

tataagcacg caaaaaaaaa aaaaaaaaaa 3029

```

<210> 8  
 <211> 904  
 <212> PRT  
 <213> Homo sapiens

<400> 8

Met Arg Gln Thr Leu Pro Cys Ile Tyr Phe Trp Gly Gly Leu Leu Pro  
 1 5 10 15

Phe Gly Met Leu Cys Ala Ser Ser Thr Thr Lys Cys Thr Val Ser His  
 20 25 30

Glu Val Ala Asp Cys Ser His Leu Lys Leu Thr Gln Val Pro Asp Asp  
 35 40 45

Leu Pro Thr Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu Arg  
 50 55 60

Arg Leu Pro Ala Ala Asn Phe Thr Arg Tyr Ser Gln Leu Thr Ser Leu

65	Asp	Val	Gly	Phe	Asn	Thr	Ile	Ser	Lys	Leu	Glu	Pro	Glu	Leu	Cys	Gln
				85						90					95	80
Lys	Leu	Pro	Met	Leu	Lys	Val	Leu	Asn	Leu	Gln	His	Asn	Glu	Leu	Ser	
			100					105					110			
Gln	Leu	Ser	Asp	Lys	Thr	Phe	Ala	Phe	Cys	Thr	Asn	Leu	Thr	Glu	Leu	
		115					120					125				
His	Leu	Met	Ser	Asn	Ser	Ile	Gln	Lys	Ile	Lys	Asn	Asn	Pro	Phe	Val	
	130					135					140					
Lys	Gln	Lys	Asn	Leu	Ile	Thr	Leu	Asp	Leu	Ser	His	Asn	Gly	Leu	Ser	
145					150					155					160	
Ser	Thr	Lys	Leu	Gly	Thr	Gln	Val	Gln	Leu	Glu	Asn	Leu	Gln	Glu	Leu	
				165					170					175		
Leu	Leu	Ser	Asn	Asn	Lys	Ile	Gln	Ala	Leu	Lys	Ser	Glu	Glu	Leu	Asp	
			180					185					190			
Ile	Phe	Ala	Asn	Ser	Ser	Leu	Lys	Lys	Leu	Glu	Leu	Ser	Ser	Asn	Gln	
	195						200					205				
Ile	Lys	Glu	Phe	Ser	Pro	Gly	Cys	Phe	His	Ala	Ile	Gly	Arg	Leu	Phe	
	210					215				220						
Gly	Leu	Phe	Leu	Asn	Asn	Val	Gln	Leu	Gly	Pro	Ser	Leu	Thr	Glu	Lys	
225					230					235					240	
Leu	Cys	Leu	Glu	Leu	Ala	Asn	Thr	Ser	Ile	Arg	Asn	Leu	Ser	Leu	Ser	
				245					250					255		
Asn	Ser	Gln	Leu	Ser	Thr	Thr	Ser	Asn	Thr	Thr	Phe	Leu	Gly	Leu	Lys	
			260					265					270			
Trp	Thr	Asn	Leu	Thr	Met	Leu	Asp	Leu	Ser	Tyr	Asn	Asn	Leu	Asn	Val	
		275					280					285				
Val	Gly	Asn	Asp	Ser	Phe	Ala	Trp	Leu	Pro	Gln	Leu	Glu	Tyr	Phe	Phe	
	290					295					300					
Leu	Glu	Tyr	Asn	Asn	Ile	Gln	His	Leu	Phe	Ser	His	Ser	Leu	His	Gly	
305					310					315					320	
Leu	Phe	Asn	Val	Arg	Tyr	Leu	Asn	Leu	Lys	Arg	Ser	Phe	Thr	Lys	Gln	
				325					330					335		
Ser	Ile	Ser	Leu	Ala	Ser	Leu	Pro	Lys	Ile	Asp	Asp	Phe	Ser	Phe	Gln	
			340					345					350			
Trp	Leu	Lys	Cys	Leu	Glu	His	Leu	Asn	Met	Glu	Asp	Asn	Asp	Ile	Pro	
		355					360					365				
Gly	Ile	Lys	Ser	Asn	Met	Phe	Thr	Gly	Leu	Ile	Asn	Leu	Lys	Tyr	Leu	
	370					375					380					
Ser	Leu	Ser	Asn	Ser	Phe	Thr	Ser	Leu	Arg	Thr	Leu	Thr	Asn	Glu	Thr	
385					390					395					400	
Phe	Val	Ser	Leu	Ala	His	Ser	Pro	Leu	His	Ile	Leu	Asn	Leu	Thr	Lys	

405 410 415  
 Asn Lys Ile Ser Lys Ile Glu Ser Asp Ala Phe Ser Trp Leu Gly His  
 420 425 430  
 Leu Glu Val Leu Asp Leu Gly Leu Asn Glu Ile Gly Gln Glu Leu Thr  
 435 440 445  
 Gly Gln Glu Trp Arg Gly Leu Glu Asn Ile Phe Glu Ile Tyr Leu Ser  
 450 455 460  
 Tyr Asn Lys Tyr Leu Gln Leu Thr Arg Asn Ser Phe Ala Leu Val Pro  
 465 470 475 480  
 Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val Asp  
 485 490 495  
 Ser Ser Pro Ser Pro Phe Gln Pro Leu Arg Asn Leu Thr Ile Leu Asp  
 500 505 510  
 Leu Ser Asn Asn Asn Ile Ala Asn Ile Asn Asp Asp Met Leu Glu Gly  
 515 520 525  
 Leu Glu Lys Leu Glu Ile Leu Asp Leu Gln His Asn Asn Leu Ala Arg  
 530 535 540  
 Leu Trp Lys His Ala Asn Pro Gly Gly Pro Ile Tyr Phe Leu Lys Gly  
 545 550 555 560  
 Leu Ser His Leu His Ile Leu Asn Leu Glu Ser Asn Gly Phe Asp Glu  
 565 570 575  
 Ile Pro Val Glu Val Phe Lys Asp Leu Phe Glu Leu Lys Ile Ile Asp  
 580 585 590  
 Leu Gly Leu Asn Asn Leu Asn Thr Leu Pro Ala Ser Val Phe Asn Asn  
 595 600 605  
 Gln Val Ser Leu Lys Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr Ser  
 610 615 620  
 Val Glu Lys Lys Val Phe Gly Pro Ala Phe Arg Asn Leu Thr Glu Leu  
 625 630 635 640  
 Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ala Trp  
 645 650 655  
 Phe Val Asn Trp Ile Asn Glu Thr His Thr Asn Ile Pro Glu Leu Ser  
 660 665 670  
 Ser His Tyr Leu Cys Asn Thr Pro Pro His Tyr His Gly Phe Pro Val  
 675 680 685  
 Arg Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu Leu  
 690 695 700  
 Phe Phe Met Ile Asn Thr Ser Ile Leu Leu Ile Phe Ile Phe Ile Val  
 705 710 715 720  
 Leu Leu Ile His Phe Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn Val  
 725 730 735  
 Ser Val His Arg Val Leu Gly Phe Lys Glu Ile Asp Arg Gln Thr Glu



740 745 750  
 Gln Phe Glu Tyr Ala Ala Tyr Ile Ile His Ala Tyr Lys Asp Lys Asp  
 755 760 765  
 Trp Val Trp Glu His Phe Ser Ser Met Glu Lys Glu Asp Gln Ser Leu  
 770 775 780  
 Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Phe Glu Leu  
 785 790 795 800  
 Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe Val  
 805 810 815  
 Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Lys Arg Phe Lys Val  
 820 825 830  
 His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile Ile  
 835 840 845  
 Leu Val Phe Leu Glu Glu Ile Pro Asp Tyr Lys Leu Asn His Ala Leu  
 850 855 860  
 Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp Pro  
 865 870 875 880  
 Val Gln Lys Glu Arg Ile Gly Ala Phe Arg His Lys Leu Gln Val Ala  
 885 890 895  
 Leu Gly Ser Lys Asn Ser Val His  
 900

&lt;210&gt; 9

&lt;211&gt; 3310

&lt;212&gt; DNA

&lt;213&gt; murine

&lt;400&gt; 9

tagaatatga tacagggatt gcaccataa tctgggctga atcatgaaag ggtgttcctc 60  
 ttatctaattg tactcctttg ggggactttt gtccctatgg attcttctgg tgtcttcac 120  
 aaaccaatgc actgtgagat acaacgtagc tgactgcagc catttgaagc taacacacat 180  
 acctgatgat cttccctcta acataacagt gttgaatctt actcacaacc aactcagaag 240  
 attaccacct accaacttta caagatacag ccaacttgct atcttggatg caggatttaa 300  
 ctccatttca aaactggagc cagaactgtg ccaaatactc cctttgttga aagtattgaa 360  
 cctgcaacat aatgagctct ctcagatttc tgatcaaacc tttgtcttct gcacgaacct 420  
 gacagaactc gatctaattgt ctaactcaat acacaaaatt aaaagcaacc ctttcaaaaa 480  
 ccagaagaat ctaatcaaat tagatttgtc tcataatggg ttatcatcta caaagttggg 540  
 aacgggggtc caactggaga acctccaaga actgctctta gcaaaaaata aaatccttgc 600  
 gttgcgaagt gaagaacttg agtttcttgg caattcttct ttacgaaagt tggacttgtc 660  
 atcaaatcca cttaaagagt tctccccggg gtgtttccag acaattggca agttattcgc 720

cctcctcttg aacaacgcc aactgaaccc ccacctcaca gagaagcttt gctgggaact	780
ttcaaacaca agcatccaga atctctctct ggctaacaac cagctgctgg ccaccagcga	840
gagcactttc tctgggctga agtggacaaa tctcaccag ctcgatcttt cctacaacaa	900
cctccatgat gtggcaacg gttccttctc ctatctccca agcctgaggt atctgtctct	960
ggagtacaac aatatacagc gtctgtcccc tcgctctttt tatggactct ccaacctgag	1020
gtacctgagt ttgaagcgag catttactaa gcaaagtgtt tcacttgctt cacatcccaa	1080
cattgacgat ttttcctttc aatgggtaaa atatttggaa tatctcaaca tggatgacaa	1140
taatattcca agtaccaaaa gcaatacctt cacgggattg gtgagtctga agtacctaag	1200
tctttccaaa actttcacaa gtttgcaaac tttacaaaat gaaacatttg tgtcacttgc	1260
tcattctccc ttgctcactc tcaacttaac gaaaaatcac atctcaaaaa tagcaaatgg	1320
tactttctct tggtagggc aactcaggat acttgatctc ggccttaatg aaattgaaca	1380
aaaactcagc ggccaggaat ggagaggtct gagaaatata tttgagatct acctatccta	1440
taacaaatac ctccaactgt ctaccagttc ctttgcattg gtccccagcc ttcaaagact	1500
gatgctcagg agggtagggc ttaaaaatgt ggatatctcc ccttcacctt tccgccctct	1560
tcgtaacttg accattctgg acttaagcaa caacaacata gccaacataa atgaggactt	1620
gctggagggt cttgagaatc tagaaatcct ggattttcag cacaataact tagccaggct	1680
ctggaaacgc gcaaaccccg gtggtcccg taatttctct aaggggctgt ctacctcca	1740
catcttgaat ttagagtcca acggcttaga tgaaatccca gtcgggggtt tcaagaactt	1800
attcgaacta aagagcatca atctaggact gaataactta aacaaacttg aaccattcat	1860
ttttgatgac cagacatctc taaggctact gaacctccag aagaacctca taacatctgt	1920
tgagaaggat gttttcgggc cgccttttca aaacctgaac agtttagata tgcgcttcaa	1980
tccgttcgac tgcacgtgtg aaagtatttc ctggtttggt aactggatca accagacca	2040
cactaatatc tttgagctgt ccactcacta cctctgtaac actccacatc attattatgg	2100
cttccccctg aagcttttctg atacatcatc ctgtaaagac agcgccccct ttgaactcct	2160
cttcataatc agcaccagta tgctcctggg ttttatactt gtggtactgc tcattcacat	2220
cgagggctgg aggatctctt tttactggaa tgtttcagtg catcggattc ttggtttcaa	2280
ggaaatagac acacaggctg agcagtttga atatacagcc tacataattc atgcccataa	2340
agacagagac tgggtctggg aacatttctc cccaatggaa gaacaagacc aatctctcaa	2400
attttgcta gaagaaaggg actttgaagc aggcgtcctt ggacttgaag caattgttaa	2460
tagcatcaaa agaagccgaa aaatcatttt cgttatcaca caccatttat taaaagacct	2520
tctgtgcaga agattcaagg tacatcacgc agttcagcaa gctattgagc aaaatctgga	2580
ttcaattata ctgatttttc tccagaatat tccagattat aaactaaacc atgcactctg	2640

```

tttgcgaaga ggaatgttta aatctcattg catcttgaac tggccagttc agaaagaacg 2700
gataaatgcc tttcatcata aattgcaagt agcacttgga tctcggaatt cagcacatta 2760
aactcatttg aagatttgga gtcggtaaag ggatagatcc aatttataaa ggtccatcat 2820
gaatctaagt tttacttgaa agttttgtat atttatttat atgtatagat gatgatatta 2880
catcacaatc caatctcagt tttgaaatat ttcggcttat ttcattgaca tctgggttat 2940
tcaactccaaa taaacacatg ggcagttaaa aacatcctct attaatagat taccattaa 3000
ttcttgaggt gtatcacagc tttaaagggt tttaaatatt tttatataaa taagactgag 3060
agttttataa atgtaatttt ttaaaactcg agtcttactg tgtagctcag aaaggcctgg 3120
aaattaatat attagagagt catgtcttga acttatttat ctctgcctcc ctctgtctcc 3180
agagtgttgc ttttaagggc atgtagcacc acaccagct atgtacgtgt gggattttat 3240
aatgctcatt tttgagacgt ttatagaata aaagataatt gcttttatgg tataaggcta 3300
cttgaggtaa 3310

```

<210> 10  
 <211> 905  
 <212> PRT  
 <213> murine

<400> 10

```

Met Lys Gly Cys Ser Ser Tyr Leu Met Tyr Ser Phe Gly Gly Leu Leu
1          5          10          15

Ser Leu Trp Ile Leu Leu Val Ser Ser Thr Asn Gln Cys Thr Val Arg
          20          25          30

Tyr Asn Val Ala Asp Cys Ser His Leu Lys Leu Thr His Ile Pro Asp
          35          40          45

Asp Leu Pro Ser Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu
          50          55          60

Arg Arg Leu Pro Pro Thr Asn Phe Thr Arg Tyr Ser Gln Leu Ala Ile
65          70          75          80

Leu Asp Ala Gly Phe Asn Ser Ile Ser Lys Leu Glu Pro Glu Leu Cys
          85          90          95

Gln Ile Leu Pro Leu Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu
          100          105          110

Ser Gln Ile Ser Asp Gln Thr Phe Val Phe Cys Thr Asn Leu Thr Glu
          115          120          125

Leu Asp Leu Met Ser Asn Ser Ile His Lys Ile Lys Ser Asn Pro Phe
          130          135          140

Lys Asn Gln Lys Asn Leu Ile Lys Leu Asp Leu Ser His Asn Gly Leu
145          150          155          160

```

Ser Ser Thr Lys Leu Gly Thr Gly Val Gln Leu Glu Asn Leu Gln Glu  
 165 170 175  
 Leu Leu Leu Ala Lys Asn Lys Ile Leu Ala Leu Arg Ser Glu Glu Leu  
 180 185 190  
 Glu Phe Leu Gly Asn Ser Ser Leu Arg Lys Leu Asp Leu Ser Ser Asn  
 195 200 205  
 Pro Leu Lys Glu Phe Ser Pro Gly Cys Phe Gln Thr Ile Gly Lys Leu  
 210 215 220  
 Phe Ala Leu Leu Leu Asn Asn Ala Gln Leu Asn Pro His Leu Thr Glu  
 225 230 235 240  
 Lys Leu Cys Trp Glu Leu Ser Asn Thr Ser Ile Gln Asn Leu Ser Leu  
 245 250 255  
 Ala Asn Asn Gln Leu Leu Ala Thr Ser Glu Ser Thr Phe Ser Gly Leu  
 260 265 270  
 Lys Trp Thr Asn Leu Thr Gln Leu Asp Leu Ser Tyr Asn Asn Leu His  
 275 280 285  
 Asp Val Gly Asn Gly Ser Phe Ser Tyr Leu Pro Ser Leu Arg Tyr Leu  
 290 295 300  
 Ser Leu Glu Tyr Asn Asn Ile Gln Arg Leu Ser Pro Arg Ser Phe Tyr  
 305 310 315 320  
 Gly Leu Ser Asn Leu Arg Tyr Leu Ser Leu Lys Arg Ala Phe Thr Lys  
 325 330 335  
 Gln Ser Val Ser Leu Ala Ser His Pro Asn Ile Asp Asp Phe Ser Phe  
 340 345 350  
 Gln Trp Leu Lys Tyr Leu Glu Tyr Leu Asn Met Asp Asp Asn Asn Ile  
 355 360 365  
 Pro Ser Thr Lys Ser Asn Thr Phe Thr Gly Leu Val Ser Leu Lys Tyr  
 370 375 380  
 Leu Ser Leu Ser Lys Thr Phe Thr Ser Leu Gln Thr Leu Thr Asn Glu  
 385 390 395 400  
 Thr Phe Val Ser Leu Ala His Ser Pro Leu Leu Thr Leu Asn Leu Thr  
 405 410 415  
 Lys Asn His Ile Ser Lys Ile Ala Asn Gly Thr Phe Ser Trp Leu Gly  
 420 425 430  
 Gln Leu Arg Ile Leu Asp Leu Gly Leu Asn Glu Ile Glu Gln Lys Leu  
 435 440 445  
 Ser Gly Gln Glu Trp Arg Gly Leu Arg Asn Ile Phe Glu Ile Tyr Leu  
 450 455 460  
 Ser Tyr Asn Lys Tyr Leu Gln Leu Ser Thr Ser Ser Phe Ala Leu Val  
 465 470 475 480  
 Pro Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val

Asp	Ile	Ser	Pro	485	Ser	Pro	Phe	Arg	Pro	490	Leu	Arg	Asn	Leu	Thr	495	Ile	Leu
			500						505						510			
Asp	Leu	Ser	Asn	Asn	Asn	Ile	Ala	Asn	Ile	Asn	Glu	Asp	Leu	Leu	Glu			
		515					520					525						
Gly	Leu	Glu	Asn	Leu	Glu	Ile	Leu	Asp	Phe	Gln	His	Asn	Asn	Leu	Ala			
		530					535				540							
Arg	Leu	Trp	Lys	Arg	Ala	Asn	Pro	Gly	Gly	Pro	Val	Asn	Phe	Leu	Lys			
545					550					555					560			
Gly	Leu	Ser	His	Leu	His	Ile	Leu	Asn	Leu	Glu	Ser	Asn	Gly	Leu	Asp			
			565						570					575				
Glu	Ile	Pro	Val	Gly	Val	Phe	Lys	Asn	Leu	Phe	Glu	Leu	Lys	Ser	Ile			
			580					585					590					
Asn	Leu	Gly	Leu	Asn	Asn	Leu	Asn	Lys	Leu	Glu	Pro	Phe	Ile	Phe	Asp			
		595					600					605						
Asp	Gln	Thr	Ser	Leu	Arg	Ser	Leu	Asn	Leu	Gln	Lys	Asn	Leu	Ile	Thr			
		610					615				620							
Ser	Val	Glu	Lys	Asp	Val	Phe	Gly	Pro	Pro	Phe	Gln	Asn	Leu	Asn	Ser			
625					630					635					640			
Leu	Asp	Met	Arg	Phe	Asn	Pro	Phe	Asp	Cys	Thr	Cys	Glu	Ser	Ile	Ser			
				645					650					655				
Trp	Phe	Val	Asn	Trp	Ile	Asn	Gln	Thr	His	Thr	Asn	Ile	Phe	Glu	Leu			
			660					665					670					
Ser	Thr	His	Tyr	Leu	Cys	Asn	Thr	Pro	His	His	Tyr	Tyr	Gly	Phe	Pro			
		675					680					685						
Leu	Lys	Leu	Phe	Asp	Thr	Ser	Ser	Cys	Lys	Asp	Ser	Ala	Pro	Phe	Glu			
		690				695					700							
Leu	Leu	Phe	Ile	Ile	Ser	Thr	Ser	Met	Leu	Leu	Val	Phe	Ile	Leu	Val			
705					710					715					720			
Val	Leu	Leu	Ile	His	Ile	Glu	Gly	Trp	Arg	Ile	Ser	Phe	Tyr	Trp	Asn			
				725					730					735				
Val	Ser	Val	His	Arg	Ile	Leu	Gly	Phe	Lys	Glu	Ile	Asp	Thr	Gln	Ala			
			740					745					750					
Glu	Gln	Phe	Glu	Tyr	Thr	Ala	Tyr	Ile	Ile	His	Ala	His	Lys	Asp	Arg			
		755					760					765						
Asp	Trp	Val	Trp	Glu	His	Phe	Ser	Pro	Met	Glu	Glu	Gln	Asp	Gln	Ser			
		770				775						780						
Leu	Lys	Phe	Cys	Leu	Glu	Glu	Arg	Asp	Phe	Glu	Ala	Gly	Val	Leu	Gly			
785					790					795					800			
Leu	Glu	Ala	Ile	Val	Asn	Ser	Ile	Lys	Arg	Ser	Arg	Lys	Ile	Ile	Phe			
				805					810					815				
Val	Ile	Thr	His	His	Leu	Leu	Lys	Asp	Pro	Leu	Cys	Arg	Arg	Phe	Lys			

[illegible]

ccacattgaa actcaaatct ctcaaaaggc ttactttcac ttccaacaaa ggtgggaatg 1260  
ctttttcaga agttgatcta ccaagccttg agtttctaga tctcagtaga aatggcttga 1320  
gtttcaaagg ttgctgttct caaagtgatt ttgggacaac cagcctaaag tatttagatc 1380  
tgagcttcaa tgggtgttatt accatgagtt caaacttctt gggcttagaa caactagaac 1440  
atctggattt ccagcattec aatttgaaac aaatgagtga gttttcagta ttcctatcac 1500  
tcagaaacct catttacctt gacatttctc atactcacac cagagttgct ttcaatggca 1560  
tcttcaatgg cttgtccagt ctggaagtct tgaaaatggc tggcaattct ttccaggaaa 1620  
acttccttcc agatatcttc acagagctga gaaacttgac cttcctggac ctctctcagt 1680  
gtcaactgga gcagttgtct ccaacagcat ttaactcact ctccagtctt caggtactaa 1740  
atatgagcca caacaacttc ttttcattgg atacgtttcc ttataagtgt ctgaactccc 1800  
tccaggttct tgattacagt ctcaatcaca taatgacttc caaaaaacag gaactacagc 1860  
attttccaag tagtctagct ttcttaaate ttactcagaa tgactttgct tgtacttgtg 1920  
aacaccagag tttcctgcaa tggatcaagg accagaggca gctcttggtg gaagttgaac 1980  
gaatggaatg tgcaaacact tcagataagc agggcatgcc tgtgctgagt ttgaatatca 2040  
cctgtcagat gaataagacc atcattggtg tgtcggtcct cagtgtgctt gtagtatctg 2100  
ttgtagcagt tctggtctat aagttctatt ttcacctgat gcttcttgct ggctgcataa 2160  
agtatggtag aggtgaaaac atctatgatg cctttgttat ctactcaagc caggatgagg 2220  
actgggtaag gaatgagcta gtaaagaatt tagaagaagg ggtgcctcca tttcagctct 2280  
gccttcacta cagagacttt attcccggtg tggccattgc tgccaacatc atccatgaag 2340  
gtttccataa aagccgaaag gtgattgttg tgggtgtcca gcacttcac cagagccgct 2400  
ggtgtatctt tgaatatgag attgctcaga cctggcagtt tctgagcagt cgtgctggta 2460  
tcatcttcat tgtcctgcag aaggtggaga agaccctgct caggcagcag gtggagctgt 2520  
accgccttct cagcaggaac acttacctgg agtgggagga cagtgtcctg gggcggcaca 2580  
tcttctggag acgactcaga aaagccctgc tggatggtaa atcatggaat ccagaaggaa 2640  
cagtgggtac aggatgcaat tggcaggaag caacatctat ctgaagagga aaaataaaaa 2700  
cctcctgagg catttcttgc ccagctgggt ccaacacttg ttcagttaat aagtattaaa 2760  
tgctgccaca tgtcaggcct tatgctaagg gtgagtaatt ccatggtgca ctagatatgc 2820  
agggtgcta atctcaagga gcttccagtg cagagggaat aaatgctaga ctaaaataca 2880  
gagtcttcca ggtgggcatt tcaaccaact cagtcaagga acccatgaca aagaaagtca 2940  
tttcaactct tacctcatca agttgaataa agacagagaa aacagaaaga gacattgttc 3000  
ttttcctgag tcttttgaat ggaaattgta ttatgttata gccatcataa aaccattttg 3060

gtagttttga ctgaactggg tggtcacttt ttcctttttg attgaataca atttaaattc 3120  
 tacttgatga ctgcagtcgt caaggggctc ctgatgcaag atgccccttc cattttaagt 3180  
 ctgtctcctt acagagggtta aagtctaatt gctaattcct aaggaaacct gattaacaca 3240  
 tgctcacaac catcctgggc attctcgaac atgtttctatt ttttaactaa tcaccctga 3300  
 tatattttta tttttatata tccagttttc atttttttac gtcttgcta taagctaata 3360  
 tcataaataa ggttggttaa gacgtgcttc aaatatccat attaaccact atttttcaag 3420  
 gaagtatgga aaagtacact ctgtcacttt gtactcgat gtcattccaa agttattgcc 3480  
 tactaagtaa tgactgtcat gaaagcagca ttgaaataat ttgtttaaag ggggcactct 3540  
 tttaaacggg aagaaaattt ccgcttcctg gtcttatcat ggacaatttg ggctataggc 3600  
 atgaaggaag tgggattacc tcaggaagtc accttttctt gattccagaa acatatgggc 3660  
 tgataaaccc ggggtgacct catgaaatga gttgcagcag atgtttattt ttttcagaac 3720  
 aagtgatgtt tgatggacct atgaatctat ttagggagac acagatggct gggatccctc 3780  
 ccctgtacct ttctcactga caggagaact a 3811

<210> 12

<211> 2845

<212> DNA

<213> Homo sapiens

<400> 12

cctctcacc ttagccag aactgctttg aatacaccaa ttgctgtggg gcggctcgag 60  
 gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggatgatgc gagccacgca 120  
 ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
 cgcgctggc tgggactctg atcccagcca tggccttcct ctctgcgtg agaccagaaa 240  
 gctgggagcc ctgctgggag gtgtgaaatc cagacaattg aagatggggc atatcagagc 300  
 ctaagccacc tctctacctt aatattgaca ggaaacocca tccagagttt agccctggga 360  
 gccttttctg gactatcaag ttacagaag ctggtggctg tggagacaaa tctagcatct 420  
 ctagagaact tccccattgg acatctcaaa actttgaaag aacttaattg ggctcacaat 480  
 cttatccaat ctttcaaatt acctgagtat ttttctaata tgaccaatct agagcacttg 540  
 gacctttcca gcaacaagat tcaaagtatt tattgcacag acttgccggg tctacatcaa 600  
 atgcccctac tcaatctctc tttagacctg tcctgaacc ctatgaactt tatccaacca 660  
 ggtgcattta aagaaattag gcttcataag ctgactttaa gaaataattt tgatagttta 720  
 aatgtaatga aaacttgat tcaaggtctg gctgggttag aagtccatcg tttggttctg 780  
 ggagaattta gaaatgaagg aaacttgaa aagtttgaca aatctgctct agagggcctg 840



tgcaatttga ccattgaaga attccgatta gcatacttag actactacct cgatgatatt	900
attgacttat ttaattgttt gacaaatgtt tcttcatttt ccctggtgag tgtgactatt	960
gaaagggtaa aagacttttc ttataatttc ggatggcaac atttagaatt agttaactgt	1020
aaatttggac agtttccac attgaaactc aaatctctca aaaggcttac tttcacttcc	1080
aacaaagggtg ggaatgcttt ttcagaagtt gatctacca gccttgagtt tctagatctc	1140
agtagaaatg gcttgagttt caaagggtgc tgttctcaaa gtgattttgg gacaaccagc	1200
ctaaagtatt tagatctgag cttcaatggt gtattacca tgagttcaaa cttcttgggc	1260
ttagaacaac tagaacatct ggatttccag cattccaatt tgaaacaaat gagtgaagttt	1320
tcagtattcc tatcactcag aaacctcatt taccttgaca tttctcatac tcacaccaga	1380
gttgctttca atggcatctt caatggcttg tccagtctcg aagtcttgaa aatggctggc	1440
aattctttcc aggaaaactt ccttccagat atcttcacag agctgagaaa cttgaccttc	1500
ctggacctct ctcagtgtca actggagcag ttgtctccaa cagcatttaa ctcactctcc	1560
agtcttcagg tactaaatat gagccacaac aacttctttt cattggatac gtttccttat	1620
aagtgtctga actccctcca ggttcttgat tacagtctca atcacataat gacttccaaa	1680
aaacaggaac tacagcattt tccaagtagt ctagctttct taaatcttac tcagaatgac	1740
tttgcttgta cttgtgaaca ccagagtttc ctgcaatgga tcaaggacca gaggcagctc	1800
ttggtggaag ttgaacgaat ggaatgtgca acaccttcag ataagcaggg catgcctgtg	1860
ctgagtttga atatcacctg tcagatgaat aagaccatca ttggtgtgtc ggtcctcagt	1920
gtgctttag tatctgttgt agcagttctg gtctataagt tctattttca cctgatgctt	1980
cttgctggct gcataaagta tggtagaggt gaaaacatct atgatgcctt tgttatctac	2040
tcaagccagg atgaggactg ggtaaggaat gagctagtaa agaatttaga agaaggggtg	2100
cctccatttc agctctgcct tctactacaga gactttattc ccggtgtggc cattgctgcc	2160
aacatcatcc atgaaggttt ccataaaagc cgaaagggtga ttgttgtggt gtcccagcac	2220
ttcatccaga gccgctgggt tatctttgaa tatgagattg ctcagacctg gcagtttctg	2280
agcagtcgtg ctggtatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg	2340
cagcaggtgg agctgtaccg ctttctcagc aggaacactt acctggagtg ggaggacagt	2400
gtcctggggc ggcacatctt ctggagacga ctcagaaaag ccctgctgga tggtaaatca	2460
tggaatccag aaggaacagt gggtagagga tgcaattggc aggaagcaac atctatctga	2520
agaggaaaaa taaaaacctc ctgaggcatt tcttgcccag ctgggtccaa cacttgttca	2580
gttaataagt attaaatgct gccacatgtc aggccttatg ctaagggtga gtaattccat	2640
gggtgactag atatgcaggg ctgctaactc caaggagctt ccagtgcaga gggaataaat	2700
gctagactaa aatacagagt cttccagggt ggcatthcaa ccaactcagt caaggaaccc	2760

atgacaaaga aagtcatttc aactcttacc tcatcaagtt gaataaagac agagaaaaca 2820  
gaaaaaaaaa aaaaaaaaaa aaaaa 2845

<210> 13  
<211> 3767  
<212> DNA  
<213> Homo sapiens

<400> 13  
cctctcacc tttagcccag aactgctttg aatacaccaa ttgctgtggg gcggctcgag 60  
gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggatgatagc gagccacgca 120  
ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
cgcgctggc tgggactctg atcccagcca tggccttcct ctctgctg agaccagaaa 240  
gctgggagcc ctgcgtggag acttggccct aaaccacaca gaagagctgg catgaaaccc 300  
agagctttca gactccggag cctcagccct tcaccccgat tccattgctt cttgctaaat 360  
gctgccgttt tatcacggag gtgtgaaatc cagacaattg aagatggggc atatcagagc 420  
ctaagccacc tctctacott aatattgaca ggaaacccca tccagagttt agccctggga 480  
gccttttctg gactatcaag tttacagaag ctggtggctg tggagacaaa tctagcatct 540  
ctagagaact tccccattgg acatctcaaa actttgaaag aacttaattg ggctcacaat 600  
cttatccaat ctttcaaatt acctgagtat ttttctaata tgaccaatct agagcacttg 660  
gacctttcca gcaacaagat tcaaagtatt tattgcacag acttgcggtt tctacatcaa 720  
atgcccctac tcaatctctc tttagacctg tccctgaacc ctatgaactt tatccaacca 780  
ggtgcattta aagaaattag gcttcataag ctgactttta gaaataattt tgatagttta 840  
aatgtaatga aaacttgat tcaaggctct gctggtttag aagtccatcg tttggttctg 900  
ggagaattta gaaatgaagg aaacttgga aagtttgaca aatctgctct agagggcctg 960  
tgcaatttga ccattgaaga attccgatta gcatacttag actactacct cgatgatatt 1020  
attgacttat ttaattgttt gacaaatgtt tcttcatttt ccctgggtgag tgtgactatt 1080  
gaaagggtta aagacttttc ttataatttc ggatggcaac atttagaatt agttaactgt 1140  
aaatttggac agtttccac attgaaactc aaatctctca aaaggcttac tttcacttcc 1200  
aacaagggtg ggaatgcttt ttcagaagtt gatctaccaa gccttgagtt tctagatctc 1260  
agtagaaatg gcttgagttt caaagggtgc tgttctcaaa gtgattttgg gacaaccagc 1320  
ctaaagtatt tagatctgag cttcaatggt gttattacca tgagttcaaa cttcttgggc 1380  
ttagaacaac tagaacatct ggatttccag cattccaatt tgaaacaaat gagtgagttt 1440  
tcagtattcc tatcactcag aaacctcatt taccttgaca tttctcatac tcacaccaga 1500

gttgctttca atggcatctt caatggcttg tccagtctcg aagtcttgaa aatggctggc 1560  
aattctttcc aggaaaactt ccttccagat atcttcacag agctgagaaa cttgaccttc 1620  
  
ctggacctct ctcagtgtca actggagcag ttgtctccaa cagcatttaa ctcactctcc 1680  
agtcttcagg tactaaatat gagccacaac aacttctttt cattggatac gtttccttat 1740  
aagtgtctga actccctcca ggttcttgat tacagtctca atcacataat gacttccaaa 1800  
aaacaggaac tacagcattt tocaagtagt ctagctttct taaatcttac tcagaatgac 1860  
tttgcttgta cttgtgaaca ccagagtttc ctgcaatgga tcaaggacca gaggcagctc 1920  
ttggtggaag ttgaacgaat ggaatgtgca acaccttcag ataagcaggg catgcctgtg 1980  
ctgagtttga atatcacctg tcagatgaat aagaccatca ttggtgtgtc ggtcctcagt 2040  
gtgctttag tagtctgtgt agcagttctg gtctataagt tctattttca cctgatgctt 2100  
cttgctggct gcataaagta tggtagaggt gaaaacatct atgatgcctt tgttatctac 2160  
tcaagccagg atgaggactg ggtaaggaat gagctagtaa agaatttaga agaaggggtg 2220  
cctccatttc agctctgcct tcactacaga gactttattc ccggtgtggc cattgctgcc 2280  
aacatcatcc atgaagggtt ccataaaagc cgaaagggtga ttgttgtggt gtcccagcac 2340  
ttcatccaga gccgctgggt tatctttgaa tatgagattg ctcagacctg gcagtttctg 2400  
agcagtcgtg ctggtatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg 2460  
cagcaggtgg agctgtaccg ccttctcagc aggaacactt acctggagtg ggaggacagt 2520  
gtcctggggc ggcacatctt ctggagacga ctcagaaaag ccctgctgga tggtaaatca 2580  
tggaatccag aaggaacagt gggtagagga tgcaattggc aggaagcaac atctatctga 2640  
agaggaaaaa taaaaacctc ctgaggcatt tcttgcccag ctgggtccaa cacttgttca 2700  
gttaataagt attaaatgct gccacatgtc aggcottatg ctaagggtga gtaattccat 2760  
ggtgcactag atatgcaggg ctgctaactt caaggagctt ccagtgcaga ggaataaat 2820  
gctagactaa aatacagagt cttccaggtg gccatttcaa ccaactcagt caaggaacct 2880  
atgacaaaga aagtcatttc aactcttacc tcatcaagtt gaataaagac agagaaaaca 2940  
gaaagagaca ttgttctttt cctgagtctt ttgaatggaa attgtattat gttatagcca 3000  
tcataaaacc attttggtag ttttgactga actgggtggt cactttttcc tttttgattg 3060  
aatacaattt aaattctact tgatgactgc agtcgtcaag gggctcctga tgcaagatgc 3120  
ccctccatt ttaagtctgt ctcttacag aggttaaagt ctagtggtta attcctaagg 3180  
aaacctgatt aacacatgct cacaaccatc ctggtcattc tcgagcatgt tctatttttt 3240  
aactaatcac ccctgatata tttttatttt tatatatcca gttttcattt ttttacgtct 3300  
tgcctataag ctaatatcat aaataagggt gttaagacg tgcttcaa atccatatta 3360  
accactattt ttcaaggaag tatggaaaag tacactctgt cactttgtca ctcgatgtca 3420

ttccaaagtt attgcctact aagtaatgac tgtcatgaaa gcagcattga aataatttgt 3480  
ttaaaggggg cactctttta aacgggaaga aaatttccgc ttcctgggtct tatcatggac 3540  
aatttgggct agaggcagga aggaagtggg atgacctcag gaggtcacct tttcttgatt 3600  
ccagaaacat atgggctgat aaacccgggg tgacctcatg aaatgagttg cagcagaagt 3660  
ttattttttt cagaacaagt gatgtttgat ggacctctga atctcttttag ggagacacag 3720  
atggctggga tccctcccct gtaccttct cactgccagg agaacta 3767

<210> 14

<211> 3814

<212> DNA

<213> Homo sapiens

<400> 14

cctctcacc ctttagcccag aactgctttg aatacaccaa ttgctgtggg ggggctcgag 60  
gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggatgatagc gagccacgca 120  
ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
cgcgccctggc tgggactctg atcccagcca tggccttct ctctgcgtg agaccagaaa 240  
gctgggagcc ctgctgtggg gtggttctta atattactta tcaatgcatg gagctgaatt 300  
tctacaaaat ccccgacaac ctccccttct caaccaagaa cctggacctg agctttaatc 360  
ccctgaggca tttaggcagc tatagcttct tcagtttccc agaactgcag gtgctggatt 420  
tatccaggtg tgaaatccag acaattgaag atggggcata tcagagccta agccacctct 480  
ctaccttaat attgacagga aaccccatcc agagttagc cctgggagcc ttttctggac 540  
tatcaagttt acagaagctg gtggctgtgg agacaaatct agcatctcta gagaacttcc 600  
ccattggaca tctcaaaact ttgaaagaac ttaatgtggc tcacaatctt atccaatctt 660  
tcaattacc tgagtatttt tctaactctga ccaatctaga gcacttgga ctttccagca 720  
acaagattca aagtatttat tgcacagact tgcgggttct acatcaaag cccctactca 780  
atctctcttt agacctgtcc ctgaacccta tgaactttat ccaaccagg gcatttaaag 840  
aaattaggct tcataagctg actttaagaa ataattttga tagtttaaag gtaatgaaaa 900  
cttgatttca aggtctggct ggtttagaag tccatcggtt ggttctggga gaatttagaa 960  
atgaaggaaa cttggaaaag tttgacaaat ctgctctaga gggcctgtgc aatttgacca 1020  
ttgaagaatt ccgattagca tacttagact actacctga tgatattatt gacttattta 1080  
attgtttgac aaatgtttct tcatcttccc tggtagtgt gactattgaa agggtaaaag 1140  
acttttctta taatttcgga tggcaacatt tagaattagt taactgtaa tttggacagt 1200  
ttccacatt gaaactcaaa tctctcaaaa ggcttacttt cacttccaac aaagggtggga 1260

atgctttttc agaagttgat ctaccaagcc ttgagtttct agatctcagt agaaatggct 1320  
 tgagtttcaa aggttgctgt tctcaaagtg attttgggac aaccagccta aagtatttag 1380  
 atctgagctt caatgggtgtt attaccatga gttcaaactt cttgggctta gaacaactag 1440  
 aacatctgga tttccagcat tccaatttga aacaaatgag tgagttttca gtattcctat 1500  
 cactcagaaa cctcatttac cttgacattt ctcatactca caccagagtt gctttcaatg 1560  
 gcatcttcaa tggcttgctc agtctcgaag tcttgaaaat ggctggcaat tctttccagg 1620  
 aaaacttcct tccagatata ttcacagagc tgagaaaactt gaccttcctg gacctctctc 1680  
 agtgtcaact ggagcagttg tctccaacag catttaactc actctccagt cttcaggtac 1740  
 taaatatgag ccacaacaac ttcttttcat tggatacggt tccttataag tgtctgaact 1800  
 ccctccaggt tcttgattac agtctcaatc acataatgac ttccaaaaaa caggaactac 1860  
 agcattttcc aagtagtcta gctttcttaa atcttactca gaatgacttt gcttgacttt 1920  
 gtgaacacca gagtttcctg caatggatca aggaccagag gcagctcttg gtggaagttg 1980  
 aacgaatgga atgtgcaaca ccttcagata agcagggcat gcctgtgctg agtttgaata 2040  
 tcacctgtca gatgaataag accatcattg gtgtgtcggc cctcagtgtg cttgtagtat 2100  
 ctgttgtagc agttctggtc tataagttct attttcacct gatgcttctt gctggctgca 2160  
 taaagtatgg tagaggtgaa aacatctatg atgcctttgt tatctactca agccaggatg 2220  
 aggactgggt aaggaatgag ctagtaaaga atttagaaga aggggtgcct ccatttcagc 2280  
 tctgccttca ctacagagac tttattcccg gtgtggccat tgctgccaac atcatccatg 2340  
 aagggtttcca taaaagccga aagggtgattg ttgtgggtgc ccagcacttc atccagagcc 2400  
 gctgggtgat ctttgaatat gagattgtc agacctggca gtttctgagc agtcgtgctg 2460  
 gtatcatctt cattgtcctg cagaagggtg agaagaccct gctcaggcag caggtggagc 2520  
 tgtaccgcct tctcagcagg aacacttacc tggagtggga ggacagtgtc ctggggcgcc 2580  
 acatcttctg gagacgactc agaaaagccc tgctggatgg taaatcatgg aatccagaag 2640  
 gaacagtggg tacaggatgc aattggcagg aagcaacatc tatctgaaga ggaaaaataa 2700  
 aaacctctg aggcatttct tgcccagctg ggtccaacac ttgttcagtt aataagtatt 2760  
 aatgctgcc acatgtcagg ctttatgcta agggtgagta attccatggt gcactagata 2820  
 tgcagggctg ctaatctcaa ggagcttcca gtgcagaggg aataaatgct agactaaaat 2880  
 acagagtctt ccagggtggc atttcaacca actcagtcaa ggaacccatg acaaagaaag 2940  
 tcatttcaac tcttacctca tcaagttgaa taaagacaga gaaaacagaa agagacattg 3000  
 ttcttttctt gagtcttttg aatggaaatt gtattatggt atagccatca taaaaccatt 3060  
 ttggtagttt tgactgaact ggggtgtcac ttttccctt ttgattgaat acaatttaaa 3120  
 ttctacttga tgactgcagt cgtcaagggg ctctgatgc aagatgcccc ttccatttta 3180

agtctgtctc cttacagagg ttaaagtcta gtggctaatt cctaaggaaa cctgattaac 3240  
 acatgctcac aaccatcctg gtcattctcg agcatgttct attttttaac taatcacccc 3300  
 tgatatatatt ttatttttat atatccagtt ttcatttttt tacgtcttgc ctataagcta 3360  
 atatcataaa taaggttggt taagacgtgc ttcaaatatc catattaacc actatttttc 3420  
 aaggaagtat ggaaaagtag actctgtcac tttgtcactc gatgtcattc caaagttatt 3480  
 gcctactaag taatgactgt catgaaagca gcattgaaat aatttgttta aagggggcac 3540  
 tcttttaaac gggaagaaaa ttccgcttc ctggctttat catggacaat ttgggctaga 3600  
 ggaggaagg aagtgggatg acctcaggag gtcacctttt ctgtattcca gaaacatatg 3660  
 ggctgataaa cccggggtga cctcatgaaa tgagttgcag cagaagttta tttttttcag 3720  
 aacaagtgat gtttgatgga cctctgaatc tctttaggga gacacagatg gctgggatcc 3780  
 ctccccgtga cccttctcac tgccaggaga acta 3814

<210> 15

<211> 3934

<212> DNA

<213> Homo sapiens

<400> 15

cctctcacc ttagcccag aactgctttg aatacaccaa ttgctgtggg gcggctcgag 60  
 gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggtgatagc gagccacgca 120  
 ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
 cgcgcctggc tgggactctg atcccagca tggccttcct ctctgcgtg agaccagaaa 240  
 gctgggagcc ctgcgtggag acttgccct aaaccacaca gaagagctgg catgaaacct 300  
 agagctttca gactccggag cctcagccct tcaccccgat tccattgctt ctgctaaat 360  
 gctgccgttt tatcacggag gtggttccta atattactta tcaatgcag gagctgaatt 420  
 tctacaaaat ccccgacaac ctccccttct caaccaagaa cctggacctg agctttaatc 480  
 ccctgaggca ttaggcagc tatagcttct tcagtttccc agaactgcag gtgctggatt 540  
 tatccagggt tgaaatccag acaattgaag atggggcata tcagagccta agccacctct 600  
 ctaccttaat attgacagga aaccccatcc agagttagc cctgggagcc tttctggac 660  
 tatcaagttt acagaagctg gtggctgtgg agacaaatct agcatctcta gagaacttcc 720  
 ccattggaca tctcaaaact ttgaaagaac ttaatgtggc tcacaatctt atccaatctt 780  
 tcaaattacc tgagtatttt tctaactga ccaatctaga gcacttgac cttccagca 840  
 acaagattca aagtatttat tgcacagact tgcgggttct acatcaaatg cccctactca 900  
 atctctcttt agacctgtcc ctgaacccta tgaactttat ccaaccagggt gcatttaaag 960

aaattaggct	tcataagctg	actttaagaa	ataatTTTga	tagTTTaaat	gtaatgaaaa	1020
cttgtattca	aggtctggct	ggTTtagaag	tccatcgttt	ggTctggga	gaatttagaa	1080
atgaaggaaa	cttgaaaaag	TTtgacaaat	ctgctctaga	gggcctgtgc	aatttgacca	1140
ttgaagaatt	ccgattagca	tacttagact	actacctcga	tgatattatt	gacttatttta	1200
attgTTtgac	aaatgTTTct	tcatTTTccc	tggtgagtgt	gactattgaa	agggtaaaaag	1260
actTTTctta	taatttcgga	tggcaacatt	tagaattagt	taactgtaaa	TTtgacagt	1320
ttccacatt	gaaactcaaa	tctctcaaaa	ggcttacttt	cacttccaac	aaaggTggga	1380
atgctTTTTc	agaagTTgat	ctaccaagcc	ttgagTTTct	agatctcagt	agaaatggct	1440
tgagTTTcaa	aggttgctgt	tctcaaagt	atTTTgggac	aaccagccta	aagtatttag	1500
atctgagctt	caatggTgtt	attaccatga	gttcaaactt	cttgggctta	gaacaactag	1560
aacatctgga	TTTccagcat	tccaattTga	aacaaatgag	tgagTTTtca	gtattcctat	1620
cactcagaaa	cctcattttac	cttgacattt	ctcatactca	caccagagtt	gctttcaatg	1680
gcatcttcaa	tggttgTtcc	agtctcgaag	tcttgaaaat	ggctggcaat	tctttccagg	1740
aaaacttcct	tccagatatc	ttcacagagc	tgagaaaactt	gaccttcctg	gacctctctc	1800
agtgtcaact	ggagcagttg	tctccaacag	catttaactc	actctccagt	cttcagggtac	1860
taaatatgag	ccacaacaac	ttctTTTcat	tggatacgTt	tccttataag	Tgtctgaact	1920
ccctccaggt	tcttgattac	agtctcaatc	acataatgac	ttccaaaaaa	caggaactac	1980
agcattttcc	aagtagtcta	gctttcttaa	atcttactca	gaatgacttt	gcttgTactt	2040
gtgaacacca	gagTTTcctg	caatggatca	aggaccagag	gcagctcttg	gtggaagttg	2100
aacgaatgga	atgtgcaaca	ccttcagata	agcagggcat	gcctgtgctg	agTTTgaata	2160
tcacctgtca	gatgaataag	accatcattg	gtgtgtcggt	cctcagtgtg	cttgtagtat	2220
ctgttgtagc	agTctggTc	tataagTtct	atTTTcacct	gatgcttctt	gctggctgca	2280
taaagtatgg	tagaggTgaa	aacatctatg	atgcctTTgt	tatctactca	agccaggatg	2340
aggactgggt	aaggaatgag	ctagtaaaga	atTTtagaaga	aggggtgcct	ccatttcagc	2400
tctgccttca	ctacagagac	TTtattcccg	gtgtggccat	tgctgccaac	atcatccatg	2460
aaggTTTcca	taaaagccga	aaggTgattg	ttgtggTgtc	ccagcacttc	atccagagcc	2520
gctggTgtat	cttTgaatat	gagattgtc	agacctggca	gtTctgagc	agTcgtgctg	2580
gtatcatctt	cattgtcctg	cagaaggTgg	agaagacct	gctcaggcag	caggTggagc	2640
Tgtaccgcct	tctcagcagg	aacacttacc	Tggagtggga	ggacagtgtc	ctggggcggc	2700
acatcttctg	gagacgactc	agaaaagccc	Tgctggatgg	taaatcatgg	aatccagaag	2760
gaacagtggg	tacaggatgc	aattggcagg	aagcaacatc	tatctgaaga	ggaaaaataa	2820
aaacctcctg	aggcatttct	Tgcccagctg	ggtccaacac	ttgttcagtt	aataagtatt	2880

```

aaatgctgcc acatgtcagg ccttatgcta agggtagta attccatggc gcactagata 2940
tgcagggctg ctaatctcaa ggagcttcca gtgcagaggg aataaatgct agactaaaat 3000
acagagtctt ccagggtggc atttcaacca actcagtcaa ggaacccatg acaaagaaag 3060
tcatttcaac tcttacctca tcaagttgaa taaagacaga gaaaacagaa agagacattg 3120
ttcttttctt gagtcttttg aatggaaatt gtattatggt atagccatca taaaaccatt 3180
ttggtagttt tgactgaact ggggtgtcac tttttcctt ttgattgaat acaatttaaa 3240
ttctacttga tgactgcagt cgtcaagggg ctctgatgc aagatgcccc ttccatttta 3300
agtctgtctc cttacagagg ttaaagtcta gtggctaatt cctaaggaaa cctgattaac 3360
acatgtctac aaccatctcg gtcattctcg agcatgttct attttttaac taatcacccc 3420
tgatatattt ttatttttat atatccagtt ttcatttttt tacgtcttgc ctataagcta 3480
atatcataaa taaggttggt taagacgtgc ttcaaatatc catattaacc actatttttc 3540
aaggaagtat ggaaaagtac actctgtcac tttgtcactc gatgtcattc caaagttatt 3600
gcctactaag taatgactgt catgaaagca gcattgaaat aatttgttta aagggggcac 3660
tcttttaaac gggaagaaaa tttccgcttc ctggctttat catggacaat ttgggctaga 3720
ggcaggaagg aagtgggatg acctcaggag gtcacctttt cttgattcca gaaacatatg 3780
ggctgataaa cccggggatg cctcatgaaa tgagttgcag cagaagttta tttttttcag 3840
aacaagtgat gtttgatgga cctctgaatc tctttaggga gacacagatg gctgggatcc 3900
ctcccctgta ccttctcac tgccaggaga acta 3934

```

&lt;210&gt; 16

&lt;211&gt; 839

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

```

Met Met Ser Ala Ser Arg Leu Ala Gly Thr Leu Ile Pro Ala Met Ala
1           5           10           15

```

```

Phe Leu Ser Cys Val Arg Pro Glu Ser Trp Glu Pro Cys Val Glu Val
          20           25           30

```

```

Val Pro Asn Ile Thr Tyr Gln Cys Met Glu Leu Asn Phe Tyr Lys Ile
          35           40           45

```

```

Pro Asp Asn Leu Pro Phe Ser Thr Lys Asn Leu Asp Leu Ser Phe Asn
50           55           60

```

```

Pro Leu Arg His Leu Gly Ser Tyr Ser Phe Phe Ser Phe Pro Glu Leu
65           70           75           80

```

```

Gln Val Leu Asp Leu Ser Arg Cys Glu Ile Gln Thr Ile Glu Asp Gly
          85           90           95

```



Ala Tyr Gln Ser Leu Ser His Leu Ser Thr Leu Ile Leu Thr Gly Asn  
 100 105 110  
 Pro Ile Gln Ser Leu Ala Leu Gly Ala Phe Ser Gly Leu Ser Ser Leu  
 115 120 125  
 Gln Lys Leu Val Ala Val Glu Thr Asn Leu Ala Ser Leu Glu Asn Phe  
 130 135 140  
 Pro Ile Gly His Leu Lys Thr Leu Lys Glu Leu Asn Val Ala His Asn  
 145 150 155 160  
 Leu Ile Gln Ser Phe Lys Leu Pro Glu Tyr Phe Ser Asn Leu Thr Asn  
 165 170 175  
 Leu Glu His Leu Asp Leu Ser Ser Asn Lys Ile Gln Ser Ile Tyr Cys  
 180 185 190  
 Thr Asp Leu Arg Val Leu His Gln Met Pro Leu Leu Asn Leu Ser Leu  
 195 200 205  
 Asp Leu Ser Leu Asn Pro Met Asn Phe Ile Gln Pro Gly Ala Phe Lys  
 210 215 220  
 Glu Ile Arg Leu His Lys Leu Thr Leu Arg Asn Asn Phe Asp Ser Leu  
 225 230 235 240  
 Asn Val Met Lys Thr Cys Ile Gln Gly Leu Ala Gly Leu Glu Val His  
 245 250 255  
 Arg Leu Val Leu Gly Glu Phe Arg Asn Glu Gly Asn Leu Glu Lys Phe  
 260 265 270  
 Asp Lys Ser Ala Leu Glu Gly Leu Cys Asn Leu Thr Ile Glu Glu Phe  
 275 280 285  
 Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu Asp Asp Ile Ile Asp Leu Phe  
 290 295 300  
 Asn Cys Leu Thr Asn Val Ser Ser Phe Ser Leu Val Ser Val Thr Ile  
 305 310 315 320  
 Glu Arg Val Lys Asp Phe Ser Tyr Asn Phe Gly Trp Gln His Leu Glu  
 325 330 335  
 Leu Val Asn Cys Lys Phe Gly Gln Phe Pro Thr Leu Lys Leu Lys Ser  
 340 345 350  
 Leu Lys Arg Leu Thr Phe Thr Ser Asn Lys Gly Gly Asn Ala Phe Ser  
 355 360 365  
 Glu Val Asp Leu Pro Ser Leu Glu Phe Leu Asp Leu Ser Arg Asn Gly  
 370 375 380  
 Leu Ser Phe Lys Gly Cys Cys Ser Gln Ser Asp Phe Gly Thr Thr Ser  
 385 390 395 400  
 Leu Lys Tyr Leu Asp Leu Ser Phe Asn Gly Val Ile Thr Met Ser Ser  
 405 410 415  
 Asn Phe Leu Gly Leu Glu Gln Leu Glu His Leu Asp Phe Gln His Ser

420 425 430  
 Asn Leu Lys Gln Met Ser Glu Phe Ser Val Phe Leu Ser Leu Arg Asn  
 435 440 445  
 Leu Ile Tyr Leu Asp Ile Ser His Thr His Thr Arg Val Ala Phe Asn  
 450 455 460  
 Gly Ile Phe Asn Gly Leu Ser Ser Leu Glu Val Leu Lys Met Ala Gly  
 465 470 475 480  
 Asn Ser Phe Gln Glu Asn Phe Leu Pro Asp Ile Phe Thr Glu Leu Arg  
 485 490 495  
 Asn Leu Thr Phe Leu Asp Leu Ser Gln Cys Gln Leu Glu Gln Leu Ser  
 500 505 510  
 Pro Thr Ala Phe Asn Ser Leu Ser Leu Gln Val Leu Asn Met Ser  
 515 520 525  
 His Asn Asn Phe Phe Ser Leu Asp Thr Phe Pro Tyr Lys Cys Leu Asn  
 530 535 540  
 Ser Leu Gln Val Leu Asp Tyr Ser Leu Asn His Ile Met Thr Ser Lys  
 545 550 555 560  
 Lys Gln Glu Leu Gln His Phe Pro Ser Ser Leu Ala Phe Leu Asn Leu  
 565 570 575  
 Thr Gln Asn Asp Phe Ala Cys Thr Cys Glu His Gln Ser Phe Leu Gln  
 580 585 590  
 Trp Ile Lys Asp Gln Arg Gln Leu Leu Val Glu Val Glu Arg Met Glu  
 595 600 605  
 Cys Ala Thr Pro Ser Asp Lys Gln Gly Met Pro Val Leu Ser Leu Asn  
 610 615 620  
 Ile Thr Cys Gln Met Asn Lys Thr Ile Ile Gly Val Ser Val Leu Ser  
 625 630 635 640  
 Val Leu Val Val Ser Val Val Ala Val Leu Val Tyr Lys Phe Tyr Phe  
 645 650 655  
 His Leu Met Leu Leu Ala Gly Cys Ile Lys Tyr Gly Arg Gly Glu Asn  
 660 665 670  
 Ile Tyr Asp Ala Phe Val Ile Tyr Ser Ser Gln Asp Glu Asp Trp Val  
 675 680 685  
 Arg Asn Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Pro Phe Gln  
 690 695 700  
 Leu Cys Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala  
 705 710 715 720  
 Asn Ile Ile His Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val  
 725 730 735  
 Val Ser Gln His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu  
 740 745 750  
 Ile Ala Gln Thr Trp Gln Phe Leu Ser Ser Arg Ala Gly Ile Ile Phe

755 760 765  
 Ile Val Leu Gln Lys Val Glu Lys Thr Leu Leu Arg Gln Gln Val Glu  
 770 775 780  
 Leu Tyr Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Ser  
 785 790 795 800  
 Val Leu Gly Arg His Ile Phe Trp Arg Arg Leu Arg Lys Ala Leu Leu  
 805 810 815  
 Asp Gly Lys Ser Trp Asn Pro Glu Gly Thr Val Gly Thr Gly Cys Asn  
 820 825 830  
 Trp Gln Glu Ala Thr Ser Ile  
 835

<210> 17  
 <211> 782  
 <212> PRT  
 <213> Homo sapiens

<400> 17

Met Lys Pro Arg Ala Phe Arg Leu Arg Ser Leu Ser Pro Ser Pro Arg  
 1 5 10 15  
 Phe His Cys Phe Leu Leu Asn Ala Ala Val Leu Ser Arg Arg Cys Glu  
 20 25 30  
 Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu Ser  
 35 40 45  
 Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly Ala  
 50 55 60  
 Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr Asn  
 65 70 75 80  
 Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu Lys  
 85 90 95  
 Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro Glu  
 100 105 110  
 Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser Asn  
 115 120 125  
 Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln Met  
 130 135 140  
 Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn Phe  
 145 150 155 160  
 Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr Leu  
 165 170 175  
 Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln Gly  
 180 185 190  
 Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg Asn  
 195 200 205

Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu Cys  
 210 215 220  
 Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu  
 225 230 235 240  
 Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser Phe  
 245 250 255  
 Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr Asn  
 260 265 270  
 Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln Phe  
 275 280 285  
 Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser Asn  
 290 295 300  
 Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu Phe  
 305 310 315 320  
 Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser Gln  
 325 330 335  
 Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe Asn  
 340 345 350  
 Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu Glu  
 355 360 365  
 His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe Ser  
 370 375 380  
 Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His Thr  
 385 390 395 400  
 His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser Leu  
 405 410 415  
 Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu Pro  
 420 425 430  
 Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser Gln  
 435 440 445  
 Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser Ser  
 450 455 460  
 Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp Thr  
 465 470 475 480  
 Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser Leu  
 485 490 495  
 Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro Ser  
 500 505 510  
 Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr Cys  
 515 520 525  
 Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu Leu

530 535 540  
 Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln Gly  
 545 550 555 560  
 Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr Ile  
 565 570 575  
 Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala Val  
 580 585 590  
 Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys Ile  
 595 600 605  
 Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr Ser  
 610 615 620  
 Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu Glu  
 625 630 635 640  
 Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe Ile  
 645 650 655  
 Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His Lys  
 660 665 670  
 Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser Arg  
 675 680 685  
 Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu Ser  
 690 695 700  
 Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys Thr  
 705 710 715 720  
 Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn Thr  
 725 730 735  
 Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp Arg  
 740 745 750  
 Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu Gly  
 755 760 765  
 Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile  
 770 775 780

<210> 18  
 <211> 799  
 <212> PRT  
 <213> Homo sapiens

<400> 18

Met Glu Leu Asn Phe Tyr Lys Ile Pro Asp Asn Leu Pro Phe Ser Thr  
 1 5 10 15  
 Lys Asn Leu Asp Leu Ser Phe Asn Pro Leu Arg His Leu Gly Ser Tyr  
 20 25 30  
 Ser Phe Phe Ser Phe Pro Glu Leu Gln Val Leu Asp Leu Ser Arg Cys  
 35 40 45

Glu Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu  
 50 55 60  
 Ser Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly  
 65 70 75 80  
 Ala Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr  
 85 90 95  
 Asn Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu  
 100 105 110  
 Lys Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro  
 115 120 125  
 Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser  
 130 135 140  
 Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln  
 145 150 155 160  
 Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn  
 165 170 175  
 Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr  
 180 185 190  
 Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln  
 195 200 205  
 Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg  
 210 215 220  
 Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu  
 225 230 235 240  
 Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr  
 245 250 255  
 Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser  
 260 265 270  
 Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr  
 275 280 285  
 Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln  
 290 295 300  
 Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser  
 305 310 315 320  
 Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu  
 325 330 335  
 Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser  
 340 345 350  
 Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe  
 355 360 365  
 Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu

370					375					380														
Glu 385	His	Leu	Asp	Phe	Gln 390	His	Ser	Asn	Leu	Lys 395	Gln	Met	Ser	Glu	Phe 400									
Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His					405					410					415									
Thr	His	Thr	Arg 420	Val	Ala	Phe	Asn	Gly 425	Ile	Phe	Asn	Gly	Leu	Ser	Ser									
Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu					435					440					445									
Pro	Asp 450	Ile	Phe	Thr	Glu	Leu	Arg	Asn	Leu	Thr	Phe 460	Leu	Asp	Leu	Ser									
Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser					465					470					475					480				
Ser	Leu	Gln	Val	Leu	Asn	Met	Ser	His	Asn	Asn	Phe	Phe	Ser	Leu	Asp									
Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser					485					490					495									
Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser					500					505					510									
Leu	Asn	His 515	Ile	Met	Thr	Ser	Lys 520	Lys	Gln	Glu	Leu	Gln	His	Phe	Pro									
Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr					530					535					540									
Cys	Glu	His	Gln	Ser	Phe 550	Leu	Gln	Trp	Ile	Lys 555	Asp	Gln	Arg	Gln	Leu									
Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln					565					570					575									
Gly	Met	Pro	Val 580	Leu	Ser	Leu	Asn	Ile 585	Thr	Cys	Gln	Met	Asn	Lys	Thr									
Ile	Ile	Gly 595	Val	Ser	Val	Leu	Ser	Val	Leu	Val	Val	Ser 605	Val	Val	Ala									
Val	Leu	Val	Tyr	Lys	Phe	Tyr 615	Phe	His	Leu	Met	Leu	Leu	Ala	Gly	Cys									
Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr					625					630					635					640				
Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu					645					650					655									
Glu	Glu	Gly	Val 660	Pro	Pro	Phe	Gln	Leu	Cys	Leu	His	Tyr	Arg	Asp	Phe									
Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His					675					680					685									
Lys	Ser	Arg	Lys	Val	Ile	Val	Val	Val	Ser	Gln	His	Phe	Ile	Gln	Ser									
Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu					690					695					700									

Met	Pro	Leu	Leu	Asn	Leu	Ser	Leu	Asp	Leu	Ser	Leu	Asn	Pro	Met	Asn
1				5					10						15
Phe	Ile	Gln	Pro	Gly	Ala	Phe	Lys	Glu	Ile	Arg	Leu	His	Lys	Leu	Thr
			20					25					30		
Leu	Arg	Asn	Asn	Phe	Asp	Ser	Leu	Asn	Val	Met	Lys	Thr	Cys	Ile	Gln
		35					40					45			
Gly	Leu	Ala	Gly	Leu	Glu	Val	His	Arg	Leu	Val	Leu	Gly	Glu	Phe	Arg
	50					55					60				
Asn	Glu	Gly	Asn	Leu	Glu	Lys	Phe	Asp	Lys	Ser	Ala	Leu	Glu	Gly	Leu
65					70					75					80
Cys	Asn	Leu	Thr	Ile	Glu	Glu	Phe	Arg	Leu	Ala	Tyr	Leu	Asp	Tyr	Tyr
				85					90					95	
Leu	Asp	Asp	Ile	Ile	Asp	Leu	Phe	Asn	Cys	Leu	Thr	Asn	Val	Ser	Ser
			100					105					110		
Phe	Ser	Leu	Val	Ser	Val	Thr	Ile	Glu	Arg	Val	Lys	Asp	Phe	Ser	Tyr
		115					120					125			
Asn	Phe	Gly	Trp	Gln	His	Leu	Glu	Leu	Val	Asn	Cys	Lys	Phe	Gly	Gln
	130					135					140				
Phe	Pro	Thr	Leu	Lys	Leu	Lys	Ser	Leu	Lys	Arg	Leu	Thr	Phe	Thr	Ser
145					150					155					160
Asn	Lys	Gly	Gly	Asn	Ala	Phe	Ser	Glu	Val	Asp	Leu	Pro	Ser	Leu	Glu
				165					170					175	
Phe	Leu	Asp	Leu	Ser	Arg	Asn	Gly	Leu	Ser	Phe	Lys	Gly	Cys	Cys	Ser
			180					185					190		
Gln	Ser	Asp	Phe	Gly	Thr	Thr	Ser	Leu	Lys	Tyr	Leu	Asp	Leu	Ser	Phe
		195					200					205			



Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu  
 210 215 220  
 Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe  
 225 230 235 240  
 Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His  
 245 250 255  
 Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser  
 260 265 270  
 Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu  
 275 280 285  
 Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser  
 290 295 300  
 Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser  
 305 310 315 320  
 Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp  
 325 330 335  
 Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser  
 340 345 350  
 Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro  
 355 360 365  
 Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr  
 370 375 380  
 Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu  
 385 390 395 400  
 Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln  
 405 410 415  
 Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr  
 420 425 430  
 Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala  
 435 440 445  
 Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys  
 450 455 460  
 Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr  
 465 470 475 480  
 Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu  
 485 490 495  
 Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe  
 500 505 510  
 Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His  
 515 520 525  
 Lys Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser

530                      535                      540  
 Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu  
 545                      550                      555                      560  
  
 Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys  
                     565                      570                      575  
  
 Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn  
                     580                      585                      590  
  
 Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp  
                     595                      600                      605  
  
 Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu  
                     610                      615                      620  
  
 Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile  
 625                      630                      635

<210> 20  
 <211> 3866  
 <212> DNA  
 <213> murine

<400> 20  
 ctgggtgcag aaaatgccag gatgatgcct cctggctcc tggctaggac tctgatcatg 60  
 gcaactgttct tctcctgcct gacaccagga agcttgaatc cctgcataga ggtagttcct 120  
 aatattacct accaatgcat ggatcagaaa ctcagcaaag tccctgatga cattccttct 180  
 tcaaccaaga acatagatct gagcttcaac cccttgaaga tcttaaaaag ctatagcttc 240  
 tccaattttt cagaacttca gtggctggat ttatccagggt gtgaaattga aacaattgaa 300  
 gacaaggcat ggcattggctt acaccacctc tcaaaactga tactgacagg aaacctatc 360  
 cagagttttt ccccgaggag tttctctgga ctaacaagtt tagagaatct ggtggctgtg 420  
 gagacaaaat tggcctctct agaaagcttc cctattggac agcttataac cttaaagaaa 480  
 ctcaatgtgg ctcacaattt tatacattcc tgtaagttac ctgcatattt ttccaatctg 540  
 acgaacctag tacatgtgga tctttcttat aactatattc aaactattac tgtcaacgac 600  
 ttacagtttc tacgtgaaaa tcacaagtc aatctctctt tagacatgtc tttgaacca 660  
 attgacttca ttcaagacca agcctttcag ggaattaagc tccatgaact gactctaaga 720  
 ggtaatttta atagctcaaa tataatgaaa acttgccttc aaaacctggc tggtttacac 780  
 gtccatcggg tgatcttggg agaatttaaa gatgaaagga atctggaaat ttttgaaccc 840  
 tctatcatgg aaggactatg tgatgtgacc attgatgagt tcaggttaac atatacaaat 900  
 gatttttcag atgatattgt taagtccat tgcttggcga atgtttctgc aatgtctctg 960  
 gcagggtgat ctataaata tctagaagat gttcctaaac atttcaaatg gcaatcctta 1020  
 tcaatcatta gatgtcaact taagcagttt ccaactctgg atctaccctt tcttaaaagt 1080

ttgacttttaa	ctatgaacaa	agggctctatc	agtttttaaaa	aagtggccct	accaagtctc	1140
agctatctag	atcttagtag	aaatgcactg	agcttttagtg	gttgctgttc	ttattctgat	1200
ttgggaacaa	acagcctgag	acacttagac	ctcagcttca	atggtgccat	cattatgagt	1260
gccaatattca	tgggtctaga	agagctgcag	cacctggatt	ttcagcactc	tacttttaaaa	1320
agggtcacag	aattctcagc	gttcttatcc	cttgaaaagc	tactttacct	tgacatctct	1380
tatactaaca	ccaaaattga	cttcgatggg	atattttcttg	gcttgaccag	tctcaacaca	1440
ttaaaaatgg	ctggcaattc	tttcaaagac	aacacccttt	caaagtctt	tgcaaacaca	1500
acaaacttga	cattcctgga	tctttctaaa	tgtcaattgg	aacaaatata	ttggggggta	1560
tttgacaccc	tccatagact	tcaattatta	aatatgagtc	acaacaatct	attgtttttg	1620
gattcatccc	attataacca	gctgtattcc	ctcagcactc	ttgattgcag	tttcaatcgc	1680
atagagacat	ctaaaggaat	actgcaacat	tttccaaaga	gtctagcctt	cttcaatctt	1740
actaacaatt	ctgttgcttg	tatatgtgaa	catcagaaat	tcctgcagtg	ggtaaggaa	1800
cagaagcagt	tcttggtgaa	tggtgaacaa	atgacatgtg	caacacctgt	agagatgaat	1860
acctccttag	tggtggattt	taataattct	acctgttata	tgtacaagac	aatcatcagt	1920
gtgtcagtg	tcagtgtgat	tggtgtatcc	actgtagcat	ttctgatata	ccacttctat	1980
tttcacctga	tacttattgc	tggtgtgtaa	aagtacagca	gaggagaaag	catctatgat	2040
gcatttgtga	tctactcgag	tcagaatgag	gactgggtga	gaaatgagct	ggtaaagaat	2100
ttagaagaag	gagtgcctcg	ctttcacctc	tgcttccact	acagagactt	tattcctggg	2160
gtagccattg	ctgccaacat	catccaggaa	ggcttccaca	agagccggaa	ggttattgtg	2220
gtagtgtcta	gacactttat	tcagagccgt	tggtgtatct	ttgaatatga	gattgctcaa	2280
acatggcagt	ttctgagcag	ccgctctggc	atcatcttca	ttgtccttga	gaaggttgag	2340
aagtccctgc	tgaggcagca	gggtgaattg	tatgccttc	ttagcagaaa	cacctacctg	2400
gaatgggagg	acaatcctct	ggggaggcac	atcttctgga	gaagacttaa	aatgcccta	2460
ttggatggaa	aagcctcgaa	tcctgagcaa	acagcagagg	aagaacaaga	aacggcaact	2520
tggaacctg	gagaacaaaa	ctctggggcc	taaaccagtg	ctgtttgcaa	ttaataaatg	2580
ctacagctca	cctggggctc	tgctatggac	cgagagccca	tggaacacat	ggctgctaag	2640
ctatagcatg	gaccttaccg	ggcagaagga	agtagcactg	acaccttctt	ttccaggggt	2700
atgaattacc	taactcggga	aaagaaacat	aatccagaat	ctttaccttt	aatctgaagg	2760
agaagaggct	aaggcctagt	gagaacagaa	aggagaacca	gtcttcaactg	ggccttttga	2820
atacaagcca	tgcatgttc	tgtgtttcag	ttgctttaga	agagtattga	tagtttcaac	2880
tgaactgaac	ggtttcttac	tttccctttt	ttctactgaa	tgcaatatta	aatagctctt	2940
tttgagaggt	cttcattcca	atttcatctt	ccattttatg	tcattttctt	ttcttttttg	3000

tttttatctg attctataag aaatatgatt gatacacgct cacagatagc ctggccaatc 3060  
ctaagaatgc tatatttatt aaatacaatt cctagtatac ttttactttt ataaattcag 3120  
ttatcgtttt tcatgccttg actataaact aatatcataa ataagattgt tacagggtatg 3180  
ctaagaaggc ccatatttga ctataatttt ttaagaaagt atataaaata tactttgtca 3240  
tattgtcact gaatgtcatt cttaagttat tacctaagtt atggatgtca cagagtcagt 3300  
gttaaaaata atttggttga tagaaatatt tttaatcagg agggaaaagt ggagaggggt 3360  
gcaggaacag aaatcatgat ttcatcattt attcttgatt tttccggaag ttcacatagc 3420  
tgaatgacaa gactacatat gctgcaactg atgttccttc tcatcaagga tactctctga 3480  
acttgagaac attttgggga ggaagaaagg tctaaccatcc ttttccttca tcattctcat 3540  
ttctggacat gccttgtag atggatcaat gttgggagta cacatttctg ctttcacctt 3600  
atctcagtc gcatgaacac tgaatatata atgtcatttc acagtgtgtg tgtgtgtgtg 3660  
atgtacatat atgaacctgt acatgtgttt aagtttaaag agaaaatagt gtacagagca 3720  
gggtgatatt tgtgataggg ctttaaataag ttgagctaatt tcagaaaagt atggaggttt 3780  
cttggtaaac caaaccaaaa gtagaatcat tacaagatct aacaataaaa attttgaaaa 3840  
aaaaaaaaa aaaaaaaaaa aaaaaa 3866

<210> 21  
<211> 2520  
<212> DNA  
<213> murine

<400> 21  
atgatgcctc cctggctcct ggctaggact ctgatcatgg cactgttctt ctctgcctg 60  
acaccaggaa gcttgaatcc ctgcatagag gtagttccta atattaccta ccaatgcatg 120  
gatcagaaac tcagcaaagt ccctgatgac attccttctt caaccaagaa catagatctg 180  
agcttcaacc ccttgaagat cttaaaaagc tatagcttct ccaatttttc agaacttcag 240  
tggtctggatt tatccagggt tgaaattgaa acaattgaag acaaggcatg gcatggctta 300  
caccacctct caaacttgat actgacagga aaccctatcc agagtttttc cccaggaagt 360  
ttctctggac taacaagttt agagaatctg gtggctgtgg agacaaaatt ggctctctca 420  
gaaagcttcc ctattggaca gcttataacc ttaaagaaac tcaatgtggc tcaaaatttt 480  
atacattcct gtaagttacc tgcataattt tccaatctga cgaacctagt acatgtggat 540  
ctttcttata actatattca aactattact gtcaacgact tacagtttct acgtgaaaat 600  
ccacaagtca atctctcttt agacatatct ttgaaccaa ttgacttcat tcaagaccaa 660  
gcctttcagg gaattaagct ccatgaactg actctaagag gtaattttta tagctcaaat 720

ataatgaaaa	cttgccttca	aaacctggct	ggtttacaca	tccatcggtt	gatcttggga	780
gaattttaaag	atgaaaggaa	tctggaaatt	tttgaaccct	ctatcatgga	aggactatgt	840
gatgtgacca	ttgatgagtt	caggttaaca	tatacaaattg	atttttcaga	tgatattggt	900
aagttccatt	gcttggcgaa	tgtttctgca	atgtctctgg	caggtgtatc	tataaaatat	960
ctagaagatg	ttcctaaaca	tttcaaattg	caatccttat	caatcattag	atgtcaactt	1020
aagcagtttc	caactctgga	tctacccttt	cttaaaagtt	tgactttaac	tatgaacaaa	1080
gggtctatca	gttttaaaaa	agtggcccta	ccaagtctca	gctatctaga	tcttagtaga	1140
aatgcactga	gcttttagtgg	ttgctgttct	tattctgatt	tggaacaaa	cagcctgaga	1200
cacttagacc	tcagcttcaa	tggtgccatc	attatgagtg	ccaatttcat	gggtctagaa	1260
gagctgcagc	acctggattt	tcagcactct	actttaaaaa	gggtcacaga	attctcagcg	1320
ttcttatccc	ttgaaaagct	actttacctt	gacatctctt	atactaacac	caaaattgac	1380
ttcgatggta	tatttcttgg	cttgaccagt	ctcaacacat	taaaaatggc	tggcaattct	1440
ttcaaagaca	acaccctttc	aaatgtcttt	gcaaacacaa	caaacttgac	attcctggat	1500
ctttctaaat	gtcaattgga	acaaatatct	tgggggggat	ttgacaccct	ccatagactt	1560
caattattaa	atatgagtca	caacaatcta	ttgtttttgg	attcatccca	ttataaccag	1620
ctgtattccc	tcagcactct	tgattgcagt	ttcaatcgca	tagagacatc	taaaggaata	1680
ctgcaacatt	ttccaaagag	tctagccttc	ttcaatctta	ctaacaattc	tggtgcttgt	1740
atatgtgaac	atcagaaatt	cctgcagtgg	gtcaaggacc	agaagcagtt	cttgggtgaat	1800
gttgaacaaa	tgacatgtgc	aacacctgta	gagatgaata	cctccttagt	gttggatttt	1860
aataattcta	cctgttatat	gtacaagaca	atcatcagtg	tgtcagtggt	cagtgtgatt	1920
gtggtatcca	ctgtagcatt	tctgatatac	cacttctatt	ttcacctgat	acttattgct	1980
ggctgtaaaa	agtacagcag	aggagaaagc	atctatgatg	catttgtgat	ctactcgagt	2040
cagaatgagg	actgggtgag	aatgagctg	gtaaagaatt	tagaagaagg	agtgccccgc	2100
ttcacctct	gccttcacta	cagagacttt	attcctggtg	tagccattgc	tgccaatatc	2160
atccaggaag	gcttcacaaa	gagccggaag	gttattgtgg	tagtgtctag	acactttatt	2220
cagagccggt	ggtgtatctt	tgaatatgag	attgctcaaa	catggcagtt	tctgagcagc	2280
cactctggca	tcattctcat	tgtccttgag	aagggtgaga	agtccctgct	gaggcagcag	2340
gtggaattgt	atcgcttct	tagcagaaac	acctacctgg	aatgggagga	caatcctctg	2400
gggaggcaca	tcttctggag	aagacttaaa	aatgccctat	tggatggaaa	agcctcgaat	2460
cctgagcaaa	cagcagagga	agaacaagaa	acggcaactt	ggacctgagg	agaaccgcgg	2520

&lt;210&gt; 22

&lt;211&gt; 3866

&lt;212&gt; DNA

&lt;213&gt; murine

&lt;400&gt; 22

ctggttgcag aaaatgccag gatgatgcct ccctggctcc tggctaggac tctgatcatg 60  
gcactgttct tctcctgcct gacaccagga agcttgaatc cctgcataga ggtagttcct 120  
aatattacct accaatgcat ggatcagaaa ctcagcaaag tccctgatga cattccttct 180  
tcaaccaaga acatagatct gagcttcaac cccttgaaga tcttaaaaag ctatagcttc 240  
tccaattttt cagaacttca gtggctggat ttatccaggt gtgaaattga aacaattgaa 300  
gacaaggcat ggcatggctt acaccacctc tcaaacttga tactgacagg aaaccctatc 360  
cagagttttt cccaggaag tttctctgga ctaacaagtt tagagaatct ggtggctgtg 420  
gagacaaaat tggcctctct agaaagcttc cctattggac agcttataac cttaaagaaa 480  
ctcaatgtgg ctcaaatctt tatacattcc tgtaagttac ctgcatattt ttccaatctg 540  
acgaacctag tacatgtgga tctttcttat aactatattc aaactattac tgtcaacgac 600  
ttacagtttc tacgtgaaaa tccacaagtc aatctctctt tagacatgtc tttgaaccca 660  
attgacttca ttcaagacca agcctttcag ggaattaagc tccatgaact gactctaaga 720  
ggtaatttta atagctcaaa tataatgaaa acttgccctc aaaacctggc tggtttacac 780  
gtccatcggt tgatcttggg agaatttaaa gatgaaagga atctggaaat ttttgaaccc 840  
tctatcatgg aaggactatg tgatgtgacc attgatgagt tcaggttaac atatacaaat 900  
gatttttcag atgatattgt taagttccat tgcttggcga atgtttctgc aatgtctctg 960  
gcaggtgtat ctataaaata tctagaagat gttcctaacc atttcaaatg gcaatcctta 1020  
tcaatcatta gatgtcaact taagcagttt ccaactctgg atctaccctt tcttaaaagt 1080  
ttgactttaa ctatgaacaa agggctctatc agttttaaaa aagtggccct accaagtctc 1140  
agctatctag atcttagtag aaatgcactg agcttttagtg gttgctgttc ttattctgat 1200  
ttgggaacaa acagcctgag acacttagac ctcagcttca atggtgccat cattatgagt 1260  
gccaatttca tgggtctaga agagctgcag cacctggatt ttcagcactc tactttaaaa 1320  
agggtcacag aattctcagc gttcttatcc cttgaaaagc tactttacct tgacatctct 1380  
tatactaaca ccaaaattga cttogatggt atatttcttg gcttgaccag tctcaacaca 1440  
ttaaaaatgg ctggcaattc tttcaaagac aacacccttt caaatgtctt tgcaaacaca 1500  
acaaacttga cattcctgga tctttctaaa tgtcaattgg aacaaatctc ttggggggta 1560  
tttgacaccc tccatagact tcaattatta aatatgagtc acaacaatct attgtttttg 1620  
gattcatccc attataacca gctgtattcc ctcagcactc ttgattgcag tttcaatcgc 1680  
atagagacat ctaaaggaat actgcaacat tttccaaaga gtctagcctt cttcaatctt 1740

actaacaatt ctgttgcttg tatatgtgaa catcagaaat tcctgcagtg ggtcaaggaa 1800  
 cagaagcagt tcttggtgaa tggtgaacaa atgacatgtg caacacctgt agagatgaat 1860  
  
 acctccttag tggtggattt taataattct acctgttata tgtacaagac aatcatcagt 1920  
 gtgtcagtggt tcagtgatgat tgtggtatcc actgtagcat ttctgatata ccacttctat 1980  
 tttcacctga tacttattgc tggctgtaaa aagtacagca gaggagaaaag catctatgat 2040  
 gcatttgtga tctactcgag tcagaatgag gactgggtga gaaatgagct ggtaaagaat 2100  
 ttagaagaag gagtgcctcg ctttcacctc tgccttcact acagagactt tattcctggt 2160  
 gtagccattg ctgccaacat catccaggaa ggcttcacaca agagccggaa ggttattgtg 2220  
 gtagtgtcta gacactttat tcagagccgt tgggtgatct ttgaatatga gattgctcaa 2280  
 acatggcagt ttctgagcag ccgctctggc atcatcttca ttgtccttga gaaggttgag 2340  
 aagtccttgc tgaggcagca ggtggaattg tatcgcttca ttagcagaaa cacctacctg 2400  
 gaatgggagg acaatcctct ggggaggcac atcttcttga gaagacttaa aaatgcccta 2460  
 ttggatggaa aagcctcgaa tcctgagcaa acagcagagg aagaacaaga aacggcaact 2520  
 tggacctgag gagaacaaaa ctctggggcc taaaccagat ctgtttgcaa ttaataaatg 2580  
 ctacagctca cctggggctc tgetatggac cgagagccca tggaacacat ggctgctaag 2640  
 ctatagcatg gaccttaccg ggcagaagga agtagcactg acaccttcct ttccaggggt 2700  
 atgaattacc taactcggga aaagaaacat aatccagaat ctttaccttt aatctgaagg 2760  
 agaagaggct aaggcctagt gagaacagaa aggagaacca gtcttcactg ggccttttga 2820  
 atacaagcca tgtcatgttc tgtgtttcag ttgttttaga agagtattga tagtttcaac 2880  
 tgaactgaac ggtttcttac tttccctttt ttctactgaa tgcaatatta aatagctctt 2940  
 tttgagaggt cttcattcca atttcatctt ccattttatg tcattttctt ttcttttttg 3000  
 tttttatcta attctataag aaatatgatt gatacacgct cacagatagc ctggccaatc 3060  
 ctaagaatgc tatatttatt aaatacaatt cctagtatac ttttactttt ataaattcag 3120  
 ttatcgtttt tcatgccttg actataaact aatatcataa ataagattgt tacaggatg 3180  
 ctaagaaggc ccatatttga ctataatttt ttaagaaagt atataaaata tactttgtca 3240  
 tattgtcact gaatgtcatt cttaagttat tacctaagtt atggatgtca cagagtcagt 3300  
 gttaaaaata atttggttga tagaaatatt tttaatcagg agggaaaagt ggagaggggt 3360  
 gcaggaacag aaatcatgat ttcatcattt attcttgatt tttccggaag ttcacatagc 3420  
 tgaatgacaa gactacatat gctgcaactg atgttccttc tcatcaagga tactctctga 3480  
 acttgagaac attttgggga ggaagaaagg tctaacatcc ttttccttca tcattctcat 3540  
 ttctggacat gccttgtgag atggatcaat gttgggagta cacatttctg ctttcacctt 3600  
 atttcagtca gcatgaacac tgaatatata atgtcatttc acagtgtgtg tgtgttgtgt 3660

atgtacatat atgaacctgt acatgtgttt aagtttaaag agaaaatagt gtacagagca 3720  
 ggtgtatatt tgtgataggg ctttaaataag ttgagctaata tcagaaaagt atggagggtt 3780  
 cttggtaaac caaaccaaaa gtagaatcat tacaagatct aacaataaaa attttgaaaa 3840  
 aaaaaaaaaa aaaaaaaaaa aaaaaa 3866

<210> 23  
 <211> 835  
 <212> PRT  
 <213> murine

<400> 23

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe  
 1 5 10 15  
 Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val  
 20 25 30  
 Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro  
 35 40 45  
 Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro  
 50 55 60  
 Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln  
 65 70 75 80  
 Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala  
 85 90 95  
 Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro  
 100 105 110  
 Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu  
 115 120 125  
 Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro  
 130 135 140  
 Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe  
 145 150 155 160  
 Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu  
 165 170 175  
 Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn  
 180 185 190  
 Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp  
 195 200 205  
 Met Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly  
 210 215 220  
 Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn  
 225 230 235 240



Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Val His Arg  
 245 250 255  
 Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu  
 260 265 270  
 Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg  
 275 280 285  
 Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys  
 290 295 300  
 Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr  
 305 310 315 320  
 Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile  
 325 330 335  
 Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys  
 340 345 350  
 Ser Leu Thr Leu Thr Met Asn Lys Gly Ser Ile Ser Phe Lys Lys Val  
 355 360 365  
 Ala Leu Pro Ser Leu Ser Tyr Leu Asp Leu Ser Arg Asn Ala Leu Ser  
 370 375 380  
 Phe Ser Gly Cys Cys Ser Tyr Ser Asp Leu Gly Thr Asn Ser Leu Arg  
 385 390 395 400  
 His Leu Asp Leu Ser Phe Asn Gly Ala Ile Ile Met Ser Ala Asn Phe  
 405 410 415  
 Met Gly Leu Glu Glu Leu Gln His Leu Asp Phe Gln His Ser Thr Leu  
 420 425 430  
 Lys Arg Val Thr Glu Phe Ser Ala Phe Leu Ser Leu Glu Lys Leu Leu  
 435 440 445  
 Tyr Leu Asp Ile Ser Tyr Thr Asn Thr Lys Ile Asp Phe Asp Gly Ile  
 450 455 460  
 Phe Leu Gly Leu Thr Ser Leu Asn Thr Leu Lys Met Ala Gly Asn Ser  
 465 470 475 480  
 Phe Lys Asp Asn Thr Leu Ser Asn Val Phe Ala Asn Thr Thr Asn Leu  
 485 490 495  
 Thr Phe Leu Asp Leu Ser Lys Cys Gln Leu Glu Gln Ile Ser Trp Gly  
 500 505 510  
 Val Phe Asp Thr Leu His Arg Leu Gln Leu Leu Asn Met Ser His Asn  
 515 520 525  
 Asn Leu Leu Phe Leu Asp Ser Ser His Tyr Asn Gln Leu Tyr Ser Leu  
 530 535 540  
 Ser Thr Leu Asp Cys Ser Phe Asn Arg Ile Glu Thr Ser Lys Gly Ile  
 545 550 555 560  
 Leu Gln His Phe Pro Lys Ser Leu Ala Phe Phe Asn Leu Thr Asn Asn

565 570 575  
 Ser Val Ala Cys Ile Cys Glu His Gln Lys Phe Leu Gln Trp Val Lys  
 580 585 590  
 Glu Gln Lys Gln Phe Leu Val Asn Val Glu Gln Met Thr Cys Ala Thr  
 595 600 605  
 Pro Val Glu Met Asn Thr Ser Leu Val Leu Asp Phe Asn Asn Ser Thr  
 610 615 620  
 Cys Tyr Met Tyr Lys Thr Ile Ile Ser Val Ser Val Val Ser Val Ile  
 625 630 635 640  
 Val Val Ser Thr Val Ala Phe Leu Ile Tyr His Phe Tyr Phe His Leu  
 645 650 655  
 Ile Leu Ile Ala Gly Cys Lys Lys Tyr Ser Arg Gly Glu Ser Ile Tyr  
 660 665 670  
 Asp Ala Phe Val Ile Tyr Ser Ser Gln Asn Glu Asp Trp Val Arg Asn  
 675 680 685  
 Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Arg Phe His Leu Cys  
 690 695 700  
 Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala Asn Ile  
 705 710 715 720  
 Ile Gln Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val Val Ser  
 725 730 735  
 Arg His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala  
 740 745 750  
 Gln Thr Trp Gln Phe Leu Ser Ser Arg Ser Gly Ile Ile Phe Ile Val  
 755 760 765  
 Leu Glu Lys Val Glu Lys Ser Leu Leu Arg Gln Gln Val Glu Leu Tyr  
 770 775 780  
 Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Asn Pro Leu  
 785 790 795 800  
 Gly Arg His Ile Phe Trp Arg Arg Leu Lys Asn Ala Leu Leu Asp Gly  
 805 810 815  
 Lys Ala Ser Asn Pro Glu Gln Thr Ala Glu Glu Glu Gln Glu Thr Ala  
 820 825 830  
 Thr Trp Thr  
 835

<210> 24  
 <211> 835  
 <212> PRT  
 <213> murine

<400> 24

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe  
 1 5 10 15

Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val  
 20 25 30  
 Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro  
 35 40 45  
 Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro  
 50 55 60  
 Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln  
 65 70 75 80  
 Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala  
 85 90 95  
 Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro  
 100 105 110  
 Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu  
 115 120 125  
 Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro  
 130 135 140  
 Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe  
 145 150 155 160  
 Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu  
 165 170 175  
 Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn  
 180 185 190  
 Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp  
 195 200 205  
 Ile Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly  
 210 215 220  
 Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn  
 225 230 235 240  
 Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Ile His Arg  
 245 250 255  
 Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu  
 260 265 270  
 Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg  
 275 280 285  
 Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys  
 290 295 300  
 Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr  
 305 310 315 320  
 Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile  
 325 330 335  
 Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys

340 345 350  
 Ser Leu Thr Leu Thr Met Asn Lys Gly Ser Ile Ser Phe Lys Lys Val  
 355 360 365  
 Ala Leu Pro Ser Leu Ser Tyr Leu Asp Leu Ser Arg Asn Ala Leu Ser  
 370 375 380  
 Phe Ser Gly Cys Cys Ser Tyr Ser Asp Leu Gly Thr Asn Ser Leu Arg  
 385 390 395 400  
 His Leu Asp Leu Ser Phe Asn Gly Ala Ile Ile Met Ser Ala Asn Phe  
 405 410 415  
 Met Gly Leu Glu Glu Leu Gln His Leu Asp Phe Gln His Ser Thr Leu  
 420 425 430  
 Lys Arg Val Thr Glu Phe Ser Ala Phe Leu Ser Leu Glu Lys Leu Leu  
 435 440 445  
 Tyr Leu Asp Ile Ser Tyr Thr Asn Thr Lys Ile Asp Phe Asp Gly Ile  
 450 455 460  
 Phe Leu Gly Leu Thr Ser Leu Asn Thr Leu Lys Met Ala Gly Asn Ser  
 465 470 475 480  
 Phe Lys Asp Asn Thr Leu Ser Asn Val Phe Ala Asn Thr Thr Asn Leu  
 485 490 495  
 Thr Phe Leu Asp Leu Ser Lys Cys Gln Leu Glu Gln Ile Ser Trp Gly  
 500 505 510  
 Val Phe Asp Thr Leu His Arg Leu Gln Leu Leu Asn Met Ser His Asn  
 515 520 525  
 Asn Leu Leu Phe Leu Asp Ser Ser His Tyr Asn Gln Leu Tyr Ser Leu  
 530 535 540  
 Ser Thr Leu Asp Cys Ser Phe Asn Arg Ile Glu Thr Ser Lys Gly Ile  
 545 550 555 560  
 Leu Gln His Phe Pro Lys Ser Leu Ala Phe Phe Asn Leu Thr Asn Asn  
 565 570 575  
 Ser Val Ala Cys Ile Cys Glu His Gln Lys Phe Leu Gln Trp Val Lys  
 580 585 590  
 Asp Gln Lys Gln Phe Leu Val Asn Val Glu Gln Met Thr Cys Ala Thr  
 595 600 605  
 Pro Val Glu Met Asn Thr Ser Leu Val Leu Asp Phe Asn Asn Ser Thr  
 610 615 620  
 Cys Tyr Met Tyr Lys Thr Ile Ile Ser Val Ser Val Val Ser Val Ile  
 625 630 635 640  
 Val Val Ser Thr Val Ala Phe Leu Ile Tyr His Phe Tyr Phe His Leu  
 645 650 655  
 Ile Leu Ile Ala Gly Cys Lys Lys Tyr Ser Arg Gly Glu Ser Ile Tyr  
 660 665 670  
 Asp Ala Phe Val Ile Tyr Ser Ser Gln Asn Glu Asp Trp Val Arg Asn

675	680	685
Glu Leu Val Lys Asn Leu	Glu Glu Gly Val Pro Arg	Phe His Leu Cys
690	695	700
Leu His Tyr Arg Asp Phe	Ile Pro Gly Val Ala	Ile Ala Ala Asn Ile
705	710	715
Ile Gln Glu Gly Phe His	Lys Ser Arg Lys Val	Ile Val Val Val Ser
725	730	735
Arg His Phe Ile Gln Ser	Arg Trp Cys Ile Phe	Glu Tyr Glu Ile Ala
740	745	750
Gln Thr Trp Gln Phe Leu	Ser Ser His Ser Gly	Ile Ile Phe Ile Val
755	760	765
Leu Glu Lys Val Glu Lys	Ser Leu Leu Arg Gln	Gln Val Glu Leu Tyr
770	775	780
Arg Leu Leu Ser Arg Asn	Thr Tyr Leu Glu Trp	Glu Asp Asn Pro Leu
785	790	795
Gly Arg His Ile Phe Trp	Arg Arg Leu Lys Asn	Ala Leu Leu Asp Gly
805	810	815
Lys Ala Ser Asn Pro Glu	Gln Thr Ala Glu Glu	Glu Gln Glu Thr Ala
820	825	830
Thr Trp Thr		
835		

&lt;210&gt; 25

&lt;211&gt; 3431

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

ggcttatagg gctcgagcgg ccgcccgggc aggtatagaa ttcagcggcc gctgaattct	60
agggttttca ggagcccagag cgagggcgcc gcttttgcgt ccgggaggag ccaaccgtgg	120
cgcaggcggc gcggggaggc gtcccagagt ctactctgc cgcccaggct ggactgcagt	180
gacacaatct cggctgactg caaccactgc ctccagggtt caagcgattc tcttgcctca	240
gcctccaag tagctgggat tacagattga tgttcatgtt cctggcacta ctacaagatt	300
catactcctg atgctactga caacgtggct tctccacagt caccaaacca gggatgctat	360
actggacttc cctactctca tctgctccag cccctgacc ttatagttgc ccagctttcc	420
tggcaattga ctttgcccat caatacacag gatttagcat ccagggaaga tgtcggagcc	480
tcagatgtta attttcta at tgagaatgtt ggcgctgtcc gaacctggag acagaaaaac	540
aaaaagtcct ttctcctgat tcacaaaaa ataaaatact gactaccatc actgtgatga	600
gattcctata gtctcaggaa ctgaagtctt taaacaacca gggaccctct gccctagaa	660
taagaacata ctagaagtcc cttctgctag gacaacgagg atcatgggag accacctgga	720

ccttctccta ggagtgggtgc tcatggccgg tccgtgtgttt ggaattcctt cctgctcctt	780
tgatggccga atagcctttt atcgtttctg caacctcacc caggtcccc aggctcctcaa	840
caccactgag aggctcctgc tgagcttcaa ctatatcagg acagtcactg cttcatcctt	900
cccccttctg gaacagctgc agctgctgga gctcgggagc cagtataccc ccttgactat	960
tgacaaggag gccttcagaa acctgcccaa ccttagaatc ttggacctgg gaagtagtaa	1020
gatatacttc ttgcatccag atgcttttca gggactgttc catctgtttg aacttagact	1080
gtatttctgt ggtctctctg atgctgtatt gaaagatggg tatttcagaa atttaaaggc	1140
tttaactcgc ttggatctat ccaaaaatca gattcgtagc ctttaccttc atccttcatt	1200
tggaagtgtg aattccttaa agtccataga ttttctctcc aaccaaatat tccttgtatg	1260
tgaacatgag ctcgagcccc tacaaggga aacgctctcc ttttttagcc tcgcagctaa	1320
tagcttgtat agcagagtct cagtggactg gggaaaatgt atgaacctat tcagaaacat	1380
gggtctggag atactagatg tttctggaaa tggctggaca gtggacatca caggaaactt	1440
tagcaatgcc atcagcaaaa gccaggcctt ctctttgatt cttgccacc acatcatggg	1500
tgccgggttt ggcttcata acatcaaaga tcctgaccag aacacatttg ctggcctggc	1560
cagaagtcca gtgagacacc tggatcttcc acatgggttt gtcttctccc tgaactcacg	1620
agtctttgag acactcaagg atttgaagg tctgaacctt gcctacaaca agataaataa	1680
gattgcagat gaagcatttt acggacttga caacctcaa gttctcaatt tgtcatataa	1740
ccttctgggg gaactttaca gttcgaattt ctatggacta cctaaggtag cctacattga	1800
tttgcaaaag aatcacattg caataattca agaccaaca ttcaaattcc tggaaaaatt	1860
acagaccttg gatctccgag acaatgctct tacaaccatt cattttattc caagcatacc	1920
cgatatcttc ttgagtggca ataaactagt gactttgcca aagatcaacc ttacagcgaa	1980
cctcatccac ttatcagaaa acaggctaga aaatctagat attctctact ttcttctacg	2040
ggtacctcat ctccagattc tcattttaaa tcaaaatcgc ttctcctcct gtagtggaga	2100
tcaaacccct tcagagaatc ccagcttaga acagcttttc cttggagaaa atatgttgca	2160
acttgccctgg gaaactgagc tctgttggga tgtttttgag ggactttctc atcttcaagt	2220
tctgtatttg aatcataact atcttaattc ccttcacca ggagtattta gccatctgac	2280
tgcattaagg ggactaagcc tcaactccaa caggctgaca gttctttctc acaatgattt	2340
acctgcta attagagatcc tggacatctc caggaaccag ctctagctc ctaatcctga	2400
tgtatttgta tcacttagtg tcttgatata aactcataac aagttcattt gtgaatgtga	2460
acttagcact tttatcaatt ggcttaatca caccaatgtc actatagctg ggcctcctgc	2520
agacatatat tgtgtgtacc ctgactcgtt ctctgggggt tccctcttct ctctttccac	2580
ggaagggtgt gatgaaggag aagtcttaaa gtccctaaag ttctcccttt tcattgtatg	2640

```

cactgtcact ctgactctgt tcctcatgac catcctcaca gtcacaaagt tccggggctt 2700
ctgttttatc tgttataaga cagcccagag actgggtgttc aaggaccatc cccagggcac 2760
agaacctgat atgtacaaat atgatgccta tttgtgcttc agcagcaaag acttcacatg 2820
gggtgcagaat gctttgctca aacacctgga cactcaatac agtgaccaa acagattcaa 2880
cctgtgcttt gaagaaagag actttgtccc aggagaaaac cgcattgcca atatccagga 2940
tgccatctgg aacagtagaa agatcgtttg tcttgtgagc agacacttcc ttagagatgg 3000
ctgggtgcctt gaagccttca gttatgccca gggcaggtgc ttatctgacc ttaacagtgc 3060
tctcatcatg gtggtggttg ggtccttgtc ccagtaccag ttgatgaaac atcaatccat 3120
cagaggcttt gtacagaaac agcagtattt gaggtggcct gaggatctcc aggatgttgg 3180
ctggtttctt cataaactct ctcaacagat actaaagaaa gaaaaagaaa agaagaaaga 3240
caataacatt ccgttgcaaa ctgtagcaac catctcctaa tcaaaggagc aatttccaac 3300
ttatctcaag ccacaaataa ctcttcactt tgtatttgca ccaagttatc attttggggt 3360
cctctctgga ggtttttttt ttctttttgc tactatgaaa acaacataaa tctctcaatt 3420
ttcgtatcaa a 3431

```

&lt;210&gt; 26

&lt;211&gt; 858

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

```

Met Gly Asp His Leu Asp Leu Leu Leu Gly Val Val Leu Met Ala Gly
1           5           10          15
Pro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe
20          25          30
Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr
35          40          45
Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser
50          55          60
Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly Ser Gln
65          70          75          80
Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn
85          90          95
Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro
100         105         110
Asp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe
115         120         125
Cys Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu

```

130 135 140  
 Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu  
 145 150 155 160  
 Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp  
 165 170 175  
 Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro  
 180 185 190  
 Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu  
 195 200 205  
 Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg  
 210 215 220  
 Asn Met Val Leu Glu Ile Leu Asp Val Ser Gly Asn Gly Trp Thr Val  
 225 230 235 240  
 Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe  
 245 250 255  
 Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His  
 260 265 270  
 Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser  
 275 280 285  
 Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn  
 290 295 300  
 Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala  
 305 310 315 320  
 Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp  
 325 330 335  
 Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Tyr  
 340 345 350  
 Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln  
 355 360 365  
 Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu  
 370 375 380  
 Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His  
 385 390 395 400  
 Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val  
 405 410 415  
 Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu  
 420 425 430  
 Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro  
 435 440 445  
 His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser  
 450 455 460  
 Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu



465                      470                      475                      480  
 Gly Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp  
                                  485                      490                      495  
  
 Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn  
                                  500                      505                      510  
  
 Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu  
                                  515                      520                      525  
  
 Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn  
                                  530                      535                      540  
  
 Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu  
 545                                   550                      555                      560  
  
 Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile  
                                  565                      570                      575  
  
 Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn  
                                  580                      585                      590  
  
 Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile  
                                  595                      600                      605  
  
 Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu Phe Ser Leu  
                                  610                      615                      620  
  
 Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe  
 625                                   630                      635                      640  
  
 Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr  
                                  645                      650                      655  
  
 Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys  
                                  660                      665                      670  
  
 Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro  
                                  675                      680                      685  
  
 Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe  
                                  690                      695                      700  
  
 Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser  
 705                                   710                      715                      720  
  
 Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro  
                                  725                      730                      735  
  
 Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg  
                                  740                      745                      750  
  
 Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys  
                                  755                      760                      765  
  
 Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn  
                                  770                      775                      780  
  
 Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu  
 785                                   790                      795                      800  
  
 Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu

Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu  
                     805                    810                    815  
                     820                    825                    830

Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys Asp Asn Asn  
                     835                    840                    845

Ile Pro Leu Gln Thr Val Ala Thr Ile Ser  
                     850                    855

<210> 27

<211> 858

<212> PRT

<213> Homo sapiens

<400> 27

Met Gly Asp His Leu Asp Leu Leu Leu Gly Val Val Leu Met Ala Gly  
   1                    5                    10                    15

Pro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe  
                     20                    25                    30

Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr  
                     35                    40                    45

Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser  
                     50                    55                    60

Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly Ser Gln  
   65                    70                    75                    80

Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn  
                     85                    90                    95

Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro  
                     100                    105                    110

Asp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe  
                     115                    120                    125

Cys Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu  
                     130                    135                    140

Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu  
   145                    150                    155                    160

Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp  
                     165                    170                    175

Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro  
                     180                    185                    190

Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu  
                     195                    200                    205

Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg  
                     210                    215                    220

Asn Met Val Leu Glu Ile Val Asp Val Ser Gly Asn Gly Trp Thr Val  
   225                    230                    235                    240

Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe  
 245 250 255  
 Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His  
 260 265 270  
 Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser  
 275 280 285  
 Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn  
 290 295 300  
 Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala  
 305 310 315 320  
 Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp  
 325 330 335  
 Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Cys  
 340 345 350  
 Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln  
 355 360 365  
 Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu  
 370 375 380  
 Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His  
 385 390 395 400  
 Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val  
 405 410 415  
 Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu  
 420 425 430  
 Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro  
 435 440 445  
 His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser  
 450 455 460  
 Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu  
 465 470 475 480  
 Gly Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp  
 485 490 495  
 Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn  
 500 505 510  
 Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu  
 515 520 525  
 Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn  
 530 535 540  
 Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu  
 545 550 555 560  
 Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile

565 570 575  
 Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn  
 580 585 590  
 Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile  
 595 600 605  
 Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu Phe Ser Leu  
 610 615 620  
 Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe  
 625 630 635 640  
 Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr  
 645 650 655  
 Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys  
 660 665 670  
 Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro  
 675 680 685  
 Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe  
 690 695 700  
 Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser  
 705 710 715 720  
 Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro  
 725 730 735  
 Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg  
 740 745 750  
 Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys  
 755 760 765  
 Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn  
 770 775 780  
 Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu  
 785 790 795 800  
 Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu  
 805 810 815  
 Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu  
 820 825 830  
 Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys Asp Asn Asn  
 835 840 845  
 Ile Pro Leu Gln Thr Val Ala Thr Ile Ser  
 850 855

&lt;210&gt; 28

&lt;211&gt; 365

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

Cys Trp Asp Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu  
 1 5 10 15  
 Asn His Asn Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu  
 20 25 30  
 Thr Ala Leu Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu  
 35 40 45  
 Ser His Asn Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg  
 50 55 60  
 Asn Gln Leu Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val  
 65 70 75 80  
 Leu Asp Ile Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr  
 85 90 95  
 Phe Ile Asn Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro  
 100 105 110  
 Ala Asp Ile Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu  
 115 120 125  
 Phe Ser Leu Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser  
 130 135 140  
 Leu Lys Phe Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe  
 145 150 155 160  
 Leu Met Thr Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile  
 165 170 175  
 Cys Tyr Lys Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly  
 180 185 190  
 Thr Glu Pro Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser  
 195 200 205  
 Lys Asp Phe Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr  
 210 215 220  
 Gln Tyr Ser Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp  
 225 230 235 240  
 Phe Val Pro Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp  
 245 250 255  
 Asn Ser Arg Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp  
 260 265 270  
 Gly Trp Cys Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser  
 275 280 285  
 Asp Leu Asn Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln  
 290 295 300  
 Tyr Gln Leu Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln  
 305 310 315 320  
 Gln Tyr Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu

<400>	29	
ttgaaatctc	acagcccggt	tgggtgcagt gacccacttc gttgaacata ttcttcctaa 60
tcctagtagt	ttcaatttgc	tctattccct ggtgtctatg catttaaadc gactatgggg 120
ccattcttcc	ttgaaccacc	acagaagaca ttagctctct gggatccttg ttaatttttt 180
ctcctcttac	atagcaccta	cgtttggaac atatgccaga cacatctgtg agacaccctt 240
tgccgctgca	gctcatggat	ggatgctgag ttccccacg caccacactt cagcaggtgg 300
gtgtatttct	gcttcacatt	atactccac acggccatgc atgtcaggca tggagcaggg 360
tcataaccca	cttaattaag	gtgatcatat cagatccttt atcaagatgc atagagtgtt 420
cagtgcctgt	actatgatct	cggatctttg ggagatgggc tagatagagt ctgggacaga 480
atacagcaga	gaaaccgata	tgttttattgt ccgatcatca gctaagcttc tgggagctag 540
gaatggggct	ccttggatga	acagaagtaa aaatgcctcg tctttatgac tttcaacttc 600
cctcagcagg	tctggaatgg	gtgaacaaac actgcctgcg tgggtgataa atagcctctt 660
tttgctgctt	gtttgctgct	tttatggttc tgggagggaa cctagaacct agcacatgct 720
agacaagtcc	tctagcactg	agctatctcc ccagcttgga tgaaatatct gtaaagtact 780
ggtgcccggt	tgtaaaatat	gcaccattaa gtgttcaaga agaaaagact gggcatttct 840
gttccaccaa	gacaagaaga	atctgccagc agaattgttg cgcagtcatt tgagcaaagg 900
ggtccaaggg	acagtaccct	ccagtgtctg ggacccatgt gccgagcctc aggctgtgat 960
gtgggtgtgt	ttttaattct	ctcttttccc ataggatcat ggcatgtcaa cttgacttgc 1020
tcataggtgt	gatcttcctg	gccagccccg tgttggtaat atctccctgt tcttcagacg 1080
gcaggatagc	ctttttccga	ggctgtaacc tcaccagat tccctggatc ctcaatacta 1140
ccactgagag	gctcctgctc	agcttcaact atatcagtat ggtgggttgc acatcatttc 1200
cactcctgga	gcggctccag	ttgctggagc tggggaccca gtatgctaac ttgaccattg 1260
gtccaggggc	tttcagaaac	ctgcccatac ttaggatctt ggacttgggc caaagccaga 1320
tcgaagtctt	gaatcgagat	gcctttcaag gtctgcccc a tctcttgga cttcggctgt 1380
tttctgtgtg	actctccagt	gctgtgttaa gtgacggtta cttcagaaat ctatattcat 1440

tagctcgctt agacctatct ggcaaccaga ttcacagcct ccgcctccat tcttcattcc	1500
gggaactgaa ttccttaagc gacgtaaatt ttgctttcaa ccaaattatc actatatgtg	1560
aagatgaact cgagcctctg cagggcaaaa cactgtcttt ctttggcctc aaattaacta	1620
agctgttcag cagagtctct gtgggctggg agacatgcag gaaccccttc agaggcgtga	1680
ggctagaaac tctagatctt tctgaaaatg gctggacggt ggacatcaca aggaacttca	1740
gcaacatcat ccagggagc cagatttcct ctttgattct taaacaccac atcatgggtc	1800
ctggcttttg cttccagaac atcagagatc ctgaccagag cacatttgcc agcctggcca	1860
gaagtccggt gctgcaactg gacctttcgc acggctttat cttctccttg aatcctcgac	1920
tgtttgggac actgaaggat ttgaagatgc tgaaccttgc cttcaacaag ataaacaaga	1980
ttggagagaa tgccctttat gggcttgaca gcctccaggt tctcaatcta tcctataatc	2040
ttttggggga actctataat tccaacttct atgggcttcc tagagtagcc tacgttgacc	2100
ttcaaaggaa ccacattggg atcattcaag accaaacatt cagattatta aaaacgttac	2160
aaaccttaga tctccgtgac aatgctctta aggccattgg ttttattcca agcatacaga	2220
tggtcctcct gggaggcaat aagctggtcc atttgccaca catccacttt actgccaact	2280
tcctagagtt atctgaaaac aggctagaaa acctgtccga cctctacttc ctctgcgag	2340
tccccagct ccagtttctc atcttgaatc agaatgcct ttcgtcatgc aaggcagccc	2400
acactccctc ggagaacca agcttagaac agcttttctt tacagagaat atgctgcagc	2460
tggcctggga gaccggcctc tgttgggatg tttttcaagg cctttcccgc ctccagattc	2520
ttacctgag taataactac cttaatttcc ttccacctgg gatatttaac gacctgggtg	2580
cattacggat gcttagtctt agtgctaaca agctgaccgt gctctctccg ggcagtttac	2640
ctgctaattt agagattctc gacatatcta gaaatcagct tttgtgtcct gacctgctt	2700
tgttttcttc gcttcgtgtt ttggacataa ctcataacga gttcgtctgc aactgtgaac	2760
ttagcacttt tatctcctgg ctcaaccaa ccaacgtcac cctgttcggc tctcctgcag	2820
acgtgtattg catgtaccct aactcactgc tagggggctc cctctacaac atatccaccg	2880
aagactgcga tgaagaggaa gccatgctgt ccctaaagtt ttcccttttc atcctgtgca	2940
cggtcacttt gactctattc ctctcatca cccttgtagt cataaagttc cggggaatct	3000
gtttcctgtg ctataagacc atccagaagc tgggtgtcaa ggacaaggtc tggagtttgg	3060
aacctggtgc atatagatat gatgcctact tctgcttcag cagcaaagac tttgaatggg	3120
cacagaatgc tttgtcaaa cacctggatg ctactacag ttcccgaac aggtcaggc	3180
tatgctttga agaaagagac ttcatccgg gggaaaacca tatctccaac atccaggcgg	3240
ctgtctgggg cagcaggaag acggtgtgtc tagtgagcag acacttcctg aaggatgggt	3300
ggtgcctgga ggccttcagg tatgccaga gccggagtct gtctgacctc aagagcatc	3360

tcatcgtggt ggtggtggga tcgctgtccc agtatcagct gatgagacat gagaccatca 3420  
 gaggggtttct gcaaaagcaa cagtacttga ggtggcctga agacctccag gatggttggt 3480  
 ggttttctga taaactctcc ggatgcattc taaaggaaga aaaaggaaaag aaaagaagca 3540  
 gttccatcca gttgcgaacc atagcaacca tttcctagca ggagcgcctc ctagcagaag 3600  
 tgcaagcatc gtagataact ctccacgctt tatccgcaca gccgctgggg gtccttccct 3660  
 ggagtcattt ttctgacaat gaaaacaaca ccaatctctt gatttttcat gtcaacaggg 3720  
 agctttgtct tcaactgtttt ccaaattgaa agtaagaggt ccagaaagct gcctctaagg 3780  
 gctctcacct gccattgatg tcctttcagg cccaatgaca tggtttccct ccatectatt 3840  
 gcgtactgtc tgctaccag gtggcaagag caccttgga gaagttacag gcagcttcat 3900  
 gctttctgtg ctgttcagtt caaaagcagg tgccttgaga atcctgaatt caagcactct 3960  
 gtagaacatg gacagacaag atgggtcctt ctctggccat aggcattgagg gccagttgct 4020  
 gaggactgct ctactacac ctaagtgcac aagtataag aagttggaca gatagacaga 4080  
 tagcagcagt cccattgctg tagccagaat gcacttattt cctgttctga ccctgcaggc 4140  
 ccagcttttg gggaccacag ccatgttctg cacgggacct ctcaacctgg cattcatgcc 4200  
 ctttcacgac ttagcaccgg cctgcccttc tttcttcccc acaactatac aagagctgtt 4260  
 gcaaccactg aaaaaaaaaa aaaaaa 4286

<210> 30  
 <211> 859  
 <212> PRT  
 <213> murine

<400> 30

Met Ala Cys Gln Leu Asp Leu Leu Ile Gly Val Ile Phe Met Ala Ser  
1 5 10 15

Pro Val Leu Val Ile Ser Pro Cys Ser Ser Asp Gly Arg Ile Ala Phe  
20 25 30

Phe Arg Gly Cys Asn Leu Thr Gln Ile Pro Trp Ile Leu Asn Thr Thr  
35 40 45

Thr Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Ser Met Val Val Ala  
50 55 60

Thr Ser Phe Pro Leu Leu Glu Arg Leu Gln Leu Leu Glu Leu Gly Thr  
65 70 75 80

Gln Tyr Ala Asn Leu Thr Ile Gly Pro Gly Ala Phe Arg Asn Leu Pro  
85 90 95

Asn Leu Arg Ile Leu Asp Leu Gly Gln Ser Gln Ile Glu Val Leu Asn  
100 105 110



Arg Asp Ala Phe Gln Gly Leu Pro His Leu Leu Glu Leu Arg Leu Phe  
 115 120 125  
 Ser Cys Gly Leu Ser Ser Ala Val Leu Ser Asp Gly Tyr Phe Arg Asn  
 130 135 140  
 Leu Tyr Ser Leu Ala Arg Leu Asp Leu Ser Gly Asn Gln Ile His Ser  
 145 150 155 160  
 Leu Arg Leu His Ser Ser Phe Arg Glu Leu Asn Ser Leu Ser Asp Val  
 165 170 175  
 Asn Phe Ala Phe Asn Gln Ile Phe Thr Ile Cys Glu Asp Glu Leu Glu  
 180 185 190  
 Pro Leu Gln Gly Lys Thr Leu Ser Phe Phe Gly Leu Lys Leu Thr Lys  
 195 200 205  
 Leu Phe Ser Arg Val Ser Val Gly Trp Glu Thr Cys Arg Asn Pro Phe  
 210 215 220  
 Arg Gly Val Arg Leu Glu Thr Leu Asp Leu Ser Glu Asn Gly Trp Thr  
 225 230 235 240  
 Val Asp Ile Thr Arg Asn Phe Ser Asn Ile Ile Gln Gly Ser Gln Ile  
 245 250 255  
 Ser Ser Leu Ile Leu Lys His His Ile Met Gly Pro Gly Phe Gly Phe  
 260 265 270  
 Gln Asn Ile Arg Asp Pro Asp Gln Ser Thr Phe Ala Ser Leu Ala Arg  
 275 280 285  
 Ser Ser Val Leu Gln Leu Asp Leu Ser His Gly Phe Ile Phe Ser Leu  
 290 295 300  
 Asn Pro Arg Leu Phe Gly Thr Leu Lys Asp Leu Lys Met Leu Asn Leu  
 305 310 315 320  
 Ala Phe Asn Lys Ile Asn Lys Ile Gly Glu Asn Ala Phe Tyr Gly Leu  
 325 330 335  
 Asp Ser Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu  
 340 345 350  
 Tyr Asn Ser Asn Phe Tyr Gly Leu Pro Arg Val Ala Tyr Val Asp Leu  
 355 360 365  
 Gln Arg Asn His Ile Gly Ile Ile Gln Asp Gln Thr Phe Arg Leu Leu  
 370 375 380  
 Lys Thr Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Lys Ala Ile  
 385 390 395 400  
 Gly Phe Ile Pro Ser Ile Gln Met Val Leu Leu Gly Gly Asn Lys Leu  
 405 410 415  
 Val His Leu Pro His Ile His Phe Thr Ala Asn Phe Leu Glu Leu Ser  
 420 425 430  
 Glu Asn Arg Leu Glu Asn Leu Ser Asp Leu Tyr Phe Leu Leu Arg Val

435 440 445  
 Pro Gln Leu Gln Phe Leu Ile Leu Asn Gln Asn Arg Leu Ser Ser Cys  
 450 455 460  
 Lys Ala Ala His Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe  
 465 470 475 480  
 Leu Thr Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Gly Leu Cys Trp  
 485 490 495  
 Asp Val Phe Gln Gly Leu Ser Arg Leu Gln Ile Leu Tyr Leu Ser Asn  
 500 505 510  
 Asn Tyr Leu Asn Phe Leu Pro Pro Gly Ile Phe Asn Asp Leu Val Ala  
 515 520 525  
 Leu Arg Met Leu Ser Leu Ser Ala Asn Lys Leu Thr Val Leu Ser Pro  
 530 535 540  
 Gly Ser Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln  
 545 550 555 560  
 Leu Leu Cys Pro Asp Pro Ala Leu Phe Ser Ser Leu Arg Val Leu Asp  
 565 570 575  
 Ile Thr His Asn Glu Phe Val Cys Asn Cys Glu Leu Ser Thr Phe Ile  
 580 585 590  
 Ser Trp Leu Asn Gln Thr Asn Val Thr Leu Phe Gly Ser Pro Ala Asp  
 595 600 605  
 Val Tyr Cys Met Tyr Pro Asn Ser Leu Leu Gly Gly Ser Leu Tyr Asn  
 610 615 620  
 Ile Ser Thr Glu Asp Cys Asp Glu Glu Glu Ala Met Arg Ser Leu Lys  
 625 630 635 640  
 Phe Ser Leu Phe Ile Leu Cys Thr Val Thr Leu Thr Leu Phe Leu Val  
 645 650 655  
 Ile Thr Leu Val Val Ile Lys Phe Arg Gly Ile Cys Phe Leu Cys Tyr  
 660 665 670  
 Lys Thr Ile Gln Lys Leu Val Phe Lys Asp Lys Val Trp Ser Leu Glu  
 675 680 685  
 Pro Gly Ala Tyr Arg Tyr Asp Ala Tyr Phe Cys Phe Ser Ser Lys Asp  
 690 695 700  
 Phe Glu Trp Ala Gln Asn Ala Leu Leu Lys His Leu Asp Ala His Tyr  
 705 710 715 720  
 Ser Ser Arg Asn Arg Leu Arg Leu Cys Phe Glu Glu Arg Asp Phe Ile  
 725 730 735  
 Pro Gly Glu Asn His Ile Ser Asn Ile Gln Ala Ala Val Trp Gly Ser  
 740 745 750  
 Arg Lys Thr Val Cys Leu Val Ser Arg His Phe Leu Lys Asp Gly Trp  
 755 760 765  
 Cys Leu Glu Ala Phe Arg Tyr Ala Gln Ser Arg Ser Leu Ser Asp Leu

770                      775                      780  
 Lys Ser Ile Leu Ile Val Val Val Gly Ser Leu Ser Gln Tyr Gln  
 785                      790                      795                      800  
 Leu Met Arg His Glu Thr Ile Arg Gly Phe Leu Gln Lys Gln Gln Tyr  
                     805                      810                      815  
 Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu Asp Lys  
                     820                      825                      830  
 Leu Ser Gly Cys Ile Leu Lys Glu Glu Lys Gly Lys Lys Arg Ser Ser  
                     835                      840                      845  
 Ser Ile Gln Leu Arg Thr Ile Ala Thr Ile Ser  
                     850                      855

<210> 31  
 <211> 3373  
 <212> DNA  
 <213> Homo sapiens

<400> 31  
 agctggctag cgtttaaacg ggcctcttag actcgagcgg ccgcgaattc actagtgatt 60  
 cacctctcat gctctgctct ctccaaccag acctctacat tccattttgg aagaagacta 120  
 aaaatggtgt ttccaatgtg gacactgaag agacaaattc ttatcctttt taacataatc 180  
 ctaattttcca aactccttgg ggctagatgg tttcctaaaa ctctgccctg tgatgtcact 240  
 ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt gacagaaatt 300  
 cctggaggta ttcccacgaa caccacgaac ctcaacctca ccattaacca cataccagac 360  
 atctccccag cgtcctttca cagactggac catctggtag agatcgattt cagatgcaac 420  
 tgtgtacctt ttccactggg gtcaaaaaac aacatgtgca tcaagaggct gcagattaaa 480  
 ccagaagct ttagtggact cacttattta aaatcccttt acctggatgg aaaccagcta 540  
 ctagagatac cgcagggcct cccgcctagc ttacagcttc tcagccttga ggccaacaac 600  
 atcttttcca tcagaaaaga gaatctaaca gaactggcca acatagaaat actctacctg 660  
 ggccaaaact gttattatcg aaatccttgt tatgtttcat attcaataga gaaagatgcc 720  
 ttcttaaact tgacaaagtt aaaagtgtc tcctgaaag ataacaatgt cacagccgtc 780  
 cctactgttt tgccatctac tttaacagaa ctatatctct acaacaacat gattgcaaaa 840  
 atccaagaag atgattttta taacctcaac caattacaaa ttcttgacct aagtggaaat 900  
 tgccctcggt gttataatgc ccatttctt tgtgcgccgt gtaaaaataa ttctccccta 960  
 cagatccctg taaatgcttt tgatgcgctg acagaattaa agtttttacg tctacacagt 1020  
 aactctcttc agcatgtgcc cccaagatgg tttaagaaca tcaacaaact ccaggaaactg 1080  
 gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaatttct gcattttctc 1140  
 ccagcctca tccaattgga tctgtctttc aattttgaac ttcaggtcta tcgtgcatct 1200

atgaatctat cacaagcatt ttcttcaactg aaaagcctga aaattctgcg gatcagagga 1260  
tatgtcttta aagagttgaa aagctttaac ctctcgccat tacataatct tcaaaatctt 1320  
gaagttcttg atcttggcac taactttata aaaattgcta acctcagcat gtttaaacia 1380  
tttaaaagac tgaaagtcac agatctttca gtgaataaaa tatcaccttc aggagattca 1440  
agtgaagttg gcttctgctc aaatgccaga acttctgtag aaagttatga accccaggtc 1500  
ctggaacaat tacattatct cagatatgat aagtatgcaa ggagttgcag attcaaaaac 1560  
aaagaggctt ctttcatgctc tgttaatgaa agctgctaca agtatgggca gaccttggat 1620  
ctaagtaaaa atagtatatt ttttgcgaag tcctctgatt ttcagcatct ttctttcctc 1680  
aaatgcctga atctgtcagg aaatctcatt agccaaactc ttaatggcag tgaattccaa 1740  
cctttagcag agctgagata tttggacttc tccaacaacc ggcttgattt actccattca 1800  
acagcatttg aagagcttca caaactggaa gttctggata taagcagtaa tagccattat 1860  
tttcaatcag aaggaattac tcatatgcta aactttacca agaacctaaa ggttctgcag 1920  
aaactgatga tgaacgacaa tgacatctct tcctccacca gcaggaccat ggagagtga 1980  
tctcttagaa ctctggaatt cagaggaaat cacttagatg ttttatggag agaaggtgat 2040  
aacagatact tacaattatt caagaatctg ctaaaattag aggaattaga catctctaaa 2100  
aattccctaa gtttcttgcc ttctggagtt tttgatggta tgccctcaaa tctaaagaat 2160  
ctctcttttg ccaaaaatgg gctcaaatct ttcagttgga agaaactcca gtgtctaaag 2220  
aacctggaaa ctttggacct cagccacaac caactgacca ctgtccctga gagattatcc 2280  
aactgttcca gaagcctcaa gaatctgatt cttagaata atcaaatcag gagtctgacg 2340  
aagtattttc tacaagatgc cttccagttg cgatatctgg atctcagctc aaataaaatc 2400  
cagatgatcc aaaagaccag cttccagaa aatgtcctca acaatctgaa gatgttgctt 2460  
ttgcatcata atcggtttct gtgcacctgt gatgctgtgt ggtttgtctg gtgggttaac 2520  
catacggagg tgactattcc ttacctggcc acagatgtga cttgtgtggg gccaggagca 2580  
cacaagggcc aaagtgtgat ctccctggat ctgtacacct gtgagttaga tctgactaac 2640  
ctgattctgt tctcactttc catatctgta tctctctttc tcatggtgat gatgacagca 2700  
agtcacctct atttctggga tgtgtggtat atttaccatt tctgtaagga caagataaag 2760  
gggtatcagc gtctaataac accagactgt tgctatgatg cttttattgt gtatgacact 2820  
aaagaccag ctgtgaccga gtgggttttg gctgagctgg tggccaaact ggaagacca 2880  
agagagaaac attttaattt atgtctcgag gaaagggaact gggtaccagg gcagccagtt 2940  
ctggaaaacc tttccagag catacagctt agcaaaaaga cagtgtttgt gatgacagac 3000  
aagtatgcaa agactgaaaa ttttaagata gcattttact tgtcccatca gaggctcatg 3060

gatgaaaaag ttgatgtgat tatcttgata tttcttgaga agccttttca gaagtccaag 3120  
ttctccagc tccggaaaag gctctgtggg agttctgtcc ttgagtggcc aacaaaaccg 3180  
caagctcacc catacttctg gcagtgtcta aagaacgccc tggccacaga caatcatgtg 3240  
gcctatagtc aggtgttcaa ggaaacggtc tagaatcgaa ttcccgcggc cgccactgtg 3300  
ctggatatct gcagaattcc accacactgg actagtggat ccgagctcgg taccaagctt 3360  
aagtttaaac cgc 3373

<210> 32

<211> 3416

<212> DNA

<213> Homo sapiens

<400> 32

tccagatata ggatcactcc atgccatcaa gaaagttgat gctattgggc ccatctcaag 60  
ctgatcttgg cacctctcat gctctgtctt cttcaaccag acctctacat tccatttttg 120  
aagaagacta aaaatgggtgt ttccaatgtg gacactgaag agacaaattc ttatcctttt 180  
taacataatc ctaatttcca aactccttgg ggctagatgg tttcctaaaa ctctgccctg 240  
tgatgtcact ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt 300  
gacagaaatt cctggaggta ttcccacgaa caccacgaac ctcaccctca ccattaacca 360  
cataccagac atctccccag cgtcctttca cagactggac catctggtag agatcgattt 420  
cagatgcaac tgtgtacctt ttccactggg gtcaaaaaac aacatgtgca tcaagaggct 480  
gcagattaaa cccagaagct ttagtggact cacttattta aaatcccttt acctggatgg 540  
aaaccagcta ctagagatac cgcagggcct cccgcctagc ttacagcttc tcagccttga 600  
ggccaacaac atcttttcca tcagaaaaga gaatctaaca gaactggcca acatagaaat 660  
actctacctg ggccaaaact gttattatcg aaatccttgt tatgtttcat attcaataga 720  
gaaagatgcc ttctaaact tgacaaagtt aaaagtgtc tccctgaaag ataacaatgt 780  
cacagcgtc cctactgttt tgccatctac tttaacagaa ctatatctct acaacaacat 840  
gattgcaaaa atccaagaag atgattttta taacctcaac caattacaaa ttcttgacct 900  
aagtggaaat tgccctcgtt gttataatgc cccatttctt tgtgcgccgt gtaaaaataa 960  
ttctccccta cagatccctg taaatgcttt tgatgcgctg acagaattaa aagttttacg 1020  
tctacacagt aactctcttc agcatgtgcc cccaagatgg tttaagaaca tcaacaaact 1080  
ccaggaaact gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaatttct 1140  
gcattttctc cccagcctca tccaattgga tctgtcttct aattttgaac ttcagggtcta 1200  
tcgtgcatct atgaatctat cacaagcatt ttcttactg aaaagcctga aaattctgcg 1260

gatcagagga tatgtcttta aagagttgaa aagctttaac ctctcgccat tacataatct	1320
tcaaaatctt gaagttcttg atcttggcac taactttata aaaattgcta acctcagcat	1380
gtttaaaciaa tttaaaagac tgaaagtcac agatctttca gtgaataaaa tatcaccttc	1440
aggagattca agtgaagttg gcttctgctc aaatgccaga acttctgtag aaagttatga	1500
accccaggtc ctggaacaat tacattatct cagatatgat aagtatgcaa ggagttgcag	1560
attcaaaaac aaagaggctt ctttcatgtc tgtaaatgaa agctgctaca agtatgggca	1620
gaccttggat ctaagtaaaa atagtatatt ttttgtcaag tcctctgatt ttcagcatct	1680
ttctttcttc aaatgcctga atctgtcagg aaatctcatt agccaaactc ttaatggcag	1740
tgaattccaa ctttagcag agttgagata tttggacttc tccaacaacc ggcttgattt	1800
actccattca acagcatttg aagagcttca caaactggaa gttctggata taagcagtaa	1860
tagccattat tttcaatcag aaggaattac tcatatgcta aactttacca agaacctaaa	1920
ggttctgcag aaactgatga tgaacgacaa tgacatctct tcctccacca gcaggaccat	1980
ggagagtga tctcttagaa ctctggaatt cagaggaaat cacttagatg ttttatggag	2040
agaaggatga aacagatact tacaattatt caagaatctg ctaaaattag aggaattaga	2100
catctctaaa aattccctaa gtttcttgcc ttctggagtt tttgatggta tgctccaaa	2160
tctaaagaat ctctcttttg ccaaaaatgg gctcaaatct ttcagttgga agaaactcca	2220
gtgtctaaag aacctggaaa ctttggacct cagccacaac caactgacca ctgtccctga	2280
gagattatcc aactgttcca gaagccacaa gaatctgatt cttaagaata atcaaatcag	2340
gagtccgacg aagtattttc tacaagatgc cttccagttg cgatatctgg atctcagctc	2400
aaataaaatc cagatgatcc aaaagaccag cttcccagaa aatgtcctca acaatctgaa	2460
gatgttgctt ttgcatcata atcgggtttc gtgcacctgt gatgctgtgt ggtttgtctg	2520
gtgggttaac catacggagg tgactattcc ttacctggcc acagatgtga cttgtgtggg	2580
gccaggagca cacaagggcc aaagtgtgat ctccctggat ctgtacacct gtgagttaga	2640
tctgactaac ctgattctgt tctcactttc catatctgta tctctctttc tcatggatga	2700
gatgacagca agtcacctct atttctggga tgtgtggtat atttaccatt tctgtaaggc	2760
caagataaag gggatcagc gtctaataac accagactgt tgctatgatg cttttattgt	2820
gtatgacact aaagaccag ctgtgaccga gtgggttttg gctgagctgg tggccaaact	2880
ggaagacca agagagaaac attttaattt atgtctcgag gaaagggact ggttaccagg	2940
gcagccagtt ctggaaaacc tttcccagag catacagctt agcaaaaaga cagtgtttgt	3000
gatgacagac aagtatgcaa agactgaaaa ttttaagata gcattttact tgtcccatca	3060
gaggctcatg gatgaaaaag ttgatgtgat tatcttgata tttcttgaga agccctttca	3120
gaagtccaag ttcctccagc tccggaaaag gctctgtggg agttctgtcc ttgagtggcc	3180

aacaaacccg caagctcacc catacttctg gcagtgtcta aagaacgccc tggccacaga 3240  
caatcatgtg gcctatagtc aggtgttcaa ggaaacggtc tagcccttct ttgcaaaaca 3300  
caactgccta gtttaccaag gagaggcctg gctgtttaaa ttgttttcat atatatcaca 3360  
ccaaaagcgt gttttgaaat tcttcaagaa atgagattgc ccatatttca ggggag 3416

<210> 33

<211> 3418

<212> DNA

<213> Homo sapiens

<400> 33

actccagata taggatcact ccatgccatc aagaaagttg atgctattgg gcccatctca 60  
agctgatctt ggacacctct atgctctgct ctcttcaacc agacctctac attccatttt 120  
ggaagaagac taaaaatggg gtttccaatg tggacactga agagacaaat tcttatcctt 180  
tttaacataa tcctaatttc caaactcctt ggggctagat ggtttcctaa aactctgccc 240  
tgtgatgtca ctctggatgt tccaaagaac catgtgatcg tggactgcac agacaagcat 300  
ttgacagaaa ttcttgaggg tattcccacg aacaccacga acctcaccct caccattaac 360  
cacataccag acatctcccc agcgtccttt cacagactgg accatctggg agagatcgat 420  
ttcagatgca actgtgtacc tattccactg ggggtcaaaaa acaacatgtg catcaagagg 480  
ctgcagatta aaccagaag ctttagtgga ctcacttatt taaaatccct ttacctggat 540  
ggaaaccagc tactagagat accgcagggc ctccgccta gcttacagct tctcagcctt 600  
gaggccaaca acatcttttc catcagaaaa gagaatctaa cagaactggc caacatagaa 660  
atactctacc tgggcaaaaa ctgttattat cgaaatcctt gttatgtttc atattcaata 720  
gagaaagatg ctttctctaaa cttgacaaag ttaaaagtgc tctccctgaa agataacaat 780  
gtcacagccg tcctactgtt tttgccatct actttaacag aactatatct ctacaacaac 840  
atgattgcaa aaatccaaga agatgatttt aataacctca accaattaca aattcttgac 900  
ctaagtggaa attgccctcg ttgttataat gccccatttc cttgtgcgcc gtgtaaaaat 960  
aattctcccc tacagatccc tgtaaatgct tttgatgcgc tgacagaatt aaaagtttta 1020  
cgtctacaca gtaactctct tcagcatgtg cccccaagat ggtttaagaa catcaacaaa 1080  
ctccaggaac tggatctgtc ccaaaacttc ttggccaaag aaattgggga tgctaaattt 1140  
ctgcattttc tccccagcct catccaattg gatctgtctt tcaattttga acttcaggtc 1200  
tatcgtgcat ctatgaatct atcacaagca ttttcttcac tgaaaagcct gaaaattctg 1260  
cggatcagag gatatgtctt taaagagttg aaaagcttta acctctcgcc attacataat 1320  
cttcaaaatc ttgaagttct tgatcttggc actaacttta taaaatttgc taacctcagc 1380

atgttttaaac aattttaaag actgaaagtc atagatcttt cagtgaataa aatatcacct 1440  
tcaggagatt caagtgaagt tggcttctgc tcaaagcca gaacttctgt agaaagtatt 1500  
gaacccagg tcctggaaca attacattat ttcagatatg ataagtatgc aaggagttgc 1560  
agattcaaaa acaaagaggc ttctttcatg tctgttaatg aaagctgcta caagtatggg 1620  
cagaccttgg atctaagtaa aaatagtata ttttttgtca agtcctctga ttttcagcat 1680  
ctttctttcc tcaaagcct gaatctgtca ggaaatctca ttagccaaac tcttaatggc 1740  
agtgaattcc aaccttttagc agagctgaga tatttggact tctccaacaa cgggcttgat 1800  
ttactccatt caacagcatt tgaagagctt cacaaactgg aagttctgga tataagcagt 1860  
aatagccatt attttcaatc agaaggaatt actcatatgc taaactttac caagaacct 1920  
aaggttctgc agaaactgat gatgaacgac aatgacatct cttcctccac cagcaggacc 1980  
atggagagtg agtctcttag aactctggaa ttcagaggaa atcacttaga tgttttatgg 2040  
agagaagggtg ataacagata cttacaatta ttcaagaatc tgctaaaatt agaggaatta 2100  
gacatctcta aaaattccct aagtttcttg ccttctggag tttttgatgg tatgcctcca 2160  
aatctaaaga atctctcttt ggccaaaaat gggctcaaat ctttcagttg gaagaaactc 2220  
cagtgtctaa agaacctgga aactttggac ctcagccaca accaactgac cactgtccct 2280  
gagagattat ccaactgttc cagaagcctc agaactctga ttcttaagaa taatcaaactc 2340  
aggagtctga cgaagtattt tctacaagat gccttccagt tgcgatatct ggatctcagc 2400  
tcaaataaaa tccagatgat ccaaaagacc agcttcccag aaaatgtcct caacaatctg 2460  
aagatgttgc ttttgcata taatcggttt ctgtgcacct gtgatgctgt gtggtttgtc 2520  
tggtgggtta accatacggg ggtgactatt ccttacctgg ccacagatgt gacttggtg 2580  
gggccaggag cacacaaggg ccaaagtgtg atctccctgg atctgtacac ctgtgagtta 2640  
gatctgacta acctgattct gttctcactt tccatatctg tatctctctt tctcatggg 2700  
atgatgacag caagtccact ctatttctgg gatgtgtggt atatttacca tttctgtaag 2760  
gccaaagataa aggggtatca gcgtctaata tcaccagact gttgctatga tgcttttatt 2820  
gtgtatgaca ctaaagacct agctgtgacc gagtgggttt tggctgagct ggtggccaaa 2880  
ctggaagacc caagagagaa acattttaat ttatgtctcg aggaaaggga ctggttacca 2940  
gggcagccag ttctggaaaa cctttcccag agcatacagc ttagcaaaaa gacagtgttt 3000  
gtgatgacag acaagtatgc aaagactgaa aattttaaga tagcatttta cttgtcccat 3060  
cagaggctca tggatgaaaa agttgatgtg attatcttga tatttcttga gaagcccttt 3120  
cagaagtcca agttcctcca gctccggaaa aggtctctgt ggagttctgt ccttgagtgg 3180  
ccaacaaacc cgcaagctca cccatacttc tggcagtgtc taaagaacgc cctggccaca 3240  
gacaatcatg tggcctatag tcagtggttc aaggaaacgg tctagccctt ctttgcaaaa 3300



cacaactgcc tagtttacca aggagaggcc tggctgttta aattgttttc atatatatca 3360

caccaaaagc gtgttttgaa attcttcaag aaatgagatt gcccatattt caggggag 3418

<210> 34

<211> 1049

<212> PRT

<213> Homo sapiens

<400> 34

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
1 5 10 15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
20 25 30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro

260 265 270  
 Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
 340 345 350  
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
 355 360 365  
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
 405 410 415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435 440 445  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485 490 495  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp  
 500 505 510  
 Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
 515 520 525  
 Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
 530 535 540  
 Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
 545 550 555 560  
 Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
 565 570 575  
 Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
 580 585 590  
 Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile

595				600				605							
Ser	Ser	Ser	Thr	Ser	Arg	Thr	Met	Glu	Ser	Glu	Ser	Leu	Arg	Thr	Leu
610						615					620				
Glu	Phe	Arg	Gly	Asn	His	Leu	Asp	Val	Leu	Trp	Arg	Glu	Gly	Asp	Asn
625					630					635					640
Arg	Tyr	Leu	Gln	Leu	Phe	Lys	Asn	Leu	Leu	Lys	Leu	Glu	Glu	Leu	Asp
			645						650					655	
Ile	Ser	Lys	Asn	Ser	Leu	Ser	Phe	Leu	Pro	Ser	Gly	Val	Phe	Asp	Gly
			660						665				670		
Met	Pro	Pro	Asn	Leu	Lys	Asn	Leu	Ser	Leu	Ala	Lys	Asn	Gly	Leu	Lys
			675				680						685		
Ser	Phe	Ser	Trp	Lys	Lys	Leu	Gln	Cys	Leu	Lys	Asn	Leu	Glu	Thr	Leu
690						695					700				
Asp	Leu	Ser	His	Asn	Gln	Leu	Thr	Thr	Val	Pro	Glu	Arg	Leu	Ser	Asn
705					710					715					720
Cys	Ser	Arg	Ser	Leu	Lys	Asn	Leu	Ile	Leu	Lys	Asn	Asn	Gln	Ile	Arg
			725						730					735	
Ser	Leu	Thr	Lys	Tyr	Phe	Leu	Gln	Asp	Ala	Phe	Gln	Leu	Arg	Tyr	Leu
			740						745					750	
Asp	Leu	Ser	Ser	Asn	Lys	Ile	Gln	Met	Ile	Gln	Lys	Thr	Ser	Phe	Pro
			755				760						765		
Glu	Asn	Val	Leu	Asn	Asn	Leu	Lys	Met	Leu	Leu	Leu	His	His	Asn	Arg
770						775					780				
Phe	Leu	Cys	Thr	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn	His
785					790					795					800
Thr	Glu	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val	Gly
			805						810					815	
Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr	Thr
			820				825						830		
Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Leu	Ser	Ile	Ser
			835				840						845		
Val	Ser	Leu	Phe	Leu	Met	Val	Met	Met	Thr	Ala	Ser	His	Leu	Tyr	Phe
			850			855					860				
Trp	Asp	Val	Trp	Tyr	Ile	Tyr	His	Phe	Cys	Lys	Ala	Lys	Ile	Lys	Gly
865					870					875					880
Tyr	Gln	Arg	Leu	Ile	Ser	Pro	Asp	Cys	Cys	Tyr	Asp	Ala	Phe	Ile	Val
			885						890					895	
Tyr	Asp	Thr	Lys	Asp	Pro	Ala	Val	Thr	Glu	Trp	Val	Leu	Ala	Glu	Leu
			900						905					910	
Val	Ala	Lys	Leu	Glu	Asp	Pro	Arg	Glu	Lys	His	Phe	Asn	Leu	Cys	Leu
			915				920						925		
Glu	Glu	Arg	Asp	Trp	Leu	Pro	Gly	Gln	Pro	Val	Leu	Glu	Asn	Leu	Ser

930                      935                      940  
 Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys  
 945                      950                      955                      960  
 Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln  
                     965                      970                      975  
 Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu  
                     980                      985                      990  
 Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys  
                     995                      1000                      1005  
 Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro  
                     1010                      1015                      1020  
 Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His  
                     1025                      1030                      1035  
 Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val  
                     1040                      1045

<210> 35  
 <211> 1049  
 <212> PRT  
 <213> Homo sapiens

<400> 35

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
 1                      5                      10                      15  
 Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
                     20                      25                      30  
 Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
                     35                      40                      45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
                     50                      55                      60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
 65                      70                      75                      80  
 Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
                     85                      90                      95  
 Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
                     100                      105                      110  
 Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
                     115                      120                      125  
 Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
                     130                      135                      140  
 Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145                      150                      155                      160  
 Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
                     165                      170                      175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
 210 215 220  
 Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
 225 230 235 240  
 Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
 260 265 270  
 Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
 340 345 350  
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
 355 360 365  
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
 405 410 415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435 440 445  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485 490 495  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp

500 505 510  
 Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
 515 520 525  
 Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
 530 535 540  
 Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
 545 550 555 560  
 Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
 565 570 575  
 Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
 580 585 590  
 Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile  
 595 600 605  
 Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu  
 610 615 620  
 Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn  
 625 630 635 640  
 Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp  
 645 650 655  
 Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly  
 660 665 670  
 Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys  
 675 680 685  
 Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu  
 690 695 700  
 Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn  
 705 710 715 720  
 Cys Ser Arg Ser His Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg  
 725 730 735  
 Ser Pro Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu  
 740 745 750  
 Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro  
 755 760 765  
 Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg  
 770 775 780  
 Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His  
 785 790 795 800  
 Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly  
 805 810 815  
 Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr  
 820 825 830  
 Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser

835 840 845  
 Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe  
 850 855 860  
 Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly  
 865 870 875 880  
 Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val  
 885 890 895  
 Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu  
 900 905 910  
 Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu  
 915 920 925  
 Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser  
 930 935 940  
 Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys  
 945 950 955 960  
 Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln  
 965 970 975  
 Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu  
 980 985 990  
 Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys  
 995 1000 1005  
 Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro  
 1010 1015 1020  
 Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His  
 1025 1030 1035  
 Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val  
 1040 1045  
  
 <210> 36  
 <211> 1049  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 36  
 Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
 1 5 10 15  
 Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
 35 40 45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
 65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
 85 90 95  
 Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
 100 105 110  
 Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
 115 120 125  
 Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140  
 Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
 210 215 220  
 Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
 225 230 235 240  
 Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
 260 265 270  
 Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
 340 345 350  
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
 355 360 365  
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met



405 410 415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435 440 445  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485 490 495  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp  
 500 505 510  
 Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
 515 520 525  
 Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
 530 535 540  
 Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
 545 550 555 560  
 Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
 565 570 575  
 Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
 580 585 590  
 Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile  
 595 600 605  
 Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu  
 610 615 620  
 Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn  
 625 630 635 640  
 Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp  
 645 650 655  
 Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly  
 660 665 670  
 Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys  
 675 680 685  
 Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu  
 690 695 700  
 Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn  
 705 710 715 720  
 Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg  
 725 730 735  
 Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu

```

      740      745      750
Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro
      755      760      765

Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg
      770      775      780

Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His
      785      790      795      800

Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly
      805      810      815

Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr
      820      825      830

Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser
      835      840      845

Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe
      850      855      860

Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly
      865      870      875      880

Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val
      885      890      895

Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu
      900      905      910

Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu
      915      920      925

Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser
      930      935      940

Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys
      945      950      955      960

Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln
      965      970      975

Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu
      980      985      990

Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys
      995      1000      1005

Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro
      1010      1015      1020

Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His
      1025      1030      1035

Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val
      1040      1045

```

&lt;210&gt; 37

&lt;211&gt; 1049

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
1 5 10 15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
20 25 30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
260 265 270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
 340 345 350  
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
 355 360 365  
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
 405 410 415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435 440 445  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485 490 495  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp  
 500 505 510  
 Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
 515 520 525  
 Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
 530 535 540  
 Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
 545 550 555 560  
 Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
 565 570 575  
 Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
 580 585 590  
 Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile  
 595 600 605  
 Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu  
 610 615 620  
 Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn  
 625 630 635 640  
 Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp

Ile	Ser	Lys	Asn	Ser	Leu	Ser	Phe	Leu	Pro	Ser	Gly	Val	Phe	Asp	Gly
			645						650					655	
			660					665					670		
Met	Pro	Pro	Asn	Leu	Lys	Asn	Leu	Ser	Leu	Ala	Lys	Asn	Gly	Leu	Lys
			675				680						685		
Ser	Phe	Ser	Trp	Lys	Lys	Leu	Gln	Cys	Leu	Lys	Asn	Leu	Glu	Thr	Leu
			690				695				700				
Asp	Leu	Ser	His	Asn	Gln	Leu	Thr	Thr	Val	Pro	Glu	Arg	Leu	Ser	Asn
705					710					715					720
Cys	Ser	Arg	Ser	Leu	Lys	Asn	Leu	Ile	Leu	Lys	Asn	Asn	Gln	Ile	Arg
				725					730					735	
Ser	Leu	Thr	Lys	Tyr	Phe	Leu	Gln	Asp	Ala	Phe	Gln	Leu	Arg	Tyr	Leu
			740					745					750		
Asp	Leu	Ser	Ser	Asn	Lys	Ile	Gln	Met	Ile	Gln	Lys	Thr	Ser	Phe	Pro
			755				760					765			
Glu	Asn	Val	Leu	Asn	Asn	Leu	Lys	Met	Leu	Leu	Leu	His	His	Asn	Arg
			770				775					780			
Phe	Leu	Cys	Thr	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn	His
785					790					795					800
Thr	Glu	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val	Gly
				805					810					815	
Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr	Thr
			820					825					830		
Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Leu	Ser	Ile	Ser
			835				840					845			
Val	Ser	Leu	Phe	Leu	Met	Val	Met	Met	Thr	Ala	Ser	His	Leu	Tyr	Phe
			850				855					860			
Trp	Asp	Val	Trp	Tyr	Ile	Tyr	His	Phe	Cys	Lys	Ala	Lys	Ile	Lys	Gly
865					870					875					880
Tyr	Gln	Arg	Leu	Ile	Ser	Pro	Asp	Cys	Cys	Tyr	Asp	Ala	Phe	Ile	Val
				885					890					895	
Tyr	Asp	Thr	Lys	Asp	Pro	Ala	Val	Thr	Glu	Trp	Val	Leu	Ala	Glu	Leu
			900					905					910		
Val	Ala	Lys	Leu	Glu	Asp	Pro	Arg	Glu	Lys	His	Phe	Asn	Leu	Cys	Leu
			915				920					925			
Glu	Glu	Arg	Asp	Trp	Leu	Pro	Gly	Gln	Pro	Val	Leu	Glu	Asn	Leu	Ser
			930				935					940			
Gln	Ser	Ile	Gln	Leu	Ser	Lys	Lys	Thr	Val	Phe	Val	Met	Thr	Asp	Lys
945					950					955					960
Tyr	Ala	Lys	Thr	Glu	Asn	Phe	Lys	Ile	Ala	Phe	Tyr	Leu	Ser	His	Gln
				965					970					975	
Arg	Leu	Met	Asp	Glu	Lys	Val	Asp	Val	Ile	Ile	Leu	Ile	Phe	Leu	Glu

	980		985		990										
Lys	Pro	Phe	Gln	Lys	Ser	Lys	Phe	Leu	Gln	Leu	Arg	Lys	Arg	Leu	Cys
	995						1000						1005		
Gly	Ser	Ser	Val	Leu	Glu	Trp	Pro	Thr	Asn	Pro	Gln	Ala	His	Pro	
	1010						1015					1020			
Tyr	Phe	Trp	Gln	Cys	Leu	Lys	Asn	Ala	Leu	Ala	Thr	Asp	Asn	His	
	1025						1030					1035			
Val	Ala	Tyr	Ser	Gln	Val	Phe	Lys	Glu	Thr	Val					
	1040						1045								

<210> 38  
 <211> 3243  
 <212> DNA  
 <213> murine

<400> 38  
 attctcctcc accagacctc ttgattccat tttgaaagaa aactgaaaat ggtgttttcg 60  
 atgtggacac ggaagagaca aattttgatc tttttaaata tgctcttagt ttctagagtc 120  
 tttgggtttc gatgggtttc taaaactcta ccttgtgaag ttaaagtaaa tatcccagag 180  
 gcccatgtga tcgtggactg cacagacaag catttgacag aaatccctga gggcattccc 240  
 actaacacca ccaatcttac ccttaccatc aaccacatac caagcatctc tccagattcc 300  
 ttccgtaggc tgaaccatct ggaagaaatc gatttaagat gcaattgtgt acctgttcta 360  
 ctgggggtcca aagccaatgt gtgtaccaag aggctgcaga ttagacctgg aagctttagt 420  
 ggactctctg acttaaaagc cctttacctg gatggaaacc aacttctgga gataccacag 480  
 gatctgccat ccagcttaca tcttctgagc cttgaggcta acaacatctt ctccatcacg 540  
 aaggagaatc taacagaact ggtcaacatt gaaacactct acctgggtca aaactgttat 600  
 tatcgaaatc cttgcaatgt ttctattctt attgaaaaag atgctttcct agttatgaga 660  
 aatttgaagg ttctctcact aaaagataac atgtcacag ctgtcccccac cactttgcc 720  
 cctaatttac tagagctcta tctttataac aatatcatta agaaaatcca agaaaatgat 780  
 ttttaataacc tcaatgagtt gcaagttctt gacctaatg gaaattgccc tcgatgttat 840  
 aatgtcccat atccgtgtac accgtgtgaa aataattccc ccttacagat ccatgacaat 900  
 gctttcaatt cattgacaga attaaaagtt ttacgtttac acagtaattc tcttcagcat 960  
 gtgcccccaa catgggtttta aaacatgaga aacctccagg aactagacct ctcccaaaac 1020  
 tacttggcca gagaaattga ggaggccaaa tttttgcatt ttcttcccaa ccttggtgag 1080  
 ttggattttt ctttcaatta tgagctgcag gtctaccatg catctataac ttaccacat 1140  
 tcactctctt cattggaaaa cttgaaaatt ctgcgtgtca aggggtatgt ctttaaagag 1200  
 ctgaaaaact ccagtctttc tgtattgcac aagcttccca ggctggaagt tcttgacctt 1260

ggcactaaact tcataaaaaat tgctgacctc aacatattca aacattttga aaacctcaaa 1320  
 ctcatagacc ttccagtga taagatatct ccttcagaag agtcaagaga agttggcttt 1380  
 tgtcctaata ctcaaacttc tgtagaccgt catgggcccc aggtccttga ggccttacac 1440  
 tatttccgat acgatgaata tgcacggagc tgcagggtca aaaacaaaga gccaccttct 1500  
 ttcttgcctt tgaatgcaga ctgccacata tatgggcaga ccttagactt aagtagaaat 1560  
 aacatatttt ttattaaacc ttctgatttt cagcatcttt cattcctcaa atgcctcaac 1620  
 ttatcaggaa acaccattgg ccaaactctt aatggcagtg aactctggcc gttgagagag 1680  
 ttggcgtact tagacttctc caacaaccgg cttgatttac tctactcaac agcctttgaa 1740  
 gagctccaga gtcttgaagt tctggatcta agtagtaaca gccactattt tcaagcagaa 1800  
 ggaattactc acatgctaaa ctttaccaag aaattacggc ttctggacaa actcatgatg 1860  
 aatgataatg acatctctac ttcgccagc aggaccatgg aaagtgactc tcttcgaatt 1920  
 ctggagttca gaggcaacca tttagatgtt ctatggagag cgggtgataa cagatacttg 1980  
 gacttcttca agaatttggt caatttagag gtattagata tctccagaaa ttccctgaat 2040  
 tccttgcctc ctgagggttt tgagggtatg ccgccaatc taaagaatct ctccttggcc 2100  
 aaaaatgggc tcaaactctt cttttgggac agactccagt tactgaagca tttggaaatt 2160  
 ttggacctca gccataacca gctgacaaaa gtacctgaga gattggccaa ctgttccaaa 2220  
 agtctcacia cactgattct taagcataat caaatcaggc aattgacaaa atattttcta 2280  
 gaagatgctt tgcaattgct ctatctagac atcagttcaa ataaaatcca ggtcattcag 2340  
 aagactagct tcccagaaaa tgcctcaac aatctggaga tgttggtttt acatcacaat 2400  
 cgctttcttt gcaactgtga tgetgtgtgg tttgtctggt gggttaacca tacagatgtt 2460  
 actattccat acctggccac tgatgtgact tgtgtaggtc caggagcaca caaaggtaa 2520  
 agtgcataat cccttgatct gtatagctgt gagttagatc tcacaaacct gattctgttc 2580  
 tcagtttcca tatcatcagt cctctttctt atggtagtta tgacaacaag tcacctcttt 2640  
 ttctgggata tgtggtacat ttattatttt tggaaagcaa agataaaggg gtatcagcat 2700  
 ctgcaatcca tggagtcttg ttatgatgct tttattgtgt atgacactaa aaactcagct 2760  
 gtgacagaat gggttttgca ggagctggtg gcaaaattgg aagatccaag agaaaaacac 2820  
 ttcaatttgt gtctagaaga aagagactgg ctaccaggac agccagttct agaaaacctt 2880  
 tcccagagca tacagctcag caaaaagaca gtgtttgtga tgacacagaa atatgctaag 2940  
 actgagagtt ttaagatggc attttatttg tctcatcaga ggctcctgga tgaaaaagt 3000  
 gatgtgatta tcttgatatt cttggaaaag cctcttcaga agtctaagtt tcttcagctc 3060  
 aggaagagac tctgcaggag ctctgtcctt gaggggcctg caaatccaca ggctcaccca 3120  
 tacttctggc agtgcctgaa aaatgcctg accacagaca atcatgtggc ttatagtcaa 3180

atgttcaagg aaacagtcta gctctctgaa gaatgtcacc acctaggaca tgccttgaat 3240  
cga 3243

<210> 39  
<211> 3747  
<212> DNA  
<213> murine

<400> 39  
gagctcaaag gctctgagag tctcggtttt ctgttgcctt ctctctgtct cagaggactc 60  
catctataga accactctat gccttcaaga aagatgtcct tggctccctt ctcaggatga 120  
tcctggccta tctctgactc tcttctctc caccagacct cttgattcca ttttgaaaga 180  
aaactgaaaa tgggtgttttc gatgtggaca cggaagagac aaattttgat ctttttaaat 240  
atgctcttag tttctagagt ctttgggttt cgatgggttt ctaaaactct accttgtgaa 300  
gttaaagtaa atatcccaga ggcccatgtg atcgtggact gcacagacaa gcatttgaca 360  
gaaatccctg agggcattcc cactaacacc accaatctta cccttaccat caaccacata 420  
ccaagcatct ctccagattc cttccgtagg ctgaaccatc tggaagaaat cgatttaaga 480  
tgcaattgtg tacctgttct actgggggtcc aaagccaatg tgtgtaccaa gaggctgcag 540  
attagacctg gaagcttttag tggactctct gacttaaaag ccctttacct ggatggaaac 600  
caacttctgg agataccaca ggatctgcc aaccagcttac atcttctgag ccttgaggct 660  
aacaacatct tctccatcac gaaggagaat ctaacagAAC tgggtcaacat tgaaacactc 720  
tacctgggtc aaaactgtta ttatcgaaat ccttgcaatg tttcctattc tattgaaaaa 780  
gatgctttcc tagttatgag aaatttgaag gttctctcac taaaagataa caatgtcaca 840  
gctgtcccca ccactttgcc acctaattta ctagagctct atctttataa caatatcatt 900  
aagaaaatcc aagaaaatga ttttaataac ctcaatgagt tgcaagttct tgacctaatg 960  
ggaaattgcc ctcgatgtta taatgtccca tatccgtgta caccgtgtga aaataattcc 1020  
cccttacaga tccatgacaa tgctttcaat tcattgacag aattaaaagt tttacgttta 1080  
cacagtaatt ctcttcagca tgtgccccca acatgggttta aaaacatgag aaacctccag 1140  
gaactagacc tctcccaaaa ctacttggtc agagaaattg aggaggccaa atttttgcat 1200  
tttcttccca accttgttga gttggatttt tctttcaatt atgagctgca ggtctaccat 1260  
gcactataaa ctttaccaca ttactctct tcattggaaa acttgaaaat tctgcgtgtc 1320  
aaggggtatg tctttaaaga gctgaaaaac tccagtcttt ctgtattgca caagcttccc 1380  
aggctggaag ttcttgacct tggcactaac ttcataaaaa ttgctgacct caacatattc 1440  
aaacattttg aaaacctcaa actcatagac ctttcagtga ataagatatc tccttcagaa 1500



gagtc aagag aagttggctt ttgtccta at gctcaaactt ctgtagaccg tcatggggccc 1560  
caggtccttg aggccttaca ctatttccga tacgatgaat atgcacggag ctgcaggttc 1620

aaaaacaaag agccaccttc tttcttgcct ttgaatgcag actgccacat atatgggcag 1680

accttagact taagtagaaa taacatattt ttatttaa ac cttctgattt tcagcatctt 1740

tcattcctca aatgcctcaa cttatcagga aacaccattg gccaaactct taatggcagt 1800

gaactctggc cgttgagaga gttgcggtac ttagacttct ccaacaaccg gcttgattta 1860

ctctactcaa cagcctttga agagctccag agtcttgaag ttctggatct aagtagtaac 1920

agccactatt ttcaagcaga aggaattact cacatgctaa actttacca gaaattacgg 1980

cttctggaca aactcatgat gaatgataat gacatctcta cttcggccag caggaccatg 2040

gaaagtgact ctcttcgaat tctggagttc agaggcaacc atttagatgt tctatggaga 2100

gccggtgata acagatactt ggacttcttc aagaatttgt tcaatttaga ggtattagat 2160

atctccagaa attccctgaa ttccctgcct cctgagggtt ttgaggggtat gccgccaat 2220

ctaaagaatc tctccttggc caaaaatggg ctcaaactct tcttttggga cagactccag 2280

ttactgaagc atttggaaat tttggacctc agccataacc agctgacaaa agtacctgag 2340

agattggcca actgttccaa aagtctcaca aactgatct ttaagcataa tcaaatcagg 2400

caattgacaa aatattttct agaagatgct ttgcaattgc gctatctaga catcagttca 2460

aataaaatcc aggtcattca gaagactagc ttcccagaaa atgtcctcaa caatctggag 2520

atgttgggtt tacatcacia tcgctttctt tgcaactgtg atgctgtgtg gtttgtctgg 2580

tgggttaacc atacagatgt tactattcca tacctggcca ctgatgtgac ttgtgtaggt 2640

ccaggagcac acaaaggcca aagtgtcata tcccttgatc tgtatacgtg tgagttagat 2700

ctcaciaaacc tgattctgtt ctcatgttcc atatcatcag tcctctttct tatggtagtt 2760

atgacaacaa gtcacctctt tttctgggat atgtggtaca ttattattt ttggaaagca 2820

aagataaagg ggtatcagca tctgcaatcc atggagctct gttatgatgc ttttattgtg 2880

tatgacacta aaaactcagc tgtgacagaa tgggttttgc aggagctggt ggcaaaattg 2940

gaagatccaa gagaaaaaca cttcaatttg tgtctagaag aaagagactg gctaccagga 3000

cagccagttc tagaaaacct ttcccagagc atacagctca gcaaaaagac agtgtttgtg 3060

atgacacaga aatatgctaa gactgagagt tttaagatgg cattttattt gtctcatcag 3120

aggctcctgg atgaaaaagt ggatgtgatt atcttgatat tcttggaaaa gcctcttcag 3180

aagtctaagt ttcttcagct caggaagaga ctctgcagga gctctgtcct tgagtggcct 3240

gcaaatccac aggctcacc atacttctgg cagtgcctga aaaatgccct gaccacagac 3300

aatcatgtgg cttatagtca aatgttcaag gaaacagtct agctctctga agaatgtcac 3360

cacctaggac atgccttggc acctgaagtt ttcataaagg tttccataaa tgaaggtctg 3420

aatttttcct aacagttgtc atggctcaga ttggtgggaa atcatcaata tatggctaag 3480  
aaattaagaa ggggagactg atagaagata atttctttct tcatgtgcca tgctcagtta 3540  
aatatttccc ctagctcaaa tctgaaaaac tgtgcctagg agacaacaca aggctttgat 3600  
ttatctgcat acaattgata agagccacac atctgccctg aagaagtact agtagtttta 3660  
gtagtagggt aaaaattaca caagctttct ctctctctga tactgaactg taccagagtt 3720  
caatgaaata aaagcccaga gaacttc 3747

<210> 40

<211> 3449

<212> DNA

<213> murine

<400> 40

gcgagtctcg gttttctggt gccttctctc tgtctcagag gactccatct atagaaccac 60  
tctatgcctt caagaaagat gtccttggct cccttctcag gatgatcctg gcctatctct 120  
gactctcttc tcctccacca gacctcttga ttccattttg aaagaaaact gaaaatggtg 180  
ttttcgatgt ggacacggaa gagacaaatt ttgatctttt taaatatgct cttagttttct 240  
agagtctttg ggtttcgatg gtttcctaaa actctacctt gtgaagttaa agtaaatatc 300  
ccagaggccc atgtgatcgt ggactgcaca gacaagcatt tgacagaaat ccctgagggc 360  
attcccacta acaccaccaa tcttaccctt accatcaacc acataccaag catctctcca 420  
gattccttcc gtaggctgaa ccatctggaa gaaatcgatt taagatgcaa ttgtgtacct 480  
gttctactgg ggtccaaagc caatgtgtgt accaagaggc tgcagattag acctggaagc 540  
tttagtggac tctctgactt aaaagccctt tacctggatg gaaaccaact tctggagata 600  
ccacaggatc tgccatccag cttacatctt ctgagccttg aggctaacaa catcttctcc 660  
atcacgaagg agaactaac agaactggtc aacattgaaa cactctacct gggcctcaaac 720  
tggtattatc gaaatccttg caatgtttcc tattctattg aaaaagatgc tttcctagtt 780  
atgagaaatt tgaaggttct ctactaaaa gataacaatg tcacagctgt cccaccact 840  
ttgccaccta atttactaga gctctatctt tataacaata tcattaagaa aatccaagaa 900  
aatgatttta ataacctcaa tgagttgcaa gttcttgacc taagtggaaa ttgccctcga 960  
tgttataatg tcccatatcc gtgtacaccg tgtgaaaata attccccctt acagatccat 1020  
gacaatgctt tcaattcatt gacagaatta aaagttttac gtttacacag taattctctt 1080  
cagcatgtgc cccaacatg gtttaaaaac atgagaaacc tccaggaact agacctctcc 1140  
caaaactact tggccagaga aattgaggag gccaaaatctt tgcattttct tccaacctt 1200  
gttgagttgg atttttcttt caattatgag ctgcaggctt accatgcac tataacttta 1260

ccacattcac tctcttcatt ggaaaacttg aaaattctgc gtgtcaagggt gtatgtcttt	1320
aaagagctga aaaactccag tctttctgta ttgcacaagc ttcccaggct ggaagttctt	1380
gaccttgga ctaacttcat aaaaattgct gacctcaaca tattcaaaca ttttgaaaac	1440
ctcaaactca tagaccttcc agtgaataag atatctcctt cagaagagtc aagagaagtt	1500
ggcttttgtc ctaatgctca aacttctgta gaccgtcatg ggccccagggt ccttgaggcc	1560
ttacactatt tccgatacga tgaatatgca cggagctgca ggttcaaaaa caaagagcca	1620
ccttctttct tgcctttgaa tgcagactgc cacatatatg ggcagacctt agacttaagt	1680
agaaataaca tattttttat taaaccttct gattttcagc atctttcatt cctcaaatgc	1740
ctcaacttat caggaaacac cattggccaa actcttaatg gcagtgaact ctggccgttg	1800
agagagttgc ggtacttaga cttctccaac aaccggcttg atttactcta ctcaacagcc	1860
tttgaagagc tccagagtct tgaagttctg gatctaagta gtaacagcca ctattttcaa	1920
gcagaaggaa ttactcacat gctaaacttt accaagaaat tacggcttct ggacaaactc	1980
atgatgaatg ataatgacat ctctacttcg gccagcagga ccatggaaag tgactctctt	2040
cgaattctgg agttcagagg caaccattta gatgttctat ggagagccgg tgataacaga	2100
tacttggact tcttcaagaa tttgttcaat ttagaggat tagatatctc cagaaattcc	2160
ctgaattcct tgcctcctga ggtttttgag ggtatgccgc caaatctaaa gaatctctcc	2220
ttggccaaaa atgggctcaa atctttcttt tgggacagac tccagttact gaagcatttg	2280
gaaattttgg acctcagcca taaccagctg acaaaagtac ctgagagatt ggccaactgt	2340
tccaaaagtc tcacaacact gattcttaag cataatcaaa tcaggcaatt gacaaaatat	2400
tttctagaag atgctttgca attgcgctat ctagacatca gttcaaataa aatccaggtc	2460
attcagaaga ctagcttccc agaaaatgtc ctcaacaatc tggagatggt ggttttacat	2520
cacaatcgct ttctttgcaa ctgtgatgct gtgtggtttg tctgggtgggt taaccatata	2580
gatgttacta ttccatacct ggccactgat gtgacttggt taggtccagg agcacacaaa	2640
ggtcaaagtg tcatatccct tgatctgtat acgtgtgagt tagatctcac aaacctgatt	2700
ctgttctcag tttccatata atcagtcctc tttcttatgg tagttatgac aacaagtcac	2760
ctctttttct gggatatgtg gtacatttat tatttttgga aagcaaagat aaaggggtat	2820
cagcatctgc aatccatgga gtcttgttat gatgctttta ttgtgtatga cactaaaaac	2880
tcagctgtga cagaatgggt tttgcaggag ctggtggcaa aattggaaga tccaagagaa	2940
aaacacttca atttgtgtct agaagaaaga gactggctac caggacagcc agttctagaa	3000
aacctttccc agagcatata gctcagcaaa aagacagtgt ttgtgatgac acagaaatat	3060
gctaagactg agagttttta gatggcattt tatttgtctc atcagaggct cctggatgaa	3120
aaagtggatg tgattatctt gatattcttg gaaaagcctc ttcagaagtc taagtttctt	3180

cagctcagga agagactctg caggagctct gtccttgagt ggcttgcaaa tccacaggct 3240  
 caccatact tctggcagtg cctgaaaaat gccctgacca cagacaatca tgtggcttat 3300  
 agtcaaagt tcaaggaaac agtctagctc tctgaagaat gtcaccacct aggacatgcc 3360  
 ttggtacctg aagttttcat aaaggtttcc ataaatgaag gtctgaattt ttctaacag 3420  
 ttgtcatggc tcagattggt gggaaatca 3449

<210> 41  
 <211> 1050  
 <212> PRT  
 <213> murine

<400> 41

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140  
 Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile

225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
 485 490 495  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
 500 505 510  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
 515 520 525  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
 530 535 540  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545 550 555 560  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser

Asn	Ser	His	Tyr	Phe	Gln	Ala	Glu	Gly	Ile	Thr	His	Met	Leu	Asn	Phe
			580					585					590		
Thr	Lys	Lys	Leu	Arg	Leu	Leu	Asp	Lys	Leu	Met	Met	Asn	Asp	Asn	Asp
		595					600					605			
Ile	Ser	Thr	Ser	Ala	Ser	Arg	Thr	Met	Glu	Ser	Asp	Ser	Leu	Arg	Ile
	610					615					620				
Leu	Glu	Phe	Arg	Gly	Asn	His	Leu	Asp	Val	Leu	Trp	Arg	Ala	Gly	Asp
625					630					635					640
Asn	Arg	Tyr	Leu	Asp	Phe	Phe	Lys	Asn	Leu	Phe	Asn	Leu	Glu	Val	Leu
				645					650					655	
Asp	Ile	Ser	Arg	Asn	Ser	Leu	Asn	Ser	Leu	Pro	Pro	Glu	Val	Phe	Glu
			660					665					670		
Gly	Met	Pro	Pro	Asn	Leu	Lys	Asn	Leu	Ser	Leu	Ala	Lys	Asn	Gly	Leu
		675					680					685			
Lys	Ser	Phe	Phe	Trp	Asp	Arg	Leu	Gln	Leu	Leu	Lys	His	Leu	Glu	Ile
	690					695					700				
Leu	Asp	Leu	Ser	His	Asn	Gln	Leu	Thr	Lys	Val	Pro	Glu	Arg	Leu	Ala
705					710					715					720
Asn	Cys	Ser	Lys	Ser	Leu	Thr	Thr	Leu	Ile	Leu	Lys	His	Asn	Gln	Ile
				725					730					735	
Arg	Gln	Leu	Thr	Lys	Tyr	Phe	Leu	Glu	Asp	Ala	Leu	Gln	Leu	Arg	Tyr
			740					745					750		
Leu	Asp	Ile	Ser	Ser	Asn	Lys	Ile	Gln	Val	Ile	Gln	Lys	Thr	Ser	Phe
	755						760					765			
Pro	Glu	Asn	Val	Leu	Asn	Asn	Leu	Glu	Met	Leu	Val	Leu	His	His	Asn
	770					775					780				
Arg	Phe	Leu	Cys	Asn	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn
785					790					795					800
His	Thr	Asp	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val
			805						810					815	
Gly	Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr
			820					825					830		
Thr	Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Val	Ser	Ile
		835					840					845			
Ser	Ser	Val	Leu	Phe	Leu	Met	Val	Val	Met	Thr	Thr	Ser	His	Leu	Phe
		850				855					860				
Phe	Trp	Asp	Met	Trp	Tyr	Ile	Tyr	Tyr	Phe	Trp	Lys	Ala	Lys	Ile	Lys
865					870					875					880
Gly	Tyr	Gln	His	Leu	Gln	Ser	Met	Glu	Ser	Cys	Tyr	Asp	Ala	Phe	Ile
				885					890					895	
Val	Tyr	Asp	Thr	Lys	Asn	Ser	Ala	Val	Thr	Glu	Trp	Val	Leu	Gln	Glu

900 905 910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915 920 925  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930 935 940  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945 950 955 960  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
 965 970 975  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
 980 985 990  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
 995 1000 1005  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
 1010 1015 1020  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
 1025 1030 1035  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
 1040 1045 1050  
  
 <210> 42  
 <211> 1050  
 <212> PRT  
 <213> murine  
  
 <400> 42  
  
 Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys



465                      470                      475                      480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
                                  485                      490                      495  
  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
                                  500                      505                      510  
  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
                                  515                      520                      525  
  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
                                  530                      535                      540  
  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
                                  545                      550                      555                      560  
  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
                                  565                      570                      575  
  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
                                  580                      585                      590  
  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
                                  595                      600                      605  
  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
                                  610                      615                      620  
  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
                                  625                      630                      635                      640  
  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
                                  645                      650                      655  
  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
                                  660                      665                      670  
  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
                                  675                      680                      685  
  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
                                  690                      695                      700  
  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
                                  705                      710                      715                      720  
  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
                                  725                      730                      735  
  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
                                  740                      745                      750  
  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
                                  755                      760                      765  
  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
                                  770                      775                      780  
  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
                                  785                      790                      795                      800  
  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val

805 810 815  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
 820 825 830  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
 835 840 845  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
 850 855 860  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865 870 875 880  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
 885 890 895  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
 900 905 910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915 920 925  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930 935 940  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945 950 955 960  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
 965 970 975  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
 980 985 990  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
 995 1000 1005  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
 1010 1015 1020  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
 1025 1030 1035  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
 1040 1045 1050

<210> 43  
 <211> 1050  
 <212> PRT  
 <213> murine

<400> 43

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140  
 Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu

370                      375                      380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385                      390                      395                      400  
  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
                     405                      410                      415  
  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
                     420                      425                      430  
  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
                     435                      440                      445  
  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
                     450                      455                      460  
  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465                      470                      475                      480  
  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
                     485                      490                      495  
  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
                     500                      505                      510  
  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
                     515                      520                      525  
  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
                     530                      535                      540  
  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545                      550                      555                      560  
  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
                     565                      570                      575  
  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
                     580                      585                      590  
  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
                     595                      600                      605  
  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
                     610                      615                      620  
  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625                      630                      635                      640  
  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
                     645                      650                      655  
  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
                     660                      665                      670  
  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
                     675                      680                      685  
  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
                     690                      695                      700  
  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala

705	Asn	Cys	Ser	Lys	Ser	Leu	Thr	Thr	Leu	Ile	Leu	Lys	His	Asn	Gln	Ile	720
					725					730						735	
Arg	Gln	Leu	Thr	Lys	Tyr	Phe	Leu	Glu	Asp	Ala	Leu	Gln	Leu	Arg	Tyr		
			740					745						750			
Leu	Asp	Ile	Ser	Ser	Asn	Lys	Ile	Gln	Val	Ile	Gln	Lys	Thr	Ser	Phe		
		755					760					765					
Pro	Glu	Asn	Val	Leu	Asn	Asn	Leu	Glu	Met	Leu	Val	Leu	His	His	Asn		
		770				775					780						
Arg	Phe	Leu	Cys	Asn	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn		
785					790					795					800		
His	Thr	Asp	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val		
				805					810					815			
Gly	Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr		
			820				825						830				
Thr	Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Val	Ser	Ile		
			835				840					845					
Ser	Ser	Val	Leu	Phe	Leu	Met	Val	Val	Met	Thr	Thr	Ser	His	Leu	Phe		
		850				855						860					
Phe	Trp	Asp	Met	Trp	Tyr	Ile	Tyr	Tyr	Phe	Trp	Lys	Ala	Lys	Ile	Lys		
865					870					875					880		
Gly	Tyr	Gln	His	Leu	Gln	Ser	Met	Glu	Ser	Cys	Tyr	Asp	Ala	Phe	Ile		
				885					890					895			
Val	Tyr	Asp	Thr	Lys	Asn	Ser	Ala	Val	Thr	Glu	Trp	Val	Leu	Gln	Glu		
			900					905						910			
Leu	Val	Ala	Lys	Leu	Glu	Asp	Pro	Arg	Glu	Lys	His	Phe	Asn	Leu	Cys		
		915					920					925					
Leu	Glu	Glu	Arg	Asp	Trp	Leu	Pro	Gly	Gln	Pro	Val	Leu	Glu	Asn	Leu		
		930				935					940						
Ser	Gln	Ser	Ile	Gln	Leu	Ser	Lys	Lys	Thr	Val	Phe	Val	Met	Thr	Gln		
945				950						955					960		
Lys	Tyr	Ala	Lys	Thr	Glu	Ser	Phe	Lys	Met	Ala	Phe	Tyr	Leu	Ser	His		
				965					970					975			
Gln	Arg	Leu	Leu	Asp	Glu	Lys	Val	Asp	Val	Ile	Ile	Leu	Ile	Phe	Leu		
			980					985						990			
Glu	Lys	Pro	Leu	Gln	Lys	Ser	Lys	Phe	Leu	Gln	Leu	Arg	Lys	Arg	Leu		
		995					1000						1005				
Cys	Arg	Ser	Ser	Val	Leu	Glu	Trp	Pro	Ala	Asn	Pro	Gln	Ala	His			
	1010					1015					1020						
Pro	Tyr	Phe	Trp	Gln	Cys	Leu	Lys	Asn	Ala	Leu	Thr	Thr	Asp	Asn			
						1030				</							

1040  
 <210> 44  
 <211> 1050  
 <212> PRT  
 <213> murine  
  
 <400> 44

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140  
 Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
 485 490 495  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
 500 505 510  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
 515 520 525  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
 530 535 540  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545 550 555 560  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
 565 570 575  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
 580 585 590  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
 595 600 605  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile

610 615 620  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625 630 635 640  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
 645 650 655  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
 660 665 670  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
 675 680 685  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
 690 695 700  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
 705 710 715 720  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
 725 730 735  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
 740 745 750  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
 755 760 765  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
 770 775 780  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785 790 795 800  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
 805 810 815  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
 820 825 830  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
 835 840 845  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
 850 855 860  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865 870 875 880  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
 885 890 895  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
 900 905 910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915 920 925  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930 935 940  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln



945                      950                      955                      960  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
                                  965                      970                      975  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
                                  980                      985                      990  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
                                  995                      1000                      1005  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
                                  1010                      1015                      1020  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
                                  1025                      1030                      1035  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
                                  1040                      1045                      1050

<210> 45  
 <211> 1050  
 <212> PRT  
 <213> murine

<400> 45

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1                      5                      10                      15  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
                                  20                      25                      30  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
                                  35                      40                      45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
                                  50                      55                      60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65                      70                      75                      80  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
                                  85                      90                      95  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
                                  100                      105                      110  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
                                  115                      120                      125  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
                                  130                      135                      140  
 Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145                      150                      155                      160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
                                  165                      170                      175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
                                  180                      185                      190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
 485 490 495  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
 500 505 510  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn

515 520 525  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
 530 535 540  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545 550 555 560  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
 565 570 575  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
 580 585 590  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
 595 600 605  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
 610 615 620  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625 630 635 640  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
 645 650 655  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
 660 665 670  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
 675 680 685  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
 690 695 700  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
 705 710 715 720  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
 725 730 735  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
 740 745 750  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
 755 760 765  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
 770 775 780  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785 790 795 800  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
 805 810 815  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
 820 825 830  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
 835 840 845  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe

850                      855                      860  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865                      870                      875                      880  
  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
                                  885                      890                      895  
  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
                                  900                      905                      910  
  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
                                  915                      920                      925  
  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
                                  930                      935                      940  
  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945                      950                      955                      960  
  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
                                  965                      970                      975  
  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
                                  980                      985                      990  
  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
                                  995                      1000                      1005  
  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
                                  1010                      1015                      1020  
  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
                                  1025                      1030                      1035  
  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
                                  1040                      1045                      1050

<210> 46  
 <211> 3311  
 <212> DNA  
 <213> Homo sapiens

<400> 46  
 ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca acagaaacat ggaaaacatg 60  
  
 ttccttcagt cgtcaatgct gacctgcatt ttcctgctaa tatctggttc ctgtgagtta 120  
  
 tgcgcggaag aaaatttttc tagaagctat ccttgatgat agaaaaagca aaatgactca 180  
  
 gttattgcag agtgcagcaa tcgtcgacta caggaagttc cccaaacggt gggcaaatat 240  
  
 gtgacagaac tagacctgtc tgataatttc atcacacaca taacgaatga atcattttcaa 300  
  
 gggctgcaaa atctcactaa aataaatcta aaccacaacc ccaatgtaca gcaccagaac 360  
  
 ggaaatcccg gtatacaatc aaatggcttg aatatcacag acggggcatt cctcaaccta 420  
  
 aaaaacctaa gggagttact gcttgaagac aaccagttac cccaaatacc ctctggtttg 480  
  
 ccagagtctt tgacagaact tagtctaatt caaaacaata tataacaacat aactaaagag 540

ggcatttcaa gacttataaa cttgaaaaat ctctatattg cctggaactg ctattttaac	600
aaagtttgcg agaaaactaa catagaagat ggagtatttg aaacgctgac aaatttgag	660
ttgctatcac tatctttcaa ttctctttca cacgtgccac ccaaactgcc aagctcccta	720
cgcaaacttt ttctgagcaa caccagatc aaatacatta gtgaagaaga tttcaaggga	780
ttgataaatt taacattact agatttaagc gggaactgtc cgagggtgctt caatgcccc	840
tttccatgcg tgccttgatga tgggtgggtgct tcaattaata tagatcgttt tgcttttcaa	900
aacttgaccc aacttcgata cctaaacctc tctagcactt ccctcaggaa gattaatgct	960
gcctgggttta aaaatatgcc tcatctgaag gtgctggatc ttgaattcaa ctatttagtg	1020
ggagaaatag cctctggggc atttttaacg atgctgcccc gcttagaaat acttgacttg	1080
tcttttaact atataaaggg gagttatcca cagcatatta atatttccag aaacttctct	1140
aaacttttgt ctctacgggc attgcattta agaggttatg tgttccagga actcagagaa	1200
gatgatttcc agccctgat gcagcttcca aacttatcga ctatcaactt gggattaat	1260
tttattaagc aaatcgattt caaacttttc caaaatttct ccaatctgga aattatttac	1320
ttgtcagaaa acagaatatc accgttggtgta aaagataccc ggcagagtta tgcaaatagt	1380
tcctcttttc aacgtcatat ccggaacga cgctcaacag attttgagtt tgaccacat	1440
tcgaactttt atcatttcac ccgtccttta ataaagccac aatgtgctgc ttatggaaaa	1500
gccttagatt taagcctcaa cagtatttct ttcatggggc caaaccaatt tgaaaatctt	1560
cctgacattg cctgtttaaa tctgtctgca aatagcaatg ctcaagtgtt aagtggaact	1620
gaattttcag ccattcctca tgtcaaatat ttggatttga caaacaatag actagacttt	1680
gataatgcta gtgctcttac tgaattgtcc gacttggaag ttctagatct cagctataat	1740
tcacactatt tcagaatagc aggcgtaaca catcatctag aatttattca aaatttcaca	1800
aatctaaaag ttttaaactt gagccacaac aacatttata cttaacaga taagtataac	1860
ctggaaagca agtccctggg agaattagtt ttcagtggca atcgcttga cattttgtgg	1920
aatgatgatg acaacaggta tatctccatt ttcaaaggtc tcaagaatct gacacgtctg	1980
gatttatccc ttaataggct gaagcacatc ccaaatgaag cattccttaa tttgccagcg	2040
agtctcactg aactacatat aaatgataat atgttaaagt tttttaactg gacattactc	2100
cagcagttcc ctgctctcga gttgcttgac ttacgtggaa acaaactact ctttttaact	2160
gatagcctat ctgactttac atcttccctt cggacactgc tgctgagtca taacaggatt	2220
tcccacctac cctctgggtt tctttctgaa gtcagtagtc tgaagcacct cgatttaagt	2280
tccaatctgc taaaaacaat caacaaatcc gcacttgaaa ctaagaccac caccaaatta	2340
tctatgttgg aactacacgg aaaccctttt gaatgcacct gtgacattgg agatttccga	2400
agatggatgg atgaacatct gaatgtcaaa attcccagac tggtagatgt catttgtgcc	2460

agtcctgggg atcaaagagg gaagagtatt gtgagtctgg agctgacaac ttgtgtttca 2520  
 gatgtcactg cagtgatatt atttttcttc acgttcttta tcaccaccat gggtatgttg 2580  
 gctgccctgg ctcaccattt gttttactgg gatgtttggg ttatatataa tgtgtgttta 2640  
 gctaaggtaa aaggctacag gtctctttcc acatcccaaa ctttctatga tgcttacatt 2700  
 tcttatgaca ccaaagatgc ctctgttact gactgggtga taaatgagct gcgctaccac 2760  
 cttgaagaga gccgagacaa aaacgttctc ctttgtctag aggagaggga ttgggacccg 2820  
 ggattggcca tcatcgacaa cctcatgcag agcatcaacc aaagcaagaa aacagtattt 2880  
 gttttaacca aaaaatatgc aaaaagctgg aactttaaaa cagcttttta cttggctttg 2940  
 cagaggctaa tggatgagaa catggatgtg attatattta tcttgctgga gccagtgtta 3000  
 cagcattctc agtatttgag gctacggcag cggatctgta agagctccat cctccagtgg 3060  
 cctgacaacc cgaaggcaga aggcttgttt tggcaaactc tgagaaatgt ggtcttgact 3120  
 gaaaatgatt cacggtataa caatatgtat gtcgattcca ttaagcaata ctaactgacg 3180  
 ttaagtcatg atttcgcgcc ataataaaga tgcaaaggaa tgacatttct gtattagtta 3240  
 tctattgcta tgtaacaaat tatcccaaaa cttagtgggt taaaacaaca catttgctgg 3300  
 cccacagttt t 3311

<210> 47

<211> 3367

<212> DNA

<213> Homo sapiens

<400> 47

ctctctgcata gagggtagca ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca 60  
 acagaaacgt gggtctcttg acacttcagt gttagggaac atcagcaaga cccatcccag 120  
 gagaccttga aggaagcctt tgaaaggagg aatgaaggag tcctctttgc aaaatagctc 180  
 ctgcagcctg ggaaaggaga ctaaaaagga aaacatgttc cttcagtcgt caatgctgac 240  
 ctgcattttc ctgctaatat ctggttcctg tgagttatgc gccgaagaaa atttttctag 300  
 aagctatcct tgtgatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg 360  
 tcgactacag gaagttcccc aaacgggtggg caaatatgtg acagaactag acctgtctga 420  
 taatttcac acacacataa cgaatgaatc atttcaaggg ctgcaaaatc tcactaaaat 480  
 aaatctaaac cacaaccca atgtacagca ccagaacgga aatcccgtga tacaatcaaa 540  
 tggcttgaat atcacagacg gggcattcct caacctaaaa aacctaaagg agttactgct 600  
 tgaagacaac cagttacccc aaataccctc tggtttgcca gagtctttga cagaacttag 660  
 tctaattcaa aacaatatat acaacataac taaagagggc atttcaagac ttataaactt 720

gaaaaatctc	tatttggcct	ggaactgcta	ttttaacaaa	gtttgcgaga	aaactaacat	780
agaagatgga	gtatttgaaa	cgctgacaaa	tttggagttg	ctatcactat	ctttcaattc	840
tctttcacac	gtgtcaccca	aactgccaa	ctccctacgc	aaactttttc	tgagcaacac	900
ccagatcaaa	tacattagtg	aagaagattt	caagggattg	ataaatttaa	cattactaga	960
tttaagcggg	aactgtccga	ggtgcttcaa	tgccccattt	ccatgcgtgc	cttgtgatgg	1020
tggtgcttca	attaatatag	atcgttttgc	ttttcaaaac	ttgacccaac	ttcgatacct	1080
aaacctctct	agcacttccc	tcaggaagat	taatgctgcc	tggtttaaaa	atatgcctca	1140
tctgaaggtg	ctggatcttg	aattcaacta	tttagtggga	gaaatagcct	ctggggcatt	1200
tttaacgatg	ctgccccgct	tagaaatact	tgacttgtct	tttaactata	taaaggggag	1260
ttatccacag	catattaata	tttccagaaa	cttctctaaa	cctttgtctc	tacgggcatt	1320
gcatttaaga	ggttatgtgt	tccaggaact	cagagaagat	gatttccagc	ccctgatgca	1380
gcttccaaac	ttatcgacta	tcaacttggg	tattaatttt	attaagcaaa	tcgatttcaa	1440
acttttccaa	aattttctcca	atctggaaat	tattttacttg	tcagaaaaca	gaatatcacc	1500
gttggtaaaa	gatacccggc	agagtatatg	aaatagttcc	tcttttcaac	gtcatatccg	1560
gaaacgacgc	tcaacagatt	ttgagtttga	cccacattcg	aacttttatc	atttcacccg	1620
tcctttaata	aagccacaat	gtgctgctta	tggaagagcc	ttagatttaa	gcctcaacag	1680
tattttcttc	attgggccaa	accaatttga	aaatcttcc	gacattgcct	gtttaaatct	1740
gtctgcaaat	agcaatgctc	aagtgttaag	tggaactgaa	ttttcagcca	ttcctcatgt	1800
caaatatttg	gatttgacaa	acaatagact	agactttgat	aatgctagtg	ctcttactga	1860
attgtccgac	ttggaagtgc	tagatctcag	ctataattca	cactatttca	gaatagcagg	1920
cgtaacacat	catctagaat	ttattcaaaa	tttcacaaat	ctaaaagttt	taaacttgag	1980
ccacaacaac	atttatactt	taacagataa	gtataacctg	gaaagcaagt	ccctggtaga	2040
attagttttc	agtggcaatc	gccttgacat	tttgtggaat	gatgatgaca	acaggtatat	2100
ctccattttc	aaaggtctca	agaatctgac	acgtctggat	ttatccctta	ataggctgaa	2160
gcacatccca	aatgaagcat	tccttaattt	gccagcgagt	ctcactgaac	tacatatata	2220
tgataaatatg	ttaaagtttt	ttaactggac	attactccag	cagtttctct	gtctcgagtt	2280
gcttgactta	cgtggaaaca	aactactctt	tttaactgat	agcctatctg	actttacatc	2340
ttcccttcgg	acactgctgc	tgagtcataa	caggatttcc	cacctaccct	ctggctttct	2400
ttctgaagtc	agtagtctga	agcacctoga	tttaagttcc	aatctgctaa	aaacaatcaa	2460
caaatccgca	cttgaaacta	agaccaccac	caaattatct	atgttggaac	tacacggaaa	2520
cccctttgaa	tgcacctgtg	acattggaga	tttccgaaga	tggtgggatg	aacatctgaa	2580
tgtcaaaatt	cccagactgg	tagatgtcat	ttgtgccagt	cctggggatc	aaagagggaa	2640

gagtattgtg agtctggagc taacaacttg tgtttcagat gtcactgcag tgatattatt 2700  
 tttcttcacg ttctttatca ccaccatggg tatgttggct gccctggctc accatttggt 2760  
 ttactgggat gtttggttta tatataatgt gtgttttagct aagataaaaag gctacaggctc 2820  
 tctttccaca tcccaaactt tctatgatgc ttacatttct tatgacacca aagatgcctc 2880  
 tgttactgac tgggtgataa atgagctgcg ctaccacctt gaagagagcc gagacaaaaa 2940  
 cgttctcctt tgtctagagg agagggattg ggacccggga ttggccatca tcgacaacct 3000  
 catgcagagc atcaacccaa gcaagaaaac agtatttggt ttaacccaaa aatatgcaaa 3060  
 aagctggaac tttaaaacag ctttttactt ggctttgcag aggctaattg atgagaacat 3120  
 ggatgtgatt atatttatcc tgctggagcc agtgttacag cattctcagt atttgaggct 3180  
 acggcagcgg atctgtaaga gctccatcct ccagtggcct gacaaccga aggcagaagg 3240  
 cttgttttgg caaactctga gaaatgtggg cttgactgaa aatgattcac ggtataacaa 3300  
 tatgtatgtc gattccatta agcaatacta actgacgtta agtcatgatt tcgcgccata 3360  
 ataaaga 3367

<210> 48

<211> 4211

<212> DNA

<213> Homo sapiens

<400> 48

ctctgcata gaggtacca ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca 60  
 acagaaacat ggaaaacatg ttcttctcagt cgtcaatgct gacctgcatt ttcttgctaa 120  
 tatctggttc ctgtgagtta tgcgccgaag aaaatttttc tagaagctat ccttgatgatg 180  
 agaaaaagca aatgactca gttattgcag agtgcagcaa tcgtcgacta caggaagttc 240  
 cccaaacggg gggcaaatat gtgacagaac tagacctgtc tgataatttc atcacacaca 300  
 taacgaatga atcatttcaa gggctgcaaa atctcactaa aataaatcta aaccacaacc 360  
 ccaatgtaca gcaccagaac ggaaatcccg gtatacaatc aatggcctg aatatcacag 420  
 acggggcatt cctcaaccta aaaaacctaa gggagttact gcttgaagac aaccagttac 480  
 cccaaatacc ctctgggttg ccagagtctt tgacagaact tagtctaatt caaaacaata 540  
 tataacaacat aactaaagag ggcatttcaa gacttataaa cttgaaaaat ctctatttgg 600  
 cctggaactg ctattttaac aaagtttgcg agaaaactaa catagaagat ggagtatttg 660  
 aaacgctgac aaatttggag ttgctatcac tatctttcaa ttctctttca cacgtgccac 720  
 ccaaactgcc aagctcccta cgcaaacttt ttctgagcaa caccagatc aaatacat 780  
 gtgaagaaga tttcaaggga ttgataaatt taacattact agatttaagc gggaactgtc 840



cgagggtgctt caatgcccc	tttccatgcg tgccttggtga	tgggtggtgct tcaattaata	900
tagatcgttt tgcttttcaa	aacttgaccc aacttcgata	cctaaacctc tctagcactt	960
ccctcaggaa gattaatgct	gcctggttta aaaatatgcc	tcatctgaag gtgctggatc	1020
ttgaattcaa ctatttagtg	ggagaaatag cctctggggc	atthttaacg atgctgcccc	1080
gcttagaaat acttgacttg	tcttttaact atataaaggg	gagttatcca cagcatatta	1140
atatttccag aaacttctct	aaacttttgt ctctacgggc	attgcattta agaggttatg	1200
tgttccagga actcagagaa	gatgatttcc agcccctgat	gcagcttcca aacttatcga	1260
ctatcaactt ggggtattaat	tttattaagc aaatcgattt	caaacttttc caaaatttct	1320
ccaatctgga aattatttac	ttgtcagaaa acagaatata	accgttggtg aaagataccc	1380
ggcagagtta tgcaaatagt	tcctcttttc aacgtcatat	ccggaaacga cgctcaacag	1440
atthtgagtt tgaccacat	tcgaactttt atcatttcac	ccgtccttta ataaagccac	1500
aatgtgctgc ttatggaaaa	gccttagatt taagcctcaa	cagtattttc ttcattgggc	1560
caaaccaatt tgaaaatctt	cctgacattg cctgtttaaa	tctgtctgca aatagcaatg	1620
ctcaagtgtt aagtggaaact	gaattttcag ccattcctca	tgtcaaatat ttggatttga	1680
caaacaatag actagacttt	gataatgcta gtgctcttac	tgaattgtcc gacttggaag	1740
ttctagatct cagctataat	tcacactatt tcagaatagc	aggcgtaaca catcatctag	1800
aatttattca aaatttcaca	aatctaaaag ttttaaactt	gagccacaac aacatttata	1860
ctttaacaga taagtataac	ctggaaagca agtccttgg	agaattagtt ttcagtggca	1920
atgccttga cattttgtgg	aatgatgatg acaacaggta	tatctccatt ttcaaaggtc	1980
tcaagaatct gacacgtctg	gatttatccc ttaataggct	gaagcacatc ccaaatgaag	2040
cattccttaa ttgcccagcg	agtctcactg aactacatat	aaatgataat atgttaaagt	2100
tttttaactg gacattactc	cagcagtttc ctctctcga	gttgcttgac ttacgtggaa	2160
acaaactact ctttttaact	gatagcctat ctgactttac	atcttccctt cggacactgc	2220
tgctgagtca taacaggatt	tcccacctac cctctggctt	tctttctgaa gtcagtagtc	2280
tgaagcacct cgatttaagt	tccaatctgc taaaaacaat	caacaaatcc gcacttgaaa	2340
ctaagaccac caccaaatta	tctatgttgg aactacacgg	aaacccttt gaatgcacct	2400
gtgacattgg agatttccga	agatggatgg atgaacatct	gaatgtcaaa attcccagac	2460
tggtagatgt catttgtgcc	agtcctgggg atcaaagagg	gaagagtatt gtgagctggt	2520
agctaacaac ttgtgtttca	gatgtcactg cagtgatatt	atthttcttc acgttcttta	2580
tcaccaccat gggtatgttg	gctgccctgg ctaccattt	gttttactgg gatgtttggt	2640
ttatatataa tgtgtgttta	gctaaggtaa aaggctacag	gtctctttcc acatcccaaa	2700
ctttctatga tgcttacatt	tcttatgaca ccaaagatgc	ctctgttact gactgggtga	2760

taaatgagct gcgctaccac cttgaagaga gccgagacaa aaacgttctc ctttgtctag 2820  
 aggagagggga ttgggatccg ggattggcca tcatcgacaa cctcatgcag agcatcaacc 2880  
 aaagcaagaa aacagtatctt gttttaacca aaaaatatgc aaaaagctgg aactttaaaa 2940  
 cagcttttta cttggctttg cagaggctaa tggatgagaa catggatgtg attatattta 3000  
 tcctgctgga gccagtgtta cagcattctc agtatttgag gctacggcag cggatctgta 3060  
 agagctccat cctccagtgg cctgacaacc cgaaggcaga aggcttgttt tggcaaactc 3120  
 tgagaaatgt ggtcttgact gaaaatgatt cacggtataa caatatgtat gtcgattcca 3180  
 ttaagcaata ctaactgacg ttaagtcattg atttcgcgcc ataataaaga tgcaaaggaa 3240  
 tgacatttct gtattagtta tctattgcta tgtaacaaat tatcccaaaa cttagtgggt 3300  
 taaaacaaca catttgctgg ccacagttt ttgaggggtca ggagtccagg ccagcataa 3360  
 ctgggtcctc tgctcagggt gtctcagagg ctgcaatgta ggtgttcacc agagacatag 3420  
 gcatcactgg ggtcacactc atgtggttgt tttctggatt caattcctcc tgggctattg 3480  
 gccaaaggct atactcatgt aagccatgcg agcctctccc acaaggcagc ttgcttcac 3540  
 agagctagca aaaaagagag gttgctagca agatgaagtc acaatctttt gtaatcgaat 3600  
 caaaaaagtg atatctcatc actttggcca tattctatct gttagaagta aaccacaggt 3660  
 cccaccagct ccatgggagt gaccacctca gtccaggga aacagctgaa gaccaagatg 3720  
 gtgagctctg attgcttcag ttggtcatca actattttcc cttgactgct gtctgggat 3780  
 ggctgctat cttgatgata gattgtgaat atcaggaggc agggatcact gtggaccatc 3840  
 ttagcagttg acctaacaca tcttcttttc aatatctaag aacttttgcc actgtgacta 3900  
 atggctctaa tattaagctg ttgtttatat ttatcatata tctatggcta catggttata 3960  
 ttatgctgtg gttgcgttcg gttttattta cagttgcttt taaaaatatt tgctgtaaca 4020  
 tttgacttct aaggtttaga tgccatttaa gaactgagat ggatagcttt taaagcatct 4080  
 tttacttctt accatttttt aaaagtatgc agctaaattc gaagcttttg gtctatattg 4140  
 ttaattgcca ttgctgtaaa tcttaaaatg aatgaataaa aatgtttcat tttacaaaaa 4200  
 aaaaaaaaaa a 4211

&lt;210&gt; 49

&lt;211&gt; 3468

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

ctcctgcata gagggtagca ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca 60

acagaaacat ggttctcttg acatttcagt gttaggaac atcagcaaga cccatcccag 120

gagaccttga aggaagcctt tgaaagggag aatgaaggag tcatccttgc aaaatagctc	180
ctgcagcctg ggaaaggaga ctaaaaagga aaacatgttc cttcagtcgt caatgctgac	240
ctgcattttc ctgctaatat ctggttcctg tgagttatgc gccgaagaaa atttttctag	300
aagctatcct tgtgatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg	360
tcgactacag gaagttcccc aaacgggtggg caaatatgtg acagaactag acctgtctga	420
taatttcac acacacataa cgaatgaatc atttcaaggg ctgcaaaatc tactataaaat	480
aatctaaaac cacaacccca atgtacagca ccagaacgga aatcccggta tacaatcaaa	540
tggcttgaat atcacagacg gggcattcct caacctaaaa aacctagggt agttactgct	600
tgaagacaac cagttacccc aaataccctc tggtttgcca gagtctttga cagaacttag	660
tctaattcaa aacaatatat acaacataac taaagagggc atttcaagac ttataaaactt	720
gaaaaatctc tatttggcct ggaactgcta ttttaacaaa gtttgcgaga aaactaacat	780
agaagatgga gtatttgaaa cgctgacaaa tttggagttg ctatcactat ctttcaattc	840
tctttcacac gtgccacca aactgccaag ctccctacgc aaactttttc tgagcaacac	900
ccagatcaaa tacattagtg aagaagattt caagggattg ataaatttaa cattactaga	960
tttaagcggg aactgtccga ggtgcttcaa tgccccattt ccatgcgtgc cttgtgatgg	1020
tggtgcttca attaatatag atcgttttgc ttttcaaaac ttgacccaac ttcgatacct	1080
aaacctctct agcacttccc tcaggaagat taatgctgcc tggtttaaaa atatgcctca	1140
tctgaagggtg ctggatcttg aattcaacta tttagtggga gaaatagcct ctggggcatt	1200
tttaacgatg ctgccccgct tagaaatact tgacttgtct ttttaactata taaaggggag	1260
ttatccacag catattaata tttccagaaa cttctctaaa cttttgtctc tacgggcatt	1320
gcatttaaga ggttatgtgt tccaggaact cagagaagat gatttccagc ccctgatgca	1380
gcttccaaac ttatcgacta tcaacttggg tattaatttt attaaagcaa tcgatttcaa	1440
acttttccaa aattttctca atctggaaat tatttacttg tcagaaaaca gaatatcacc	1500
gttggttaaaa gatacccggc agagttatgc aaatagttcc tcttttcaac gtcatatccg	1560
gaaacgacgc tcaacagatt ttgagtttga cccacattcg aacttttatc atttcacccg	1620
tcctttaata aagccacaat gtgctgctta tggaaaagcc ttagatttaa gcctcaacag	1680
tattttcttc attgggccaa accaatttga aaatcttcct gacattgcct gtttaaactc	1740
gtctgcaaat agcaatgctc aagtgttaag tggaactgaa ttttcagcca ttcctcatgt	1800
caaatatttg gatttgacaa acaatagact agactttgat aatgctagtg ctcttactga	1860
attgtccgac ttggaagttc tagatctcag ctataattca cactatttca gaatagcagg	1920
cgtaacacat catctagaat ttattcaaaa tttcacaaat ctaaaagttt taaacttgag	1980
ccacaacaac atttatactt taacagataa gtataacctg gaaagcaagt ccctggtaga	2040

```

attagttttc agtggcaatc gccttgacat tttgtggaat gatgatgaca acaggtatat 2100
ctccattttc aaaggtctca agaattctgac acgtctggat ttatccctta ataggctgaa 2160
gcacatccca aatgaagcat tccttaattt gccagcgagt ctactgaac tacatataaa 2220
tgataatatg ttaaagtttt ttaactggac attactocag cagtttcctc gtctcgagtt 2280
gcttgactta cgtggaaaca aactactctt tttaactgat agcctatctg actttacatc 2340
ttcccttcgg acactgctgc tgagtcataa caggatttcc cacctaccct ctggctttct 2400
ttctgaagtc agtagtctga agcacctcga tttaagttcc aatctgctaa aaacaatcaa 2460
caaatccgca cttgaaacta agaccaccac caaattatct atgttggaac tacacggaaa 2520
cccccttgaa tgcacctgtg acattggaga tttccgaaga tggatggatg aacatctgaa 2580
tgtcaaaatt ccagactgg tagatgtcat ttgtgccagt cctggggatc aaagagggaa 2640
gagtattgtg agtctggagc taacaacttg tgtttcagat gtactgcag tgatattatt 2700
ttcttccacg ttctttatca ccaccatggt tatgttggt gccctggctc accatttggt 2760
ttactgggat gtttggttta tatataatgt gtgtttagct aaggtaaaag gctacaggtc 2820
tctttccaca toccaaactt totatgatgc ttacatttct tatgacacca aagatgcctc 2880
tgttactgac tgggtgataa atgagctgcy ctaccacctt gaagagagcc gagacaaaaa 2940
cgttctcctt tgtctagagg agagggattg ggatccggga ttggccatca tcgacaacct 3000
catgcagagc atcaacaaaa gcaagaaaac agtatttggt ttaacaaaaa aatatgcaaa 3060
aagctggaac tttaaaacag ctttttactt ggctttgcag aggctaattg atgagaacat 3120
ggatgtgatt atatttatcc tgctggagcc agtgttacag cattctcagt atttgaggct 3180
acggcagcgg atctgtaaga gctccatcct ccagtggcct gacaaccga aggcagaagg 3240
cttggttttg caaactctga gaaatgtggt cttgactgaa aatgattcac ggtataacaa 3300
tatgtatgtc gattccatta agcaatacta actgacgtta agtcatgatt tcgcgccata 3360
ataaagatgc aaaggaatga cttttctgta ttagttatct attgctatgt aacaaattat 3420
ccaaaaactt agtgggttaa aacaacacat ttgctggccc acagtttt 3468

```

&lt;210&gt; 50

&lt;211&gt; 1041

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

```

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu
1             5             10             15

```

```

Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg
20             25             30

```

Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
 35 40 45  
 Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
 50 55 60  
 Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
 65 70 75 80  
 Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
 85 90 95  
 Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
 100 105 110  
 Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
 115 120 125  
 Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
 130 135 140  
 Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
 145 150 155 160  
 Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
 165 170 175  
 Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
 180 185 190  
 Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
 195 200 205  
 Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
 210 215 220  
 Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
 225 230 235 240  
 Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
 245 250 255  
 Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
 260 265 270  
 Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
 275 280 285  
 Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
 290 295 300  
 Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
 305 310 315 320  
 Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
 325 330 335  
 Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
 340 345 350  
 Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser

355 360 365  
 Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
 370 375 380  
 Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn  
 385 390 395 400  
 Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn  
 405 410 415  
 Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro  
 420 425 430  
 Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln  
 435 440 445  
 Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His  
 450 455 460  
 Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala  
 465 470 475 480  
 Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile  
 485 490 495  
 Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu  
 500 505 510  
 Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala  
 515 520 525  
 Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe  
 530 535 540  
 Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp  
 545 550 555 560  
 Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His  
 565 570 575  
 Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser  
 580 585 590  
 His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys  
 595 600 605  
 Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp  
 610 615 620  
 Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn  
 625 630 635 640  
 Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn  
 645 650 655  
 Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn  
 660 665 670  
 Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro  
 675 680 685  
 Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr

690	695	700
Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser		
705	710	715 720
His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser		
	725	730 735
Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn		
	740	745 750
Lys Ser Ala Leu Glu Thr Lys Thr Thr Thr Lys Leu Ser Met Leu Glu		
	755	760 765
Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg		
	770	775 780
Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp		
	785	790 795 800
Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser		
	805	810 815
Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe		
	820	825 830
Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala		
	835	840 845
His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu		
	850	855 860
Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr		
	865	870 875 880
Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp		
	885	890 895
Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn		
	900	905 910
Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile		
	915	920 925
Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe		
	930	935 940
Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe		
	945	950 955 960
Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile		
	965	970 975
Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu		
	980	985 990
Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro		
	995	1000 1005
Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu		
	1010	1015 1020
Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile		

1025  
Lys Gln Tyr  
1040

1030

1035

<210> 51  
<211> 1059  
<212> PRT  
<213> Homo sapiens  
  
<400> 51

Met Lys Glu Ser Ser Leu Gln Asn Ser Ser Cys Ser Leu Gly Lys Glu  
1 5 10 15

Thr Lys Lys Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile  
20 25 30

Phe Leu Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe  
35 40 45

Ser Arg Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile  
50 55 60

Ala Glu Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly  
65 70 75 80

Lys Tyr Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile  
85 90 95

Thr Asn Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu  
100 105 110

Asn His Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln  
115 120 125

Ser Asn Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn  
130 135 140

Leu Arg Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser  
145 150 155 160

Gly Leu Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile  
165 170 175

Tyr Asn Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn  
180 185 190

Leu Tyr Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr  
195 200 205

Asn Ile Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu  
210 215 220

Ser Leu Ser Phe Asn Ser Leu Ser His Val Ser Pro Lys Leu Pro Ser  
225 230 235 240

Ser Leu Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser  
245 250 255

Glu Glu Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser  
260 265 270



Gly Asn Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys  
 275 280 285  
 Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu  
 290 295 300  
 Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile  
 305 310 315 320  
 Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu  
 325 330 335  
 Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr  
 340 345 350  
 Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys  
 355 360 365  
 Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Pro  
 370 375 380  
 Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu  
 385 390 395 400  
 Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr  
 405 410 415  
 Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe  
 420 425 430  
 Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile  
 435 440 445  
 Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser  
 450 455 460  
 Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp  
 465 470 475 480  
 Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln  
 485 490 495  
 Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe  
 500 505 510  
 Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu  
 515 520 525  
 Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe  
 530 535 540  
 Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu  
 545 550 555 560  
 Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val  
 565 570 575  
 Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr  
 580 585 590  
 His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn

595 600 605  
 Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu  
 610 615 620  
 Ser Lys Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile  
 625 630 635 640  
 Leu Trp Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu  
 645 650 655  
 Lys Asn Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile  
 660 665 670  
 Pro Asn Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His  
 675 680 685  
 Ile Asn Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln  
 690 695 700  
 Phe Pro Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe  
 705 710 715 720  
 Leu Thr Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu  
 725 730 735  
 Leu Ser His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu  
 740 745 750  
 Val Ser Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr  
 755 760 765  
 Ile Asn Lys Ser Ala Leu Glu Thr Lys Thr Thr Thr Lys Leu Ser Met  
 770 775 780  
 Leu Glu Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp  
 785 790 795 800  
 Phe Arg Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu  
 805 810 815  
 Val Asp Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile  
 820 825 830  
 Val Ser Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile  
 835 840 845  
 Leu Phe Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala  
 850 855 860  
 Leu Ala His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val  
 865 870 875 880  
 Cys Leu Ala Lys Ile Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr  
 885 890 895  
 Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr  
 900 905 910  
 Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp  
 915 920 925  
 Lys Asn Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu

930                      935                      940  
 Ala Ile Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr  
 945                      950                      955                      960  
 Val Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr  
                          965                      970                      975  
 Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val  
                          980                      985                      990  
 Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu  
                          995                      1000                      1005  
 Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro  
                          1010                      1015                      1020  
 Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn  
                          1025                      1030                      1035  
 Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val  
                          1040                      1045                      1050  
 Asp Ser Ile Lys Gln Tyr  
                          1055

<210> 52  
 <211> 1041  
 <212> PRT  
 <213> Homo sapiens

<400> 52

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu  
 1                      5                      10                      15  
 Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg  
                          20                      25                      30  
 Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
                          35                      40                      45  
 Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
                          50                      55                      60  
 Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
                          65                      70                      75                      80  
 Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
                          85                      90                      95  
 Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
                          100                      105                      110  
 Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
                          115                      120                      125  
 Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
                          130                      135                      140  
 Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
                          145                      150                      155                      160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
 165 170 175  
 Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
 180 185 190  
 Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
 195 200 205  
 Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
 210 215 220  
 Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
 225 230 235 240  
 Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
 245 250 255  
 Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
 260 265 270  
 Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
 275 280 285  
 Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
 290 295 300  
 Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
 305 310 315 320  
 Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
 325 330 335  
 Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
 340 345 350  
 Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser  
 355 360 365  
 Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
 370 375 380  
 Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn  
 385 390 395 400  
 Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn  
 405 410 415  
 Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro  
 420 425 430  
 Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln  
 435 440 445  
 Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His  
 450 455 460  
 Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala  
 465 470 475 480  
 Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile

[illegible]

820 825 830  
 Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala  
 835 840 845  
 His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu  
 850 855 860  
 Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr  
 865 870 875 880  
 Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp  
 885 890 895  
 Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn  
 900 905 910  
 Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile  
 915 920 925  
 Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe  
 930 935 940  
 Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe  
 945 950 955 960  
 Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile  
 965 970 975  
 Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu  
 980 985 990  
 Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro  
 995 1000 1005  
 Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu  
 1010 1015 1020  
 Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile  
 1025 1030 1035  
 Lys Gln Tyr  
 1040

<210> 53  
 <211> 1041  
 <212> PRT  
 <213> Homo sapiens

<400> 53

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu  
 1 5 10 15  
 Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg  
 20 25 30  
 Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
 35 40 45  
 Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
 50 55 60

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
 65 70 75 80  
 Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
 85 90 95  
 Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
 100 105 110  
 Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
 115 120 125  
 Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
 130 135 140  
 Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
 145 150 155 160  
 Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
 165 170 175  
 Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
 180 185 190  
 Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
 195 200 205  
 Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
 210 215 220  
 Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
 225 230 235 240  
 Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
 245 250 255  
 Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
 260 265 270  
 Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
 275 280 285  
 Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
 290 295 300  
 Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
 305 310 315 320  
 Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
 325 330 335  
 Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
 340 345 350  
 Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser  
 355 360 365  
 Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
 370 375 380  
 Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn

385                      390                      395                      400  
 Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn  
                                  405                      410                      415  
  
 Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro  
                                  420                      425                      430  
  
 Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln  
                                  435                      440                      445  
  
 Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His  
                                  450                      455                      460  
  
 Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala  
 465                                   470                      475                      480  
  
 Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile  
                                  485                      490                      495  
  
 Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu  
                                  500                      505                      510  
  
 Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala  
                                  515                      520                      525  
  
 Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe  
                                  530                      535                      540  
  
 Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp  
 545                                   550                      555                      560  
  
 Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His  
                                  565                      570                      575  
  
 Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser  
                                  580                      585                      590  
  
 His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys  
                                  595                      600                      605  
  
 Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp  
                                  610                      615                      620  
  
 Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn  
 625                                   630                      635                      640  
  
 Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn  
                                  645                      650                      655  
  
 Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn  
                                  660                      665                      670  
  
 Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro  
                                  675                      680                      685  
  
 Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr  
                                  690                      695                      700  
  
 Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser  
 705                                   710                      715                      720  
  
 His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser



[illegible]

<210> 54  
 <211> 1059  
 <212> PRT  
 <213> Homo sapiens

<400> 54

```

Met Lys Glu Ser Ser Leu Gln Asn Ser Ser Cys Ser Leu Gly Lys Glu
1          5          10          15

Thr Lys Lys Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile
20        25        30

Phe Leu Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe
35        40        45

Ser Arg Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile
50        55        60

Ala Glu Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly
65        70        75        80

Lys Tyr Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile
85        90        95

Thr Asn Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu
100       105       110

Asn His Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln
115       120       125

Ser Asn Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn
130       135       140

Leu Arg Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser
145       150       155       160

Gly Leu Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile
165       170       175

Tyr Asn Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn
180       185       190

Leu Tyr Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr
195       200       205

Asn Ile Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu
210       215       220

Ser Leu Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser
225       230       235       240

Ser Leu Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser
245       250       255

Glu Glu Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser
260       265       270

Gly Asn Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys
275       280       285

```

Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu  
 290 295 300  
 Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile  
 305 310 315 320  
 Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu  
 325 330 335  
 Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr  
 340 345 350  
 Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys  
 355 360 365  
 Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu  
 370 375 380  
 Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu  
 385 390 395 400  
 Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr  
 405 410 415  
 Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe  
 420 425 430  
 Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile  
 435 440 445  
 Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser  
 450 455 460  
 Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp  
 465 470 475 480  
 Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln  
 485 490 495  
 Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe  
 500 505 510  
 Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu  
 515 520 525  
 Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe  
 530 535 540  
 Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu  
 545 550 555 560  
 Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val  
 565 570 575  
 Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr  
 580 585 590  
 His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn  
 595 600 605  
 Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu

610 615 620  
 Ser Lys Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile  
 625 630 635 640  
 Leu Trp Asn Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu  
 645 650 655  
 Lys Asn Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile  
 660 665 670  
 Pro Asn Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His  
 675 680 685  
 Ile Asn Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln  
 690 695 700  
 Phe Pro Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe  
 705 710 715 720  
 Leu Thr Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu  
 725 730 735  
 Leu Ser His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu  
 740 745 750  
 Val Ser Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr  
 755 760 765  
 Ile Asn Lys Ser Ala Leu Glu Thr Lys Thr Thr Thr Lys Leu Ser Met  
 770 775 780  
 Leu Glu Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp  
 785 790 795 800  
 Phe Arg Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu  
 805 810 815  
 Val Asp Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile  
 820 825 830  
 Val Ser Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile  
 835 840 845  
 Leu Phe Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala  
 850 855 860  
 Leu Ala His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val  
 865 870 875 880  
 Cys Leu Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr  
 885 890 895  
 Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr  
 900 905 910  
 Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp  
 915 920 925  
 Lys Asn Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu  
 930 935 940  
 Ala Ile Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr

945                      950                      955                      960  
 Val Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr  
                                  965                      970                      975  
  
 Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val  
                                  980                      985                      990  
  
 Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu  
                                  995                      1000                      1005  
  
 Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro  
                                  1010                      1015                      1020  
  
 Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn  
                                  1025                      1030                      1035  
  
 Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val  
                                  1040                      1045                      1050  
  
 Asp Ser Ile Lys Gln Tyr  
                                  1055

<210> 55  
 <211> 3220  
 <212> DNA  
 <213> murine

<400> 55  
 attcagagtt ggatgttaag agagaaacaa acgtttttacc ttcctttgtc tatagaacat 60  
  
 ggaaaacatg cccctcagtc catggattct gacgtgcttt tgtctgctgt cctctggaac 120  
  
 cagtgccatc ttccataaag cgaactattc cagaagctat ccttgtgacg agataaggca 180  
  
 caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaagtgc cccaaactat 240  
  
 aggcaagtat gtgacaaaca tagacttgct agacaatgcc attacacata taacgaaaga 300  
  
 gtcctttcaa aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaaacaaca 360  
  
 gcaccccaat gaaaataaaa atggtatgaa tattacagaa ggggcacttc tcagcctaag 420  
  
 aaatctaaca gttttactgc tggaagacaa ccagttatat actatacctg ctgggttgcc 480  
  
 tgagtctttg aaagaactta gcctaattca aaacaatata tttcaggtaa ctaaaaacaa 540  
  
 cacttttggg cttaggaact tggaaagact ctatttgggc tggaactgct attttaaatg 600  
  
 taatcaaacc tttaaggtag aagatggggc atttaaaaat cttatacact tgaaggtag 660  
  
 ctcatatctt ttcaataacc ttttctatgt gcccccaaa ctaccaagtt ctctaaggaa 720  
  
 actttttctg agtaatgcca aaatcatgaa catcactcag gaagacttca aaggactgga 780  
  
 aaatttaaca ttactagatc tgagtggaaa ctgtccaagg tgttacaatg ctccatttcc 840  
  
 ttgcacacct tgcaaggaaa actcatccat ccacatacat cctctggctt ttcaaagtct 900  
  
 cacccaactt ctctatctaa acctttccag cacttccctc aggacgattc cttctacctg 960  
  
 gtttgaaaat ctgtcaaact tgaaggaact ccatcttgaa ttcaactatt tagttcaaga 1020

aattgcctcg ggggcatttt taacaaaact acccagttta caaatccttg atttgcctt 1080  
caactttcaa tataaggaat atttacaatt tattaatatt tcctcaaatt tctctaagct 1140  
tcgttctctc aagaagttgc acttaagagg ctatgtgttc cgagaactta aaaagaagca 1200  
tttcgagcat ctccagagtc ttccaaactt ggcaaccatc aacttgggca ttaactttat 1260  
tgagaaaatt gatttcaaag ctttccagaa tttttccaaa ctgcagctta tctatttatc 1320  
aggaaatcgc atagcatctg tattagatgg tacagattat tcctcttggc gaaatcgtct 1380  
tcggaaacct ctctcaacag acgatgatga gtttgatcca cacgtgaatt tttaccatag 1440  
caccaaactt ttaataaagc cacagtgtac tgcttatggc aaggccttgg atttaagttt 1500  
gaacaatatt ttcattattg ggaaaagcca atttgaaggt tttcaggata tcgcctgctt 1560  
aaatctgtcc ttcaatgcca atactcaagt gtttaatggc acagaattct cctccatgcc 1620  
ccacattaaa tatttggatt taaccaacaa cagactagac tttgatgata acaatgcttt 1680  
cagtgatctt cacgatctag aagtgtgga cctgagccac aatgcacact atttcagtat 1740  
agcaggggta acgcaccgtc taggatttat ccagaactta ataaacctca ggggtgttaa 1800  
cctgagccac aatggcattt acaccctcac agaggaaagt gagctgaaaa gcatctcact 1860  
gaaagaattg gttttcagtg gaaatcgtct tgaccatttg tggaatgcaa atgatggcaa 1920  
atactgggtcc atttttaaaa gtctccagaa tttgatacgc ctggacttat catacaataa 1980  
ccttcaacaa atcccaaag gagcattcct caatttgcct cagagcctcc aagagttact 2040  
tatcagtggg aacaaattac gtttctttta ttggacatta ctccagtatt ttctcacct 2100  
tcacttgctg gatttatoga gaaatgagct gtattttcta cccaattgcc tatctaagtt 2160  
tgcacattcc ctggagacac tgctactgag ccataatcat ttctctcacc taccctctgg 2220  
cttctctcc gaagccagga atctggtgca cctggatcta agtttcaaca caataaagat 2280  
gatcaataaa tcctccctgc aaaccaagat gaaaacgaac ttgtctattc tggagctaca 2340  
tggaactat tttgactgca cgtgtgacat aagtgatttt cgaagctggc tagatgaaaa 2400  
tctgaatata acaattccta aattggtaaa tgttatatgt tccaatcctg gggatcaaaa 2460  
atcaaagagt atcatgagcc tagatctcac gacttgtgta tcggatacca ctgcagctgt 2520  
cctgtttttc ctacattcc ttaccacctc catggttatg ttggctgctc tggttcacca 2580  
cctgttttac tgggatgttt ggtttatcta tcacatgtgc tctgctaagt taaaaggcta 2640  
caggacttca tccacatccc aaactttcta tgatgcttat atttcttatg acaccaaaaga 2700  
tgcactgtgt actgactggg taatcaatga actgcgctac caccttgaag agagtgaaga 2760  
caaaagtgtc ctctttgtt tagaggagag ggattgggat ccaggattac ccatcattga 2820  
taacctcatg cagagcataa accagagcaa gaaaacaatc tttgttttaa ccaagaaata 2880

tgccaagagc tggaaacttta aaacagcttt ctacttggcc ttgcagaggc taatggatga 2940  
 gaacatggat gtgattatth tcatcctcct ggaaccagtg ttacagtact cacagtacct 3000  
 gaggcttcgg cagaggatct gtaagagctc catcctccag tggcccaaca atcccaaagc 3060  
 agaaaaacttg ttttggcaaa gtctgaaaaa tgtggtcttg actgaaaatg attcacggta 3120  
 tgacgatttg tacattgatt ccattaggca atactagtga tgggaagtca cgactctgcc 3180  
 atcataaaaa cacacagctt ctctttacaa tgaaccgaat 3220

<210> 56  
 <211> 3220  
 <212> DNA  
 <213> murine

<400> 56  
 attcagagtt ggatgttaag agagaaacaa acgttttacc ttcctttgtc tatagaacat 60  
 ggaaaaacatg cccctcagc catggattct gacgtgcttt tgtctgctgt cctctggaac 120  
 cagtgccatc ttccataaag cgaactattc cagaagctat ccttgtgacg agataaggca 180  
 caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaagtgc cccaaactat 240  
 aggcaagtat gtgacaaaca tagacttgct agacaatgcc attacacata taacgaaaga 300  
 gtcctttcaa aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaaacaaca 360  
 gcacccaaat gaaaataaaa atgggtatgaa tattacagaa ggggcacttc tcagcctaag 420  
 aaatctaaca gttttactgc tggaagacaa ccagttatat actatacctg ctgggttgcc 480  
 tgagtctttg aaagaactta gcctaattca aaacaatata tttcaggtaa ctaaaaacaa 540  
 cacttttggg cttaggaact tggaagact ctatttgggc tggaactgct attttaaatg 600  
 taatcaaacc ttttaaggtag aagatggggc atttaaaaat cttatacact tgaagggtact 660  
 ctcatatct ttcaataacc ttttctatgt gcccccaaa ctaccaagtt ctctaaggaa 720  
 actttttctg agtaatgcca aaatcatgaa catcactcag gaagacttca aaggactgga 780  
 aaatttaaca ttactagatc tgagtggaaa ctgtccaagg tgttacaatg ctccatttcc 840  
 ttgcacacct tgcaaggaaa actcatccat ccacatacat cctctggctt ttcaaagtct 900  
 caccacaactt ctctatctaa acctttccag cacttcctc aggacgattc cttctacctg 960  
 gtttgaaaat ctgtcaaatc tgaaggaaact ccatcttgaa ttcaactatt tagttcaaga 1020  
 aattgcctcg ggggcatttt taacaaaact acccagttta caaatccttg atttgtcctt 1080  
 caactttcaa tataaggaaat atttacaatt tattaatatt tcctcaaatt tctctaagct 1140  
 tcgttctctc aagaagttgc acttaagagg ctatgtgttc cgagaactta aaaagaagca 1200  
 tttcgagcat ctccagagtc ttccaaactt ggcaaccatc aacttgggca ttaactttat 1260

tgagaaaatt gatttcaaag ctttccagaa tttttccaaa ctgcacgtta tctattttatc	1320
aggaaatcgc atagcatctg tattagatgg tacagattat tcctcttggc gaaatcgtct	1380
tcggaaacct ctctcaacag acgatgatga gtttgatcca cacgtgaatt tttaccatag	1440
caccaaacct ttaataaagc cacagtgtac tgcttatggc aaggccttgg atttaagttt	1500
gaacaatatt ttcatatttg ggaaaagcca atttgaaggt tttcaggata tcgcctgctt	1560
aaatctgtcc ttcaatgcc aatactcaagt gtttaaatggc acagaattct cctccatgcc	1620
ccacattaaa tatttggatt taaccaacaa cagactagac tttgatgata acaatgcttt	1680
cagtgatctt cagatctag aagtgtctga cctgagccac aatgcacact atttcagtat	1740
agcaggggta acgcaccgtc taggatttat ccagaactta ataaacctca ggggtgttaa	1800
cctgagccac aatggcattt acaccctcac agaggaaagt gagctgaaaa gcctctcact	1860
gaaagaattg gttttcagt gaaatcgtct tgaccatttg tggaatgcaa atgatggcaa	1920
atactggctc atttttaaaa gtctccagaa tttgatacgc ctggacttat catacataa	1980
ccttcaacaa atcccaaag gagcattcct caatttgcct cagagcctcc aagagttact	2040
tatcagtggg aacaaattac gtttctttaa ttggacatta ctccagtatt ttctcacct	2100
tcacttgctg gatttatcga gaaatgagct gtattttcta cccaattgcc tatctaagtt	2160
tgacatttcc ctggagacac tgctactgag ccataatcat ttctctcacc taccctctgg	2220
cttctctccc gaagccagga atctggtgca cctggatcta agtttcaaca caataaagat	2280
gatcaataaa tcctccctgc aaaccaagat gaaaacgaac ttgtctattc tggagctaca	2340
tgggaactat ttgactgca cgtgtgacat aagtgtattt cgaagctggc tagatgaaaa	2400
tctgaatatc acaattccta aattggtaaa tgttatatgt tccaatcctg gggatcaaaa	2460
atcaaagagt atcatgagcc tagatctcac gacttgtgta tcggatacca ctgcagctgt	2520
cctgtttttc ctcacattcc ttaccacctc catggttatg ttggctgctc tggttcacca	2580
cctgtttttac tgggatgttt gttttatcta tcacatgtgc tctgctaagt taaaaggcta	2640
caggacttca tccacatccc aaactttcta tgatgcttat atttcttatg acaccaaaga	2700
tgcactctgt actgactggg taatcaatga actgcctac caccttgaag agagtgaaga	2760
caaaagtgtc ctctttgtt tagaggagag ggattgggat ccaggattac ccatcattga	2820
taacctcatg cagagcataa accagagcaa gaaaacaatc tttgttttaa ccaagaaata	2880
tgccaagagc tggaacttta aaacagcttt ctacttggcc ttgcagaggc taatggatga	2940
gaacatggat gtgattattt tcatcctcct ggaaccagtg ttacagtact cacagtacct	3000
gaggtctcgg cagaggatct gtaagagctc catcctccag tggcccaaca atcccaaagc	3060
agaaaacttg ttttggcaaa gtctgaaaaa tgtggctctg actgaaaatg attcacggta	3120
tgacgatttg tacattgatt ccattaggca atactagtga tgggaagtca cgactctgcc	3180



atcataaaaa cacacagctt ctccttataaa tgaaccgaat

3220

&lt;210&gt; 57

&lt;211&gt; 1032

&lt;212&gt; PRT

&lt;213&gt; murine

&lt;400&gt; 57

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
 1 5 10 15

Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
 20 25 30

Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
 35 40 45

Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
 50 55 60

Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
 65 70 75 80

Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
 85 90 95

Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
 100 105 110

Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
 115 120 125

Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
 130 135 140

Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
 145 150 155 160

Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
 165 170 175

Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
 180 185 190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
 195 200 205

Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
 210 215 220

Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
 225 230 235 240

Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
 245 250 255

Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
 260 265 270

Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
 275 280 285  
 Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
 290 295 300  
 Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
 305 310 315 320  
 Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
 325 330 335  
 Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
 340 345 350  
 Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
 355 360 365  
 Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
 370 375 380  
 Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
 385 390 395 400  
 Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
 405 410 415  
 Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
 420 425 430  
 Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp  
 435 440 445  
 Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
 450 455 460  
 Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
 465 470 475 480  
 Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
 485 490 495  
 Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
 500 505 510  
 Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu  
 515 520 525  
 Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu  
 530 535 540  
 His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
 545 550 555 560  
 Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
 565 570 575  
 Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
 580 585 590  
 Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly

595 600 605  
 Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser  
 610 615 620  
 Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn  
 625 630 635 640  
 Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser  
 645 650 655  
 Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp  
 660 665 670  
 Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg  
 675 680 685  
 Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser  
 690 695 700  
 Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser  
 705 710 715 720  
 Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe  
 725 730 735  
 Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys  
 740 745 750  
 Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr  
 755 760 765  
 Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile  
 770 775 780  
 Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln  
 785 790 795 800  
 Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp  
 805 810 815  
 Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met  
 820 825 830  
 Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp  
 835 840 845  
 Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser  
 850 855 860  
 Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys  
 865 870 875 880  
 Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu  
 885 890 895  
 Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp  
 900 905 910  
 Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn  
 915 920 925  
 Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser

930                      935                      940  
 Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp  
 945                      950                      955                      960  
 Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln  
                     965                      970                      975  
 Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile  
                     980                      985                      990  
 Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser  
                     995                      1000                      1005  
 Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp  
                     1010                      1015                      1020  
 Leu Tyr Ile Asp Ser Ile Arg Gln Tyr  
                     1025                      1030

<210> 58  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 58

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
 1                      5                      10                      15  
 Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
                     20                      25                      30  
 Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
                     35                      40                      45  
 Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
                     50                      55                      60  
 Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
                     65                      70                      75                      80  
 Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
                     85                      90                      95  
 Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
                     100                      105                      110  
 Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
                     115                      120                      125  
 Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
                     130                      135                      140  
 Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
                     145                      150                      155                      160  
 Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
                     165                      170                      175  
 Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
                     180                      185                      190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
 195 200 205  
 Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
 210 215 220  
 Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
 225 230 235 240  
 Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
 245 250 255  
 Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
 260 265 270  
 Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
 275 280 285  
 Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
 290 295 300  
 Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
 305 310 315 320  
 Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
 325 330 335  
 Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
 340 345 350  
 Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
 355 360 365  
 Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
 370 375 380  
 Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
 385 390 395 400  
 Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
 405 410 415  
 Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
 420 425 430  
 Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp  
 435 440 445  
 Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
 450 455 460  
 Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
 465 470 475 480  
 Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
 485 490 495  
 Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
 500 505 510  
 Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu

515	520	525
Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu		
530	535	540
His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser		
545	550	555
Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn		
565	570	575
Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu		
580	585	590
Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly		
595	600	605
Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser		
610	615	620
Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn		
625	630	635
Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser		
645	650	655
Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp		
660	665	670
Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg		
675	680	685
Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser		
690	695	700
Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser		
705	710	715
Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe		
725	730	735
Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys		
740	745	750
Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr		
755	760	765
Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile		
770	775	780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln		
785	790	795
Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp		
805	810	815
Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met		
820	825	830
Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp		
835	840	845
Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser		

850                      855                      860  
 Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys  
 865                      870                      875                      880  
 Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu  
                     885                      890                      895  
 Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp  
                     900                      905                      910  
 Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn  
                     915                      920                      925  
 Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser  
                     930                      935                      940  
 Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp  
 945                      950                      955                      960  
 Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln  
                     965                      970                      975  
 Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile  
                     980                      985                      990  
 Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser  
                     995                      1000                      1005  
 Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp  
                     1010                      1015                      1020  
 Leu Tyr Ile Asp Ser Ile Arg Gln Tyr  
                     1025                      1030

<210> 59  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 59

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
 1                      5                      10                      15  
 Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
                     20                      25                      30  
 Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
                     35                      40                      45  
 Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
                     50                      55                      60  
 Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
 65                      70                      75                      80  
 Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
                     85                      90                      95  
 Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
                     100                      105                      110

Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
 115 120 125  
 Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
 130 135 140  
 Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
 145 150 155 160  
 Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
 165 170 175  
 Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
 180 185 190  
 Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
 195 200 205  
 Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
 210 215 220  
 Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
 225 230 235 240  
 Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
 245 250 255  
 Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
 260 265 270  
 Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
 275 280 285  
 Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
 290 295 300  
 Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
 305 310 315 320  
 Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
 325 330 335  
 Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
 340 345 350  
 Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
 355 360 365  
 Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
 370 375 380  
 Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
 385 390 395 400  
 Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
 405 410 415  
 Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
 420 425 430  
 Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp



435 440 445  
 Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
 450 455 460  
 Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
 465 470 475 480  
 Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
 485 490 495  
 Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
 500 505 510  
 Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu  
 515 520 525  
 Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu  
 530 535 540  
 His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
 545 550 555 560  
 Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
 565 570 575  
 Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
 580 585 590  
 Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly  
 595 600 605  
 Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser  
 610 615 620  
 Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn  
 625 630 635 640  
 Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser  
 645 650 655  
 Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp  
 660 665 670  
 Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg  
 675 680 685  
 Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser  
 690 695 700  
 Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser  
 705 710 715 720  
 Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe  
 725 730 735  
 Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys  
 740 745 750  
 Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr  
 755 760 765  
 Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile

```

      770              775              780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln
785              790              795              800

Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp
      805              810              815

Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met
      820              825              830

Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp
      835              840              845

Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser
      850              855              860

Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys
865              870              875              880

Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu
      885              890              895

Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp
      900              905              910

Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn
      915              920              925

Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser
      930              935              940

Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp
945              950              955              960

Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln
      965              970              975

Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile
      980              985              990

Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser
      995              1000              1005

Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp
      1010              1015              1020

Leu Tyr Ile Asp Ser Ile Arg Gln Tyr
      1025              1030

```

&lt;210&gt; 60

&lt;211&gt; 3352

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

aggctggtat aaaaatctta cttcctctat tctctgagcc gctgctgccc ctgtgggaag 60

ggacctcgag tgtgaagcat ccttcctgt agctgctgtc cagtctgccc gccagaccct 120

ctggagaagc cctgcccc cagcatgggt ttctgccgca gcgcctgca cccgctgtct 180

ctcctggtgc	aggccatcat	gctggccatg	accctggccc	tgggtacctt	gcctgccttc	240
ctaccctgtg	agctccagcc	ccacggcctg	gtgaactgca	actggctgtt	cctgaagtct	300
gtgcccact	tctccatggc	agcaccccg	ggcaatgtca	ccagcctttc	cttgtcctcc	360
aaccgcatcc	accacctcca	tgattctgac	tttggccacc	tgcccagcct	gcggcatctc	420
aacctcaagt	ggaactgccc	gccggttggc	ctcagcccca	tgcaattccc	ctgccacatg	480
accatcgagc	ccagcacctt	cttggctgtg	cccaccctgg	aagagctaaa	cctgagctac	540
aacaacatca	tgactgtgcc	tgcgctgccc	aaatccctca	tatccctgtc	cctcagccat	600
accaacatcc	tgatgctaga	ctctgccagc	ctcgccggcc	tgcatgccct	gcgcttccta	660
ttcatggacg	gcaactgtta	ttacaagaac	ccctgcaggc	aggcaactgga	ggtggccccg	720
ggtgccctcc	ttggcctggg	caacctcacc	cacctgtcac	tcaagtacaa	caacctcact	780
gtggtgcccc	gcaacctgcc	ttccagcctg	gagtatctgc	tggtgtccta	caaccgcatc	840
gtcaaaactgg	cgcctgagga	cctggccaat	ctgaccgccc	tgctgtgtgt	cgatgtgggc	900
ggaaattgcc	gccgctgcga	ccacgctccc	aaccctgca	tggagtgcc	tcgtcacttc	960
ccccagctac	atcccgatac	cttcagccac	ctgaccgctc	ttgaaggcct	ggtgttgaag	1020
gacagttctc	tctcctggct	gaatgccagt	tggttcctgt	ggctgggaaa	cctccgagtg	1080
ctggacctga	gtgagaactt	cctctacaaa	tgcatcacta	aaaccaaggc	cttccagggc	1140
ctaacacagc	tgcgcaagct	taacctgtcc	ttcaattacc	aaaagagggg	gtcctttgcc	1200
cacctgtctc	tggcccttc	cttcgggagc	ctggctgccc	tgaaggagct	ggacatgcac	1260
ggcatcttct	tccgctcact	cgatgagacc	acgctccggc	cactggcccg	cctgcccattg	1320
ctccagactc	tgctgtgca	gatgaacttc	atcaaccagg	cccagctcgg	catcttcagg	1380
gccttccctg	gcctgcgcta	cgtggacctg	tcggacaacc	gcatcagcgg	agcttcggag	1440
ctgacagcca	ccatggggga	ggcagatgga	ggggagaagg	tctggctgca	gcctggggac	1500
cttgtccggg	ccccagtgga	cactcccagc	tctgaagact	tcaggcccaa	ctgcagcacc	1560
ctcaacttca	ccttggatct	gtcacggaac	aacctggtga	ccgtgcagcc	ggagatgttt	1620
gccagctct	cgcacctgca	gtgcctgcgc	ctgagccaca	actgcatctc	gcaggcagtc	1680
aatggctccc	agttcctgcc	gctgaccggg	ctgcaggtgc	tagacctgtc	ccgcaataag	1740
ctggacctct	accacgagca	ctcattcaag	gagctaccgc	gactggaggc	cctggacctc	1800
agctacaaca	gccagccctt	tggcatgcag	ggcgtggggc	acaacttcag	cttcgtgggt	1860
cacctgcgca	cctgcgcca	cctcagcctg	gccacaaca	acatccacag	ccaagtgtcc	1920
cagcagctct	gcagtacgtc	gctgcggggc	ctggacttca	gcggcaatgc	actgggccat	1980
atgtgggccc	aggagacct	ctatctgcac	ttcttccaag	gcctgagcgg	tttgatctgg	2040
ctggacttgt	cccagaaccg	cctgcacacc	ctcctgcccc	aaacctgcg	caacctcccc	2100

aagagcctac aggtgctgcg tctccgtgac aattacctgg ccttctttaa gtggtggagc 2160  
ctccacttcc tgcccaaact ggaagtcctc gacctggcag gaaaccggct gaaggccctg 2220  
accaatggca gcctgcctgc tggcaccgag ctccggaggc tggatgtcag ctgcaacagc 2280  
atcagcttcg tggcccccg cttcttttcc aaggccaagg agctgcgaga gctcaacctt 2340  
agcgccaacg ccctcaagac agtggaccac tcctggtttg ggccccctggc gagtgccttg 2400  
caaatactag atgtaagcgc caacctctcg cactgcgctt gtggggcggc ctttatggac 2460  
ttcctgctgg aggtgcaggc tgcctgccc ggtctgccc gccgggtgaa gtgtggcagt 2520  
ccgggccagc tccagggcct cagcatcttt gcacaggacc tgcgcctctg cctggatgag 2580  
gccctctcct gggactgttt cgccctctcg ctgctggctg tggtctctggg cctgggtgtg 2640  
cccattgctgc atcacctctg tggtggggac ctctggtact gcttccacct gtgcctggcc 2700  
tggtctccct ggcgggggcg gcaaagtggg cgagatgagg atgccctgcc ctacgatgcc 2760  
ttcgtggtct tcgacaaaac gcagagcgca gtggcagact ggggtgtacaa cgagcttcgg 2820  
gggcagctgg aggagtgcg tgggcgctgg gcactccgcc tgtgcctgga ggaacgcgac 2880  
tggtgcctg gaaaaacct ctttgagaac ctgtgggcct cggctctatgg cagccgcaag 2940  
acgtgttttg tgctggccc cacggaccgg gtcagtggtc tcttgcgcgc cagcttcttg 3000  
ctggcccagc agcgctgct ggaggaccgc aaggacgtcg tgggtgctggt gatcctgagc 3060  
cctgaaggcc gccgctccc ctacgtgcgg ctgcgccagc gcctctgcc ccagagtgtc 3120  
ctcctctggc cccaccagcc cagtggtcag cgcagcttct gggcccagct gggcatggcc 3180  
ctgaccaggg acaaccacca cttctataac cggaacttct gccagggacc cacggccgaa 3240  
tagccgtgag ccggaatcct gcacggtgcc acctccacac tcacctcacc tctgcctgcc 3300  
tggtctgacc ctcccctgct cgctccctc accccacacc tgacacagag ca 3352

&lt;210&gt; 61

&lt;211&gt; 3257

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 61

ccgctgctgc ccctgtggga agggacctcg agtgtgaagc atccttccct gtagctgctg 60  
tcagctctgc ccgccagacc ctctggagaa gccctgccc ccagcatgg gtttctgccg 120  
cagcgccctg caccgctgt ctctcctggt gcaggccatc atgctggcca tgacctggc 180  
cctgggtacc ttgcctgcct tcctaccctg tgagctccag cccacggcc tggtgaaactg 240  
caactggctg ttctgaagt ctgtgcccc cttctccatg gcagcaccgc gtggcaatgt 300  
caccagcctt tccttgcct ccaaccgcat ccaccacctc catgattctg actttgccc 360

cctgcccagc	ctgcggcatc	tcaacctcaa	gtggaactgc	ccgccggttg	gcctcagccc	420
catgcacttc	ccctgccaca	tgaccatcga	gcccagcacc	ttcttggttg	tgcccaccct	480
ggaagagcta	aacctgagct	acaacaacat	catgactgtg	cctgcgctgc	ccaaatccct	540
catatccctg	tcctcagcc	ataccaacat	cctgatgcta	gactctgcca	gcctcgccgg	600
cctgcatgcc	ctgcgcttcc	tattcatgga	cggcaactgt	tattacaaga	accctgcag	660
gcaggcactg	gaggtggccc	cgggtgccct	ccttggcctg	ggcaacctca	cccacctgtc	720
actcaagtac	aacaacctca	ctgtggtgcc	ccgcaacctg	ccttccagcc	tggagtatct	780
gctgttgctc	tacaaccgca	tcgtcaaact	ggcgctgag	gacctggcca	atctgaccgc	840
cctgcgtgtg	ctcgatgtgg	gcggaaattg	ccgccgctgc	gaccacgctc	ccaacccctg	900
catggagtgc	cctcgtcact	tcctccagct	acatcccgat	accttcagcc	acctgagccg	960
tcttgaaggc	ctggtgttga	aggacagttc	tctctcctgg	ctgaatgcca	gttggttccg	1020
tgggctggga	aacctccgag	tgctggacct	gagtgagaac	ttcctctaca	aatgcatcac	1080
taaaaccaag	gccttccagg	gcctaacaca	gctgcgcaag	cttaacctgt	ccttcaatta	1140
ccaaaagagg	gtgtcctttg	cccacctgtc	tctggccoct	tccttcggga	gcctggtcgc	1200
cctgaaggag	ctggacatgc	acggcatctt	cttccgctca	ctcgatgaga	ccacgctccg	1260
gccactggcc	cgctgccc	tgctccagac	tctgcgtctg	cagatgaact	tcacaaacca	1320
ggcccagctc	ggcatcttca	gggccttccc	tggcctgcgc	tacgtggacc	tgctggacaa	1380
ccgcatcagc	ggagcttcgg	agctgacagc	caccatgggg	gaggcagatg	gaggggagaa	1440
ggtctggctg	cagcctgggg	accttgcctc	ggccccagtg	gacactccca	gctctgaaga	1500
cttcaggccc	aactgcagca	ccctcaactt	caccttggtg	ctgtcacgga	acaacctggt	1560
gaccgtgcag	ccggagatgt	ttgcccagct	ctcgacacctg	cagtgcctgc	gcctgagcca	1620
caactgcac	tcgcaggcag	tcaatggctc	ccagttcctg	ccgctgaccg	gtctgcagggt	1680
gctagacctg	tcacacaata	agctggacct	ctaccacgag	cactcattca	cggagctacc	1740
acgactggag	gccctggacc	tcagctacaa	cagccagccc	tttggcatgc	agggcggtgg	1800
ccacaacttc	agcttcgtgg	ctcacctgcg	caccctgcgc	cacctcagcc	tgggccacaa	1860
caacatccac	agccaagtgt	cccagcagct	ctgcagtacg	tcgctgcggg	ccctggactt	1920
cagcggcaat	gcactggggc	atatgtgggc	cgaggagagac	ctctatctgc	acttcttcca	1980
aggcctgagc	ggtttgatct	ggctggactt	gtcccagaac	cgctgcaca	ccctcctgcc	2040
ccaaacccctg	cgcaacctcc	ccaagagcct	acaggtgctg	cgtctccgtg	acaattacct	2100
ggccttcttt	aagtgggtga	gcctccactt	cctgccc aaa	ctggaagtcc	tcgacctggc	2160
aggaaaccag	ctgaaggccc	tgaccaatgg	cagcctgcct	gctggcacc	ggctccggag	2220
gctggatgtc	agctgcaaca	gcacagctt	cgtggccccc	ggcttctttt	ccaaggccaa	2280

ggagctgcga gagctcaacc ttagcgccaa cgccctcaag acagtggacc actcctgggt 2340  
 tgggcccctg gcgagtggcc tgcaaatact agatgtaagc gccaacccctc tgcactgcgc 2400  
 ctgtggggcg gcctttatgg acttctctgt ggagggtgcag gctgccgtgc ccggtctgcc 2460  
 cagccgggtg aagtgtggca gtccgggcca gctccagggc ctcagcatct ttgcacagga 2520  
 cctgcgcctc tgcctggatg aggcctctc ctgggactgt ttgcctctc cgctgctggc 2580  
 tgtggctctg ggctgggtg tgcccatgct gcatcacctc tgtggctggg acctctggta 2640  
 ctgcttcac ctgtgcctgg cctggcttcc ctggcggggg cggcaaagtg ggcgagatga 2700  
 ggatgcctg ccctacgatg ccttcgtggt cttcgacaaa acgcagagcg cagtggcaga 2760  
 ctgggtgtac aacgagcttc gggggcagct ggaggagtgc cgtgggcgct gggcactccg 2820  
 cctgtgcctg gaggaacgcg actggctgcc tggcaaaacc ctctttgaga acctgtgggc 2880  
 ctcggtctat ggcagccgca agacgtgtt tgtgctggcc cacacggacc gggtcagtgg 2940  
 tctcttgccg gccagcttcc tgctggccca gcagcgctg ctggaggacc gcaaggacgt 3000  
 cgtggtgctg gtgacctga gccctgacgg ccgcgctcc cgctacgtgc ggctgcgcca 3060  
 gcgcctctgc cgccagagtg tcctcctctg gcccaccag ccagtggtc agcgcagctt 3120  
 ctgggcccag ctgggcatgg ccctgaccag ggacaaccac cacttctata accggaactt 3180  
 ctgccaggga cccacggccg aatagccgtg agccggaatc ctgcacggtg ccacctccac 3240  
 actcacctca cctctgc 3257

&lt;210&gt; 62

&lt;211&gt; 1032

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 62

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln  
 1 5 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
 50 55 60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp  
 65 70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp  
 85 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met

100	105	110
Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu		
115	120	125
Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser		
130	135	140
Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser		
145	150	155
160		
Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly		
165	170	175
Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro		
180	185	190
Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr		
195	200	205
Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr		
210	215	220
Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu		
225	230	235
240		
Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg		
245	250	255
Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe		
260	265	270
Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly		
275	280	285
Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe		
290	295	300
Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu		
305	310	315
320		
Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu		
325	330	335
Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala		
340	345	350
His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu		
355	360	365
Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu		
370	375	380
Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met		
385	390	395
400		
Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly		
405	410	415
Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu		
420	425	430
Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu		

435 440 445  
 Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu  
 450 455 460  
 Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser  
 465 470 475 480  
 Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser  
 485 490 495  
 His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val  
 500 505 510  
 Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu  
 515 520 525  
 Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu  
 530 535 540  
 Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly  
 545 550 555 560  
 Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr  
 565 570 575  
 Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser  
 580 585 590  
 Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn  
 595 600 605  
 Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe  
 610 615 620  
 Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu  
 625 630 635 640  
 His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln  
 645 650 655  
 Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser  
 660 665 670  
 Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg  
 675 680 685  
 Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg  
 690 695 700  
 Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe  
 705 710 715 720  
 Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala  
 725 730 735  
 Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu  
 740 745 750  
 Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala  
 755 760 765  
 Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu



```

      770              775              780
Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser
785              790              795              800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp
      805              810              815

Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val
      820              825              830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His
      835              840              845

Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp
      850              855              860

Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln
865              870              875              880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu
      885              890              895

Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp
      900              905              910

Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr
      915              920              925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
      930              935              940

Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945              950              955              960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg
      965              970              975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
      980              985              990

Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln
      995              1000              1005

Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg
1010              1015              1020

Asn Phe Cys Gln Gly Pro Thr Ala Glu
1025              1030

```

```

<210> 63
<211> 1032
<212> PRT
<213> Homo sapiens

```

```

<400> 63

```

```

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
1          5          10          15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20          25          30

```

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
 35 40 45  
 Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
 50 55 60  
 Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp  
 65 70 75 80  
 Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp  
 85 90 95  
 Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met  
 100 105 110  
 Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu  
 115 120 125  
 Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser  
 130 135 140  
 Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser  
 145 150 155 160  
 Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu  
 225 230 235 240  
 Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe  
 260 265 270  
 Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe  
 290 295 300  
 Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala  
 340 345 350  
 His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu

355 360 365  
 Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu  
 370 375 380  
 Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly  
 405 410 415  
 Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu  
 420 425 430  
 Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu  
 435 440 445  
 Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu  
 450 455 460  
 Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser  
 465 470 475 480  
 Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser  
 485 490 495  
 His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val  
 500 505 510  
 Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu  
 515 520 525  
 Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu  
 530 535 540  
 Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly  
 545 550 555 560  
 Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr  
 565 570 575  
 Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser  
 580 585 590  
 Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn  
 595 600 605  
 Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe  
 610 615 620  
 Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu  
 625 630 635 640  
 His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln  
 645 650 655  
 Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser  
 660 665 670  
 Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln  
 675 680 685  
 Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg

690 695 700  
 Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe  
 705 710 715 720  
 Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala  
 725 730 735  
 Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu  
 740 745 750  
 Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala  
 755 760 765  
 Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu  
 770 775 780  
 Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser  
 785 790 795 800  
 Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp  
 805 810 815  
 Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val  
 820 825 830  
 Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His  
 835 840 845  
 Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp  
 850 855 860  
 Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln  
 865 870 875 880  
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu  
 885 890 895  
 Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp  
 900 905 910  
 Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr  
 915 920 925  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
 930 935 940  
 Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
 945 950 955 960  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg  
 965 970 975  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val  
 980 985 990  
 Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln  
 995 1000 1005  
 Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg  
 1010 1015 1020  
 Asn Phe Cys Gln Gly Pro Thr Ala Glu

1025                      1030  
 <210> 64  
 <211> 333  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 64  
  
 Met Pro Met Lys Trp Ser Gly Trp Arg Trp Ser Trp Gly Pro Ala Thr  
 1                      5                      10                      15  
  
 His Thr Ala Leu Pro Pro Pro Gln Gly Phe Cys Arg Ser Ala Leu His  
                     20                      25                      30  
  
 Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu Ala  
                     35                      40                      45  
  
 Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His Gly  
                     50                      55                      60  
  
 Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe Ser  
 65                      70                      75                      80  
  
 Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser Asn  
                     85                      90                      95  
  
 Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser Leu  
                     100                      105                      110  
  
 Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser Pro  
                     115                      120                      125  
  
 Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu Ala  
                     130                      135                      140  
  
 Val Pro Thr Leu Glu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met Thr  
 145                      150                      155                      160  
  
 Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His Thr  
                     165                      170                      175  
  
 Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala Leu  
                     180                      185                      190  
  
 Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys Arg  
                     195                      200                      205  
  
 Gln Ala Leu Glu Val Ala Pro Gly Ala Leu Leu Gly Leu Gly Asn Leu  
                     210                      215                      220  
  
 Thr His Leu Ser Leu Lys Tyr Asn Asn Leu Thr Val Val Pro Arg Asn  
 225                      230                      235                      240  
  
 Leu Pro Ser Ser Leu Glu Tyr Leu Leu Leu Ser Tyr Asn Arg Ile Val  
                     245                      250                      255  
  
 Lys Leu Ala Pro Glu Asp Leu Ala Asn Leu Thr Ala Leu Arg Val Leu  
                     260                      265                      270  
  
 Asp Val Gly Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys  
                     275                      280                      285

Met Glu Cys Pro Arg His Phe Pro Gln Leu His Pro Asp Thr Phe Ser  
 290 295 300

His Leu Ser Arg Leu Glu Gly Leu Val Leu Lys Asp Ser Ser Leu Ser  
 305 310 315 320

Trp Leu Asn Ala Ser Trp Phe Arg Gly Leu Gly Asn Leu  
 325 330

<210> 65

<211> 216

<212> PRT

<213> Homo sapiens

<400> 65

Met Leu Tyr Ser Ser Cys Lys Ser Arg Leu Leu Asp Ser Val Glu Gln  
 1 5 10 15

Asp Phe His Leu Glu Ile Ala Lys Lys Gly Phe Cys Arg Ser Ala Leu  
 20 25 30

His Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu  
 35 40 45

Ala Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His  
 50 55 60

Gly Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe  
 65 70 75 80

Ser Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser  
 85 90 95

Asn Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser  
 100 105 110

Leu Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser  
 115 120 125

Pro Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu  
 130 135 140

Ala Val Pro Thr Leu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met  
 145 150 155 160

Thr Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His  
 165 170 175

Thr Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala  
 180 185 190

Leu Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys  
 195 200 205

Arg Gln Ala Leu Glu Val Ala Pro  
 210 215

<210> 66

<211> 117  
 <212> PRT  
 <213> Homo sapiens

<400> 66

```

Met Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala
1              5              10              15

Phe Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp
              20              25              30

Leu Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly
              35              40              45

Asn Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His
              50              55              60

Asp Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys
65              70              75              80

Trp Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His
              85              90              95

Met Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu
              100              105              110

Leu Asn Leu Ser Tyr
              115
  
```

<210> 67  
 <211> 1032  
 <212> PRT  
 <213> Homo sapiens

<400> 67

```

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
1              5              10              15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
              20              25              30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
              35              40              45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn
              50              55              60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp
65              70              75              80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
              85              90              95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met
              100              105              110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
              115              120              125
  
```

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser  
 130 135 140  
 Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser  
 145 150 155 160  
 Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu  
 225 230 235 240  
 Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe  
 260 265 270  
 Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe  
 290 295 300  
 Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala  
 340 345 350  
 His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu  
 355 360 365  
 Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu  
 370 375 380  
 Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly  
 405 410 415  
 Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu  
 420 425 430  
 Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu  
 435 440 445  
 Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu



450                      455                      460  
 Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser  
 465                      470                      475                      480  
 Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser  
                     485                      490                      495  
 His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val  
                     500                      505                      510  
 Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu  
                     515                      520                      525  
 Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu  
                     530                      535                      540  
 Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly  
 545                      550                      555                      560  
 Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr  
                     565                      570                      575  
 Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser  
                     580                      585                      590  
 Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn  
                     595                      600                      605  
 Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe  
                     610                      615                      620  
 Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu  
 625                      630                      635                      640  
 His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln  
                     645                      650                      655  
 Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser  
                     660                      665                      670  
 Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln  
                     675                      680                      685  
 Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg  
                     690                      695                      700  
 Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe  
 705                      710                      715                      720  
 Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala  
                     725                      730                      735  
 Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu  
                     740                      745                      750  
 Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala  
                     755                      760                      765  
 Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu  
                     770                      775                      780  
 Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser

785                      790                      795                      800  
 Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp  
                                  805                      810                      815  
  
 Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val  
                                  820                      825                      830  
  
 Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His  
                                  835                      840                      845  
  
 Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp  
                                  850                      855                      860  
  
 Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln  
 865                                   870                      875                      880  
  
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu  
                                  885                      890                      895  
  
 Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp  
                                  900                      905                      910  
  
 Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr  
                                  915                      920                      925  
  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
                                  930                      935                      940  
  
 Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
 945                                   950                      955                      960  
  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg  
                                  965                      970                      975  
  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val  
                                  980                      985                      990  
  
 Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln  
                                  995                      1000                      1005  
  
 Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg  
                                  1010                      1015                      1020  
  
 Asn Phe Cys Gln Gly Pro Thr Ala Glu  
                                  1025                      1030

&lt;210&gt; 68

&lt;211&gt; 3200

&lt;212&gt; DNA

&lt;213&gt; murine

&lt;400&gt; 68

tgtcagaggg agcctcggga gaatcctcca tctcccaaca tggttctccg tcgaaggact	60
ctgcacccct tgtccctcct ggtacaggct gcagtgtctgg ctgagactct ggccctgggt	120
accctgcctg ccttcctacc ctgtgagctg aagcctcatg gcctgggtgga ctgcaattgg	180
ctgttcctga agtctgtacc ccgtttctct gcggcagcat cctgtctcaa catcaccgcg	240
ctctccttga tctccaaccg tatccaccac ctgcacaact ccgacttcgt ccacctgtcc	300

aacctgcggc agctgaacct caagtggaac tgtccacca ctggccttag cccctgcac 360  
ttctcttgcc acatgaccat tgagcccaga accttcctgg ctatgcgtac actggaggag 420  
ctgaacctga gctataatgg taccacct gtgccccgac tgcccagctc cctgggtgaat 480  
ctgagcctga gccacaccaa catcctgggt ctatagctga acagcctcgc cggcctatac 540  
agcctgcgcg ttctcttcat ggacgggaac tgctactaca agaaccctg cacaggagcg 600  
gtgaaggtga cccagggcg cctcctgggc ctgagcaatc tcaccatct gtctctgaag 660  
tataacaacc tcacaaaggt gcccggccaa ctgccccca gcctggagta cctcctgggtg 720  
tcctataacc tcattgtcaa gctggggcct gaagacctgg ccaatctgac ctcccttcga 780  
gtacttgatg tgggtgggaa ttgctgcgc tgcgaccatg ccccaatcc ctgtatagaa 840  
tgtggccaaa agtcctcca cctgcacct gagaccttc atcacctgag ccatctggaa 900  
ggcctgggtgc tgaaggacag ctctctccat aactgaact cttcctgggt ccaaggctg 960  
gtcaacctct cgggtgctga cctaagcgag aactttctct atgaaagcat caaccacacc 1020  
aatgcctttc agaacctaac ccgctgcgc aagctcaacc tgccttcaa ttaccgcaag 1080  
aaggatcct ttgcccgcct ccacctggca agttccttca agaacctgg gtactgcag 1140  
gagctgaaca tgaacggcat cttcttcgc togtcaaca agtacacgct cagatggctg 1200  
gccgatctgc ccaaactcca cactctgcat cttcaaata acttcatcaa ccaggcacag 1260  
ctcagcatct ttggtacctt ccgagccctt cgctttgtgg acttgtcaga caatcgcatc 1320  
agtgggcctt caacgctgtc agaagccacc cctgaagagg cagatgatgc agagcaggag 1380  
gagctgttgt ctgcggatcc tcaccagct ccactgagca cccctgcttc taagaacttc 1440  
atggacaggt gtaagaactt caagttcacc atggacctgt ctggaacaa cctgggtgact 1500  
atcaagccag agatgttgt caatctctca cgctccagt gtcttagcct gagccacaac 1560  
tcattgcac aggtgtcaa tggctctcag ttctgccc tgactaatct gcagggtgtg 1620  
gacctgtccc ataacaaact ggactgttac cactggaaat cgttcagtga gctaccacag 1680  
ttgcaggccc tggacctgag ctacaacagc cagcccttta gcatgaaggg tataggccac 1740  
aatttcagtt ttgtggccca tctgtccatg ctacacagcc ttagcctggc acacaatgac 1800  
attcataccc gtgtgtctc acatctcaac agcaactcag tgaggtttct tgacttcagc 1860  
ggcaacggta tggccgcat gtgggatgag gggggcctt atctccattt cttccaaggc 1920  
ctgagtggcc tgctgaagct ggacctgtct caaataacc tgcatatcct ccggccccag 1980  
aaccttgaca acctcccaa gagcctgaag ctgctgagcc tccgagacaa ctacctatct 2040  
ttctttaact ggaccagtct gtccttctg ccaacctgg aagtcctaga cctggcaggc 2100  
aaccagctaa aggcctgac caatggcacc ctgcctaag gcaccctct ccagaaactg 2160

gatgtcagca gcaacagtat cgtctctgtg gtcccagcct tcttcgctct ggcggtcgag 2220  
ctgaaagagg tcaacctcag ccacaacatt ctcaagacgg tggatcgctc ctggtttggg 2280  
cccattgtga tgaacctgac agttctagac gtgagaagca accctctgca ctgtgcctgt 2340  
ggggcagcct tcgtagactt actgttggag gtgcagacca aggtgcctgg cctggctaata 2400  
gggtggaagt gtggcagccc cggccagctg cagggccgta gcatcttcgc acaggacctg 2460  
cggctgtgcc tggatgaggt cctctcttgg gactgctttg gcctttcact cttggctgtg 2520  
gccgtgggca tgggtgtgcc tatactgcac catctctgcg gctgggacgt ctggtactgt 2580  
tttcatctgt gcctggcatg gctacctttg ctggcccga gccgacgcag cgcccaagct 2640  
ctccccatg atgccttctt ggtgttcgat aaggcacaga gcgcagttgc ggactgggtg 2700  
tataacgagc tgcgggtgcg gctggaggag cggcgcggtc gccgagccct acgcttgtgt 2760  
ctggaggacc gagattggct gcctggccag acgctcttcg agaacctctg ggcttccatc 2820  
tatgggagcc gcaagactct atttgtgtg gccacacgg accgcgtcag tggcctcctg 2880  
cgcaccagct tcctgtggc tcagcagcgc ctgttgaag accgcaagga cgtgggtgtg 2940  
ttggtgatcc tgcgtccgga tgcccaccgc tcccgctatg tgcgactgcg ccagcgtctc 3000  
tgccgccaga gtgtgctctt ctggccccag cagcccaacg ggcagggggg cttctggggc 3060  
cagctgagta cagccctgac tagggacaac cgccacttct ataaccagaa cttctgccgg 3120  
ggacctacag cagaatagct cagagcaaca gctggaaaca gctgcatctt catgcctggt 3180  
tcccgagttg ctctgcctgc 3200

&lt;210&gt; 69

&lt;211&gt; 3471

&lt;212&gt; DNA

&lt;213&gt; murine

&lt;400&gt; 69

tgaaagtgtc acttcctcaa ttctctgaga gaccctgggtg tggaacatca ttctctgccg 60  
cccagtttgt cagagggagc ctggggagaa tcctccatct cccaacatgg ttctccgtcg 120  
aaggactctg cacccttctt cctcctggt acaggctgca gtgctggctg agactctggc 180  
cctgggtacc ctgctgcct tcctaccctg tgagctgaag cctcatggcc tgggtggactg 240  
caattggctg ttctgaagt ctgtaccccg ttctctgctg gcagcatcct gctccaacat 300  
caccgcctc tccttgatct ccaaccgtat ccaccacctg cacaactccg acttcgtcca 360  
cctgtccaac ctgcggcagc tgaacctcaa gtggaactgt ccaccactg gccttagccc 420  
cctgcacttc tcttgccaca tgaccattga gcccagaacc ttctgggcta tgcgtacact 480  
ggaggagctg aacctgagct ataatggtat caccactgtg ccccgactgc ccagctccct 540

ggtgaatctg agcctgagcc acaccaacat cctggttcta gatgctaaca gcctcgccgg	600
cctatacagc ctgcgcgttc tcttcattgga cgggaactgc tactacaaga acccctgcac	660
aggagcgggtg aaggtgaccc caggcgcctt cctgggcctg agcaatctca cccatctgtc	720
tctgaagtat aacaacctca caaagggtgcc ccgccaactg cccccagcc tggagtacct	780
cctggtgtcc tataacctca ttgtcaagct ggggcctgaa gacctggcca atctgacctc	840
ccttcgagta cttgatgtgg gtgggaattg ccgtcgctgc gacctgccc ccaatccctg	900
tatagaatgt ggccaaaagt ccctccacct gcaccctgag accttccatc acctgagcca	960
tctggaaggc ctggtgctga aggacagctc tctccataca ctgaactctt cctggttcca	1020
aggtctggtc aacctctcgg tgctggacct aagcgagaac tttctctatg aaagcatcaa	1080
ccacaccaat gcctttcaga acctaaccgg cctgcgcaag ctcaacctgt ccttcaatta	1140
ccgcaagaag gtatcctttg ccgcctcca cctggcaagt tccttcaaga acctggtgtc	1200
actgcaggag ctgaacatga acggcatctt cttccgctcg ctcaacaagt acacgctcag	1260
atggctggcc gatctgccc aactccacac tctgcatctt caaatgaact tcatcaacca	1320
ggcacagctc agcatctttg gtaccttcgg agcccttcgc tttgtggact tgtcagacaa	1380
tgcgcatcagt gggccttcaa cgctgtcaga agccaccct gaagaggcag atgatgcaga	1440
gcaggaggag ctgttgtctg cggatcctca ccagctcca ctgagcacc ctgcttctaa	1500
gaacttcatg gacaggtgta agaacttcaa gttcaccatg gacctgtctc ggaacaacct	1560
ggtgactatc aagccagaga tgtttgtcaa tctctcacgc ctccagtgtc ttagcctgag	1620
ccacaactcc attgcacagg ctgtcaatgg ctctcagttc ctgccgctga ctaatctgca	1680
ggtgctggac ctgtcccata acaaactgga cttgtaccac tggaaatcgt tcagtgagct	1740
accacagttg caggccctgg acctgagcta caacagccag cccttttagca tgaagggtat	1800
agggcacaat ttcagttttg tgacctatct gtccatgcta cagagcctta gcctggcaca	1860
caatgacatt catacccggtg tgtcctcaca tctcaacagc aactcagtga ggtttcttga	1920
cttcagcggc aacgggtatgg gccgcatgtg ggatgagggg ggcctttatc tccatttctt	1980
ccaaggcctg agtggcctgc tgaagctgga cctgtctcaa aataacctgc atatcctccg	2040
gccccagaac cttgacaacc tccccagag cctgaagctg ctgagcctcc gagacaacta	2100
cctatctttc tttaactgga ccagtctgtc cttcctaccc aacctggaag tcctagacct	2160
ggcaggcaac cagctaaagg ccctgaccaa tggcaccctg cctaattggca ccctcctcca	2220
gaaactcgat gtcagtagca acagtatcgt ctctgtggtc ccagccttct tcgctctggc	2280
ggtcgagctg aaagaggtca acctcagcca caacattctc aagacgggtg atcgctcctg	2340
gtttggggcc attgtgatga acctgacagt tctagacgtg agaagcaacc ctctgcactg	2400
tgctgtggg gcagccttcg tagacttact gttggagggt cagaccaagg tgctggcct	2460

ggctaattggt gtgaagtgtg gcagccccgg ccagctgcag ggccgtagca tcttcgcgca 2520  
 ggacctgcgg ctgtgcctgg atgaggtcct ctcttgggac tgctttggcc ttctactott 2580  
 ggctgtggcc gtgggcatgg tgggtgcctat actgcacat ctctgcggct gggacgtctg 2640  
 gtactgtttt catctgtgcc tggcatggct acctttgctg gcccgcagcc gacgcagcgc 2700  
 ccaaactctc cttatgatg ctttcgtgggt gtccgataag gcacagagcg cagttgccga 2760  
 ctgggtgtat aacgagctgc ggggtcggct ggaggagcgg cgcggtcgcc gagccctacg 2820  
 cttgtgtctg gaggaccgag attggtgcc tggccagacg ctcttcgaga acctctgggc 2880  
 ttccatctat gggagccgca agactctatt tgtgctggcc cacacggacc gcgtcagtgg 2940  
 cctcctgcgc accagcttcc tgcctggctca gcagcgcctg ttggaagacc gcaaggacgt 3000  
 ggtggtgttg gtgatcctgc gtccggatgc ccaccgctcc cgctatgtgc gactgcgcca 3060  
 gcgtctctgc cgccagagtg tgcctctctg gcccagcag cccaacgggc aggggggctt 3120  
 ctggggccag ctgagtacag ccctgactag ggacaaccgc cacttctata accagaactt 3180  
 ctgccgggga cctacagcag aatagctcag agcaacagct ggaaacagct gcattctcat 3240  
 gcctgggtcc cgagttgctc tgctgcctt gctctgtctt actacaccgc tatttggcaa 3300  
 gtgcgcaata tatgctacca agccaccagg cccacggagc aaagggttggc agtaaagggt 3360  
 agttttcttc ccatgcatct ttcaggagag tgaagataga caccagacc acacagaaca 3420  
 ggactggagt tcattctctg cccctccacc ccactttgcc tgtctctgta t 3471

<210> 70  
 <211> 3340  
 <212> DNA  
 <213> murine

<400> 70  
 tctctgagag accctgggtg ggaacatcat tctctgccgc ccagtttgct agaggagacc 60  
 tcgggagaat cctccatctc ccaacatggt tctccgtcga aggactctgc accccttgct 120  
 cctcctggta caggctgcag tgcctggctga gactctggcc ctgggtaccc tgctgcctt 180  
 cctaccctgt gagctgaagc ctcatggcct ggtggactgc aattggctgt tctgaagtc 240  
 tgtacccctg ttctctgcgg cagcatcctg ctccaacatc accgcctct ccttgatctc 300  
 caaccgtatc caccacctgc acaactccga cttcgtccac ctgtccaacc tgcggcagct 360  
 gaacctcaag tggaaactgt caccactgg ccttagcccc ctgcacttct cttgccacat 420  
 gaccattgag ccagaaacct tcctggctat gcgtacactg gaggagctga acctgagcta 480  
 taatggatat accactgtgc cccgactgcc cagctccctg gtgaatctga gcctgagcca 540  
 caccaacatc ctggttctag atgctaacag cctcgccggc ctatacagcc tgcgcgttct 600

**THIS PAGE BLANK (USPTO)**

**THIS PAGE BLANK (USPTO)**



cttcatggac	gggaactgct	actacaagaa	ccctgcaca	ggagcgggta	aggtgacccc	660
aggcgccctc	ctgggcctga	gcaatctcac	ccatctgtct	ctgaagtata	acaacctcac	720
aaaggtgccc	cgccaactgc	ccccagcct	ggagtacctc	ctggtgtcct	ataacctcat	780
tgtcaagctg	gggcctgaag	acctggccaa	tctgacctcc	cttcgagtac	ttgatgtggg	840
tgggaattgc	cgtcgtgcg	accatgcccc	caatccctgt	atagaatgtg	gccaaaagtc	900
cctccacctg	cacctgaga	ccttccatca	cctgagccat	ctggaaggcc	tgggtgctgaa	960
ggacagctct	ctccatacac	tgaactcttc	ctggttccaa	ggtctggtca	acctctcggt	1020
gctggacctt	agcgagaact	ttctctatga	aagcatcaac	cacaccaatg	cctttcagaa	1080
cctaaccgcg	ctgcgcaagc	tcaacctgtc	cttcaattac	cgcaagaagg	tatcctttgc	1140
ccgcctccac	ctggcaagtt	ccttcaagaa	cctggtgtca	ctgcaggagc	tgaacatgaa	1200
cgcatcttct	ttccgctcgc	tcaacaagta	cacgctcaga	tggctggccg	atctgccccaa	1260
actccacact	ctgcatcttc	aatgaactt	catcaaccag	gcacagctca	gcctctttgg	1320
taccttccga	gcccttcgct	ttgtggactt	gtcagacaat	cgcctcagtg	ggccttcaac	1380
gctgtcagaa	gccacccttg	aagaggcaga	tgatgcagag	caggaggagc	tgttgtctgc	1440
ggatcctcac	ccagctccac	tgagcaccct	tgcttctaag	aacttcatgg	acaggtgtaa	1500
gaacttcaag	ttcaccatgg	acctgtctcg	gaacaacctg	gtgactatca	agccagagat	1560
gtttgtcaat	ctctcacgcc	tccagtgtct	tagcctgagc	cacaactcca	ttgcacaggc	1620
tgtcaatggc	tctcagttcc	tgccgtgac	taatctgcag	gtgctggacc	tgtcccataa	1680
caaaactggac	ttgtaccact	ggaaatcggt	cagtgcagta	ccacagttgc	aggccctgga	1740
cctgggctac	aacagccagc	cctttagcat	aaagggata	ggccacaatt	tcagttttgt	1800
ggcccatctg	tccatgctac	acagccttag	cctggcacac	aatgacattc	ataccctgtg	1860
gtcctcacat	ctcaacagca	actcagtgcg	gtttcttgac	ttcagcggca	acggtatggg	1920
ccgcatgtgg	gatgaggggg	gcctttatct	ccatttcttc	caaggcctga	gtggcctgct	1980
gaagctggac	ctgtctcaaa	ataacctgca	tatcctccgg	ccccagaacc	ttgacaacct	2040
ccccaaagac	ctgaagctgc	tgagcctccg	agacaactac	ctatctttct	ttaactggac	2100
cagtctgtcc	ttcctgcccc	acctggaagt	cctagacctg	gcaggcaacc	agctaaaggc	2160
cctgaccaat	ggcaccctgc	ctaattggac	cctcctccag	aaactggatg	tcagcagcaa	2220
cagtatcgtc	tctgtgggtc	cagccttctt	cgctctggcg	gtcgagctga	aagaggtcaa	2280
cctcagccac	aacattctca	agacgggtga	tcgctcctgg	tttgggcccc	ttgtgatgaa	2340
cctgacagtt	ctagacgtga	gaagcaacct	tctgcactgt	gcctgtgggg	cagccttcgt	2400
agacttactg	ttggaggtgc	agaccaaggt	gcctggcctg	gctaattggtg	tgaagtgtgg	2460
cagccccggc	cagctgcagg	gccgtagcat	cttcgcacag	gacctgcggc	tgtgcctgga	2520

tgaggctctc tcttgggact gctttggcct ttcactcttg gctgtggcgc tgggcatggt	2580
ggtgcctata ctgcaccatc tctgcggctg ggacgtctgg tactgttttc atctgtgcct	2640
ggcatggcta cctttgctgg cccgcagccg acgcagcgcc caagctctcc cctatgatgc	2700
cttcgtgggtg ttcgataagg cacagagcgc agttgcggac tgggtgtata acgagctgcg	2760
ggtgcggctg gaggggcggc gcggtcgccg agccctacgc ttgtgtctgg aggaccgaga	2820
ttggctgcct ggccagacgc tcttcgagaa cctctgggct tccatctatg ggagccgcaa	2880
gactctatct gtgctggccc acacggaccg cgtcagtggc ctctcgcgca ccagcttcct	2940
gctggctcag cagcgctctg tggaaagacc caaggacgtg gtggtgttgg tgatcctgcg	3000
tccggatgcc caccgctccc gctatgtgcg actgcgccag cgtctctgcc gccagagtgt	3060
gctcttttgg ccccagcagc ccaacgggca ggggggcttc tgggcccagc tgagtacagc	3120
cctgactagg gacaaccgcc acttctataa ccagaacttc tgccggggac ctacagcaga	3180
atagctcaga gcaacagctg gaaacagctg catcttcatg cctgggtccc gagttgctct	3240
gcctgccttg ctctgtctta ctacaccgct atttggcaag tgcgcaatat atgctaccaa	3300
gccaccgggc ccacggagca aagggtggct gtaaagggtg	3340

<210> 71  
 <211> 3471  
 <212> DNA  
 <213> murine

<400> 71	
tgaaagtgtc acttcctcaa ttctctgaga gaccctggtg tggaaacatca ttctctgccg	60
cccagtttgt cagagggagc ctcgggagaa tcctccatct cccaacatgg ttctccgtcg	120
aaggactctg cacccttgtt ccctcctggt acaggctgca gtgctggctg agactctggc	180
cctgggtacc ctgcctgcct tcctaccctg tgagctgaag cctcatggcc tgggtggactg	240
caattggctg ttcttgaagt ctgtaccccg tttctctgcg gcagcatcct gctccaacat	300
caccgcctc tccttgatct ccaaccgtat ccaccacctg cacaactcgc acttcgtcca	360
cctgtccaac ctgcggcagc tgaacctcaa gtggaactgt ccaccactg gccttagccc	420
cctgcacttc tcttgccaca tgaccattga gcccagaacc ttcttggtta tgcgtacact	480
ggaggagctg aacctgagct ataatggtat caccactgtg ccccgactgc ccagctccct	540
ggtgaatctg agcctgagcc acaccaacat cctggttcta gatgctaaca gcctcgccgg	600
cctatacagc ctgcgcgttc tcttcatgga cgggaactgc tactacaaga acccctgcac	660
aggagcgggtg aagggtgaccc caggcgccct cctgggcctg agcaatctca cccatctgtc	720
tctgaagtat aacaacctca caaagggtgcc ccgccaactg cccccagcc tggagtacct	780

cctggtgtcc	tataacctca	ttgtcaagct	ggggcctgaa	gacctggcca	atctgacctc	840
ccttcgagta	cttgatgtgg	gtgggaattg	ccgtcgctgc	gaccatgccc	ccaatccctg	900
tatagaatgt	ggccaaaagt	ccctccacct	gcacctgag	accttccatc	acctgagcca	960
tctggaaggc	ctggtgctga	aggacagctc	tctccataca	ctgaactctt	cctggttcca	1020
aggtctggtc	aacctctcgg	tgctggacct	aagcgagaac	tttctctatg	aaagcatcaa	1080
ccacaccaat	gcctttcaga	acctaaccgg	cctgcgcaag	ctcaacctgt	ccttcaatta	1140
ccgcaagaag	gtatcctttg	cccgcctcca	cctggcaagt	tccttcaaga	acctggtgtc	1200
actgcaggag	ctgaacatga	acggcatctt	cttcgctcg	ctcaacaagt	acacgctcag	1260
atggctggcc	gatctgcca	aactccacac	tctgcatctt	caaatgaact	tcacaaacca	1320
ggcacagctc	agcatctttg	gtaccttccg	agcccttcgc	tttgtggact	tgtcagacaa	1380
tgcacatcag	gggccttcaa	cgctgtcaga	agccaccct	gaagaggcag	atgatgcaga	1440
gcaggaggag	ctgttgtctg	cggtacctca	cccagctcca	ctgagcacc	ctgcttctaa	1500
gaacttcatg	gacaggtgta	agaacttcaa	gttcaccatg	gacctgtctc	ggaacaacct	1560
ggtgactatc	aagccagaga	tgtttgtcaa	tctctcacgc	ctccagtgtc	ttagcctgag	1620
ccacaactcc	attgcacagg	ctgtcaatgg	ctctcagttc	ctgccgctga	ctaacttgca	1680
ggtgctggac	ctgtcccata	acaaactgga	cttgaccac	tggaaatcgt	tcagttagct	1740
accacagttg	caggccctgg	acctgagcta	caacagccag	cccttttagca	tgaaggggat	1800
agggcacaat	ttcagttttg	tgacctatct	gtccatgcta	cagagcctta	gcctggcaca	1860
caatgacatt	catacccggt	tgctctcaca	tctcaacagc	aactcagtga	ggtttcttga	1920
cttcagcggc	aacgggtatg	gccgcatgtg	ggatgagggg	ggcctttatc	tccatttctt	1980
ccaaggcctg	agtggcctgc	tgaagctgga	cctgtctcaa	aataacctgc	atatcctccg	2040
gccccagaac	cttgacaacc	tccccagag	cctgaagctg	ctgagcctcc	gagacaacta	2100
cctatctttc	tttaactgga	ccagtctgtc	cttcctaccc	aacctggaag	tcctagacct	2160
ggcaggcaac	cagctaaagg	ccctgaccaa	tggcaccctg	cctaattggca	ccctcctcca	2220
gaaactcgat	gtcagtagca	acagtatcgt	ctctgtggtc	ccagccttct	tcgctctggc	2280
ggtcgagctg	aaagagggtca	acctcagcca	caacattctc	aagacgggtg	atcgctcctg	2340
gtttggggcc	attgtgatga	acctgacagt	tctagacgtg	agaagcaacc	ctctgcactg	2400
tgcctgtggg	gcagccttcg	tagacttact	gttggagggtg	cagaccaagg	tgcttggcct	2460
ggctaattgg	gtgaagtgtg	gcagccccgg	ccagctgcag	ggccgtagca	tcttcgcgca	2520
ggacctgcgg	ctgtgcctgg	atgaggctct	ctcttgggac	tgctttggcc	tttcaactctt	2580
ggctgtggcc	gtgggcatgg	tggtgcctat	actgcacat	ctctgaggct	gggacgtctg	2640
gtactgtttt	catctgtgcc	tggcatggct	acctttgtctg	gcccgcagcc	gacgcagcgc	2700

ccaaactctc ccttatgatg ccttcgtggt gttcgataag gcacagagcg cagttgccga 2760  
 ctgggtgtat aacgagctgc gggcgcggtt ggaggagcgg cgcggtcgcc gagccctacg 2820  
 cttgtgtctg gaggaccgag attggctgcc tggccagacg ctcttcgaga acctctgggc 2880  
 ttccatctat gggagccgca agactctatt tgtgtggccc cacacggacc gcgtcagtgg 2940  
 cctcctgcgc accagcttcc tgctggctca gcagcgctg ttggaagacc gcaaggacgt 3000  
 ggtggtgttg gtgatcctgc gtccggatgc ccaccgctcc cgctatgtgc gactgcgcca 3060  
 gcgtctctgc cgccagagtg tgctcttctg gccccagcag cccaacgggc agggggggctt 3120  
 ctggggcccag ctgagtacag ccttgactag ggacaaccgc cacttctata accagaactt 3180  
 ctgccgggga cctacagcag aatagctcag agcaacagct ggaacagct gcatcttcat 3240  
 gcctggttcc cgagttgctc tgctgcctt gctctgtctt actacaccgc tatttgga 3300  
 gtgcgcaata tatgctacca agccaccagg ccacaggagc aaaggttggc agtaaaggg 3360  
 agttttcttc ccatgcatct ttcaggagag tgaagataga caccagaccc acacagaaca 3420  
 ggactggagt tcattctctg cccctccacc ccactttgcc tgtctctgta t 3471

&lt;210&gt; 72

&lt;211&gt; 1032

&lt;212&gt; PRT

&lt;213&gt; murine

&lt;400&gt; 72

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
 1 5 10 15  
 Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20 25 30  
 Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
 35 40 45  
 Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn  
 50 55 60  
 Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
 65 70 75 80  
 Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
 85 90 95  
 Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
 100 105 110  
 Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
 115 120 125  
 Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
 130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
 145 150 155 160  
 Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
 225 230 235 240  
 Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
 260 265 270  
 Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
 290 295 300  
 Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
 340 345 350  
 Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
 355 360 365  
 Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
 370 375 380  
 Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
 405 410 415  
 Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
 420 425 430  
 Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
 435 440 445  
 Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
 450 455 460  
 Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu

465                      470                      475                      480  
 Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
                                  485                      490                      495  
  
 Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
                                  500                      505                      510  
  
 Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
                                  515                      520                      525  
  
 Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
                                  530                      535                      540  
  
 Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
                                  545                      550                      555                      560  
  
 Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser  
                                  565                      570                      575  
  
 Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val  
                                  580                      585                      590  
  
 Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly  
                                  595                      600                      605  
  
 Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe  
                                  610                      615                      620  
  
 Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn  
                                  625                      630                      635                      640  
  
 Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu  
                                  645                      650                      655  
  
 Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr  
                                  660                      665                      670  
  
 Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn  
                                  675                      680                      685  
  
 Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu  
                                  690                      695                      700  
  
 Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala  
                                  705                      710                      715                      720  
  
 Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn  
                                  725                      730                      735  
  
 Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn  
                                  740                      745                      750  
  
 Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly  
                                  755                      760                      765  
  
 Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly  
                                  770                      775                      780  
  
 Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg  
                                  785                      790                      795                      800  
  
 Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser

385	Asn	Phe	Ile	Asn	Gln	Ala	Gln	Leu	Ser	Ile	Phe	Gly	Thr	Phe	Arg	Ala	400
				405						410						415	
Leu	Arg	Phe	Val	Asp	Leu	Ser	Asp	Asn	Arg	Ile	Ser	Gly	Pro	Ser	Thr		
			420					425					430				
Leu	Ser	Glu	Ala	Thr	Pro	Glu	Glu	Ala	Asp	Asp	Ala	Glu	Gln	Glu	Glu		
		435					440					445					
Leu	Leu	Ser	Ala	Asp	Pro	His	Pro	Ala	Pro	Leu	Ser	Thr	Pro	Ala	Ser		
		450				455						460					
Lys	Asn	Phe	Met	Asp	Arg	Cys	Lys	Asn	Phe	Lys	Phe	Thr	Met	Asp	Leu		
465					470					475					480		
Ser	Arg	Asn	Asn	Leu	Val	Thr	Ile	Lys	Pro	Glu	Met	Phe	Val	Asn	Leu		
				485					490					495			
Ser	Arg	Leu	Gln	Cys	Leu	Ser	Leu	Ser	His	Asn	Ser	Ile	Ala	Gln	Ala		
		500						505					510				
Val	Asn	Gly	Ser	Gln	Phe	Leu	Pro	Leu	Thr	Asn	Leu	Gln	Val	Leu	Asp		
		515					520					525					
Leu	Ser	His	Asn	Lys	Leu	Asp	Leu	Tyr	His	Trp	Lys	Ser	Phe	Ser	Glu		
	530				535						540						
Leu	Pro	Gln	Leu	Gln	Ala	Leu	Asp	Leu	Gly	Tyr	Asn	Ser	Gln	Pro	Phe		
545					550					555					560		
Ser	Ile	Lys	Gly	Ile	Gly	His	Asn	Phe	Ser	Phe	Val	Ala	His	Leu	Ser		
			565					570						575			
Met	Leu	His	Ser	Leu	Ser	Leu	Ala	His	Asn	Asp	Ile	His	Thr	Arg	Val		
			580					585					590				
Ser	Ser	His	Leu	Asn	Ser	Asn	Ser	Val	Arg	Phe	Leu	Asp	Phe	Ser	Gly		
		595					600					605					
Asn	Gly	Met	Gly	Arg	Met	Trp	Asp	Glu	Gly	Gly	Leu	Tyr	Leu	His	Phe		
610						615					620						
Phe	Gln	Gly	Leu	Ser	Gly	Leu	Leu	Lys	Leu	Asp	Leu	Ser	Gln	Asn	Asn		
625					630					635					640		
Leu	His	Ile	Leu	Arg	Pro	Gln	Asn	Leu	Asp	Asn	Leu	Pro	Lys	Ser	Leu		
			645					650						655			
Lys	Leu	Leu	Ser	Leu	Arg	Asp	Asn	Tyr	Leu	Ser	Phe	Phe	Asn	Trp	Thr		
			660					665					670				
Ser	Leu	Ser	Phe	Leu	Pro	Asn	Leu	Glu	Val	Leu	Asp	Leu	Ala	Gly	Asn		
		675					680					685					
Gln	Leu	Lys	Ala	Leu	Thr	Asn	Gly	Thr	Leu	Pro	Asn	Gly	Thr	Leu	Leu		
		690				695					700						
Gln	Lys	Leu	Asp	Val	Ser	Ser	Asn	Ser	Ile	Val	Ser	Val	Val	Pro	Ala		
705					710	</											

```

              725              730              735
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn
              740              745              750

Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly
              755              760              765

Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly
              770              775              780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg
785              790              795              800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser
              805              810              815

Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val
              820              825              830

Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe
              835              840              845

His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser
              850              855              860

Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln
865              870              875              880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu
              885              890              895

Gly Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp
              900              905              910

Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr
              915              920              925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
              930              935              940

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945              950              955              960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His
              965              970              975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
              980              985              990

Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln
              995              1000              1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln
              1010              1015              1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu
              1025              1030

```

&lt;210&gt; 74

&lt;211&gt; 1032

&lt;212&gt; PRT



&lt;213&gt; murine

&lt;400&gt; 74

```

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1          5          10          15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20          25          30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
35          40          45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn
50          55          60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn
65          70          75          80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
85          90          95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met
100         105         110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu
115         120         125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130         135         140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145         150         155         160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly
165         170         175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro
180         185         190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195         200         205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210         215         220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu
225         230         235         240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245         250         255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser
260         265         270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly
275         280         285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe
290         295         300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305         310         315         320

```

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
 340 345 350  
 Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
 355 360 365  
 Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
 370 375 380  
 Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
 405 410 415  
 Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
 420 425 430  
 Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
 435 440 445  
 Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
 450 455 460  
 Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu  
 465 470 475 480  
 Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
 485 490 495  
 Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
 500 505 510  
 Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
 515 520 525  
 Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
 530 535 540  
 Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
 545 550 555 560  
 Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser  
 565 570 575  
 Met Leu Gln Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val  
 580 585 590  
 Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly  
 595 600 605  
 Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe  
 610 615 620  
 Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn  
 625 630 635 640  
 Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu

645 650 655  
 Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr  
 660 665 670  
 Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn  
 675 680 685  
 Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu  
 690 695 700  
 Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala  
 705 710 715 720  
 Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn  
 725 730 735  
 Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn  
 740 745 750  
 Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly  
 755 760 765  
 Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly  
 770 775 780  
 Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg  
 785 790 795 800  
 Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser  
 805 810 815  
 Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val  
 820 825 830  
 Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe  
 835 840 845  
 His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser  
 850 855 860  
 Ala Gln Thr Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln  
 865 870 875 880  
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu  
 885 890 895  
 Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp  
 900 905 910  
 Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr  
 915 920 925  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
 930 935 940  
 Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
 945 950 955 960  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His  
 965 970 975  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val

980                      985                      990  
 Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln  
          995                      1000                      1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln  
          1010                      1015                      1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu  
          1025                      1030

<210> 75  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 75

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
 1                      5                      10                      15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
          20                      25                      30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
          35                      40                      45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn  
          50                      55                      60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
 65                      70                      75                      80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
          85                      90                      95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
          100                      105                      110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
          115                      120                      125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
          130                      135                      140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
 145                      150                      155                      160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
          165                      170                      175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
          180                      185                      190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
          195                      200                      205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
          210                      215                      220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
 225                      230                      235                      240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
 260 265 270  
 Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
 290 295 300  
 Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
 340 345 350  
 Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
 355 360 365  
 Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
 370 375 380  
 Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
 405 410 415  
 Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
 420 425 430  
 Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
 435 440 445  
 Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
 450 455 460  
 Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu  
 465 470 475 480  
 Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
 485 490 495  
 Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
 500 505 510  
 Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
 515 520 525  
 Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
 530 535 540  
 Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
 545 550 555 560  
 Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser

565 570 575  
 Met Leu Gln Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val  
 580 585 590  
 Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly  
 595 600 605  
 Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe  
 610 615 620  
 Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn  
 625 630 635 640  
 Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu  
 645 650 655  
 Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr  
 660 665 670  
 Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn  
 675 680 685  
 Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu  
 690 695 700  
 Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala  
 705 710 715 720  
 Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn  
 725 730 735  
 Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn  
 740 745 750  
 Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly  
 755 760 765  
 Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly  
 770 775 780  
 Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg  
 785 790 795 800  
 Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser  
 805 810 815  
 Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val  
 820 825 830  
 Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe  
 835 840 845  
 His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser  
 850 855 860  
 Ala Gln Thr Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln  
 865 870 875 880  
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu  
 885 890 895  
 Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp

900 905 910  
 Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr  
 915 920 925  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
 930 935 940  
 Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
 945 950 955 960  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His  
 965 970 975  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val  
 980 985 990  
 Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln  
 995 1000 1005  
 Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln  
 1010 1015 1020  
 Asn Phe Cys Arg Gly Pro Thr Ala Glu  
 1025 1030

<210> 76  
 <211> 3002  
 <212> DNA  
 <213> Homo sapiens

<400> 76  
 gtggcttggt attcactggc aggtttcaga catttagatc tttcttttaa tgactaacac 60  
 catgcctatc tgtggagaag ctggcaacat gtcacacctg gaaattgttt ttcaacatta 120  
 atactattat ttggcagtaa tccagattgc ttttgccacc aacctgaaga catatagagg 180  
 cagaaggaca ggaataattc tatttgtttc ctgttttgaa acttccatct gtaaggctat 240  
 caaaaggaga tgtgagagag ggtattgagt ctggcctgac aatgcagttc ttaaaccaaa 300  
 ggtccattat gcttctctc tctgagaatc ctgaacttacc tcaacaacgg agacatggca 360  
 cagtagccag cttggagact tctcagccaa tgctctgaga tcaagtcgaa gaccaatat 420  
 acagggtttt gagctcatct tcatcattca tatgaggaaa taagtggtaa aatccttgga 480  
 aatacaatga gactcatcag aaacatttac atattttgta gtattgttat gacagcagag 540  
 ggtgatgctc cagagctgcc agaagaaagg gaactgatga ccaactgctc caacatgtct 600  
 ctaagaaagg ttcccgaga cttgaccca gccacaacga cactggattt atcctataac 660  
 ctcctttttc aactccagag ttcagatttt cattctgtct ccaaactgag agttttgatt 720  
 ctatgccata acagaattca acagctggat ctcaaacct ttgaattcaa caaggagtta 780  
 agatatttag atttgtctaa taacagactg aagagtgtaa cttggtattt actggcaggt 840  
 ctcaggatt tagatctttc ttttaatgac tttgacacca tgctatctg tgaggaagct 900

ggcaacatgt cacacctgga aatcctaggt ttgagtgggg caaaaataca aaaatcagat	960
ttccagaaaa ttgctcatct gcatctaaat actgtcttct taggattcag aactcttcct	1020
cattatgaag aaggtagcct gcccatctta aacacaacaa aactgcacat tgtttttacca	1080
atggacacaa atttctgggt tcttttgcgt gatggaatca agacttcaaa aatattagaa	1140
atgacaaata tagatggcaa aagccaattt gtaagttatg aaatgcaacg aaatcttagt	1200
ttagaaaatg ctaagacatc ggttctattg cttaataaag ttgatttact ctgggacgac	1260
cttttcctta tcttacaatt tgtttggcat acatcagtg aacactttca gatccgaaat	1320
gtgacttttg gtggttaaggc ttatcttgac cacaattcat ttgactactc aaatactgta	1380
atgagaacta taaaattgga gcatgtacat ttcagagtgt tttacattca acaggataaa	1440
atctatttgc ttttgaccaa aatggacata gaaaacctga caatatcaaa tgcacaaatg	1500
ccacacatgc ttttcccgaa ttatcctacg aaattccaat atttaaattt tgccaataat	1560
atcttaacag acgagttggt taaaagaact atccaactgc ctcaattgaa aactctcatt	1620
ttgaatggca ataaactgga gacactttct ttagtaagtt gctttgctaa caacacaccc	1680
ttggaacact tggatctgag tcaaaatcta ttacaacata aaaatgatga aaattgctca	1740
tgccagaaa ctgtggtcaa tatgaatctg tcatacaata aattgtctga ttctgtcttc	1800
aggtgcttgc caaaaagtat tcaaaactct gacctaaata ataaccaaat ccaaactgta	1860
cctaaagaga ctattcatct gatggcctta cgagaactaa atattgcatt taattttcta	1920
actgatctcc ctggatgcag tcatttcagt agactttcag ttctgaacat tgaaatgaac	1980
ttcattctca gcccatctct ggattttggt cagagctgcc aggaagttaa aactctaaat	2040
gcgggaagaa atccattccg gtgtacctgt gaattaaaaa atttcattca gcttgaaaca	2100
tattcagagg tcatgatggt tggatggtca gattcataca cctgtgaata ccctttaaac	2160
ctaaggggaa ttaggttaaa agacgttcat ctccacgaat tatcttgcaa cacagctctg	2220
ttgattgtca ccattgtggt tattatgcta gttctggggt tggctgtggc cttctgctgt	2280
ctccactttg atctgccctg gtatctcagg atgctaggtc aatgcacaca aacatggcac	2340
agggttagga aaacaaccca agaacaactc aagagaaatg tccgattcca cgcatttatt	2400
tcatacagtg aacatgattc tctgtgggtg aagaatgaat tgatcccaa tctagagaag	2460
gaagatggtt ctatcttgat ttgcctttat gaaagctact ttgacctgg caaaagcatt	2520
agtgaaaata ttgtaagctt cattgagaaa agctataagt ccatctttgt tttgtctccc	2580
aactttgtcc agaatgagtg gtgccattat gaattttact ttgccacca caatctcttc	2640
catgaaaatt ctgatcatat aattcttatt ttactggaac ccattccatt ctattgcatt	2700
cccaccaggt atcataaact gaaagctctc ctggaaaaaa aagcatactt ggaatggccc	2760
aaggataggc gtaaatgtgg gcttttctgg gcaaacttc gagctgctat taatgttaat	2820



gtattagcca ccagagaaat gtatgaactg cagacattca cagagttaaa tgaagagtct 2880  
 cgagggttcta caatctctct gatgagaaca gattgtctat aaaatcccac agtccttggg 2940  
 aagttgggga ccacatacac tgttgggatg tacattgata caacctttat gatggcaatt 3000  
 tg 3002

<210> 77  
 <211> 811  
 <212> PRT  
 <213> Homo sapiens

<400> 77

Met Arg Leu Ile Arg Asn Ile Tyr Ile Phe Cys Ser Ile Val Met Thr  
 1 5 10 15  
 Ala Glu Gly Asp Ala Pro Glu Leu Pro Glu Glu Arg Glu Leu Met Thr  
 20 25 30  
 Asn Cys Ser Asn Met Ser Leu Arg Lys Val Pro Ala Asp Leu Thr Pro  
 35 40 45  
 Ala Thr Thr Thr Leu Asp Leu Ser Tyr Asn Leu Leu Phe Gln Leu Gln  
 50 55 60  
 Ser Ser Asp Phe His Ser Val Ser Lys Leu Arg Val Leu Ile Leu Cys  
 65 70 75 80  
 His Asn Arg Ile Gln Gln Leu Asp Leu Lys Thr Phe Glu Phe Asn Lys  
 85 90 95  
 Glu Leu Arg Tyr Leu Asp Leu Ser Asn Asn Arg Leu Lys Ser Val Thr  
 100 105 110  
 Trp Tyr Leu Leu Ala Gly Leu Arg Tyr Leu Asp Leu Ser Phe Asn Asp  
 115 120 125  
 Phe Asp Thr Met Pro Ile Cys Glu Glu Ala Gly Asn Met Ser His Leu  
 130 135 140  
 Glu Ile Leu Gly Leu Ser Gly Ala Lys Ile Gln Lys Ser Asp Phe Gln  
 145 150 155 160  
 Lys Ile Ala His Leu His Leu Asn Thr Val Phe Leu Gly Phe Arg Thr  
 165 170 175  
 Leu Pro His Tyr Glu Glu Gly Ser Leu Pro Ile Leu Asn Thr Thr Lys  
 180 185 190  
 Leu His Ile Val Leu Pro Met Asp Thr Asn Phe Trp Val Leu Leu Arg  
 195 200 205  
 Asp Gly Ile Lys Thr Ser Lys Ile Leu Glu Met Thr Asn Ile Asp Gly  
 210 215 220  
 Lys Ser Gln Phe Val Ser Tyr Glu Met Gln Arg Asn Leu Ser Leu Glu  
 225 230 235 240

Asn Ala Lys Thr Ser Val Leu Leu Leu Asn Lys Val Asp Leu Leu Trp  
 245 250 255  
 Asp Asp Leu Phe Leu Ile Leu Gln Phe Val Trp His Thr Ser Val Glu  
 260 265 270  
 His Phe Gln Ile Arg Asn Val Thr Phe Gly Gly Lys Ala Tyr Leu Asp  
 275 280 285  
 His Asn Ser Phe Asp Tyr Ser Asn Thr Val Met Arg Thr Ile Lys Leu  
 290 295 300  
 Glu His Val His Phe Arg Val Phe Tyr Ile Gln Gln Asp Lys Ile Tyr  
 305 310 315 320  
 Leu Leu Leu Thr Lys Met Asp Ile Glu Asn Leu Thr Ile Ser Asn Ala  
 325 330 335  
 Gln Met Pro His Met Leu Phe Pro Asn Tyr Pro Thr Lys Phe Gln Tyr  
 340 345 350  
 Leu Asn Phe Ala Asn Asn Ile Leu Thr Asp Glu Leu Phe Lys Arg Thr  
 355 360 365  
 Ile Gln Leu Pro His Leu Lys Thr Leu Ile Leu Asn Gly Asn Lys Leu  
 370 375 380  
 Glu Thr Leu Ser Leu Val Ser Cys Phe Ala Asn Asn Thr Pro Leu Glu  
 385 390 395 400  
 His Leu Asp Leu Ser Gln Asn Leu Leu Gln His Lys Asn Asp Glu Asn  
 405 410 415  
 Cys Ser Trp Pro Glu Thr Val Val Asn Met Asn Leu Ser Tyr Asn Lys  
 420 425 430  
 Leu Ser Asp Ser Val Phe Arg Cys Leu Pro Lys Ser Ile Gln Ile Leu  
 435 440 445  
 Asp Leu Asn Asn Asn Gln Ile Gln Thr Val Pro Lys Glu Thr Ile His  
 450 455 460  
 Leu Met Ala Leu Arg Glu Leu Asn Ile Ala Phe Asn Phe Leu Thr Asp  
 465 470 475 480  
 Leu Pro Gly Cys Ser His Phe Ser Arg Leu Ser Val Leu Asn Ile Glu  
 485 490 495  
 Met Asn Phe Ile Leu Ser Pro Ser Leu Asp Phe Val Gln Ser Cys Gln  
 500 505 510  
 Glu Val Lys Thr Leu Asn Ala Gly Arg Asn Pro Phe Arg Cys Thr Cys  
 515 520 525  
 Glu Leu Lys Asn Phe Ile Gln Leu Glu Thr Tyr Ser Glu Val Met Met  
 530 535 540  
 Val Gly Trp Ser Asp Ser Tyr Thr Cys Glu Tyr Pro Leu Asn Leu Arg  
 545 550 555 560  
 Gly Ile Arg Leu Lys Asp Val His Leu His Glu Leu Ser Cys Asn Thr

565 570 575  
 Ala Leu Leu Ile Val Thr Ile Val Val Ile Met Leu Val Leu Gly Leu  
 580 585 590  
 Ala Val Ala Phe Cys Cys Leu His Phe Asp Leu Pro Trp Tyr Leu Arg  
 595 600 605  
 Met Leu Gly Gln Cys Thr Gln Thr Trp His Arg Val Arg Lys Thr Thr  
 610 615 620  
 Gln Glu Gln Leu Lys Arg Asn Val Arg Phe His Ala Phe Ile Ser Tyr  
 625 630 635 640  
 Ser Glu His Asp Ser Leu Trp Val Lys Asn Glu Leu Ile Pro Asn Leu  
 645 650 655  
 Glu Lys Glu Asp Gly Ser Ile Leu Ile Cys Leu Tyr Glu Ser Tyr Phe  
 660 665 670  
 Asp Pro Gly Lys Ser Ile Ser Glu Asn Ile Val Ser Phe Ile Glu Lys  
 675 680 685  
 Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Asn Glu  
 690 695 700  
 Trp Cys His Tyr Glu Phe Tyr Phe Ala His His Asn Leu Phe His Glu  
 705 710 715 720  
 Asn Ser Asp His Ile Ile Leu Ile Leu Leu Glu Pro Ile Pro Phe Tyr  
 725 730 735  
 Cys Ile Pro Thr Arg Tyr His Lys Leu Lys Ala Leu Leu Glu Lys Lys  
 740 745 750  
 Ala Tyr Leu Glu Trp Pro Lys Asp Arg Arg Lys Cys Gly Leu Phe Trp  
 755 760 765  
 Ala Asn Leu Arg Ala Ala Ile Asn Val Asn Val Leu Ala Thr Arg Glu  
 770 775 780  
 Met Tyr Glu Leu Gln Thr Phe Thr Glu Leu Asn Glu Glu Ser Arg Gly  
 785 790 795 800  
 Ser Thr Ile Ser Leu Met Arg Thr Asp Cys Leu  
 805 810

<210> 78  
 <211> 2760  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (2529)..(2529)  
 <223> n is a, c, g, or t

<400> 78  
 aagaatttgg actcatatca agatgctctg aagaagaaca acccttttagg atagccactg 60  
 caacatcatg accaaagaca aagaacctat tggttaaagc ttccattttg ttgcttat 120

gatcataata gttggaacca gaatccagtt ctccgacgga aatgaatttg cagtagacaa	180
gtcaaaaaga ggtcttattc atgttccaaa agacctaccg ctgaaaacca aagtcttaga	240
tatgtctcag aactacatcg ctgagcttca ggtctctgac atgagctttc tatcagagtt	300
gacagttttg agactttccc ataacagaat ccagctactt gatttaagtg ttttcaagtt	360
caaccaggat ttagaatatt tggatttatc tcataatcag ttgcaaaaga taccctgcca	420
tcctatttg agtttcaggc atttagatct ctcatcatt gatttcaagg ccctgccc	480
ctgtaaggaa tttggcaact taccacaact gaatttcttg ggattgagtg ctatgaagct	540
gcaaaaatta gatttgctgc caattgctca cttgcatcta agttatatcc ttttggtt	600
aagaaattat tatataaaag aaaatgagac agaaagtcta caaattctga atgcaaaaac	660
ccttcacctt gtttttcacc caactagttt attcgctatc caagtgaaca taccagttaa	720
tactttaggg tgcttacaac tgactaatat taaattgaat gatgacaact gtcaagttt	780
cattaaattt ttaccagaac tcaccagagg tccaacctta ctgaatttta ccctcaacca	840
catagaaacg acttggaat gcctggtcag agtctttcaa tttctttggc ccaaacctgt	900
ggaatatctc aatatttaca atttaacaat aattgaaagc attcgtgaag aagattttac	960
ttattctaaa acgacattga aagcattgac aatagaacat atcacgaacc aagtttttct	1020
gttttcacag acagctttgt acaccgtgtt ttctgagatg aacattatga tgtaaccat	1080
ttcagatata ctttttatac acatgctgtg tcctcatgca ccaagcacat tcaagtttt	1140
gaactttacc cagaacgttt tcacagatag tatttttgaa aaatgttcca cgttagttaa	1200
attggagaca cttatcttac aaaagaatgg attaaaagac cttttcaaag taggtctcat	1260
gacgaaggat atgccttctt tggaaatact ggatgttagc tggaaattct tggaaatctg	1320
tagacataaa gaaaactgca cttgggttga gattatagtg gtgttaaatt tgtcttcaa	1380
tatgcttact gactctgttt tcagatgttt acctccagg atcaaggtag ttgatcttca	1440
cagcaataaa ataaagagcg ttcttaaaac agtcgtaaaa ctggaagctt tgcaagaact	1500
caatgttgct ttcaattctt taactgacct tcctggatgt ggcagcttta gcagctttc	1560
tgtattgatc attgatcaca attcagtttc ccacctatcg gctgatttct tccagagctg	1620
ccagaagatg aggtcaataa aagcagggga caatccattc caatgtacct gtgagctaag	1680
agaatttgct aaaaatatag accaagtatc aagtgaagtg ttagagggtt ggctgattc	1740
ttataagtg gactaccag aaagttatag aggaagcca ctaaaggact ttcacatgct	1800
tgaattatcc tgcaacataa ctctgctgat cgtcaccatc ggtgccacca tgctggtgtt	1860
ggctgtgact gtgacctccc tctgcatcta cttggatctg ccctggatc tcaggatggt	1920
gtgccagtgg acccagactc ggcgcagggc caggaacata cccttagaag aactccaaag	1980
aaacctccag tttcatgctt ttatttcata tagtgaacat gattctgcct gggtgaaaag	2040

tgaattggta ccttacctag aaaaagaaga tatacagatt tgtcttcacg agaggaactt 2100  
tgtccctggc aagagcattg tggaaaatat catcaactgc attgagaaga gttacaagtc 2160  
catctttgtt ttgtctccca actttgtcca gagtgagtgg tgccattacg aactctatct 2220  
tgcccatcac aatctctttc atgaaggatc taataactta atcctcatct tactggaacc 2280  
cattccacag aacagcattc ccaacaagta ccacaagctg aaggctctca tgacgcagcg 2340  
gacttatttg cagtggccca aggagaaaag caaacgtggg ctcttttggg ctaacattag 2400  
agccgctttt aatatgaaat taacactagt cactgaaaac aatgatgtga aatcttaaaa 2460  
aaatttagga aattcaactt aagaaacat tatttacttg gatgatggtg aatagtacag 2520  
tcgtaagtna ctgtctggag gtgcctccat taccctcatg ccttcaggaa agacttaaca 2580  
aaaacaatgt ttcactctggg gaactgagct aggcggtgag gttagcctgc cagttagaga 2640  
cagcccagtc tcttctggtt taatcattat gtttcaaatt gaaacagtct cttttgagta 2700  
aatgctcagt ttttcagctc ctctccactc tgctttccca aatggattct gttggtgaag 2760

<210> 79  
<211> 2753  
<212> DNA  
<213> Homo sapiens

<400> 79  
agaatttgga ctcatatcaa gatgctctga agaagaacaa cccttttagga tagccactgc 60  
aacatcatga ccaaagacaa agaacctatt gttaaaagct tccattttgt ttgccttatg 120  
atcataatag ttggaaccag aatccagttc tccgacggaa atgaatttgc agtagacaag 180  
tcaaaaagag gtcttattca tgttccaaaa gacctaccgc tgaaaaccaa agtcttagat 240  
atgtctcaga actacatcgc tgagcttcag gtctctgaca tgagctttct atcagagttg 300  
acagttttga gactttccca taacagaatc cagctacttg atttaagtgt tttcaagttc 360  
aaccaggatt tagaatatct ggatttatct cataatcagt tgcaaaagat atcctgccat 420  
cctatttgta gtttcaggca tttagatctc tcattcaatg atttcaaggc cctgcccac 480  
tgtaaggaat ttggcaactt atcacaactg aatttcttgg gattgagtgc tatgaagctg 540  
caaaaattag atttgctgcc aattgctcac ttgcatctaa gttatatcct tctggattta 600  
agaaattatt atataaaaga aatgagaca gaaagtctac aaattctgaa tgcaaaaacc 660  
cttcaccttg tttttcacc aactagttta ttcgctatcc aagtgaacat atcagttaat 720  
actttagggg gcttacaact gactaatatt aaattgaatg atgacaactg tcaagttttc 780 ;  
attaaatttt tatcagaact caccagaggt tcaaccttac tgaattttac cctcaaccac 840  
atagaaacga cttggaaatg cctggtcaga gtctttcaat ttctttggcc caaacctgtg 900

gaatatctca atatttacaa tttacaata attgaaagca ttcgtgaaga agattttact	960
tattctaaaa cgacattgaa agcattgaca atagaacata tcacgaacca agtttttctg	1020
ttttcacaga cagctttgta caccgtgttt tctgagatga acattatgat gttaaccatt	1080
tcagatacac cttttataca catgctgtgt cctcatgcac caagcacatt caagtttttg	1140
aactttaccc agaacgtttt cacagatagt atttttgaaa aatgttccac gttagttaaa	1200
ttggagacac ttatcttaca aaaaaatgga ttaaaagacc ttttcaaagt aggtctcatg	1260
acgaaggata tgccttcttt ggaaatactg gatgttagct ggaattcttt ggaatctggt	1320
agacataaag aaaactgcac ttgggttgag agtatagtgg tgttaaattt gtcttcaa	1380
atgcttactg actctgtttt cagatgttta cctcccagga tcaaggctact tgatcttcac	1440
agcaataaaa taaagagcgt tcctaaacaa gtcgtaaaac tggagcttt gcaagaactc	1500
aatgttgctt tcaattcttt aactgacctt cctggatgtg gcagctttag cagcctttct	1560
gtattgatca ttgatcacia ttcagtttcc caccatcgg ctgatttctt ccagagctgc	1620
cagaagatga ggtcaataaa agcaggggac aatccattcc aatgtacctg tgagctaaga	1680
gaatttgtca aaaatataga ccaagtatca agtgaagtgt tagagggtg gcctgattct	1740
tataagtgtg actaccaga aagttataga ggaagcccac taaaggactt tcacatgtct	1800
gaattatcct gcaacataac tctgctgac gtcaccatcg gtgccaccat gctggtgtg	1860
gctgtgactg tgacctcct ctgcatctac ttggatctgc cctggatatct caggatggtg	1920
tgccagtga cccagactcg gcgcagggcc aggaacatac ccttagaaga actccaaaga	1980
aacctccagt ttcagtcttt tatttcatat agtgaacatg attctgcctg ggtgaaaagt	2040
gaattggtac cttacctaga aaaagaagat atacagattt gtcttcatga gaggaacttt	2100
gtccctggca agagcattgt ggaaaatatc atcaactgca ttgagaagag ttacaagtcc	2160
atctttgttt tgtctcccaa ctttgtocag agtgagtggg gccattacga actctatatt	2220
gcccatacaca atctctttca tgaaggatct aataacttaa tctcatctt actggaaccc	2280
attccacaga acagcattcc caacaagtac cacaagctga aggtctctcat gacgcagcgg	2340
acttatattgc agtggcccaa ggagaaaagc aaacgtgggc tcttttgggc taacattaga	2400
gccgctttta atatgaaatt aacactagtc actgaaaaca atgatgtgaa atcttaaaaa	2460
aatttaggaa attcaactta agaaaccatt atttacttgg atgatggtga atagtacagt	2520
cgtaagtaac tgtctggagg tgcctccatt atcctcatgc cttcaggaaa gacttaacaa	2580
aaacaatgtt tcatctgggg aactgagcta ggcggtgagg ttagcctgcc agttagagac	2640
agcccagtct cttctggttt aatcattatg tttcaaattg aaacagtctc ttttgagtaa	2700
atgctcagtt tttcagctcc tctccactct gctttcccaa atggattctg ttg	2753

<210> 80  
 <211> 796  
 <212> PRT  
 <213> Homo sapiens

<400> 80

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
 1 5 10 15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
 20 25 30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
 35 40 45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
 50 55 60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
 65 70 75 80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
 85 90 95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
 100 105 110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
 115 120 125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
 130 135 140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
 145 150 155 160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
 165 170 175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
 180 185 190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
 195 200 205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
 210 215 220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
 225 230 235 240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu  
 245 250 255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
 260 265 270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
 275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
 290 295 300  
 Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
 305 310 315 320  
 Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
 325 330 335  
 Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
 340 345 350  
 Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
 355 360 365  
 Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
 370 375 380  
 Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
 385 390 395 400  
 Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
 405 410 415  
 Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
 420 425 430  
 Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu  
 435 440 445  
 Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
 450 455 460  
 Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
 465 470 475 480  
 Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
 485 490 495  
 Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
 500 505 510  
 Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
 515 520 525  
 Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
 530 535 540  
 Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
 545 550 555 560  
 Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
 565 570 575  
 Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
 580 585 590  
 Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr  
 595 600 605  
 Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr



610 615 620  
 Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
 625 630 635 640  
 Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
 645 650 655  
 Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
 660 665 670  
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
 675 680 685  
 Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
 690 695 700  
 Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
 705 710 715 720  
 His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu  
 725 730 735  
 Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
 740 745 750  
 Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
 755 760 765  
 Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys  
 770 775 780  
 Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
 785 790 795

<210> 81  
 <211> 796  
 <212> PRT  
 <213> Homo sapiens

<400> 81

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
 1 5 10 15  
 Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
 20 25 30  
 Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
 35 40 45  
 Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
 50 55 60  
 Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
 65 70 75 80  
 Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
 85 90 95  
 Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
 100 105 110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
 115 120 125  
 Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
 130 135 140  
 Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
 145 150 155 160  
 Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
 165 170 175  
 Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
 180 185 190  
 Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
 195 200 205  
 Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
 210 215 220  
 Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
 225 230 235 240  
 Phe Leu Ser Glu Leu Thr Arg Gly Ser Thr Leu Leu Asn Phe Thr Leu  
 245 250 255  
 Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
 260 265 270  
 Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
 275 280 285  
 Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
 290 295 300  
 Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
 305 310 315 320  
 Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
 325 330 335  
 Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
 340 345 350  
 Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
 355 360 365  
 Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
 370 375 380  
 Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
 385 390 395 400  
 Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
 405 410 415  
 Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
 420 425 430  
 Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu

435 440 445  
 Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
 450 455 460  
 Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
 465 470 475 480  
 Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
 485 490 495  
 Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
 500 505 510  
 Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
 515 520 525  
 Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
 530 535 540  
 Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
 545 550 555 560  
 Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
 565 570 575  
 Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
 580 585 590  
 Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr  
 595 600 605  
 Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr  
 610 615 620  
 Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
 625 630 635 640  
 Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
 645 650 655  
 Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
 660 665 670  
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
 675 680 685  
 Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
 690 695 700  
 Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
 705 710 715 720  
 His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu  
 725 730 735  
 Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
 740 745 750  
 Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
 755 760 765  
 Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys

770                      775                      780  
 Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
 785                      790                      795

<210> 82  
 <211> 796  
 <212> PRT  
 <213> Homo sapiens

<400> 82

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
 1                      5                      10                      15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
 20                      25                      30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
 35                      40                      45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
 50                      55                      60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
 65                      70                      75                      80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
 85                      90                      95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
 100                      105                      110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
 115                      120                      125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
 130                      135                      140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
 145                      150                      155                      160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
 165                      170                      175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
 180                      185                      190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
 195                      200                      205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
 210                      215                      220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
 225                      230                      235                      240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu  
 245                      250                      255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
 260                      265                      270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
 275 280 285  
 Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
 290 295 300  
 Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
 305 310 315 320  
 Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
 325 330 335  
 Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
 340 345 350  
 Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
 355 360 365  
 Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
 370 375 380  
 Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
 385 390 395 400  
 Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
 405 410 415  
 Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
 420 425 430  
 Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu  
 435 440 445  
 Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
 450 455 460  
 Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
 465 470 475 480  
 Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
 485 490 495  
 Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
 500 505 510  
 Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
 515 520 525  
 Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
 530 535 540  
 Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
 545 550 555 560  
 Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
 565 570 575  
 Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
 580 585 590  
 Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr

595                      600                      605  
 Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr  
 610                      615                      620  
 Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
 625                      630                      635                      640  
 Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
 645                      650                      655  
 Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
 660                      665                      670  
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
 675                      680                      685  
 Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
 690                      695                      700  
 Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
 705                      710                      715                      720  
 His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu  
 725                      730                      735  
 Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
 740                      745                      750  
 Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
 755                      760                      765  
 Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys  
 770                      775                      780  
 Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
 785                      790                      795

<210> 83  
 <211> 2604  
 <212> DNA  
 <213> murine

<400> 83  
 aagtaaaaat gctgtgaaga atggtaaagt ccctctgga tagcctctgc aacatgagcc 60  
 aagacagaaa acccatcgtg gggagtttcc actttgtttg cgccctggcc ttaatagtcg 120  
 gaagcatgac cccgttctct aatgaacttg agtctatggt agactattca aacaggaacc 180  
 ttactcatgt ccccaaagac ctgccaccaa gaacaaaagc cctgagtctg tctcaaaact 240  
 ctatatctga gcttcggatg cctgatatca gctttctgtc agagctgaga gttctgagac 300  
 tctccacaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag 360  
 aatacctgga tgtctcacac aatcggttgc aaaacatctc ttgctgccct atggcgagcc 420  
 tgaggcatct agacctctca ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg 480  
 gcaacctgac gaagctgact ttctgggat taagtgtctc caagttccga caactggatc 540

tgtctccagt tgcctcacttg catctaagct gcattcttct ggacttagtg agtcatcata 600  
taaaaggcgg ggaaacagaa agtcttcaga ttcccaatac caccgttctc catttggtct 660  
ttcatccaaa tagcttggtc tctgttcaag tgaacatgct tgtaaacgct ttaggacatt 720  
tacaactgag taatattaaa ttgaatgatg aaaactgtca aagggttaatg acatttttat 780  
cagaactcac cagaggcca accttattga atgtgacct ccagcacata gaaacaacct 840  
ggaagtgtc ggtaaactt ttccaattct tttggcccc accggtggag tacctcaata 900  
tttacaactt aacgataact gagagaatcg acagggaaga atttacttac tcggagacag 960  
cactgaagtc actgatgata gagcacgtca aaaaccaagt gttcctcttt tcaaaggagg 1020  
cgctatactc ggtgtttgct gagatgaaca tcaagatgct ctctatctca gacacctt 1080  
tcatccacat ggtgtgcccc ccatcccaa gctcatttac atttctgaac ttaccaga 1140  
atgtttttac tgacagtgtt tttcaaggct gttccacctt aaagagattg cagacactta 1200  
tcttacaag gaatggttg aagaactttt taaagtagc tctcatgact aagaatatgt 1260  
cctctctgga aactttggat gtagtttga attctttgaa ctctcatgca tatgacagga 1320  
catgcgcctg ggctgagagc atattggtgt tgaatttgtc ttogaatatg cttacaggct 1380  
ctgtcttcag atgcttacct cccaaggta aggtccttga ccttcacaac aacaggataa 1440  
tgagcatccc taaagatgtc acccacctgc aggtcttga ggaactcaat gtagcatcca 1500  
actccttaac tgaccttctt ggggtgtggg ccttcagcag cctttctgtg ctggtcatcg 1560  
accataactc agtttcccat ccctctgagg atttcttcca gagctgtcag aatattagat 1620  
ccctaacagc gggaaacaac ccattccaat gcacatgtga gctgagggac tttgtcaaga 1680  
acataggctg ggtagcaaga gaagtgttg agggctggcc tgactcttac aggtgtgact 1740  
accagaaaag ctctaaggga actgcactga gggacttcca catgtctcca ctgtcctgtg 1800  
atactgttct gctgactgtc accatcgggg ccactatgct ggtgctggct gtcactgggg 1860  
ctttcctctg tctctacttt gacctgccct ggtatgtgag gatgctgtgt cagtggacac 1920  
agaccaggca cagggccagg cacatcccct tagaggaact ccagagaaac ctccagttcc 1980  
atgcttttgt ctcatacagt gagcatgatt ctgctgggt gaagaacgaa ttactacca 2040  
acctagagaa agatgacatc cgggtttgcc tccatgagag gaactttgtc cctggcaaga 2100  
gcattgtgga gaacatcatc aatttcattg agaagagtta caaggccatc tttgtgctgt 2160  
ctccccactt catccagagt gagtgggtgcc attatgaact ctattttgcc catcataatc 2220  
tcttccatga aggtctgat aacttaatcc tcatcttgct ggaaccatt ctacagaaca 2280  
acattcccag tagataccac aagctgcggg ctctcatggc acagcggact tacttggaat 2340  
ggcctactga gaagggcaaa cgtgggctgt tttgggcaa ccttagagct tcatttatta 2400  
tgaagttagc cttagtcaat gaggatgatg tgaaaacttg aaacttggt ttctaactta 2460

ataaaactgtc aacctgggct ctcatagaaca ctgtgggtttt cagttcctac ctggagggtac 2520  
ttctgttgtg gtgtcttagt ttgctctgtg cttatgataa ataacatgtt tagaagtagt 2580  
ttatgaagggt gctaagttca ttaa 2604

<210> 84  
<211> 2604  
<212> DNA  
<213> murine

<400> 84  
aagtaaaaat gctgtgaaga atggtaaagt ccctctggga tagcctctgc aacatgagcc 60  
aagacagaaa acccatcgtg gggagtttcc actttgtttg cggcctggcc ttaatagtcg 120  
gaagcatgac cccgttctct aatgaacttg agtctatggg agactattca aacaggaacc 180  
ttactcatgt ccccaaagac ctgccaccaa gaacaaaagc cctgagtctg tctcaaaact 240  
ctatatctga gcttcggatg cctgatatca gctttctgtc agagctgaga gttctgagac 300  
tctcccacaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag 360  
aatacctgga tgtctcacac aatcgggtgc aaaacatctc ttgctgccct atggcgagcc 420  
tgaggcatct agacctctca ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg 480  
gcaacctgac gaagctgact ttccctgggat taagtgtgc caagttccga caactggatc 540  
tgctcccagt tgctcacttg catctaagct gcattcttct ggacttagtg agtcatcata 600  
taaaaggcgg ggaaacagaa agtcttcaga ttccaatac caccgttctc catttggtct 660  
ttcatccaaa tagcttggtc tctgttcaag tgaacatgtc tgtaaacgct ttaggacatt 720  
tacaactgag taatattaaa ttgaatgatg aaaactgtca aaggttaatg acatttttat 780  
cagaactcac cagaggcca accttattga atgtgaccct ccagcacata gaaacaacct 840  
ggaagtgtc ggttaaaact ttccaattct tttggccccg accggtggag tacctcaata 900  
tttacaactt aacgataact gagagaatcg acaggaaga atttacttac tcggagacag 960  
cactgaagtc actgatgata gagcacgtca aaaaccaagt gttcctcttt tcaaaggagg 1020  
cgctatactc ggtgtttgct gagatgaaca tcaagatgct ctctatctca gacaccctt 1080  
tcatccacat ggtgtgcccg ccatcccaa gctcatttac atttctgaac tttaccaga 1140  
atgtttttac tgacagtgtt tttcaaggct gttccacctt aaagagattg cagacactta 1200  
tcttaciaag gaatggttg aagaactttt ttaaagtagc tctcatgact aagaatatgt 1260  
cctctctgga aactttggat gttagtttga attctttgaa ctctcatgca tatgacagga 1320  
catgcgcctg ggctgagagc atattggtgt tgaatttgc ttcgaatatg cttacaggct 1380  
ctgtcttcag atgcttacct cccaaggta aggtccttga ccttcacaac aacaggataa 1440



tgagcatccc	taaagatgtc	acccacctgc	aggctttgca	ggaactcaat	gtagcatcca	1500
actccttaac	tgaccttcct	gggtgtgggg	ccttcagcag	cctttctgtg	ctgggtcatcg	1560
accataactc	agtttcccat	ccctctgagg	atttcttcca	gagctgtcag	aatattagat	1620
ccctaacagc	gggaaacaac	ccattccaat	gcacatgtga	gctgagggac	tttgtcaaga	1680
acataggctg	ggtagcaaga	gaagtgggtg	agggtgggcc	tgactcttac	aggtgtgact	1740
acccagaaag	ctctaagggg	actgcactga	gggacttcca	catgtctcca	ctgtcctgtg	1800
atactgttct	gctgactgtc	accatcgggg	ccactatgct	ggtgctgggt	gtcactgggg	1860
ctttcctctg	tctctacttt	gacctgccct	ggtatgtgag	gatgctgtgt	cagtggacac	1920
agaccaggca	cagggccagg	cacatcccct	tagaggaact	ccagagaaac	ctccagttcc	1980
atgcttttgt	ctcatacagt	gagcatgatt	ctgcctgggt	gaagaacgaa	ttactaccca	2040
acctagagaa	agatgacatc	cgggtttgcc	tccatgagag	gaactttgtc	cctggcaaga	2100
gcattgtgga	gaacatcatc	aatttcattg	agaagagtta	caaggccatc	tttgtgtgtg	2160
ctccccactt	catccagagt	gagtgggtgc	attatgaact	ctattttgcc	catcataatc	2220
tcttccatga	aggctctgat	aacttaatcc	tcctcttgct	ggaaccatt	ctacagaaca	2280
acattcccag	tagataccac	aagctgcggg	ctctcatggc	acagcggact	tacttggaat	2340
ggcctactga	gaagggcaaa	cgtgggctgt	tttgggcaa	ccttagagct	tcatttatta	2400
tgaagttagc	cttagtcaat	gaggatgatg	tgaaaacttg	aaacttggtg	ttctaactta	2460
ataaactgtc	aacctgggct	ctcatgaaca	ctgtggtttt	cagttcctac	ctggaggtac	2520
ttctgttgtg	gtgtcttagt	ttgctctgtg	cttatgataa	ataacatgtt	tagaagtagt	2580
ttatgaagg	gctaagttca	ttaa				2604

<210> 85  
 <211> 2421  
 <212> DNA  
 <213> murine

<400> 85	
atggtaaagt	ccctctggga tagcctctgc aacatgagcc aagacagaaa acccatcgtg 60
gggagtttcc	actttgtttg cgccctggcc ttaatagtcg gaagcatgac ccggttctct 120
aatgaacttg	agtctatggt agactattca aacaggaacc ttactcatgt ccccaaagac 180
ctgccaccaa	gaacaaaagc cctgagtctg tctcaaaact ctatatctga gcttcggatg 240
cctgatatca	gctttctgtc agagctgaga gttctgagac tctcccacaa caggatacgg 300
agccttgatt	tccatgtatt cttgttcaat caggacttag aatacctgga tgtctcacac 360
aatcggttgc	aaaacatctc ttgctgccct atggcgagcc tgaggcatct agacctctca 420
ttcaatgact	ttgatgtact gcctgtgtgt aaggaatttg gcaacctgac gaagctgact 480

ttcctgggat taagtgtgc aaagttccga caactggatc tgctcccagt tgctcacttg	540
catctaagct gcattcttct ggacttagtg agttatcata taaaaggcgg ggaaacagaa	600
agtcttcaga ttcccaatac caccgttctc catttggtct ttcattccaaa tagcttgttc	660
tctgttcaag tgaacatgtc tgtaaacgct ttaggacatt tacaactgag taatattaaa	720
ttgaatgatg aaaactgtca aagggttaatg acatttttat cagaactcac cagagggtcca	780
accttattga atgtgacctt ccagcacata gaaacaacct ggaagtgtc gggttaaactt	840
ttccaattct tttggccccg accggtggag tacctcaata ttacaactt aacgataact	900
gagagaatcg acaggaaga atttacttac tcggagacag cactgaagtc actgatgata	960
gagcacgtca aaaaccaagt gttcctcttt tcaaaggagg cgctatactc ggtgtttgct	1020
gagatgaaca tcaagatgct ctctatctca gacaccctt tcatccacat ggtgtgccccg	1080
ccatcccaa gctcatttac atttctgaac tttaccaga atgtttttac tgacagtgtt	1140
tttcaaggct gttccacctt aaagagattg cagacactta tcttacaag gaatggtttg	1200
aagaactttt ttaaagtagc tctcatgact aagaatatgt cctctctgga aactttggat	1260
gttagtttga attctttgaa ctctcatgca tatgacagga catgcgcctg ggctgagagc	1320
atattggtgt tgaatttgtc ttogaatatg cttacaggct ctgtcttcag atgcttacct	1380
ccaagggtca aggtccttga ccttcacaac aacaggataa tgagcatccc taaagatgtc	1440
accacctgc aggttttgca ggaactcaat gtagcatcca actccttaac tgaccttct	1500
gggtgtgggg ccttcagcag ctttctgtg ctggtcatcg accataactc agtttcccat	1560
ccctctgagg atttcttcca gagctgtcag aatattagat ccctaacagc gggaaacaac	1620
ccattccaat gcacatgtga gctgaggac tttgtcaaga acataggctg ggtagcaaga	1680
gaagtgggtg agggctggcc tgactcttac aggtgtgact acccagaaag ctctaaggga	1740
actgcactga gggacttcca catgtctcca ctgtcctgtg atactgttct gctgactgtc	1800
accatcgggg ccactatgct ggtgctggt gtactgggg ctttctctg tctctacttt	1860
gacctgcctt ggtatgtgag gatgctgtgt cagtggacac agaccaggca cagggccagg	1920
cacatccct tagaggaact ccagagaaac ctccagttcc atgcttttgt ctcatagct	1980
gagcatgatt ctgcctgggt gaagaacgaa ttactacca acctagagaa agatgacatc	2040
cgggtttgcc tccatgagag gaactttgtc cctggcaaga gcattgtgga gaacatcatc	2100
aatttcattg agaagagtta caaggccatc tttgtgtgt ctccccactt catccagagt	2160
gagtgggtgcc attatgaact ctattttgcc catcataatc tcttccatga aggctctgat	2220
aacttaatcc tcatcttgtc ggaaccatt ctacagaaca acattcccag tagataccac	2280
aagctgctgg ctctcatggc acagcggact tacttggaat ggcctactga gaagggcaaa	2340
cgtgggctgt tttgggcaa ccttagagct tcatttatta tgaagttagc cttagtcaat	2400

gaggatgatg tgaaaacttg a

2421

&lt;210&gt; 86

&lt;211&gt; 806

&lt;212&gt; PRT

&lt;213&gt; murine

&lt;400&gt; 86

Met	Val	Lys	Ser	Leu	Trp	Asp	Ser	Leu	Cys	Asn	Met	Ser	Gln	Asp	Arg
1				5					10					15	

Lys	Pro	Ile	Val	Gly	Ser	Phe	His	Phe	Val	Cys	Ala	Leu	Ala	Leu	Ile
			20					25					30		

Val	Gly	Ser	Met	Thr	Pro	Phe	Ser	Asn	Glu	Leu	Glu	Ser	Met	Val	Asp
		35					40					45			

Tyr	Ser	Asn	Arg	Asn	Leu	Thr	His	Val	Pro	Lys	Asp	Leu	Pro	Pro	Arg
	50					55					60				

Thr	Lys	Ala	Leu	Ser	Leu	Ser	Gln	Asn	Ser	Ile	Ser	Glu	Leu	Arg	Met
65					70					75					80

Pro	Asp	Ile	Ser	Phe	Leu	Ser	Glu	Leu	Arg	Val	Leu	Arg	Leu	Ser	His
				85					90					95	

Asn	Arg	Ile	Arg	Ser	Leu	Asp	Phe	His	Val	Phe	Leu	Phe	Asn	Gln	Asp
			100					105					110		

Leu	Glu	Tyr	Leu	Asp	Val	Ser	His	Asn	Arg	Leu	Gln	Asn	Ile	Ser	Cys
		115					120					125			

Cys	Pro	Met	Ala	Ser	Leu	Arg	His	Leu	Asp	Leu	Ser	Phe	Asn	Asp	Phe
		130				135					140				

Asp	Val	Leu	Pro	Val	Cys	Lys	Glu	Phe	Gly	Asn	Leu	Thr	Lys	Leu	Thr
145					150					155					160

Phe	Leu	Gly	Leu	Ser	Ala	Ala	Lys	Phe	Arg	Gln	Leu	Asp	Leu	Leu	Pro
				165					170					175	

Val	Ala	His	Leu	His	Leu	Ser	Cys	Ile	Leu	Leu	Asp	Leu	Val	Ser	His
			180					185					190		

His	Ile	Lys	Gly	Gly	Glu	Thr	Glu	Ser	Leu	Gln	Ile	Pro	Asn	Thr	Thr
		195					200						205		

Val	Leu	His	Leu	Val	Phe	His	Pro	Asn	Ser	Leu	Phe	Ser	Val	Gln	Val
	210					215					220				

Asn	Met	Ser	Val	Asn	Ala	Leu	Gly	His	Leu	Gln	Leu	Ser	Asn	Ile	Lys
225					230					235					240

Leu	Asn	Asp	Glu	Asn	Cys	Gln	Arg	Leu	Met	Thr	Phe	Leu	Ser	Glu	Leu
			245						250					255	

Thr	Arg	Gly	Pro	Thr	Leu	Leu	Asn	Val	Thr	Leu	Gln	His	Ile	Glu	Thr
			260					265					270		

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
 275 280 285  
 Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
 290 295 300  
 Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
 305 310 315 320  
 Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
 325 330 335  
 Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
 340 345 350  
 Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
 355 360 365  
 Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
 370 375 380  
 Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
 385 390 395 400  
 Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu  
 405 410 415  
 Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
 420 425 430  
 Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
 435 440 445  
 Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
 450 455 460  
 Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
 465 470 475 480  
 Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
 485 490 495  
 Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
 500 505 510  
 Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
 515 520 525  
 Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
 530 535 540  
 Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg  
 545 550 555 560  
 Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu  
 565 570 575  
 Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser  
 580 585 590  
 Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val

595 600 605  
 Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp  
 610 615 620  
 Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg  
 625 630 635 640  
 His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe  
 645 650 655  
 Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu  
 660 665 670  
 Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn  
 675 680 685  
 Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu  
 690 695 700  
 Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser  
 705 710 715 720  
 Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His  
 725 730 735  
 Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu Glu Pro Ile Leu Gln  
 740 745 750  
 Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln  
 755 760 765  
 Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe  
 770 775 780  
 Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn  
 785 790 795 800  
 Glu Asp Asp Val Lys Thr  
 805

<210> 87  
 <211> 806  
 <212> PRT  
 <213> murine

<400> 87

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
 1 5 10 15  
 Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
 20 25 30  
 Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
 35 40 45  
 Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
 50 55 60  
 Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
 65 70 75 80

Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His  
85 90 95

Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
100 105 110

Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
115 120 125

Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
130 135 140

Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
145 150 155 160

Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
165 170 175

Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser Tyr  
180 185 190

His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
195 200 205

Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
210 215 220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
225 230 235 240

Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
245 250 255

Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
260 265 270

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
275 280 285

Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
290 295 300

Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
305 310 315 320

Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
325 330 335

Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
340 345 350

Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
355 360 365

Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
370 375 380

Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
385 390 395 400

Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu

405 410 415  
 Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
 420 425 430  
 Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
 435 440 445  
 Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
 450 455 460  
 Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
 465 470 475 480  
 Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
 485 490 495  
 Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
 500 505 510  
 Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
 515 520 525  
 Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
 530 535 540  
 Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg  
 545 550 555 560  
 Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu  
 565 570 575  
 Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser  
 580 585 590  
 Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val  
 595 600 605  
 Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp  
 610 615 620  
 Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg  
 625 630 635 640  
 His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe  
 645 650 655  
 Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu  
 660 665 670  
 Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn  
 675 680 685  
 Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu  
 690 695 700  
 Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser  
 705 710 715 720  
 Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His  
 725 730 735  
 Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu Glu Pro Ile Leu Gln

740 745 750  
 Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln  
 755 760 765  
 Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe  
 770 775 780  
 Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn  
 785 790 795 800  
 Glu Asp Asp Val Lys Thr  
 805

<210> 88  
 <211> 806  
 <212> PRT  
 <213> murine

<400> 88

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
 1 5 10 15  
 Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
 20 25 30  
 Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
 35 40 45  
 Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
 50 55 60  
 Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
 65 70 75 80  
 Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His  
 85 90 95  
 Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
 100 105 110  
 Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
 115 120 125  
 Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
 130 135 140  
 Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
 145 150 155 160  
 Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
 165 170 175  
 Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser His  
 180 185 190  
 His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
 195 200 205  
 Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
 210 215 220



Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
 225 230 235 240  
 Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
 245 250 255  
 Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
 260 265 270  
 Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
 275 280 285  
 Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
 290 295 300  
 Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
 305 310 315 320  
 Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
 325 330 335  
 Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
 340 345 350  
 Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
 355 360 365  
 Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
 370 375 380  
 Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
 385 390 395 400  
 Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu  
 405 410 415  
 Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
 420 425 430  
 Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
 435 440 445  
 Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
 450 455 460  
 Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
 465 470 475 480  
 Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
 485 490 495  
 Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
 500 505 510  
 Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
 515 520 525  
 Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
 530 535 540  
 Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg

545                      550                      555                      560  
 Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu  
                                  565                      570                      575  
  
 Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser  
                                  580                      585                      590  
  
 Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val  
                                  595                      600                      605  
  
 Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp  
                                  610                      615                      620  
  
 Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg  
                                  625                      630                      635                      640  
  
 His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe  
                                  645                      650                      655  
  
 Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu  
                                  660                      665                      670  
  
 Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn  
                                  675                      680                      685  
  
 Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu  
                                  690                      695                      700  
  
 Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser  
                                  705                      710                      715                      720  
  
 Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His  
                                  725                      730                      735  
  
 Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu Glu Pro Ile Leu Gln  
                                  740                      745                      750  
  
 Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln  
                                  755                      760                      765  
  
 Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe  
                                  770                      775                      780  
  
 Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn  
                                  785                      790                      795                      800  
  
 Glu Asp Asp Val Lys Thr  
                                  805

<210> 89  
 <211> 795  
 <212> PRT  
 <213> murine

<400> 89

Met Ser Gln Asp Arg Lys Pro Ile Val Gly Ser Phe His Phe Val Cys  
 1                      5                      10                      15

Ala Leu Ala Leu Ile Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu  
                                  20                      25                      30

Glu Ser Met Val Asp Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys  
 35 40 45  
 Asp Leu Pro Pro Arg Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile  
 50 55 60  
 Ser Glu Leu Arg Met Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val  
 65 70 75 80  
 Leu Arg Leu Ser His Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe  
 85 90 95  
 Leu Phe Asn Gln Asp Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu  
 100 105 110  
 Gln Asn Ile Ser Cys Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu  
 115 120 125  
 Ser Phe Asn Asp Phe Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn  
 130 135 140  
 Leu Thr Lys Leu Thr Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln  
 145 150 155 160  
 Leu Asp Leu Leu Pro Val Ala His Leu His Leu Ser Cys Ile Leu Leu  
 165 170 175  
 Asp Leu Val Ser Tyr His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln  
 180 185 190  
 Ile Pro Asn Thr Thr Val Leu His Leu Val Phe His Pro Asn Ser Leu  
 195 200 205  
 Phe Ser Val Gln Val Asn Met Ser Val Asn Ala Leu Gly His Leu Gln  
 210 215 220  
 Leu Ser Asn Ile Lys Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr  
 225 230 235 240  
 Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu  
 245 250 255  
 Gln His Ile Glu Thr Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe  
 260 265 270  
 Phe Trp Pro Arg Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
 275 280 285  
 Thr Glu Arg Ile Asp Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu  
 290 295 300  
 Lys Ser Leu Met Ile Glu His Val Lys Asn Gln Val Phe Leu Phe Ser  
 305 310 315 320  
 Lys Glu Ala Leu Tyr Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu  
 325 330 335  
 Ser Ile Ser Asp Thr Pro Phe Ile His Met Val Cys Pro Pro Ser Pro  
 340 345 350  
 Ser Ser Phe Thr Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser

355 360 365  
 Val Phe Gln Gly Cys Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu  
 370 375 380  
 Gln Arg Asn Gly Leu Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys  
 385 390 395 400  
 Asn Met Ser Ser Leu Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn  
 405 410 415  
 Ser His Ala Tyr Asp Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val  
 420 425 430  
 Leu Asn Leu Ser Ser Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu  
 435 440 445  
 Pro Pro Lys Val Lys Val Leu Asp Leu His Asn Asn Arg Ile Met Ser  
 450 455 460  
 Ile Pro Lys Asp Val Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val  
 465 470 475 480  
 Ala Ser Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser  
 485 490 495  
 Leu Ser Val Leu Val Ile Asp His Asn Ser Val Ser His Pro Ser Glu  
 500 505 510  
 Asp Phe Phe Gln Ser Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn  
 515 520 525  
 Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile  
 530 535 540  
 Gly Trp Val Ala Arg Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg  
 545 550 555 560  
 Cys Asp Tyr Pro Glu Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His  
 565 570 575  
 Met Ser Pro Leu Ser Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly  
 580 585 590  
 Ala Thr Met Leu Val Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr  
 595 600 605  
 Phe Asp Leu Pro Trp Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr  
 610 615 620  
 Arg His Arg Ala Arg His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
 625 630 635 640  
 Gln Phe His Ala Phe Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
 645 650 655  
 Lys Asn Glu Leu Leu Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys  
 660 665 670  
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
 675 680 685  
 Ile Asn Phe Ile Glu Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro

690 695 700  
His Phe Ile Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
705 710 715 720  
His Asn Leu Phe His Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu  
725 730 735  
Glu Pro Ile Leu Gln Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg  
740 745 750  
Ala Leu Met Ala Gln Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly  
755 760 765  
Lys Arg Gly Leu Phe Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys  
770 775 780  
Leu Ala Leu Val Asn Glu Asp Asp Val Lys Thr  
785 790 795

<210> 90  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> consensus p50 subunit

<220>  
<221> misc\_feature  
<222> (7)..(7)  
<223> N = c or t

<400> 90  
ggggatnccc

10

<210> 91  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> consensus p65 subunit

<220>  
<221> misc\_feature  
<222> (4)..(4)  
<223> N = a or g

<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = a, c, g, or t

<400> 91  
gggnntttcc

10

<210> 92

<211> 22  
<212> DNA  
<213> artificial sequence

<220>

<223> consensus subunit

<400> 92  
agttgagggg actttcccag gc

22

<210> 93  
<211> 27  
<212> DNA  
<213> artificial sequence

<220>

<223> CREB binding site

<400> 93  
agagattgcc tgacgtcaga gagctag

27

<210> 94  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>

<223> AP-1 binding site

<400> 94  
cgcttgatga gtcagccgga a

21

<210> 95  
<211> 15  
<212> DNA  
<213> artificial sequence

<220>

<223> AP-1 binding site

<400> 95  
cgcatgagtc agaca

15

<210> 96  
<211> 19  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 96

1  
1  
tgcagaagtg aaactgagg

19

&lt;210&gt; . 97

&lt;211&gt; 11

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; ISRE

&lt;400&gt; 97

agaacgaaac a

11

&lt;210&gt; 98

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; artificial sequence .

&lt;220&gt;

&lt;223&gt; ISRE

&lt;400&gt; 98

gagaagtgaa agtgg

15

&lt;210&gt; 99

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; ISRE

&lt;400&gt; 99

taagaacatg aaactgaa

18

&lt;210&gt; 100

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; ISRE

&lt;400&gt; 100

atgaaactga aagta

15

&lt;210&gt; 101

&lt;211&gt; 16

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; ISRE

<400> 101  
tgaaaaccga aagcgc

16

<210> 102  
<211> 13  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 102  
agaaatggaa agt

13

<210> 103  
<211> 9  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 103  
tcacccac

9

<210> 104  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 104  
ctcacccac

10

<210> 105  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 105  
gccaccctac

10

<210> 106  
<211> 17  
<212> DNA  
<213> artificial sequence



<220>

<223> NFAT

<400> 106

tatgaaacag tttttcc

17

<210> 107

<211> 9

<212> DNA

<213> artificial sequence

<220>

<223> NFAT

<400> 107

aggaaactc

9

<210> 108

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> NFAT

<220>

<221> misc\_feature

<222> (2)..(2)

<223> N = a or g

<220>

<221> misc\_feature

<222> (5)..(5)

<223> N = a or g

<400> 108

anganattcc

10

<210> 109

<211> 16

<212> DNA

<213> artificial sequence

<220>

<223> NFAT

<400> 109

ccagttgagc cagaga

16

<210> 110

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> GAS

<400> 110

ctttcagttt catattactc taaatccatt

30

<210> 111

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> p53 consensus site

<220>

<221> misc\_feature

<222> (1)..(3)

<223> N = a or g

<220>

<221> misc\_feature

<222> (5)..(6)

<223> N = a or t

<220>

<221> misc\_feature

<222> (8)..(10)

<223> N = c or t

<400> 111

nnncnngnnn

10

<210> 112

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> p53 consensus site

<400> 112

aggcatgcct

10

<210> 113

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> p53 consensus site

<400> 113

gggcttgccc

10

<210> 114

<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 114  
gggcttgctt

10

<210> 115  
<211> 13  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 115  
gcctggactt gcc

13

<210> 116  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 116  
ggacatgccc gggcatgtcc

20

<210> 117  
<211> 23  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 117  
gtagcattag cccagacatg tcc

23

<210> 118  
<211> 36  
<212> DNA  
<213> artificial sequence

<220>

<223> TARE

<400> 118  
gaggtatgca gacaagagtc agagtttccc cttgaa

36

<210> 119  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> SRF

<220>  
<221> misc\_feature  
<222> (3)..(8)  
<223> N = a or t

<400> 119  
ccnnnnnnngg

10

<210> 120  
<211> 11  
<212> DNA  
<213> artificial sequence

<220>

<223> SRF

<400> 120  
ccaaataagg c

11

<210> 121  
<211> 670  
<212> DNA  
<213> Homo sapiens

<400> 121  
agaaaaattt taaaaaatta ttcattcata tttttaggag ttttgaatga ttggatatgt 60  
aattatattc atattattaa tgtgtatcta tatagatttt tattttgcat atgtactttg 120  
atacaaaatt tacatgaaca aattacacta aaagttattc cacaaatata cttatcaaatt 180  
taagttaaatt gtcaatagct tttaaactta aatttttagtt taacttttct gtcattcttt 240  
actttgaata aaaagagcaa actttgtagt ttttatctgt gaagtagagg tatacgtaat 300  
atacataaat agatatgcc aatctgtgtt attaaaattt catgaagatt tcaattagaa 360  
aaaaatacca taaaaggctt tgagtgcagg tgaaaaatag gcaatgatga aaaaaaatga 420  
aaaacttttt aaacacatgt agagagtgcg taaagaaagc aaaaacagag atagaagta 480  
caactagggga atttagaaaa tggaaattag tatgttcact atttaagacc tatgcacaga 540  
gcaaagtctt cagaaaacct agaggccgaa gttcaagggt atccatctca agtagcctag 600  
caatatattgc aacatcccaa tggccctgtc cttttcttta ctgatggccg tgctggtgct 660  
cagctacaaa 670

<210> 122  
<211> 207  
<212> DNA  
<213> Homo sapiens

<400> 122  
aggttctctg aaggccttgc ttctgcaga tgccttaaat agggaacata ctgatttcca 60  
ctttcttaat gcttctggac catttccatt tctgtttttg ctttcttct taactcttta 120  
catgagttta gagccgtgtt tctcaaatga tgggctagca cgcgtaagag ctcggtacct 180  
atcgatagag aaatgttctg gcacctg 207

<210> 123  
<211> 161  
<212> DNA  
<213> Homo sapiens

<400> 123  
aggttctctg aaggctttgc ttctgcaga tgccttaaat agggaacata ctgatttcca 60  
ctttcttaat gcttctggac cactttccat ttctgttttt gctttcttc ttgaactctt 120  
tacatgagtt tagagccgtg tttctcaacc atttgtttt t 161

<210> 124  
<211> 300  
<212> DNA  
<213> Homo sapiens

<400> 124  
ttctcaggtc gtttgctttc ctttgctttc tcccaagtct tgttttacaa tttgctttag 60  
tcattcactg aaactttaaa aaacattaga aaacctcaca gtttgtaaat ctttttccct 120  
attatatata tcataagata ggagcttaaa taaagagttt tagaaactac taaaatgtaa 180  
atgacatagg aaaactgaaa gggagaagtg aaagtgggaa attcctctga atagagagag 240  
gaccatctca tataaatagg ccatacccac ggagaaagga cattctaact gcaacctttc 300

<210> 125  
<211> 401  
<212> DNA  
<213> Homo sapiens

<400> 125  
gatctgtaat gaataagcag gaactttgaa gactcagtga ctcagtgagt aataaagact 60  
cagtgacttc tgatcctgtc ctaactgcc a ctccttggtg tcccaagaaa gcggcttcct 120  
gctctctgag gaggaccct tccctggaag gtaaaactaa ggatgtcagc agagaaattt 180  
ttccaccatt ggtgcttggt caaagaggaa actgatgagc tcaactctaga tgagagagca 240  
gtgagggaga gacagagact cgaatttccg gagctatttc agttttcttt tccgttttgt 300

gcaatttcac ttatgatacc ggccaatgct tggttgctat tttggaaact ccccttaggg 360  
 gatgcccctc aactggccct ataaagggcc agcctgagct g 401

<210> 126  
 <211> 781  
 <212> DNA  
 <213> Homo sapiens

<400> 126  
 ggttgtctgt atgcctccct gagggtatct cactttctgc tcccatccgc ccctatgagc 60  
 gagtacctat gagcacagga tgtgcacata tttgagtctt attagtggta cagcagttt 120  
 tatcatctcc ccaggtctgt gtctgtatga aatgtgcatg ggtgtgtgtg tgcacgcgtg 180  
 tgttcccact cggggaatgt ggggagaggt gcatggagcc aagatgggtg gtaaatagta 240  
 tgtttctgaa attaaaggac taatgtggag gaaggcgcgc cagatgtact aaaccctttg 300  
 ccttcatctc atcctctctg acttgggaag aaccaggatt ttgtttttta gcccttgggc 360  
 atacagttgt tccatcccga catgaactca gcctcccgtc tgaccgcccc ttggccttcc 420  
 ttcttctctg atctgtggaa cccagggaat ctgcctagtg ctgtctccaa gcaccttggc 480  
 catgatgtaa acccagagaa attagcatct ccatctcctt ccttattccc caccctttt 540  
 tcatttctct ttagttcatt acctgggatt ttgatgtcta tgttccctcc tcgttattga 600  
 tacacacaca gagagagaca aacaaaaaag gaacttcttg aaattcccc agaaggtttt 660  
 gagagttggt ttcaatgttg caacaagtca gtttctagtt taagtttcca tcagaaagga 720  
 gtagagtata taagttccag taccagcaac agcagcagaa gaaacaacat ctgtttcagg 780  
 g 781

<210> 127  
 <211> 277  
 <212> DNA  
 <213> Homo sapiens

<400> 127  
 gcatctccat ctcttccctt attccccacc caaaagtcac ttctcttagg ttcattacct 60  
 gggattttga tgtctatggt ccctcctcgt tattgatata cacacagaga gagacaaaca 120  
 aaaaagggaac ttcttgaaat tccccagaa ggttttgaga gttgttttca atgttgcaac 180  
 aagtcagttt ctagttttaag ttccatcag aaaggagtag agtatataag ttccagtacc 240  
 agcaacagca gcagaagaaa caacatctgt ttcaggg 277

<210> 128  
 <211> 305  
 <212> DNA  
 <213> Homo sapiens

<400> 128

caagacatgc caagtgctga gtcactaata aagaaaaaag aagtaaagga agagtgggttc 60  
tgcttcttag cgctagcctc aatgacgacc taagctgcac ttttccccct agttgtgtct 120  
tgcgatgeta aaggacgtca ttgcacaatc ttaataaggt ttccaatcag cccacccgc 180  
tctggcccca ccctcaccct ccaacaaaga tttatcaa atgtgggatttt cccatgagtc 240  
tcaatattag agtctcaacc cccaataaat ataggactgg agatgtctct gaggtcatt 300  
ctgcc 305

<210> 129  
<211> 1181  
<212> DNA  
<213> Homo sapiens

<400> 129  
cctgcaagag acaccatcct gaggggaaga gggcttctga accagcttga cccaataaga 60  
aattcttggg tgccgacggg gacagcagat tcagagccta gagccgtgcc tgcgtccgta 120  
gtttccttct agcttctttt tgatttcaaa tcaagactta cagggagagg gagcgataaa 180  
cacaaactct gcaagatgcc acaaggctct cctttgacat cccaacaaa gaaggtagt 240  
agtaatctcc cccttcttgc cctgaaccaa gtggcttcag taagtttcag ggctccagga 300  
gacctgggca tgcaggtgcc gatgaaacag tgggaagag actcagtgcc agtggcagtg 360  
gggagagcac tcgcagcaca ggcaaacctc tggcacaaga gcaaagtcct cactggagga 420  
ttccaaggg tcaactggga gagggcaggc agcagccaac ctctcttaag tgggctgaag 480  
caggtgaaga aatggcagaa gacgcggtgg tggcaaaaag gagtcacaca ctccacctgg 540  
agacgccttg aagtaactgc acgaaatttg agggtgcca ggcagttcta caacagccgc 600  
ctcacaggga gagccagaac acagcaagaa ctcatatgac tggtagtatt accttcttca 660  
taatcccagg cttggggggc tgcgatggag tcagaggaaa ctcatgagc aacatctttg 720  
gtttttacaa tacaaattaa ctggaacgct aaattctagc ctgttaatct ggtcactgaa 780  
aaaaaaaaa tttttttttt ttcaaaaaac atagcttttag cttatttttt ttttctcttt 840  
gtaaaacttc gtgcatgact tcagctttac tcttgtcaag acatgccaaag tgctgagtc 900  
ctaataaaga aaaaagaagt aaaggaagag tggttctgct tcttagcgct agcctcaatg 960  
acgacctaa ctgcactttt cccctagtt gtgtcttgcg atgctaaagg acgtcattgc 1020  
acaatcttaa taaggtttcc aatcagcccc acccgctctg gccccaccct caccctccaa 1080  
caaagattta tcaaatgtgg gatcttccca tgagtctcaa tattagagtc tcaaccccca 1140  
ataaatatag gactggagat gtctctgagg ctcatctgc c 1181

<210> 130  
<211> 778  
<212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 130

```

ctaccacttg tctattctgc tatatagtca gtccttacat tgctttcttc ttctgataga      60
ccaaactott taaggacaag tacctagtct tatctatttc tagatcccc acattactca      120
gaaagttact ccataaatgt ttgtggaact gatttctatg tgaagacatg tgccccctca      180
ctctgttaac tagcattaga aaaacaaatc ttttgaaaag ttgtagtatg cccctaagag      240
cagtaacagt tcctagaaac tctctaaaat gcttagaaaa agatttattt taaattacct      300
ccccaataaa atgattggct ggcttatctt caccatcatg atagcatctg taattaactg      360
aaaaaaaaata attatgccat taaaagaaaa tcatccatga tcttgttcta acacctgcca      420
ctctagtact atatctgtca catggtctat gataaagtta tctagaaata aaaaagcata      480
caattgataa ttcaccaa at tgtggagctt cagtatttta aatgtatatt aaaattaaat      540
tatttttaaag atcaaagaaa actttcgtca tactccgtat ttgataagga acaaatagga      600
agtgtgatga ctcagggttg ccctgagggg atgggccatc agttgcaa at cgtggaattt      660
cctctgacat aatgaaaaga tgaggggtgca taagttctct agtagggtga tgatataaaa      720
agccaccgga gcactccata aggcacaaac tttcagagac agcagagcac acaagctt      778

```

&lt;210&gt; 131

&lt;211&gt; 207

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 131

```

actccgtatt tgataaggaa caaataggaa gtgtgatgac tcaggtttgc cctgagggga      60
tgggccatca gttgcaa atc gtggaatttc ctctgacata atgaaaagat gaggggtgcat      120
aagttctcta gtaggggtgat gatataaaaa gccaccggag cactccataa ggcacaaact      180
ttcagagaca gcagagcaca caagctt      207

```

&lt;210&gt; 132

&lt;211&gt; 645

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 132

```

gggggtgatt tcactccccg gggctgtccc aggcttgtcc ctgctaccg caccagcct      60
ttcctgaggc ctcaagcctg ccaccaagcc ccagctcct tctccccgca gggcccaa ac      120
acaggcctca ggactcaaca cagcttttcc ctccaacccc gttttctctc cctcaacgga      180
ctcagctttc tgaagccctt ccagttctta gttctatctt tttcctgcat cctgtctgga      240
agttagaagg aaacagacca cagacctggg ccccaaaaga aatggaggca ataggttttg      300
aggggcatgg ggacgggggt cagcctccag ggtcctacac acaaatcagt cagtggccca      360

```



gaagaccccc ctcggaatcg gagcagggag gatggggagt gtgaggggta tccttgatgc 420  
 ttgtgtgtcc ccaactttcc aaatccccgc ccccgcatg gagaagaaac cgagacagaa 480

gggtgcagggc cactaccgc ttcctccaga tgagctcatg ggtttctcca ccaaggaagt 540

tttccgctgg ttgaatgatt ctttccccgc cctcctctcg cccagggac atataaaggc 600

agttgttggc acaccagcc agcagacgct ccctcagcaa ggaca 645

<210> 133  
 <211> 457  
 <212> DNA  
 <213> Homo sapiens

<400> 133  
 gcctgtactc agccaagggt gcagagatgt tatatatgat tgctcttcag ggaaccgggc 60

ctccagctca caccacagct gctcaaccac ctctctctg aattgactgt cccttctttg 120

gaactctagg cctgacccca ctccctggcc ctccagccc acgattcccc tgaccgact 180

ccctttccca gaactcagtc gcctgaacc ccagcctgtg gttctctcct aggcctcagc 240

ctttcctgcc tttgactgaa acagcagtat cttctaagcc ctgggggctt ccccgggccc 300

cagccccgac ctagaacccg cccgctgcct gccacgctgc cactgccgct tcctctataa 360

agggacctga gcgtccgggc ccaggggctc cgcacagcag gtgaggctct cctgccccat 420

ctccttgggc tgcccgtgct tcgtgctttg gactacc 457

<210> 134  
 <211> 973  
 <212> DNA  
 <213> Homo sapiens

<400> 134  
 gcagcaaadc agaatggcag tttgattcat ggtgctgaga ctggagggtc ctctgctgta 60

ggctcagaat atgtctaagc aattgaggaa tgtctcagaa aacgtggggc tagtgtgcca 120

tatttatctg caaagccatt ttccctccct aattctgatt ggataagggc attacagttg 180

acttagcaaa acctgctggc tgttctctggg gaagtcccat gttgcagact cgaaggat 240

atttattgta gcctccaagt tacggaattt ccctctgctc ctcttttttt ggtaatagt 300

aattaggttt cactttccaa aacatgaact gtttcttgaa aaaaagaact tcattgcata 360

tagaaaaaaa caaagggtgc aatccattct aactataatg ctttttctca aacttaaac 420

ttttacagtt actttcagag gttatttttc aaaatatccc cagtaataga aatttttcat 480

cctttatagg taaacctaat tttttggtaa cagcaagttg tgccctgatta ttagaacagt 540

gatttacctg gacagtcctc cttgatcaaa tactataaag taataggact ggctgcttt 600

gacaggggtc aagatctgga actggcaagt tttaaataat tcaataaatg ctttgatcat 660

tcataacacc attagattaa gtaaatagcc tccaacataa ctattttgag ggaaaacatt 720

gctcatttgg gtatctgatt tgtggtgtgt taaaacaagt ttcacgtctt atagcagtcc 780  
 ctgaatgaaa acatcataag atggtatcta gaatggtgtg agaaaaggat tcatagctat 840  
 cctaggggta ttgtaaaaaa caaaggggtgc tttttgagga aatgaattta aaagcggggg 900  
 ggcacgcata gagacagacc ttgggaaagt agcttgagac agaagggaaa caggttgatt 960  
 tacgatgggg ttc 973

<210> 135  
 <211> 333  
 <212> DNA  
 <213> Homo sapiens

<400> 135  
 gctaccttaa gaaggctggt taccatctgg gttttcacag tgctttcaca ttcttatcac 60  
 tttcaacact actgcaaata ggaagggaca gtaacattta gaagagaaca aaacagaaac 120  
 tcttggaagc aggaaagggt catgactcaa agagggaaat tcctgtgcc aaaaaggatt 180  
 gctggtgtat aaaatgctct atatatgcc attatcaatt tcctttcatg ttcagcattt 240  
 ctactccttc caagaagagc agcaaagctg aagttagcag cagcagcacc agcagcaaca 300  
 gcaaaaaaca aacatgagtg tgaagggcat ggc 333

<210> 136  
 <211> 1048  
 <212> DNA  
 <213> Homo sapiens

<400> 136  
 ggtgaccaag aatgtgagca agcccaggca cagccactgt gggcgctga ccaaacagca 60  
 ctaaatttgt gtgggacatg atcccagagg tgtgtggctt caccctcaa cgagtggcgt 120  
 ggcattggagt tactgaatct ccaagggtcaa acaggccctc aaattcatca agaaaagggt 180  
 agggacaaac atctgtacca agagaaggca ggaggagctg agcaacgtcc tgctgccatg 240  
 aggaaagcag ctgccaagaa ggactgagcc cctgccatct gcctataatg aaagctttgc 300  
 aaaataaaat aaatataaaa taaagtaata aaattaaatt aaatttaaaa ataaaataaa 360  
 gcaaaacaaa ataaaatata taaagtaaaa attgttaaaa tgcaaaacaa tatggacata 420  
 aatacagaaa cacagggaaa cttctttagg cactcattta caggtaaaaa tatgaaattg 480  
 aataaaggtc atctggtgtc aaataatata ggccttatct attataagag tttggactga 540  
 aaagcaaaag tgagataaca aaaaaagct tttcagaata ttattttgta tagatatgtg 600  
 aaggatgaag ggtgggtgaa aggaccacaa acagaaacac agtcttcctg aatgaatgac 660  
 aatcagaatt ccgctgcccc aagtagtccg acaattaaat ggatttctag gaaaagctac 720  
 cttaagaagg ctggttacca tctgggtttt cacagtgcct tcacattctt atcactttca 780

acactactgc aaataggaag ggacagtaac atttagaaga gaacaaaaca gaaactcttg 840  
gaagcaggaa aggtgcatga ctcaaagagg gaaattcctg tgccataaaa ggattgctgg 900  
tgtataaaat gctctatata tgccaattat caatttcctt tcatgttcag catttctact 960  
ccttccaaga agagcagcaa agctgaagtt agcagcagca gcaccagcag caacagcaaa 1020  
aaacaaacat gagtgtgaag ggcatggc 1048

<210> 137  
<211> 504  
<212> DNA  
<213> Homo sapiens

<400> 137  
agggggcccc gcagcagccc cttggcttcc cttctccctt gcctccccctc cgggggtccg 60  
gttcagaggc actctgggcg cctgctacag cttccaaact gcgccgcttc cttcttcggc 120  
agaaaaggac tttcagatgc ggcggcggcg gcggcgggga ctcaggacag cgtccccctcc 180  
cctaacggcc gcctctccct ctccccctcg ccgcgcccg cccccccacc tctgggaagg 240  
cgctgggggt gtggccaggg accggtataa agtccggggg agccgggtccc gggcagccgc 300  
tcagccccct gcccctcgcc gccgcgcgcc tgcctgggcc gggccgagga tgcggcgag 360  
cgctcgggcg gccaggttg ctccctccgg cagcctgct aacttcccc gctacgtccc 420  
cgttcgcccc cggggccgcc ccgtctcccc gcgcctccg ggtcgggtcc tccaggagcg 480  
ccaggcgtg ccgcgtgtg ccct 504

<210> 138  
<211> 1042  
<212> DNA  
<213> Homo sapiens

<400> 138  
gatcacaaca gctctacaaa tacacaatga ttacaaggaa tgggtgcccc ctggagttgt 60  
tcaacgcaaa acttgacat tgcaagtggc aatctcccag gcctgcctcc ctccacgagt 120  
gggtctgaat gggcctgaga ggcaaacatc caagaaggag gaagaggctc ggcggcacct 180  
ccctcccccg gagttctgct gattccatct tggggaagca gggtggaacca gggcccaaat 240  
gcgccctggg gagattgcgg gggcgggaga ggttgcaagg ggcaagtggc aagagcctgt 300  
taacgtctta gggcctccag gcctttctgt gccctagct gtgcctgtac gctttacccc 360  
acctcaggag gcttggcttc cagcggttga ggctggaagc accgggggtgc ggtggaagg 420  
gctctgtcca ggaagaccgg atccgcagag ccgggagtcc gggctaggaa gtccctttct 480  
cgggtgggaga ctgaggccgc cttggcgggg cgggacgaga ctctccgag gtcgggaaag 540  
ggggccccgc agcagcccc tggcttcct tctcccttgc ctccccctcg gggctccggt 600

tcagaggcac tctgggcgcc tgctacagct tccaaactgc gccgtttcct tcttcggcag 660  
aaaaggactt tcagatgcgg cggcggcggc ggcggcgact caggacagcg cccctcccc 720  
taacggccgc ctctccctct cccctcgcc cgcccgggt cccccacctc tgggaaggcg 780  
ctgggggtgt ggccaggac cgtataaag tccggggag ccggtcccg gcagccgctc 840  
agccccctgc cctcgccgc ccgcccctg cctgggcgg gccgaggatg cggcgagcg 900  
cctcggcggc caggcttgt cctccggca cgcctgctaa cttccccgc tacgtcccc 960  
ttcgcccgcc gggcgcccc gtctccccgc gccctccggg tcgggtcctc caggagcgcc 1020  
aggcgctgcc gccgtgtgcc ct 1042

<210> 139  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 139  
tcgtcgtttt gacgttttgt cgtt 24

<210> 140  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 140  
tcgtcgtttt gtcgtttttt tcga 24

<210> 141  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 141  
tcgtcgtttc gtcgtttcgt cgtt 24

<210> 142  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<400> 142  
tcgtcgtttc gtcgttttgt cggt 24

<210> 143  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<400> 143  
tcgtcgtttt tcggtcgttt t 21

<210> 144  
<211> 22  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<400> 144  
tcgtcgtttt tcgtgcgttt tt 22

<210> 145  
<211> 22  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<400> 145  
tcgtcgtttt cggcggccgc cg 22

<210> 146  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<400> 146  
tcgtcgtttt acggcgccgt gccg 24

<210> 147  
<211> 24  
<212> DNA

<213> artificial sequence  
<220>

<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (13)..(13)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (21)..(21)  
<223> N = 5-methylcytosine

<400> 147  
tngtngtttt gtngttttgt ngtt

24

<210> 148  
<211> 27  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (7)..(7)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (11)..(11)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (13)..(14)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (16)..(16)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (19)..(19)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (22)..(22)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (26)..(27)  
<223> N = 5-methylcytosine

<400> 148  
tngtngtgtg ntngngtntnt tnttggn

27

<210> 149  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (8)..(8)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (10)..(10)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (13)..(13)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (16)..(16)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (20)..(20)

<223> N = 5-methylcytosine  
<400> 149  
gngtttgntn ttnttnttgn g

21

<210> 150  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(4)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (8)..(8)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (12)..(12)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (15)..(16)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (19)..(19)  
<223> N = 5-methylcytosine

<400> 150  
gnnnaagntg gnatnngtna

20

<210> 151  
<211> 15  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 151  
tcctggcggg gaagt

15

<210> 152  
<211> 42  
<212> DNA  
<213> artificial sequence

<220>



WO 2004/094671

PCT/US2004/012788

<400> 152  
gaaactcgag ccaccatgag acagactttg ccttgatatct ac

42

<210> 153  
<211> 37  
<212> DNA  
<213> artificial sequence

<220>

<223> Oligonucleotide

<400> 153  
gaaagaattc ttaatgtaca gagtttttgg atccaag

37

<210> 154  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 154  
tgctgctttt gtgcttttgt gctt

24

<210> 155  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 155  
tccatgacgt tcctgatgct

20

<210> 156  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 156  
tccatgagct tcctgatgct

20

<210> 157  
<211> 20  
<212> DNA  
<213> artificial sequence

WO 2004/094671

PCT/US2004/012788

<223> Immunostimulatory nucleic acid

<220>

<221> misc\_feature

<222> (8)..(8)

<223> N = 5-methylcytosine

<400> 157

tccatgangt tcctgatgct

20

<210> 158

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 158

tcgtcgtttt cggcgccgcg cg

22

<210> 159

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 159

ggggacgacg tcgtgggggg g

21

<210> 160

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 160

tgctgctttt cggcgccgcg cg

22

<210> 161

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 161

ggggagcagc tgctgggggg g

21

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number  
**WO 2004/094671 A2**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68

(21) International Application Number:  
PCT/US2004/012788

(22) International Filing Date: 22 April 2004 (22.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/464,586 22 April 2003 (22.04.2003) US  
60/464,588 22 April 2003 (22.04.2003) US

(71) Applicants (for all designated States except US): COLEY PHARMACEUTICAL GmbH [DE/DE]; Elisabeth-Selbert-Strasse 9, D-40764 Langenfeld (DE). COLEY PHARMACEUTICAL GROUP, INC. [US/US]; 93 Worcester Street, Suite 101, Wellesley, MA 02481 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VOLLMER, Jörg [DE/DE]; Kohlrauschweg 24, D-40591 Duesseldorf (DE).

JURK, Marion [DE/DE]; Klosterstr. 4, D-41540 Dornagel (DE). LIPFORD, Grayson, B. [GB/US]; 38 Bates Road, Watertown, MA 02472 (US). SCHETTER, Christian [DE/DE]; Oerkhaushof 35, D-40723 Hilden (DE). FORSBACH, Alexandra [DE/DE]; Raiffeisenstrasse N°1, D-40764 Rantingen (DE). KRIEG, Arthur, M. [US/US]; 173 Winding River Road, Wellesley, MA 02482 (US).


(74) Agent: TREVISAN, Maria, A.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT OF TLR LIGANDS



(57) Abstract: The invention provides in part novel screening methods and compositions for identifying and distinguishing between candidate immunomodulatory compounds. The invention further provides methods for assessing biological activity of composition containing a known TLR ligand. These latter methods can be used for quality assessment and selection of various lots of test compositions, including pharmaceutical products for clinical use.

WO 2004/094671 A2



GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:

27 January 2005

(15) Information about Correction:

see PCT Gazette No. 04/2005 of 27 January 2005, Section II

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT  
OF TLR LIGANDS**

**Background of the Invention**

5       Nucleic acids with immunostimulatory activity have been identified. The first recognized immunostimulatory motif was the CpG motif in which at least the C of the dinucleotide was unmethylated. It has been postulated that mammalian subjects recognize the unmethylated dinucleotide as being of bacterial origin, and thus mount a heightened immune response following exposure. The ensuing immune response includes both cell mediated and  
10   humoral aspects. Since the discovery of the CpG immunostimulatory motif, other immunostimulatory motifs have also been identified including the poly-T and T-rich motifs, the TG motif and the poly-G motif. In some instances, immunostimulation has also been observed in response to exposure to methylated CpG motifs and motif-less nucleic acids having phosphorothioate backbone linkages.

15       The responses induced by immunostimulatory nucleic acids are varied and can include production and secretion of cytokines, chemokines, and other growth factors. The nucleic acids can induce a heightened immune stimulation regardless of whether an antigen is also introduced to the subject. Identification of new motifs as well as of subtle differences between response profiles of different nucleic acids oftentimes can be laborious, and a high  
20   throughput system for screening nucleic acids for their ability to be immunostimulatory as well as to determine the profile of responses they induce would be useful.

**Summary of the Invention**

25       The invention provides in its broadest sense screening methods and tools for identification and discrimination of immunomodulatory molecules and assessment and standardization of samples containing known immunomodulatory molecules. The immunomodulatory molecules can be immunostimulatory or immunoinhibitory, and most preferably are Toll-like receptor (TLR) ligands.

30       In one aspect, the invention provides a screening method for identifying TLR agonists. The method comprises contacting a cell line endogenously expressing at least one TLR with a test compound and measuring a test level of TLR signaling activity, wherein a positive test level is indicative of a TLR agonist (i.e., an immunostimulatory compound). The positive test

- 2 -

level may be apparent without referring to a control. Preferably, however, it is determined relative to a control (i.e., the TLR signaling activity from a reference compound).

In some embodiments, the reference compound is a compound that induces no response (i.e., a zero response) or a minimal response. In this case, a test level that is greater  
5 than the reference level is indicative of a compound with TLR signaling activity. More preferably, the reference compound is a compound that induces a positive response (i.e., a non-zero response) and that is immunostimulatory. These reference compounds are referred to herein as negative and positive reference compounds, respectively. If the reference compound is immunostimulatory (i.e., a positive reference compound), a non-zero test level  
10 that is lower than the reference level is still indicative of an immunostimulatory test compound. In this latter embodiment, the test compound is less immunostimulatory than the reference compound (for that particular readout), but it is nonetheless immunostimulatory given the non-zero response induced. There may be one or more concurrent or consecutive assays with a negative reference compound, a positive reference compound, or both. The  
15 reference may also be a standard curve or data generated previously.

In a related aspect, the screening method involves exposing the same cell to a positive reference compound and a test compound in order to identify a test compound that inhibits the immunostimulatory response of the positive reference compound (i.e., a TLR antagonist or an immunoinhibitory compound).

20 In still a related aspect, the screening method involves exposing the same cells to a positive reference compound and a test compound in order to identify a test compound that enhances the immunostimulatory response of the positive reference compound (i.e., an enhancer).

In both of these latter aspects, the assay requires a co-incubation of the positive  
25 reference compound, the test compound and the cells. Separate assays with positive reference compound alone and optionally negative reference compound alone are usually also performed.

The positive reference compound is a known TLR ligand. Non-limiting examples include but are not limited to TLR3 ligands, TLR7 ligands, TLR8 ligands and TLR9 ligands.  
30 In some embodiments, the positive reference compound is an immunostimulatory nucleic acid. In some embodiments, the positive reference compound is a CpG nucleic acid, a poly-T nucleic acid, a T-rich nucleic acid or a poly-G nucleic acid. Another example of a positive

reference compound is a nucleic acid comprising a backbone that contains at least one phosphorothioate linkage.

It has been further discovered according to the invention that the RPMI 8226 cell line expresses TLR7 and responds to the imidazoquinoline compound R-848 (Resiquimod) which is known to signal through TLR7 and TLR8. Accordingly, the screening method can be performed using RPMI 8226, Raji or RAMOS cells and an imidazoquinoline compound such as R-848 or R-847 (Imiquimod) as the positive reference compound.

In one embodiment, the test compound is a nucleic acid such as but not limited to a DNA, an RNA and a DNA/RNA hybrid. The test compound may be a nucleic acid that does not comprise motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif. The test compound may be a nucleic acid that comprises a phosphorothioate backbone linkage. In another embodiment, the test compound is a non-nucleic acid small molecule. The non-nucleic acid small molecule may be derived from a molecular library. In other embodiments, the test compound comprises amino acids, carbohydrates such as polysaccharides. It may be a hormone or a lipid or contain moieties derived therefrom. In other embodiments, the test compounds are putative ligands for TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10 or TLR11.

In one embodiment, the cell is a RPMI 8226 cell, a Raji cell, a RAMOS cell, a THP-1 cells, a Nalm cell or a KG-1 cell and the TLR is TLR9. In another embodiment, the cell is a RPMI 8226 cell, a Raji cell or a RAMOS cell and the TLR is TLR7. In yet another embodiment, the cell is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

In another embodiment, the cell is an RPMI 8226 cell and the TLR is TLR7 or TLR9. In still another embodiment, the cell is a Raji cell and the TLR is TLR9, TLR7 or TLR3.

Depending upon the embodiment, the TLR signaling activity may be measured or detected in a number of ways. In one embodiment, the TLR signaling activity is measured by cytokine, chemokine, or growth factor secretion. The cytokine secretion may be selected from the group consisting of IL-6 secretion, IL-10 secretion, IL-12 secretion, IFN- $\alpha$  secretion and TNF- $\alpha$  secretion, but is not so limited. The chemokine secretion may be IP-10 secretion or IL-8 secretion, but is not so limited.

In another embodiment, the TLR signaling activity is measured by antibody secretion. The antibody secretion may be IgM secretion, but is not limited to this antibody subtype.

- 4 -

In another embodiment, the TLR signaling activity is measured by phosphorylation. The total level of phosphorylation in the cell or the level of phosphorylation of particular factors in the cell may be measured. These factors are preferably signaling factors and can be selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, Jun, c-fos, and subunits of NF- $\kappa$ B, but are not so limited.

In still a further embodiment, the TLR signaling activity is measured by cell surface marker expression. In one embodiment, the TLR signaling activity is measured by an increase in cell surface marker expression. Examples of cell surface markers to be analyzed include CD71, CD86, HLA-DR, CD80, HLA Class I, CD54 and CD69. In other embodiments, the TLR signaling activity is measured by a decrease in cell surface marker expression. Cell surface marker expression can be determined using flow cytometry. TLR signaling activity can also be measured by protein production (e.g., by Western blot).

In another embodiment, the TLR signaling activity is measured by gene expression. Gene expression profiles may be determined using Northern blot analysis or RT-PCR that uses mRNA or total RNA as a starting material. The gene expression of interest may be that of the chemokines and cytokines and cell surface molecules recited above. Gene expression analysis can be performed using microarray techniques.

In yet another embodiment, the TLR signaling activity is measured by cell proliferation. Cell proliferation assays can be measured in a number of ways including but not limited to  $^3$ H-thymidine incorporation.

In one embodiment, the cell is an RPMI 8226 cell and TLR signaling is indicated by expression of a marker such as CD71, CD86 and/or HLA-DR or by expression, production or secretion of a factor such as IL-8, IL-10, IP-10 and/or TNF- $\alpha$ . Preferably, in this latter embodiment, the RPMI 8226 cell is unmodified. In another embodiment, the cell is a Raji cell and the TLR signaling is indicated by IL-6 or IFN- $\alpha$ 2 expression, production or secretion. In yet another embodiment, the cell is a RAMOS cell and the TLR signaling is indicated by CD80 cell surface expression.

TLR signaling activity can be measured via a native readout or an artificial readout or both. A native readout is one that does not rely on introduction of a reporter construct into the cell of interest.

The cell line may be used in a modified or unmodified form. In one embodiment, the cell line is transfected with a reporter construct. The transfection may be transient or stable. The reporter construct generally comprises a promoter, a coding sequence and a



polyadenylation signal. The coding sequence may comprise a reporter sequence selected from the group consisting of an enzyme (e.g., luciferase, alkaline phosphatase,  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein (GFP, U.S. Patent No. 5,491,084), etc.), a surface-expressed molecule (e.g., CD25), a secreted molecule (e.g., IL-8, IL-12 p40, TNF- $\alpha$ , etc.), and other detectable protein sequences known to those of skill in the art. Preferably, the coding sequence encodes a protein, the level or activity of which can be quantified, with preferably a wide linear range.

In some embodiments, the promoter is a promoter that is responsive to TLR signaling pathways (i.e., a "TLR responsive promoter"). In some embodiments, the promoter contains a binding site for a transcription factor activated upon CpG nucleic acid exposure, such as for example NF- $\kappa$ B. In other embodiments, the promoter contains a binding site for a transcription factor that is activated by a positive reference compound other than CpG nucleic acids. The transcription factor binding site may be selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE, as well as others known to those of skill in the art.

In another embodiment, the promoter contains a functional promoter element from an IL-1 gene, an IL-6 gene, an IL-8 gene, an IL-10 gene, an IL-12 p40 gene, an IFN- $\alpha$ 1 gene, an IFN- $\alpha$ 4 gene, an IFN- $\beta$  gene, an IFN- $\gamma$  gene, a TNF- $\alpha$  gene, a TNF- $\beta$  gene, an IP-9 gene, an IP-10 gene, a RANTES gene, an ITAC gene, a MCP-1 gene, an IGFBP4 gene, a CD54 gene, a CD69 gene, a CD71 gene, a CD80 gene, a CD86 gene, a HLA-DR gene, and a HLA class I gene.

The TLR responsive promoter may be a TLR1 responsive promoter, a TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter, a TLR10 responsive promoter or a TLR11 responsive promoter.

In these latter embodiments, the cell line may be transfected with a reporter construct having a promoter derived from a particular cytokine, chemokine, or cell surface marker, and a unique reporter coding sequence conjugated thereto. In this way, the readout from a particular reporter construct is a surrogate readout for cytokine, chemokine, or cell surface marker readout. Measuring readout from the reporter coding sequences described herein is in

some instances easier than measuring cytokine or chemokine secretion, or upregulation of a cell surface marker.

In these latter embodiments, the cell line may be transfected with a number of reporter constructs each having a promoter derived from a particular cytokine, chemokine, or cell surface marker, and a unique distinguishable coding sequence conjugated thereto. In these  
5       embodiments, multiple readouts are possible from one screen. In other embodiments, multiple native readouts are also possible from one screen.

In a related embodiment, the cell may be further transfected with a nucleic acid that codes for a TLR polypeptide or a fragment thereof. Preferably, the TLR is one that is not  
10       endogenously expressed by the cell. As an example, if the cell is an RPMI 8226 cell which has been shown to express TLR7 and TLR9 according to the invention, then it may be modified to express TLRs other than these (e.g., TLR8) in some embodiments. In this aspect, the RPMI 8226 cell is responsive to TLR8 ligands. In preferred embodiments, the TLR is a human TLR (i.e., hTLR).

In another aspect, the invention provides an RPMI 8226 cell transfected with a TLR nucleic acid. In still another embodiment, the TLR nucleic acid is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR8, TLR10 and TLR11. The encoded TLRs nucleic acids can derive from human or non-human sources. Examples of non-human sources include, but are not limited to, murine, bovine, canine, feline, ovine,  
20       porcine, and equine species. Other species include chicken and fish, e.g., aquaculture species. The TLR nucleic acids can also include chimeric sequences consisting of domains originating from different species. In preferred embodiments, the TLR is a human TLR.

In still another aspect, the invention provides kits including the cells lines (e.g., the RPMI 8226 cell line), the reporter constructs and/or expression constructs described above,  
25       and instructions for use.

Other aspects of the invention provide methods for analyzing the biological activity of individual lots of material containing previously identified specific TLR ligands (i.e., specific compounds which are ligands for a particular TLR) intended for use as, or for use in the preparation of, pharmaceutical compositions. The methods permit a qualitative and,  
30       importantly, a quantitative assessment of biological activity of individual lots of TLR ligands, pre-formulation as well as post-formulation. Such methods are useful in the manufacture and validation of pharmaceutical compositions containing, as an active agent, at least one specific ligand of at least one specific TLR. The specific TLR can be any known TLR, including

without limitation TLR3, TLR7, TLR8 and TLR9. The specific TLR ligand is an isolated TLR ligand, either found in nature or synthetic (not found in nature), including in particular certain nucleic acid molecules and small molecules. Nucleic acid molecules that are specific TLR ligands include synthetic and naturally-occurring oligonucleotides having specific base sequence motifs. Furthermore, specific TLR ligands include both agonists and antagonists of specific TLR.

These methods are to be distinguished from test procedures and acceptance criteria for new drug substances and new drug products which are classified as chemical substances.

Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the instant invention deal specifically with characterizing drug substances and drug products which are classified as oligonucleotides. Oligonucleotides are explicitly excluded in ICH Topic Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Step 4 – Consensus Guideline: 6 October 1999, § 1.3.

Further still, the methods of the instant invention are to be distinguished from test procedures and acceptance criteria for biotechnological/biological products. Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the invention deal specifically with characterizing biotechnological/biological products which are classified as DNA products. DNA products are explicitly excluded in ICH Harmonised Tripartite Guideline Specifications: Test Procedures and Acceptance Criteria for

Biotechnological/Biological Products, Step 4 – 10 March 1999, § 1.3.

In one aspect, the invention provides a method for quality assessment of a test composition containing a known TLR ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule; measuring a test activity of a test composition comprising the known TLR ligand; and comparing the test activity to the reference activity. In one embodiment the method further involves the step of selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

In one embodiment, the reference composition is a first production lot of a pharmaceutical composition comprising the known TLR ligand, and the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for finished pharmaceutical products containing a known TLR ligand.

In another embodiment, the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and the test composition is a second in-process lot of a composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for raw materials and/or other in-process materials containing a known TLR ligand bound for use in a pharmaceutical product.

In one embodiment according to this aspect of the invention, measuring the reference activity involves contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and measuring the test activity involves contacting the test composition with the isolated cell expressing the TLR responsive to the known TLR ligand. Further, in one embodiment the isolated cell expressing the TLR responsive to the known TLR ligand includes an expression vector for the TLR responsive to the known TLR ligand. Such expression vector, and likewise for any expression vector according to the instant invention, can be introduced into the cell using any suitable method.

In one embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand. Such a cell can be naturally occurring or it can be a cell line, provided the cell does not include an expression vector introduced into the cell for the purpose of artificially inducing the cell to express or overexpress the TLR.

In one particular embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is Raji, RAMOS, Nalm, THP-1 or KG-1 and the TLR is TLR9. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226, Raji or RAMOS and the TLR is TLR7. In yet another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a HeLa cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

Further according to this aspect of the invention, in one embodiment measuring the reference activity and measuring the test activity each comprises measuring signaling activity mediated by a TLR responsive to the known TLR ligand. As described in greater detail elsewhere herein, TLR signaling involves a series of intracellular signaling events. These signaling events give rise to various downstream products, including certain transcription

factors (e.g., NF- $\kappa$ B and AP-1), cytokines, chemokines, etc., which can affect the activity of certain gene promoters. For example, in one embodiment the signaling activity is activity of a reporter gene or reporter construct under the control of a NF- $\kappa$ B response element.

In other embodiments, the signaling activity is activity of a reporter gene or reporter  
5 construct under the control of an interferon-stimulated response element (ISRE); an IFN- $\alpha$  promoter; an IFN- $\beta$  promoter; an IL-6 promoter; an IL-8 promoter; an IL-12 p40 promoter; a RANTES promoter; an IL-10 promoter or an IP-10 promoter.

In one embodiment, the known TLR ligand is an immunostimulatory nucleic acid. An immunostimulatory nucleic acid can include, without limitation, a CpG nucleic acid. In  
10 another embodiment, the known TLR ligand is an immunoinhibitory nucleic acid. When the known TLR ligand is a TLR antagonist (e.g., an immunoinhibitory oligonucleotide), the method according to this aspect of the invention can further involve measuring the reference activity of the reference composition and measuring the test activity of the test composition, each performed in the presence of a known immunostimulatory TLR ligand.

15 In various embodiments, the known TLR ligand is a ligand for a particular TLR. Thus in one embodiment the known TLR ligand is a TLR9 ligand. More specifically, in one embodiment the known TLR ligand is a CpG nucleic acid.

In one embodiment, the known TLR ligand is a TLR3 ligand. Such a ligand can include, for example, a double-stranded RNA or a homolog thereof.

20 In one embodiment, the known TLR ligand is a TLR7 ligand. In one embodiment the known TLR ligand is a TLR8 ligand.

The invention provides in another aspect a method for quality assessment of a test lot of a pharmaceutical product containing a known TLR9 ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference lot of a  
25 pharmaceutical product comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid molecule; measuring a test activity of a test lot of a pharmaceutical product comprising the known TLR9 ligand; comparing the test activity to the reference activity; and rejecting the test lot if the test activity falls outside of a predetermined range of variance about the reference activity.

30 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT GTC GTT-3' (SEQ ID NO:1).

- 10 -

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGA CGT TTT GTC GTT-3' (SEQ ID NO:139).

5 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT TTT CGA-3' (SEQ ID NO:140).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTC GTC GTT-3' (SEQ ID NO:141).

10 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3' (SEQ ID NO:142).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GGT CGT TTT-3' (SEQ ID NO:143).

15 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GTG CGT TTT T-3' (SEQ ID NO:144).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TCG GCG GCC GCC G-3' (SEQ ID NO:145).

20 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TC\_G TTT TAC\_GGC GCC\_GTG CCG-3' (SEQ ID NO:146), wherein every internucleoside linkage is  
25 phosphorothioate except for those indicated by “\_”, which are phosphodiester.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

30

### **Brief Description of the Figures**

Fig. 1 is a bar graph showing cell surface expression of various markers by RPMI 8226 24 hours and 48 hours following stimulation with CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), LPS and IL-1.

Fig. 2 is a bar graph showing IL-8 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 3 is a bar graph showing IL-6 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 4 is a bar graph showing IP-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 5 is a bar graph showing IL-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 6 is a dose response curve showing fold induction of IL-8 production 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1) and non-CpG nucleic acid (SEQ ID NO: 2). The  $EC_{50}$  for CpG nucleic acid is 19 nM and the  $EC_{50}$  for non-CpG nucleic acid is 263 nM.

Fig. 7 is a bar graph showing NF- $\kappa$ B activation in RPMI 8226 transfected transiently with a NF- $\kappa$ B-luciferase reporter gene construct as a function of cell density and nucleic acid amount transfected, following exposure to CpG nucleic acid (SEQ ID NO: 1), LPS and TNF- $\alpha$ . NF- $\kappa$ B activation is measured by luciferase activity.

Fig. 8 is a bar graph showing RT-PCR results from RNA isolated from RPMI 8226 using gene specific primers for TLR7, TLR8 and TLR9 genes.

Fig. 9 is a dose response curve showing IP-10 production induced by SEQ ID NO: 1, and inhibition thereof in the presence of SEQ ID NO: 151, a immunoinhibitory nucleic acid.

Fig. 10 is a bar graph showing the results of a TLR9 RT-PCR analysis of a number of cell lines.

Fig. 11 is a bar graph showing the results of a TLR7 RT-PCR analysis of a number of cell lines.

Fig. 12 is a bar graph showing the results of a TLR3 RT-PCR analysis of a number of cell lines.

Fig. 13 is a bar graph showing the results of a TLR3, TLR7, TLR8 and TLR9 RT-PCR analysis of the Raji cell line.

Fig. 14 is a graph showing IL-6 production by the Raji cell line upon stimulation with various ODN (SEQ ID NO:1; SEQ ID NO:154; SEQ ID NO:158; SEQ ID NO:160; SEQ ID  
5 NO:159; SEQ ID NO:161).

Fig. 15 is a bar graph showing IL-6 production of the Raji cell line upon stimulation with poly I:C and R-848.

Fig. 16 is a bar graph showing IFN- $\alpha$ 2 production by the Raji cell line upon stimulation with CpG ODN (SEQ ID NO: 1), R-848 and poly I:C.

10 Fig. 17 is a bar graph showing CD80 expression (by flow cytometry) by the RAMOS cell line upon stimulation with CpG ODN (SEQ ID NO: 1) and non-CpG ODN (SEQ ID NO: 2).

Fig. 18A is a bar graph showing the induction of NF- $\kappa$ B by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-  
15 ODN, GpC-ODN, LPS, and medium.

Fig. 18B is a bar graph showing the amount of IL-8 produced by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-ODN, GpC-ODN, LPS, and medium.

Fig. 19 is a bar graph showing the induction of NF- $\kappa$ B-luc produced by stably  
20 transfected 293-mTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

Fig. 20 is a bar graph showing the induction of NF- $\kappa$ B-luc produced by stably transfected 293-hTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

25 Fig. 21 is a series of gel images depicting the results of reverse transcriptase-polymerase chain reaction (RT-PCR) assays for murine TLR9 (mTLR9), human TLR9 (hTLR9), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in untransfected control 293 cells, 293 cells transfected with mTLR9 (293-mTLR9), and 293 cells transfected with hTLR9 (293-hTLR9).

30

It is to be understood that the Figures are not required for enablement of the invention.

### **Brief Description of Sequences**



SEQ ID NO:1 is the nucleotide sequence of an immunostimulatory nucleic acid (TLR9 ligand).

SEQ ID NO:2 is the nucleotide sequence of a non-CpG nucleic acid.

SEQ ID NO:3 is the nucleotide sequence of human TLR2 cDNA (U88878).

5 SEQ ID NO:4 is the amino acid sequence of human TLR2 protein (AAC34133).

SEQ ID NO:5 is the nucleotide sequence of murine TLR2 cDNA (AF165189).

SEQ ID NO:6 is the amino acid sequence of murine TLR2 protein (NP\_036035).

SEQ ID NO:7 is the nucleotide sequence of human TLR3 cDNA (NM\_003265).

SEQ ID NO:8 is the amino acid sequence of human TLR3 protein (NP\_003256).

10 SEQ ID NO:9 is the nucleotide sequence of murine TLR3 cDNA (AF355152).

SEQ ID NO:10 is the amino acid sequence of murine TLR3 protein (AAK26117).

SEQ ID NO:11 is the nucleotide sequence of human TLR4 cDNA (U88880).

SEQ ID NO:12 is the nucleotide sequence of human TLR4 cDNA transcript variant 4 (NM\_138557).

15 SEQ ID NO:13 is the nucleotide sequence of human TLR4 cDNA transcript variant 2 (NM\_138556).

SEQ ID NO:14 is the nucleotide sequence of human TLR4 cDNA transcript variant 1 (NM\_138554).

20 SEQ ID NO:15 is the nucleotide sequence of human TLR4 cDNA transcript variant 3 (NM\_003266).

SEQ ID NO:16 is the amino acid sequence of human TLR4 protein isoform A (NP\_612564).

SEQ ID NO:17 is the amino acid sequence of human TLR4 protein isoform B (NP\_612566).

25 SEQ ID NO:18 is the amino acid sequence of human TLR4 protein isoform C (NP\_003257).

SEQ ID NO:19 is the amino acid sequence of human TLR4 protein isoform D (NP\_612567).

SEQ ID NO:20 is the nucleotide sequence of murine TLR4 cDNA (NM\_021297).

30 SEQ ID NO:21 is the nucleotide sequence of murine TLR4 mRNA (AF185285).

SEQ ID NO:22 is the nucleotide sequence of murine TLR4 mRNA (AF110133).

SEQ ID NO:23 is the amino acid sequence of murine TLR4 protein (AAD29272).

SEQ ID NO:24 is the amino acid sequence of murine TLR4 protein (AAF04278).

- SEQ ID NO:25 is the nucleotide sequence of human TLR5 cDNA (AB060695).  
SEQ ID NO:26 is the amino acid sequence of human TLR5 protein (BAB43558).  
SEQ ID NO:27 is the amino acid sequence of human TLR5 protein (O60602).  
SEQ ID NO:28 is the amino acid sequence of human TLR5 protein (AAC34136).  
5 SEQ ID NO:29 is the nucleotide sequence of murine TLR5 cDNA (AF186107).  
SEQ ID NO:30 is the amino acid sequence of murine TLR5 protein (AAF65625).  
SEQ ID NO:31 is the nucleotide sequence of human TLR7 cDNA (AF240467).  
SEQ ID NO:32 is the nucleotide sequence of human TLR7 cDNA (AF245702).  
SEQ ID NO:33 is the nucleotide sequence of human TLR7 cDNA (NM\_016562).  
10 SEQ ID NO:34 is the amino acid sequence of human TLR7 protein (AAF60188).  
SEQ ID NO:35 is the amino acid sequence of human TLR7 protein (AAF78035).  
SEQ ID NO:36 is the amino acid sequence of human TLR7 protein (NP\_057646).  
SEQ ID NO:37 is the amino acid sequence of human TLR7 protein (Q9NYK1).  
SEQ ID NO:38 is the nucleotide sequence of murine TLR7 cDNA (AY035889).  
15 SEQ ID NO:39 is the nucleotide sequence of murine TLR7 splice variant  
(NM\_133211).  
SEQ ID NO:40 is the nucleotide sequence of murine TLR7 splice variant (AF334942).  
SEQ ID NO:41 is the amino acid sequence of murine TLR7 protein (AAK62676).  
SEQ ID NO:42 is the amino acid sequence of murine TLR7 protein (AAL73191).  
20 SEQ ID NO:43 is the amino acid sequence of murine TLR7 protein (AAL73192).  
SEQ ID NO:44 is the amino acid sequence of murine TLR7 protein (NP\_573474).  
SEQ ID NO:45 is the amino acid sequence of murine TLR7 protein (P58681).  
SEQ ID NO:46 is the nucleotide sequence of human TLR8 cDNA (AF245703).  
SEQ ID NO:47 is the nucleotide sequence of human TLR8 cDNA (AF246971).  
25 SEQ ID NO:48 is the nucleotide sequence of human TLR8 cDNA (NM\_138636).  
SEQ ID NO:49 is the nucleotide sequence of human TLR8 cDNA (NM\_016610).  
SEQ ID NO:50 is the amino acid sequence of human TLR8 protein (AAF78036).  
SEQ ID NO:51 is the amino acid sequence of human TLR8 protein (AAF64061).  
SEQ ID NO:52 is the amino acid sequence of human TLR8 protein (Q9NR97).  
30 SEQ ID NO:53 is the amino acid sequence of human TLR8 protein (NP\_619542).  
SEQ ID NO:54 is the amino acid sequence of human TLR8 protein (NP\_057694).  
SEQ ID NO:55 is the nucleotide sequence of murine TLR8 cDNA (AY035890).  
SEQ ID NO:56 is the nucleotide sequence of murine TLR8 cDNA (NM\_133212).

- SEQ ID NO:57 is the amino acid sequence of murine TLR8 protein (AAK62677).  
SEQ ID NO:58 is the amino acid sequence of murine TLR8 protein (NP\_573475).  
SEQ ID NO:59 is the amino acid sequence of murine TLR8 protein (P58682).  
SEQ ID NO:60 is the nucleotide sequence of human TLR9 cDNA (AF245704).  
5 SEQ ID NO:61 is the nucleotide sequence of human TLR9 cDNA (AB045180).  
SEQ ID NO:62 is the amino acid sequence of human TLR9 protein (AAF78037).  
SEQ ID NO:63 is the amino acid sequence of human TLR9 protein (AAF72189).  
SEQ ID NO:64 is the amino acid sequence of human TLR9 protein (AAG01734).  
SEQ ID NO:65 is the amino acid sequence of human TLR9 protein (AAG01735).  
10 SEQ ID NO:66 is the amino acid sequence of human TLR9 protein (AAG01736).  
SEQ ID NO:67 is the amino acid sequence of human TLR9 protein (BAB19259).  
SEQ ID NO:68 is the nucleotide sequence of murine TLR9 cDNA (AF348140).  
SEQ ID NO:69 is the nucleotide sequence of murine TLR9 cDNA (AB045181).  
SEQ ID NO:70 is the nucleotide sequence of murine TLR9 cDNA (AF314224).  
15 SEQ ID NO:71 is the nucleotide sequence of murine TLR9 cDNA (NM\_031178).  
SEQ ID NO:72 is the amino acid sequence of murine TLR9 protein (AAK29625).  
SEQ ID NO:73 is the amino acid sequence of murine TLR9 protein (AAK28488).  
SEQ ID NO:74 is the amino acid sequence of murine TLR9 protein (BAB19260).  
SEQ ID NO:75 is the amino acid sequence of murine TLR9 protein (NP\_112455).  
20 SEQ ID NO:76 is the nucleotide sequence of human TLR10 cDNA (AF296673).  
SEQ ID NO:77 is the amino acid sequence of human TLR10 protein (AAK26744).  
SEQ ID NO:78 is the nucleotide sequence of human TLR6 cDNA (AB020807).  
SEQ ID NO:79 is the nucleotide sequence of human TLR6 mRNA (NM\_006068).  
SEQ ID NO:80 is the amino acid sequence of human TLR6 protein (BAA78631).  
25 SEQ ID NO:81 is the amino acid sequence of human TLR6 protein (NP\_006059).  
SEQ ID NO:82 is the amino acid sequence of human TLR6 protein (Q9Y2C9).  
SEQ ID NO:83 is the nucleotide sequence of murine TLR6 cDNA (AB020808).  
SEQ ID NO:84 is the nucleotide sequence of murine TLR6 cDNA (NM\_011604).  
SEQ ID NO:85 is the nucleotide sequence of murine TLR6 cDNA (AF314636).  
30 SEQ ID NO:86 is the amino acid sequence of murine TLR6 protein (BAA78632).  
SEQ ID NO:87 is the amino acid sequence of murine TLR6 protein (AAG38563).  
SEQ ID NO:88 is the amino acid sequence of murine TLR6 protein (NP\_035734).  
SEQ ID NO:89 is the amino acid sequence of murine TLR6 protein (Q9EPW9).

SEQ ID NO:90 is the nucleotide sequence of a consensus sequence for NF- $\kappa$ B p50 subunit.

SEQ ID NO:91 is the nucleotide sequence of a consensus sequence for NF- $\kappa$ B p65 subunit.

5        SEQ ID NO:92 is the nucleotide sequence of an example of an NF- $\kappa$ B p65 subunit binding site.

SEQ ID NO:93 is the nucleotide sequence of an example of a murine CREB binding site.

10       SEQ ID NO:94 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:95 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:96 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:97 is the nucleotide sequence of an example of an ISRE.

15       SEQ ID NO:98 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:99 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:100 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:101 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:102 is the nucleotide sequence of an example of an ISRE.

20       SEQ ID NO:103 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:104 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:105 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:106 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:107 is the nucleotide sequence of an example of an NFAT binding site.

25       SEQ ID NO:108 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:109 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:110 is the nucleotide sequence of an example of a GAS.

SEQ ID NO:111 is the nucleotide sequence of a p53 binding site consensus sequence.

SEQ ID NO:112 is the nucleotide sequence of an example of a p53 binding site.

30       SEQ ID NO:113 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:114 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:115 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:116 is the nucleotide sequence of an example of a p53 binding site.

- 17 -

SEQ ID NO:117 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:118 is the nucleotide sequence of an example of a TARE (TNF- $\alpha$  response element).

SEQ ID NO:119 is the nucleotide sequence of an example of an SRF binding site.

5 SEQ ID NO:120 is the nucleotide sequence of an example of an SRF binding site.

SEQ ID NO:121 is the nucleotide sequence of the -620 to +50 promoter region of IFN- $\alpha$ 4.

SEQ ID NO:122 is the nucleotide sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1.

10 SEQ ID NO:123 is the nucleotide sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1 (point mutation, AL353732).

SEQ ID NO:124 is the nucleotide sequence of the -280 to +20 promoter region of IFN- $\beta$ .

15 SEQ ID NO:125 is the nucleotide sequence of the -397 to +5 promoter region of human RANTES (AB023652).

SEQ ID NO:126 is the nucleotide sequence of the -751 to +30 promoter region of human IL-12 p40.

SEQ ID NO:127 is the nucleotide sequence of the -250 to +30 promoter region of human IL-12 p40.

20 SEQ ID NO:128 is the nucleotide sequence of the -288 to +7 promoter region of human IL-6.

SEQ ID NO:129 is the nucleotide sequence of the IL-6 gene promoter from -1174 to +7 (M22111).

25 SEQ ID NO:130 is the nucleotide sequence of the -734 to +44 promoter region derived from human IL-8.

SEQ ID NO:131 is the nucleotide sequence of the -162 to 44 promoter region of human IL-8.

SEQ ID NO:132 is the nucleotide sequence of the -615 to +30 promoter region of human TNF- $\alpha$ .

30 SEQ ID NO:133 is the nucleotide sequence of a promoter region of human TNF- $\beta$ .

SEQ ID NO:134 is the nucleotide sequence of the -875 to +97 promoter region of human IP-10.

SEQ ID NO:135 is the nucleotide sequence of the -219 to +114 promoter region of human CXCL11 (IP-9).

SEQ ID NO:136 is the nucleotide sequence of the full length promoter region of human CXCL11 (IP-9).

5 SEQ ID NO:137 is the nucleotide sequence of the -289 to +217 promoter region of IGFBP4 (Insulin growth factor binding protein 4).

SEQ ID NO:138 is the nucleotide sequence of the full length promoter region of IGFBP4.

10 SEQ ID NO:139 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:140 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:141 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:142 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:143 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:144 is the nucleotide sequence of an immunostimulatory nucleic acid.

15 SEQ ID NO:145 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:146 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:147 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

20 SEQ ID NO:148 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

SEQ ID NO:149 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

SEQ ID NO:150 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

25 SEQ ID NO:151 is the nucleotide sequence of an immunoinhibitory nucleic acid.

SEQ ID NO:152 is the nucleotide sequence of a sense primer for human TLR3.

SEQ ID NO:153 is the nucleotide sequence of an antisense primer for human TLR3.

SEQ ID NO:154 is the nucleotide sequence of a GpC nucleic acid.

SEQ ID NO:155 is the nucleotide sequence of a CpG ODN.

30 SEQ ID NO:156 is the nucleotide sequence of a GpC ODN.

SEQ ID NO:157 is the nucleotide sequence of a Me-CpG ODN.

SEQ ID NO:158 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:159 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:160 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:161 is the nucleotide sequence of a TLR9 ligand.

### **Detailed Description of the Invention**

5 In its broadest sense, the invention relates to screening methods and tools to be used to identify and discriminate between newly discovered immunomodulatory molecules and to compare and standardize compositions of known immunomodulatory molecules. The immunomodulatory molecules are preferably TLR ligands.

10 Thus, the invention is based in part on the discovery that cell lines expressing endogenous TLR respond to TLR ligands in a manner similar to the response of peripheral blood mononuclear cells (PBMC). PBMC respond to immunomodulatory TLR ligands by modulating one or more parameters including gene expression, cell surface marker expression, cytokine and/or chemokine production and secretion, cell cycle status, phosphorylation status, and the like. TLR ligands can be categorized and distinguished based on the cellular changes they induce (i.e., their induction profiles). The ability of a TLR ligand to provide therapeutic or prophylactic benefit to a subject depends on its induction profile. The ability to screen new TLR ligands for a panel of response indicators or parameters allows for rapid discrimination and categorization of TLR ligands. Moreover, the similarity between the cell line responses and those observed after in vivo administration of the TLR ligand indicates that the cell lines are suitable predictors of in vivo activity. The use of in vitro propagated cell lines additionally overcomes the variability encountered when using freshly isolated PBMC.

25 The TLR ligands identified according to the invention therefore can be used therapeutically or prophylactically in a more patient- or disorder-specific manner. The invention allows for the tailoring of TLR ligands for particular patients or disorders.

30 The invention identifies a number of cell lines that can be used to identify TLR ligands based on endogenous TLR expression such as TLR3, TLR7 and TLR9 expression. As an example, the invention is premised in part on the discovery of TLR9 expression in a number of cell lines including RPMI 8226, Raji, RAMOS, THP-1, Nalm-6 and KG-1. Cell lines RPMI 8226, Raji and RAMOS have been determined to express TLR7 according to the invention. Cell lines KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a HeLa cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell have been discovered to express TLR3 according to the invention.

It is further premised in part on the discovery that RPMI 8226 cells respond to the imidazoquinoline compound R-848. Consistent with this latter finding, it was also discovered  
5 that RPMI 8226 cells express TLR7.

The invention in other aspects provides for screening methods and tools for verifying and standardizing compositions containing known TLR ligands. These compositions may be for example commercial production lots to be used in a clinical setting. Accordingly, the invention provides methods for standardizing lots of known TLR ligands prior to distribution  
10 and use clinically. In this way, production processes can be observed and controlled and substandard production lots can be identified and eliminated prior to shipment.

The methods of the instant invention can be used at any step in the preparation and production of clinical material, i.e., pharmaceutical product. In particular, the methods will find use in characterizing or validating raw materials, in-process materials, finished product  
15 materials (e.g., pre-release materials), and post-production materials (e.g., post-release materials). The methods can also be used to validate existing process methods, as well as to validate new or changed process methods used in the production of the pharmaceutical product.

## 20 Screening Assays Generally

The screening assays provided herein may be used to identify immunomodulatory agents. Immunomodulatory agents are agents that either stimulate or inhibit immune responses in a subject. Accordingly, as used herein, immunomodulation embraces both immunostimulation and immunoinhibition.

25 The screening methods are used to identify TLR agonists and antagonists. The methods can also be used to identify compounds that enhance the immunostimulation induced by a TLR agonist. This latter set of compounds is referred to herein as "enhancers". A TLR agonist is a compound that stimulates TLR signaling activity. A TLR antagonist is a compound that inhibits TLR signaling activity. Agonists are generally referred to herein as  
30 immunostimulatory compounds because stimulation of TLR is associated with immune stimulation. Antagonists are generally referred to herein as immunoinhibitory compounds because inhibition of TLR is associated with immune inhibition. TLR antagonists include compounds that reduce (or eliminate completely) the immunostimulation induced by a TLR



agonist. In some embodiments, the agonists, antagonists and enhancers are TLR ligands (i.e., they bind to a TLR). In other embodiments, the test compounds with agonist, antagonist or enhancer activity may act downstream or upstream of the TLR-TLR ligand interaction.

An "immunostimulatory compound" as used herein refers to a natural or synthetic compound that characteristically induces a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunostimulatory compound is a natural or synthetic compound that induces a TLR-mediated response when contacted with a cell that naturally or artificially expresses a suitable functional TLR polypeptide. Depending on the aspect of the invention, the cell may be an experimental cell or a primary cell such as a PBMC.

Examples of immunostimulatory compounds include the following immunostimulatory nucleic acids, which are discussed in further detail below:

	5'-TCGTCGTTTTGTCGTTTTGTCGTT-3'	(SEQ ID NO:1)
	5'-TCGTCGTTTTGACGTTTTGTCGTT-3'	(SEQ ID NO:139)
15	5'-TCGTCGTTTTGTCGTTTTTTTCGA-3'	(SEQ ID NO:140)
	5'-TCGTCGTTTCGTCGTTTCGTCGTT-3'	(SEQ ID NO:141)
	5'-TCGTCGTTTCGTCGTTTGTGTCGTT-3'	(SEQ ID NO:142)
	5'-TCGTCGTTTTTCGGTCGTTTT-3'	(SEQ ID NO:143)
	5'-TCGTCGTTTTTCGTGCGTTTTT-3'	(SEQ ID NO:144)
20	5'-TCGTCGTTTTTCGGCGGCCGCCG-3'	(SEQ ID NO:145)
	5'-TCGTC_GTTTTAC_GGCGCC_GTGCCG-3'	(SEQ ID NO:146)

Imidazoquinolines are immune response modifiers thought to induce expression of several cytokines including interferons (e.g., IFN- $\alpha$  and IFN- $\beta$ ), TNF- $\alpha$  and some interleukins (e.g., IL-1, IL-6 and IL-12) as well as chemokines (e.g., IP-10 and IL-8). Imidazoquinolines are capable of stimulating a Th1 immune response, as evidenced in part by their ability to induce increases in IgG2a levels. Imidazoquinoline agents reportedly are also capable of inhibiting production of Th2 cytokines such as IL-4, IL-5, and IL-13. Some of the cytokines induced by imidazoquinolines are produced by macrophages and dendritic cells. Some species of imidazoquinolines have been reported to increase NK cell lytic activity and to stimulate B cells proliferation and differentiation, thereby inducing antibody production and secretion. Imidazoquinoline mimics can also be tested using the screening methods.

An "immunoinhibitory compound" as used herein refers to a natural or synthetic compound that characteristically inhibits a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunoinhibitory compound is a natural or synthetic compound that inhibits a TLR-mediated response when contacted with a cell that naturally or artificially expresses a suitable functional TLR polypeptide.

In addition to the immunoinhibitory nucleic acids disclosed elsewhere herein, immunoinhibitory compounds and TLR antagonists encompass certain small molecules (chloroquine, quinacrine, 9-aminoacridines and 4-aminoquinolines, and derivatives thereof) described by Macfarlane and colleagues in U.S. Pat. 6,221,882; U.S. Pat. 6,399,630; U.S. Pat. 6,479,504; U.S. Pat. 6,521,637; and published U.S. Pat. application 2002/0151564, the contents of all of which are hereby incorporated by reference in their entirety.

The invention provides in part methods and tools that utilize cell lines, in modified or unmodified form, as surrogates for PBMC. Immunomodulation by TLR ligands can be assessed using one or preferably more parameters including but not limited to cytokine and chemokine secretion, upregulation of cell surface markers, changes in cell proliferation, phosphorylation changes, and the like. These parameters may be native readouts or artificial readouts as described herein.

The cellular response to immunostimulatory nucleic acids by the cell lines described herein (e.g., RPMI 8226, Raji, RAMOS, and the like) so resembles that of PBMC that these cells can be used to identify and differentiate between immunomodulatory compounds based on the extent of the induced response and the particular profile of that response. The invention provides a number of cell lines each with a particular endogenous TLR expression profile, as described herein.

The cell lines can be used to identify immunomodulatory compounds with particular response profiles. As an example, the cell lines can be used to identify molecules that are mimics to known TLR ligands. The cell lines can also be used to identify TLR ligands that trigger some but not necessarily all of the responses induced by known TLR ligands. For example, the cell line can be used to distinguish between compounds based on individual or group cytokine or chemokine secretion, or based on upregulation of one, a subset or all cell surface markers. As an example, in some therapeutic instances, it may be desirable to use a compound that induces the secretion of relatively high levels of chemokine such as IP-10, yet induces only relatively low levels of one or more other factors. The screening methods of the invention allow for the identification of such a compound with this type of induction profile.

It is to be understood that the screening method also can be used to determine effective amounts of known and newly identified immunomodulatory compounds. For example, the  $EC_{50}$  value of a TLR ligand for the production of a particular cytokine or chemokine can be determined, thereby facilitating comparison between different nucleic acids.

5           Generally, these assays require the incubation of cells with a reference compound and a test compound, and an analysis of the readout. Depending on the embodiment, the same cells are exposed to the reference compound and the test compound. An example of this latter embodiment is a screening assay for compounds that enhance the immunostimulatory effects of a TLR agonist. Another example is a screening assay for compounds that inhibit the  
10 immunostimulatory effects of a TLR agonist. In both examples, the reference compound is a positive reference compound (i.e., it is itself immunostimulatory).

          In other embodiments, particularly those directed at identifying immunostimulatory compounds, separate aliquots from the same cell line (or from the same freshly harvested cell population) are exposed to either the reference compound or the test compound, and the  
15 readouts from each are measured and compared to the other. If the reference compound is a negative reference compound (i.e., it is inert and neither immunostimulatory nor immunoinhibitory), then any test level that is greater than the reference level is indicative of a test compound that has at least some immunostimulatory capacity. Generally, the negative reference compound is used to set background levels of immunostimulation or  
20 immunoinhibition observed in the absence of the test compound. If the reference compound is a positive reference compound (i.e., it is immunostimulatory), then it is possible to compare and contrast the induction profile of the test compound to that of the reference compound.

          In some instances, separate reference assays individually containing a positive and a negative reference compound are performed alongside the test assay. For example, if the test  
25 assay is a screen for an immunostimulatory TLR ligand, then reference assays can be a positive reference assay (in which the reference compound is immunostimulatory), a negative reference assay (in which the reference compounds is immunologically inert or neutral), or both. A test compound is defined as immunostimulatory if it induces a response greater than that of the negative reference compound. The level and profile of the immunostimulatory  
30 response can be compared to the level and profile induced by the positive reference compound. It is to be understood that a test compound that induces a level of immunostimulation less than that of the positive reference compound may still be considered immunostimulatory according to the invention. Modifications to these screening assays for a

- 24 -

desired readout will be apparent to those of ordinary skill in the art based on the teachings provided herein.

If the test assay is a screen for an immunoinhibitory TLR ligand, then the assay may generally involve co-incubation of the test compound and a positive reference compound.

5 The control assay may include co-incubation of the negative and positive reference compounds. As used herein, co-incubation embraces simultaneous or consecutive addition of the reference and test compounds. The test compound may be added before or after the positive reference compound. An immunoinhibitory test compound may be identified by a diminution of the immunostimulatory response induced by the positive reference compound  
10 when in the presence of the test compound. If the level of the response is less in the presence of the test compound, this indicates that the test compound is capable of interfering with the immunostimulatory effects of the positive reference compound. As an example, simultaneous or consecutive addition of a putative immunoinhibitory test compound can reduce the amount of cytokines or chemokines secreted by cells in response to the positive reference compound  
15 alone, indicating an inhibition of the immunostimulatory effects of the positive reference compound.

The reference immunoinhibitory compound can be used at one or more concentrations in conjunction with a selected or constant concentration of reference immunostimulatory compound. Under proper conditions, the immunostimulatory effect of the reference  
20 immunostimulatory compound will be less in the presence of the immunoinhibitory substance than in the absence of the immunoinhibitory substance. Furthermore, under proper conditions, the immunostimulatory effect of the reference immunostimulatory compound will decrease with increasing concentration of the immunoinhibitory substance.

The breadth of response by the cell line to immunomodulatory compounds, and its  
25 facile manipulation, allows for the identification of novel compounds. The cell line allows the rapid discovery of such compounds given that it lends itself to high throughput screening methods such as those provided herein. These methods and compositions are described in greater detail below. The invention therefore provides screening methods that utilize cell  
lines that either endogenous express TLRs such as the RPMI 8226 cell line as well as cell  
30 lines that have been modified to express TLRs. The invention further provides compositions that comprise such cell lines.

The verification and standardization methods of the invention generally involve assays in which an isolated cell expressing a functional TLR is contacted with each of two

- 25 -

compositions, each composition containing a known ligand for the TLR. One composition is a reference composition, and the assay using the reference composition yields a reference activity. The second composition is a test composition, and the assay using the test composition yields a test activity. The two contacting steps can be performed on separate cells that are alike, and typically will be performed on separate populations of cells that are alike. For example, the separate cells or the separate populations of cells can be drawn from a single population of cells. In typical usage according to this embodiment, the reference and test activities are measured essentially concurrently, although the use of historical reference activity is also contemplated by the methods of the invention. As an alternative, the two contacting steps can be performed on a single cell or on a single population of cells, usually in an essentially concurrent manner when it is desirable to have competition between reference and test compositions. In one embodiment the known TLR ligand is a nucleic acid molecule.

The assays of the invention are performed under specific conditions so that comparison can be made between reference and test activities or levels. The results of the comparison can be used as a basis upon which to accept or reject the test material as suitable for its intended use.

The biological characterization of the reference composition will generally entail a series of biological activity measurements of the reference composition using a single assay under defined conditions in order to define a range of inter-test variance. The range of inter-test variance so obtained using reference composition can be used to define an acceptable range of variance within which a subsequent test measurement must fall in order to satisfy quality standards. Such a range of acceptable variance can serve as a basis for developing predetermined range of variance about the reference activity, i.e., acceptance criteria for a particular test composition or test lot. For example, a particular reference composition can be assayed under defined conditions in a number of independent measurements and found to yield a result expressed as  $100 \pm 5$  units of activity. Under this same example, a subsequent test measurement of a test composition performed using the same assay and defined conditions is found to yield 97 units of activity. The activity of the test composition under this example thus yielded a result that falls within the normal range of inter-test variance observed for the reference composition. Accordingly, the test material under this example could be selected on the basis of the test activity falling within a predetermined range of variance about the reference activity. In short, the test material can be deemed acceptable

- 26 -

provided the test activity falls within a predetermined range of activity that is related to the activity of the reference material.

In one embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of the same particular TLR ligand. Such comparison is useful for quality control assessment of the test lot of material, also referred to  
5 herein as validation, e.g., product validation. Such comparison is also useful for process validation.

In another embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of a different TLR ligand. In a simple  
10 example, where a test TLR ligand (T) is expected to have little or no activity characteristic of reference TLR ligand (R), comparison can be made between T and R to confirm the lack of R-like activity possessed by T. In a more complex example, where a test TLR ligand (C) is capable of exerting two different effects, wherein each effect is characteristic of one of two different classes of TLR ligand and is best characterized by one of two different reference  
15 TLR ligands (A and B), the test TLR ligand (C) can be compared with either of the two reference TLR ligands (A or B). In this second example, test composition C could be found, for example, to possess 50 percent A-like activity compared with reference A and 70 percent B-like activity compared with reference B. Test composition C could thus independently meet or fail to meet predetermined standards for each of A-like activity and B-like activity.  
20 Such comparison is also useful for quality control assessment of the test lot of material, e.g., product validation. Of course test TLR ligand C can alternatively or additionally be compared against reference TLR ligand C, as described in the preceding paragraph.

To facilitate the methods of the invention, certain conditions for carrying out the assays are standardized and used for measurements of both reference activity and test activity.  
25 In this way direct comparison between reference activity and test activity can be made readily. Conditions that can be standardized and used in this manner can include, without limitation, readout, temperature, media characteristics, duration (time between introduction of reference composition or test composition and activity measurement), methods of sampling, etc. In some embodiments the methods of the invention can be at least partially automated in order to  
30 increase throughput and/or to reduce inter-test variability. For example, robotic devices and workstations with the capacity to dispense and/or sample fluids in a set or programmable fashion are now well known in the art and can be used in performing the methods of the instant invention.

- 27 -

In one embodiment a standard curve of reference composition activity is employed. Typically the standard curve is generated by selecting conditions including concentration of the reference composition such that the dose-response curve is essentially linear (and the slope is non-zero) over a range of concentrations that includes the effective concentration at which activity is 50 percent of maximum (EC50). In one embodiment the standard curve spans a range of concentrations defined by  $EC50 \pm 1 \log$  concentration, e.g.,  $1 \times 10^{-7} \text{ M} - 1 \times 10^{-5} \text{ M}$ , where EC50 is  $1 \times 10^{-6} \text{ M}$ . In another embodiment the standard curve spans a broader range of concentrations defined by  $EC50 \pm 2 \log$  concentration, e.g.,  $1 \times 10^{-8} \text{ M} - 1 \times 10^{-4} \text{ M}$ , where EC50 is  $1 \times 10^{-6} \text{ M}$ . In yet another embodiment the standard curve spans a narrower range of concentrations defined by  $EC50 \pm 0.5 \log$  concentration, e.g.,  $3.16 \times 10^{-7} \text{ M} - 3.16 \times 10^{-6} \text{ M}$ , where EC50 is  $1 \times 10^{-6} \text{ M}$ . The foregoing embodiments are intended to be exemplary and not limiting in any way. One of skill in the art will be able to select, for a given reference composition and without undue experimentation, an appropriate range of concentrations about some middle value in order to generate an essentially linear standard curve with a non-zero slope.

In one embodiment a non-linear standard curve of reference and test composition activity is employed. The standard curve can be generated by selecting conditions including concentrations of the reference composition such that the dose-response curve is sigmoidal and the EC50 value can be determined. Comparison of reference and test activity can be done by comparing, e.g., the EC50 values of both curves. Concentration range is chosen to yield a complete sigmoidal response, e.g., concentration should include  $EC50 \pm 3 \log$  concentration or  $EC50 \pm 4 \log$  concentration. In the case of testing an inhibitory compound the value determined would be the IC50, i.e., concentration where inhibition of the stimulatory signal is half-maximal.

The methods of the invention can be adapted to be automated or at least partially automated methods, as well as to parallel array or high throughput format methods. For example, the assays can be set up using multiwell plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery device suited to the geometry of the multiwell plate. Manual and robotic multiwell delivery devices suitable for use in a high throughput screening assay are known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are

known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully robotic systems are known in the art for applications such as generation and analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. Pat. Nos. 5,443,791 and 5,708,158.

### Cell lines

The screening methods may use experimental cells. As used herein, an experimental cell is a non-primary cell (i.e., it is not a cell that has been recently harvested from a subject). It excludes, for example, freshly harvested PBMCs. An experimental cell includes a cell from a cell line such as the RPMI 8226 cell line.

In certain embodiments, the cell naturally expresses a functional TLR. In one embodiment relating to the verification and standardization aspects of the invention, the cell may be a PBMC, preferably a PBMC freshly harvested from a subject.

Cells that would be suitable for identification of TLR agonists, antagonists or enhancers according to the invention may possess one or more particular attributes. These attributes include but are not limited to being of human origin, being an immortalized stable cell line, endogenously expressing at least one functional TLR or a combination of functional TLRs, having intact signaling mechanisms, having intact uptake mechanisms, being able to upregulate cytokines, chemokines or cell surface markers, deriving from normal human B cells or from myeloma or B cell leukemia, deriving from human plasmacytoid and myeloid dendritic cells, and readily activatable by TLR ligands such as TLR7 ligands, TLR8 ligands or TLR9 ligands such as CpG nucleic acids or nucleic acids having other immunostimulatory sequence motifs or small molecules such as imidazoquinoline compounds.

In some embodiments, the cell line is the Raji cell line which expresses TLR3, TLR7 and TLR9. This latter cell line secretes, for example, IL-6 and IFN- $\alpha$ 2 upon CpG nucleic acid exposure. In other embodiments, the cell line is RPMI 8226 which expresses TLR7 and TLR9. Upon CpG nucleic acid exposure, this cell line expresses, produces and/or secretes IL-8, IL-10, IP-10 and TNF- $\alpha$ . It also expresses at its cell surface CD86, HLA-DR and CD71. In yet other embodiments, the cell line is the RAMOS cell line which expresses TLR3, TLR7 and TLR9. This cell line at least induces CD80 cell surface expression in response to CpG nucleic acid exposure.



The cell lines have been observed to respond in a concentration dependent manner to TLR ligands such as but not limited to CpG nucleic acids and some non-CpG nucleic acids including T-rich nucleic acids, poly-T nucleic acids and poly-G nucleic acids. The highest responses have been observed using CpG nucleic acids.

5       The screening methods employ a variety of cell lines as shown in the Examples. These include A549 (human lung carcinoma, ATCC CCL-185), BeWo (human choriocarcinoma, ATCC CCL-98), HeLa (human cervix carcinoma, ATCC CCL-2), Hep-2 (human cervix carcinoma, ATCC CCL-23), KG-1 (human acute myeloid leukemia, ATCC CCL-246), MUTZ-3 (human acute myelomonocytic leukemia, German Collection of Cell  
10 lines and Microorganisms (DSZM) ACC-295), Nalm-6 (human B cell precursor leukemia, DSZM ACC-128), NK-92 (human Natural killer cell line, ATCC CRL-2407), NK-92 MI (IL-2 independent human Natural killer cell line, ATCC CRL-2408), Raji (human B lymphocyte Burkitt's lymphoma, ATCC CCL-86), RAMOS (B lymphocyte Burkitt's lymphoma, ATCC CRL-1596), RPMI 8226 (human B lymphocyte multiple myeloma, ATCC CCL-155), THP-1  
15 (human acute monocytic leukemia, ATCC TIB 202), U937 (human lymphoma, ATCC CRL-1593.2) and Jurkat (human T cell leukemia, ATCC TIB 152).

As shown in the Examples, each of the afore-mentioned cell lines has a particular endogenous TLR expression profile which dictates its suitability in a particular screening assay.

20       A cell that artificially expresses a functional TLR can be a cell that does not express the functional TLR but for a transfected TLR expression vector. For example, human 293 fibroblasts (ATCC CRL-1573) do not express TLR7, TLR8 or TLR9, and they express very little TLR3. As described in the examples below, such cells can be transiently or stably transfected with suitable expression vector (or vectors) so as to yield cells that do express  
25 TLR3, TLR7, TLR8, TLR9, or any combination thereof. Alternatively, a cell that artificially expresses a functional TLR can be a cell that expresses the functional TLR at a significantly higher level with the TLR expression vector than it does without the TLR expression vector. Transfected cells are considered modified cells, as used herein.

A cell that artificially expresses an expression or reporter construct is preferably stably  
30 transfected.

RPMI

The RPMI 8226 cell line is a human multiple myeloma cell line. The cell line was established from the peripheral blood of a 61 year old man at the time of diagnosis for multiple myeloma (IgG lambda type). RPMI 8226 was previously reported as responsive to CpG nucleic acids as evidenced by the production and secretion of IL-6 protein and production of IL-12p40 mRNA. (Takeshita et al. (2000), *Eur. J. Immunol.* 30, 108-116, and Takeshita et al. (2000) *Ibid.* 30, 1967-1976) Takeshita et al. however used the cell line solely to study promoter constructs in order to identify transcription factor binding sites important for CpG nucleic acid signaling. It is now known according to the invention that the cell line produces a number of other chemokines and cytokines including IL-8, IL-10 and IP-10. It has also been discovered according to the invention that the cell line responds to immunostimulatory nucleic acids by upregulating cell surface expression of particular markers. Many of these markers, including CD71, CD86 and HLA-DR, are similarly upregulated in PBMCs exposed to immunostimulatory nucleic acids. This has been observed using flow cytometric analysis of the cell line following CpG nucleic acid exposure. In other aspects of the invention, the cell line can be used in similar screening assays that involve secretion of IL-6, IL-12 and/or TNF- $\alpha$ .

It has recently been discovered that R-848 mediates its immunostimulatory effects via other TLR family members, namely TLR7 and TLR8. TLR7 has previously been found expressed on human B cells. It has now also been discovered according to the invention that RPMI 8226 expresses TLR9 as well as TLR7, thus making it a suitable cell line for identifying immunostimulatory nucleic acid and/or imidazoquinoline (e.g., R-848) mimics or other small molecules that also signal through TLR7 and/or TLR9. Incubation of RPMI 8226 cells with the imidazoquinoline R-848 (Resiquimod) induces for example IL-8, IL-10 and IP-10 production.

25

#### Known TLR Ligands

Ligands for many but not all of the TLRs have been described. For instance, it has been reported that TLR1 and TLR2 signals in response to peptidoglycan and lipopeptides. Yoshimura A et al. (1999) *J Immunol* 163:1-5; Brightbill HD et al. (1999) *Science* 285:732-6; Aliprantis AO et al. (1999) *Science* 285:736-9; Takeuchi O et al. (1999) *Immunity* 11:443-51; Underhill DM et al. (1999) *Nature* 401:811-5. TLR4 has been reported to signal in response to lipopolysaccharide (LPS). Hoshino K et al. (1999) *J Immunol* 162:3749-52; Poltorak A et al. (1998) *Science* 282:2085-8; Medzhitov R et al. (1997) *Nature* 388:394-7. Bacterial

30

flagellin has been reported to be a natural ligand for TLR5. Hayashi F et al. (2001) *Nature* 410:1099-1103. TLR6, in conjunction with TLR2, has been reported to signal in response to proteoglycan. Ozinsky A et al. (2000) *Proc Natl Acad Sci USA* 97:13766-71; Takeuchi O et al. (2001) *Int Immunol* 13:933-40.

- 5 TLR9 is a receptor for CpG DNA. Hemmi H et al. (2000) *Nature* 408:740-5. Other TLR9 ligands are described herein under "Immunostimulatory Nucleic Acids". Certain imidazoquinoline compounds having antiviral activity are ligands of TLR7 and TLR8. Imidazoquinolines are potent synthetic activators of immune cells with antiviral and antitumor properties. R-848 is a ligand for human TLR7 and TLR8. Jurk M et al. (2002) *Nat Immunol* 3:499. Ligands of TLR3 include poly(I:C) and double-stranded RNA (dsRNA). Alexopoulou et al. (2001) *Nature* 413:732-738. For purposes of this invention, poly(I:C) and double-stranded RNA (dsRNA) are classified as oligonucleotide molecules. TLR3 may have a role in host defense against viruses.

## 15 Reference and Test Compounds

- A test and/or reference compound can be a nucleic acid such as an oligonucleotide or a polynucleotide, an oligopeptide, a polypeptide, a lipid such as a lipopolysaccharide, a carbohydrate such as an oligosaccharide or a polysaccharide, or a small molecule. Alternatively, these compounds may also comprise or be synthesized from elements such as amino acids, carbohydrates, hormones, lipids, organic molecules, and the like.

- 20 Small molecules in general include naturally occurring, synthetic, and semisynthetic organic and organometallic compounds with molecular weight less than about 2.5 kDa. Examples of small molecules include most drugs, subunits of polymeric materials, and analogs and derivatives thereof.

- 25 Some specific examples of small molecules include the imidazoquinolines. As used herein, imidazoquinolines include imidazoquinoline amines (imidazoquinolinamines), imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2 bridged imidazoquinoline amines. These compounds have been described in U.S. Pat. Nos. 4,689,338; 4,929,624; 5,238,944; 5,266,575; 5,268,376; 5,346,905; 5,352,784; 5,389,640; 30 5,395,937; 5,482,936; 5,494,916; 5,525,612; 6,039,969 and 6,110,929. Particular species of imidazoquinoline agents include resiquimod (R-848; S-28463; 4-amino-2 ethoxymethyl- $\alpha,\alpha$ -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol); and imiquimod (R-837; S-26308; 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinoline-4-amine). Further examples of specific small

molecules include 4-aminoquinoline and derivatives thereof, 9-aminoacridine and derivatives thereof, and additional compounds disclosed in U.S. Pat. Nos. 6,221,882; 6,399,630; 6,479,504; and 6,521,637; and published U.S. Pat. Application No. 2002/0151564 A1, the entire contents of which are hereby incorporated by reference.

5           The test and reference compounds may be formulated for pharmaceutical use or not. For example, a test compound not formulated for pharmaceutical use can be a compound (e.g., a lot or batch of the compound) under evaluation for possible use in preparing a pharmaceutical formulation of the compound.

10           A reference compound, as used herein, is a compound having a known activity in the presence of a TLR. The reference compound may stimulate TLR signaling (and is therefore regarded as a positive reference compound), or it may be inert in the presence of a TLR (and is therefore regarded as a negative reference compound). If it is a positive reference compound, it need not be the best known stimulator of TLR signaling (i.e., it is possible that other reference compounds and even test compounds will stimulate TLR signaling to a greater  
15           extent). The readout of the screening assay may simply be stated relative to the level of signaling that occurs in the presence of the reference compound. Preferably, the reference compound is analyzed prior to the screening assay in order to determine its level of activity on a TLR. In some aspects of the invention, the reference compound and the test compound will be assayed separately (i.e., in separate wells); in other aspects, the reference compound and  
20           the test compound will be assayed together (i.e., in the same well). These latter aspects are designed to measure the ability of a test compound to modulate the activity of the reference compound. The activity of the test compound and the reference compound combined (i.e., when assayed together in the same well) may be the same as that of the positive reference compound alone, indicating at a minimum that the test compound is not inhibitory; or it may  
25           be less than that of the positive reference compound, indicating at a minimum that it is inhibitory to the effect of the reference compound; or it may be additive or synergistic possibly indicating that the test compound is an enhancer. The effect of an enhance may be due to its ability to stimulate TLR signaling independently of the positive reference compound.

30           A "reference composition" as used herein refers to a composition that includes a reference compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A reference compound may be an immunostimulatory compound or it may be an immunoinhibitory compound.

As discussed further below, in some aspects of the invention the reference compositions include both finished products, e.g., finished pharmaceutical products, as well as raw materials and other in-process materials used for the preparation of such finished products, all of which contain a known TLR ligand. As used herein, a "production lot" shall refer to a batch or lot of a completed product prepared for release as clinical material, e.g., a pharmaceutical product. As used herein, an "in-process lot" shall refer to a batch or lot of unfinished product that is prepared in the course of making a production lot; an "in-process lot" shall also refer to a batch or lot of raw material provided for use in the production of a production lot.

10 In some aspects of the invention, the reference compositions of the invention are highly characterized in terms of their chemical, physical, and biological properties. A reference composition will be a specific composition previously determined to have a specific activity, or range of specific activity, of the particular known TLR ligand present in the composition. As used herein, "specific activity" refers to an amount of activity per unit mass or per unit volume of the reference composition as a whole, as determined using a defined assay under defined conditions. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR ligand at a determined concentration or activity.

At least the following parameters are typically very well defined for a given reference composition: chemical formula of the active ingredient TLR ligand (e.g., nucleobase sequence and type of backbone of a nucleic acid; structural formula of a small molecule); concentration; diluent composition; and purity. Such parameters as purity and concentration can be determined using any appropriate physicochemical method, e.g., optical spectroscopy including absorbance at one or more specified wavelengths; nuclear magnetic resonance (NMR) spectroscopy; mass spectrometry (MS), including matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS); melting point; specific gravity; chromatography including as appropriate high pressure liquid chromatography (HPLC), one- and two-dimensional polyacrylamide gel electrophoresis (PAGE), capillary electrophoresis, and the like; as well as other methods known to those of skill in the art.

Reference compositions can also be very well characterized in terms of their biological activity, independent of the methods of the invention, although the methods of the

- 34 -

invention generally include such characterization, at least in part. A reference composition can be very well characterized in terms of its biological activity by characterizing, both qualitatively and quantitatively, the response by sensitive cells to the reference composition under defined conditions. For example, a reference composition can be a specific CpG oligonucleotide such as SEQ ID NO:1 which in a specific assay and under specific conditions of temperature, concentration, duration of contact between the CpG oligonucleotide and a population of TLR9-expressing cells, and particular readout, reliably yields a specific result or range of results. Results can be expressed in any suitable manner, but can include results expressed on a per-cell basis, e.g., picograms of particular cytokine per cell per hour of contact with the reference composition. Reference compositions can be very well characterized in terms of their biological activity according to one or more parameters, for example, according to their capacity to induce each of a plurality of cytokines.

The methods of the invention also involve measurement of a test activity of a test composition containing a known TLR ligand. A "test composition" as used herein refers to a composition that includes a test compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A test compound can be an immunostimulatory compound or it can be an immunoinhibitory compound. In some aspects of the invention, the test compound is a known TLR ligand. Test compositions of the invention may comprise known TLR agonist or TLR antagonist compounds, generally but not necessarily nominally the same as the reference compositions against which comparison is to be made according to some aspects of the invention. Thus test compositions may encompass immunostimulatory compounds, immunoinhibitory compounds, known TLR ligands, finished pharmaceutical products, and raw materials and other in-process materials used for the preparation of such finished products.

Unlike a reference composition, a test composition is not characterized at all, or is only partially characterized, or is not as well characterized as the reference composition, in terms of its chemical, physical, or (most particularly) biological properties. The methods of the invention permit further characterization of the test composition by comparison with a reference composition. In some aspects, a test composition will be a specific composition previously determined to be a ligand of a specific TLR. In one embodiment the test composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the test composition is a representative sample of a particular lot or batch of

a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR ligand at a determined concentration or activity.

#### Immunostimulatory and Immunoinhibitory Nucleic Acids

5 Nucleic acids useful as reference compounds and as test compounds in the methods of the invention include single- and double-stranded natural and synthetic nucleic acids, including those with phosphodiester, stabilized, and chimeric backbones. Also encompassed are at least the following classes of nucleic acids, which are described in detail below: immunostimulatory CpG nucleic acids (CpG nucleic acids), including but not limited to types  
10 A, B, and C; immunostimulatory non-CpG nucleic acids, including without limitation methylated CpG nucleic acids, T-rich nucleic acids, TG-motif nucleic acids, CpI motif nucleic acids, and poly-G nucleic acids; and immunoinhibitory nucleic acids. Nucleic acids useful as reference compounds and as test compounds in the methods of the invention also include nucleic acids with modified backbones, including "soft" and "semi-soft" oligonucleotides as  
15 described herein. As will be appreciated from the descriptions below, certain of these various classes of nucleic acids can coexist in a given nucleic acid molecule.

A "nucleic acid" as used herein with respect to test compounds and reference compounds used in the methods of the invention, shall refer to any polymer of two or more individual nucleoside or nucleotide units. Typically individual nucleoside or nucleotide units  
20 will include any one or combination of deoxyribonucleosides, ribonucleosides, deoxyribonucleotides, and ribonucleotides. The individual nucleotide or nucleoside units of the nucleic acid can be naturally occurring or not naturally occurring. For example, the individual nucleotide units can include deoxyadenosine, deoxycytidine, deoxyguanosine, thymidine, and uracil. In addition to naturally occurring 2'-deoxy and 2'-hydroxyl forms,  
25 individual nucleosides also include synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g., as described in Uhlmann E et al. (1990) *Chem Rev* 90:543-84. The linkages between individual nucleotide or nucleoside units can be naturally occurring or not naturally occurring. For example, the linkages can be phosphodiester, phosphorothioate, phosphorodithioate, phosphoramidate, as well as peptide linkages and other  
30 covalent linkages, known in the art, suitable for joining adjacent nucleoside or nucleotide units. The linkages can also be mixed in a single polymer (e.g., a semi-soft backbone). The nucleic acid test compounds and nucleic acid reference compounds typically range in size from 3-4 units to a few tens of units, e.g., 18-40 units.

- 36 -

In some embodiments the nucleic acids are oligonucleotides made up of 2 to about 100 nucleotides, and more typically 4 to about 40 nucleotides. Oligonucleotides composed exclusively of deoxynucleotides are termed oligodeoxyribonucleotides or, equivalently, oligodeoxynucleotides (ODN).

5 A CpG nucleic acid is an immunostimulatory nucleic acid which contains a cytosine-guanine (CG) dinucleotide, the C residue of which is unmethylated. The effects of CpG nucleic acids on immune modulation have been described extensively in U.S. Pat. Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068; and published patent applications, such as PCT/US95/01570 (WO 96/02555); PCT/US98/04703 (WO 98/40100);  
10 and PCT/US99/09863 (WO 99/56755). The entire contents of each of these patents and published patent applications is hereby incorporated by reference. The entire immunostimulatory nucleic acid can be unmethylated or portions can be unmethylated, but at least the C of the 5'-CG-3' must be unmethylated. The CpG nucleic acid sequences of the invention include, without limitation, those broadly described above as well as those disclosed  
15 in U.S. Pat. Nos. 6,207,646 and 6,239,116.

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTGTCGTTTTGTCGTT-3' (SEQ ID NO:1).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTGACGTTTTGTCGTT-3' (SEQ ID NO:139).

20 In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTGTCGTTTTTTTCGA-3' (SEQ ID NO:140).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTCGTCGTTTCGTCGTT-3' (SEQ ID NO:141).

25 In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTCGTCGTTTTGTCGTT-3' (SEQ ID NO:142).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTTCGGTCGTTTT-3' (SEQ ID NO:143).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTTCGTGCGTTTTT-3' (SEQ ID NO:144).

30 In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTTCGGCGGCCGCGG-3' (SEQ ID NO:145).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTC\_GTTTTAC\_GGCGCC\_GTGCCG-3' (SEQ ID NO:146).



The oligonucleotides described by SEQ ID NOs: 1, 139-145 are fully stabilized phosphorothioate backbone ODN. The oligonucleotide of SEQ ID NO:146 has a chimeric backbone in which all internucleoside linkages are phosphorothioate except for those indicated by “\_”, which are phosphodiester.

5 CpG nucleic acids have been further classified by structure and function into at least the following three types, all of which are intended to be encompassed within the methods of the instant invention: Type B CpG nucleic acids such as SEQ ID NO:1 include the earliest described CpG nucleic acids and characteristically activate B cells but do not induce or only weakly induce expression of IFN- $\alpha$ . Type B nucleic acids are described in U.S. Patents  
10 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068. Type A CpG nucleic acids, described in published international application PCT/US00/26527 (WO 01/22990), incorporate a CpG motif, include a hybrid phosphodiester/phosphorothioate backbone, and characteristically induce plasmacytoid dendritic cells to express large amounts of IFN- $\alpha$  but do not activate or only weakly activate B cells. Type C oligonucleotides incorporate a CpG,  
15 include a chimeric backbone, include a GC-rich palindromic or nearly-palindromic region, and are capable of both activating B cells and inducing expression of IFN- $\alpha$ . These have been described, for example, in copending U.S. Pat. application Ser. No. 10/224,523, filed August 19, 2002. Exemplary sequences of A, B and C class nucleic acids are described in the afore-mentioned references, patents and patent applications, the entire contents of which are  
20 hereby incorporated by reference herein.

In other embodiments of the invention, a non-CpG nucleic acid is used. A non-CpG nucleic acid is an immunostimulatory nucleic acid which either does not have a CpG motif in its sequence, or has a CpG motif which contains a methylated C residue. In some instances, the non-CpG nucleic acid may still be immunostimulatory by virtue of its having other  
25 immunostimulatory motifs such as those described herein and known in the art. In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid. In some instances the non-CpG nucleic acid is still immunostimulatory despite methylation of the C of the CpG motif, even without having another non-CpG immunostimulatory motif described herein and known in the art.

30 In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGTTTTGTZGTTTTGTZGTT-3' (SEQ ID NO:147), wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGZTGTZTZZGZTTZTTZTTGZZ-3' (SEQ ID NO:148), wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having  
5 a base sequence provided by 5'-GZGTTTGZTZZTTZTTZTTGZG-3' (SEQ ID NO:149),  
wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-GZZZAAGZTGGZATZZGTZA-3' (SEQ ID NO:150), wherein Z represents 5-methylcytosine.

10 Non-CpG nucleic acids include T-rich immunostimulatory nucleic acids. The T-rich immunostimulatory nucleic acids include those disclosed in published PCT patent application PCT/US00/26383 (WO 01/22972), the entire contents of which are incorporated herein by reference. In some embodiments, T-rich nucleic acids 24 bases in length are used. A T-rich nucleic acid is a nucleic acid which includes at least one poly T sequence and/or which has a  
15 nucleotide composition of greater than 25% T nucleotide residues. A nucleic acid having a poly-T sequence includes at least four Ts in a row, such as 5'-TTTT-3'. In some embodiments the T-rich nucleic acid includes more than one poly T sequence. In important embodiments, the T-rich nucleic acid may have 2, 3, 4, or more poly T sequences, such as SEQ ID NO:1.

Non-CpG nucleic acids also include poly-G immunostimulatory nucleic acids. A  
20 variety of references describe the immunostimulatory properties of poly-G nucleic acids. Pisetsky DS et al. (1993) *Mol Biol Reports* 18:217-221; Krieger M et al. (1994) *Ann Rev Biochem* 63:601-637; Macaya RF et al. (1993) *Proc Natl Acad Sci USA* 90:3745-3749; Wyatt JR et al. (1994) *Proc Natl Acad Sci USA* 91:1356-1360; Rando and Hogan, 1998, In *Applied Antisense Oligonucleotide Technology*, Krieg and Stein, eds., pp. 335-352; Kimura Y et al.  
25 (1994) *J Biochem (Tokyo)* 116:991-994.

The immunostimulatory nucleic acids of the invention can also be those which do not possess CpG, methylated CpG, T-rich, or poly-G motifs.

Exemplary immunostimulatory nucleic acid sequences include but are not limited to those immunostimulatory sequences described and listed in U.S. Non-Provisional Pat.  
30 Application No. 09/669,187, filed on September 25, 2000, and in corresponding published PCT patent application PCT/US00/26383 (WO 01/22972).

Immunoinhibitory nucleic acids have been described in Lenert P et al. (2001) *Antisense Nucleic Acid Drug Dev* 11:247-56 and in Stunz L et al. (2002) *Eur J Immunol*

32:1212-22. These inhibitory phosphorothioate ODN (S-ODN) differ from stimulatory S-ODN by having 2-3 G substitutions in the central motif. As inhibitory S-ODN did not directly interfere with the NF- $\kappa$ B DNA binding but prevented CpG-induced NF- $\kappa$ B nuclear translocation of p50, p65, and c-Rel and blocked p105, I $\kappa$ B $\alpha$ , and I $\kappa$ B $\beta$  degradation, Lenert et al. suggested that the putative target of immunoinhibitory ODN would lie upstream of inhibitory kinase (IKK) activation. Stunz et al. reported that replacing GCGTT or ACGTT with GCGGG or ACGGG converted a stimulatory 15-mer ODN into an inhibitory ODN. All inhibitory ODN had three consecutive G, and a fourth G increased inhibitory activity, but a deazaguanosine substitution to prevent planar stacking did not affect activity. Inhibitory ODN blocked apoptosis protection and cell-cycle entry induced by stimulatory ODN, but not that induced by lipopolysaccharide, anti-CD40 or anti-IgM+IL-4. ODN-driven up-regulation of cyclin D(2), c-Myc, c-Fos, c-Jun and Bcl(XL) and down-regulation of cyclin kinase inhibitor p27(kip1) were all blocked by inhibitory ODN. Stunz et al. also reported that interference with uptake of stimulatory ODN did not account for the inhibitory effects of the immunoinhibitory nucleic acids.

In one embodiment the immunoinhibitory nucleic acid has a base sequence provided by 5'-TCCTGGCGGGGAAGT-3' (SEQ ID NO:151).

Immunoinhibitory nucleic acids have also been described in U.S. Pat. No. 6,194,388, issued to Krieg et al. The immunoinhibitory oligonucleotides disclosed by Krieg et al. are oligonucleotides with GCG trinucleotides at or near the ends of the oligonucleotide and are represented by the formula 5' GCGX<sub>n</sub>GCG 3' in which X is a nucleotide and n is an integer between 0 and 50.

The nucleic acids used as either test or reference compounds can be double-stranded or single-stranded. They can be deoxyribonucleotide (DNA) or ribonucleotide (RNA) molecules. Generally, double-stranded molecules are more stable in vivo, while single-stranded molecules have increased immune activity. Thus in some the nucleic acid is single-stranded and in other embodiments the nucleic acid is double-stranded. In certain embodiments, while the nucleic acid is single-stranded, it is capable of forming secondary and tertiary structures (e.g., by folding back on itself, or by hybridizing with itself either throughout its entirety or at select segments along its length). Accordingly, while the primary structure of such a nucleic acid may be single-stranded, its higher order structures may be double- or triple-stranded.

For facilitating uptake into cells, the nucleic acids are preferably in the range of 6 to 100 bases in length. However, nucleic acids of any size equal to or greater than 6 nucleotides (even many kb long) are capable of inducing an immune response. Preferably the nucleic acid is in the range of between 8 and 100 and in some embodiments between 8 and 50 or 8 and 30 nucleotides in size.

The terms "nucleic acid" and "oligonucleotide" are used interchangeably to mean multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)). As used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms "nucleic acid" and "oligonucleotide" shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g., genomic or cDNA), but are preferably synthetic (e.g., produced by nucleic acid synthesis).

The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with substitutions or modifications, such as in the bases and/or sugars. For example, they include nucleic acids having backbone sugars that are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other than a phosphate group or hydroxy group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose or 2'-fluoroarabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have an amino acid backbone with nucleic acid bases). Other examples are described in more detail below.

The immunostimulatory and immunoinhibitory nucleic acids can encompass various chemical modifications and substitutions, in comparison to natural RNA and DNA, involving a phosphodiester internucleoside bridge, a  $\beta$ -D-ribose unit and/or a natural nucleoside base (adenine, guanine, cytosine, thymine, uracil). Examples of chemical modifications are known to the skilled person and are described, for example, in Uhlmann E et al. (1990) *Chem Rev* 90:543; "Protocols for Oligonucleotides and Analogs" Synthesis and Properties & Synthesis and Analytical Techniques, S. Agrawal, Ed, Humana Press, Totowa, USA 1993; Crooke ST et al. (1996) *Annu Rev Pharmacol Toxicol* 36:107-129; and Hunziker J et al. (1995) *Mod Synth*

*Methods* 7:331-417. An oligonucleotide according to the invention may have one or more modifications, wherein each modification is located at a particular phosphodiester internucleoside bridge and/or at a particular  $\beta$ -D-ribose unit and/or at a particular natural nucleoside base position in comparison to an oligonucleotide of the same sequence which is  
 5 composed of natural DNA or RNA.

For example, the oligonucleotides may comprise one or more modifications and wherein each modification is independently selected from:

- a) the replacement of a phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside by a modified internucleoside bridge,
- 10 b) the replacement of phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge,
- c) the replacement of a sugar phosphate unit from the sugar phosphate backbone by another unit,
- d) the replacement of a  $\beta$ -D-ribose unit by a modified sugar unit, and
- 15 e) the replacement of a natural nucleoside base by a modified nucleoside base.

More detailed examples for the chemical modification of an oligonucleotide are as follows.

The oligonucleotides may include modified internucleotide linkages, such as those described in (a) or (b) above. These modified linkages may be partially resistant to  
 20 degradation (e.g., are stabilized). A "stabilized oligonucleotide molecule" shall mean an oligonucleotide that is relatively resistant to *in vivo* degradation (e.g., via an exo- or endonuclease) resulting from such modifications. Oligonucleotides having phosphorothioate linkages, in some embodiments, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases.

25 A phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside can be replaced by a modified internucleoside bridge, wherein the modified internucleoside bridge is for example selected from phosphorothioate, phosphorodithioate,  $\text{NR}^1\text{R}^2$ -phosphoramidate, boranophosphate,  $\alpha$ -hydroxybenzyl phosphonate, phosphate-( $\text{C}_1$ - $\text{C}_{21}$ )-O-alkyl ester, phosphate-[( $\text{C}_6$ - $\text{C}_{12}$ )aryl-( $\text{C}_1$ - $\text{C}_{21}$ )-O-alkyl]ester, ( $\text{C}_1$ - $\text{C}_8$ )alkylphosphonate  
 30 and/or ( $\text{C}_6$ - $\text{C}_{12}$ )arylphosphonate bridges, ( $\text{C}_7$ - $\text{C}_{12}$ )- $\alpha$ -hydroxymethyl-aryl (e.g., disclosed in WO 95/01363), wherein ( $\text{C}_6$ - $\text{C}_{12}$ )aryl, ( $\text{C}_6$ - $\text{C}_{20}$ )aryl and ( $\text{C}_6$ - $\text{C}_{14}$ )aryl are optionally substituted by halogen, alkyl, alkoxy, nitro, cyano, and where  $\text{R}^1$  and  $\text{R}^2$  are, independently of each other, hydrogen, ( $\text{C}_1$ - $\text{C}_{18}$ )-alkyl, ( $\text{C}_6$ - $\text{C}_{20}$ )-aryl, ( $\text{C}_6$ - $\text{C}_{14}$ )-aryl-( $\text{C}_1$ - $\text{C}_8$ )-alkyl, preferably hydrogen,

(C<sub>1</sub>-C<sub>8</sub>)-alkyl, preferably (C<sub>1</sub>-C<sub>4</sub>)-alkyl and/or methoxyethyl, or R<sup>1</sup> and R<sup>2</sup> form, together with the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain a further heteroatom from the group O, S and N.

The replacement of a phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge (dephospho bridges are described, for example, in Uhlmann E and Peyman A in "Methods in Molecular Biology", Vol. 20, "Protocols for Oligonucleotides and Analogs", S. Agrawal, Ed., Humana Press, Totowa, 1993, Chapter 16, pp. 355 ff), wherein a dephospho bridge is for example selected from the dephospho bridges formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethyl-hydrazo, dimethylenesulfone and/or silyl groups.

A sugar phosphate unit (i.e., a  $\beta$ -D-ribose and phosphodiester internucleoside bridge together forming a sugar phosphate unit) from the sugar phosphate backbone (i.e., a sugar phosphate backbone is composed of sugar phosphate units) can be replaced by another unit, wherein the other unit is for example suitable to build up a "morpholino-derivative" oligomer (as described, for example, in Stirchak EP et al. (1989) *Nucleic Acids Res* 17:6129-41), that is, e.g., the replacement by a morpholino-derivative unit; or to build up a polyamide nucleic acid ("PNA"; as described for example, in Nielsen PE et al. (1994) *Bioconjug Chem* 5:3-7), that is, e.g., the replacement by a PNA backbone unit, e.g., by 2-aminoethylglycine. The oligonucleotide may have other carbohydrate backbone modifications and replacements, such as peptide nucleic acids with phosphate groups (PHONA), locked nucleic acids (LNA), and oligonucleotides having backbone sections with alkyl linkers or amino linkers. The alkyl linker may be branched or unbranched, substituted or unsubstituted, and chirally pure or a racemic mixture.

A  $\beta$ -ribose unit or a  $\beta$ -D-2'-deoxyribose unit can be replaced by a modified sugar unit, wherein the modified sugar unit is for example selected from  $\beta$ -D-ribose,  $\alpha$ -D-2'-deoxyribose, L-2'-deoxyribose, 2'-F-2'-deoxyribose, 2'-F-arabinose, 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose, preferably 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose is 2'-O-methylribose, 2'-O-(C<sub>2</sub>-C<sub>6</sub>)alkenyl-ribose, 2'-[O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl]-ribose, 2'-NH<sub>2</sub>-2'-deoxyribose,  $\beta$ -D-xylo-furanose,  $\alpha$ -arabinofuranose, 2,4-dideoxy- $\beta$ -D-erythro-hexo-pyranose, and carbocyclic (described, for example, in Froehler J (1992) *Am Chem Soc* 114:8320) and/or open-chain sugar analogs (described, for example, in Vandendriessche et al. (1993) *Tetrahedron* 49:7223) and/or bicyclosugar analogs (described, for example, in Tarkov M et al. (1993) *Helv Chim Acta* 76:481).

In some embodiments the sugar is 2'-O-methylribose, particularly for one or both nucleotides linked by a phosphodiester or phosphodiester-like internucleoside linkage.

In some embodiments, the nucleic acids may be soft or semi-soft nucleic acids. A soft nucleic acid is an immunostimulatory nucleic acid having a partially stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages occur only within and immediately adjacent to at least one internal pyrimidine-purine dinucleotide (YZ). Preferably YZ is YG, a pyrimidine-guanosine (YG) dinucleotide. The at least one internal YZ dinucleotide itself has a phosphodiester or phosphodiester-like internucleotide linkage. A phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide can be 5', 3', or both 5' and 3' to the at least one internal YZ dinucleotide.

In particular, phosphodiester or phosphodiester-like internucleotide linkages involve "internal dinucleotides". An internal dinucleotide in general shall mean any pair of adjacent nucleotides connected by an internucleotide linkage, in which neither nucleotide in the pair of nucleotides is a terminal nucleotide, i.e., neither nucleotide in the pair of nucleotides is a nucleotide defining the 5' or 3' end of the nucleic acid. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 dinucleotides and only n-3 internal dinucleotides. Each internucleotide linkage in an internal dinucleotide is an internal internucleotide linkage. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 internucleotide linkages and only n-3 internal internucleotide linkages. The strategically placed phosphodiester or phosphodiester-like internucleotide linkages, therefore, refer to phosphodiester or phosphodiester-like internucleotide linkages positioned between any pair of nucleotides in the nucleic acid sequence. In some embodiments the phosphodiester or phosphodiester-like internucleotide linkages are not positioned between either pair of nucleotides closest to the 5' or 3' end.

Preferably a phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide is itself an internal internucleotide linkage. Thus for a sequence  $N_1$  YZ  $N_2$ , wherein  $N_1$  and  $N_2$  are each, independent of the other, any single nucleotide, the YZ dinucleotide has a phosphodiester or phosphodiester-like internucleotide linkage, and in addition (a)  $N_1$  and Y are linked by a phosphodiester or phosphodiester-like internucleotide linkage when  $N_1$  is an internal nucleotide, (b) Z and  $N_2$  are linked by a phosphodiester or phosphodiester-like internucleotide linkage when  $N_2$  is an internal nucleotide, or (c)  $N_1$  and Y are linked by a phosphodiester or

- 44 -

phosphodiester-like internucleotide linkage when  $N_1$  is an internal nucleotide and Z and  $N_2$  are linked by a phosphodiester or phosphodiester-like internucleotide linkage when  $N_2$  is an internal nucleotide.

Soft nucleic acids according to the instant invention are believed to be relatively  
5 susceptible to nuclease cleavage compared to completely stabilized nucleic acids. Without meaning to be bound to a particular theory or mechanism, it is believed that soft nucleic acids of the invention are cleavable to fragments with reduced or no immunostimulatory activity relative to full-length soft nucleic acids. Incorporation of at least one nuclease-sensitive internucleotide linkage, particularly near the middle of the nucleic acid, is believed to provide  
10 an "off switch" which alters the pharmacokinetics of the nucleic acid so as to reduce the duration of maximal immunostimulatory activity of the nucleic acid. This can be of particular value in tissues and in clinical applications in which it is desirable to avoid injury related to chronic local inflammation or immunostimulation, e.g., the kidney.

A semi-soft nucleic acid is an immunostimulatory nucleic acid having a partially  
15 stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages occur only within at least one internal pyrimidine-purine (YZ) dinucleotide. Semi-soft nucleic acids generally possess increased immunostimulatory potency relative to corresponding fully stabilized immunostimulatory nucleic acids. Due to the greater potency of semi-soft nucleic acids, semi-soft nucleic acids may be used, in some instances, at lower  
20 effective concentrations and have lower effective doses than conventional fully stabilized immunostimulatory nucleic acids in order to achieve a desired biological effect.

It is believed that the foregoing properties of semi-soft nucleic acids generally increase with increasing "dose" of phosphodiester or phosphodiester-like internucleotide linkages involving internal YZ dinucleotides. Thus it is believed, for example, that generally for a  
25 given nucleic acid sequence with five internal YZ dinucleotides, an nucleic acid with five internal phosphodiester or phosphodiester-like YZ internucleotide linkages is more immunostimulatory than an nucleic acid with four internal phosphodiester or phosphodiester-like YG internucleotide linkages, which in turn is more immunostimulatory than an nucleic acid with three internal phosphodiester or phosphodiester-like YZ internucleotide linkages,  
30 which in turn is more immunostimulatory than an nucleic acid with two internal phosphodiester or phosphodiester-like YZ internucleotide linkages, which in turn is more immunostimulatory than an nucleic acid with one internal phosphodiester or phosphodiester-like YZ internucleotide linkage. Importantly, inclusion of even one internal phosphodiester or



phosphodiester-like YZ internucleotide linkage is believed to be advantageous over no internal phosphodiester or phosphodiester-like YZ internucleotide linkage. In addition to the number of phosphodiester or phosphodiester-like internucleotide linkages, the position along the length of the nucleic acid can also affect potency.

5           The soft and semi-soft nucleic acids will generally include, in addition to the phosphodiester or phosphodiester-like internucleotide linkages at preferred internal positions, 5' and 3' ends that are resistant to degradation. Such degradation-resistant ends can involve any suitable modification that results in an increased resistance against exonuclease digestion over corresponding unmodified ends. For instance, the 5' and 3' ends can be stabilized by the  
10           inclusion thereof at least one phosphate modification of the backbone. In a preferred embodiment, the at least one phosphate modification of the backbone at each end is independently a phosphorothioate, phosphorodithioate, methylphosphonate, or methylphosphorothioate internucleotide linkage. In another embodiment, the degradation-resistant end includes one or more nucleotide units connected by peptide or amide linkages at  
15           the 3' end.

          A phosphodiester internucleotide linkage is the type of linkage characteristic of nucleic acids found in nature. The phosphodiester internucleotide linkage includes a phosphorus atom flanked by two bridging oxygen atoms and bound also by two additional oxygen atoms, one charged and the other uncharged. Phosphodiester internucleotide linkage  
20           is particularly preferred when it is important to reduce the tissue half-life of the nucleic acid.

          A phosphodiester-like internucleotide linkage is a phosphorus-containing bridging group that is chemically and/or diastereomerically similar to phosphodiester. Measures of similarity to phosphodiester include susceptibility to nuclease digestion and ability to activate RNAse H. Thus for example phosphodiester, but not phosphorothioate, nucleic acids are  
25           susceptible to nuclease digestion, while both phosphodiester and phosphorothioate nucleic acids activate RNAse H. In a preferred embodiment the phosphodiester-like internucleotide linkage is boranophosphate (or equivalently, boranophosphonate) linkage. U.S. Patent No. 5,177,198; U.S. Patent No. 5,859,231; U.S. Patent No. 6,160,109; U.S. Patent No. 6,207,819; Sergueev et al., (1998) *J Am Chem Soc* 120:9417-27. In another preferred embodiment the  
30           phosphodiester-like internucleotide linkage is diastereomerically pure Rp phosphorothioate. It is believed that diastereomerically pure Rp phosphorothioate is more susceptible to nuclease digestion and is better at activating RNAse H than mixed or diastereomerically pure Sp phosphorothioate. Stereoisomers of CpG nucleic acids are the subject of co-pending U.S.

patent application 09/361,575 filed July 27, 1999, and published PCT application PCT/US99/17100 (WO 00/06588). It is to be noted that for purposes of the instant invention, the term "phosphodiester-like internucleotide linkage" specifically excludes phosphorodithioate and methylphosphonate internucleotide linkages.

5           As described above the soft and semi-soft nucleic acids of the invention may have phosphodiester like linkages between C and G. One example of a phosphodiester-like linkage is a phosphorothioate linkage in an  $R_p$  conformation. Nucleic acid p-chirality can have apparently opposite effects on the immune activity of a CpG nucleic acid, depending upon the time point at which activity is measured. At an early time point of 40 minutes, the  $R_p$  but not  
10       the  $S_p$  stereoisomer of phosphorothioate CpG nucleic acid induces JNK phosphorylation in mouse spleen cells. In contrast, when assayed at a late time point of 44 hr, the  $S_p$  but not the  $R_p$  stereoisomer is active in stimulating spleen cell proliferation. This difference in the kinetics and bioactivity of the  $R_p$  and  $S_p$  stereoisomers does not result from any difference in cell uptake, but rather most likely is due to two opposing biologic roles of the p-chirality.  
15       First, the enhanced activity of the  $R_p$  stereoisomer compared to the  $S_p$  for stimulating immune cells at early time points indicates that the  $R_p$  may be more effective at interacting with the CpG receptor, TLR9, or inducing the downstream signaling pathways. On the other hand, the faster degradation of the  $R_p$  PS-nucleic acids compared to the  $S_p$  results in a much shorter duration of signaling, so that the  $S_p$  PS-nucleic acids appear to be more biologically  
20       active when tested at later time points.

          A surprisingly strong effect is achieved by the p-chirality at the CpG dinucleotide itself. In comparison to a stereo-random CpG nucleic acid the congener in which the single CpG dinucleotide was linked in  $R_p$  was slightly more active, while the congener containing an  $S_p$  linkage was nearly inactive for inducing spleen cell proliferation.

25           Nucleic acids also include substituted purines and pyrimidines such as C-5 propyne pyrimidine and 7-deaza-7-substituted purine modified bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, and thymine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

30           A modified base is any base which is chemically distinct from the naturally occurring bases typically found in DNA and RNA such as T, C, G, A, and U, but which share basic chemical structures with these naturally occurring bases. The modified nucleoside base may be, for example, selected from hypoxanthine, uracil, dihydrouracil, pseudouracil, 2-thiouracil,

4-thiouracil, 5-aminouracil, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine, 5-bromocytosine, N<sup>2</sup>-dimethylguanine, 2,4-diamino-purine, 8-azapurine, a substituted 7-deazapurine, preferably 7-deaza-7-substituted and/or 7-deaza-8-substituted purine, 5-hydroxymethylcytosine, N<sup>4</sup>-alkylcytosine, e.g., N<sup>4</sup>-ethylcytosine, 5-hydroxydeoxycytidine, 5-hydroxymethyldeoxycytidine, N<sup>4</sup>-alkyldeoxycytidine, e.g., N<sup>4</sup>-ethyldeoxycytidine, 6-thiodeoxyguanosine, and deoxyribonucleosides of nitropyrrole, C5-propynylpyrimidine, and diaminopurine e.g., 2,6-diaminopurine, inosine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, hypoxanthine or other modifications of a natural nucleoside bases. This list is meant to be exemplary and is not to be interpreted to be limiting.

Modified cytosines include but are not limited to 5-substituted cytosines (e.g., 5-methyl-cytosine, 5-fluoro-cytosine, 5-chloro-cytosine, 5-bromo-cytosine, 5-iodo-cytosine, 5-hydroxy-cytosine, 5-hydroxymethyl-cytosine, 5-difluoromethyl-cytosine, and unsubstituted or substituted 5-alkynyl-cytosine), 6-substituted cytosines, N<sup>4</sup>-substituted cytosines (e.g., N<sup>4</sup>-ethyl-cytosine), 5-aza-cytosine, 2-mercapto-cytosine, isocytosine, pseudo-isocytosine, cytosine analogs with condensed ring systems (e.g., N,N'-propylene cytosine or phenoxazine), and uracil and its derivatives (e.g., 5-fluoro-uracil, 5-bromo-uracil, 5-bromovinyl-uracil, 4-thio-uracil, 5-hydroxy-uracil, 5-propynyl-uracil). In another embodiment, the cytosine base is substituted by a universal base (e.g., 3-nitropyrrole, P-base), an aromatic ring system (e.g., fluorobenzene or difluorobenzene) or a hydrogen atom (dSpacer).

Modified guanines include but are not limited to 7-deazaguanine, 7-deaza-7-substituted guanine (such as 7-deaza-7-(C<sub>2</sub>-C<sub>6</sub>)alkynylguanine), 7-deaza-8-substituted guanine, hypoxanthine, N<sup>2</sup>-substituted guanines (e.g., N<sup>2</sup>-methyl-guanine), 5-amino-3-methyl-3H,6H-thiazolo[4,5-d]pyrimidine-2,7-dione, 2,6-diaminopurine, 2-aminopurine, purine, indole, adenine, substituted adenines (e.g., N<sup>6</sup>-methyl-adenine, 8-oxo-adenine) 8-substituted guanine (e.g., 8-hydroxyguanine and 8-bromoguanine), and 6-thioguanine. In another embodiment, the guanine base is substituted by a universal base (e.g., 4-methyl-indole, 5-nitro-indole, and K-base), an aromatic ring system (e.g., benzimidazole or dichloro-benzimidazole, 1-methyl-1H-[1,2,4]triazole-3-carboxylic acid amide) or a hydrogen atom (dSpacer).

For use in the instant invention, the oligonucleotide reference compounds and test compounds can be synthesized *de novo* using any of a number of procedures well known in the art, for example, the  $\beta$ -cyanoethyl phosphoramidite method (Beaucage SL et al. (1981) *Tetrahedron Lett* 22:1859), or the nucleoside H-phosphonate method (Garegg et al. (1986) *Tetrahedron Lett* 27:4051-4; Froehler BC et al. (1986) *Nucleic Acids Res* 14:5399-407; Garegg et al (1986) *Tetrahedron Lett* 27:4055-8; Gaffney et al. (1988) *Tetrahedron Lett* 29:2619-22). These chemistries can be performed by a variety of automated nucleic acid synthesizers available in the market. These oligonucleotides are referred to as synthetic oligonucleotides. An isolated oligonucleotide generally refers to an oligonucleotide which is separated from components which it is normally associated with in nature. As an example, an isolated oligonucleotide may be one which is separated from a cell, from a nucleus, from mitochondria or from chromatin.

Modified backbones such as phosphorothioates can be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Pat. No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (e.g., Uhlmann E et al. (1990) *Chem Rev* 90:544; Goodchild J (1990) *Bioconjugate Chem* 1:165).

#### TLR expression

The cell lines can be used in their native state without any modification. For example, in the case of the RPMI 8226 cell line, it can be used to identify compounds that signal through at least TLR9 and/or TLR7. In other instances, however, the cell line can be modified to express a TLR that it does not naturally express. In still other instances, the cell to be used in the screening method may express one or more endogenous TLR and yet still be manipulated to express an additional TLR different from those it endogenously expresses. The cell may also be manipulated in order to increase or decrease the level of TLR that it endogenously expresses. The cells may be stably or transiently transfected.

A cell that does not naturally express a protein or polypeptide, but is genetically manipulated to do so is referred to as ectopically expressing the protein or polypeptide.

The basic screening method remains the same regardless of which TLR is expressed by the cell. However, the reference compound and the readout may vary depending upon the TLR(s) expressed. In the most simple aspect, the screening method is used to identify a compound that signals through a TLR such as for example TLR9. In this case, the positive reference compound may be an immunostimulatory compound already known to act through TLR9 (e.g., CpG nucleic acid).

The methods of the invention involve, in part, contacting a functional TLR with a test composition. A functional TLR is a full-length TLR protein or a fragment thereof capable of inducing or inhibiting a signal in response to interaction with its ligand. Generally the functional TLR will include at least a TLR ligand-binding fragment of the extracellular domain of the full-length TLR and at least a fragment of a TIR domain capable of interacting with another Toll homology domain-containing polypeptide, e.g., MyD88. In various embodiments the functional TLR is a full-length TLR selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and TLR10.

To date, there are eleven TLRs known. Nucleic acid and amino acid sequences for ten currently known human TLRs are available from public databases such as GenBank. Similarly, nucleic acid and amino acid sequences for various TLRs from numerous non-human species are also available from public databases including GenBank. For example, nucleic acid and amino acid sequences for human TLR9 (hTLR9) can be found as GenBank accession numbers AF245704 (coding region spanning nucleotides 145-3243) (SEQ ID NO: 60) and AAF78037 (SEQ ID NO: 62), respectively. Nucleic acid and amino acid sequences for murine TLR9 (mTLR9) can be found as GenBank accession numbers AF348140 (coding region spanning nucleotides 40-3138) (SEQ ID NO: 68) and AAK29625 (SEQ ID NO: 72), respectively.

Nucleic acid and amino acid sequences for human TLR8 (hTLR8) can be found as GenBank accession numbers AF245703 (coding region spanning nucleotides 49-3174) (SEQ ID NO: 46) and AAF78036 (SEQ ID NO: 50), respectively. Nucleic acid and amino acid sequences for murine TLR8 (mTLR8) can be found as GenBank accession numbers AY035890 (coding region spanning nucleotides 59-3157) (SEQ ID NO: 55) and AAK62677 (SEQ ID NO: 57), respectively.

Nucleic acid and amino acid sequences for human TLR7 (hTLR7) can be found as GenBank accession numbers AF240467 (coding region spanning nucleotides 135-3285) (SEQ ID NO: 31) and AAF60188 (SEQ ID NO: 34), respectively. Nucleic acid and amino acid

sequences for murine TLR7 (mTLR7) can be found as GenBank accession numbers AY035889 (coding region spanning nucleotides 49-3201) (SEQ ID NO: 38) and AAK62676 (SEQ ID NO: 41), respectively.

5 Nucleic acid and amino acid sequences for human TLR3 (hTLR3) can be found as GenBank accession numbers NM\_003265 (coding region spanning nucleotides 102-2816) (SEQ ID NO: 7) and NP\_003256 (SEQ ID NO: 8), respectively. Nucleic acid and amino acid sequences for murine TLR3 (hTLR3) can be found as GenBank accession numbers AF355152 (coding region spanning nucleotides 44-2761) (SEQ ID NO: 9) and AAK26117 (SEQ ID NO: 10), respectively.

10 Nucleic acid and amino acid sequences for human TLR1 (hTLR1) can be found as GenBank accession numbers NM\_003263 and NP\_003254, respectively. Nucleic acid and amino acid sequences for murine TLR1 (mTLR1) can be found as GenBank accession numbers NM\_030682 and NP\_109607, respectively.

The functional TLR also is not limited to native TLR polypeptides. As used herein, a  
15 native TLR is one that is naturally occurring. The TLR may be a non-native (or non-naturally occurring TLR). An example is a chimeric TLR having an extracellular domain and the cytoplasmic domain derived from TLRs from different species. Such chimeric TLR polypeptides can include, for example, a human TLR extracellular domain and a murine TLR cytoplasmic domain. In alternative embodiments, such chimeric TLR polypeptides can  
20 include chimerae created with different TLR splice variants or allotypes.

#### TLR Signaling Pathways

The screening methods provided by the invention measure TLR signaling activity. TLR signaling activity is activity that results from interaction of a TLR with a TLR ligand.  
25 TLR signaling can be measured in a number of ways including but not limited to interaction between a TLR and a protein or factor (such as an adaptor protein), interaction between downstream proteins or factors (such as an adaptor protein) with each other, activation of nuclear factors such as transcription factors or transcription complexes, up- or down-  
30 regulation of genes, phosphorylation or dephosphorylation of proteins or factors in the signaling cascade, expression, production and/or secretion of cytokines and/or chemokines, changes in cell cycle status, up- or down-regulation of cell surface marker expression, and the like. Those of ordinary skill in the art are familiar with assays for measuring these latter

events including but not limited to gel shift assays, immunoprecipitations, phosphorylation status analysis of proteins, Northern analysis, RT-PCR analysis, etc.

The following is an exemplary TLR signaling pathway or cascade. It is to be understood that this is meant to be illustrative and that different factors may be involved in the signaling of particular TLR. One TLR signaling pathway is known to use the cytoplasmic Toll/IL-1 receptor (TIR) homology domain, present in all TLRs. This domain interacts (e.g., binds to) and thereby transduces a signal to a similar domain on an adapter protein (e.g., MyD88). This type of interaction is referred to as a like:like interaction of TIR domains. This interaction is followed by an another interaction between the adapter protein and a kinase, through their respective "death domains". In the case of at least TLR4 signaling, the kinase then interacts with tumor necrosis factor (TNF) receptor-associated factor-6 (TRAF6). Medzhitov R et al., *Mol Cell* 2:253 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15 (1999). After TRAF6, two sequential kinase activation steps lead to phosphorylation of the inhibitory protein I kappa B and its dissociation from NF- $\kappa$ B. The first kinase is a mitogen-activated kinase kinase kinase (MAPKKK) known as NIK, for NF- $\kappa$ B-inducing kinase. The target of this kinase is another kinase made up of two chains, called I kappa B kinase  $\alpha$  (IKK  $\alpha$ ) and I kappa B kinase  $\beta$  (IKK  $\beta$ ), that together form a heterodimer of IKK $\alpha$ :IKK $\beta$ , which phosphorylates I kappa B. NF- $\kappa$ B translocates to the nucleus to activate genes with kappa B binding sites in their promoters and enhancers such as the genes encoding IL-6, IL-8, the p40 subunit of IL-12, and the costimulatory molecule CD86. The signaling mechanisms of TLRs are not limited to this pathway; other signaling pathways exist and can be used in the screening readouts of the methods provided herein.

The screening assays employ a number of readouts (or parameters). The readouts can be native readouts. A native readout is one that does not rely on introduction of a reporter construct into the cell of interest. The readouts can be artificial. An artificial readout is one that relies on introduction of a reporter construct into the cell of interest. Examples of both are provided herein. In still other embodiments, a given assay may measure one or more native readouts and one or more artificial readouts. Each readout whether native or artificial is related to signaling pathways that ensue after TLR engagement with a ligand.

Each cell line described herein will be associated with a particular set of native readouts which the invention seeks to determine in the screening assays provided. As an example, the response of the RPMI 8226 cell line to an immunomodulatory molecule can be assessed in terms of native readouts such as CD71 expression, CD86 expression, HLA-DR

expression, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion. RAMOS response can be assessed, inter alia, by CD80 cell surface expression. Raji response can be assessed, inter alia, by IL-6 secretion.

As described in greater detail herein, the cell line can be used in an unmodified form. In one respect, an unmodified cell line will naturally respond to a TLR ligand through a native readout system. For example, an RPMI 8226 cell exposed to an immunostimulatory TLR ligand may increase expression of IP-10 from the native gene locus. Alternatively, the cell line may be modified to contain a reporter construct that acts as a surrogate for the IP-10 gene locus. For example, the reporter construct may contain the TLR responsive promoter elements that are naturally found in the native IP-10 locus operably linked to a reporter coding sequence that encodes a gene product that is detectable and quantifiable. The structure and variability of suitable reporter constructs will be discussed in greater detail herein.

Readouts typically include the induction of a gene under control of a specific promoter such as a NF- $\kappa$ B promoter. The gene under the control of the NF- $\kappa$ B promoter can be a gene which naturally includes an NF- $\kappa$ B promoter or it can be a gene in a construct in which an NF- $\kappa$ B promoter has been inserted. Endogenous genes and transfected constructs which include the NF- $\kappa$ B promoter include but are not limited to IL-8, IL-12 p40, NF- $\kappa$ B-luc, IL-12 p40-luc, and TNF-luc.

Increases in cytokine levels can result from increased production, increased stability, increased secretion, or any combination of the forgoing, of the cytokine in response to the TLR-mediated signaling. Cytokines generally include, without limitation, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-11, IL-12, IL-13, IL-15, IL-18, IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , TNF- $\alpha$ , GM-CSF, G-CSF, M-CSF. Th1 cytokines include but are not limited to IL-2, IFN- $\gamma$ , and IL-12. Th2 cytokines include but are not limited to IL-4, IL-5, and IL-10.

Increases in chemokine levels can result from increased production, increased stability, increased secretion, or any combination of the forgoing, of the chemokine in response to the TLR-mediated signaling. Chemokines of particular significance in the invention include but are not limited to CCL5 (RANTES), CXCL9 (Mig), CXCL10 (IP-10), CXCL11 (I-TAC), IL-8, and MCP-1.



TLR signaling activity can also be measured by phosphorylation, such as total cellular phosphorylation or phosphorylation of specific factors such as but not limited to IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

TLR signaling activity can be measured by changes in gene expression. The  
5 expression of CD71, CD86, CD80, CD69, CD54, HLA-DR, HLA class I, IL-6, IL-8, IL-10, IP-9, IP-10, IFN- $\alpha$ , TNF- $\alpha$ , and the like can be assessed as a measure of TLR signaling activity. Gene expression analysis may be performed using microarray techniques.

TLR signaling activity can also be measured by cell proliferation status or changes thereto.

10 TLR signaling activity can also be measured by cell surface marker expression such as the cell surface expression of markers such as but not limited to CD71, CD86, HLA-DR, CD80, HLA class I, CD54 and CD69.

TLR signaling activity can also be measured by antibody secretion such as but not limited to IgM secretion.

15

#### Reporter and Expression Constructs

The cells can be manipulated by the introduction of expression and/or reporter constructs. The expression constructs preferably comprise a TLR coding sequence, as described above. The reporter constructs can be used as surrogate measures of native TLR  
20 signaling activity. These reporter constructs are intended to substitute for the “native” readouts capable with the cell line. In order to act as substitutes, the reporter constructs include a promoter element derived from a gene known to be modulated following TLR engagement with a TLR ligand. The reporter construct further includes a coding sequence linked to the promoter. The coding sequence is usually that of a reporter (i.e., a protein that is  
25 detectable or quantifiable).

The reporter construct generally includes a promoter, a coding sequence and a polyadenylation signal. These nucleic acids shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, in addition to  
30 promoter elements that are responsive to TLR signaling. The nucleic acid constructs may optionally include enhancer sequences or upstream activator sequences as desired.

The promoter in the reporter construct will include a TLR responsive promoter element, and will therefore be regarded as a TLR responsive promoter. As used herein, a

TLR responsive promoter is a promoter having an activity that is modulated (i.e., either activated or inhibited) by signaling through a TLR (e.g., by TLR interaction with its ligand). In order to be modulated by TLR signaling, the promoter contains sites that are bound by transcription factors modulated by TLR signaling. The factors may be activated or inhibited  
5 by TLR signaling. Activation of the transcription factor includes increases in the activity of the transcription factor per se, increases in its ability to interact with other factors or with DNA that serve to increase its activity, and increases in its transcription and translation (i.e., increased mRNA and protein levels of the transcription factor). Conversely, inhibition of the transcription factor includes decreases in the activity of the transcription factor per se,  
10 decreases in its ability to interact with other factors or with DNA that serve to decrease its activity, and decreases in its transcription and translation (i.e., decreased mRNA and protein levels of the transcription factor). The effect on the transcription factor is usually the downstream result of other interactions in the signaling pathway. The expression of coding sequences linked to such promoters will therefore be modulated by TLR signaling events, and  
15 it is the level of expression of these coding sequences that can be used as a readout of TLR signaling in the screening methods provided herein.

The TLR responsive promoter may comprise a transcription factor binding site selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an interferon-stimulated response element (ISRE), a GAS, an ATF2 binding site, an  
20 IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE, among others. These binding sites and their sequences are known in the art. Below is a exemplary list of these sequences.

W = A or T, R = A or G, Y = C or T

25 NF- $\kappa$ B Binding site:

Consensus p50 subunit  
5' GGGGATYCCC 3' (SEQ ID NO:90)

30 Consensus p65 subunit  
5' GGGRNTTTC 3' (SEQ ID NO:91)

Example of p65 subunit binding site  
35 5' AGT TGA GGG GAC TTT CCC AGG C 3' (SEQ ID NO:92)

CREB Binding site:  
5'AGA GAT TGC CTG ACG TCA GAG AGC TAG 3' (SEQ ID NO:93)

- 55 -

## AP-1 Binding site:

5'- CGC TTG ATG AGT CAG CCG GAA -3' (SEQ ID NO:94)  
5'- CGC ATG AGT CAG ACA -3' (SEQ ID NO:95)

## 5 ISRE :

5'- TGCAGAAGTGAAACTGAGG-3' (SEQ ID NO:96)  
5'- AGAACGAAACA-3' (SEQ ID NO:97)  
5'- GAGAAGTGAAAGTGG-3' (SEQ ID NO:98)  
5'- TAAGAACATGAAACTGAA-3' (SEQ ID NO:99)  
10 5'- ATGAAACTGAAAGTA-3' (SEQ ID NO:100)  
5'- TGAAAACCGAAAGCGC-3' (SEQ ID NO:101)  
5'- AGAAATGGAAAGT-3' (SEQ ID NO:102)

## SRE

15 5'- TCACCCAC-3' (SEQ ID NO:103)  
5'- CTCACCCAC-3' (SEQ ID NO:104)  
5'- GCCACCCTAC-3' (SEQ ID NO:105)

## NFAT:

20 5'- TATGAAACAGTTTTTCC -3' (SEQ ID NO:106)  
5'- AGGAAACTC -3' (SEQ ID NO:107)  
5'- ARGARATTCC -3' (SEQ ID NO:108)  
5'- CCAGTTGAGCCAGAGA -3' (SEQ ID NO:109)

## 25 GAS:

5'- CTTTCAGTTTCATATTACTCTAAATCCATT -3' (SEQ ID NO:110)

## p53 Binding Site :

30 p53 Consensus site:  
5'- RRRCWWGYYY -3' (SEQ ID NO:111)

## Examples of p53 binding sites:

35 5'- AGGCATGCCT -3' (SEQ ID NO:112)  
5'- GGGCTTGCCC -3' (SEQ ID NO:113)  
5'- GGGCTTGCTT -3' (SEQ ID NO:114)  
5'- GCCTGGACTTGCC -3' (SEQ ID NO:115)  
5'- GGACATGCCCCGGGCATGTCC -3' (SEQ ID NO:116)  
5'- GTAGCATTAGCCCAGACATGTCC -3' (SEQ ID NO:117)

40

TARE (TNF- $\alpha$  response element):

e.g. from the COL1A1 promoter

5'GAGGTATGCAGACAAGAGTCAGAGTTTCCCCTTGAA 3' (SEQ ID

NO:118)

45

## SRF

5'- CCWWWWWWGG -3' (SEQ ID NO:119)  
5'- CCAAATAAGGC -3' (SEQ ID NO:120)

The TLR responsive promoter element can be derived from the promoter of a naturally occurring (i.e., an endogenous) gene that is activated or inhibited by TLR signaling (such as the IL-6 gene, the IL-8 gene, the IL-10 gene, the IL-12 p40 gene, the IP-9 gene, the IP-10 gene, the type 1 IFN gene, the IFN- $\alpha$ 4 gene, the IFN- $\beta$  gene, the TNF- $\alpha$  gene, the TNF- $\beta$  gene, the RANTES gene, the ITAC gene, the IGFBP4 gene, the CD54 gene, the CD69 gene, the CD71 gene, the CD80 gene, the CD86 gene, the HLA-DR gene, the HLA class I gene, and the like). The afore-mentioned genes are genes that are known to be activated in response to TLR interaction with its ligand.

Suitable promoter regions are described in the Examples. Briefly, the upstream (5') – 620 to +50 promoter region of IFN- $\alpha$ 4 or the upstream (5') –140 to +9 promoter region of IFN- $\alpha$ 1 can be used. In one embodiment, the IFN- $\alpha$ 4 sequence is cloned into the *Sma*I site of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') promoter region of IFN- $\alpha$ 4.

The promoter can also be the upstream (5') –280 to +20 promoter region of IFN- $\beta$ .  
The promoter can also be the upstream (5') –397 to +5 promoter region of RANTES. In one embodiment, the RANTES promoter sequence is cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') –397 to +5 promoter region of RANTES.

The promoter can also be the upstream truncated (–250 to +30) and full length (–860 to +30) promoter regions derived from human IL-12 p40 genomic DNA. In one embodiment, the truncated IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p $\beta$ gal-Basic (Promega) resulting in an expression vector that includes a  $\beta$  gal gene under the control of the upstream (5') –250 to +30 promoter region of human IL-12 p40. In another embodiment, the full length IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p $\beta$ gal-Basic (Promega) resulting in an expression vector that includes a  $\beta$  gal gene under the control of the upstream (5') –751 to +30 promoter region of human IL-12 p40. In another embodiment, the truncated –250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') –250 to +30 promoter region of human IL-12 p40. In yet another embodiment, the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the

- 57 -

pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') -751 to +30 promoter region of human IL-12 p40.

The promoter can also be the upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. The promoter can also be derived from the full-length promoter  
5 region of the IL-6 gene from -1174 to +7 (Accession No M22111, SEQ ID NO:129).

The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71.

The promoter can also be derived from the -615 to +30 promoter region of human  
10 TNF- $\alpha$ .

The promoter can also be derived from a promoter region of human TNF- $\beta$ .

The promoter can also be derived from the -875 to +97 promoter region of human IP-  
10.

The promoter can also be derived from the -219 to +114 promoter region of human  
15 CXCL11 (IP9). The promoter can also be derived from the full length (-934 to +114) promoter region of human CXCL11 (IP9).

The promoter can also be derived from the -289 to +217 promoter region of human IGFBP4 (Insulin growth factor binding protein 4). The promoter can also be derived from the full length (-836 to +217) promoter region of human IGFBP4.

20 The promoter response element generally will be present in multiple copies, e.g., as tandem repeats. For example, in one reporter construct, coding sequence for luciferase is under control of an upstream 6X tandem repeat of NF- $\kappa$ B response element. In another example, an ISRE-luciferase reporter construct useful in the invention is available from Stratagene (catalog no. 219092) and includes a 5x ISRE tandem repeat joined to a TATA box  
25 upstream of a luciferase reporter gene.

The reporter construct coding sequence is preferably any nucleotide sequence that codes for a protein capable of detection or quantification. The protein can be an enzyme (e.g., luciferase, alkaline phosphatase,  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein  
30 (GFP, U.S. Pat. No. 5,491,084), etc.), blue fluorescent protein (BFP, e.g., U.S. Pat. No. 6,486,382), etc.), a surface-expressed molecule (e.g., CD25, CD80, CD86), a secreted molecule (e.g., IL-1, IL-6, IL-8, IL-12 p40, TNF- $\alpha$ ), a hapten or antigen, and other detectable protein products known to those of skill in the art. For assays relying on enzyme activity

readout, substrate can be supplied as part of the assay, and detection can involve measurement of chemiluminescence, fluorescence, color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using flow cytometry (FACS) analysis or functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many of these and other suitable readout systems are well known in the art and are commercially available. Preferably, the coding sequence encodes a protein having a level or an activity that is quantifiable, preferably with a wide linear range.

The expression construct coding sequence is preferably a TLR coding sequence derived from the sequences listed herein. Preferably, the expression construct promoter is a constitutive promoter, although in some embodiments it may be inducible. Those of ordinary skill in the art are familiar with such promoters.

As used herein, a coding sequence and the regulatory sequences (such as promoters) are said to be operably linked when they are covalently linked in such a way as to place the expression or transcription and/or translation of the coding sequence under the influence or control of the regulatory sequence. Two DNA sequences are said to be operably linked if induction of a promoter in the 5' regulatory sequence results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a regulatory sequence would be operably linked to a coding sequence if the gene expression sequence were capable of effecting transcription of that coding sequence such that the resulting transcript is translated into the desired protein or polypeptide.

Methods for nucleic acid introduction into cells are known in the art.

The nucleic acid may be delivered to the cells alone or in association with a vector. In its broadest sense, a vector is any vehicle capable of facilitating the transfer of the nucleic acid to the cells so that the reporter can be expressed. The vector generally transports the nucleic acid to the cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antigen nucleic acid sequences. Viral vectors are a preferred type of vector and include, but are not limited

to, nucleic acid sequences from the following viruses: retrovirus, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, murine mammary tumor virus, and Rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. Most useful are those retroviruses that are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., Gene Transfer and Expression, A Laboratory Manual W.H. Freeman C.O., New York (1990) and Murray, E.J. Methods in Molecular Biology, vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

A preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication-deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, wild-type adeno-associated virus manifest some preference for integration sites into human cellular DNA, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression characteristic of retroviral infection. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

Recombinant adeno-associated viruses that lack the replicase protein apparently lack this integration sequence specificity.

Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al.,  
5 Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been found to be particularly advantageous for delivering genes to cells *in vivo* because of their inability to replicate within and integrate into a host genome. These plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid.  
10 Some commonly used plasmids include pBR322, pUC18, pUC19, pRc/CMV, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.

In general, the vectors useful in the invention are divided into two classes: biological  
15 vectors and chemical/physical vectors. Biological vectors and chemical/physical vectors are useful in the delivery and/or uptake of reporter constructs of the invention.

Most biological vectors are used for delivery of nucleic acids and thus would be most appropriate in the delivery of nucleic acids.

As used herein, a "chemical/physical vector" refers to a natural or synthetic molecule,  
20 other than those derived from bacteriological or viral sources, capable of delivering the reference and test compound.

A preferred chemical/physical vector of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a  
25 liposome. Liposomes are artificial membrane vessels which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vessels (LUV), which range in size from 0.2 - 4.0  $\mu\text{m}$  can encapsulate large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., *Trends Biochem. Sci.*, (1981) 6:77).

30 Liposomes may be targeted to a particular tissue by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to an immune cell include, but are not limited to, intact or fragments of molecules which interact with immune cell specific receptors and molecules,



- 61 -

such as antibodies, which interact with the cell surface markers of immune cells. Such ligands may easily be identified by binding assays well known to those of skill in the art. In still other embodiments, the liposome may be targeted to the cancer by coupling it to a one of the immunotherapeutic antibodies discussed earlier. Additionally, the vector may be coupled  
5 to a nuclear targeting peptide, which will direct the vector to the nucleus of the host cell.

Lipid formulations for transfection are commercially available from QIAGEN, for example, as EFFECTENE™ (a non-liposomal lipid with a special DNA condensing enhancer) and SUPERFECT™ (a novel acting dendrimeric technology).

Liposomes are commercially available from Gibco BRL, for example, as  
10 LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2, 3 dioleoyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications. Liposomes also have been reviewed by Gregoriadis, G. in *Trends in Biotechnology*, (1985) 3:235-241. In some preferred  
15 embodiments, the method of choice for delivering DNA (for transfection) to the cells is electroporation, particularly where a stably transfected cell line is sought.

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting.

20

### Examples

#### **Example 1. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using Cells Stably Transfected with hTLR9 Expression Vector**

CpG ODN (SEQ ID NO:1) is currently in preclinical and clinical trials for a number of  
25 clinical applications. SEQ ID NO:1 has been discovered to induce signaling through TLR9. In order to assess different lots of clinical material, the methods of the invention are employed, using a highly characterized lot of SEQ ID NO:1 as a reference.

In a TLR9 assay, the CpG-non-responsive human embryonal kidney cell line HEK293 (e.g., ATCC CRL-1573) was stably transfected with a hTLR9 expression construct and found  
30 to express full-length human TLR9 constitutively. The cells also contained a genomic copy of a reporter construct with a 6x NF- $\kappa$ B binding site and a luciferase gene reporter cassette. Incubation of the cells with CpG ODN (SEQ ID NO:1) activates NF- $\kappa$ B driven expression of luciferase, while incubation with medium alone (negative control) does not. The cells are

then lysed and activity of the luciferase protein determined by its catalytic activity of luciferin oxidation which is measured in a luminometer. Results are expressed as fold induction above medium control.

Assay set-up includes a reference standard material which is highly pure and well  
5 characterized. The reference material is used to create a standard curve within a defined range where the dose-response curve is linear (e.g., in the range of the EC50 value for SEQ ID NO:1, 70-100 nM). The test material is dissolved for testing and assayed at a defined concentration. Activity of the test material is calculated using the standard curve of the reference material. Quality of the tested material is deemed acceptable if activity of the test  
10 material compared to activity of the reference material falls within predetermined limits.

**Example 2. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using RPMI 8226 Cells**

The assay of Example 1 is performed using RPMI 8226 cells (ATCC CCL-155) in  
15 place of the stably transfected HEK cells of Example 1. RPMI 8226 cells naturally express human TLR9. The cells are stably transfected with a 6x NF- $\kappa$ B-luciferase reporter construct. It is to be understood that the assay could also be carried out by measuring a native readout such as IL-10 secretion.

**20 Example 3. Expression Vectors for Human TLR3 (hTLR3) and Murine TLR3 (mTLR3)**

To create an expression vector for human TLR3, human TLR3 cDNA was amplified by the polymerase chain method (PCR) from a cDNA made from human 293 cells using the primers 5'-GAAACTCGAGCCACCATGAGACAGACTTTGCCTTGTATCTAC-3' (sense, SEQ ID NO:152) and 5'-GAAAGAATTCTTAATGTACAGAGTTTTTGGATCCAAG-3' (antisense, SEQ ID NO:153). The primers introduce *Xho*I and *Eco*RI restriction endonuclease  
25 sites at their 5' ends for use in subsequent cloning into the expression vector. The resulting amplification product fragment was cloned into pGEM-T Easy vector (Promega), isolated, cut with *Xho*I and *Eco*RI restriction endonucleases, ligated into an *Xho*I/*Eco*RI-digested pcDNA3.1 expression vector (Invitrogen). The insert was fully sequenced and translated into  
30 protein. The cDNA sequence corresponds to the published cDNA sequence for hTLR3, available as GenBank accession no. NM\_003265 (SEQ ID NO:7). The open reading frame codes for a protein 904 amino acids long, having the sequence corresponding to GenBank accession no. NP\_003256 (SEQ ID NO:8).

Corresponding nucleotide and amino acid sequences for murine TLR3 (mTLR3) are known. The nucleotide sequence of mTLR3 cDNA has been reported as GenBank accession no. AF355152 (SEQ ID NO:9), and the amino acid sequence of mTLR3 has been reported as GenBank accession no. AAK26117 (SEQ ID NO:10).

5

#### **Example 4. Reconstitution of TLR3 Signaling in 293 Fibroblasts**

Human TLR3 cDNA and murine TLR3 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *EcoRI* site. The resulting expression vectors mentioned above were transfected into  
10 CpG-DNA non-responsive human 293 fibroblast cells (ATCC, CRL-1573) using the calcium phosphate method. Utilizing a “gain of function” assay it was possible to reconstitute human TLR3 (hTLR3) and murine TLR3 (mTLR3) signaling in 293 fibroblast cells.

Since NF- $\kappa$ B activation is central to the IL-1/TLR signal transduction pathway (Medzhitov R et al. (1998) *Mol Cell* 2:253-8; Muzio M et al. (1998) *J Exp Med*  
15 187:2097-101), in a first set of experiments human 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an NF- $\kappa$ B-driven luciferase reporter construct.

Likewise, in a second set of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an IFN- $\alpha$ 4-driven luciferase reporter  
20 construct (described in Example 8 below).

In a third group of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and a RANTES-driven luciferase reporter construct (described in Example 14 below).

#### **25 Example 5. Reconstitution of TLR7 Signaling**

Methods for cloning murine and human TLR7 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated herein by reference. Human TLR7 cDNA and murine TLR7 cDNA in pT-Adv  
30 vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *EcoRI* site. Utilizing a “gain of function” assay it was possible to reconstitute human TLR7 (hTLR7) and murine TLR7 (mTLR7) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors

mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

#### **Example 6. Reconstitution of TLR8 Signaling**

5           Methods for cloning murine and human TLR8 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated by reference. Human TLR8 cDNA and murine TLR8 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from  
10   Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR8 (hTLR8) and murine TLR8 (mTLR8) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

15

#### **Example 7. Reconstitution of TLR9 Signaling in 293 Fibroblasts**

          Methods for cloning murine and human TLR9 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are  
20   incorporated by reference. Human TLR9 cDNA and murine TLR9 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors  
25   mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

          To generate stable clones expressing human TLR9, murine TLR9, or either TLR9 with the NF- $\kappa$ B-luc reporter plasmid, 293 cells were transfected in 10 cm plates ( $2 \times 10^6$  cells/plate) with 16  $\mu$ g of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH, Cölbe,  
30   Germany). Clones were tested for TLR9 expression by RT-PCR, for example as shown in Fig. 21. The clones were also screened for IL-8 production or NF- $\kappa$ B-luciferase activity after stimulation with ODN. Four different types of clones were generated.

293-hTLR9-luc: expressing human TLR9 and 6x NF- $\kappa$ B-luciferase reporter  
 293-mTLR9-luc: expressing murine TLR9 and 6x NF- $\kappa$ B-luciferase reporter  
 293-hTLR9: expressing human TLR9  
 293-mTLR9: expressing murine TLR9

5

Human 293 fibroblast cells were transiently transfected with hTLR9 and a 6x NF- $\kappa$ B-luciferase reporter plasmid (NF- $\kappa$ B-luc, kindly provided by Patrick Baeuerle, Munich, Germany) (Fig. 18A) or with hTLR9 alone (Fig. 18B). After stimulus with CpG-ODN (2 $\mu$ M, TCGTCGTTTTGTCGTTTTGTCGTT, SEQ ID NO:1), GpC-ODN (2 $\mu$ M, TGCTGCTTTTGTGCTTTTGTGCTT, SEQ ID NO:154), LPS (100 ng/ml) or media, NF- $\kappa$ B activation by luciferase readout (8h, Fig. 18A) or IL-8 production by ELISA (48h, Fig. 18B) was monitored. Results are representative of three independent experiments. Fig. 18 shows that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

Human 293 fibroblast cells were transiently transfected with mTLR9 and the NF- $\kappa$ B-luc construct. Similar data was obtained for IL-8 production (not shown). Thus expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG DNA stimulation similar to hTLR4 reconstitution of LPS responses.

Figs. 19 and 20 demonstrate the responsiveness of a stable 293-mTLR9-luc and 293-hTLR9-luc clones after stimulation with CpG-ODN (2 $\mu$ M, SEQ ID NO:1), GpC-ODN (2 $\mu$ M, SEQ ID NO:154), Me-CpG-ODN (2 $\mu$ M; TZGTZGTTTTGTZGTTTTGTZGTT, Z = 5-methylcytidine, SEQ ID NO:147), LPS (100 ng/ml) or media, as measured by monitoring NF- $\kappa$ B activation. Similar results were obtained utilizing IL-8 production with the stable clones. These results demonstrate that CpG-DNA non-responsive cell lines can be stably genetically complemented with TLR9 to become responsive to CpG DNA in a motif-specific manner.

25

#### **Example 8. Method of Making IFN- $\alpha$ 4 Reporter Vector**

A number of reporter vectors may be used in the practice of the invention. Some of the reporter vectors are commercially available, e.g., the luciferase reporter vectors pNF- $\kappa$ B-Luc (Stratagene) and pAP1-Luc (Stratagene). These two reporter vectors place the luciferase gene under control of an upstream (5') promoter region derived from genomic DNA for NF- $\kappa$ B or AP1, respectively. Other reporter vectors can be constructed following standard

30

methods using the desired promoter and a vector containing a suitable reporter, such as luciferase,  $\beta$ -galactosidase ( $\beta$ -gal), chloramphenicol acetyltransferase (CAT), and other reporters known by those skilled in the art. Following are some examples of reporter vectors constructed for use in the present invention.

5           IFN- $\alpha$ 4 is an immediate-early type 1 IFN. Sequence-specific PCR products for the -620 to +50 promoter region of IFN- $\alpha$ 4 were derived from genomic DNA of human 293 cells and cloned into the *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -620 to +50 promoter region of IFN- $\alpha$ 4. The sequence of the -620 to +50 promoter region of IFN- $\alpha$ 4 is provided as  
10   SEQ ID NO:121.

**Example 9. Method of Making IFN- $\alpha$ 1 Reporter Vector**

IFN- $\alpha$ 1 is a late type 1 IFN. Sequence-specific PCR products for the -140 to +9 promoter region of IFN- $\alpha$ 1 were derived from genomic DNA of human 293 cells and cloned  
15   into *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -140 to +9 promoter region of IFN- $\alpha$ 1. A sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1 is provided as SEQ ID NO:122.

**Example 10. Method of Making IFN- $\beta$  Reporter Vector**

20           IFN- $\beta$  is an immediate-early type 1 IFN. The -280 to +20 promoter region of IFN- $\beta$  was derived from the pUC $\beta$ 26 vector (Algarté M et al. (1999) *J Virol* 73:2694-702) by restriction at *Eco*RI and *Taq*I sites. The 300 bp restriction fragment was filled in by Klenow enzyme and cloned into *Nhe*I-digested and filled in pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -280  
25   to +20 promoter region of IFN- $\beta$ . A sequence of the -280 to +20 promoter region of IFN- $\beta$  is provided as SEQ ID NO:123.

**Example 11. Method of Making Human IL-6 Reporter Vectors**

Reporter constructs are made using the -285 to +7 promoter region derived from  
30   human IL-6 genomic DNA. (Takeshita et al. Eur. J. Immunol. 2000. 30: 108-116.) In one reporter construct the IL-6 promoter region is cloned as a *Kpn*I-*Xho*I insert into pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of

- 67 -

an upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. A sequence of the -288 to +7 promoter region of human IL-6 is provided as SEQ ID NO:128.

The promoter can also be derived from the full-length promoter region of the IL-6 gene from -1174 to +7 (GenBank Accession No M22111) as shown below as SEQ ID

5 NO:129.

#### Example 12. Method of Making Human IL-8 Reporter Vectors

Reporter constructs have been made using a -546 to +44 and a truncated -133 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71. In each reporter construct the IL-8 promoter region was cloned as a *KpnI-XhoI* insert into pGL3-Basic Vector (Promega). One of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -546 to +44 promoter region derived from human IL-8 genomic DNA. Another of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -133 to +44 promoter region derived from human IL-8 genomic DNA.

The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71. A sequence of the -734 to +44 promoter region derived from human IL-8 is provided below as SEQ ID NO: 130.

#### Example 13. Method of Making Human IL-12 p40 Reporter Vectors

Reporter constructs have been made using truncated (-250 to +30, SEQ ID NO:127) and full length (-751 to +30, SEQ ID NO:126) promoter regions derived from human IL-12 p40 genomic DNA. (Takeshita et al. Eur. J. Immunol. 2000. 30: 108-116.) In one reporter construct the truncated IL-12 p40 promoter was cloned as a *KpnI-XhoI* insert into p $\beta$ gal-Basic (Promega). The resulting expression vector includes a  $\beta$  gal gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a second reporter construct the full length IL-12 p40 promoter was cloned as a *KpnI-XhoI* insert into p $\beta$ gal-Basic (Promega). The resulting expression vector includes a  $\beta$  gal gene under control of an upstream (5') -751 to +30 promoter region of human IL-12 p40. In a third reporter construct the truncated -250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a

- 68 -

fourth reporter construct the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -751 to +30 promoter region of human IL-12 p40. A sequence of the -751 to +30 promoter region of human IL-12 p40 is provided as SEQ ID NO: 126.

#### Example 14. Method of Making RANTES Reporter Vector

Transcription of the chemokine RANTES is believed to be regulated at least in part by IRF3 and by NF- $\kappa$ B. Lin R et al. (1999) *J Mol Cell Biol* 19(2):959-66; Genin P et al. (2000) *J Immunol* 164:5352-61. A 483 bp sequence-specific PCR product including the -397 to +5 promoter region of RANTES was derived from genomic DNA of human 293 cells, restricted with *Pst*I and cloned into pCAT-Basic Vector (Promega) using *Hind*III (filled in with Klenow) and *Pst*I sites (filled in). The -397 to +5 promoter region of RANTES was then isolated from the resulting RANTES/chloramphenicol acetyltransferase (CAT) reporter plasmid by restriction with *Bgl*II and *Sal*I, filled in with Klenow enzyme, and cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -397 to +5 promoter region of RANTES. Comparison of the insert sequence -397 to +5 of Genin P et al. (2000) *J Immunol* 164:5352-61 and GenBank accession no. AB023652 (SEQ ID NO:125) revealed two point deletions (at positions 105 and 273 of SEQ ID NO:125) which do not create new restriction sites. A sequence of the -397 to +5 promoter region of RANTES is provided as SEQ ID NO:125.

#### Example 15. RT-PCR Analysis of Cell Lines for TLR Expression

TLR expression was determined using total RNA of cells prepared by standard methods (QIAGEN). RNA was transcribed to cDNA using AMV Reverse Transcriptase (Roche). Quantitative PCR was performed with TLR-gene specific primer sets using a LightCycler Instrument (Roche). Controls for genomic DNA impurities were performed by a similar PCR method using RNA (but without reverse transcriptase).

A variety of cell lines was screened for their expression of TLR3, 7, 8 and 9. These cell lines are A549 (human lung carcinoma), BeWo (human choriocarcinoma), HeLa (human cervix carcinoma), Hep-2 (human cervix carcinoma), KG-1 (human acute myeloid leukemia), MUTZ-3 (human acute myelomonocytic leukemia), Nalm-6 (human B cell precursor



leukemia), NK-92 (human Natural killer cell line), NK-92 MI (human Natural killer cell line, IL-2 independent), Raji (human Burkitt's lymphoma, B lymphocyte), RAMOS (Burkitt's lymphoma, B lymphocyte), RPMI 8226 (human multiple myeloma, B lymphocyte), THP-1 (human acute monocytic leukemia), U937 (human lymphoma) and Jurkat (human T cell leukemia).

All B cell lines express, as determined by Real Time-PCR (RT-PCR), endogenous TLR9. In addition, all lines except NALM co-express TLR7. Nevertheless, none of the other cell lines appeared to express TLR7, whereas low TLR9 expression on the mRNA level was observed for KG-1 and THP-1. TLR3 appeared to be expressed in most of these cell lines, with the highest mRNA levels for example in the NK cell lines (e.g., NK-92).

Raji cells contain high levels of TLR9 mRNA and low levels of TLR3 and TLR7 mRNA suggesting high expression of TLR9 protein and lower levels of TLR3 and TLR7 protein.

These results indicate that the cell lines expressing TLR9 can be used to screen potential new TLR9 ligands (CpG ODN, etc.), cell lines expressing TLR7 to screen potential new TLR7 ligands (ORN (oligoribonucleotides), small molecules, etc.), and cell lines expressing both receptors may be used to screen for "hybrid" TLR7 and 9 agonists. In addition, cell lines lacking TLR8 expression (i.e., all cell lines tested) can be used to confirm the specificity of a TLR7 versus a TLR8 ligand (i.e., the latter should not be able to stimulate TLR7-expressing cells). In contrast, cell lines expressing TLR3 (e.g., Raji cells) may be used to screen for potential new TLR3 ligands (dsRNA, etc.).

#### **Example 16. Screening of Various Cell Lines for Responses to TLR Ligands**

Except where otherwise indicated, the following general methods were used. Cells were plated at  $5 \times 10^5$ /ml in 48 well plates in RPMI medium with 10% FBS. Stimulation was performed by addition of the oligonucleotides or other compounds diluted to the test concentrations in TE. Cells were incubated for 24 or 48h and the supernatants were taken to analyse for the presence of cytokines or chemokines.

The TLR ligands used are as follows:

TLR3: Poly I:C

TLR7, TLR8: R-848

TLR9:

T\*C\*C\*A\*G\*G\*A\*C\*T\*T\*C\*T\*C\*T\*C\*A\*G\*G\*T\*T (SEQ ID NO: 2);

- 70 -

- T\*C\*G\*T\*C\*G\*T\*T\*T\*T\*G\*T\*C\*G\*T\*T\*T\*G\*T\*C\*G\*T\*T (SEQ ID NO: 1);  
 T\*G\*C\*T\*G\*C\*T\*T\*T\*T\*G\*T\*G\*C\*T\*T\*T\*G\*T\*G\*C\*T\*T (SEQ ID NO: 154);  
 T\*C\*G\*T\*C\*G\*T\*T\*T\*T\*C\*G\*G\*C\*G\*C\*G\*C\*G\*C\*C\*G (SEQ ID NO: 158);  
 G\*G\*G\_G\_A\_C\_G\_A\_C\_G\_T\_C\_G\_T\_G\_G\*G\*G\*G\*G\*G (SEQ ID NO: 159);  
 5 T\*G\*C\*T\*G\*C\*T\*T\*T\*T\*C\*G\*G\*C\*G\*G\*C\*C\*G\*C\*C\*G (SEQ ID NO: 160);  
 G\*G\*G\_G\_A\_G\_C\_A\_G\_C\_T\_G\_C\_T\_G\_G\*G\*G\*G\*G\*G (SEQ ID NO: 161).  
 \* phosphorothioate linkage; \_ phosphodiester linkage.

Increased expression of cell surface markers was determined using cells stimulated as  
 10 described above and then stained with different monoclonal antibody combinations specific  
 for the cell surface markers. Analysis of the cells was performed by flow cytometry.

Changes in reporter gene activity were determined using cells transfected with a  
 NF- $\kappa$ B reporter construct (Stratagene) and a  $\beta$ -galactosidase reporter control plasmid  
 (Invitrogen) using electroporation. For NF- $\kappa$ B analysis, a 5x NF- $\kappa$ B-Luciferase Vector  
 15 (Stratagene) was used. The amount of DNA transfected as well as cell concentration was  
 varied. Stimulation was performed 24h after transfection. Cells were stimulated with the  
 indicated amounts of ODN, R-848, LPS, TNF- $\alpha$ , or IL-1  $\beta$  for the indicated incubation times.  
 Cell extracts were prepared by lysing the cells in 100  $\mu$ l reporter lysis buffer (Promega) using  
 the freeze-thaw method. All data were normalized for  $\beta$ -galactosidase expression.  
 20 Stimulation indices were calculated in reference to luciferase activity of medium without  
 addition of ODN.

Stimulation of the Raji cell line with a TLR9 ligand (CpG ODN), a TLR3 ligand (poly  
 I:C) or a TLR7 ligand (R-848) results in the ligand-specific secretion of cytokines. Figs. 14  
 and 15 show IL-6 production of Raji cells upon stimulation with ODN, poly I:C or R-848.  
 25 Fig. 16 shows IFN- $\alpha$ 2 production of Raji cells upon stimulation with ODN, poly I:C or R-848.  
 In all assays, cells were incubated with Na-Butyrate for 48h before stimulation with TLR  
 ligands. CpG stimulation of the RAMOS cell lines can result in the CpG-specific up-  
 regulation of cell surface markers such as CD80, as shown in Fig. 17.

### 30 **Example 17. Inhibition of a Positive Reference Compound Response with an Inhibitory Test Compound**

Inhibition of CpG mediated chemokine production was determined using RPMI 8226  
 cells incubated with increasing amounts of SEQ ID NO:1 in the presence of an

- 71 -

immunoinhibitory ODN (SEQ ID NO: 151). IP-10 production was measured 24h later by ELISA (Fig. 9).

### Equivalents

5           The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described  
10   herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

          All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

15

We claim:

- 72 -

**Claims**

1. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising  
contacting an RPMI 8226 cell that expresses a TLR with a test compound and  
5 measuring a test level of TLR signaling activity,  
wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and  
wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-8 production, IL-8  
10 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.
2. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising  
15 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,  
wherein a test level that is positive is indicative of an immunostimulatory compound, and  
wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-  
20 1 cell.
3. The method of claim 1 or 2, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a reference TLR signaling activity.  
25
4. The method of claim 3, wherein the reference compound is a positive reference compound
5. The method of claim 4, wherein the positive reference compound is  
30 selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

- 73 -

6. The method of claim 3, wherein the reference compound is a negative reference compound.
7. The method of claim 6, wherein the negative reference compound is  
5 medium alone.
8. The method of claim 5, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.
- 10 9. The method of claim 5, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.
10. The method of claim 1 or 2, wherein the test compound is a nucleic  
15 acid.
11. The method of claim 10, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.
- 20 12. The method of claim 10, wherein the nucleic acid comprises a phosphorothioate backbone linkage.
13. The method of claim 10, wherein the nucleic acid is a DNA, an RNA or  
25 a DNA-RNA hybrid.
14. The method of claim 1 or 2, wherein the test compound is a non-nucleic acid small molecule.
- 30 15. The method of claim 1 or 2, wherein the test compound comprises an amino acid, a carbohydrate, a lipid, or a hormone.
16. The method of claim 15, wherein the carbohydrate is a polysaccharide.

17. The method of claim 1 or 2, wherein the test compound is derived from a molecular library.
- 5 18. The method of claim 1, wherein the cell is transfected with a nucleic acid.
19. The method of claim 18, wherein the nucleic acid encodes a TLR or a reporter construct.
- 10 20. The method of claim 2, wherein the cell is transfected with a nucleic acid.
21. The method of claim 20, wherein the nucleic acid encodes a TLR or a reporter construct.
- 15 22. The method of claim 19 or 21, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.
- 20 23. The method of claim 22, wherein the TLR is a human TLR.
24. The method of claim 19 or 21, wherein the reporter construct is selected from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.
- 25 25. The method of claim 19 or 21, wherein the reporter construct comprises a TLR responsive promoter.
- 30 26. The method of claim 25, wherein the TLR responsive promoter comprises a transcription factor binding site selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an

- 75 -

IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

27. The method of claim 25, wherein the TLR responsive promoter is a  
5 promoter region selected from the group consisting of an IL-1 promoter region, an IL-6  
promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter  
region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an  
IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter  
region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a  
10 MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69  
promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region,  
a HLA-DR promoter region, and a HLA class I promoter region.

28. The method of claim 18 or 20, wherein the cell is stably transfected.  
15

29. The method of claim 1 or 2, wherein the TLR signaling activity is  
measured by cytokine secretion or chemokine secretion.

30. The method of claim 1, wherein the TLR signaling activity is selected  
20 from the group consisting of IL-8 secretion, IL-10 secretion, IP-10 secretion and TNF- $\alpha$   
secretion.

31. The method of claim 2, wherein the TLR signaling activity is selected  
from the group consisting of IL-6 expression, IL-6 production, IL-6 secretion, IL-8  
25 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10  
secretion, IP-10 expression, IP-10 production, IP-10 secretion, IL-12 expression, IL-12  
production, IL-12 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.

32. The method of claim 2, wherein the TLR signaling activity is measured  
30 by phosphorylation.

33. The method of claim 32, wherein phosphorylation is total cellular  
phosphorylation.

34. The method of claim 32, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NFkB subunits, c-Jun and c-Fos.

5

35. The method of claim 1 or 2, wherein the TLR signaling activity is measured by gene expression.

36. The method of claim 1, wherein the TLR signaling activity is measured by gene expression selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression, IP-10 expression, and TNF- $\alpha$  expression.

37. The method of claim 35, wherein TLR signaling activity is measured by microarray techniques.

38. The method of claim 2, wherein the TLR signaling activity is measured by cell proliferation.

39. The method of claim 1 or 2, wherein TLR signaling activity is measured by cell surface marker expression.

40. The method of claim 1, wherein TLR signaling activity is measured by cell surface expression of CD71, CD86 or HLA-DR.

25

41. The method of claim 2, wherein TLR signaling activity is measured by CD71 cell surface expression, CD86 cell surface expression, HLA-DR cell surface expression, CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

30

42. The method of claim 2, wherein TLR signaling activity is measured by antibody secretion.



- 77 -

43. The method of claim 42, wherein the antibody secretion is IgM secretion.

44. A composition comprising  
an RPMI 8226 cell stably transfected with a nucleic acid encoding a TLR  
5 polypeptide, or a fragment thereof.

45. The composition of claim 44, further comprising a reporter construct  
comprising a promoter and a reporter sequence wherein the promoter is a TLR responsive  
promoter.

10

46. The composition of claim 45, wherein the TLR responsive promoter  
comprises a nucleic acid sequence selected from the group consisting of an NF- $\kappa$ B binding  
site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3  
binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding  
15 site, and a TARE.

47. The composition of claim 45, wherein the reporter sequence is selected  
from the group consisting of a luciferase sequence, a  $\beta$ -galactosidase sequence, a green  
fluorescent protein sequence, a secreted alkaline phosphatase sequence and a chloramphenicol  
20 transferase sequence.

48. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is a human TLR polypeptide or fragment thereof.

25 49. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6,  
TLR7, TLR8, TLR9 and TLR10.

50. The composition of claim 44, wherein the TLR polypeptide or fragment  
30 thereof is a human TLR polypeptide.

51. A screening method for identifying agonists of Toll-like receptor (TLR)  
signaling activity, comprising

contacting an cell that ectopically expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

5 wherein the cell that ectopically expresses a TLR is selected from the group consisting of RPMI 8226, RAMOS, Raji, Nalm, THP-1, KG-1 and 293 HEK.

52. The method of claim 51, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a  
10 reference TLR signaling activity.

53. The method of claim 52, wherein the reference compound is a positive reference compound.

15 54. The method of claim 53, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

55. The method of claim 54, wherein the immunostimulatory nucleic acid  
20 is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

56. The method of claim 54, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.  
25

57. The method of claim 52, wherein the reference compound is negative reference compound.

58. The method of claim 57, wherein the negative reference compound is  
30 medium alone.

59. The method of claim 51, wherein the test compound is a nucleic acid.

- 79 -

60. The method of claim 59, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.

5 61. The method of claim 59, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

62. The method of claim 59, wherein the nucleic acid is a DNA, an RNA, or a DNA-RNA hybrid.

10

63. The method of claim 51, wherein the test compound is a non-nucleic acid small molecule.

64. The method of claim 51, wherein the test compound comprises an amino acid, a carbohydrate, a lipid, or a hormone.

15

65. The method of claim 64, wherein the carbohydrate is a polysaccharide.

66. The method of claim 51, wherein the test compound is derived from a molecular library.

20

67. The method of claim 51, wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-6 expression, IL-6 production, IL-6 secretion, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IL-12 expression, IL-12 production, IL-12 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.

25

68. The method of claim 51, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

30

69. The method of claim 51, wherein the TLR is a human TLR.

70. The method of claim 51, wherein the cell is transfected with a reporter construct.

71. The method of claim 70, wherein the reporter construct is selected from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

72. The method of claim 71, wherein the TLR signaling activity is measured by luciferase expression,  $\beta$ -galactosidase expression, chloramphenicol expression, acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.

73. The method of claim 71, wherein the reporter construct comprises a TLR responsive promoter.

74. The method of claim 25 or 73, wherein the TLR responsive promoter is a TLR1 responsive promoter, a TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a TLR10 responsive promoter.

75. The method of claim 73, wherein the TLR responsive promoter comprises a transcription factor binding site selected from the group consisting of an NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

76. The method of claim 73, wherein the TLR responsive promoter is a promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter

region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

5

77. The method of claim 51, wherein the cell is stably transfected with a TLR nucleic acid.

10

78. The method of claim 70, wherein the cell is stably transfected with the reporter construct.

79. The method of claim 51, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

15

80. The method of claim 79, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, TNF- $\alpha$  secretion, IL-10 secretion and IP-10 secretion.

20

81. The method of claim 79, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-6 secretion and IL-12 secretion.

82. The method of claim 51, wherein the TLR signaling activity is measured by phosphorylation.

25

83. The method of claim 82, wherein phosphorylation is total cellular phosphorylation.

30

84. The method of claim 82, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

85. The method of claim 51, wherein the TLR signaling activity is measured by gene expression.

86. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-8 expression, IL-10 expression, IP-10 expression, CD71 expression, CD86 expression and HLA-DR expression.

5

87. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- $\alpha$  expression.

88. The method of claim 51, wherein the TLR signaling activity is  
10 measured by microarray techniques.

89. The method of claim 51, wherein the TLR signaling activity is measured by cell proliferation.

90. The method of claim 51, wherein the TLR signaling activity is  
15 measured by cell surface marker expression.

91. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface  
20 expression and HLA-DR cell surface expression.

92. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

25

93. The method of claim 51, wherein the TLR signaling activity is measured by antibody secretion.

94. The method of claim 93, wherein the antibody secretion is IgM  
30 secretion.

95. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

- 83 -

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

5                    wherein a test level that is less than a reference level is indicative of test compound that is a TLR antagonist, and

                  wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell.

10                   96.           The method of claim 95, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an immunostimulatory imidazoquinoline compound.

                  97.           The method of claim 96, wherein the immunostimulatory nucleic acid  
15 is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

                  98.           The method of claim 96, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

20

                  99.           The method of claim 95, wherein the test compound is a nucleic acid.

                  100.          The method of claim 99, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a  
25 poly-G motif.

                  101.          The method of claim 99, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

30                   102.          The method of claim 99, wherein the nucleic acid is a DNA, an RNA or a DNA-RNA hybrid.

- 84 -

103. The method of claim 95, wherein the test compound is a non-nucleic acid small molecule.

104. The method of claim 95, wherein the test compound comprises an  
5 amino acid, a carbohydrate, a lipid, or a hormone.

105. The method of claim 104, wherein the carbohydrate is a polysaccharide.

106. The method of claim 95, wherein the test compound is derived from a  
10 molecular library.

107. The method of claim 95, wherein the experimental cell is transfected with a nucleic acid.  
15

108. The method of claim 107, wherein the nucleic acid encodes a TLR or a reporter construct.

109. The method of claim 108, wherein the TLR is selected from the group  
20 consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

110. The method of claim 108, wherein the TLR is a human TLR.

111. The method of claim 108, wherein the reporter construct is selected  
25 from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

112. The method of claim 111, wherein the TLR signaling activity is  
30 selected from the group consisting of luciferase expression,  $\beta$ -galactosidase expression, chloramphenicol acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.



113. The method of claim 108, wherein the reporter construct comprises a TLR responsive promoter.

114. The method of claim 113, wherein the TLR responsive promoter  
5 comprises a transcription factor binding site selected from the group consisting of an NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

10 115. The method of claim 113, wherein the TLR responsive promoter is a promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter  
15 region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

20 116. The method of claim 113, wherein the TLR responsive promoter is selected from the group consisting of a TLR1 responsive promoter, TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a TLR10 responsive promoter.

25

117. The method of claim 107, wherein the cell is stably transfected with the nucleic acid.

118. The method of claim 95, wherein the TLR signaling activity is  
30 measured by cytokine secretion or chemokine secretion.

119. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-6 secretion, IL-12 secretion and TNF- $\alpha$  secretion.

5 120. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, IL-10 secretion and IP-10 secretion.

121. The method of claim 95, wherein the TLR signaling activity is  
10 measured by phosphorylation.

122. The method of claim 121, wherein phosphorylation is total cellular phosphorylation.

15 123. The method of claim 122, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

124. The method of claim 95, wherein the TLR signaling activity is  
20 measured by gene expression.

125. The method of claim 124, wherein the gene expression is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression and IP-10 expression.

25 126. The method of claim 124, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- $\alpha$  expression.

127. The method of claim 95, wherein the TLR signaling activity is  
30 measured by microarray techniques.

128. The method of claim 95, wherein the TLR signaling activity is measured by cell proliferation.

129. The method of claim 95, wherein the TLR signaling activity is measured by cell surface marker expression.

5 130. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface expression and HLA-DR MHC class II cell surface expression.

10 131. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

132. The method of claim 95, wherein the TLR signaling activity is measured by antibody secretion.

15

133. The method of claim 132, wherein the antibody secretion is IgM secretion.

20 134. The method of claim 95, wherein the cell is contacted to the positive reference compound and the test compound simultaneously.

135. The method of claim 95, wherein the cell is contacted to the positive reference compound prior to contact with the test compound.

25 136. The method of claim 95, wherein the cell is contacted to the test compound prior to contact with the positive reference compound.

30 137. A method for quality assessment of a test composition containing a known Toll like receptor (TLR) ligand, comprising:  
measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule;  
measuring a test activity of a test composition comprising the known TLR ligand; and  
comparing the test activity to the reference activity.

138. The method of claim 137, further comprising selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

5

139. The method of claim 1, wherein the reference composition is a first production lot of a pharmaceutical composition comprising the known TLR ligand, and wherein the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand.

10

140. The method of claim 137, wherein the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and wherein the test composition is a second in-process lot of a composition comprising the known TLR ligand.

15

141. The method of claim 137, wherein the measuring the reference activity comprises contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and wherein the measuring the test activity comprises contacting the test composition with the isolated cell expressing a TLR responsive to the known TLR ligand.

20

142. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand comprises an expression vector for the TLR responsive to the known TLR ligand.

25

143. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand.

30

144. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226.

145. The method of claim 137, wherein the measuring the reference activity and the measuring the test activity each comprise measuring signaling activity mediated by a TLR responsive to the known TLR ligand.

5 146. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of NF- $\kappa$ B response element.

147. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of interferon-stimulated response element (ISRE).

10

148. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IFN- $\alpha$  promoter.

149. The method of claim 145, wherein the signaling activity is activity of a  
15 reporter gene under control of an IFN- $\beta$  promoter.

150. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-6 promoter.

20 151. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-8 promoter.

152. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-12 p40 promoter.

25

153. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of a RANTES promoter.

154. The method of claim 137, wherein the known TLR ligand is a TLR9  
30 ligand.

155. The method of claim 137, wherein the known TLR ligand is a TLR3 ligand.

156. The method of claim 137, wherein the known TLR ligand is a TLR7 ligand.

5 157. The method of claim 137, wherein the known TLR ligand is a TLR8 ligand.

158. The method of claim 137, wherein the known TLR ligand is an immunostimulatory nucleic acid.

10

159. The method of claim 137, wherein the known TLR ligand is a CpG nucleic acid.

160. The method of claim 137, wherein the known TLR ligand is an immunoinhibitory nucleic acid.

15

161. A method for quality assessment of a test lot of a pharmaceutical product containing a known TLR9 ligand, comprising:

measuring a reference activity of a reference lot of a pharmaceutical product

20 comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid molecule;

measuring a test activity of a test lot of a pharmaceutical product comprising the known TLR9 ligand;

comparing the test activity to the reference activity; and

25 rejecting the test lot if the test activity falls outside of a predetermined range of variance about the reference activity.

162. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence TCGTCGTTTGTGTCGTTTGTGTCGTT (SEQ ID

30 NO:1).

- 91 -

163. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTGACGTTTTGTCGTT-3' (SEQ ID NO:139).

5 164. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTGTCGTTTTTTTCGA-3' (SEQ ID NO:140).

165. The method of claim 161, wherein the known TLR9 ligand is an  
10 oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGTCGTTTCGTCGTT-3' (SEQ ID NO:141).

166. The method of claim 161, wherein the known TLR9 ligand is an  
15 oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGTCGTTTTGTCGTT-3' (SEQ ID NO:142).

167. The method of claim 161, wherein the known TLR9 ligand is an  
oligonucleotide comprising a base sequence 5'-TCGTCGTTTTTCGGTCGTTTT-3' (SEQ ID  
20 NO:143).

168. The method of claim 161, wherein the known TLR9 ligand is an  
oligonucleotide comprising a base sequence 5'-TCGTCGTTTTTCGTGCGTTTTT-3' (SEQ  
ID NO:144).

25 169. The method of claim 161, wherein the known TLR9 ligand is an  
oligonucleotide comprising a base sequence 5'-TCGTCGTTTTCGGCGGCCGCCG-3' (SEQ  
ID NO:145).

170. The method of claim 161, wherein the known TLR9 ligand is an  
30 oligonucleotide comprising a base sequence 5'-TCGTC\_GTTTTAC\_GGCGCC\_GTGCCG-3'  
(SEQ ID NO:146), wherein every internucleoside linkage is phosphorothioate except for  
those indicated by “\_”, which are phosphodiester.

- 92 -

171. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising  
contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,  
5 wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and  
wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-1 cell, and the TLR is TLR9.
- 10 172. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising  
contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,  
wherein a test level that is positive is indicative of a test compound that is a TLR  
15 agonist, and  
wherein the cell is a Raji cell or a RAMOS cell, and the TLR is TLR7.
173. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising  
20 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,  
wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and  
wherein the cell is a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat  
25 cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell, and the TLR is TLR3.
174. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising  
30 contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,  
contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,



- 93 -

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell, and the TLR is TLR9.

5

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

10 contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

15 wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell and a Raji cell, and the TLR is TLR7.

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

20 contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

25 wherein the cell is selected from the group consisting of a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is TLR3.

176. A screening method for identifying an enhancer of a Toll-like receptor (TLR) agonist, comprising

30 contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity, and

contacting a cell with the positive reference compound and a test compound and measuring a test level of TLR signaling activity,

wherein the positive reference compound is a TLR agonist, and a test level that is greater than the reference level is indicative of a test compound that is an enhancer of a TLR agonist.

177. The method of claim 176, wherein the positive reference compound is an immunostimulatory nucleic acid.

178. The method of claim 176, wherein the positive reference compound is an imidazoquinoline compound.

180. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, a RAMOS cell, a Jurkat cell, a HeLa cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is TLR3.

181. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, an RPMI 8226 cell, a RAMOS cell, and a THP-1 cell, and the TLR is TLR9.

182. The method of claim 176, wherein the cell is selected from the group consisting of a Raji cell, an RPMI 8226 cell and a RAMOS cell, and the TLR is TLR7.

183. The method of claim 1, wherein the TLR is TLR7 or TLR9.

184. The method of claim 172-175 or 176, wherein the cell is unmodified.




Fig. 1

2/15




Fig. 2

3/15




Fig. 3

4/15




Fig. 4

5/15





Fig. 5

6/15

**Fig. 6**



7/15




Fig. 7

8/15




Fig. 8

9/15




Fig. 9

10/15




Fig. 10




Fig. 11

11/15




Fig. 12

12/15




Fig. 13




Fig. 14

13/15




Fig. 15




Fig. 16




Fig. 17

14/15




Fig. 18A




Fig. 18B






Fig. 19




Fig. 20




Fig. 21

## SEQUENCE LISTING

<110> COLEY PHARMACEUTICAL GmbH  
COLEY PHARMACEUTICAL GROUP INC.

<120> METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT OF TLR  
LIGANDS

<130> C1041.70024WO00

<140> not yet assigned  
<141> 2004-04-22

<150> US 60/464,586  
<151> 2003-04-22

<150> US 60/464,588  
<151> 2003-04-22

<160> 161

<170> PatentIn version 3.2

<210> 1  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 1  
tcgtcgtttt gtcgttttgt cggt 24

<210> 2  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 2  
tccaggactt ctctcagggt 20

<210> 3  
<211> 2600  
<212> DNA  
<213> Homo sapiens

<400> 3  
ggatccaaag gagacctata gtgactccca ggagctctta gtgaccaagt gaaggtaacct 60  
gtggggctca ttgtgcccat tgctctttca ctgctttcaa ctggtagtgt tgggttgaag 120  
cactggacaa tgccacatac tttgtggatg gtgtgggtct tgggggtcat catcagcctc 180  
tccaaggaag aatcctccaa tcaggcttct ctgtcttgtg accgcaatgg tatctgcaag 240

```

ggcagctcag gatctttaaa ctccattccc tcagggctca cagaagctgt aaaaagcctt    300
gacctgtcca acaacaggat cacctacatt agcaacagtg acctacagag gtgtgtgaac    360
ctccaggctc tgggtgctgac atccaatgga attaacacaa tagaggaaga ttctttttct    420
tccttgggca gtcttgaaca tttagactta tcctataatt acttatctaa tttatcgtct    480
tcctggttca agcccccttc ttctttaaca ttcttaaact tactgggaaa tccttacaaa    540
accctagggg aaacatctct tttttctcat ctcacaaaat tgcaaatcct gagagtggga    600
aatatggaca ccttcactaa gattcaaaga aaagattttg ctggacttac cttocttgag    660
gaacttgaga ttgatgcttc agatctacag agctatgagc caaaaagttt gaagtcaatt    720
cagaacgtaa gtcattctgat ccttcatatg aagcagcata ttttactgct ggagattttt    780
gtagatgtta caagtccgt ggaatgtttg gaactgagag atactgattt ggacactttc    840
catttttctcag aactatccac tggtgaaaca aattcattga ttaaaaagtt tacatttaga    900
aatgtgaaaa tcaccgatga aagtttggtt caggttatga aacttttgaa tcagatttct    960
ggattgttag aattagagtt tgatgactgt acccttaatg gagttggtaa ttttagagca   1020
tctgataatg acagagttat agatccaggt aaagtggaaa cgttaacaat ccggaggctg   1080
catattccaa ggttttactt attttatgat ctgagcactt tatattcact tacagaaaga   1140
gttaaaagaa tcacagtaga aaacagtaaa gtttttctgg ttccttggtt actttcacia   1200
catttaaaat cattagaata cttggatctc agtgaaaatt tgatggttga agaatacttg   1260
aaaaattcag cctgtgagga tgcctggccc tctctacaaa cttaattttt aaggcaaaat   1320
catttgcat cattggaaaa aaccggagag actttgctca ctctgaaaaa cttgactaac   1380
attgatatca gtaagaatag ttttcattct atgcctgaaa cttgtcagtg gccagaaaag   1440
atgaaatatt tgaacttatc cagcacacga atacacagtg taacaggctg cattcccaag   1500
aactggaaa ttttagatgt tagcaacaac aatctcaatt tattttcttt gaatttgccg   1560
caactcaaag aactttatat ttccagaaat aagttgatga ctctaccaga tgcctccctc   1620
ttacccatgt tactagtatt gaaaatcagt aggaatgcaa taactacgtt ttctaaggag   1680
caacttgact catttcacac actgaagact ttggaagctg gtggcaataa cttcatttgc   1740
tcctgtgaat tcctctcctt cactcaggag cagcaagcac tggccaaagt cttgattgat   1800
tggccagcaa attacctgtg tgactctcca tcccatgtgc gtggccagca ggttcaggat   1860
gtccgcctct cggtgtcgga atgtcacagg acagcactgg tgtctggcat gtgtgtgct   1920
ctgttcctgc tgatcctgct cacgggggtc ctgtgccacc gtttccatgg cctgtgggat   1980
atgaaaatga tgtgggcctg gctccaggcc aaaaggaagc ccaggaaagc tcccagcagg   2040
aacatctgct atgatgcatt tgtttcttac agtgagcggg atgcctactg ggtggagaac   2100

```

cttatgggtcc aggagctgga gaacttcaat ccccccttca agttgtgtct tcataagcgg 2160  
 gacttcattc ctggcaagtg gatcattgac aatatcattg actccattga aaagagccac 2220  
 aaaactgtct ttgtgctttc tgaaaacttt gtgaagagtg agtggtgcaa gtatgaactg 2280  
 gacttctccc atttccgtct ttttgaagag aacaatgatg ctgccattct cattcttctg 2340  
 gagcccattg agaaaaaagc cattccccag cgcttctgca agctgcggaa gataatgaac 2400  
 accaagacct acctggagtg gcccatggac gaggctcagc gggaaggatt ttgggtaaat 2460  
 ctgagagctg cgataaagtc ctaggttccc atatttaaga ccagtctttg tctagttggg 2520  
 atctttatgt cactagttat agttaagttc attcagacat aattatataa aaactacgtg 2580  
 gatgtaccgt catttgagga 2600

&lt;210&gt; 4

&lt;211&gt; 784

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

Met Pro His Thr Leu Trp Met Val Trp Val Leu Gly Val Ile Ile Ser  
 1 5 10 15  
 Leu Ser Lys Glu Glu Ser Ser Asn Gln Ala Ser Leu Ser Cys Asp Arg  
 20 25 30  
 Asn Gly Ile Cys Lys Gly Ser Ser Gly Ser Leu Asn Ser Ile Pro Ser  
 35 40 45  
 Gly Leu Thr Glu Ala Val Lys Ser Leu Asp Leu Ser Asn Asn Arg Ile  
 50 55 60  
 Thr Tyr Ile Ser Asn Ser Asp Leu Gln Arg Cys Val Asn Leu Gln Ala  
 65 70 75 80  
 Leu Val Leu Thr Ser Asn Gly Ile Asn Thr Ile Glu Glu Asp Ser Phe  
 85 90 95  
 Ser Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Tyr Asn Tyr Leu  
 100 105 110  
 Ser Asn Leu Ser Ser Ser Trp Phe Lys Pro Leu Ser Ser Leu Thr Phe  
 115 120 125  
 Leu Asn Leu Leu Gly Asn Pro Tyr Lys Thr Leu Gly Glu Thr Ser Leu  
 130 135 140  
 Phe Ser His Leu Thr Lys Leu Gln Ile Leu Arg Val Gly Asn Met Asp  
 145 150 155 160  
 Thr Phe Thr Lys Ile Gln Arg Lys Asp Phe Ala Gly Leu Thr Phe Leu  
 165 170 175  
 Glu Glu Leu Glu Ile Asp Ala Ser Asp Leu Gln Ser Tyr Glu Pro Lys  
 180 185 190

Ser Leu Lys Ser Ile Gln Asn Val Ser His Leu Ile Leu His Met Lys  
 195 200 205  
 Gln His Ile Leu Leu Leu Glu Ile Phe Val Asp Val Thr Ser Ser Val  
 210 215 220  
 Glu Cys Leu Glu Leu Arg Asp Thr Asp Leu Asp Thr Phe His Phe Ser  
 225 230 235 240  
 Glu Leu Ser Thr Gly Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe  
 245 250 255  
 Arg Asn Val Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu  
 260 265 270  
 Leu Asn Gln Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr  
 275 280 285  
 Leu Asn Gly Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile  
 290 295 300  
 Asp Pro Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His Ile Pro  
 305 310 315 320  
 Arg Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Leu Tyr Ser Leu Thr Glu  
 325 330 335  
 Arg Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro  
 340 345 350  
 Cys Leu Leu Ser Gln His Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser  
 355 360 365  
 Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp  
 370 375 380  
 Ala Trp Pro Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala  
 385 390 395 400  
 Ser Leu Glu Lys Thr Gly Glu Thr Leu Leu Thr Leu Lys Asn Leu Thr  
 405 410 415  
 Asn Ile Asp Ile Ser Lys Asn Ser Phe His Ser Met Pro Glu Thr Cys  
 420 425 430  
 Gln Trp Pro Glu Lys Met Lys Tyr Leu Asn Leu Ser Ser Thr Arg Ile  
 435 440 445  
 His Ser Val Thr Gly Cys Ile Pro Lys Thr Leu Glu Ile Leu Asp Val  
 450 455 460  
 Ser Asn Asn Asn Leu Asn Leu Phe Ser Leu Asn Leu Pro Gln Leu Lys  
 465 470 475 480  
 Glu Leu Tyr Ile Ser Arg Asn Lys Leu Met Thr Leu Pro Asp Ala Ser  
 485 490 495  
 Leu Leu Pro Met Leu Leu Val Leu Lys Ile Ser Arg Asn Ala Ile Thr  
 500 505 510  
 Thr Phe Ser Lys Glu Gln Leu Asp Ser Phe His Thr Leu Lys Thr Leu

515                      520                      525  
 Glu Ala Gly Gly Asn Asn Phe Ile Cys Ser Cys Glu Phe Leu Ser Phe  
 530                      535                      540  
  
 Thr Gln Glu Gln Gln Ala Leu Ala Lys Val Leu Ile Asp Trp Pro Ala  
 545                      550                      555                      560  
  
 Asn Tyr Leu Cys Asp Ser Pro Ser His Val Arg Gly Gln Gln Val Gln  
 565                      570                      575  
  
 Asp Val Arg Leu Ser Val Ser Glu Cys His Arg Thr Ala Leu Val Ser  
 580                      585                      590  
  
 Gly Met Cys Cys Ala Leu Phe Leu Leu Ile Leu Leu Thr Gly Val Leu  
 595                      600                      605  
  
 Cys His Arg Phe His Gly Leu Trp Tyr Met Lys Met Met Trp Ala Trp  
 610                      615                      620  
  
 Leu Gln Ala Lys Arg Lys Pro Arg Lys Ala Pro Ser Arg Asn Ile Cys  
 625                      630                      635                      640  
  
 Tyr Asp Ala Phe Val Ser Tyr Ser Glu Arg Asp Ala Tyr Trp Val Glu  
 645                      650                      655  
  
 Asn Leu Met Val Gln Glu Leu Glu Asn Phe Asn Pro Pro Phe Lys Leu  
 660                      665                      670  
  
 Cys Leu His Lys Arg Asp Phe Ile Pro Gly Lys Trp Ile Ile Asp Asn  
 675                      680                      685  
  
 Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser  
 690                      695                      700  
  
 Glu Asn Phe Val Lys Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser  
 705                      710                      715                      720  
  
 His Phe Arg Leu Phe Glu Glu Asn Asn Asp Ala Ala Ile Leu Ile Leu  
 725                      730                      735  
  
 Leu Glu Pro Ile Glu Lys Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu  
 740                      745                      750  
  
 Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Met Asp Glu  
 755                      760                      765  
  
 Ala Gln Arg Glu Gly Phe Trp Val Asn Leu Arg Ala Ala Ile Lys Ser  
 770                      775                      780

&lt;210&gt; 5

&lt;211&gt; 2824

&lt;212&gt; DNA

&lt;213&gt; murine

&lt;400&gt; 5

gcccccatg gccatatggg caccggggag cggcggctgg aggactccta ggctcctggg 60

caggcgggtca catggcagaa gatgtgtccg caatcatagt ttctgatggg gaaggttggg 120

cggcagtcctc tgcgacctag aagtggaaaa gatgtcgttc aaggaggtgc ggactgtttc 180

cttctgacca ggatcttgtt tctgagtgtg ggggcttcac ttctctgctt ttcgttcac	240
tctggagcat ccgaattgca tcaccggtca gaaaacaact taccgaaacc tcagacaaaag	300
cgtaaatct cagaggatgc tacgagctct ttggctcttc tggatcttgg tggccataac	360
agtcctcttc agcaaacgct gttctgctca ggagtctctg tcatgtgatg cttctgggg	420
gtgtgatggc cgctccaggt ctttcacctc tattccctcc ggactcacag cagccatgaa	480
aagccttgac ctgtctttca acaagatcac ctacattggc catggtgacc tccgagcgtg	540
tgcgaacctc caggttctga ttttgaagtc cagcagaatc aatacaatag agggagacgc	600
cttttattct ctgggcagtc ttgaacattt ggatttgtct gataatcac tatctagttt	660
atcttcctcc tgggtcgggc ccctttctc tttgaaatac ttaacttaa tgggaaatcc	720
ttaccagaca ctgggggtaa catcgctttt tcccaatctc acaaatttac aaacctcag	780
gataggaaat gtagagactt tcagtggatg aaggagaata gattttgctg ggctgacttc	840
tctcaatgaa cttgaaatta aggcattaag tctccggaat tatcagtcac aaagtctaaa	900
gtcgatccgc gacatccatc acctgactct tcacttaagc gagtctgctt tcctgctgga	960
gatttttgca gatattctga gttctgtgag atatttagaa ctaagagata ctaactggc	1020
caggttccag ttttcaccac tgcccgtaga tgaagtcagc tcaccgatga agaagctggc	1080
attccgaggc tcggttctca ctgatgaaag ctttaacgag ctctgaagc tgttgcggtta	1140
catcttgaa ctgtcggagg tagagttcga cgactgtacc ctcaatgggc tcggcgattt	1200
caacccctcg gaggcagacg tagtgagcga gctgggtaaa gtagaaacag tcactatccg	1260
gaggttgcac atccccagc tctatttgtt ttatgacctg agtactgtct attccctcct	1320
ggagaagggtg aagcgaatca cagtagagaa cagcaaggtc ttcttggttc cctgctcgtt	1380
ctcccagcat ttaaaatcat tagaattctt agacctcagc gaaaatctga tggttgaaga	1440
atatttgaag aactcagcct gtaaggagc ctggccttct ctacaaacct tagttttgag	1500
ccagaatcat ttgagatcaa tgcaaaaaac aggagagatt ttgctgactc tgaaaaacct	1560
gacctccctt gacatcagca ggaacacttt tcatccgatg cccgacagct gtcagtggcc	1620
agaaaagatg cgcttcctga atttgtccag tacagggatc cgggttggtta aaacgtgcat	1680
tcctcagacg ctggaggtgt tggatgttag taacaacaat cttgactcat tttctttgtt	1740
cttgccctcg ctgcaagagc tctatatctt cagaaataag ctgaaaacac tcccagatgc	1800
ttcgttgttc cctgtgttgc tggatcatgaa aatcagagag aatgcagtaa gtactttctc	1860
taaagaccaa cttggttctt ttcccaaact ggagactctg gaagcaggcg acaaccactt	1920
tgtttgctcc tgcgaactcc tatcctttac tatggagacg ccagctctgg ctcaaatcct	1980
ggttgactgg ccagacagct acctgtgtga ctctccgct cgctgcacg gccacaggct	2040
tcaggatgcc cggccctccg tcttggaatg tcaccaggct gcactggtgt ctggagtctg	2100

ctgtgccctt ctcctgttga tcttgctcgt aggtgccctg tgccaccatt tccacgggct 2160  
 gtggtacctg agaatgatgt gggcgtggct ccaggccaag aggaagccca agaaagctcc 2220  
 ctgcaggggac gtttgctatg atgcctttgt ttcctacagt gagcaggatt cccattgggt 2280  
 ggagaacctc atggtccagc agctggagaa ctctgacctg ccctttaagc tgtgtctcca 2340  
 caagcgggac ttcgttcggt gcaaattgat cattgacaac atcatcgatt ccatcgaaaa 2400  
 gagccacaaa actgtgttcg tgctttctga gaacttcgta cggagcgagt ggtgcaagta 2460  
 cgaactggac ttctccact tcaggctctt tgacgagaac aacgacgcgg ccatccttgt 2520  
 tttgctggag cccattgaga ggaaagccat tcccagcgc ttctgcaaac tgcgcaagat 2580  
 aatgaacacc aagacctacc tggagtggcc cttggatgaa ggccagcagg aagtgttttg 2640  
 ggtaaactctg agaactgcaa taaagtccca ggttctccac ccagttcctg acttccttaa 2700  
 ctaaggctctt tgtgacacaa actgtaacaa agtttataag taacatagaa ttgtattatt 2760  
 gaggatatta actatggggt ttgtcttgaa tactgttata taaatatgtg acatcaggct 2820  
 ttag 2824

<210> 6  
 <211> 784  
 <212> PRT  
 <213> murine

<400> 6

Met	Leu	Arg	Ala	Leu	Trp	Leu	Phe	Trp	Ile	Leu	Val	Ala	Ile	Thr	Val
1				5					10					15	
Leu	Phe	Ser	Lys	Arg	Cys	Ser	Ala	Gln	Glu	Ser	Leu	Ser	Cys	Asp	Ala
			20					25					30		
Ser	Gly	Val	Cys	Asp	Gly	Arg	Ser	Arg	Ser	Phe	Thr	Ser	Ile	Pro	Ser
		35					40					45			
Gly	Leu	Thr	Ala	Ala	Met	Lys	Ser	Leu	Asp	Leu	Ser	Phe	Asn	Lys	Ile
	50					55				60					
Thr	Tyr	Ile	Gly	His	Gly	Asp	Leu	Arg	Ala	Cys	Ala	Asn	Leu	Gln	Val
65					70					75				80	
Leu	Ile	Leu	Lys	Ser	Ser	Arg	Ile	Asn	Thr	Ile	Glu	Gly	Asp	Ala	Phe
			85						90					95	
Tyr	Ser	Leu	Gly	Ser	Leu	Glu	His	Leu	Asp	Leu	Ser	Asp	Asn	His	Leu
		100						105					110		
Ser	Ser	Leu	Ser	Ser	Ser	Trp	Phe	Gly	Pro	Leu	Ser	Ser	Leu	Lys	Tyr
		115					120					125			
Leu	Asn	Leu	Met	Gly	Asn	Pro	Tyr	Gln	Thr	Leu	Gly	Val	Thr	Ser	Leu
	130					135						140			



Phe Pro Asn Leu Thr Asn Leu Gln Thr Leu Arg Ile Gly Asn Val Glu  
 145 150 155 160  
 Thr Phe Ser Glu Ile Arg Arg Ile Asp Phe Ala Gly Leu Thr Ser Leu  
 165 170 175  
 Asn Glu Leu Glu Ile Lys Ala Leu Ser Leu Arg Asn Tyr Gln Ser Gln  
 180 185 190  
 Ser Leu Lys Ser Ile Arg Asp Ile His His Leu Thr Leu His Leu Ser  
 195 200 205  
 Glu Ser Ala Phe Leu Leu Glu Ile Phe Ala Asp Ile Leu Ser Ser Val  
 210 215 220  
 Arg Tyr Leu Glu Leu Arg Asp Thr Asn Leu Ala Arg Phe Gln Phe Ser  
 225 230 235 240  
 Pro Leu Pro Val Asp Glu Val Ser Ser Pro Met Lys Lys Leu Ala Phe  
 245 250 255  
 Arg Gly Ser Val Leu Thr Asp Glu Ser Phe Asn Glu Leu Leu Lys Leu  
 260 265 270  
 Leu Arg Tyr Ile Leu Glu Leu Ser Glu Val Glu Phe Asp Asp Cys Thr  
 275 280 285  
 Leu Asn Gly Leu Gly Asp Phe Asn Pro Ser Glu Ser Asp Val Val Ser  
 290 295 300  
 Glu Leu Gly Lys Val Glu Thr Val Thr Ile Arg Arg Leu His Ile Pro  
 305 310 315 320  
 Gln Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Val Tyr Ser Leu Leu Glu  
 325 330 335  
 Lys Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro  
 340 345 350  
 Cys Ser Phe Ser Gln His Leu Lys Ser Leu Glu Phe Leu Asp Leu Ser  
 355 360 365  
 Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Lys Gly  
 370 375 380  
 Ala Trp Pro Ser Leu Gln Thr Leu Val Leu Ser Gln Asn His Leu Arg  
 385 390 395 400  
 Ser Met Gln Lys Thr Gly Glu Ile Leu Leu Thr Leu Lys Asn Leu Thr  
 405 410 415  
 Ser Leu Asp Ile Ser Arg Asn Thr Phe His Pro Met Pro Asp Ser Cys  
 420 425 430  
 Gln Trp Pro Glu Lys Met Arg Phe Leu Asn Leu Ser Ser Thr Gly Ile  
 435 440 445  
 Arg Val Val Lys Thr Cys Ile Pro Gln Thr Leu Glu Val Leu Asp Val  
 450 455 460  
 Ser Asn Asn Asn Leu Asp Ser Phe Ser Leu Phe Leu Pro Arg Leu Gln

```

465          470          475          480
Glu Leu Tyr Ile Ser Arg Asn Lys Leu Lys Thr Leu Pro Asp Ala Ser
          485          490          495

Leu Phe Pro Val Leu Leu Val Met Lys Ile Arg Glu Asn Ala Val Ser
          500          505          510

Thr Phe Ser Lys Asp Gln Leu Gly Ser Phe Pro Lys Leu Glu Thr Leu
          515          520          525

Glu Ala Gly Asp Asn His Phe Val Cys Ser Cys Glu Leu Leu Ser Phe
          530          535          540

Thr Met Glu Thr Pro Ala Leu Ala Gln Ile Leu Val Asp Trp Pro Asp
545          550          555          560

Ser Tyr Leu Cys Asp Ser Pro Pro Arg Leu His Gly His Arg Leu Gln
          565          570          575

Asp Ala Arg Pro Ser Val Leu Glu Cys His Gln Ala Ala Leu Val Ser
          580          585          590

Gly Val Cys Cys Ala Leu Leu Leu Leu Ile Leu Leu Val Gly Ala Leu
          595          600          605

Cys His His Phe His Gly Leu Trp Tyr Leu Arg Met Met Trp Ala Trp
610          615          620

Leu Gln Ala Lys Arg Lys Pro Lys Lys Ala Pro Cys Arg Asp Val Cys
625          630          635          640

Tyr Asp Ala Phe Val Ser Tyr Ser Glu Gln Asp Ser His Trp Val Glu
          645          650          655

Asn Leu Met Val Gln Gln Leu Glu Asn Ser Asp Pro Pro Phe Lys Leu
          660          665          670

Cys Leu His Lys Arg Asp Phe Val Pro Gly Lys Trp Ile Ile Asp Asn
675          680          685

Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser
690          695          700

Glu Asn Phe Val Arg Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser
705          710          715          720

His Phe Arg Leu Phe Asp Glu Asn Asn Asp Ala Ala Ile Leu Val Leu
          725          730          735

Leu Glu Pro Ile Glu Arg Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu
          740          745          750

Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Leu Asp Glu
          755          760          765

Gly Gln Gln Glu Val Phe Trp Val Asn Leu Arg Thr Ala Ile Lys Ser
770          775          780

```

&lt;210&gt; 7

&lt;211&gt; 3029

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

gcgggccgct cgacgaaatg tctggatttg gactaaagaa aaaaggaaaag gctagcagtc 60  
atccaacaga atcatgagac agactttgcc ttgtatctac ttttgggggg gccttttgcc 120  
ctttgggatg ctgtgtgcat cctccaccac caagtgcact gttagccatg aagttgctga 180  
ctgcagccac ctgaagttga ctcaggtacc cgatgatcta cccacaaaca taacagtgtt 240  
gaaccttacc cataatcaac tcagaagatt accagccgcc aacttcacaa ggtatagcca 300  
gctaactagc ttggatgtag gatttaacac catctcaaaa ctggagccag aattgtgcca 360  
gaaacttccc atgttaaaag ttttgaacct ccagcacaat gagctatctc aactttctga 420  
taaaaccttt gccttctgca cgaatttgac tgaactccat ctcagtcca actcaatcca 480  
gaaaattaaa aataatccct ttgtcaagca gaagaattta atcacattag atctgtctca 540  
taatggcttg tcatctacaa aattaggaac tcaggttcag ctggaaaatc tccaagagct 600  
tctattatca aacaataaaa ttcaagcgt aaaaagtga gaactggata tctttgccaa 660  
ttcatcttta aaaaaattag agttgtcatc gaatcaaatt aaagagtttt ctccaggtg 720  
ttttcacgca attggaagat ttttggcct ctttctgaac aatgtccagc tgggtcccag 780  
ccttacagag aagctatgtt tggaattagc aaacacaagc attcggaatc tgtctctgag 840  
taacagccag ctgtccacca ccagcaatac aactttcttg ggactaaagt ggacaaatct 900  
cactatgctc gatctttcct acaacaactt aaatgtggtt ggtaacgatt cctttgcttg 960  
gcttcacaa ctagaatatt tcttcctaga gtataataat atacagcatt tgttttctca 1020  
ctctttgcac gggcttttca atgtgaggta cctgaatttg aaacggctct ttactaaaca 1080  
aagtatttcc cttgcctcac tccccagat tgatgatttt tcttttcagt ggctaaaatg 1140  
tttgagcac cttaacatgg aagataatga tattccaggc ataaaaagca atatgttcac 1200  
aggattgata aacctgaaat acttaagtct atccaactcc tttacaagtt tgcgaaacttt 1260  
gacaaatgaa acatttgtat cacttgctca ttctccctta cacatactca acctaacca 1320  
gaataaaatc taaaaaatag agagtgatgc tttctcttgg ttggggccacc tagaagtact 1380  
tgacctgggc cttaatgaaa ttgggcaaga actcacaggc caggaatgga gaggtctaga 1440  
aaatattttc gaaatctatc tttcctacaa caagtacctg cagctgacta ggaactcctt 1500  
tgccttggtc ccaagccttc aacgactgat gctccgaagg gtggccctta aaaatgtgga 1560  
tagctctcct tcaccattcc agcctcttcg taacttgacc attctggatc taagcaacaa 1620  
caacatagcc aacataaatg atgacatgtt ggagggctct gagaaactag aaattctcga 1680  
tttgacgat aacaacttag cacggctctg gaaacacgca aaccctggtg gtcccattta 1740  
tttcctaaag ggtctgtctc acctccacat ccttaacttg gagtccaacg gctttgacga 1800

gatccagtt gaggtcttca aggatttatt tgaactaaag atcatcgatt taggattgaa 1860  
taattttaaac acacttccag catctgtctt taataatcag gtgtctctaa agtcattgaa 1920  
  
ccttcagaag aatctcataa catccgttga gaagaagggtt ttcgggccag ctttcaggaa 1980  
cctgactgag ttagatatgc gctttaatcc ctttgattgc acgtgtgaaa gtattgcctg 2040  
gtttgttaat tggattaacg agaccatac caacatccct gagctgtcaa gccactacct 2100  
ttgcaacact ccacctcact atcatggggtt cccagtgaga ctttttgata catcatcttg 2160  
caaagacagt gccccctttg aactcttttt catgatcaat accagtatcc tgttgatttt 2220  
tatcttttatt gtactttctca tccactttga gggctggagg atatcttttt attggaatgt 2280  
ttcagtagat cgagttcttg gtttcaaaga aatagacaga cagacagaac agtttgaata 2340  
tgcagcatat ataattcatg cctataaaga taaggattgg gtctgggaac atttctcttc 2400  
aatggaaaag gaagaccaat ctctcaaatt ttgtctggaa gaaagggact ttgaggcggg 2460  
tgtttttgaa ctagaagcaa ttgttaacag catcaaaaga agcagaaaaa ttatttttgt 2520  
tataacacac catctattaa aagaccatt atgcaaaaga ttcaaggtag atcatgcagt 2580  
tcaacaagct attgaacaaa atctggattc cattatattg gttttccttg aggagattcc 2640  
agattataaa ctgaaccatg cactctgttt gcgaagagga atgtttaaat ctactgcat 2700  
cttgaactgg ccagttcaga aagaacggat aggtgccttt cgtcataaat tgcaagtagc 2760  
acttgatcc aaaaactctg tacattaaat ttatttaaatt attcaattag caaaggagaa 2820  
actttctcaa tttaaaaagt tctatggcaa atttaagttt tccataaagg tgttataatt 2880  
tgtttattca tatttgtaaa tgattatatt ctatcacaat tacatctctt ctaggaaaaa 2940  
gtgtctcctt atttcaggcc tatttttgac aattgactta attttaccoc aaataaaaca 3000  
tataagcacg caaaaaaaaa aaaaaaaaaa 3029

<210> 8  
<211> 904  
<212> PRT  
<213> Homo sapiens

<400> 8

Met Arg Gln Thr Leu Pro Cys Ile Tyr Phe Trp Gly Gly Leu Leu Pro  
1 5 10 15  
Phe Gly Met Leu Cys Ala Ser Ser Thr Thr Lys Cys Thr Val Ser His  
20 25 30  
Glu Val Ala Asp Cys Ser His Leu Lys Leu Thr Gln Val Pro Asp Asp  
35 40 45  
Leu Pro Thr Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu Arg  
50 55 60  
Arg Leu Pro Ala Ala Asn Phe Thr Arg Tyr Ser Gln Leu Thr Ser Leu

12/231

405 410 415  
 Asn Lys Ile Ser Lys Ile Glu Ser Asp Ala Phe Ser Trp Leu Gly His  
 420 425 430  
 Leu Glu Val Leu Asp Leu Gly Leu Asn Glu Ile Gly Gln Glu Leu Thr  
 435 440 445  
 Gly Gln Glu Trp Arg Gly Leu Glu Asn Ile Phe Glu Ile Tyr Leu Ser  
 450 455 460  
 Tyr Asn Lys Tyr Leu Gln Leu Thr Arg Asn Ser Phe Ala Leu Val Pro  
 465 470 475 480  
 Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val Asp  
 485 490 495  
 Ser Ser Pro Ser Pro Phe Gln Pro Leu Arg Asn Leu Thr Ile Leu Asp  
 500 505 510  
 Leu Ser Asn Asn Asn Ile Ala Asn Ile Asn Asp Asp Met Leu Glu Gly  
 515 520 525  
 Leu Glu Lys Leu Glu Ile Leu Asp Leu Gln His Asn Asn Leu Ala Arg  
 530 535 540  
 Leu Trp Lys His Ala Asn Pro Gly Gly Pro Ile Tyr Phe Leu Lys Gly  
 545 550 555 560  
 Leu Ser His Leu His Ile Leu Asn Leu Glu Ser Asn Gly Phe Asp Glu  
 565 570 575  
 Ile Pro Val Glu Val Phe Lys Asp Leu Phe Glu Leu Lys Ile Ile Asp  
 580 585 590  
 Leu Gly Leu Asn Asn Leu Asn Thr Leu Pro Ala Ser Val Phe Asn Asn  
 595 600 605  
 Gln Val Ser Leu Lys Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr Ser  
 610 615 620  
 Val Glu Lys Lys Val Phe Gly Pro Ala Phe Arg Asn Leu Thr Glu Leu  
 625 630 635 640  
 Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ala Trp  
 645 650 655  
 Phe Val Asn Trp Ile Asn Glu Thr His Thr Asn Ile Pro Glu Leu Ser  
 660 665 670  
 Ser His Tyr Leu Cys Asn Thr Pro Pro His Tyr His Gly Phe Pro Val  
 675 680 685  
 Arg Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu Leu  
 690 695 700  
 Phe Phe Met Ile Asn Thr Ser Ile Leu Leu Ile Phe Ile Phe Ile Val  
 705 710 715 720  
 Leu Leu Ile His Phe Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn Val  
 725 730 735  
 Ser Val His Arg Val Leu Gly Phe Lys Glu Ile Asp Arg Gln Thr Glu

740 745 750  
 Gln Phe Glu Tyr Ala Ala Tyr Ile Ile His Ala Tyr Lys Asp Lys Asp  
 755 760 765  
 Trp Val Trp Glu His Phe Ser Ser Met Glu Lys Glu Asp Gln Ser Leu  
 770 775 780  
 Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Phe Glu Leu  
 785 790 795 800  
 Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe Val  
 805 810 815  
 Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Lys Arg Phe Lys Val  
 820 825 830  
 His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile Ile  
 835 840 845  
 Leu Val Phe Leu Glu Glu Ile Pro Asp Tyr Lys Leu Asn His Ala Leu  
 850 855 860  
 Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp Pro  
 865 870 875 880  
 Val Gln Lys Glu Arg Ile Gly Ala Phe Arg His Lys Leu Gln Val Ala  
 885 890 895  
 Leu Gly Ser Lys Asn Ser Val His  
 900

<210> 9  
 <211> 3310  
 <212> DNA  
 <213> murine

<400> 9  
 tagaatatga tacagggatt gcaccataa tctgggctga atcatgaaag ggtgttcctc 60  
 ttatctaattg tactcctttg ggggactttt gtccctatgg attcttcttg tgtcttccac 120  
 aaaccaatgc actgtgagat acaacgtagc tgactgcagc catttgaagc taacacacat 180  
 acctgatgat cttccctcta acataacagt gttgaatctt actcacaacc aactcagaag 240  
 attaccacct accaacttta caagatacag ccaacttgct atcttgatg caggatttaa 300  
 ctccatttca aaactggagc cagaactgtg ccaaatactc cctttgttga aagtattgaa 360  
 cctgcaacat aatgagctct ctcagatttc tgatcaaacc tttgtcttct gcacgaacct 420  
 gacagaactc gatctaattg ctaactcaat acacaaaatt aaaagcaacc ctttcaaaaa 480  
 ccagaagaat ctaatcaaat tagatttgct tcataatggg ttatcatcta caaagtggg 540  
 aacgggggtc caactggaga acctccaaga actgctctta gcaaaaaata aaatccttgc 600  
 gttgcgaagt gaagaacttg agtttcttgg caattcttct ttacgaaagt tggacttgct 660  
 atcaaatcca cttaaagagt tctccccggg gtgtttccag acaattggca agttattcgc 720

cctcctcttg aacaacgccc aactgaaccc ccacctcaca gagaagcttt gctgggaact	780
ttcaaacaca agcatccaga atctctctct ggctaacaac cagctgctgg ccaccagcga	840
gagcactttc tctgggctga agtggacaaa tctcaccag ctcgatcttt cctacaacaa	900
cctccatgat gtcggcaacg gttccttctc ctatctccca agcctgaggt atctgtctct	960
ggagtacaac aatatacagc gtctgtcccc tcgctctttt tatggactct ccaacctgag	1020
gtacctgagt ttgaagcgag catttactaa gcaaagtgtt tcacttgctt cacatcccaa	1080
cattgacgat ttttcccttc aatgggtaaa atatttgga tatctcaaca tggatgacaa	1140
taatattcca agtaccaaaa gcaatacctt cacgggattg gtgagtctga agtacctaag	1200
tctttccaaa actttcacaa gtttgcaaac tttaacaaat gaaacatttg tgtcacttgc	1260
tcattctccc ttgctcactc tcaacttaac gaaaaatcac atctcaaaaa tagcaaatgg	1320
tactttctct tggtagggc aactcaggat acttgatctc ggccttaatg aaattgaaca	1380
aaaactcagc ggccaggaat ggagaggtct gagaaatata tttagatct acctatccta	1440
taacaaatac ctccaactgt ctaccagttc ctttgcatctg gtccccagcc ttcaaagact	1500
gatgctcagg agggtagggc ttaaaaatgt ggatatctcc ccttcacctt tccgccctct	1560
tcgtaacttg accattctgg acttaagcaa caacaacata gccaacataa atgaggactt	1620
gctggagggt cttgagaatc tagaaatcct ggattttcag cacaataact tagccaggct	1680
ctggaaacgc gcaaaccccg gtggtcccg taatttctctg aaggggctgt ctcacctcca	1740
catcttgaat ttagagtcca acggcttaga tgaaatccca gtcgggggtt tcaagaactt	1800
attcgaacta aagagcatca atctaggact gaataactta aacaaacttg aaccattcat	1860
ttttgatgac cagacatctc taaggctact gaacctccag aagaacctca taacatctgt	1920
tgagaaggat gttttcgggc cgccttttca aaacctgaac agtttagata tgcgcttcaa	1980
tccgttcgac tgcacgtgtg aaagtatttc ctggtttggt aactggatca accagacca	2040
cactaatatc tttgagctgt ccactcacta cctctgtaac actccacatc attattatgg	2100
cttccccctg aagcttttctg atacatcatc ctgtaaagac agcgccccct ttgaactcct	2160
cttcataatc agcaccagta tgctcctggg ttttatactt gtggtactgc tcattcacat	2220
cgagggctgg aggatctctt tttactggaa tgtttcagtg catcggaatc ttggtttcaa	2280
ggaaatagac acacaggctg agcagtttga atatacagcc tacataatc atgcccataa	2340
agacagagac tgggtctggg aacatttctc cccaatggaa gaacaagacc aatctctcaa	2400
attttgccta gaagaaaggg actttgaagc aggcgtcctt ggacttgaag caattgttaa	2460
tagcatcaaa agaagccgaa aaatcatttt cgttatcaca caccatttat taaaagacct	2520
tctgtgcaga agattcaagg tacatcacgc agttcagcaa gctattgagc aaaatctgga	2580
ttcaattata ctgatttttc tccagaatat tccagattat aaactaaacc atgcactctg	2640



```

tttgcgaaga ggaatgttta aatctcattg catcttgaac tggccagttc agaaagaacg 2700
gataaatgcc tttcatcata aattgcaagt agcacttgga tctcggaatt cagcacatta 2760
aactcatttg aagatttgga gtcggtaaag ggatagatcc aatttataaa ggtccatcat 2820
gaatctaagt tttacttgaa agttttgtat atttatttat atgtatagat gatgatatta 2880
catcacaatc caatctcagt tttgaaatat ttcggcttat ttcattgaca tctggtttat 2940
tcactccaaa taaacacatg ggcagttaaa aacatcctct attaatagat taccatttaa 3000
ttcttgaggt gtatcacagc tttaaagggg tttaaatatt tttatataaa taagactgag 3060
agttttataa atgtaatttt ttaaaactcg agtcttactg tgtagctcag aaaggcctgg 3120
aaattaatat attagagagt catgtcttga acttatttat ctctgcctcc ctctgtctcc 3180
agagtgttgc ttttaagggc atgtagcacc acaccagct atgtacgtgt gggattttat 3240
aatgctcatt tttgagacgt ttatagaata aaagataatt gcttttatgg tataaggcta 3300
cttgaggtaa 3310

```

<210> 10  
 <211> 905  
 <212> PRT  
 <213> murine

<400> 10

```

Met Lys Gly Cys Ser Ser Tyr Leu Met Tyr Ser Phe Gly Gly Leu Leu
1          5          10          15

Ser Leu Trp Ile Leu Leu Val Ser Ser Thr Asn Gln Cys Thr Val Arg
20          25          30

Tyr Asn Val Ala Asp Cys Ser His Leu Lys Leu Thr His Ile Pro Asp
35          40          45

Asp Leu Pro Ser Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu
50          55          60

Arg Arg Leu Pro Pro Thr Asn Phe Thr Arg Tyr Ser Gln Leu Ala Ile
65          70          75          80

Leu Asp Ala Gly Phe Asn Ser Ile Ser Lys Leu Glu Pro Glu Leu Cys
85          90          95

Gln Ile Leu Pro Leu Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu
100         105         110

Ser Gln Ile Ser Asp Gln Thr Phe Val Phe Cys Thr Asn Leu Thr Glu
115         120         125

Leu Asp Leu Met Ser Asn Ser Ile His Lys Ile Lys Ser Asn Pro Phe
130         135         140

Lys Asn Gln Lys Asn Leu Ile Lys Leu Asp Leu Ser His Asn Gly Leu
145         150         155         160

```

Ser Ser Thr Lys Leu Gly Thr Gly Val Gln Leu Glu Asn Leu Gln Glu  
 165 170 175  
 Leu Leu Leu Ala Lys Asn Lys Ile Leu Ala Leu Arg Ser Glu Glu Leu  
 180 185 190  
 Glu Phe Leu Gly Asn Ser Ser Leu Arg Lys Leu Asp Leu Ser Ser Asn  
 195 200 205  
 Pro Leu Lys Glu Phe Ser Pro Gly Cys Phe Gln Thr Ile Gly Lys Leu  
 210 215 220  
 Phe Ala Leu Leu Leu Asn Asn Ala Gln Leu Asn Pro His Leu Thr Glu  
 225 230 235 240  
 Lys Leu Cys Trp Glu Leu Ser Asn Thr Ser Ile Gln Asn Leu Ser Leu  
 245 250 255  
 Ala Asn Asn Gln Leu Leu Ala Thr Ser Glu Ser Thr Phe Ser Gly Leu  
 260 265 270  
 Lys Trp Thr Asn Leu Thr Gln Leu Asp Leu Ser Tyr Asn Asn Leu His  
 275 280 285  
 Asp Val Gly Asn Gly Ser Phe Ser Tyr Leu Pro Ser Leu Arg Tyr Leu  
 290 295 300  
 Ser Leu Glu Tyr Asn Asn Ile Gln Arg Leu Ser Pro Arg Ser Phe Tyr  
 305 310 315 320  
 Gly Leu Ser Asn Leu Arg Tyr Leu Ser Leu Lys Arg Ala Phe Thr Lys  
 325 330 335  
 Gln Ser Val Ser Leu Ala Ser His Pro Asn Ile Asp Asp Phe Ser Phe  
 340 345 350  
 Gln Trp Leu Lys Tyr Leu Glu Tyr Leu Asn Met Asp Asp Asn Asn Ile  
 355 360 365  
 Pro Ser Thr Lys Ser Asn Thr Phe Thr Gly Leu Val Ser Leu Lys Tyr  
 370 375 380  
 Leu Ser Leu Ser Lys Thr Phe Thr Ser Leu Gln Thr Leu Thr Asn Glu  
 385 390 395 400  
 Thr Phe Val Ser Leu Ala His Ser Pro Leu Leu Thr Leu Asn Leu Thr  
 405 410 415  
 Lys Asn His Ile Ser Lys Ile Ala Asn Gly Thr Phe Ser Trp Leu Gly  
 420 425 430  
 Gln Leu Arg Ile Leu Asp Leu Gly Leu Asn Glu Ile Glu Gln Lys Leu  
 435 440 445  
 Ser Gly Gln Glu Trp Arg Gly Leu Arg Asn Ile Phe Glu Ile Tyr Leu  
 450 455 460  
 Ser Tyr Asn Lys Tyr Leu Gln Leu Ser Thr Ser Ser Phe Ala Leu Val  
 465 470 475 480  
 Pro Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val

Asp	Ile	Ser	Pro	485	Pro	Phe	Arg	Pro	490	Leu	Arg	Asn	Leu	Thr	495	Ile	Leu
			500					505						510			
Asp	Leu	Ser	Asn	Asn	Asn	Ile	Ala	Asn	Ile	Asn	Glu	Asp	Leu	Leu	Glu		
		515					520					525					
Gly	Leu	Glu	Asn	Leu	Glu	Ile	Leu	Asp	Phe	Gln	His	Asn	Asn	Leu	Ala		
		530				535					540						
Arg	Leu	Trp	Lys	Arg	Ala	Asn	Pro	Gly	Gly	Pro	Val	Asn	Phe	Leu	Lys		
545					550					555					560		
Gly	Leu	Ser	His	Leu	His	Ile	Leu	Asn	Leu	Glu	Ser	Asn	Gly	Leu	Asp		
			565					570						575			
Glu	Ile	Pro	Val	Gly	Val	Phe	Lys	Asn	Leu	Phe	Glu	Leu	Lys	Ser	Ile		
		580						585						590			
Asn	Leu	Gly	Leu	Asn	Asn	Leu	Asn	Lys	Leu	Glu	Pro	Phe	Ile	Phe	Asp		
		595					600					605					
Asp	Gln	Thr	Ser	Leu	Arg	Ser	Leu	Asn	Leu	Gln	Lys	Asn	Leu	Ile	Thr		
	610					615					620						
Ser	Val	Glu	Lys	Asp	Val	Phe	Gly	Pro	Pro	Phe	Gln	Asn	Leu	Asn	Ser		
625					630					635					640		
Leu	Asp	Met	Arg	Phe	Asn	Pro	Phe	Asp	Cys	Thr	Cys	Glu	Ser	Ile	Ser		
			645						650					655			
Trp	Phe	Val	Asn	Trp	Ile	Asn	Gln	Thr	His	Thr	Asn	Ile	Phe	Glu	Leu		
		660					665						670				
Ser	Thr	His	Tyr	Leu	Cys	Asn	Thr	Pro	His	His	Tyr	Tyr	Gly	Phe	Pro		
		675					680					685					
Leu	Lys	Leu	Phe	Asp	Thr	Ser	Ser	Cys	Lys	Asp	Ser	Ala	Pro	Phe	Glu		
	690					695					700						
Leu	Leu	Phe	Ile	Ile	Ser	Thr	Ser	Met	Leu	Leu	Val	Phe	Ile	Leu	Val		
705					710					715					720		
Val	Leu	Leu	Ile	His	Ile	Glu	Gly	Trp	Arg	Ile	Ser	Phe	Tyr	Trp	Asn		
			725					730						735			
Val	Ser	Val	His	Arg	Ile	Leu	Gly	Phe	Lys	Glu	Ile	Asp	Thr	Gln	Ala		
		740						745						750			
Glu	Gln	Phe	Glu	Tyr	Thr	Ala	Tyr	Ile	Ile	His	Ala	His	Lys	Asp	Arg		
		755					760					765					
Asp	Trp	Val	Trp	Glu	His	Phe	Ser	Pro	Met	Glu	Glu	Gln	Asp	Gln	Ser		
	770					775						780					
Leu	Lys	Phe	Cys	Leu	Glu	Glu	Arg	Asp	Phe	Glu	Ala	Gly	Val	Leu	Gly		
785					790					795					800		
Leu	Glu	Ala	Ile	Val	Asn	Ser	Ile	Lys	Arg	Ser	Arg	Lys	Ile	Ile	Phe		
			805					810						815			
Val	Ile	Thr	His	His	Leu	Leu	Lys	Asp	Pro	Leu	Cys	Arg	Arg	Phe	Lys		

<400>	11
acaggggccac tgctgctcac agaagcagtg aggatgatgc caggatgatg tctgcctcgc	60
gcctggcttg gactctgata ccagccatgg ccttcctctc ctgcgtgaga ccagaaagct	120
gggagccctg cgtggagact tggccctaaa ccacacagaa gagctggcat gaaaccacga	180
gctttcagac tcgggagcct cagcccttca ccccattcc attgcttctt gctaatgct	240
gccgttttat cacggaggcg gtaccttaata ttacttatca atgcattggag ctgaatttgt	300
aaaaaacccc cgacaacctc cctttctcaa ccaagaacct ggacctgagc tttaatcccc	360
ttaggcattt aggcagctat agcttcttca gtttccaga actgcaggcg ctggatttat	420
ccagggtgta aatccagaca attgaagatg gggcataatca gagcctaagc cacctctcta	480
ccttaatat gacaggaaac cccatccaga gtttagccct gggagccttt tctggactat	540
caagtttac gaagctggcg gctgtggaga caaatctagc atctctagag aacttcccc	600
ttggacatct caaaactttg aaagaactta atgtggctca caatcttatc caatctttca	660
aattacctga gtatttttgt aatctgacca atctagagca cttggacctt tccagcaaca	720
agattcaaag tattttattg acagacttgc gggttctaca tcaaatgcc ctactcaatc	780
tctcttta ga cctgtccctg aaccctatga actttatcca accaggcgca tttaaagaaa	840
ttaggcttca taagctgact ttaagaaata attttgatag tttaaatgta atgaaaactt	900
gtattcaagg tctggctggg ttagaagtcc atcgtttggg tctgggagaa tttagaagt	960
aaggaaaactt ggaaaagtgt gacaaatctg ctctagaggg cctgtgcaat ttgaccattg	1020
agaattccg attagcatat ttagactact acctcgatga tattattgac ttatttaat	1080
gtttgacaaa tgtttcttca ttttccctgg tgagtgtgac tattgaaagg gtaaaagact	1140
tttcttataa tttcggatgg caacatttag aattagttaa ctgtaaaattt ggacagtttc	1200

ccacattgaa actcaaactct ctcaaaaggc ttactttcac ttccaacaaa ggtgggaatg 1260  
 ctttttcaga agttgatcta ccaagccttg agttttctaga tctcagtaga aatggcttga 1320  
 gtttcaaagg ttgctgttct caaagtgatt ttgggacaac cagcctaaag tatttagatc 1380  
 tgagcttcaa tgggtgttatt accatgagtt caaacttctt gggcttagaa caactagaac 1440  
 atctggattt ccagcattcc aatttgaaac aaatgagtga gttttcagta ttcctatcac 1500  
 tcagaaacct catttacctt gacatttctc atactcacac cagagttgct ttcaatggca 1560  
 tcttcaatgg cttgtccagt ctcgaagtct tgaaaatggc tggcaattct ttccaggaaa 1620  
 acttccttcc agatatcttc acagagctga gaaacttgac cttcctggac ctctctcagt 1680  
 gtcaactgga gcagttgtct ccaacagcat ttaactcact ctccagtctt caggtagtaa 1740  
 atatgagcca caacaacttc ttttcattgg atacgtttcc ttataagtgt ctgaactccc 1800  
 tccaggttct tgattacagt ctcaatcaca taatgacttc caaaaaacag gaactacagc 1860  
 attttccaag tagtctagct ttcttaaate ttactcagaa tgactttgct tgtacttggtg 1920  
 aacaccagag tttcctgcaa tggatcaagg accagaggca gctcttggtg gaagttgaac 1980  
 gaatggaatg tgcaacacct tcagataagc agggcatgcc tgtgctgagt ttgaatatca 2040  
 cctgtcagat gaataagacc atcattgggtg tgtcgggtcct cagtgtgctt gtagtatctg 2100  
 ttgtagcagt tctgggtctat aagttctatt ttcacctgat gcttcttgct ggctgcataa 2160  
 agtatggtag aggtgaaaac atctatgatg cctttgttat ctactcaagc caggatgagg 2220  
 actgggtaag gaatgagcta gtaaagaatt tagaagaagg ggtgcctcca tttcagctct 2280  
 gccttcacta cagagacttt attcccgggtg tggccattgc tgccaacatc atccatgaag 2340  
 gtttccataa aagccgaaag gtgattgttg tgggtgtcca gcacttcac cagagccgct 2400  
 ggtgtatctt tgaatatgag attgctcaga cctggcagtt tctgagcagt cgtgctggta 2460  
 tcatcttcat tgtcctgcag aaggtggaga agaccctgct caggcagcag gtggagctgt 2520  
 accgccttct cagcaggaac acttacctgg agtgggagga cagtgtcctg gggcggcaca 2580  
 tcttctggag acgactcaga aaagccctgc tggatggtaa atcatggaat ccagaaggaa 2640  
 cagtgggtac aggatgcaat tggcaggaag caacatctat ctgaagagga aaaataaaaa 2700  
 cctcctgagg catttcttgc ccagctgggt ccaacacttg ttcagttaat aagtattaaa 2760  
 tgctgccaca tgtcaggcct tatgctaagg gtgagtaatt ccatggtgca ctagatatgc 2820  
 agggctgcta atctcaagga gcttccagtg cagagggaat aaatgctaga ctaaaataca 2880  
 gagtcttcca ggtgggcatt tcaaccaact cagtcaagga acccatgaca aagaaagtca 2940  
 tttcaactct tacctcatca agttgaataa agacagagaa aacagaaaga gacattgttc 3000  
 ttttcctgag tcttttgaat ggaaattgta ttatgttata gccatcataa aaccattttg 3060

gtagttttga ctgaactggg tgttcacttt ttcctttttg attgaataca atttaaattc 3120  
 tacttgatga ctgcagtcgt caaggggctc ctgatgcaag atgccccttc cattttaagt 3180  
 ctgtctcctt acagagggtta aagtctaattg gctaattcct aaggaaacct gattaacaca 3240  
 tgctcacaac catcctgggc attctcgaac atgttctatt ttttaactaa tcaccctga 3300  
 tatattttta tttttatata tccagttttc atttttttac gtcttgcta taagctaata 3360  
 tcataaataa ggttggttaa gacgtgcttc aaatatccat attaaccact atttttcaag 3420  
 gaagtatgga aaagtacact ctgtcacttt gtcactcgat gtcattccaa agttattgcc 3480  
 tactaagtaa tgactgtcat gaaagcagca ttgaaataat ttgtttaaag ggggcactct 3540  
 tttaaacggg aagaaaattt ccgcttcctg gtcttatcat ggacaatttg ggctataggc 3600  
 atgaaggaag tgggattacc tcaggaagtc accttttctt gattccagaa acatatgggc 3660  
 tgataaaccg ggggtgacct catgaaatga gttgcagcag atgtttattt ttttcagaac 3720  
 aagtgatgtt tgatggacct atgaatctat ttagggagac acagatggct gggatccctc 3780  
 ccctgtacc tttcactga caggagaact a 3811

<210> 12  
 <211> 2845  
 <212> DNA  
 <213> Homo sapiens

<400> 12  
 cctctcacc tttagcccag aactgctttg aatacaccaa ttgctgtggg gcggtcgag 60  
 gaagagaaga caccagtgc tcagaaactg ctcggtcaga cggatagc gagccacgca 120  
 ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
 cgcgcctggc tgggactctg atcccagcca tggccttcct ctctgcgtg agaccagaaa 240  
 gctgggagcc ctgcgtggag gtgtgaaatc cagacaattg aagatggggc atatcagagc 300  
 ctaagccacc tctctacctt aatattgaca ggaaacccca tccagagttt agccctggga 360  
 gccttttctg gactatcaag tttacagaag ctggtggctg tggagacaaa tctagcatct 420  
 ctagagaact tccccattgg acatctcaaa actttgaaag aacttaattg ggctcacaat 480  
 cttatccaat ctttcaaatt acctgagtat ttttctaac tgaccaatct agagcacttg 540  
 gacctttcca gcaacaagat tcaaagtatt tattgcacag acttgcggtg tctacatcaa 600  
 atgcccctac tcaatctctc tttagacctg tccctgaacc ctatgaactt tatccaacca 660  
 ggtgcattta aagaaattag gttcataag ctgactttta gaaataattt tgatagttaa 720  
 aatgtaatga aaacttgat tcaaggctct gctgggttag aagtccatcg tttgggtctg 780  
 ggagaattta gaaatgaagg aaacttgga aagtttgaca aatctgctct agagggcctg 840

tgcaatttga ccattgaaga attccgatta gcatacttag actactacct cgatgatatt	900
attgacttat ttaattgttt gacaaatgtt tcttcatttt ccttggtgag tgtgactatt	960
gaaagggtaa aagacttttc ttataatttc ggatggcaac atttagaatt agttaactgt	1020
aaatttggac agtttccac attgaaactc aaatctctca aaaggcttac tttcacttcc	1080
aacaaagggtg ggaatgcttt ttcagaagtt gatctacca gccttgagtt tctagatctc	1140
agtagaaatg gcttgagttt caaagggtgc tgttctcaaa gtgattttgg gacaaccagc	1200
ctaaagtatt tagatctgag cttcaatggt gttattacca tgagttcaaa cttcttgggc	1260
ttagaacaac tagaacatct ggatttccag cattccaatt tgaaacaaat gagtgagttt	1320
tcagtattcc tatcactcag aaacctcatt taccttgaca tttctcatac tcacaccaga	1380
gttgctttca atggcatctt caatggcttg tccagtctcg aagtcttgaa aatggctggc	1440
aattctttcc aggaaaactt ccttcagat atcttcacag agctgagaaa cttgaccttc	1500
ctggacctct ctcagtgtca actggagcag ttgtctccaa cagcatttaa ctcactctcc	1560
agtcttcagg tactaaatat gagccacaac aacttctttt cattggatac gtttccttat	1620
aagtgtctga actccctcca ggttcttgat tacagtctca atcacataat gacttccaaa	1680
aaacaggaac tacagcattt tccaagtagt ctagctttct taaatcttac tcagaatgac	1740
tttgcttgta cttgtgaaca ccagagtttc ctgcaatgga tcaaggacca gaggcagctc	1800
ttggtggaag ttgaacgaat ggaatgtgca acaccttcag ataagcaggg catgcctgtg	1860
ctgagtttga atatcacctg tcagatgaat aagaccatca ttggtgtgtc ggtcctcagt	1920
gtgctttag tagtctgtgt agcagttctg gtctataagt tctattttca cctgatgctt	1980
cttgctggct gcataaagta tggtagaggt gaaaacatct atgatgcctt tgttatctac	2040
tcaagccagg atgaggactg ggtaaggaat gagctagtaa agaatttaga agaaggggtg	2100
cctccatttc agctctgcct tcactacaga gactttattc ccggtgtggc cattgctgcc	2160
aacatcatcc atgaaggttt ccataaaagc cgaaagggtga ttgttgtggt gtcccagcac	2220
ttcatccaga gccgctgggt tatctttgaa tatgagattg ctcagacctg gcagtttctg	2280
agcagtcgtg ctggtatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg	2340
cagcaggtgg agctgtaccg ctttctcagc aggaacactt acctggagtg ggaggacagt	2400
gtcctggggc ggcacatctt ctggagacga ctcagaaaag ccctgctgga tggtaaatca	2460
tggaatccag aaggaacagt gggtagagga tgcaattggc aggaagcaac atctatctga	2520
agaggaaaaa taaaaacctc ctgaggcatt tcttgcccag ctgggtccaa cacttggtca	2580
gttaataagt attaaatgct gccacatgtc aggccttatg ctaagggtga gtaattccat	2640
gggtgcactag atatgcaggg ctgctaactc caaggagctt ccagtgcaga gggaataaat	2700
gctagactaa aatacagagt cttccaggtg ggcatttcaa ccaactcagt caaggaaccc	2760

atgacaaaaga aagtcatttc aactcttacc tcatcaagtt gaataaagac agagaaaaca 2820  
gaaaaaaaaa aaaaaaaaaa aaaaa 2845

<210> 13  
<211> 3767  
<212> DNA  
<213> Homo sapiens

<400> 13  
cctctcaccc tttagcccag aactgctttg aatacaccaa ttgctgtggg gcggctcgag 60  
gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggatgtagc gagccacgca 120  
ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
cgcgcctggc tgggactctg atcccagcca tggccttcct ctctgcgtg agaccagaaa 240  
gctgggagcc ctgctgggag acttggccct aaaccacaca gaagagctgg catgaaaccc 300  
agagctttca gactccggag cctcagccct tcaccccgat tccattgctt cttgctaaat 360  
gctgccgttt tatcacggag gtgtgaaatc cagacaattg aagatggggc atatcagagc 420  
ctaagccacc tctctacctt aatattgaca ggaaacccca tccagagttt agccctggga 480  
gccttttctg gactatcaag tttacagaag ctgggtggctg tggagacaaa tctagcatct 540  
ctagagaact tccccattgg acatctcaaa actttgaaag aacttaatgt ggctcacaat 600  
cttatccaat ctttcaaatt acctgagtat ttttctaata tgaccaatct agagcacttg 660  
gacctttcca gcaacaagat tcaaagtatt tattgcacag acttgccggg tctacatcaa 720  
atgcccttac tcaatctctc tttagacctg tccctgaacc ctatgaactt tatccaacca 780  
ggatgcattha aagaaattag gcttcataag ctgactttaa gaaataattt tgatagttta 840  
aatgtaatga aaacttgtat tcaaggctctg gctgggttag aagtocatcg tttgggtctg 900  
ggagaattta gaaatgaagg aaacttgga aagtttgaca aatctgctct agagggcctg 960  
tgcaatttga ccattgaaga attccgatta gcatacttag actactacct cgatgatatt 1020  
attgacttat ttaattgttt gacaaatgtt tcttcatttt ccctgggtgag tgtgactatt 1080  
gaaagggtta aagacttttc ttataatttc ggatggcaac atttagaatt agttaactgt 1140  
aaatttggac agtttccac attgaaactc aaatctctca aaaggcttac tttcacttcc 1200  
aacaagggtg ggaatgcttt ttcagaagtt gatctaccaa gccttgagtt tctagatctc 1260  
agtagaaatg gcttgagttt caaagggtgc tgttctcaaa gtgattttgg gacaaccagc 1320  
ctaaagtatt tagatctgag cttcaatggt gttattacca tgagttcaaa cttcttgggc 1380  
ttagaacaac tagaacatct ggatttccag cattccaatt tgaaacaaat gagtgaagtt 1440  
tcagtattcc tatcactcag aaacctcatt taccttgaca tttctcatac tcacaccaga 1500



gttgctttca atggcatctt caatggcttg tccagtctcg aagtcttgaa aatggctggc	1560
aattctttcc agggaaactt ccttcagat atcttcacag agctgagaaa cttgaccttc	1620
ctggacctct ctcaagtgtca actggagcag ttgtctccaa cagcatttaa ctcactctcc	1680
agtcttcagg tactaaatat gagccacaac aacttctttt cattggatac gtttccttat	1740
aagtgtctga actccctcca ggttcttgat tacagtctca atcacataat gacttccaaa	1800
aaacaggaac tacagcattt tccaagtagt ctagctttct taaatcttac tcagaatgac	1860
tttgcttgta cttgtgaaca ccagagtttc ctgcaatgga tcaaggacca gaggcagctc	1920
ttggtggaag ttgaacgaat ggaatgtgca acaccttcag ataagcaggg catgcctgtg	1980
ctgagtttga atatcacctg tcagatgaat aagaccatca ttggtgtgtc ggtcctcagt	2040
gtgcttgtag tatctgttgt agcagttctg gtctataagt tctattttca cctgatgctt	2100
cttgctggct gcataaagta tggtagaggt gaaaacatct atgatgcctt tgttatctac	2160
tcaagccagg atgaggactg ggtaaggaat gagctagtaa agaatttaga agaaggggtg	2220
cctccatttc agctctgcct tctactacaga gactttatc ccggtgtggc cattgctgcc	2280
aacatcatcc atgaagggtt ccataaaagc cgaaagggtga ttggtgtggt gtcccagcac	2340
ttcatccaga gccgctggtg tatctttgaa tatgagattg ctcagacctg gcagtttctg	2400
agcagtcgtg ctggtatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg	2460
cagcaggttg agctgtaccg cttctcagc aggaacactt acctggagtg ggaggacagt	2520
gtcctggggc ggcacatctt ctggagacga ctcagaaaag ccctgctgga tggtaaataca	2580
tggaatccag aaggaacagt gggtagagga tgcaattggc aggaagcaac atctatctga	2640
agaggaaaaa taaaaacctc ctgaggcatt tcttgcccag ctgggtccaa cacttgttca	2700
gttaataagt attaaatgct gccacatgtc aggccttatg ctaagggtga gtaattccat	2760
ggtgcactag atatgcaggg ctgctaattc caaggagctt ccagtgcaga gggaataaat	2820
gctagactaa aatacagagt cttccaggtg ggcatttcaa ccaactcagt caaggaacct	2880
atgacaaaga aagtcatttc aactcttacc tcatcaagtt gaataaagac agagaaaaca	2940
gaaagagaca ttgttctttt cctgagtctt ttgaatggaa attgtattat gttatagcca	3000
tcataaaacc attttggtag ttttgactga actgggtgtt cactttttcc tttttgattg	3060
aatacaattt aaattctact tgatgactgc agtcgtcaag gggctcctga tgcaagatgc	3120
cccttcatt ttaagtctgt ctcttacag aggttaaagt ctagtggcta attcctaagg	3180
aaacctgatt aacacatgct cacaaccatc ctggtcattc tcgagcatgt tctatTTTTT	3240
aactaatcac ccctgatata tttttatttt tatatatcca gttttcattt ttttacgtct	3300
tgctataag ctaatatcat aaataagggt gttaagacg tgcttcaa atccatatta	3360
accactatTT ttcaaggaag tatggaaaag tacactctgt cactttgtca ctcgatgtca	3420

ttccaaagtt attgcctact aagtaatgac tgtcatgaaa gcagcattga aataatttgt 3480  
 ttaaaggggg cactctttta aacgggaaga aaatttccgc ttcctggtct tatcatggac 3540  
 aatttgggct agaggcagga aggaagtggg atgacctcag gaggtcacct tttcttgatt 3600  
 ccagaaacat atgggctgat aaacccgggg tgacctcatg aaatgagttg cagcagaagt 3660  
 ttatTTTTTTT cagaacaagt gatgtttgat ggacctctga atctcttttag ggagacacag 3720  
 atggctggga tccctcccct gtaccttct cactgccagg agaacta 3767

<210> 14

<211> 3814

<212> DNA

<213> Homo sapiens

<400> 14

cctctcacc ctttagccag aactgctttg aatacaccaa ttgctgtggg gcggctcgag 60  
 gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggatgtagc gagccacgca 120  
 ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
 cgcgcttggc tgggactctg atcccagcca tggccttctt ctctgctg agaccagaaa 240  
 gctgggagcc ctgctgggag gtggttctta atattactta tcaatgcatt gagctgaatt 300  
 tctacaaaat ccccgacaac ctccccttct caaccaagaa cctggacctg agctttaatc 360  
 ccctgaggca tttaggcagc tatagcttct tcagtttccc agaactgcag gtgctggatt 420  
 tatccagggt tgaaatccag acaattgaag atggggcata tcagagccta agccacctct 480  
 ctaccttaat attgacagga aaccccatcc agagttagc cctgggagcc tttctggac 540  
 tatcaagttt acagaagctg gtggctgtgg agacaaatct agcatctcta gagaacttcc 600  
 ccattggaca tctcaaaact ttgaaagaac ttaatgtggc tcacaatctt atccaatctt 660  
 tcaaattacc tgagtatttt tctaattctga ccaatctaga gcacttggac ctttccagca 720  
 acaagattca aagtatttat tgcacagact tgcgggttct acatcaaatg cccctactca 780  
 atctctcttt agacctgtcc ctgaacccta tgaactttat ccaaccagggt gcatttaaag 840  
 aaattaggct tcataagctg actttaagaa ataattttga tagtttaaag gtaatgaaaa 900  
 cttgtattca aggtctggct ggtttagaag tccatcgttt ggttctggga gaatttagaa 960  
 atgaaggaaa cttggaaaag tttgacaaat ctgctctaga gggcctgtgc aatttgacca 1020  
 ttgaagaatt ccgattagca tacttagact actacctga tgatattatt gacttattta 1080  
 attgtttgac aaatgtttct tcattttccc tggtagtgt gactattgaa agggtaaaag 1140  
 acttttctta taatttcgga tggcaacatt tagaattagt taactgtaaa tttggacagt 1200  
 ttccacatt gaaactcaaa tctctcaaaa ggcttacttt cacttccaac aaaggtggga 1260

atgcttttttc	agaagttgat	ctaccaagcc	ttgagtttct	agatctcagt	agaaatggct	1320
tgagtttcaa	aggttgctgt	tctcaaagt	attttgggac	aaccagccta	aagtatttag	1380
atctgagctt	caatgggtgtt	attaccatga	gttcaaactt	cttgggctta	gaacaactag	1440
aacatctgga	tttccagcat	tccaatttga	aacaaatgag	tgagttttca	gtattcctat	1500
cactcagaaa	cctcatttac	cttgacattt	ctcatactca	caccagagtt	gctttcaatg	1560
gcatcttcaa	tggcttgtcc	agtctcgaag	tcttgaaaat	ggctggcaat	tctttccagg	1620
aaaacttcct	tccagatata	ttcacagagc	tgagaaactt	gaccttcctg	gacctctctc	1680
agtgtcaact	ggagcagttg	tctccaacag	catttaactc	actctccagt	cttcaggtac	1740
taaatatgag	ccacaacaac	ttcttttcat	tggatacggt	tccttataag	tgtctgaact	1800
ccctccaggt	tcttgattac	agtctcaatc	acataatgac	ttccaaaaaa	caggaactac	1860
agcattttcc	aagtagtcta	gctttcttaa	atcttactca	gaatgacttt	gcttgtactt	1920
gtgaacacca	gagtttctctg	caatggatca	aggaccagag	gcagctcttg	gtggaagttg	1980
aacgaatgga	atgtgcaaca	ccttcagata	agcagggcat	gcctgtgctg	agtttgaata	2040
tcacctgtca	gatgaataag	accatcattg	gtgtgtcggt	cctcagtgtg	cttgtagtat	2100
ctgttgtagc	agttctggtc	tataagttct	attttcacct	gatgcttctt	gctggctgca	2160
taaagtatgg	tagaggtgaa	aacatctatg	atgcctttgt	tatctactca	agccaggatg	2220
aggactgggt	aaggaatgag	ctagtaaaga	atttagaaga	aggggtgcct	ccatttcagc	2280
tctgccttca	ctacagagac	tttattcccg	gtgtggccat	tgctgccaac	atcatccatg	2340
aaggtttcca	taaaagccga	aagggtgattg	ttgtgggtgc	ccagcacttc	atccagagcc	2400
gctgggtgat	ctttgaatat	gagattgctc	agacctggca	gtttctgagc	agtcgtgctg	2460
gtatcatctt	cattgtcctg	cagaagggtg	agaagaccct	gctcaggcag	caggtggagc	2520
tgtaccgcct	tctcagcagg	aacacttacc	tggagtggga	ggacagtgtc	ctggggcggc	2580
acatcttctg	gagacgactc	agaaaagccc	tgctggatgg	taaatcatgg	aatccagaag	2640
gaacagtggg	tacaggatgc	aattggcagg	aagcaacatc	tatctgaaga	ggaaaaataa	2700
aaacctcctg	aggcatttct	tgcccagctg	ggtccaacac	ttgttcagtt	aataagtatt	2760
aaatgctgcc	acatgtcagg	ccttatgcta	agggtgagta	attccatggg	gactagata	2820
tgcagggctg	ctaattctca	ggagcttcca	gtgcagaggg	aataaatgct	agactaaaat	2880
acagagtctt	ccaggtgggc	atttcaacca	actcagtcaa	ggaacccatg	acaaagaaag	2940
tcatattcaac	tcttacctca	tcaagttgaa	taaagacaga	gaaaacagaa	agagacattg	3000
ttcttttctt	gagtcttttg	aatggaaatt	gtattatggt	atagccatca	taaaaccatt	3060
ttggtagttt	tgactgaact	gggtgttcac	tttttctttt	ttgattgaat	acaatttaaa	3120
ttctacttga	tgactgcagt	cgtcaagggg	ctctgatgc	aagatgcccc	ttccatttta	3180

agtctgtctc cttacagagg tttaaagtcta gtggctaatt cctaaggaaa cctgattaac 3240  
 acatgctcac aaccatcctg gtcattctcg agcatgttct attttttaac taatcacccc 3300  
 tgatatattt ttatttttat atatccagtt ttcatttttt tacgtcttgc ctataagcta 3360  
 atatcataaa taaggttgtt taagacgtgc ttcaaatatc catattaacc actatttttc 3420  
 aaggaagtat ggaaaagtac actctgtcac tttgtcactc gatgtcattc caaagttatt 3480  
 gcctactaag taatgactgt catgaaagca gcattgaaat aatttgttta aagggggcac 3540  
 tcttttaaac gggaagaaaa tttccgcttc ctgggtcttat catggacaat ttgggctaga 3600  
 ggcaggaagg aagtgggatg acctcaggag gtcacctttt cttgattcca gaaacatatg 3660  
 ggctgataaa cccgggggtga cctcatgaaa tgagttgcag cagaagtta tttttttcag 3720  
 aacaagtgat gtttgatgga cctctgaatc tctttaggga gacacagatg gctgggatcc 3780  
 ctccccgtga cccttctcac tgccaggaga acta 3814

<210> 15

<211> 3934

<212> DNA

<213> Homo sapiens

<400> 15

cctctcaccc tttagcccag aactgctttg aatacaccaa ttgctgtggg ggggctcgag 60  
 gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggatgatagc gagccacgca 120  
 ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
 cgcgcttgcc tgggactctg atcccagcca tggccttcct ctctgctg agaccagaaa 240  
 gctgggagcc ctgctgggag acttgccct aaaccacaca gaagagctgg catgaaaccc 300  
 agagctttca gactccggag cctcagccct tcaccccgat tccattgctt cttgctaaat 360  
 gctgccgttt tatcacggag gtggttccta atattactta tcaatgcatg gagctgaatt 420  
 tctacaaaat ccccgacaac ctccccttct caaccaagaa cctggacctg agctttaatc 480  
 ccctgaggca tttaggcagc tatagcttct tcagtttccc agaactgcag gtgctggatt 540  
 tatccaggty tgaaatccag acaattgaag atggggcata tcagagccta agccacctct 600  
 ctacottaat attgacagga aaccccatcc agagttagc cctgggagcc tttctggac 660  
 tatcaagttt acagaagctg gtggctgtgg agacaaatct agcatctcta gagaacttcc 720  
 ccattggaca tctcaaaact ttgaaagaac ttaatgtggc tcacaatctt atccaatctt 780  
 tcaaattacc tgagtatttt tctaattctga ccaatctaga gcaattggac ctttccagca 840  
 acaagattca aagtatttat tgcacagact tgcgggttct acatcaaagt cccctactca 900  
 atctctcttt agacctgtcc ctgaacccta tgaactttat ccaaccaggt gcatttaaag 960

aaattaggct tcataagctg actttaagaa ataattttga tagtttaa	aatgaaaa	1020
cttgtattca aggtctggct ggtttagaag tccatcggtt ggtctcggga	gaatttagaa	1080
atgaagggaaa cttggaaaag tttgacaaat ctgctctaga gggcctgtgc	aatttgacca	1140
ttgaagaatt ccgattagca tacttagact actacctcga tgatattatt	gacttattta	1200
attgtttgac aaatgtttct tcattttccc tggtgagtgt gactattgaa	agggtaaaag	1260
acttttctta taatttcgga tggcaacatt tagaattagt taactgtaaa	tttggacagt	1320
ttcccacatt gaaactcaaa tctctcaaaa ggcttacttt cacttccaac	aaaggtggga	1380
atgctttttc agaagttgat ctaccaagcc ttgagtttct agatctcagt	agaaatggct	1440
tgagtttcaa aggttgctgt tctcaaagtg attttgggac aaccagccta	aagtatttag	1500
atctgagctt caatggtgtt attaccatga gttcaaactt cttgggctta	gaacaactag	1560
aacatctgga tttccagcat tccaatttga acaaatgag tgagttttca	gtattcctat	1620
cactcagaaa cctcatttac cttgacattt ctcatactca caccagagtt	gctttcaatg	1680
gcatcttcaa tggcttgtcc agtctcgaag tcttgaaaat ggctggcaat	tctttccagg	1740
aaaacttcct tccagatata ttcacagagc tgagaaactt gaccttcctg	gacctctctc	1800
agtgtaact ggagcagttg tctccaacag catttaactc actctccagt	cttcaggtac	1860
taaatatgag ccacaacaac ttcttttcat tggatacggt tccttataag	tgtctgaact	1920
ccctccagggt tcttgattac agtctcaatc acataatgac ttccaaaaaa	caggaaactac	1980
agcattttcc aagtagtcta gctttcttaa atcttactca gaatgacttt	gcttgacttt	2040
gtgaacacca gagtttcctg caatggatca aggaccagag gcagctcttg	gtggaagttg	2100
aacgaatgga atgtgcaaca ccttcagata agcagggcat gcctgtgctg	agtttgaata	2160
tcacctgtca gatgaataag accatcattg gtgtgtcggt cctcagtgtg	cttgtagtat	2220
ctgttgtagc agttctggtc tataagttct attttcacct gatgcttctt	gctggctgca	2280
taaagtatgg tagaggtgaa aacatctatg atgcctttgt tatctactca	agccaggatg	2340
aggactgggt aaggaatgag ctagtaaaga atttagaaga aggggtgcct	ccatttcagc	2400
tctgccttca ctacagagac ttatttcccg gtgtggccat tgctgccaac	atcatccatg	2460
aaggttttcca taaaagccga aagggtgattg ttgtggtgtc ccagcacttc	atccagagcc	2520
gctggtgtat ctttgaatat gagattgtct agacctggca gtttctgagc	agtcgtgctg	2580
gtatcatctt cattgtcctg cagaagggtg agaagaccct gctcaggcag	caggtggagc	2640
tgtaccgcct tctcagcagg aacacttacc tggagtggga ggacagtgtc	ctggggcggc	2700
acatcttctg gagacgactc agaaaagccc tgctggatgg taaatcatgg	aatccagaag	2760
gaacagtggg tacaggatgc aattggcagg aagcaacatc tatctgaaga	ggaaaaataa	2820
aaacctcctg aggcatttct tgcccagctg ggtccaacac ttgttcagtt	aataagtatt	2880

```

aatgctgcc acatgtcagg ccttatgcta agggtagta attccatggg gcactagata 2940
tgcagggctg ctaatctcaa ggagcttcca gtgcagaggg aataaatgct agactaaaat 3000
acagagtctt ccaggtgggc atttcaacca actcagtcaa ggaacccatg acaaagaaag 3060
tcatttcaac tcttacctca tcaagttgaa taaagacaga gaaaacagaa agagacattg 3120
ttcttttctt gagtcttttg aatggaaatt gtattatggt atagccatca taaaaccatt 3180
ttggtagttt tgactgaact ggggtgtcac tttttccttt ttgattgaat acaattttaa 3240
ttctacttga tgactgcagt cgtcaagggg ctctgatgc aagatgcccc ttccatttta 3300
agtctgtctc cttacagagg ttaaagtcta gtggctaatt cctaaggaaa cctgattaac 3360
acatgtcac aaccatcctg gtcattctcg agcatgttct attttttaac taatcacccc 3420
tgatatattt ttatttttat atatccagtt ttcatttttt tacgtcttgc ctataagcta 3480
atatcataaa taaggttggt taagacgtgc ttcaaatac catattaacc actatttttc 3540
aaggaagtat ggaaaagtac actctgtcac tttgtcactc gatgtcattc caaagttatt 3600
gcctactaag taatgactgt catgaaagca gcattgaaat aatttgttta aagggggcac 3660
tcttttaaac gggaagaaaa tttccgcttc ctggtcttat catggacaat ttgggctaga 3720
ggcaggaagg aagtgggatg acctcaggag gtcacctttt cttgattcca gaaacatatg 3780
ggctgataaa cccgggggtga cctcatgaaa tgagttgcag cagaagtta tttttttcag 3840
aacaagtgat gtttgatgga cctctgaatc tctttaggga gacacagatg gctgggatcc 3900
ctccccgtga cccttctcac tgccaggaga acta 3934

```

<210> 16  
 <211> 839  
 <212> PRT  
 <213> Homo sapiens

<400> 16

Met Met Ser Ala Ser Arg Leu Ala Gly Thr Leu Ile Pro Ala Met Ala  
 1 5 10 15

Phe Leu Ser Cys Val Arg Pro Glu Ser Trp Glu Pro Cys Val Glu Val  
 20 25 30

Val Pro Asn Ile Thr Tyr Gln Cys Met Glu Leu Asn Phe Tyr Lys Ile  
 35 40 45

Pro Asp Asn Leu Pro Phe Ser Thr Lys Asn Leu Asp Leu Ser Phe Asn  
 50 55 60

Pro Leu Arg His Leu Gly Ser Tyr Ser Phe Phe Ser Phe Pro Glu Leu  
 65 70 75 80

Gln Val Leu Asp Leu Ser Arg Cys Glu Ile Gln Thr Ile Glu Asp Gly  
 85 90 95

Ala Tyr Gln Ser Leu Ser His Leu Ser Thr Leu Ile Leu Thr Gly Asn  
 100 105 110  
 Pro Ile Gln Ser Leu Ala Leu Gly Ala Phe Ser Gly Leu Ser Ser Leu  
 115 120 125  
 Gln Lys Leu Val Ala Val Glu Thr Asn Leu Ala Ser Leu Glu Asn Phe  
 130 135 140  
 Pro Ile Gly His Leu Lys Thr Leu Lys Glu Leu Asn Val Ala His Asn  
 145 150 155 160  
 Leu Ile Gln Ser Phe Lys Leu Pro Glu Tyr Phe Ser Asn Leu Thr Asn  
 165 170 175  
 Leu Glu His Leu Asp Leu Ser Ser Asn Lys Ile Gln Ser Ile Tyr Cys  
 180 185 190  
 Thr Asp Leu Arg Val Leu His Gln Met Pro Leu Leu Asn Leu Ser Leu  
 195 200 205  
 Asp Leu Ser Leu Asn Pro Met Asn Phe Ile Gln Pro Gly Ala Phe Lys  
 210 215 220  
 Glu Ile Arg Leu His Lys Leu Thr Leu Arg Asn Asn Phe Asp Ser Leu  
 225 230 235 240  
 Asn Val Met Lys Thr Cys Ile Gln Gly Leu Ala Gly Leu Glu Val His  
 245 250 255  
 Arg Leu Val Leu Gly Glu Phe Arg Asn Glu Gly Asn Leu Glu Lys Phe  
 260 265 270  
 Asp Lys Ser Ala Leu Glu Gly Leu Cys Asn Leu Thr Ile Glu Glu Phe  
 275 280 285  
 Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu Asp Asp Ile Ile Asp Leu Phe  
 290 295 300  
 Asn Cys Leu Thr Asn Val Ser Ser Phe Ser Leu Val Ser Val Thr Ile  
 305 310 315 320  
 Glu Arg Val Lys Asp Phe Ser Tyr Asn Phe Gly Trp Gln His Leu Glu  
 325 330 335  
 Leu Val Asn Cys Lys Phe Gly Gln Phe Pro Thr Leu Lys Leu Lys Ser  
 340 345 350  
 Leu Lys Arg Leu Thr Phe Thr Ser Asn Lys Gly Gly Asn Ala Phe Ser  
 355 360 365  
 Glu Val Asp Leu Pro Ser Leu Glu Phe Leu Asp Leu Ser Arg Asn Gly  
 370 375 380  
 Leu Ser Phe Lys Gly Cys Cys Ser Gln Ser Asp Phe Gly Thr Thr Ser  
 385 390 395 400  
 Leu Lys Tyr Leu Asp Leu Ser Phe Asn Gly Val Ile Thr Met Ser Ser  
 405 410 415  
 Asn Phe Leu Gly Leu Glu Gln Leu Glu His Leu Asp Phe Gln His Ser

420 425 430  
 Asn Leu Lys Gln Met Ser Glu Phe Ser Val Phe Leu Ser Leu Arg Asn  
 435 440 445  
 Leu Ile Tyr Leu Asp Ile Ser His Thr His Thr Arg Val Ala Phe Asn  
 450 455 460  
 Gly Ile Phe Asn Gly Leu Ser Ser Leu Glu Val Leu Lys Met Ala Gly  
 465 470 475 480  
 Asn Ser Phe Gln Glu Asn Phe Leu Pro Asp Ile Phe Thr Glu Leu Arg  
 485 490 495  
 Asn Leu Thr Phe Leu Asp Leu Ser Gln Cys Gln Leu Glu Gln Leu Ser  
 500 505 510  
 Pro Thr Ala Phe Asn Ser Leu Ser Ser Leu Gln Val Leu Asn Met Ser  
 515 520 525  
 His Asn Asn Phe Phe Ser Leu Asp Thr Phe Pro Tyr Lys Cys Leu Asn  
 530 535 540  
 Ser Leu Gln Val Leu Asp Tyr Ser Leu Asn His Ile Met Thr Ser Lys  
 545 550 555 560  
 Lys Gln Glu Leu Gln His Phe Pro Ser Ser Leu Ala Phe Leu Asn Leu  
 565 570 575  
 Thr Gln Asn Asp Phe Ala Cys Thr Cys Glu His Gln Ser Phe Leu Gln  
 580 585 590  
 Trp Ile Lys Asp Gln Arg Gln Leu Leu Val Glu Val Glu Arg Met Glu  
 595 600 605  
 Cys Ala Thr Pro Ser Asp Lys Gln Gly Met Pro Val Leu Ser Leu Asn  
 610 615 620  
 Ile Thr Cys Gln Met Asn Lys Thr Ile Ile Gly Val Ser Val Leu Ser  
 625 630 635 640  
 Val Leu Val Val Ser Val Val Ala Val Leu Val Tyr Lys Phe Tyr Phe  
 645 650 655  
 His Leu Met Leu Leu Ala Gly Cys Ile Lys Tyr Gly Arg Gly Glu Asn  
 660 665 670  
 Ile Tyr Asp Ala Phe Val Ile Tyr Ser Ser Gln Asp Glu Asp Trp Val  
 675 680 685  
 Arg Asn Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Pro Phe Gln  
 690 695 700  
 Leu Cys Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala  
 705 710 715 720  
 Asn Ile Ile His Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val  
 725 730 735  
 Val Ser Gln His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu  
 740 745 750  
 Ile Ala Gln Thr Trp Gln Phe Leu Ser Ser Arg Ala Gly Ile Ile Phe



755 760 765  
 Ile Val Leu Gln Lys Val Glu Lys Thr Leu Leu Arg Gln Gln Val Glu  
 770 775 780  
 Leu Tyr Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Ser  
 785 790 795 800  
 Val Leu Gly Arg His Ile Phe Trp Arg Arg Leu Arg Lys Ala Leu Leu  
 805 810 815  
 Asp Gly Lys Ser Trp Asn Pro Glu Gly Thr Val Gly Thr Gly Cys Asn  
 820 825 830  
 Trp Gln Glu Ala Thr Ser Ile  
 835  
 <210> 17  
 <211> 782  
 <212> PRT  
 <213> Homo sapiens  
 <400> 17  
 Met Lys Pro Arg Ala Phe Arg Leu Arg Ser Leu Ser Pro Ser Pro Arg  
 1 5 10 15  
 Phe His Cys Phe Leu Leu Asn Ala Ala Val Leu Ser Arg Arg Cys Glu  
 20 25 30  
 Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu Ser  
 35 40 45  
 Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly Ala  
 50 55 60  
 Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr Asn  
 65 70 75 80  
 Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu Lys  
 85 90 95  
 Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro Glu  
 100 105 110  
 Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser Asn  
 115 120 125  
 Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln Met  
 130 135 140  
 Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn Phe  
 145 150 155 160  
 Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr Leu  
 165 170 175  
 Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln Gly  
 180 185 190  
 Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg Asn  
 195 200 205

Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu Cys  
 210 215 220  
 Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu  
 225 230 235 240  
 Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser Phe  
 245 250 255  
 Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr Asn  
 260 265 270  
 Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln Phe  
 275 280 285  
 Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser Asn  
 290 295 300  
 Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu Phe  
 305 310 315 320  
 Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser Gln  
 325 330 335  
 Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe Asn  
 340 345 350  
 Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu Glu  
 355 360 365  
 His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe Ser  
 370 375 380  
 Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His Thr  
 385 390 395 400  
 His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser Leu  
 405 410 415  
 Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu Pro  
 420 425 430  
 Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser Gln  
 435 440 445  
 Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser Ser  
 450 455 460  
 Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp Thr  
 465 470 475 480  
 Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser Leu  
 485 490 495  
 Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro Ser  
 500 505 510  
 Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr Cys  
 515 520 525  
 Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu Leu

530                      535                      540  
 Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln Gly  
 545                      550                      555                      560  
 Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr Ile  
                     565                      570                      575  
 Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala Val  
                     580                      585                      590  
 Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys Ile  
                     595                      600                      605  
 Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr Ser  
                     610                      615                      620  
 Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu Glu  
 625                      630                      635                      640  
 Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe Ile  
                     645                      650                      655  
 Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His Lys  
                     660                      665                      670  
 Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser Arg  
                     675                      680                      685  
 Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu Ser  
                     690                      695                      700  
 Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys Thr  
 705                      710                      715                      720  
 Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn Thr  
                     725                      730                      735  
 Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp Arg  
                     740                      745                      750  
 Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu Gly  
                     755                      760                      765  
 Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile  
                     770                      775                      780

<210> 18  
 <211> 799  
 <212> PRT  
 <213> Homo sapiens

<400> 18

Met Glu Leu Asn Phe Tyr Lys Ile Pro Asp Asn Leu Pro Phe Ser Thr  
 1                      5                      10                      15  
 Lys Asn Leu Asp Leu Ser Phe Asn Pro Leu Arg His Leu Gly Ser Tyr  
                     20                      25                      30  
 Ser Phe Phe Ser Phe Pro Glu Leu Gln Val Leu Asp Leu Ser Arg Cys  
                     35                      40                      45

Glu Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu  
 50 55 60  
 Ser Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly  
 65 70 75 80  
 Ala Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr  
 85 90 95  
 Asn Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu  
 100 105 110  
 Lys Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro  
 115 120 125  
 Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser  
 130 135 140  
 Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln  
 145 150 155 160  
 Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn  
 165 170 175  
 Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr  
 180 185 190  
 Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln  
 195 200 205  
 Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg  
 210 215 220  
 Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu  
 225 230 235 240  
 Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr  
 245 250 255  
 Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser  
 260 265 270  
 Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr  
 275 280 285  
 Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln  
 290 295 300  
 Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser  
 305 310 315 320  
 Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu  
 325 330 335  
 Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser  
 340 345 350  
 Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe  
 355 360 365  
 Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu

370 375 380  
 Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe  
 385 390 395 400  
 Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His  
 405 410 415  
 Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser  
 420 425 430  
 Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu  
 435 440 445  
 Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser  
 450 455 460  
 Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser  
 465 470 475 480  
 Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp  
 485 490 495  
 Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser  
 500 505 510  
 Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro  
 515 520 525  
 Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr  
 530 535 540  
 Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu  
 545 550 555 560  
 Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln  
 565 570 575  
 Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr  
 580 585 590  
 Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala  
 595 600 605  
 Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys  
 610 615 620  
 Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr  
 625 630 635 640  
 Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu  
 645 650 655  
 Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe  
 660 665 670  
 Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His  
 675 680 685  
 Lys Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser  
 690 695 700  
 Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu

705                      710                      715                      720  
 Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys  
                          725                      730                      735  
  
 Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn  
                          740                      745                      750  
  
 Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp  
                          755                      760                      765  
  
 Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu  
                          770                      775                      780  
  
 Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile  
 785                      790                      795  
  
  
 <210> 19  
 <211> 639  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 19  
  
 Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn  
 1                      5                      10                      15  
  
 Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr  
                          20                      25                      30  
  
 Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln  
                          35                      40                      45  
  
 Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg  
                          50                      55                      60  
  
 Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu  
 65                      70                      75                      80  
  
 Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr  
                          85                      90                      95  
  
 Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser  
                          100                      105                      110  
  
 Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr  
                          115                      120                      125  
  
 Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln  
                          130                      135                      140  
  
 Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser  
 145                      150                      155                      160  
  
 Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu  
                          165                      170                      175  
  
 Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser  
                          180                      185                      190  
  
 Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe  
                          195                      200                      205

Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu  
 210 215 220  
 Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe  
 225 230 235 240  
 Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His  
 245 250 255  
 Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser  
 260 265 270  
 Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu  
 275 280 285  
 Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser  
 290 295 300  
 Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser  
 305 310 315 320  
 Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp  
 325 330 335  
 Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser  
 340 345 350  
 Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro  
 355 360 365  
 Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr  
 370 375 380  
 Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu  
 385 390 395 400  
 Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln  
 405 410 415  
 Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr  
 420 425 430  
 Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala  
 435 440 445  
 Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys  
 450 455 460  
 Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr  
 465 470 475 480  
 Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu  
 485 490 495  
 Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe  
 500 505 510  
 Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His  
 515 520 525  
 Lys Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser

530                      535                      540  
 Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu  
 545                      550                      555                      560  
  
 Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys  
                     565                      570                      575  
  
 Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn  
                     580                      585                      590  
  
 Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp  
                     595                      600                      605  
  
 Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu  
                     610                      615                      620  
  
 Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile  
 625                      630                      635

<210> 20  
 <211> 3866  
 <212> DNA  
 <213> murine

<400> 20  
 ctggttgccag aaaatgccag gatgatgcct ccctggctcc tggctaggac tctgatcatg 60  
  
 gcaactgttct tctcctgcct gacaccagga agcttgaatc cctgcataga ggtagttcct 120  
  
 aatattacct accaatgcat ggatcagaaa ctcagcaaag tccctgatga cattccttct 180  
  
 tcaaccaaga acatagatct gagcttcaac cccttgaaga tcttaaaaag ctatagcttc 240  
  
 tccaattttt cagaacttca gtggctggat ttatccagggt gtgaaattga aacaattgaa 300  
  
 gacaaggcat ggcattggctt acaccacctc tcaaaactga tactgacagg aaaccctatc 360  
  
 cagagttttt cccaggaag tttctctgga ctaacaagtt tagagaatct ggtggctgtg 420  
  
 gagacaaaat tggcctctct agaaagcttc cctattggac agcttataac cttaaagaaa 480  
  
 ctcaatgtgg ctcaaatctt tatacattcc tgtaagttac ctgcatatct ttccaatctg 540  
  
 acgaacctag tacatgtgga tctttcttat aactatatc aaactattac tgtcaacgac 600  
  
 ttacagtttc tacgtgaaaa tccacaagtc aatctctctt tagacatgtc tttgaaccca 660  
  
 attgacttca ttcaagacca agcctttcag ggaattaagc tccatgaact gactctaaga 720  
  
 ggtaatttta atagctcaaa tataatgaaa acttgccctc aaaacctggc tggtttacac 780  
  
 gtccatcggg tgatcttggg agaatttaaa gatgaaagga atctggaaat ttttgaaccc 840  
  
 tctatcatgg aaggactatg tgatgtgacc attgatgagt tcaggttaac atatacaaat 900  
  
 gatttttcag atgatattgt taagttccat tgcttggcga atgtttctgc aatgtctctg 960  
  
 gcaggtgtat ctataaata tctagaagat gttcctaaac atttcaaatg gcaatcctta 1020  
  
 tcaatcatta gatgtcaact taagcagttt ccaactctgg atctaccctt tcttaaaagt 1080



ttgacttttaa ctatgaacaa agggctctatc agtttttaaaa aagtggccct accaagtctc	1140
agctatctag atcttagtag aaatgcactg agcttttagtg gttgctgttc ttattctgat	1200
ttgggaacaa acagcctgag acacttagac ctcagcttca atggtgccat cattatgagt	1260
gccaatttca tgggtctaga agagctgcag cacctggatt ttcagcactc tacttttaaaa	1320
agggtcacag aattctcagc gttcttatcc cttgaaaagc tactttacct tgacatctct	1380
tatactaaca ccaaaattga cttcgatggg atatttcttg gcttgaccag tctcaacaca	1440
ttaaaaatgg ctggcaattc ttccaaagac aacacccttt caaatgtctt tgcaaacaca	1500
acaaacttga cattcctgga tctttctaaa tgtcaattgg aacaaatatc ttggggggta	1560
tttgacaccc tccatagact tcaattatta aatatgagtc acaacaatct attgtttttg	1620
gattcatccc attataacca gctgtattcc ctcagcactc ttgattgcag tttcaatcgc	1680
atagagacat cttaaaggaat actgcaacat tttccaaaga gtctagcctt cttcaatctt	1740
actaacaatt ctgttgcttg tatatgtgaa catcagaaat tcctgcagtg ggtcaaggaa	1800
cagaagcagt tcttggtgaa tgttgaacaa atgacatgtg caacacctgt agagatgaat	1860
acctccttag tgttggtatt taataattct acctgttata tgtacaagac aatcatcagt	1920
gtgtcagtgg tcagtgtgat tgtggtatcc actgtagcat ttctgatata ccacttctat	1980
tttcacctga tacttattgc tggctgtaaa aagtacagca gaggagaaag catctatgat	2040
gcatttgtga tctactcgag tcagaatgag gactgggtga gaaatgagct ggtaaagaat	2100
ttagaagaag gagtgcctcg ctttcacctc tgccttcact acagagactt tattcctggg	2160
gtagccattg ctgccaacat catccaggaa ggcttcaca agagccggaa gggtattgtg	2220
gtagtgtcta gacactttat tcagagccgt tgggtgatct ttgaatatga gattgctcaa	2280
acatggcagt ttctgagcag ccgctctggc atcatcttca ttgtccttga gaaggttgag	2340
aagtccctgc tgaggcagca ggtggaattg tatgccttc ttagcagaaa cacctacctg	2400
gaatgggagg acaatcctct ggggaggcac atcttctgga gaagacttaa aaatgcccta	2460
ttggatggaa aagcctcgaa tcctgagcaa acagcagagg aagaacaaga aacggcaact	2520
tggacctgag gagaacaaaa ctctggggcc taaaccagct ctgtttgcaa ttaataaatg	2580
ctacagctca cctggggctc tgctatggac cgagagccca tggaacacat ggctgctaag	2640
ctatagcatg gaccttaccg ggcagaagga agtagcactg acaccttctt ttccaggggt	2700
atgaattacc taactcggga aaagaaacat aatccagaat ctttaccttt aatctgaagg	2760
agaagaggct aaggcctagt gagaacagaa aggagaacca gtcttcaactg ggccttttga	2820
atacaagcca tgtcatgttc tgtgtttcag ttgctttaga agagtattga tagtttcaac	2880
tgaactgaac ggtttcttac tttccctttt ttctactgaa tgcaatatta aatagctctt	2940
tttgagaggt cttcattcca atttcatctt ccattttatg tcattttctt ttcttttttg	3000

tttttatcta attctataag aaatatgatt gatacacgct cacagatagc ctggccaatc 3060  
 ctaagaatgc tatatttatt aaatacaatt cctagtatac ttttactttt ataaattcag 3120  
 ttatcgtttt tcatgccttg actataaaact aatatcataa ataagattgt tacagggtatg 3180  
 ctaagaaggc ccatatttga ctataatttt ttaagaaagt atataaaata tactttgtca 3240  
 tattgtcact gaatgtcatt ctttaagttat tacctaagtt atggatgtca cagagtcagt 3300  
 gttaaaaata atttggttga tagaaatatt tttaatcagg agggaaaagt ggagaggggt 3360  
 gcaggaacag aaatcatgat ttcatcattt attcttgatt tttccggaag ttcacatagc 3420  
 tgaatgacaa gactacatat gctgcaactg atgttccttc tcatcaagga tactctctga 3480  
 acttgagaac attttgggga ggaagaaagg totaacatcc ttttccttca tcattctcat 3540  
 ttctggacat gccttgtgag atggatcaat gttgggagta cacatttctg ctttcacctt 3600  
 atttcagtcg gcatgaacac tgaatatata atgtcatttc acagtgtgtg tgtgttgtgt 3660  
 atgtacatat atgaacctgt acatgtgttt aagtttaaag agaaaatagt gtacagagca 3720  
 ggtgtatatt tgtgataggg ctttaaataag ttgagcta atcagaaaagt atggaggttt 3780  
 cttggtaaac caaaccaaaa gtagaatcat tacaagatct aacaataaaa attttgaaaa 3840  
 aaaaaaaaaa aaaaaaaaaa aaaaaa 3866

<210> 21  
 <211> 2520  
 <212> DNA  
 <213> murine

<400> 21  
 atgatgcctc cctggctcct ggctaggact ctgatcatgg cactgttctt ctctgcctg 60  
 acaccaggaa gcttgaatcc ctgcatagag gtagttccta atattaccta ccaatgcatg 120  
 gatcagaaac tcagcaaagt ccctgatgac attccttctt caaccaagaa catagatctg 180  
 agcttcaacc ccttgaagat cttaaaaagc tatagcttct ccaatttttc agaacttcag 240  
 tggctggatt tatccagggt tgaaattgaa acaattgaag acaaggcatg gcatggctta 300  
 caccacctct caaacttgat actgacagga aacctatcc agagtttttc cccaggaagt 360  
 ttctctggac taacaagttt agagaatctg gtggctgtgg agacaaaatt ggcctctcta 420  
 gaaagcttcc ctattggaca gcttataacc ttaaagaaac tcaatgtggc tcacaatttt 480  
 atacattcct gtaagttacc tgcataattt tccaatctga cgaacctagt acatgtggat 540  
 ctttcttata actatattca aactattact gtcaacgact tacagtttct acgtgaaaat 600  
 ccacaagtca atctctcttt agacatatct ttgaacccaa ttgacttcat tcaagaccaa 660  
 gcctttcagg gaattaagct ccatgaactg actctaagag gtaattttta tagctcaaat 720

ataatgaaaa	cttgcccttca	aaacctggct	ggtttacaca	tccatcgggt	gatcttggga	780
gaatttaaag	atgaaaggaa	tctggaaatt	tttgaaccct	ctatcatgga	aggactatgt	840
gatgtgacca	ttgatgagtt	caggttaaca	tatacaaatg	atttttcaga	tgatattgtt	900
aagttccatt	gcttggcgaa	tgtttctgca	atgtctctgg	cagggtgtatc	tataaaatat	960
ctagaagatg	ttcctaaaca	tttcaaattg	caatccttat	caatcattag	atgtcaactt	1020
aagcagtttc	caactctgga	tctacccttt	cttaaaagtt	tgactttaac	tatgaacaaa	1080
gggtctatca	gttttaaaaa	agtggcccta	ccaagtctca	gctatctaga	tcttagtaga	1140
aatgcactga	gcttttagtgg	ttgctgttct	tattctgatt	tggaacaaa	cagcctgaga	1200
cacttagacc	tcagcttcaa	tggtgccatc	attatgagtg	ccaatttcat	gggtctagaa	1260
gagctgcagc	acctggattt	tcagcactct	actttaaaaa	gggtcacaga	attctcagcg	1320
ttcttatccc	ttgaaaagct	actttacctt	gacatctctt	atactaacac	caaaattgac	1380
ttcgatggta	tatttcttgg	cttgaccagt	ctcaacacat	taaaaatggc	tggcaattct	1440
ttcaaagaca	acaccctttc	aaatgtcttt	gcaaacacaa	caaacttgac	attcctggat	1500
ctttctaaat	gtcaattgga	acaaatatct	tgggggggat	ttgacaccct	ccatagactt	1560
caattattaa	atatgagtca	caacaatcta	ttgttttttg	attcatcca	ttataaccag	1620
ctgtattccc	tcagcactct	tgattgcagt	ttcaatcgca	tagagacatc	taaaggaata	1680
ctgcaacatt	ttccaaagag	tctagccttc	ttcaatctta	ctaacaattc	tgttgcttgt	1740
atatgtgaac	atcagaaatt	cctgcagtgg	gtcaaggacc	agaagcagtt	cttggtgaat	1800
gttgaacaaa	tgacatgtgc	aacacctgta	gagatgaata	cctccttagt	gttggaattt	1860
aataattcta	cctgttatat	gtacaagaca	atcatcagtg	tgtcagtgg	cagtgtgatt	1920
gtggtatcca	ctgtagcatt	tctgatatac	cacttctatt	ttcacctgat	acttattgct	1980
ggctgtaaaa	agtacagcag	aggagaaagc	atctatgatg	catttgatg	ctactcgagt	2040
cagaatgagg	actgggtgag	aatgagctg	gtaaagaatt	tagaagaagg	agtccccgc	2100
tttcacctct	gccttcaacta	cagagacttt	attcctgggtg	tagccattgc	tgccaatatc	2160
atccaggaag	gcttccacaa	gagccggaag	gttattgtgg	tagtgtctag	acaatttatt	2220
cagagccgtt	ggtgtatctt	tgaatatgag	attgctcaaa	catggcagtt	tctgagcagc	2280
cactctggca	tcacttcat	tgtccttgag	aagggtgaga	agtccttgct	gaggcagcag	2340
gtggaattgt	atgccttct	tagcagaaac	acctacctgg	aatgggagga	caatcctctg	2400
gggaggcaca	tcttctggag	aagacttaaa	aatgccctat	tggatggaaa	agcctcgaat	2460
cctgagcaaa	cagcagagga	agaacaagaa	acggcaactt	ggacctgagg	agaaccgcgg	2520

&lt;210&gt; 22

&lt;211&gt; 3866

&lt;212&gt; DNA

&lt;213&gt; murine

&lt;400&gt; 22

```

ctggttgcag aaaatgccag gatgatgcct ccctggctcc tggctaggac tctgatcatg      60
gcaactgttct tctcctgcct gacaccagga agcttgaatc cctgcataga ggtagttcct      120
aatattacct accaatgcat ggatcagaaa ctcagcaaag tccctgatga cattccttct      180
tcaaccaaga acatagatct gagcttcaac cccttgaaga tcttaaaaag ctatagcttc      240
tccaatTTTT cagaacttca gtggctggat ttatccaggt gtgaaattga aacaattgaa      300
gacaaggcat ggcatggctt acaccacctc tcaaacttga tactgacagg aaaccctatc      360
cagagttttt cccaggaag tttctctgga ctaacaagtt tagagaatct ggtggctgtg      420
gagacaaaat tggcctctct agaaagcttc cctattggac agcttataac cttaaagaaa      480
ctcaatgtgg ctcaaatTTT tatacattcc tgtaagttac ctgcatattt ttccaatctg      540
acgaacctag tacatgtgga tctttcttat aactatattc aaactattac tgtcaacgac      600
ttacagtttc tacgtgaaaa tccacaagtc aatctctctt tagacatgtc tttgaaccca      660
attgacttca ttcaagacca agcctttcag ggaattaagc tccatgaact gactctaaga      720
ggtaattttt atagctcaaa tataatgaaa acttgccctc aaaacctggc tggtttacac      780
gtccatcggg tgatcttggg agaatttaaa gatgaaagga atctggaaat ttttgaaccc      840
tctatcatgg aaggactatg tgatgtgacc attgatgagt tcaggttaac atatacaaat      900
gatttttcag atgatattgt taagttccat tgcttggcga atgtttctgc aatgtctctg      960
gcaggtgtat ctataaaata tctagaagat gttcctaaac atttcaaatg gcaatcctta     1020
tcaatcatta gatgtcaact taagcagttt ccaactctgg atctaccctt tcttaaaagt     1080
ttgactttaa ctatgaacaa agggctctatc agtttttaaa aagtggccct accaagtctc     1140
agctatctag atcttagtag aaatgcactg agcttttagtg gttgctgttc ttattctgat     1200
ttgggaacaa acagcctgag acacttagac ctcagcttca atggtgccat cattatgagt     1260
gccaatTTTca tgggtctaga agagctgcag cacctggatt ttcagcactc tactttaaaa     1320
agggtcacag aattctcagc gttcttatcc cttgaaaagc tactttacct tgacatctct     1380
tatactaaca ccaaaattga cttcgatggg atatttcttg gcttgaccag tctcaacaca     1440
ttaaaaatgg ctggcaattc tttcaaagac aacacccttt caaatgtctt tgcaaacaca     1500
acaaacttga cattcctgga tcttttctaaa tgtcaattgg aacaaatata ttggggggta     1560
tttgacaccc tccatagact tcaattatta aatatgagtc acaacaatct attgtttttg     1620
gattcatccc attataacca gctgtattcc ctcagcactc ttgattgcag tttcaatcgc     1680
atagagacat ctaaaggaat actgcaacat tttccaaaga gtctagcctt cttcaatctt     1740

```

actaacaatt ctgttgcttg tataatgtgaa catcagaaat tcctgcagtg ggtcaaggaa	1800
cagaagcagt tcttggtgaa tgttgaacaa atgacatgtg caacacctgt agagatgaat	1860
acctccttag tgttggtattt taataattct acctgttata tgtacaagac aatcatcagt	1920
gtgtcagtggt tcagtgtgat tgtggtatcc actgtagcat ttctgatata ccacttctat	1980
tttcacctga tacttattgc tggctgtaaa aagtacagca gaggagaaag catctatgat	2040
gcatttgtga tctactcgag tcagaatgag gactgggtga gaaatgagct ggtaaagaat	2100
ttagaagaag gagtgcctcg ctttcacctc tgccttcact acagagactt tattcctggt	2160
gtagccattg ctgccaacat catccaggaa ggcttcacac agagccggaa ggttattgtg	2220
gtagtgtcta gacactttat tcagagccgt tgggtgtatct ttgaatatga gattgtctaa	2280
acatggcagt ttctgagcag ccgctctggc atcatcttca ttgtccttga gaaggttgag	2340
aagtccctgc tgaggcagca ggtggaattg tategccttc ttagcagaaa cacctacctg	2400
gaatgggagg acaatcctct ggggaggcac atcttctgga gaagacttaa aaatgcccta	2460
ttggatggaa aagcctcgaa tcctgagcaa acagcagagg aagaacaaga aacggcaact	2520
tggacctgag gagaacaaaa ctctggggcc taaaccagct ctgtttgcaa ttaataaatg	2580
ctacagctca cctggggctc tgctatggac cgagagccca tggaacacat ggctgctaag	2640
ctatagcatg gaccttaccg ggcagaagga agtagcactg acaccttcct ttccaggggt	2700
atgaattacc taactcggga aaagaaacat aatccagaat ctttaccttt aatctgaagg	2760
agaagaggct aaggcctagt gagaacagaa aggagaacca gtcttccactg ggccttttga	2820
atacaagcca tgtcatgttc tgtgtttcag ttgctttaga agagtattga tagtttcaac	2880
tgaactgaac ggtttcttac tttccctttt ttctactgaa tgcaatatta aatagctctt	2940
tttgagaggt cttcattcca atttcatctt ccattttatg tcattttctt ttcttttttg	3000
tttttatcta attctataag aaatatgatt gatacacgct cacagatagc ctggccaatc	3060
ctaagaatgc tatatttatt aaatacaatt cctagtatac ttttactttt ataaattcag	3120
ttatcgtttt tcatgccttg actataaact aatatcataa ataagattgt tacaggtatg	3180
ctaagaaggc ccatatttga ctataatttt ttaagaaagt atataaaata tactttgtca	3240
tattgtcact gaatgtcatt cttaagttat tacctaagtt atggatgtca cagagtcagt	3300
gttaaaaata atttggttga tagaaatatt tttaatcagg agggaaaagt ggagaggggt	3360
gcaggaacag aaatcatgat ttcatcattt attcttgatt tttccggaag ttcacatagc	3420
tgaatgacaa gactacatat gctgcaactg atgttccttc tcatcaagga tactctctga	3480
acttgagaac attttgggga ggaagaaagg tctaacatcc ttttccttca tcattctcat	3540
ttctggacat gccttgtgag atggatcaat gttgggagta cacatttctg ctttcacctt	3600
atttcagtca gcatgaacac tgaatatata atgtcatttc acagtgtgtg tgtgtgtgtg	3660

atgtacatat atgaacctgt acatgtgttt aagttttaaag agaaaatagt gtacagagca 3720  
 ggtgtatatatt tgtgataggg ctttaaataag ttgagctaatt tcagaaaagt atggagggttt 3780  
 cttggttaaac caaaccaaaa gtagaatcat tacaagatct aacaataaaa attttgaaaa 3840  
 aaaaaaaaaa aaaaaaaaaa aaaaaa 3866

<210> 23  
 <211> 835  
 <212> PRT  
 <213> murine

<400> 23

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe  
 1 5 10 15  
 Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val  
 20 25 30  
 Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro  
 35 40 45  
 Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro  
 50 55 60  
 Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln  
 65 70 75 80  
 Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala  
 85 90 95  
 Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro  
 100 105 110  
 Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu  
 115 120 125  
 Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro  
 130 135 140  
 Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe  
 145 150 155 160  
 Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu  
 165 170 175  
 Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn  
 180 185 190  
 Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp  
 195 200 205  
 Met Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly  
 210 215 220  
 Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn  
 225 230 235 240

Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Val His Arg  
 245 250 255  
 Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu  
 260 265 270  
 Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg  
 275 280 285  
 Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys  
 290 295 300  
 Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr  
 305 310 315 320  
 Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile  
 325 330 335  
 Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys  
 340 345 350  
 Ser Leu Thr Leu Thr Met Asn Lys Gly Ser Ile Ser Phe Lys Lys Val  
 355 360 365  
 Ala Leu Pro Ser Leu Ser Tyr Leu Asp Leu Ser Arg Asn Ala Leu Ser  
 370 375 380  
 Phe Ser Gly Cys Cys Ser Tyr Ser Asp Leu Gly Thr Asn Ser Leu Arg  
 385 390 395 400  
 His Leu Asp Leu Ser Phe Asn Gly Ala Ile Ile Met Ser Ala Asn Phe  
 405 410 415  
 Met Gly Leu Glu Glu Leu Gln His Leu Asp Phe Gln His Ser Thr Leu  
 420 425 430  
 Lys Arg Val Thr Glu Phe Ser Ala Phe Leu Ser Leu Glu Lys Leu Leu  
 435 440 445  
 Tyr Leu Asp Ile Ser Tyr Thr Asn Thr Lys Ile Asp Phe Asp Gly Ile  
 450 455 460  
 Phe Leu Gly Leu Thr Ser Leu Asn Thr Leu Lys Met Ala Gly Asn Ser  
 465 470 475 480  
 Phe Lys Asp Asn Thr Leu Ser Asn Val Phe Ala Asn Thr Thr Asn Leu  
 485 490 495  
 Thr Phe Leu Asp Leu Ser Lys Cys Gln Leu Glu Gln Ile Ser Trp Gly  
 500 505 510  
 Val Phe Asp Thr Leu His Arg Leu Gln Leu Leu Asn Met Ser His Asn  
 515 520 525  
 Asn Leu Leu Phe Leu Asp Ser Ser His Tyr Asn Gln Leu Tyr Ser Leu  
 530 535 540  
 Ser Thr Leu Asp Cys Ser Phe Asn Arg Ile Glu Thr Ser Lys Gly Ile  
 545 550 555 560  
 Leu Gln His Phe Pro Lys Ser Leu Ala Phe Phe Asn Leu Thr Asn Asn

```

          565          570          575
Ser Val Ala Cys Ile Cys Glu His Gln Lys Phe Leu Gln Trp Val Lys
          580          585          590

Glu Gln Lys Gln Phe Leu Val Asn Val Glu Gln Met Thr Cys Ala Thr
          595          600          605

Pro Val Glu Met Asn Thr Ser Leu Val Leu Asp Phe Asn Asn Ser Thr
          610          615          620

Cys Tyr Met Tyr Lys Thr Ile Ile Ser Val Ser Val Val Ser Val Ile
625          630          635          640

Val Val Ser Thr Val Ala Phe Leu Ile Tyr His Phe Tyr Phe His Leu
          645          650          655

Ile Leu Ile Ala Gly Cys Lys Lys Tyr Ser Arg Gly Glu Ser Ile Tyr
          660          665          670

Asp Ala Phe Val Ile Tyr Ser Ser Gln Asn Glu Asp Trp Val Arg Asn
          675          680          685

Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Arg Phe His Leu Cys
          690          695          700

Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala Asn Ile
705          710          715          720

Ile Gln Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val Val Ser
          725          730          735

Arg His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala
          740          745          750

Gln Thr Trp Gln Phe Leu Ser Ser Arg Ser Gly Ile Ile Phe Ile Val
          755          760          765

Leu Glu Lys Val Glu Lys Ser Leu Leu Arg Gln Gln Val Glu Leu Tyr
          770          775          780

Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Asn Pro Leu
785          790          795          800

Gly Arg His Ile Phe Trp Arg Arg Leu Lys Asn Ala Leu Leu Asp Gly
          805          810          815

Lys Ala Ser Asn Pro Glu Gln Thr Ala Glu Glu Glu Gln Glu Thr Ala
          820          825          830

Thr Trp Thr
          835

```

<210> 24  
 <211> 835  
 <212> PRT  
 <213> murine

<400> 24

```

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe
1          5          10          15

```



Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val  
                   20                                  25                                  30  
 Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro  
                   35                                  40                                  45  
 Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro  
                   50                                  55                                  60  
 Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln  
                   65                                  70                                  75                                  80  
 Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala  
                                   85                                  90                                  95  
 Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro  
                   100                                  105                                  110  
 Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu  
                   115                                  120                                  125  
 Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro  
                   130                                  135                                  140  
 Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe  
                   145                                  150                                  155                                  160  
 Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu  
                                   165                                  170                                  175  
 Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn  
                   180                                  185                                  190  
 Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp  
                   195                                  200                                  205  
 Ile Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly  
                   210                                  215                                  220  
 Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn  
                   225                                  230                                  235                                  240  
 Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Ile His Arg  
                                   245                                  250                                  255  
 Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu  
                   260                                  265                                  270  
 Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg  
                   275                                  280                                  285  
 Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys  
                   290                                  295                                  300  
 Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr  
                   305                                  310                                  315                                  320  
 Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile  
                                   325                                  330                                  335  
 Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys

340 345 350  
 Ser Leu Thr Leu Thr Met Asn Lys Gly Ser Ile Ser Phe Lys Lys Val  
 355 360 365  
 Ala Leu Pro Ser Leu Ser Tyr Leu Asp Leu Ser Arg Asn Ala Leu Ser  
 370 375 380  
 Phe Ser Gly Cys Cys Ser Tyr Ser Asp Leu Gly Thr Asn Ser Leu Arg  
 385 390 395 400  
 His Leu Asp Leu Ser Phe Asn Gly Ala Ile Ile Met Ser Ala Asn Phe  
 405 410 415  
 Met Gly Leu Glu Glu Leu Gln His Leu Asp Phe Gln His Ser Thr Leu  
 420 425 430  
 Lys Arg Val Thr Glu Phe Ser Ala Phe Leu Ser Leu Glu Lys Leu Leu  
 435 440 445  
 Tyr Leu Asp Ile Ser Tyr Thr Asn Thr Lys Ile Asp Phe Asp Gly Ile  
 450 455 460  
 Phe Leu Gly Leu Thr Ser Leu Asn Thr Leu Lys Met Ala Gly Asn Ser  
 465 470 475 480  
 Phe Lys Asp Asn Thr Leu Ser Asn Val Phe Ala Asn Thr Thr Asn Leu  
 485 490 495  
 Thr Phe Leu Asp Leu Ser Lys Cys Gln Leu Glu Gln Ile Ser Trp Gly  
 500 505 510  
 Val Phe Asp Thr Leu His Arg Leu Gln Leu Leu Asn Met Ser His Asn  
 515 520 525  
 Asn Leu Leu Phe Leu Asp Ser Ser His Tyr Asn Gln Leu Tyr Ser Leu  
 530 535 540  
 Ser Thr Leu Asp Cys Ser Phe Asn Arg Ile Glu Thr Ser Lys Gly Ile  
 545 550 555 560  
 Leu Gln His Phe Pro Lys Ser Leu Ala Phe Phe Asn Leu Thr Asn Asn  
 565 570 575  
 Ser Val Ala Cys Ile Cys Glu His Gln Lys Phe Leu Gln Trp Val Lys  
 580 585 590  
 Asp Gln Lys Gln Phe Leu Val Asn Val Glu Gln Met Thr Cys Ala Thr  
 595 600 605  
 Pro Val Glu Met Asn Thr Ser Leu Val Leu Asp Phe Asn Asn Ser Thr  
 610 615 620  
 Cys Tyr Met Tyr Lys Thr Ile Ile Ser Val Ser Val Val Ser Val Ile  
 625 630 635 640  
 Val Val Ser Thr Val Ala Phe Leu Ile Tyr His Phe Tyr Phe His Leu  
 645 650 655  
 Ile Leu Ile Ala Gly Cys Lys Lys Tyr Ser Arg Gly Glu Ser Ile Tyr  
 660 665 670  
 Asp Ala Phe Val Ile Tyr Ser Ser Gln Asn Glu Asp Trp Val Arg Asn

675                      680                      685  
 Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Arg Phe His Leu Cys  
 690                      695                      700  
  
 Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala Asn Ile  
 705                      710                      715                      720  
  
 Ile Gln Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val Val Ser  
 725                      730                      735  
  
 Arg His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala  
 740                      745                      750  
  
 Gln Thr Trp Gln Phe Leu Ser Ser His Ser Gly Ile Ile Phe Ile Val  
 755                      760                      765  
  
 Leu Glu Lys Val Glu Lys Ser Leu Leu Arg Gln Gln Val Glu Leu Tyr  
 770                      775                      780  
  
 Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Asn Pro Leu  
 785                      790                      795                      800  
  
 Gly Arg His Ile Phe Trp Arg Arg Leu Lys Asn Ala Leu Leu Asp Gly  
 805                      810                      815  
  
 Lys Ala Ser Asn Pro Glu Gln Thr Ala Glu Glu Glu Gln Glu Thr Ala  
 820                      825                      830  
  
 Thr Trp Thr  
 835

<210> 25  
 <211> 3431  
 <212> DNA  
 <213> Homo sapiens

<400> 25  
 ggcttatagg gctcgagcgg ccgcccgggc aggtatagaa ttcagcggcc gctgaattct 60  
  
 agggttttca ggagcccgag cgagggcgcc gcttttgcgt ccgggaggag ccaaccgtgg 120  
  
 cgcagggcggc gcggggaggc gtcccagagt ctactctgc cgccaggct ggactgcagt 180  
  
 gacacaatct cggtgactg caaccactgc ctccagggtt caagcgattc tcttgctca 240  
  
 gcctcccaag tagctgggat tacagattga tgttcatgtt cctggcacta ctacaagatt 300  
  
 catactctctg atgctactga caacgtggct tctccacagt caccaaacca gggatgctat 360  
  
 actggacttc cctactctca tctgtccag cccctgacc ttatagttgc ccagctttcc 420  
  
 tggcaattga ctttgcccat caatacacag gatttagcat ccaggaaga tgtcggagcc 480  
  
 tcagatgtta attttcta attgagaatgtt ggcgctgtcc gaacctggag acagaaaaac 540  
  
 aaaaagtcct ttctcctgat tcacaaaaa ataaaatact gactaccatc actgtgatga 600  
  
 gattcctata gtctcaggaa ctgaagtctt taaacaacca gggaccctct gccctagaa 660  
  
 taagaacata ctagaagtcc cttctgctag gacaacgagg atcatgggag accacctgga 720

ccttctccta	ggagtgggtgc	tcatggccgg	tcctgtgttt	ggaattcctt	cctgctcctt	780
tgatggccga	atagcctttt	atcgtttctg	caacctcacc	caggtccccc	aggtcctcaa	840
caccactgag	aggctcctgc	tgagcttcaa	ctatatcagg	acagtcaactg	cttcacacctt	900
cccctttctg	gaacagctgc	agctgctgga	gctcgggagc	cagtataccc	ccttgactat	960
tgacaaggag	gccttcagaa	acctgcccc	ccttagaatc	ttggacctgg	gaagtagtaa	1020
gatatacttc	ttgcatccag	atgcttttca	gggactgttc	catctgtttg	aacttagact	1080
gtatttctgt	ggctctctctg	atgctgtatt	gaaagatgg	tatttcagaa	atttaaaggc	1140
tttaactcgc	ttggatctat	ccaaaaatca	gattcgtagc	ctttaccttc	atccttcatt	1200
tggaagttg	aattccttaa	agtccataga	tttttcctcc	aaccaaata	tccttgtagt	1260
tgaacatgag	ctcgagcccc	tacaaggga	aacgctctcc	tttttttagc	tcgcagctaa	1320
tagcttgtag	agcagagtct	cagtggactg	gggaaaatgt	atgaacccat	tcagaaacat	1380
gggtgctggag	atactagatg	tttctggaaa	tggtctggaca	gtggacatca	caggaaactt	1440
tagcaatgcc	atcagcaaaa	gccaggcctt	ctctttgatt	cttgcccacc	acatcatggg	1500
tgccgggttt	ggcttccata	acatcaaaga	tcctgaccag	aacacatttg	ctggcctggc	1560
cagaagttca	gtgagacacc	tggtcttttc	acatgggttt	gtcttctccc	tgaactcacg	1620
agtctttgag	acactcaagg	atttgaagg	tctgaacctt	gcctacaaca	agataaataa	1680
gattgcagat	gaagcatttt	acggacttga	caacctccaa	gttctcaatt	tgtcatataa	1740
ccttctgggg	gaactttaca	gttcgaattt	ctatggacta	cctaaggtag	cctacattga	1800
tttgcaaaag	aatcacattg	caataattca	agaccaaaaca	ttcaaattcc	tggaataatt	1860
acagaccttg	gatctccgag	acaatgctct	tacaaccatt	cattttattc	caagcatacc	1920
cgatatcttc	ttgagtggca	ataaactagt	gactttgcca	aagatcaacc	ttacagcgaa	1980
cctcatccac	ttatcagaaa	acaggctaga	aaatctagat	attctctact	ttcttctacg	2040
ggtacctcat	ctccagattc	tcattttaaa	tcaaaatcgc	ttctcctcct	gtagtggaga	2100
tcaaacccct	tcagagaatc	ccagcttaga	acagcttttc	cttgagagaa	atatgttgca	2160
acttgccctg	gaaactgagc	tctgttggga	tgtttttgag	ggactttctc	atcttcaagt	2220
tctgtatttg	aatcataact	atcttaattc	ccttccacca	ggagtattta	gccatctgac	2280
tgcattaagg	ggactaagcc	tcaactccaa	caggctgaca	gttctttctc	acaatgattt	2340
acctgcta	atagagatcc	tggaacatc	caggaaccag	ctcctagctc	ctaatcctga	2400
tgtatttgta	tcacttagtg	tcttgatgat	aactcataac	aagttcattt	gtgaatgtga	2460
acttagcact	tttatcaatt	ggcttaatca	caccaatgtc	actatagctg	ggcctcctgc	2520
agacatatat	tgtgtgtacc	ctgactcggt	ctctgggggt	tcctctctct	ctctttccac	2580
ggaaggttgt	gatgaagagg	aagtcttaaa	gtccctaaag	ttctcccttt	tcattgtatg	2640

cactgtcact ctgactctgt tcctcatgac catcctcaca gtcacaaagt tccggggctt 2700  
 ctgttttatac tgttataaga cagcccagag actgggtgttc aaggaccatc cccagggcac 2760  
 agaacctgat atgtacaaat atgatgccta tttgtgcttc agcagcaaag acttcacatg 2820  
 ggtgcagaat gctttgctca aacacctgga cactcaatac agtgaccaa acagattcaa 2880  
 cctgtgcttt gaagaaagag actttgtccc aggagaaaac cgcattgcca atatccagga 2940  
 tgccatctgg aacagtagaa agatcgtttg tcttgtgagc agacacttcc ttagagatgg 3000  
 ctgggtgcctt gaagccttca gttatgccc gggcagggtgc ttatctgacc ttaacagtgc 3060  
 tctcatcatg gtgggtggtg ggtccttgtc ccagtaccag ttgatgaaac atcaatccat 3120  
 cagaggcttt gtacagaaac agcagtattt gaggtggcct gaggatctcc aggatgttgg 3180  
 ctggtttctt cataaactct ctcaacagat actaaagaaa gaaaaagaaa agaagaaaga 3240  
 caataacatt ccgttgcaaa ctgtagcaac catctcctaa tcaaaggagc aatttccaac 3300  
 ttatctcaag ccacaaataa ctcttcactt tgtatttgca ccaagttatc attttgggg 3360  
 cctctctgga gggtttttttt ttctttttgc tactatgaaa acaacataaa tctctcaatt 3420  
 ttcgtatcaa a 3431

<210> 26

<211> 858

<212> PRT

<213> Homo sapiens

<400> 26

Met Gly Asp His Leu Asp Leu Leu Leu Gly Val Val Leu Met Ala Gly  
1 5 10 15

Pro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe  
20 25 30

Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr  
35 40 45

Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser  
50 55 60

Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly Ser Gln  
65 70 75 80

Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn  
85 90 95

Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro  
100 105 110

Asp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe  
115 120 125

Cys Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu

130 135 140  
 Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu  
 145 150 155 160  
 Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp  
 165 170 175  
 Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro  
 180 185 190  
 Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu  
 195 200 205  
 Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg  
 210 215 220  
 Asn Met Val Leu Glu Ile Leu Asp Val Ser Gly Asn Gly Trp Thr Val  
 225 230 235 240  
 Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe  
 245 250 255  
 Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His  
 260 265 270  
 Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser  
 275 280 285  
 Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn  
 290 295 300  
 Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala  
 305 310 315 320  
 Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp  
 325 330 335  
 Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Tyr  
 340 345 350  
 Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln  
 355 360 365  
 Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu  
 370 375 380  
 Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His  
 385 390 395 400  
 Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val  
 405 410 415  
 Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu  
 420 425 430  
 Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro  
 435 440 445  
 His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser  
 450 455 460  
 Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu

54/231

805 810 815  
 Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu  
 820 825 830  
 Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys Asp Asn Asn  
 835 840 845  
 Ile Pro Leu Gln Thr Val Ala Thr Ile Ser  
 850 855

<210> 27  
 <211> 858  
 <212> PRT  
 <213> Homo sapiens

<400> 27

Met Gly Asp His Leu Asp Leu Leu Leu Gly Val Val Leu Met Ala Gly  
 1 5 10 15  
 Pro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe  
 20 25 30  
 Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr  
 35 40 45  
 Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser  
 50 55 60  
 Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly Ser Gln  
 65 70 75 80  
 Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn  
 85 90 95  
 Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro  
 100 105 110  
 Asp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe  
 115 120 125  
 Cys Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu  
 130 135 140  
 Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu  
 145 150 155 160  
 Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp  
 165 170 175  
 Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro  
 180 185 190  
 Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu  
 195 200 205  
 Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg  
 210 215 220  
 Asn Met Val Leu Glu Ile Val Asp Val Ser Gly Asn Gly Trp Thr Val  
 225 230 235 240



Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe  
 245 250 255  
 Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His  
 260 265 270  
 Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser  
 275 280 285  
 Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn  
 290 295 300  
 Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala  
 305 310 315 320  
 Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp  
 325 330 335  
 Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Cys  
 340 345 350  
 Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln  
 355 360 365  
 Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu  
 370 375 380  
 Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His  
 385 390 395 400  
 Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val  
 405 410 415  
 Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu  
 420 425 430  
 Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro  
 435 440 445  
 His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser  
 450 455 460  
 Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu  
 465 470 475 480  
 Gly Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp  
 485 490 495  
 Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn  
 500 505 510  
 Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu  
 515 520 525  
 Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn  
 530 535 540  
 Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu  
 545 550 555 560  
 Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile

```

      565      570      575
Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn
      580      585      590

Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile
      595      600      605

Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu Phe Ser Leu
      610      615      620

Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe
      625      630      635      640

Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr
      645      650      655

Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys
      660      665      670

Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro
      675      680      685

Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe
      690      695      700

Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser
      705      710      715      720

Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro
      725      730      735

Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg
      740      745      750

Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys
      755      760      765

Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn
      770      775      780

Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu
      785      790      795      800

Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu
      805      810      815

Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu
      820      825      830

Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys Asp Asn Asn
      835      840      845

Ile Pro Leu Gln Thr Val Ala Thr Ile Ser
      850      855

```

```

<210> 28
<211> 365
<212> PRT
<213> Homo sapiens

```

```

<400> 28

```

Cys Trp Asp Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu  
 1 5 10 15  
 Asn His Asn Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu  
 20 25 30  
 Thr Ala Leu Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu  
 35 40 45  
 Ser His Asn Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg  
 50 55 60  
 Asn Gln Leu Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val  
 65 70 75 80  
 Leu Asp Ile Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr  
 85 90 95  
 Phe Ile Asn Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro  
 100 105 110  
 Ala Asp Ile Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu  
 115 120 125  
 Phe Ser Leu Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser  
 130 135 140  
 Leu Lys Phe Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe  
 145 150 155 160  
 Leu Met Thr Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile  
 165 170 175  
 Cys Tyr Lys Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly  
 180 185 190  
 Thr Glu Pro Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser  
 195 200 205  
 Lys Asp Phe Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr  
 210 215 220  
 Gln Tyr Ser Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp  
 225 230 235 240  
 Phe Val Pro Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp  
 245 250 255  
 Asn Ser Arg Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp  
 260 265 270  
 Gly Trp Cys Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser  
 275 280 285  
 Asp Leu Asn Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln  
 290 295 300  
 Tyr Gln Leu Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln  
 305 310 315 320  
 Gln Tyr Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu

<400>	29
ttgaaatctc acagcccggt tgggtgcagt gaccaccttc gttgaacata ttcttcta	60
tactagtact ttcaatttgc tctattccct ggtgtctatg catttaaate gactatgggg	120
ccattcttcc ttgaaccacc acagaagaca ttagctctct gggatccttg ttaatttttt	180
ctcctcttac atagcaccta cgcttggaac atatgccaga cacatctgtg agacaccct	240
tgcgcgtgca gctcatggat ggatgctgag ttccccacg caccacactt cagcagggtg	300
gtgtatttct gcttcacatt atactcccac acggccatgc atgtcaggca tggagcaggc	360
tcataacca cttaattaag gtgatcata ttagatcctt atcaagatgc atagagtgt	420
cagtgcctgt actatgatct cggatccttg ggagatgggc tagatagagt ctgggacaga	480
atacagcaga gaaaccgata tgtttatgtt ccgatcatca gctaagcttc tgggagctag	540
gaatggggct ccttg gatga acagaagtaa aaatgcctcg tctttatgac tttcaacttc	600
cctcagcagg tctggaatgg gtgaacaaac actgcctgcg tgggtgataa atagcctctt	660
tttgctgett gtttgetgct tttatggttc tgggagggaa cctagaacct agcacatgct	720
agacaagtcc tctagcactg agctatctcc ccagcttggg taaaatatct gtaaagtact	780
gggtcccggtg tgaaaaatat gcaccattaa gtgttcaa ga aaaagact gggcatttct	840
gttccacca gacaagaaga atctgccagc agaattgttg cgcagtcatt tgagcaaagg	900
ggccaaggg acagtaccct ccagtgttg ggacccatgt gccgagcctc aggcttgtat	960
gtgggtgtgt ttttaattct ctctttccc ataggatcat ggcattgtca cttgacttgc	1020
tcatagggtg gatcttcatg gccagccccg tgttggtaat atctccctgt tcttcagacg	1080
gcaggatagc ctttttccga ggctgtaacc tcaccagat tccctggatc ctcaatacta	1140
ccactgagag gctcctgctc agcttcaact atatcagtat ggtgggtgac acatcatttc	1200
cactcctgga gcggctccag ttgctggagc tggggacca gtatgctaac ttgaccattg	1260
gtccaggggc tttcagaaac ctgccaatc ttaggatctt ggacttgggc caaagccaga	1320
tcgaagtctt gaatcgagat gcctttcaag gtctgcccc tctcttgga cttcggctgt	1380
tttctgtgg actctccagt gctgtgttaa gtgacgggta cttcagaaat ctatattcat	1440

tagctcgctt agacctatct ggcaaccaga ttcacagcct ccgcctccat tcttcattcc	1500
gggaactgaa ttccttaagc gacgtaaatt ttgctttcaa ccaaattattc actatatgtg	1560
aagatgaact cgagcctctg cagggcaaaa cactgtcttt ctttggcctc aaattaacta	1620
agctgttcag cagagtctct gtgggctggg agacatgcag gaacccttc agaggcgtga	1680
ggctagaaac tctagatctt tctgaaaatg gctggacggg ggacatcaca aggaacttca	1740
gcaacatcat ccaggaagc cagatttcct ctttgattct taaacaccac atcatgggtc	1800
ctggctttgg cttccagaac atcagagatc ctgaccagag cacatttgcc agcctggcca	1860
gaagtccggg gctgcaactg gacctttcgc acggctttat cttctccttg aatcctcgac	1920
tgtttgggac actgaaggat ttgaagatgc tgaaccttgc cttcaacaag ataaacaaga	1980
ttggagagaa tgccttttat gggttgaca gcctccaggg tctcaatcta tcctataatc	2040
ttttggggga actctataat tccaacttct atgggcttcc tagagtagcc tacgttgacc	2100
ttcaaaggaa ccacattggg atcattcaag accaaacatt cagattatta aaaacgttac	2160
aaaccttaga tctccgtgac aatgctctta aggccattgg ttttattcca agcatacaga	2220
tggtcctcct gggaggcaat aagctgggtc atttgccaca catccacttt actgccaaact	2280
tcctagagtt atctgaaaac aggtagaaa acctgtccga cctctacttc ctctgcgag	2340
tccccagct ccagtttctc atcttgaatc agaatcgct ttcgtcatgc aaggcagccc	2400
acactccctc ggagaacca agcttagaac agcttttcct tacagagaat atgctgcagc	2460
tggcctggga gaccggcctc tgttgggatg tttttcaagg cttttccgc ctccagattc	2520
ttacctgag taataactac cttaatttcc ttccacctgg gatatttaac gacctgggtg	2580
cattacggat gcttagtctt agtgctaaca agctgaccgt gctctctccg ggcagtttac	2640
ctgctaattt agagattctc gacatatcta gaaatcagct tttgtgtcct gaccctgctt	2700
tgttttcttc gcttcgtgtt ttggacataa ctcataacga gttcgtctgc aactgtgaac	2760
ttagcacttt tatctcctgg ctcaacaaa ccaacgtcac cctgttcggc tctcctgcag	2820
acgtgtattg catgtaccct aactcactgc tagggggctc cctctacaac atatccaccg	2880
aagactgcga tgaagaggaa gccatgctgt ccctaaagt ttcccttttc atcctgtgca	2940
cggtcacttt gactctattc ctctcatca ccctttagt cataaagttc cggggaatct	3000
gtttcctgtg ctataagacc atccagaagc tgggtgttcaa ggacaaggtc tggagtgtg	3060
aacctggtgc atagatat gatgcctact tctgcttcag cagcaaagac tttgaatggg	3120
cacagaatgc tttgctcaaa cacctggatg ctactacag ttcccgaac aggtccaggc	3180
tatgctttga agaaagagac ttcatccgg gggaaaacca tatctccaac atccaggcgg	3240
ctgtctgggg cagcaggaag acgggtgtgc tagtgagcag acacttcctg aaggatgggt	3300
ggtgcctgga ggccttcagg tatgccaga gccggagtct gtctgacctc aagagcattc	3360

tcacgcgtggt ggtggtggga tcgctgtccc agtatcagct gatgagacat gagaccatca 3420  
 gaggggtttct gcaaaagcaa cagtacttga ggtggcctga agacctccag gatgttggct 3480  
 ggtttctcga taaactctcc ggatgcattc taaaggaaga aaaaggaaag aaaagaagca 3540  
 gttccatcca gttgcgaacc atagcaacca tttcctagca ggagcgcctc ctagcagaag 3600  
 tgcaagcatc gtagataact ctccacgctt tatccgcaca gccgctgggg gtccttcctt 3660  
 ggagtcattt ttctgacaat gaaaacaaca ccaatctctt gatttttcat gtcaacaggg 3720  
 agctttgtct tcaactgttt ccaaatggaa agtaagaggt ccagaaagct gcctctaagg 3780  
 gctctcacct gccattgatg tcctttcagg cccaatgaca tggtttcctt ccacctattt 3840  
 gcgtactgtc tgctaccag gtggcaagag caccttggga gaagttacag gcagcttcat 3900  
 gctttctgtg ctgttcagtt caaaagcagg tgccttgaga atcctgaatt caagcactct 3960  
 gtagaacatg gacagacaag atgggtcctt ctctggccat aggcattgagg gccagttgct 4020  
 gaggactgct ctactacac ctaagtgcac aagtataag aagttggaca gatagacaga 4080  
 tagcagcagt cccattgctg tagccagaat gcacttattt cctgttctga ccctgcaggc 4140  
 ccagcttttg gggaccacag ccatgttctg caggggacct ctcaacctgg cattcatgcc 4200  
 ctttcacgac ttagcaccgg cctgcccttc tttcttcccc acaactatac aagagctggt 4260  
 gcaaccactg aaaaaaaaaa aaaaaa 4286

<210> 30  
 <211> 859  
 <212> PRT  
 <213> murine

<400> 30

Met Ala Cys Gln Leu Asp Leu Leu Ile Gly Val Ile Phe Met Ala Ser  
1 5 10 15

Pro Val Leu Val Ile Ser Pro Cys Ser Ser Asp Gly Arg Ile Ala Phe  
20 25 30

Phe Arg Gly Cys Asn Leu Thr Gln Ile Pro Trp Ile Leu Asn Thr Thr  
35 40 45

Thr Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Ser Met Val Val Ala  
50 55 60

Thr Ser Phe Pro Leu Leu Glu Arg Leu Gln Leu Leu Glu Leu Gly Thr  
65 70 75 80

Gln Tyr Ala Asn Leu Thr Ile Gly Pro Gly Ala Phe Arg Asn Leu Pro  
85 90 95

Asn Leu Arg Ile Leu Asp Leu Gly Gln Ser Gln Ile Glu Val Leu Asn  
100 105 110

Arg Asp Ala Phe Gln Gly Leu Pro His Leu Leu Glu Leu Arg Leu Phe  
 115 120 125  
 Ser Cys Gly Leu Ser Ser Ala Val Leu Ser Asp Gly Tyr Phe Arg Asn  
 130 135 140  
 Leu Tyr Ser Leu Ala Arg Leu Asp Leu Ser Gly Asn Gln Ile His Ser  
 145 150 155 160  
 Leu Arg Leu His Ser Ser Phe Arg Glu Leu Asn Ser Leu Ser Asp Val  
 165 170 175  
 Asn Phe Ala Phe Asn Gln Ile Phe Thr Ile Cys Glu Asp Glu Leu Glu  
 180 185 190  
 Pro Leu Gln Gly Lys Thr Leu Ser Phe Phe Gly Leu Lys Leu Thr Lys  
 195 200 205  
 Leu Phe Ser Arg Val Ser Val Gly Trp Glu Thr Cys Arg Asn Pro Phe  
 210 215 220  
 Arg Gly Val Arg Leu Glu Thr Leu Asp Leu Ser Glu Asn Gly Trp Thr  
 225 230 235 240  
 Val Asp Ile Thr Arg Asn Phe Ser Asn Ile Ile Gln Gly Ser Gln Ile  
 245 250 255  
 Ser Ser Leu Ile Leu Lys His His Ile Met Gly Pro Gly Phe Gly Phe  
 260 265 270  
 Gln Asn Ile Arg Asp Pro Asp Gln Ser Thr Phe Ala Ser Leu Ala Arg  
 275 280 285  
 Ser Ser Val Leu Gln Leu Asp Leu Ser His Gly Phe Ile Phe Ser Leu  
 290 295 300  
 Asn Pro Arg Leu Phe Gly Thr Leu Lys Asp Leu Lys Met Leu Asn Leu  
 305 310 315 320  
 Ala Phe Asn Lys Ile Asn Lys Ile Gly Glu Asn Ala Phe Tyr Gly Leu  
 325 330 335  
 Asp Ser Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu  
 340 345 350  
 Tyr Asn Ser Asn Phe Tyr Gly Leu Pro Arg Val Ala Tyr Val Asp Leu  
 355 360 365  
 Gln Arg Asn His Ile Gly Ile Ile Gln Asp Gln Thr Phe Arg Leu Leu  
 370 375 380  
 Lys Thr Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Lys Ala Ile  
 385 390 395 400  
 Gly Phe Ile Pro Ser Ile Gln Met Val Leu Leu Gly Gly Asn Lys Leu  
 405 410 415  
 Val His Leu Pro His Ile His Phe Thr Ala Asn Phe Leu Glu Leu Ser  
 420 425 430  
 Glu Asn Arg Leu Glu Asn Leu Ser Asp Leu Tyr Phe Leu Leu Arg Val

435 440 445  
 Pro Gln Leu Gln Phe Leu Ile Leu Asn Gln Asn Arg Leu Ser Ser Cys  
 450 455 460  
 Lys Ala Ala His Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe  
 465 470 475 480  
 Leu Thr Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Gly Leu Cys Trp  
 485 490 495  
 Asp Val Phe Gln Gly Leu Ser Arg Leu Gln Ile Leu Tyr Leu Ser Asn  
 500 505 510  
 Asn Tyr Leu Asn Phe Leu Pro Pro Gly Ile Phe Asn Asp Leu Val Ala  
 515 520 525  
 Leu Arg Met Leu Ser Leu Ser Ala Asn Lys Leu Thr Val Leu Ser Pro  
 530 535 540  
 Gly Ser Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln  
 545 550 555 560  
 Leu Leu Cys Pro Asp Pro Ala Leu Phe Ser Ser Leu Arg Val Leu Asp  
 565 570 575  
 Ile Thr His Asn Glu Phe Val Cys Asn Cys Glu Leu Ser Thr Phe Ile  
 580 585 590  
 Ser Trp Leu Asn Gln Thr Asn Val Thr Leu Phe Gly Ser Pro Ala Asp  
 595 600 605  
 Val Tyr Cys Met Tyr Pro Asn Ser Leu Leu Gly Gly Ser Leu Tyr Asn  
 610 615 620  
 Ile Ser Thr Glu Asp Cys Asp Glu Glu Glu Ala Met Arg Ser Leu Lys  
 625 630 635 640  
 Phe Ser Leu Phe Ile Leu Cys Thr Val Thr Leu Thr Leu Phe Leu Val  
 645 650 655  
 Ile Thr Leu Val Val Ile Lys Phe Arg Gly Ile Cys Phe Leu Cys Tyr  
 660 665 670  
 Lys Thr Ile Gln Lys Leu Val Phe Lys Asp Lys Val Trp Ser Leu Glu  
 675 680 685  
 Pro Gly Ala Tyr Arg Tyr Asp Ala Tyr Phe Cys Phe Ser Ser Lys Asp  
 690 695 700  
 Phe Glu Trp Ala Gln Asn Ala Leu Leu Lys His Leu Asp Ala His Tyr  
 705 710 715 720  
 Ser Ser Arg Asn Arg Leu Arg Leu Cys Phe Glu Glu Arg Asp Phe Ile  
 725 730 735  
 Pro Gly Glu Asn His Ile Ser Asn Ile Gln Ala Ala Val Trp Gly Ser  
 740 745 750  
 Arg Lys Thr Val Cys Leu Val Ser Arg His Phe Leu Lys Asp Gly Trp  
 755 760 765  
 Cys Leu Glu Ala Phe Arg Tyr Ala Gln Ser Arg Ser Leu Ser Asp Leu



770                      775                      780  
 Lys Ser Ile Leu Ile Val Val Val Gly Ser Leu Ser Gln Tyr Gln  
 785                      790                      795                      800  
  
 Leu Met Arg His Glu Thr Ile Arg Gly Phe Leu Gln Lys Gln Gln Tyr  
                     805                      810                      815  
  
 Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu Asp Lys  
                     820                      825                      830  
  
 Leu Ser Gly Cys Ile Leu Lys Glu Glu Lys Gly Lys Lys Arg Ser Ser  
                     835                      840                      845  
  
 Ser Ile Gln Leu Arg Thr Ile Ala Thr Ile Ser  
                     850                      855

<210> 31  
 <211> 3373  
 <212> DNA  
 <213> Homo sapiens

<400> 31  
 agctggcctag cgtttaaacg ggcctcttag actcgagcgg ccgccaattc actagtgtt 60  
  
 cacctctcat gctctgctct cttcaaccag acctctacat tccatttttg aagaagacta 120  
  
 aaaaagggtg ttccaatgtg gacactgaag agacaaattc ttatcctttt taacataatc 180  
  
 ctaatttcca aactccttgg ggctagatgg tttcctaaaa ctctgccctg tgatgtcact 240  
  
 ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt gacagaaatt 300  
  
 cctggaggta ttcccacgaa caccacgaac ctaccctca ccattaacca cataccagac 360  
  
 atctccccag cgtcctttca cagactggac catctggtag agatcgattt cagatgcaac 420  
  
 tgtgtaccta ttccactggg gtcaaaaaac aacatgtgca tcaagaggct gcagattaaa 480  
  
 cccagaagct ttagtggact cacttattta aaatcccttt acctggatgg aaaccagcta 540  
  
 ctagagatac cgcagggcct cccgcctagc ttacagcttc tcagccttga ggccaacaac 600  
  
 atcttttcca tcagaaaaga gaatctaaca gaactggcca acatagaaat actctacctg 660  
  
 ggccaaaact gttattatcg aaatccttgt tatgtttcat attcaataga gaaagatgcc 720  
  
 ttcttaaact tgacaaagtt aaaagtgtc tccctgaaag ataacaatgt cacagccgtc 780  
  
 cctactgttt tgccatctac tttaacagaa ctatatctct acaacaacat gattgcaaaa 840  
  
 atccaagaag atgattttta taacctcaac caattacaaa ttcttgacct aagtggaaat 900  
  
 tgccctcggt gttataatgc ccatttcct tgtgcgccgt gtaaaaataa ttctccccta 960  
  
 cagatcccctg taaatgcttt tgatgcgctg acagaattaa aagttttacg tctacacagt 1020  
  
 aactctcttc agcatgtgcc cccaagatgg tttaagaaca tcaacaaact ccaggaactg 1080  
  
 gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaatttct gcattttctc 1140  
  
 cccagcctca tccaattgga tctgtctttc aattttgaac ttcaggtcta tcgtgcatct 1200

atgaatctat cacaagcatt ttcttcactg aaaagcctga aaattctgcg gatcagagga 1260  
 tatgtcttta aagagttgaa aagctttaac ctctcgccat tacataatct tcaaaatctt 1320  
 gaagttcttg atcttggcac taactttata aaaattgcta acctcagcat gtttaaacia 1380  
 tttaaaagac tgaaagtcac agatctttca gtgaataaaa taccaccttc aggagattca 1440  
 agtgaagttg gcttctgctc aaatgccaga acttctgtag aaagttatga accccaggtc 1500  
 ctggaacaat tacattatct cagatatgat aagtatgcaa ggagttgcag attcaaaaac 1560  
 aaagaggctt ctttcatgtc tgtaaatgaa agctgtaca agtatgggca gaccttggtat 1620  
 ctaagtaaaa atagtatatt ttttgtcaag tcctctgatt ttcagcatct ttctttcctc 1680  
 aaatgcctga atctgtcagg aaatctcatt agccaaactc ttaatggcag tgaattccaa 1740  
 ccttttagcag agctgagata tttggacttc tccaacaacc ggcttgattt actccattca 1800  
 acagcatttg aagagcttca caaactggaa gttctggata taagcagtaa tagccattat 1860  
 tttcaatcag aaggaattac tcatatgcta aactttacca agaacctaaa ggttctgcag 1920  
 aaactgatga tgaacgacaa tgacatctct tcctccacca gcaggaccat ggagagtgag 1980  
 tctcttagaa ctctggaatt cagaggaaat cacttagatg ttttatggag agaagggtgat 2040  
 aacagatact tacaattatt caagaatctg ctaaaattag aggaattaga catctctaaa 2100  
 aattccctaa gtttcttgcc ttctggagtt tttgatggta tgctccaaa tctaaagaat 2160  
 ctctcttttg ccaaaaatgg gctcaaatct ttcagttgga agaaactcca gtgtctaaag 2220  
 aacctggaaa ctttggacct cagccacaac caactgacca ctgtccctga gagattatcc 2280  
 aactgttcca gaagcctcaa gaatctgatt cttaagaata atcaaatcag gagtctgacg 2340  
 aagtattttc tacaagatgc cttccagttg cgatatctgg atctcagctc aaataaaatc 2400  
 cagatgatcc aaaagaccag cttccagaaa aatgtcctca acaatctgaa gatgttgctt 2460  
 ttgcatcata atcggtttct gtgcacctgt gatgctgtgt ggtttgtctg gtgggttaac 2520  
 catacggagg tgactattcc ttacctggcc acagatgtga cttgtgtggg gccaggagca 2580  
 cacaagggcc aaagtgtgat ctccctggat ctgtacacct gtgagttaga tctgactaac 2640  
 ctgattctgt tctcactttc catatctgta tctctctttc tcatgggtgat gatgacagca 2700  
 agtcacctct atttctggga tgtgtggtat atttaccatt tctgtaaggc caagataaag 2760  
 gggatcagc gtctaataac accagactgt tgctatgatg cttttattgt gtatgacact 2820  
 aaagaccag ctgtgaccga gtgggttttg gctgagctgg tggccaaact ggaagacca 2880  
 agagagaaac attttaattt atgtctcgag gaaagggact ggttaccagg gcagccagtt 2940  
 ctggaaaacc tttccagag catacagctt agcaaaaaga cagtgtttgt gatgacagac 3000  
 aagtatgcaa agactgaaaa ttttaagata gcattttact tgtcccatca gaggctcatg 3060

gatgaaaaag ttgatgtgat tatcttgata tttcttgaga agccttttca gaagtccaag 3120  
 ttcctccagc tccggaaaag gctctgtggg agttctgtcc ttgagtggcc aacaaacccg 3180  
 caagctcacc catacttctg gcagtgtcta aagaacgccc tggccacaga caatcatgtg 3240  
 gcctatagtc aggtgttcaa ggaaacgggc tagaatcgaa ttcccggggc cgccactgtg 3300  
 ctggatatct gcagaattcc accacactgg actagtggat ccgagctcgg taccaagctt 3360  
 aagtttaaac cgc 3373

<210> 32

<211> 3416

<212> DNA

<213> Homo sapiens

<400> 32

tccagatata ggatcactcc atgccatcaa gaaagttgat gctattgggc ccactcaag 60  
 ctgatcttgg cacctctcat gctctgctct cttcaaccag acctctacat tccatttttg 120  
 aagaagacta aaaaagggtg ttccaatgtg gacactgaag agacaaattc ttatcctttt 180  
 taacataatc ctaatttcca aactccttgg ggctagatgg tttcctaaaa ctctgcccctg 240  
 tgatgtcact ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt 300  
 gacagaaaatt cctggaggta ttcccacgaa caccacgaac ctaccctca ccattaacca 360  
 cataccagac atctccccag cgtcctttca cagactggac catctggtag agatcgattt 420  
 cagatgcaac tgtgtacctt ttccactggg gtcaaaaaac aacatgtgca tcaagaggct 480  
 gcagattaaa ccagaagct ttagtggact cacttattta aaatcccttt acctggatgg 540  
 aaaccagcta ctagagatac cgcagggcct cccgcctagc ttacagcttc tcagccttga 600  
 ggccaacaac atcttttcca tcagaaaaga gaatctaaca gaactggcca acatagaaat 660  
 actctacctg ggccaaaact gttattatcg aaatccttgt tatgtttcat attcaataga 720  
 gaaagatgcc ttcctaaact tgacaaagtt aaaagtgtc tccctgaaag ataacaatgt 780  
 cacagccgtc cctactgttt tgccatctac tttaacagaa ctatatctct acaacaacat 840  
 gattgcaaaa atccaagaag atgattttta taacctcaac caattacaaa ttcttgacct 900  
 aagtggaaat tgccctcggt gttataatgc ccatttctc tgtgcgccgt gtaaaaataa 960  
 ttctccccta cagatccctg taaatgcttt tgatgcgtg acagaattaa aagttttacg 1020  
 tctacacagt aactctcttc agcatgtgcc cccaagatgg tttaagaaca tcaacaact 1080  
 ccaggaaact gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaatttct 1140  
 gcattttctc ccagcctca tccaattgga tctgtctttc aattttgaac ttcaggtcta 1200  
 tcgtgcatct atgaatctat cacaagcatt ttcttctactg aaaagcctga aaattctgcg 1260

gatcagagga tatgtcttta aagagttgaa aagctttaac ctctcgccat tacataatct	1320
tcaaaatctt gaagttcttg atcttggcac taactttata aaaattgcta acctcagcat	1380
gtttaaaciaa tttaaaagac tgaaagtcac agatctttca gtgaataaaa tatcaccttc	1440
aggagattca agtgaagttg gcttctgctc aaatgccaga acttctgtag aaagttatga	1500
accccaggtc ctggaacaat tacattatct cagatatgat aagtatgcaa ggagttgcag	1560
attcaaaaac aaagaggctt ctttcatgtc tgtaaatgaa agctgctaca agtatgggca	1620
gaccttgat ctaagtaaaa atagtatatt ttttgtcaag tcctctgatt ttcagcatct	1680
ttctttcttc aaatgcctga atctgtcagg aaatctcatt agccaaactc ttaatggcag	1740
tgaattccaa ctttagcag agttgagata tttggacttc tccaacaacc ggcttgattt	1800
actccattca acagcatttg aagagcttca caaactggaa gttctggata taagcagtaa	1860
tagccattat tttcaatcag aaggaattac tcatatgcta aactttacca agaacctaaa	1920
ggttctgcag aaactgatga tgaacgacaa tgacatctct tcctccacca gcaggacct	1980
ggagagtga tctcttagaa ctctggaatt cagaggaaat cacttagatg ttttatggag	2040
agaaggtgat aacagatact tacaattatt caagaatctg ctaaaattag aggaattaga	2100
catctctaaa aattccctaa gtttcttgcc ttctggagtt tttgatggta tgccctcaaa	2160
tctaaagaat ctctctttgg ccaaaaatgg gctcaaactt ttcagttgga agaaactcca	2220
gtgtctaaag aacctggaaa ctttggaact cagccacaac caactgacca ctgtccctga	2280
gagattatcc aactgttcca gaagccacaa gaatctgatt cttaagaata atcaaatcag	2340
gagtcagagc aagtatcttc tacaagatgc cttccagttg cgatatctgg atctcagctc	2400
aaataaaaatc cagatgatcc aaaagaccag cttcccagaa aatgtcctca acaatctgaa	2460
gatgttgctt ttgcatcata atcggtttct gtgcacctgt gatgctgtgt ggtttgtctg	2520
gtgggttaac catagggagg tgactattcc ttacctggcc acagatgtga cttgtgtggg	2580
gccaggagca cacaagggcc aaagtgtgat ctccctggat ctgtacacct gtgagttaga	2640
tctgactaac ctgattctgt tctcactttc catatctgta tctctctttc tcatggtgat	2700
gatgacagca agtcacctct atttctggga tgtgtggtat atttaccatt tctgtaaggc	2760
caagataaag gggatcagc gtctaataatc accagactgt tgctatgatg cttttattgt	2820
gtatgacact aaagaccag ctgtgaccga gtgggttttg gctgagctgg tggccaaact	2880
ggaagacca agagagaaac attttaattt atgtctcgag gaaagggact ggttaccagg	2940
gcagccagtt ctggaaaacc tttcccagag catagcctt agcaaaaaga cagtgtttgt	3000
gatgacagac aagtatgcaa agactgaaaa ttttaagata gcattttact tgtcccatca	3060
gaggctcatg gatgaaaaag ttgatgtgat tatcttgata tttcttgaga agccctttca	3120
gaagtccaag ttcctccagc tccggaaaag gctctgtggg agttctgtcc ttgagtggcc	3180

aacaaacccg caagctcacc catacttctg gcagtgtcta aagaacgccc tggccacaga 3240  
 caatcatgtg gcctatagtc aggtgttcaa ggaaacggtc tagcccttct ttgcaaaaca 3300  
 caactgccta gtttaccag gagaggcctg gctgtttaaa ttgttttcat atatatcaca 3360  
 ccaaaagcgt gttttgaaat tcttcaagaa atgagattgc ccatatttca ggggag 3416

<210> 33

<211> 3418

<212> DNA

<213> Homo sapiens

<400> 33

actccagata taggatcact ccatgccatc aagaaagttg atgctattgg gcccatctca 60  
 agctgatctt ggcacctctc atgctctgct ctcttcaacc agacctctac attccatttt 120  
 ggaagaagac taaaaatggg gtttccaatg tggacactga agagacaaat tcttatcctt 180  
 tttaacataa tcctaatttc caaactcctt ggggctagat ggtttcctaa aactctgccc 240  
 tgtgatgtca ctctggatgt tccaaagaac catgtgatcg tggactgcac agacaagcat 300  
 ttgacagaaa ttcttgagg tattcccacg aacaccacga acctcacct caccattaac 360  
 cacataccag acatctcccc agcgtccttt cacagactgg accatctggg agagatcgat 420  
 ttcagatgca actgtgtacc tattccactg ggggtcaaaaa acaacatgtg catcaagagg 480  
 ctgcagatta aaccagaag cttagtgga ctacttatt taaaatccct ttacctggat 540  
 ggaaaccagc tactagagat accgcagggc ctccgccta gcttacagct tctcagcctt 600  
 gaggccaaca acatcttttc catcagaaaa gagaatctaa cagaactggc caacatagaa 660  
 atactctacc tgggcaaaaa ctgttattat cgaaatcctt gttatgtttc atattcaata 720  
 gagaaagatg ctttctctaaa ctgacaaaag ttaaaagtgc tctccctgaa agataacaat 780  
 gtcacagccg tccctactgt tttgccatct actttaacag aactatatct ctacaacaac 840  
 atgattgcaa aaatccaaga agatgatttt aataacctca accaattaca aattcttgac 900  
 ctaagtggaa attgccctcg ttgttataat gcccatttc cttgtgcgcc gtgtaaaaat 960  
 aattctcccc tacagatccc tgtaaatgct tttgatgcgc tgacagaatt aaaagtttta 1020  
 cgtctacaca gtaactctct tcagcatgtg cccccaagat ggtttaagaa catcaacaaa 1080  
 ctccaggaac tggatctgtc ccaaaacttc ttggccaaag aaattgggga tgctaaattt 1140  
 ctgcattttc tccccagct catccaattg gatctgtctt tcaattttga acttcaggtc 1200  
 tatcgtgcat ctatgaatct atcacaagca tttcttctac tgaaaagcct gaaaattctg 1260  
 cggatcagag gatatgtctt taaagagttg aaaagcttta acctctcgcc attacataat 1320  
 cttcaaaatc ttgaagttct tgatcttggc actaacttta taaaaattgc taacctcagc 1380

atgtttaaac	aattttaaaag	actgaaagtc	atagatcttt	cagtgaataa	aatatcacct	1440
tcaggagatt	caagtgaagt	tggtctctgc	tcaaagtgcca	gaacttctgt	agaaagttat	1500
gaacccagg	tcctggaaca	attacattat	ttcagatatg	ataagtatgc	aaggagtgtc	1560
agattcaaaa	acaaagaggc	ttctttcatg	tctgttaatg	aaagctgcta	caagtatggg	1620
cagaccttgg	atctaagtaa	aaatagtata	ttttttgtca	agtcctctga	ttttcagcat	1680
ctttctttcc	tcaaagcct	gaatctgtca	ggaaatctca	ttagccaaac	tcttaatggc	1740
agtgaattcc	aacctttagc	agagctgaga	tatttggact	tctccaacaa	ccggcttgat	1800
ttactccatt	caacagcatt	tgaagagctt	cacaaactgg	aagttctgga	tataagcagt	1860
aatagccatt	atcttcaatc	agaaggaatt	actcatatgc	taaactttac	caagaacctc	1920
aaggttctgc	agaaactgat	gatgaacgac	aatgacatct	cttcctccac	cagcaggacc	1980
atggagagtg	agtctcttag	aactctggaa	ttcagaggaa	atcacttaga	tgttttatgg	2040
agagaaggty	ataacagata	cttacaatta	ttcaagaatc	tgctaaaatt	agaggaatta	2100
gacatctcta	aaaattccct	aagtttcttg	ccttctggag	tttttgatgg	tatgcctcca	2160
aatctaaaga	atctctcttt	ggccaaaaat	gggctcaaat	ctttcagttg	gaagaaactc	2220
cagtgtctaa	agaacctgga	aactttggac	ctcagccaca	accaactgac	cactgtccct	2280
gagagattat	ccaactgttc	cagaagcctc	agaatctga	ttcttaagaa	taatcaaatc	2340
aggagtctga	cgaagtatct	tctacaagat	gccttccagt	tgcgatatct	ggatctcagc	2400
tcaaataaaa	tccagatgat	ccaaaagacc	agcttcccag	aaaatgtcct	caacaatctg	2460
aagatgttgc	ttttgcatca	taatcggttt	ctgtgcacct	gtgatgctgt	gtggtttgtc	2520
tggtgggtta	accatacgga	ggtgactatt	ccttacctgg	ccacagatgt	gacttgtgtg	2580
gggccaggag	cacacaaggg	ccaaagtgtg	atctccctgg	atctgtacac	ctgtgagtta	2640
gatctgacta	acctgattct	gttctcaatt	tccatatctg	tatctctctt	tctcatggty	2700
atgatgacag	caagtcacct	ctatctctgg	gatgtgtggt	atatttacca	tttctgtaag	2760
gccagataa	aggggtatca	gcgtctaata	tcaccagact	gttgctatga	tgcttttatt	2820
gtgtatgaca	ctaaagaccc	agctgtgacc	gagtgggttt	tggtgagct	ggtggccaaa	2880
ctggaagacc	caagagagaa	acattttaat	ttatgtctcg	aggaaaggga	ctggttacca	2940
gggcagccag	ttctggaaaa	cctttcccag	agcatcacgc	ttagcaaaaa	gacagtgttt	3000
gtgatgacag	acaagtatgc	aaagactgaa	aattttaaga	tagcatttta	cttgccccat	3060
cagaggctca	tggtatgaaa	agttgatgtg	attatcttga	tatttcttga	gaagcccttt	3120
cagaagtcca	agttcctcca	gctccggaaa	aggctctgtg	ggagtctctg	ccttgagtgg	3180
ccaacaaacc	cgcaagctca	cccatacttc	tggcagtgtc	taaagaacgc	cctggccaca	3240
gacaatcatg	tggcctatag	tcaggtgttc	aaggaaacgg	tctagccctt	ctttgcaaaa	3300

cacaactgcc tagtttacca aggagaggcc tggctgttta aattgttttc atatatatca 3360  
 caccaaaagc gtgttttgaa attcttcaag aaatgagatt gcccatattt cagggggag 3418

<210> 34  
 <211> 1049  
 <212> PRT  
 <213> Homo sapiens

<400> 34

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
 1 5 10 15  
 Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
 35 40 45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
 65 70 75 80  
 Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
 85 90 95  
 Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
 100 105 110  
 Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
 115 120 125  
 Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140  
 Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
 210 215 220  
 Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
 225 230 235 240  
 Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro

260 265 270  
 Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
 340 345 350  
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
 355 360 365  
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
 405 410 415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435 440 445  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485 490 495  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp  
 500 505 510  
 Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
 515 520 525  
 Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
 530 535 540  
 Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
 545 550 555 560  
 Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
 565 570 575  
 Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
 580 585 590  
 Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile



			595				600				605						
Ser	Ser	Ser	Thr	Ser	Arg	Thr	Met	Glu	Ser	Glu	Ser	Leu	Arg	Thr	Leu		
610						615						620					
Glu	Phe	Arg	Gly	Asn	His	Leu	Asp	Val	Leu	Trp	Arg	Glu	Gly	Asp	Asn		
625					630					635					640		
Arg	Tyr	Leu	Gln	Leu	Phe	Lys	Asn	Leu	Leu	Lys	Leu	Glu	Glu	Leu	Asp		
				645					650						655		
Ile	Ser	Lys	Asn	Ser	Leu	Ser	Phe	Leu	Pro	Ser	Gly	Val	Phe	Asp	Gly		
			660					665					670				
Met	Pro	Pro	Asn	Leu	Lys	Asn	Leu	Ser	Leu	Ala	Lys	Asn	Gly	Leu	Lys		
		675					680					685					
Ser	Phe	Ser	Trp	Lys	Lys	Leu	Gln	Cys	Leu	Lys	Asn	Leu	Glu	Thr	Leu		
690						695					700						
Asp	Leu	Ser	His	Asn	Gln	Leu	Thr	Thr	Val	Pro	Glu	Arg	Leu	Ser	Asn		
705					710				715						720		
Cys	Ser	Arg	Ser	Leu	Lys	Asn	Leu	Ile	Leu	Lys	Asn	Asn	Gln	Ile	Arg		
				725				730						735			
Ser	Leu	Thr	Lys	Tyr	Phe	Leu	Gln	Asp	Ala	Phe	Gln	Leu	Arg	Tyr	Leu		
			740					745					750				
Asp	Leu	Ser	Ser	Asn	Lys	Ile	Gln	Met	Ile	Gln	Lys	Thr	Ser	Phe	Pro		
		755					760					765					
Glu	Asn	Val	Leu	Asn	Asn	Leu	Lys	Met	Leu	Leu	Leu	His	His	Asn	Arg		
770						775					780						
Phe	Leu	Cys	Thr	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn	His		
785					790					795					800		
Thr	Glu	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val	Gly		
				805					810					815			
Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr	Thr		
			820					825					830				
Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Leu	Ser	Ile	Ser		
		835					840					845					
Val	Ser	Leu	Phe	Leu	Met	Val	Met	Met	Thr	Ala	Ser	His	Leu	Tyr	Phe		
850						855					860						
Trp	Asp	Val	Trp	Tyr	Ile	Tyr	His	Phe	Cys	Lys	Ala	Lys	Ile	Lys	Gly		
865					870					875					880		
Tyr	Gln	Arg	Leu	Ile	Ser	Pro	Asp	Cys	Cys	Tyr	Asp	Ala	Phe	Ile	Val		
				885					890					895			
Tyr	Asp	Thr	Lys	Asp	Pro	Ala	Val	Thr	Glu	Trp	Val	Leu	Ala	Glu	Leu		
			900					905					910				
Val	Ala	Lys	Leu	Glu	Asp	Pro	Arg	Glu	Lys	His	Phe	Asn	Leu	Cys	Leu		
		915					920					925					
Glu	Glu	Arg	Asp	Trp	Leu	Pro	Gly	Gln	Pro	Val	Leu	Glu	Asn	Leu	Ser		

930                      935                      940  
 Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys  
 945                      950                      955                      960  
 Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln  
                     965                      970                      975  
 Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu  
                     980                      985                      990  
 Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys  
                     995                      1000                      1005  
 Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro  
                     1010                      1015                      1020  
 Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His  
                     1025                      1030                      1035  
 Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val  
                     1040                      1045

<210> 35  
 <211> 1049  
 <212> PRT  
 <213> Homo sapiens

<400> 35

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
 1                      5                      10                      15  
 Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
                     20                      25                      30  
 Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
                     35                      40                      45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
                     50                      55                      60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
 65                      70                      75                      80  
 Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
                     85                      90                      95  
 Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
                     100                      105                      110  
 Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
                     115                      120                      125  
 Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
                     130                      135                      140  
 Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145                      150                      155                      160  
 Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
                     165                      170                      175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
 210 215 220  
 Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
 225 230 235 240  
 Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
 260 265 270  
 Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
 340 345 350  
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
 355 360 365  
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
 405 410 415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435 440 445  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485 490 495  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp

75/231

835 840 845  
 Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe  
 850 855 860  
 Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly  
 865 870 875 880  
 Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val  
 885 890 895  
 Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu  
 900 905 910  
 Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu  
 915 920 925  
 Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser  
 930 935 940  
 Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys  
 945 950 955 960  
 Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln  
 965 970 975  
 Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu  
 980 985 990  
 Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys  
 995 1000 1005  
 Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro  
 1010 1015 1020  
 Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His  
 1025 1030 1035  
 Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val  
 1040 1045

<210> 36  
 <211> 1049  
 <212> PRT  
 <213> Homo sapiens

<400> 36

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
 1 5 10 15  
 Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
 35 40 45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
 65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
 85 90 95  
 Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
 100 105 110  
 Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
 115 120 125  
 Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140  
 Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
 210 215 220  
 Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
 225 230 235 240  
 Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
 260 265 270  
 Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
 340 345 350  
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
 355 360 365  
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met

405 410 415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435 440 445  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485 490 495  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp  
 500 505 510  
 Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
 515 520 525  
 Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
 530 535 540  
 Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
 545 550 555 560  
 Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
 565 570 575  
 Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
 580 585 590  
 Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile  
 595 600 605  
 Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu  
 610 615 620  
 Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn  
 625 630 635 640  
 Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp  
 645 650 655  
 Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly  
 660 665 670  
 Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys  
 675 680 685  
 Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu  
 690 695 700  
 Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn  
 705 710 715 720  
 Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg  
 725 730 735  
 Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu

```

      740      745      750
Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro
      755      760      765

Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg
      770      775      780

Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His
      785      790      795      800

Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly
      805      810      815

Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr
      820      825      830

Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser
      835      840      845

Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe
      850      855      860

Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly
      865      870      875      880

Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val
      885      890      895

Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu
      900      905      910

Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu
      915      920      925

Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser
      930      935      940

Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys
      945      950      955      960

Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln
      965      970      975

Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu
      980      985      990

Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys
      995      1000      1005

Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro
      1010      1015      1020

Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His
      1025      1030      1035

Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val
      1040      1045

```

<210> 37  
 <211> 1049  
 <212> PRT



&lt;213&gt; Homo sapiens

&lt;400&gt; 37

```

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe
1           5           10           15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys
          20           25           30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile
          35           40           45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro
          50           55           60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile
65           70           75           80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe
          85           90           95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys
          100          105          110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr
          115          120          125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln
130          135          140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile
145          150          155          160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile
          165          170          175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser
          180          185          190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val
          195          200          205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro
210          215          220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile
225          230          235          240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu
          245          250          255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro
          260          265          270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala
          275          280          285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
          290          295          300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp
305          310          315          320

```

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
 340 345 350  
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
 355 360 365  
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
 405 410 415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435 440 445  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485 490 495  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp  
 500 505 510  
 Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
 515 520 525  
 Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
 530 535 540  
 Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
 545 550 555 560  
 Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
 565 570 575  
 Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
 580 585 590  
 Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile  
 595 600 605  
 Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu  
 610 615 620  
 Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn  
 625 630 635 640  
 Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp

645 650 655  
 Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly  
 660 665 670  
 Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys  
 675 680 685  
 Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu  
 690 695 700  
 Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn  
 705 710 715 720  
 Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg  
 725 730 735  
 Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu  
 740 745 750  
 Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro  
 755 760 765  
 Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg  
 770 775 780  
 Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His  
 785 790 795 800  
 Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly  
 805 810 815  
 Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr  
 820 825 830  
 Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser  
 835 840 845  
 Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe  
 850 855 860  
 Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly  
 865 870 875 880  
 Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val  
 885 890 895  
 Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu  
 900 905 910  
 Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu  
 915 920 925  
 Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser  
 930 935 940  
 Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys  
 945 950 955 960  
 Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln  
 965 970 975  
 Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu

<210>	38		
<211>	3243		
<212>	DNA		
<213>	murine		
<400>	38		
attctcctcc accagacctc ttgattccat tttgaaagaa aactgaaaat ggtgttttcg			60
atgtggacac ggaagagaca aattttgatc tttttaata tgctcttagt ttctagagtc			120
tttgggtttc gatggtttcc taaaactcta ccttgtgaag ttaaagtaaa tatcccagag			180
gcccatgtga tcgtggactg cacagacaag catttgacag aaatccctga gggcattccc			240
actaacacca ccaatcttac ccttaccatc aaccacatac caagcatctc tccagattcc			300
ttccgtaggc tgaaccatct ggaagaaatc gatttaagat gcaattgtgt acctgttcta			360
ctgggggtcca aagccaatgt gtgtaccaag aggetgcaga ttagacctgg aagctttagt			420
ggactctctg acttaaaagc cctttacctg gatggaaacc aacttctgga gataccacag			480
gatctgccat ccagettaca tcttctgagc cttgaggcta acaacatctt ctccatcacg			540
aaggagaatc taacagaact ggccaacatt gaaacactct acctgggtca aaactgttat			600
tatcgaaatc cttgcaatgt ttcctattct attgaaaaag atgctttcct agttatgaga			660
aatttgaagg ttctctcact aaaagataac aatgtcacag ctgtccccac cactttgcca			720
cctaatttac tagagctcta tctttataac aatatatta agaaaatcca agaaaatgat			780
tttaataacc tcaatgagtt gcaagttctt gacctaatgt gaaattgccc tcgatgttat			840
aatgtcccat atccgtgtac accgtgtgaa aataattccc ccttacagat ccatgacaat			900
gctttcaatt cattgacaga attaaaagtt ttacgtttac acagtaattc tcttcagcat			960
gtgcccccaa catgggttta aaacatgaga aacctccagg aactagacct ctcccaaaac			1020
tacttgGCCA gagaaattga ggaggccaaa tttttgcatt ttcttcccaa ccttgttgag			1080
ttggattttt ctttcaatta tgagctgcag gtctaccatg catctataac ttaccacat			1140
tcactctctt cattggaaaa cttgaaaatt ctgcgtgtca aggggtatgt ctttaaagag			1200
ctgaaaaaact ccagctcttc tgtattgcac aagcttccca ggctggaagt tottgacctt			1260

```

ggcactaact tcataaaaat tgctgacctc aacatattca aacattttga aaacctcaaa 1320
ctcatagacc tttcagtga taagatatct ccttcagaag agtcaagaga agttggcttt 1380

tgtoctaata ctcaaacttc tgtagaccgt catgggcccc aggtccttga ggccttacac 1440
tatttccgat acgatgaata tgcacggagc tgcaggttca aaaacaaaga gccaccttct 1500
ttcttgccct tgaatgcaga ctgccacata tatgggcaga ccttagactt aagtagaaat 1560
aacatatttt ttattaaacc ttctgatttt cagcatcttt cattcctcaa atgcctcaac 1620
ttatcaggaa acaccattgg ccaaactctt aatggcagtg aactctggcc gttgagagag 1680
ttgcggtact tagactttct caacaaccgg cttgatttac tctactcaac agcctttgaa 1740
gagctccaga gtcttgaagt tctggatcta agtagtaaca gccactattt tcaagcagaa 1800
ggaattactc acatgctaaa ctttaccagg aaattacggc ttctggacaa actcatgatg 1860
aatgataatg acatctctac ttcgccagc aggaccatgg aaagtgactc tcttcgaatt 1920
ctggagtcca gaggcaacca tttagatgtt ctatggagag ccggtgataa cagatacttg 1980
gacttcttca agaatttggt caatttagag gtattagata tctccagaaa ttcctgaat 2040
tccttgccct ctgaggtttt tgagggtatg ccgccaaatc taaagaatct ctcttgggc 2100
aaaaatgggc tcaaactctt cttttgggac agactccagt tactgaagca tttggaaatt 2160
ttggacctca gccataacca gctgacaaaa gtacctgaga gattggccaa ctgttccaaa 2220
agtctcacia cactgattct taagcataat caaatcaggc aattgacaaa atattttcta 2280
gaagatgctt tgcaattgag ctatctagac atcagttcaa ataaaatcca ggtcattcag 2340
aagactagct tcccagaaaa tgcctcaac aatctggaga tgttggtttt acatcacaat 2400
cgctttcttt gcaactgtga tgctgtgtgg tttgtctggt gggttaacca tacagatgtt 2460
actattccat acctggccac tgatgtgact tgtgtaggtc caggagcaca caaaggtaaa 2520
agtgtcatat cccttgatct gtatacgtgt gagttagatc tcacaaacct gattctgttc 2580
tcagtttcca tatcatcagt cctctttctt atggtagtta tgacaacaag tcacctcttt 2640
ttctgggata tgtggtacat ttattatttt tggaaagcaa agataaaggg gtatcagcat 2700
ctgcaatcca tggagtcttg ttatgatgct tttattgtgt atgacactaa aaactcagct 2760
gtgacagaat gggttttgca ggagctggtg gcaaaattgg aagatccaag agaaaaacac 2820
ttcaatttgt gtctagaaga aagagactgg ctaccaggac agccagttct agaaaacctt 2880
tcccagagca tacagctcag caaaaagaca gtgtttgtga tgacacagaa atatgctaag 2940
actgagagtt ttaagatggc attttatttg tctcatcaga ggctcctgga tgaaaaagtg 3000
gatgtgatta tcttgatatt cttggaaaag cctcttcaga agtctaagtt tcttcagctc 3060
aggaagagac tctgcaggag ctctgtcctt gagtggcctg caaatccaca ggctcaccac 3120
tacttctggc agtgcctgaa aaatgccctg accacagaca atcatgtggc ttatagtcaa 3180

```

atgttcaagg aaacagtcta gctctctgaa gaatgtcacc acctaggaca tgccttgaat 3240  
 cga 3243

<210> 39  
 <211> 3747  
 <212> DNA  
 <213> murine

<400> 39  
 gagctcaaag gctctgcgag tctcggtttt ctgttgccct ctctctgtct cagaggactc 60  
 catctataga accactctat gccttcaaga aagatgtcct tggctccctt ctcaggatga 120  
 tcttggccta tctctgactc tcttctcctc caccagacct cttgattcca ttttgaaaga 180  
 aaactgaaaa tgggtgttttc gatgtggaca cggaagagac aaattttgat ctttttaaata 240  
 atgctcttag tttctagagt ctttgggttt cgatgggttc ctaaaactct accttgtgaa 300  
 gttaaagtaa atatcccaga ggcccatgtg atcgtggact gcacagacaa gcatttgaca 360  
 gaaatccctg agggcattcc cactaacacc accaatctta cccttaccat caaccacata 420  
 ccaagcatct ctccagattc cttccgtagg ctgaaccatc tggaagaaat cgatttaaga 480  
 tgcaattgtg tacctgttct actgggggtcc aaagccaatg tgtgtacca gaggctgcag 540  
 attagacctg gaagcttttag tggactctct gacttaaaag ccctttacct ggatggaaac 600  
 caacttctgg agataccaca ggatctgcca tccagcttac atcttctgag ccttgaggct 660  
 aacaacatct tctccatcac gaaggagaat ctaacagAAC tggtaacat tgaaacactc 720  
 tacctgggtc aaaactgtta ttatcgaaat ccttgcaatg tttcctattc tattgaaaaa 780  
 gatgctttcc tagttatgag aaatttgaag gttctctcac taaaagataa caatgtcaca 840  
 gctgtcccca ccactttgcc acctaattta ctagagctct atctttataa caatatcatt 900  
 aagaaaatcc aagaaaatga ttttaataac ctcaatgagt tgcaagttct tgacctaatg 960  
 ggaaattgcc ctogatgtta taatgtccca tatccgtgta caccgtgtga aaataattcc 1020  
 cccttacaga tccatgacaa tgctttcaat tcattgacag aattaaaagt tttacgttta 1080  
 cacagtaatt ctcttcagca tgtgccccca acatgggttta aaaacatgag aaacctccag 1140  
 gaactagacc tctcccaaaa ctacttggtc agagaaattg aggaggccaa atttttgcat 1200  
 tttcttccca accttgttga gttggatttt tctttcaatt atgagctgca ggtctaccat 1260  
 gcatctataa ctttaccaca ttactctctc tcattggaaa acttgaaaat tctgcgtgtc 1320  
 aaggggtatg tctttaaaga gctgaaaaac tccagtcttt ctgtattgca caagcttccc 1380  
 aggctggaag ttcttgacct tggcactaac ttcataaaaa ttgctgacct caacatattc 1440  
 aaacattttg aaaacctcaa actcatagac ctttcagtga ataagatatc tccttcagaa 1500

gagtc	aagag	aagttggctt	ttgtccta	at	gctcaa	actt	ctgtag	accg	tcat	ggggccc	1560	
caggtc	ccttg	aggccttaca	ctatttccga	tacgat	gaat	atgcac	ggag	ctgc	cagg	ttc	1620	
aaaaa	caaag	agccac	ccttc	tttcttgc	cct	ttgaat	gcag	actgcc	acat	atatgggcag	1680	
acctta	gact	taagtagaaa	taacata	ttt	ttaa	aac	cttctg	attt	tcag	catcctt	1740	
tcattc	ctca	aatgcctcaa	cttatcagga	aacacc	attg	gccaaa	actct	taat	ggcag	t	1800	
gaactc	tggc	cgttgagaga	gttgcggtac	ttagact	ttct	ccaaca	aaccg	gcttg	attta		1860	
ctctac	tcaa	cagcctttga	agagctccag	agtcttga	ag	ttctgg	atct	aagtag	taac		1920	
agccact	att	ttcaagcaga	aggaattact	cacatg	ctaa	actttac	caa	gaaatt	acgg		1980	
cttctg	gaca	aactcatgat	gaatgataat	gacatct	cta	cttcgg	ccag	caggac	catg		2040	
gaaagt	gact	ctcttcgaat	tctggagttc	agaggca	acc	atttag	atgt	tctatg	ggaga		2100	
gccggt	gata	acagatactt	ggacttcttc	aagaattt	gt	tcaattt	aga	ggtatt	tagat		2160	
atctcc	agaa	attccctgaa	ttccttgc	cctgag	gttt	ttgagg	gtat	gccgcc	aaat		2220	
ctaaag	aatc	tctccttggc	caaaaatggg	ctcaa	atctt	tctttt	ggga	cagact	ccag		2280	
ttactg	aaagc	atttggaat	tttggac	ctc	agccata	acc	agctga	caaaa	agtac	ctgag	2340	
agattg	ggcca	actgttccaa	aagtctcaca	acactg	at	ttaa	gcataa	tcaaat	cagg		2400	
caattg	acaa	aatattttct	agaagatgct	ttgca	attgc	gctat	ctaga	catcag	ttca		2460	
aataaa	atcc	aggtcattca	gaagactagc	ttccc	agaaa	atgtc	cctcaa	caatct	ggag		2520	
atgttg	gtttt	tacatcacaa	tcgctttctt	tgcaac	tg	atgctg	tg	gtttg	tctgg		2580	
tgggtt	aacc	atacagatgt	tactattcca	tacctg	ggcca	ctgat	gtgac	ttgtg	taggt		2640	
ccaggag	cac	acaaagg	tca	aagtgt	cata	tcctt	gatc	tgtata	cgtg	tgagttagat	2700	
ctcacaa	acc	tgattctgtt	ctcagtttcc	atatcat	cag	tcctc	tttct	tatgg	tagtt		2760	
atgaca	acaa	gtcacctctt	tttctgggat	atgtgg	taca	tttatt	attt	ttggaa	agca		2820	
aagataa	agg	ggtatcagca	tctgcaatcc	atggag	tctt	gttat	gatgc	ttttat	tgtg		2880	
tatgac	acta	aaaactcagc	tgtgacagaa	tgggttttgc	aggag	ctggt	ggcaaaa	attg			2940	
gaagat	ccaa	gagaaaaaca	cttcaatttg	tgtctaga	ag	aaagag	actg	gctacc	agga		3000	
cagccag	ttc	tagaaa	acct	ttccc	agagc	atacag	ctca	gcaaaa	agac	agtgtttgtg	3060	
atgacac	aga	aatatg	ctaa	gactgag	agt	tttaag	atgg	catttt	attt	gtctcatcag	3120	
aggctc	cttg	atgaaaa	agt	ggatgt	gatt	atctt	gat	at	tcttg	gaaaa	gcctcttcag	3180
aagtcta	agt	ttcttcag	ct	cagga	agaga	ctctg	cagga	gctctg	tcct	tgagtggcct	3240	
gcaaat	ccac	aggctc	accc	atactt	ctgg	cagtgc	ctga	aaaatg	ccct	gaccacagac	3300	
aatcat	gtgg	cttatag	tca	aatgtt	caag	gaaacag	tct	agctct	ctga	agaatgtcac	3360	
cacctag	gac	atgcctt	ggt	acctga	agtt	ttcataa	agg	tttcata	aaa	tgaagg	tctg	3420

aatttttccct aacagttgtc atggctcaga ttggtgggaa atcatcaata tatggctaag 3480  
aaattaagaa ggggagactg atagaagata atttctttct tcatgtgcca tgctcagtta 3540  
aatatttccc ctagctcaaa tctgaaaaac tgtgcctagg agacaacaca aggctttgat 3600  
ttatctgcat acaattgata agagccacac atctgccttg aagaagtact agtagtttta 3660  
gtagtagggg aaaaattaca caagctttct ctctctctga tactgaactg taccagagtt 3720  
caatgaaata aaagcccaga gaacttc 3747

<210> 40  
<211> 3449  
<212> DNA  
<213> murine

<400> 40  
gcgagtctcg gttttctggt gccttctctc tgtctcagag gactccatct atagaaccac 60  
tctatgcctt caagaaagat gtccttggct cccttctcag gatgatcctg gcctatctct 120  
gactctcttc tctccacca gacctcttga ttccattttg aaagaaaact gaaaatgggtg 180  
ttttcgatgt ggacacggaa gagacaaatt ttgatctttt taaatatgct cttagtttct 240  
agagtctttg ggtttcgatg gtttctctaa actctacctt gtgaagttaa agtaaatatc 300  
ccagaggccc atgtgatcgt ggactgcaca gacaagcatt tgacagaaat ccctgagggc 360  
attcccacta acaccaccaa tcttaccctt accatcaacc acataccaag catctctcca 420  
gattccttcc gtaggctgaa ccatctggaa gaaatcgatt taagatgcaa ttgtgtacct 480  
gttctactgg ggtccaaagc caatgtgtgt accaagaggc tgcagattag acctggaagc 540  
tttagtggac tctctgactt aaaagccctt tacctggatg gaaaccaact tctggagata 600  
ccacaggatc tgccatccag cttacatctt ctgagccttg aggctaacaa catcttctcc 660  
atcacgaagg agaactctaa agaactggtc aacattgaaa cactctacct gggcctctga 720  
tgttattatc gaaatccttg caatgtttcc tattctattg aaaaagatgc tttcctagtt 780  
atgagaaatt tgaaggttct ctactaaaa gataacaatg tcacagctgt cccaccact 840  
ttgccaccta atttactaga gctctatctt tataacaata tcattaagaa aatccaagaa 900  
aatgatttta ataacctcaa tgagttgcaa gttcttgacc taagtggaaa ttgccctcga 960  
tggtataatg tcccatatcc gtgtacaccg tgtgaaaata attccccctt acagatccat 1020  
gacaatgctt tcaattcatt gacagaatta aaagttttac gtttacacag taattctctt 1080  
cagcatgtgc ccccaacatg gtttaaaaac atgagaaacc tccaggaact agacctctcc 1140  
caaaactact tggccagaga aattgaggag gccaaathtt tgcattttct tcccaacctt 1200  
gttgagttgg atttttcttt caattatgag ctgcaggtct accatgcac tataacttta 1260



ccacattcac tctcttcatt ggaaaacttg aaaattctgc gtgtcaaggg gtatgtcttt	1320
aaagagctga aaaactccag tctttctgta ttgcacaagc ttcccaggct ggaagttctt	1380
gaccttgga ctaacttcat aaaaattgct gacctcaaca tattcaaaaca ttttgaaaac	1440
ctcaaaactca tagacctttc agtgaataag atatctcctt cagaagagtc aagagaagtt	1500
ggcttttgtc ctaatgctca aacttctgta gaccgtcatg ggccccaggc ccttgaggcc	1560
ttacactatt tccgatacga tgaatatgca cggagctgca gggtcaaaaa caaagagcca	1620
ccttctttct tgcctttgaa tgcagactgc cacatatatg ggcagacctt agacttaagt	1680
agaaataaca tttttttat taaaccttct gattttcagc atctttcatt cctcaaatgc	1740
ctcaacttat caggaaacac cattggccaa actcttaatg gcagtgaact ctggccgttg	1800
agagagttgc ggtacttaga cttctccaac aaccggcttg atttactcta ctcaacagcc	1860
tttgaagagc tccagagtct tgaagttctg gatctaagta gtaacagcca ctattttcaa	1920
gcagaaggaa ttactcacat gctaaacttt accaagaaat tacggcttct ggacaaactc	1980
atgatgaatg ataatgacat ctctacttcg gccagcagga ccatggaaag tgactctctt	2040
cgaattcttg agttcagagg caaccattta gatgttctat ggagagccgg tgataacaga	2100
tacttggaact tcttcaagaa tttgttcaat ttagagggtat tagatatctc cagaaattcc	2160
ctgaattcct tgcctcctga ggtttttgag ggtatgccgc caaatctaaa gaatctctcc	2220
ttggccaaaa atgggctcaa atctttcttt tgggacagac tccagttact gaagcatttg	2280
gaaattttg acctcagcca taaccagctg acaaaaagtac ctgagagatt ggccaactgt	2340
tccaaaagtc tcacaacact gattcttaag cataatcaaa tcaggcaatt gacaaaatat	2400
tttctagaag atgctttgca attgcgctat ctagacatca gttcaaataa aatccaggtc	2460
attcagaaga ctagcttccc agaaaatgtc ctcaacaatc tggagatgtt ggttttacat	2520
cacaatcgtc ttctttgcaa ctgtgatgct gtgtggtttg tctggtgggt taaccataca	2580
gatgttacta ttccatacct ggccactgat gtgacttggt taggtccagg agcacacaaa	2640
gggtcaaagt tcatatccct tgatctgtat acgtgtgagt tagatctcac aaacctgatt	2700
ctgttctcag tttccatatc atcagtcctc tttcttatgg tagttatgac aacaagtcac	2760
ctctttttct gggatatgtg gtacatttat ttttttgga aagcaaagat aaaggggtat	2820
cagcatctgc aatccatgga gtcttggtat gatgctttta ttgtgtatga cactaaaaac	2880
tcagctgtga cagaatgggt ttgacaggag ctgggtggca aattggaaga tccaagagaa	2940
aaacacttca atttgtgtct agaagaaaga gactggctac caggacagcc agttctagaa	3000
aacctttccc agagcataca gctcagcaaa aagacagtgt ttgtgatgac acagaaatat	3060
gctaagactg agagttttta gatggcattt ttttgtctc atcagaggct cctggatgaa	3120
aaagtggatg tgattatctt gatattcttg gaaaagcctc ttcagaagtc taagtttctt	3180

cagctcagga agagactctg caggagctct gtccttgagt ggcctgcaaa tccacaggct 3240  
 caccataact tctggcagtg cctgaaaaat gccctgacca cagacaatca tgtgggttat 3300  
 agtcaaagt tcaaggaaac agtctagctc tctgaagaat gtcaccacct aggacatgcc 3360  
 ttggtacctg aagttttcat aaaggtttcc ataatgaag gtctgaattt ttcctaacag 3420  
 ttgtcatggc tcagattggg gggaaatca 3449

<210> 41  
 <211> 1050  
 <212> PRT  
 <213> murine

<400> 41

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140  
 Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile

90/231

565 570 575  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
 580 585 590  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
 595 600 605  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
 610 615 620  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625 630 635 640  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
 645 650 655  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
 660 665 670  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
 675 680 685  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
 690 695 700  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
 705 710 715 720  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
 725 730 735  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
 740 745 750  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
 755 760 765  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
 770 775 780  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785 790 795 800  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
 805 810 815  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
 820 825 830  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
 835 840 845  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
 850 855 860  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865 870 875 880  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
 885 890 895  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu

900 905 910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915 920 925  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930 935 940  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945 950 955 960  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
 965 970 975  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
 980 985 990  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
 995 1000 1005  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
 1010 1015 1020  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
 1025 1030 1035  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
 1040 1045 1050

<210> 42  
 <211> 1050  
 <212> PRT  
 <213> murine

<400> 42

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys

465                      470                      475                      480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
                                  485                      490                      495  
  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
                                  500                      505                      510  
  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
                                  515                      520                      525  
  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
                                  530                      535                      540  
  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545                                   550                      555                      560  
  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
                                  565                      570                      575  
  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
                                  580                      585                      590  
  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
                                  595                      600                      605  
  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
                                  610                      615                      620  
  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625                                   630                      635                      640  
  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
                                  645                      650                      655  
  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
                                  660                      665                      670  
  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
                                  675                      680                      685  
  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
                                  690                      695                      700  
  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
 705                                   710                      715                      720  
  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
                                  725                      730                      735  
  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
                                  740                      745                      750  
  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
                                  755                      760                      765  
  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
                                  770                      775                      780  
  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785                                   790                      795                      800  
  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val

805 810 815  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
 820 825 830  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
 835 840 845  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
 850 855 860  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865 870 875 880  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
 885 890 895  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
 900 905 910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915 920 925  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930 935 940  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945 950 955 960  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
 965 970 975  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
 980 985 990  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
 995 1000 1005  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
 1010 1015 1020  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
 1025 1030 1035  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
 1040 1045 1050

<210> 43  
 <211> 1050  
 <212> PRT  
 <213> murine

<400> 43

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45



Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140  
 Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu

370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
 485 490 495  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
 500 505 510  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
 515 520 525  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
 530 535 540  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545 550 555 560  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
 565 570 575  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
 580 585 590  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
 595 600 605  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
 610 615 620  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625 630 635 640  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
 645 650 655  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
 660 665 670  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
 675 680 685  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
 690 695 700  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala

705				710				715				720			
Asn	Cys	Ser	Lys	Ser	Leu	Thr	Thr	Leu	Ile	Leu	Lys	His	Asn	Gln	Ile
725				730				735							
Arg	Gln	Leu	Thr	Lys	Tyr	Phe	Leu	Glu	Asp	Ala	Leu	Gln	Leu	Arg	Tyr
740				745				750							
Leu	Asp	Ile	Ser	Ser	Asn	Lys	Ile	Gln	Val	Ile	Gln	Lys	Thr	Ser	Phe
755				760				765							
Pro	Glu	Asn	Val	Leu	Asn	Asn	Leu	Glu	Met	Leu	Val	Leu	His	His	Asn
770				775				780							
Arg	Phe	Leu	Cys	Asn	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn
785				790				795				800			
His	Thr	Asp	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val
805				810				815							
Gly	Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr
820				825				830							
Thr	Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Val	Ser	Ile
835				840				845							
Ser	Ser	Val	Leu	Phe	Leu	Met	Val	Val	Met	Thr	Thr	Ser	His	Leu	Phe
850				855				860							
Phe	Trp	Asp	Met	Trp	Tyr	Ile	Tyr	Tyr	Phe	Trp	Lys	Ala	Lys	Ile	Lys
865				870				875				880			
Gly	Tyr	Gln	His	Leu	Gln	Ser	Met	Glu	Ser	Cys	Tyr	Asp	Ala	Phe	Ile
885				890				895							
Val	Tyr	Asp	Thr	Lys	Asn	Ser	Ala	Val	Thr	Glu	Trp	Val	Leu	Gln	Glu
900				905				910							
Leu	Val	Ala	Lys	Leu	Glu	Asp	Pro	Arg	Glu	Lys	His	Phe	Asn	Leu	Cys
915				920				925							
Leu	Glu	Glu	Arg	Asp	Trp	Leu	Pro	Gly	Gln	Pro	Val	Leu	Glu	Asn	Leu
930				935				940							
Ser	Gln	Ser	Ile	Gln	Leu	Ser	Lys	Lys	Thr	Val	Phe	Val	Met	Thr	Gln
945				950				955				960			
Lys	Tyr	Ala	Lys	Thr	Glu	Ser	Phe	Lys	Met	Ala	Phe	Tyr	Leu	Ser	His
965				970				975							
Gln	Arg	Leu	Leu	Asp	Glu	Lys	Val	Asp	Val	Ile	Ile	Leu	Ile	Phe	Leu
980				985				990							
Glu	Lys	Pro	Leu	Gln	Lys	Ser	Lys	Phe	Leu	Gln	Leu	Arg	Lys	Arg	Leu
995				1000				1005							
Cys	Arg	Ser	Ser	Val	Leu	Glu	Trp	Pro	Ala	Asn	Pro	Gln	Ala	His	
1010				1015				1020							
Pro	Tyr	Phe	Trp	Gln	Cys	Leu	Lys	Asn	Ala	Leu	Thr	Thr	Asp	Asn	
1025				1030				1035							
His	Val	Ala	Tyr	Ser	Gln	Met	Phe	Lys	Glu	Thr	Val				

1040  
 <210> 44  
 <211> 1050  
 <212> PRT  
 <213> murine  
  
 <400> 44  
  
 Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15  
  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30  
  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45  
  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60  
  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80  
  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95  
  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110  
  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125  
  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140  
  
 Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
 485 490 495  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
 500 505 510  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
 515 520 525  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
 530 535 540  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545 550 555 560  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
 565 570 575  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
 580 585 590  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
 595 600 605  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile

610                      615                      620  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625                      630                      635                      640  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
 645                      650                      655  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
 660                      665                      670  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
 675                      680                      685  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
 690                      695                      700  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
 705                      710                      715                      720  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
 725                      730                      735  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
 740                      745                      750  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
 755                      760                      765  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
 770                      775                      780  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785                      790                      795                      800  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
 805                      810                      815  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
 820                      825                      830  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
 835                      840                      845  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
 850                      855                      860  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865                      870                      875                      880  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
 885                      890                      895  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
 900                      905                      910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915                      920                      925  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930                      935                      940  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln

Met 1	Val	Phe	Ser	Met 5	Trp	Thr	Arg	Lys	Arg 10	Gln	Ile	Leu	Ile	Phe 15	Leu
Asn	Met	Leu	Leu 20	Val	Ser	Arg	Val	Phe 25	Gly	Phe	Arg	Trp	Phe 30	Pro	Lys
Thr	Leu	Pro 35	Cys	Glu	Val	Lys	Val 40	Asn	Ile	Pro	Glu	Ala 45	His	Val	Ile
Val	Asp 50	Cys	Thr	Asp	Lys	His 55	Leu	Thr	Glu	Ile	Pro 60	Glu	Gly	Ile	Pro
Thr 65	Asn	Thr	Thr	Asn 70	Leu	Thr	Leu	Thr	Ile 75	Asn	His	Ile	Pro	Ser 80	Ile
Ser	Pro	Asp	Ser	Phe 85	Arg	Arg	Leu	Asn	His 90	Leu	Glu	Glu	Ile	Asp 95	Leu
Arg	Cys	Asn	Cys 100	Val	Pro	Val	Leu	Leu 105	Gly	Ser	Lys	Ala	Asn 110	Val	Cys
Thr	Lys	Arg 115	Leu	Gln	Ile	Arg	Pro 120	Gly	Ser	Phe	Ser	Gly 125	Leu	Ser	Asp
Leu 130	Lys	Ala	Leu	Tyr	Leu	Asp 135	Gly	Asn	Gln	Leu	Leu 140	Glu	Ile	Pro	Gln
Asp 145	Leu	Pro	Ser	Ser	Leu 150	His	Leu	Leu	Ser	Leu 155	Glu	Ala	Asn	Asn	Ile 160
Phe	Ser	Ile	Thr	Lys 165	Glu	Asn	Leu	Thr	Glu 170	Leu	Val	Asn	Ile	Glu 175	Thr
Leu	Tyr	Leu	Gly 180	Gln	Asn	Cys	Tyr	Tyr 185	Arg	Asn	Pro	Cys	Asn 190	Val	Ser

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
 485 490 495  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
 500 505 510  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn



Thr	Ile	Gly	Gln	Thr	Leu	Asn	Gly	Ser	Glu	Leu	Trp	Pro	Leu	Arg	Glu
530						535					540				
Leu	Arg	Tyr	Leu	Asp	Phe	Ser	Asn	Asn	Arg	Leu	Asp	Leu	Leu	Tyr	Ser
545					550					555					560
Thr	Ala	Phe	Glu	Glu	Leu	Gln	Ser	Leu	Glu	Val	Leu	Asp	Leu	Ser	Ser
				565					570					575	
Asn	Ser	His	Tyr	Phe	Gln	Ala	Glu	Gly	Ile	Thr	His	Met	Leu	Asn	Phe
			580					585					590		
Thr	Lys	Lys	Leu	Arg	Leu	Leu	Asp	Lys	Leu	Met	Met	Asn	Asp	Asn	Asp
		595					600					605			
Ile	Ser	Thr	Ser	Ala	Ser	Arg	Thr	Met	Glu	Ser	Asp	Ser	Leu	Arg	Ile
	610					615					620				
Leu	Glu	Phe	Arg	Gly	Asn	His	Leu	Asp	Val	Leu	Trp	Arg	Ala	Gly	Asp
625					630					635					640
Asn	Arg	Tyr	Leu	Asp	Phe	Phe	Lys	Asn	Leu	Phe	Asn	Leu	Glu	Val	Leu
				645					650					655	
Asp	Ile	Ser	Arg	Asn	Ser	Leu	Asn	Ser	Leu	Pro	Pro	Glu	Val	Phe	Glu
			660					665					670		
Gly	Met	Pro	Pro	Asn	Leu	Lys	Asn	Leu	Ser	Leu	Ala	Lys	Asn	Gly	Leu
		675					680					685			
Lys	Ser	Phe	Phe	Trp	Asp	Arg	Leu	Gln	Leu	Leu	Lys	His	Leu	Glu	Ile
	690					695						700			
Leu	Asp	Leu	Ser	His	Asn	Gln	Leu	Thr	Lys	Val	Pro	Glu	Arg	Leu	Ala
705					710					715					720
Asn	Cys	Ser	Lys	Ser	Leu	Thr	Thr	Leu	Ile	Leu	Lys	His	Asn	Gln	Ile
				725					730					735	
Arg	Gln	Leu	Thr	Lys	Tyr	Phe	Leu	Glu	Asp	Ala	Leu	Gln	Leu	Arg	Tyr
			740					745					750		
Leu	Asp	Ile	Ser	Ser	Asn	Lys	Ile	Gln	Val	Ile	Gln	Lys	Thr	Ser	Phe
		755					760					765			
Pro	Glu	Asn	Val	Leu	Asn	Asn	Leu	Glu	Met	Leu	Val	Leu	His	His	Asn
	770					775					780				
Arg	Phe	Leu	Cys	Asn	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn
785					790					795					800
His	Thr	Asp	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val
			805						810					815	
Gly	Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr
			820				825						830		
Thr	Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Val	Ser	Ile
		835					840					845			
Ser	Ser	Val	Leu	Phe	Leu	Met	Val	Val	Met	Thr	Thr	Ser	His	Leu	Phe

850                      855                      860  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865                      870                      875                      880  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
                                  885                      890                      895  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
                                  900                      905                      910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
                                  915                      920                      925  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
                                  930                      935                      940  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945                      950                      955                      960  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
                                  965                      970                      975  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
                                  980                      985                      990  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
                                  995                      1000                      1005  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
                                  1010                      1015                      1020  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
                                  1025                      1030                      1035  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
                                  1040                      1045                      1050

&lt;210&gt; 46

&lt;211&gt; 3311

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca acagaaacat ggaaaacatg 60  
 ttcttctcagt cgtcaatgct gacctgcatt ttcttgctaa tatctgggtc ctgtgagtta 120  
 tgccgccaag aaaatttttc tagaagctat ctttgtgatg agaaaaagca aaatgactca 180  
 gttattgcag agtgcagcaa tcgtcgacta caggaagttc cccaaacggt gggcaaatat 240  
 gtgacagaac tagacctgtc tgataatttc atcacacaca taacgaatga atcatttcaa 300  
 gggctgcaaa atctcactaa aataaatcta aaccacaacc ccaatgtaca gcaccagaac 360  
 ggaaatcccg gtatacaatc aaatggcttg aatatcacag acggggcatt cctcaacctt 420  
 aaaaacctaa gggagttact gcttgaagac aaccagttac cccaaatacc ctctggtttg 480  
 ccagagtctt tgacagaact tagtctaatt caaaacaata tataacaacat aactaaagag 540

ggcatttcaa gacttataaa cttgaaaaat ctctatattg cctggaactg ctattttaac	600
aaagtttgcg agaaaactaa catagaagat ggagtatttg aaacgctgac aaatttgag	660
ttgctatcac tatctttcaa ttctctttca cacgtgccac ccaaactgcc aagctcccta	720
cgcaaacttt ttctgagcaa caccagatc aaatacatta gtgaagaaga tttcaaggga	780
ttgataaatt taacattact agatttaagc gggaactgtc cgagggtgctt caatgcccc	840
tttccatgcg tgccttgatg tgggtggtgct tcaattaata tagatcgttt tgcttttcaa	900
aacttgaccc aacttcgata cctaaacctc tctagcactt ccctcaggaa gattaatgct	960
gcctgggttta aaaatatgcc tcatctgaag gtgctggatc ttgaattcaa ctatttagtg	1020
ggagaaatag cctctggggc atttttaacg atgctgcccc gcttagaaat acttgacttg	1080
tcttttaact atataaaggg gagttatcca cagcatatta atatttccag aaacttctct	1140
aaacttttgt ctctacgggc attgcattta agaggttatg tgttccagga actcagagaa	1200
gatgatttcc agccctgat gcagcttcca aacttatcga ctatcaactt gggattaat	1260
tttattaagc aaatcgattt caaacttttc caaaatttct ccaatctgga aattatttac	1320
ttgtcagaaa acagaatatc accgttggtg aaagataccc ggcagagtta tgcaaatagt	1380
tcctcttttc aacgtcatat ccggaacga cgctcaacag attttgagtt tgaccacat	1440
tcgaactttt atcatttcac ccgtccttta ataaagccac aatgtgctgc ttatggaaaa	1500
gccttagatt taagcctcaa cagtattttc ttcatgggc caaaccaatt tgaaaatctt	1560
cctgacattg cctgtttaaa tctgtctgca aatagcaatg ctcaagtgtt aagtggact	1620
gaattttcag ccattcctca tgtcaaatat ttggatttga caaacaatag actagacttt	1680
gataatgcta gtgctcttac tgaattgtcc gacttggaag ttctagatct cagctataat	1740
tcacactatt tcagaatagc aggcgtaaca catcatctag aatttattca aaatttcaca	1800
aatctaaaag ttttaactt gagccacaac aacatttata ctttaacaga taagtataac	1860
ctggaaagca agtccctggt agaattagtt ttcagtggca atcgccctga cattttgtgg	1920
aatgatgatg acaacaggta tatctccatt ttcaaaggtc tcaagaatct gacacgtctg	1980
gatttatccc ttaataggct gaagcacatc ccaaatgaag cattccttaa ttgcccagcg	2040
agtctcactg aactacatat aaatgataat atgttaaagt tttttaactg gacattactc	2100
cagcagttcc ctgctctcga gttgcttgac ttacgtggaa acaaactact ctttttaact	2160
gatagcctat ctgactttac atcttccctt cggacactgc tgctgagtca taacaggatt	2220
ttccacctac cctctggctt tctttctgaa gtcagtagtc tgaagcacct cgatttaagt	2280
ttcaatctgc taaaaacaat caacaaatcc gcacttgaaa ctaagaccac caccaaatta	2340
totatgttgg aactacacgg aaacccttt gaatgcacct gtgacattgg agatttccga	2400
agatggatgg atgaacatct gaatgtcaaa attcccagac tggtagatgt catttgtgcc	2460

agtcctgggg atcaaagagg gaagagtatt gtgagtcctgg agctgacaac ttgtgtttca 2520  
 gatgtcactg cagtgatatt atttttcttc acgttcttta tcaccaccat gggtatgttg 2580  
 gctgccctgg ctccacattt gttttactgg gatgtttggg ttatatataa tgtgtgttta 2640  
 gctaaggtaa aaggctacag gtctctttcc acatcccaaa ctttctatga tgcttacatt 2700  
 tcttatgaca ccaaagatgc ctctgttact gactgggtga taaatgagct gcgctaccac 2760  
 cttgaagaga gccgagacaa aaacgttctc ctttgtctag aggagagggg ttgggacccg 2820  
 ggattggcca tcatcgacaa cctcatgcag agcatcaacc aaagcaagaa aacagtattt 2880  
 gttttaacca aaaaatatgc aaaaagctgg aactttaaaa cagcttttta cttggctttg 2940  
 cagaggctaa tggatgagaa catggatgtg attatattta tcctgctgga gccagtgtta 3000  
 cagcattctc agtatttgag gctacggcag cggatctgta agagctccat cctccagtgg 3060  
 cctgacaacc cgaaggcaga aggcttgttt tggcaaactc tgagaaatgt ggtcttgact 3120  
 gaaaatgatt cacggtataa caatatgtat gtcgattcca ttaagcaata ctaactgacg 3180  
 ttaagtcatg atttcgcgcc ataataaaga tgcaaaggaa tgacatttct gtattagtta 3240  
 tctattgcta tgtaacaaat tatcccaaaa cttagtgggt taaaacaaca catttgctgg 3300  
 cccacagttt t 3311

<210> 47

<211> 3367

<212> DNA

<213> Homo sapiens

<400> 47

ctctgcata gaggtacca ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca 60  
 acagaaacgt ggttctcttg acacttcagt gttagggaac atcagcaaga cccatcccag 120  
 gagaccttga aggaagcctt tgaaaggagg aatgaaggag tcatctttgc aaaatagctc 180  
 ctgcagcctg ggaaaggaga ctaaaaagga aaacatgttc cttcagtcgt caatgctgac 240  
 ctgcattttc ctgctaatat ctggttcctg tgagttatgc gccgaagaaa atttttctag 300  
 aagctatcct tgtgatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg 360  
 tcgactacag gaagttcccc aaacgggtggg caaatatgtg acagaactag acctgtctga 420  
 taatttcatt acacacataa cgaatgaatc atttcaaggg ctgcaaaatc tcactaaaat 480  
 aaatctaaac cacaacccca atgtacagca ccagaacgga aatcccggta tacaatcaaa 540  
 tggcttgaat atcacagacg gggcattcct caacctaaaa aacctaaagg agttactgct 600  
 tgaagacaac cagttacccc aaataccctc tggtttgcca gagtctttga cagaacttag 660  
 tctaattcaa aacaatatat acaacataac taaagagggc atttcaagac ttataaactt 720

gaaaaatctc tatttggcct ggaactgcta ttttaacaaa gtttgcgaga aaactaacat	780
agaagatgga gtatttgaaa cgctgacaaa tttggagttg ctatcactat ctttcaattc	840
tctttcacac gtgtcaccca aactgccaag ctccctacgc aaactttttc tgagcaacac	900
ccagatcaaa tacattagtg aagaagattt caagggattg ataaatttaa cattactaga	960
tttaagcggg aactgtccga ggtgcttcaa tgccccattt ccatgcgtgc cttgtgatgg	1020
tggtgcttca attaatatag atcgttttgc ttttcaaaac ttgacccaac ttcgatacct	1080
aaacctctct agcacttccc tcaggaagat taatgctgcc tggtttaaaa atatgcctca	1140
tctgaaggtg ctggatcttg aattcaacta tttagtggga gaaatagcct ctggggcatt	1200
tttaacgatg ctgccccgct tagaaatact tgacttgtct ttttaactata taaaggggag	1260
ttatccacag catattaata tttccagaaa cttctctaaa cttttgtctc tacgggcatt	1320
gcatttaaga ggttatgtgt tccaggaact cagagaagat gatttccagc ccctgatgca	1380
gcttccaaac ttatcgacta tcaacttggg tattaatttt attaaagcaa tcgatttcaa	1440
acttttccaa aattttctcca atctggaaat tatttacttg tcagaaaaca gaatatcacc	1500
gttggttaaaa gatacccggc agagttatgc aaatagttcc tcttttcaac gtcatatccg	1560
gaaacgacgc tcaacagatt ttgagtttga cccacattcg aacttttatc atttcacccg	1620
tcctttaata aagccacaat gtgctgctta tggaaaagcc ttagatttaa gcctcaacag	1680
tattttcttc attgggccaa accaatttga aaatcttcc gacattgcct gtttaaactc	1740
gtctgcaaat agcaatgctc aagtgttaag tggaactgaa ttttcagcca ttcctcatgt	1800
caaataattg gatttgacaa acaatagact agactttgat aatgctagtg ctcttactga	1860
attgtccgac ttggaagttc tagatctcag ctataattca cactatttca gaatagcagg	1920
cgtaacacat catctagaat ttattcaaaa tttcacaaat ctaaaagttt taaacttgag	1980
ccacaacaac atttatactt taacagataa gtataacctg gaaagcaagt ccctggtaga	2040
attagttttc agtggcaatc gccttgacat tttgtggaat gatgatgaca acaggtatat	2100
ctccattttc aaaggtctca agaacttgac acgtctggat ttatccctta ataggctgaa	2160
gcacatccca aatgaagcat tccttaattt gccagcgagt ctactgaac tacatataaa	2220
tgataatatg ttaaagtttt ttaactggac attactccag cagtttcctc gtctcgagtt	2280
gcttgactta cgtggaaaca aactactctt ttttaactgat agcctatctg actttacatc	2340
ttcccttcgg acactgctgc tgagtcataa caggatttcc cacctaccct ctggctttct	2400
ttctgaagtc agtagtctga agcacctega ttttaagttcc aatctgctaa aaacaatcaa	2460
caaatccgca cttgaaacta agaccaccac caaattatct atgttggaac tacacggaaa	2520
cccctttgaa tgcacctgtg acattggaga tttccgaaga tggatggatg aacatctgaa	2580
tgtcaaaatt ccagactgg tagatgtcat ttgtgccagt cctgggggatc aaagagggaa	2640

gagtattgtg agtctggagc taacaacttg tgtttcagat gtcactgcag tgatattatt 2700  
 tttcttcacg ttctttatca ccaccatggg tatgtttggc gccctggctc accattttgtt 2760  
 ttactgggat gtttggttta tatataatgt gtgttttagct aagataaaaag gctacaggctc 2820  
 tctttccaca tcccaaactt tctatgatgc ttacatttct tatgacacca aagatgcctc 2880  
 tgttactgac tgggtgataa atgagctgcg ctaccacctt gaagagagcc gagacaaaaa 2940  
 cgttctcctt tgtctagagg agagggattg ggacccggga ttggccatca tcgacaacct 3000  
 catgcagagc atcaacaaaa gcaagaaaac agtattttgtt ttaacaaaaa aatatgcaaa 3060  
 aagctggaac tttaaaacag ctttttactt ggctttgcag aggctaattg atgagaacat 3120  
 ggatgtgatt atatttatcc tgctggagcc agtgttacag cattctcagt atttgaggct 3180  
 acggcagcgg atctgtaaga gctccatcct ccagtggcct gacaacccga aggcagaagg 3240  
 cttgttttgg caaactctga gaaatgtggt cttgactgaa aatgattcac ggtataacaa 3300  
 tatgtatgtc gattccatta agcaatacta actgacgtta agtcatgatt tcgcgccata 3360  
 ataaaga 3367

<210> 48

<211> 4211

<212> DNA

<213> Homo sapiens

<400> 48

ctctgcata gaggtacca ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca 60  
 acagaaacat ggaaaacatg ttcttctcagt cgtcaatgct gacctgcatt ttctgctaa 120  
 tatctggttc ctgtgagtta tgcgccgaag aaaatttttc tagaagctat ccttgtgatg 180  
 agaaaaagca aaatgactca gttattgcag agtgcagcaa tcgtcgacta caggaagttc 240  
 cccaaacggg gggcaaatat gtgacagaac tagacctgtc tgataatttc atcacacaca 300  
 taacgaatga atcatttcaa gggctgcaaa atctcactaa aataaatcta aaccacaacc 360  
 ccaatgtaca gcaccagaac ggaaatcccg gtatacaatc aaatggcttg aatatcacag 420  
 acgggggcatt cctcaaccta aaaaacctaa gggagttact gcttgaagac aaccagttac 480  
 cccaaatacc ctctggtttg ccagagtctt tgacagaact tagtctaatt caaaacaata 540  
 tataacaacat aactaaagag ggcatttcaa gacttataaa cttgaaaaat ctctatttgg 600  
 cctggaactg ctattttaac aaagtttgcg agaaaactaa catagaagat ggagtatttg 660  
 aaacgctgac aaatttggag ttgctatcac tatctttcaa ttctctttca cacgtgccac 720  
 ccaaactgcc aagctcccta cgcaaacttt ttctgagcaa caccagatc aaatacat 780  
 gtgaagaaga tttcaaggga ttgataaatt taacattact agatttaagc gggaactgtc 840

cgagggtgctt caatgccccca tttccatgcg tgccttgtga tgggtgggtgct tcaattaata	900
tagatcgttt tgcttttcaa aacttgaccc aacttcgata cctaaacctc tctagcactt	960
ccctcaggaa gattaatgct gcctgggttta aaaatatgcc tcatctgaag gtgctggatc	1020
ttgaattcaa ctatttagtg ggagaaatag cctctggggc atttttaacg atgctgcccc	1080
gcttagaaat acttgacttg tcttttaact atataaaggg gagttatcca cagcatatta	1140
atatttccag aaacttctct aaacttttgt ctctacgggc attgcattta agagggtatg	1200
tgttccagga actcagagaa gatgatttcc agccctgat gcagcttcca aacttatcga	1260
ctatcaactt gggattaat tttattaagc aaatcgattt caaacttttc caaaatttct	1320
ccaatctgga aattatttac ttgtcagaaa acagaatatc accgttggtta aaagataccc	1380
ggcagagtta tgcaaatagt tcctcttttc aacgtcatat ccggaaacga cgctcaacag	1440
attttgagtt tgaccacat tcgaactttt atcatttcac ccgtccttta ataaagccac	1500
aatgtgctgc ttatggaaaa gccttagatt taagcctcaa cagtattttc ttcattgggc	1560
caaaccaatt tgaaaatctt cctgacattg cctgtttaaa tctgtctgca aatagcaatg	1620
ctcaagtgtt aagtggaact gaattttcag ccattcctca tgtcaaatat ttggatttga	1680
caaacaatag actagacttt gataatgcta gtgctcttac tgaattgtcc gacttggaag	1740
ttctagatct cagctataat tcacactatt tcagaatagc aggcgtaaca catcatctag	1800
aattttattca aaatttcaca aatctaaaag ttttaaactt gagccacaac aacatttata	1860
ctttaacaga taagtataac ctggaaagca agtccctggg agaattagtt ttcagtggca	1920
atcgccctga cattttgtgg aatgatgatg acaacaggta tatctccatt ttcaaaggtc	1980
tcaagaatct gacacgtctg gatattatccc ttaataggct gaagcacatc ccaaataag	2040
cattccttaa ttgcccagcg agtctcactg aactacatat aaatgataat atgttaaagt	2100
tttttaactg gacattactc cagcagtttc ctgctctcga gttgcttgac ttacgtggaa	2160
acaaactact ctttttaact gatagcctat ctgactttac atcttccctt cggacactgc	2220
tgctgagtca taacaggatt tcccacctac cctctggctt tctttctgaa gtcagtagtc	2280
tgaagcacct cgatttaagt tccaatctgc taaaaacaat caacaaatcc gcacttgaaa	2340
ctaagaccac caccaaatta tctatgttgg aactacacgg aaaccctttt gaatgcacct	2400
gtgacattgg agatttccga agatggatgg atgaacatct gaatgtcaaa attcccagac	2460
tggtagatgt catttgtgcc agtcctgggg atcaaaggag gaagagtatt gtgagtctgg	2520
agctaacaac ttgtgtttca gatgtcactg cagtgatatt atttttcttc acgttcttta	2580
tcaccaccat gggtatgttg gctgccctgg ctccacattt gttttactgg gatgtttggt	2640
ttatatataa tgtgtgttta gctaaggtaa aaggctacag gtctctttcc acatcccaaa	2700
ctttctatga tgcttacatt tcttatgaca ccaaagatgc ctctgttact gactgggtga	2760

```

taaatgagct gcgctaccac cttgaagaga gccgagacaa aaacgttctc ctttgtctag 2820
aggagagggga ttgggatccg ggattggcca tcatcgacaa cctcatgcag agcatcaacc 2880
aaagcaagaa aacagtatctt gttttaacca aaaaatatgc aaaaagctgg aactttaaaa 2940
cagcttttta cttggctttg cagaggctaa tggatgagaa catggatgtg attatatatta 3000
tcctgctgga gccagtgtta cagcattctc agtatttgag gctacggcag cggatctgta 3060
agagctccat cctccagtgg cctgacaacc cgaaggcaga aggcttggtt tggcaaactc 3120
tgagaaatgt ggtcttgact gaaaatgatt cacggtataa caatatgtat gtcgattcca 3180
ttaagcaata ctaactgacg ttaagtcatg atttcgcgcc ataataaaga tgcaaaggaa 3240
tgacatttct gtattagtta tctattgcta tgtaacaaat tatcccaaaa cttagtgggt 3300
taaaacaaca catttgctgg ccacagttt ttgaggggtca ggagtccagg ccagcataa 3360
ctgggtcctc tgctcagggt gtctcagagg ctgcaatgta ggtgttcacc agagacatag 3420
gcatcactgg ggtcacactc atgtggttgt tttctggatt caattcctcc tgggctattg 3480
gccaaaggct atactcatgt aagccatgcg agcctctccc acaaggcagc ttgcttcac 3540
agagctagca aaaaagagag gttgctagca agatgaagtc acaatctttt gtaatcgaat 3600
caaaaaagtg atatctcatc actttggcca tattctatct gttagaagta aaccacaggt 3660
cccaccagct ccatgggagt gaccacctca gtccaggga aacagctgaa gaccaagatg 3720
gtgagctctg attgcttcag ttggatcatc actattttcc cttgactgct gtcctgggat 3780
ggcctgctat cttgatgata gattgtgaat atcaggaggc agggatcact gtggaccatc 3840
ttagcagttg acctaacaca tcttcttttc aatatctaag aacttttgcc actgtgacta 3900
atggctcctaa tattaagctg ttgtttatat ttatcatata tctatggcta catggttata 3960
ttatgctgtg gttgcgttcg gttttattta cagttgcttt taaaaatatt tgctgtaaca 4020
tttgacttct aagggtttaga tgccatttaa gaactgagat ggatagcttt taaagcatct 4080
tttacttctt accattttttt aaaagtatgc agctaaatc gaagcttttg gtctatattg 4140
ttaattgcc a ttgctgtaaa tcttaaaatg aatgaataaa aatgtttcat ttacaaaaa 4200
aaaaaaaaa a 4211

```

&lt;210&gt; 49

&lt;211&gt; 3468

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

ctcctgcata gaggttacca ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca 60

acagaaacat ggttctcttg acatttcagt gttaggaac atcagcaaga cccatccag 120



gagaccttga aggaagcctt tgaaagggag aatgaaggag tcatctttgc aaaatagctc	180
ctgcagcctg ggaagggaga ctaaaaagga aaacatgttc cttcagtcgt caatgctgac	240
ctgcattttc ctgctaatat ctggttcctg tgagttatgc gccgaagaaa atttttctag	300
aagctatcct tgtgatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg	360
tcgactacag gaagttcccc aaacgggtggg caaatatgtg acagaactag acctgtctga	420
taatttcac acacacataa cgaatgaatc atttcaaggg ctgcaaaatc tcactaaaat	480
aaatctaaac cacaacccca atgtacagca ccagaacgga aatcccggta tacaatcaaa	540
tggtctgaat atcacagacg gggcattcct caacctaaaa aacctaaagg agttactgct	600
tgaagacaac cagttacccc aaataccctc tggtttgcca gagtctttga cagaacttag	660
tctaattcaa aacaatatat acaacataac taaagagggc atttcaagac ttataaactt	720
gaaaaatctc tatttggcct ggaactgcta ttttaacaaa gtttgcgaga aaactaacat	780
agaagatgga gtatttgaaa cgctgacaaa tttggagttg ctatcactat ctttcaattc	840
tctttcacac gtgccacca aactgccaag ctccctacgc aaactttttc tgagcaacac	900
ccagatcaaa tacatttagt aagaagattt caagggattg ataaatttaa cattactaga	960
tttaagcggg aactgtccga ggtgcttcaa tgccccattt ccatgcgtgc cttgtgatgg	1020
tgggtgcttca attaatatag atcgttttgc ttttcaaaac ttgacccaac ttcgatacct	1080
aaacctctct agcacttccc tcaggaagat taatgctgcc tggtttaaaa atatgcctca	1140
tctgaagggtg ctggatcttg aattcaacta tttagtggga gaaatagcct ctggggcatt	1200
tttaacgatg ctgccccgct tagaaatact tgacttgtct ttttaactata taaaggggag	1260
ttatccacag catattaata tttccagaaa cttctctaaa cttttgtctc tacgggcatt	1320
gcatttaaga ggttatgtgt tccaggaact cagagaagat gatttccagc ccctgatgca	1380
gcttccaaac ttatcgacta tcaacttggg tattaatttt attaaagcaa tcgatttcaa	1440
acttttccaa aatttctcca atctggaaat tatttacttg tcagaaaaca gaatatcacc	1500
gttggtaaaa gataccgggc agagttatgc aaatagttcc tcttttcaac gtcatatccg	1560
gaaacgacgc tcaacagatt ttgagtttga cccacattcg aacttttatc atttcacccg	1620
tcctttaata aagccacaat gtgctgctta tggaaaagcc ttagatttaa gcctcaacag	1680
tattttcttc attgggcca accaatttga aaatcttcct gacattgcct gtttaaactc	1740
gtctgcaaat agcaatgctc aagtgttaag tggaactgaa ttttcagcca ttctcatgt	1800
caaatatttg gatttgacaa acaatagact agactttgat aatgctagtg ctcttactga	1860
attgtccgac ttggaagttc tagatctcag ctataattca cactatttca gaatagcagg	1920
cgtaacacat catctagaat ttattcaaaa tttcacaaat ctaaaagttt taaacttgag	1980
ccacaacaac atttatactt taacagataa gtataacctg gaaagcaagt ccctggtaga	2040

```

attagttttc agtggcaatc gccttgacat tttgtggaat gatgatgaca acaggtatat 2100
ctccattttc aaaggtctca agaatctgac acgtctggat ttatccctta ataggctgaa 2160
gcacatccca aatgaagcat tccttaattt gccagcgagt ctactgaac tacatataaa 2220
tgataatatg ttaaagtttt ttaactggac attactccag cagtttcctc gtctcgagtt 2280
gcttgactta cgtggaaaca aactactctt tttactgat agcctatctg actttacatc 2340
ttcccttcgg aactgctgc tgagtcataa caggatttcc cacctaccct ctggctttct 2400
ttctgaagtc agtagtctga agcacctcga ttttaagttcc aatctgctaa aaacaatcaa 2460
caaatccgca cttgaaacta agaccaccac caaattatct atgttggaac tacacggaaa 2520
cccctttgaa tgcacctgtg acattggaga tttccgaaga tggatggatg aacatctgaa 2580
tgtcaaaatt ccagactgg tagatgtcat ttgtgccagt cctggggatc aaagagggaa 2640
gagtattgtg agtctggagc taacaacttg tgtttcagat gtcactgcag tgatattatt 2700
ttcttccag ttctttatca ccaccatggc tatgttggtt gccctggctc accatttggt 2760
ttactgggat gtttggttta tatataatgt gtgtttagct aaggtaaaag gctacaggtc 2820
tctttccaca tcccaaactt tctatgatgc ttacatttct tatgacacca aagatgcctc 2880
tgttactgac tgggtgataa atgagctgcg ctaccacctt gaagagagcc gagacaaaaa 2940
cgttctcctt tgtctagagg agagggattg ggatccggga ttggccatca tcgacaacct 3000
catgcagagc atcaaccaa gcaagaaaac agtatttggt ttaacaaaaa aatatgcaa 3060
aagctggaac tttaaaacag ctttttactt ggctttgcag aggctaattg atgagaacat 3120
ggatgtgatt atatttatcc tgctggagcc agtgttacag cattctcagt atttgaggct 3180
acggcagcgg atctgtaaga gctccatcct ccagtggcct gacaaccga aggcagaagg 3240
cttgtttttg caaactctga gaaatgtggt cttgactgaa aatgattcac ggtataacaa 3300
tatgtatgtc gattccatta agcaatacta actgacgtta agtcatgatt tcgcgccata 3360
ataaagatgc aaaggaatga ctttctgtga ttagttatct attgctatgt aacaaattat 3420
cccaaaactt agtgggttaa aacaacacat ttgctggccc acagtttt 3468

```

<210> 50

<211> 1041

<212> PRT

<213> Homo sapiens

<400> 50

```

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu
1           5           10           15

```

```

Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg
          20           25           30

```

Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
 35 40 45  
 Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
 50 55 60  
 Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
 65 70 75 80  
 Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
 85 90 95  
 Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
 100 105 110  
 Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
 115 120 125  
 Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
 130 135 140  
 Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
 145 150 155 160  
 Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
 165 170 175  
 Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
 180 185 190  
 Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
 195 200 205  
 Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
 210 215 220  
 Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
 225 230 235 240  
 Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
 245 250 255  
 Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
 260 265 270  
 Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
 275 280 285  
 Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
 290 295 300  
 Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
 305 310 315 320  
 Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
 325 330 335  
 Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
 340 345 350  
 Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser

```

      355              360              365
Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu
  370              375              380

Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn
385              390              395              400

Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn
              405              410              415

Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro
              420              425              430

Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln
              435              440              445

Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His
              450              455              460

Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala
465              470              475              480

Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile
              485              490              495

Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu
              500              505              510

Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala
              515              520              525

Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe
              530              535              540

Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp
545              550              555              560

Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His
              565              570              575

Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser
              580              585              590

His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys
              595              600              605

Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp
              610              615              620

Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn
625              630              635              640

Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn
              645              650              655

Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn
              660              665              670

Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro
              675              680              685

Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr

```

```

        690                695                700
Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser
705                710                715                720

His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser
        725                730                735

Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn
        740                745                750

Lys Ser Ala Leu Glu Thr Lys Thr Thr Thr Lys Leu Ser Met Leu Glu
        755                760                765

Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg
        770                775                780

Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp
785                790                795                800

Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser
        805                810                815

Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe
        820                825                830

Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala
        835                840                845

His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu
        850                855                860

Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr
865                870                875                880

Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp
        885                890                895

Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn
        900                905                910

Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile
        915                920                925

Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe
        930                935                940

Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe
945                950                955                960

Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile
        965                970                975

Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu
        980                985                990

Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro
        995                1000                1005

Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu
        1010                1015                1020

Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile

```

1025  
 Lys Gln Tyr  
 1040

1030

1035

<210> 51  
 <211> 1059  
 <212> PRT  
 <213> Homo sapiens

<400> 51

Met Lys Glu Ser Ser Leu Gln Asn Ser Ser Cys Ser Leu Gly Lys Glu  
 1 5 10 15

Thr Lys Lys Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile  
 20 25 30

Phe Leu Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe  
 35 40 45

Ser Arg Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile  
 50 55 60

Ala Glu Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly  
 65 70 75 80

Lys Tyr Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile  
 85 90 95

Thr Asn Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu  
 100 105 110

Asn His Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln  
 115 120 125

Ser Asn Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn  
 130 135 140

Leu Arg Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser  
 145 150 155 160

Gly Leu Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile  
 165 170 175

Tyr Asn Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn  
 180 185 190

Leu Tyr Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr  
 195 200 205

Asn Ile Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu  
 210 215 220

Ser Leu Ser Phe Asn Ser Leu Ser His Val Ser Pro Lys Leu Pro Ser  
 225 230 235 240

Ser Leu Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser  
 245 250 255

Glu Glu Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser  
 260 265 270

Gly Asn Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys  
 275 280 285  
 Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu  
 290 295 300  
 Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile  
 305 310 315 320  
 Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu  
 325 330 335  
 Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr  
 340 345 350  
 Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys  
 355 360 365  
 Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Pro  
 370 375 380  
 Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu  
 385 390 395 400  
 Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr  
 405 410 415  
 Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe  
 420 425 430  
 Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile  
 435 440 445  
 Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser  
 450 455 460  
 Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp  
 465 470 475 480  
 Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln  
 485 490 495  
 Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe  
 500 505 510  
 Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu  
 515 520 525  
 Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe  
 530 535 540  
 Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu  
 545 550 555 560  
 Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val  
 565 570 575  
 Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr  
 580 585 590  
 His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn

595 600 605  
 Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu  
 610 615 620  
 Ser Lys Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile  
 625 630 635 640  
 Leu Trp Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu  
 645 650 655  
 Lys Asn Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile  
 660 665 670  
 Pro Asn Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His  
 675 680 685  
 Ile Asn Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln  
 690 695 700  
 Phe Pro Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe  
 705 710 715 720  
 Leu Thr Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu  
 725 730 735  
 Leu Ser His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu  
 740 745 750  
 Val Ser Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr  
 755 760 765  
 Ile Asn Lys Ser Ala Leu Glu Thr Lys Thr Thr Thr Lys Leu Ser Met  
 770 775 780  
 Leu Glu Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp  
 785 790 795 800  
 Phe Arg Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu  
 805 810 815  
 Val Asp Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile  
 820 825 830  
 Val Ser Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile  
 835 840 845  
 Leu Phe Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala  
 850 855 860  
 Leu Ala His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val  
 865 870 875 880  
 Cys Leu Ala Lys Ile Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr  
 885 890 895  
 Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr  
 900 905 910  
 Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp  
 915 920 925  
 Lys Asn Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu



930                      935                      940  
 Ala Ile Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr  
 945                      950                      955                      960  
 Val Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr  
                     965                      970                      975  
 Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val  
                     980                      985                      990  
 Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu  
                     995                      1000                      1005  
 Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro  
                     1010                      1015                      1020  
 Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn  
                     1025                      1030                      1035  
 Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val  
                     1040                      1045                      1050  
 Asp Ser Ile Lys Gln Tyr  
                     1055

<210> 52  
 <211> 1041  
 <212> PRT  
 <213> Homo sapiens

<400> 52

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu  
 1                      5                      10                      15  
 Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg  
                     20                      25                      30  
 Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
                     35                      40                      45  
 Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
                     50                      55                      60  
 Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
 65                      70                      75                      80  
 Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
                     85                      90                      95  
 Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
                     100                      105                      110  
 Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
                     115                      120                      125  
 Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
                     130                      135                      140  
 Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
 145                      150                      155                      160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
 165 170 175  
 Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
 180 185 190  
 Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
 195 200 205  
 Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
 210 215 220  
 Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
 225 230 235 240  
 Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
 245 250 255  
 Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
 260 265 270  
 Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
 275 280 285  
 Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
 290 295 300  
 Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
 305 310 315 320  
 Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
 325 330 335  
 Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
 340 345 350  
 Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser  
 355 360 365  
 Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
 370 375 380  
 Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn  
 385 390 395 400  
 Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn  
 405 410 415  
 Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro  
 420 425 430  
 Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln  
 435 440 445  
 Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His  
 450 455 460  
 Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala  
 465 470 475 480  
 Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile

122/231

820 825 830  
 Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala  
 835 840 845  
 His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu  
 850 855 860  
 Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr  
 865 870 875 880  
 Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp  
 885 890 895  
 Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn  
 900 905 910  
 Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile  
 915 920 925  
 Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe  
 930 935 940  
 Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe  
 945 950 955 960  
 Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile  
 965 970 975  
 Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu  
 980 985 990  
 Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro  
 995 1000 1005  
 Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu  
 1010 1015 1020  
 Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile  
 1025 1030 1035  
 Lys Gln Tyr  
 1040

<210> 53  
 <211> 1041  
 <212> PRT  
 <213> Homo sapiens

<400> 53

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu  
 1 5 10 15  
 Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg  
 20 25 30  
 Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
 35 40 45  
 Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
 50 55 60

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
 65 70 75 80  
 Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
 85 90 95  
 Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
 100 105 110  
 Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
 115 120 125  
 Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
 130 135 140  
 Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
 145 150 155 160  
 Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
 165 170 175  
 Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
 180 185 190  
 Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
 195 200 205  
 Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
 210 215 220  
 Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
 225 230 235 240  
 Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
 245 250 255  
 Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
 260 265 270  
 Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
 275 280 285  
 Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
 290 295 300  
 Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
 305 310 315 320  
 Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
 325 330 335  
 Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
 340 345 350  
 Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser  
 355 360 365  
 Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
 370 375 380  
 Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn

385                                      390                                      395                                      400  
 Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn  
    405                                      410                                      415  
  
 Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro  
    420                                      425                                      430  
  
 Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln  
    435                                      440                                      445  
  
 Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His  
    450                                      455                                      460  
  
 Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala  
 465                                      470                                      475                                      480  
  
 Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile  
    485                                      490                                      495  
  
 Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu  
    500                                      505                                      510  
  
 Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala  
    515                                      520                                      525  
  
 Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe  
    530                                      535                                      540  
  
 Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp  
 545                                      550                                      555                                      560  
  
 Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His  
    565                                      570                                      575  
  
 Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser  
    580                                      585                                      590  
  
 His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys  
    595                                      600                                      605  
  
 Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp  
    610                                      615                                      620  
  
 Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn  
 625                                      630                                      635                                      640  
  
 Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn  
    645                                      650                                      655  
  
 Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn  
    660                                      665                                      670  
  
 Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro  
    675                                      680                                      685  
  
 Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr  
    690                                      695                                      700  
  
 Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser  
 705                                      710                                      715                                      720  
  
 His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser

Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn  
 725 730 735  
 740 745 750  
 Lys Ser Ala Leu Glu Thr Lys Thr Thr Thr Lys Leu Ser Met Leu Glu  
 755 760 765  
 Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg  
 770 775 780  
 Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp  
 785 790 795 800  
 Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser  
 805 810 815  
 Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe  
 820 825 830  
 Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala  
 835 840 845  
 His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu  
 850 855 860  
 Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr  
 865 870 875 880  
 Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp  
 885 890 895  
 Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn  
 900 905 910  
 Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile  
 915 920 925  
 Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe  
 930 935 940  
 Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe  
 945 950 955 960  
 Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile  
 965 970 975  
 Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu  
 980 985 990  
 Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro  
 995 1000 1005  
 Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu  
 1010 1015 1020  
 Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile  
 1025 1030 1035  
 Lys Gln Tyr  
 1040

<210> 54  
 <211> 1059  
 <212> PRT  
 <213> Homo sapiens

<400> 54

Met Lys Glu Ser Ser Leu Gln Asn Ser Ser Cys Ser Leu Gly Lys Glu  
 1 5 10 15

Thr Lys Lys Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile  
 20 25 30

Phe Leu Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe  
 35 40 45

Ser Arg Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile  
 50 55 60

Ala Glu Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly  
 65 70 75 80

Lys Tyr Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile  
 85 90 95

Thr Asn Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu  
 100 105 110

Asn His Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln  
 115 120 125

Ser Asn Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn  
 130 135 140

Leu Arg Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser  
 145 150 155 160

Gly Leu Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile  
 165 170 175

Tyr Asn Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn  
 180 185 190

Leu Tyr Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr  
 195 200 205

Asn Ile Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu  
 210 215 220

Ser Leu Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser  
 225 230 235 240

Ser Leu Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser  
 245 250 255

Glu Glu Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser  
 260 265 270

Gly Asn Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys  
 275 280 285



Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu  
 290 295 300  
 Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile  
 305 310 315 320  
 Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu  
 325 330 335  
 Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr  
 340 345 350  
 Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys  
 355 360 365  
 Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu  
 370 375 380  
 Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu  
 385 390 395 400  
 Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr  
 405 410 415  
 Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe  
 420 425 430  
 Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile  
 435 440 445  
 Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser  
 450 455 460  
 Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp  
 465 470 475 480  
 Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln  
 485 490 495  
 Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe  
 500 505 510  
 Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu  
 515 520 525  
 Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe  
 530 535 540  
 Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu  
 545 550 555 560  
 Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val  
 565 570 575  
 Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr  
 580 585 590  
 His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn  
 595 600 605  
 Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu

610	615	620
Ser Lys Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile		
625	630	635 640
Leu Trp Asn Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu		
	645	650 655
Lys Asn Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile		
	660	665 670
Pro Asn Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His		
	675	680 685
Ile Asn Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln		
	690	695 700
Phe Pro Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe		
	705	710 715 720
Leu Thr Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu		
	725	730 735
Leu Ser His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu		
	740	745 750
Val Ser Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr		
	755	760 765
Ile Asn Lys Ser Ala Leu Glu Thr Lys Thr Thr Thr Lys Leu Ser Met		
	770	775 780
Leu Glu Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp		
	785	790 795 800
Phe Arg Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu		
	805	810 815
Val Asp Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile		
	820	825 830
Val Ser Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile		
	835	840 845
Leu Phe Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala		
	850	855 860
Leu Ala His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val		
	865	870 875 880
Cys Leu Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr		
	885	890 895
Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr		
	900	905 910
Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp		
	915	920 925
Lys Asn Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu		
	930	935 940
Ala Ile Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr		

945                      950                      955                      960  
 Val Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr  
                          965                      970                      975  
  
 Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val  
                          980                      985                      990  
  
 Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu  
                          995                      1000                      1005  
  
 Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro  
                          1010                      1015                      1020  
  
 Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn  
                          1025                      1030                      1035  
  
 Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val  
                          1040                      1045                      1050  
  
 Asp Ser Ile Lys Gln Tyr  
                          1055

<210> 55  
 <211> 3220  
 <212> DNA  
 <213> murine

<400> 55  
 attcagagtt ggatgttaag agagaaacaa acgttttacc ttcctttgtc tatagaacat 60  
 ggaaaacatg cccctcagc catggattct gacgtgcttt tgtctgctgt cctctggaac 120  
 cagtgccatc ttccataaag cgaactattc cagaagctat ccttgtagcg agataaggca 180  
 caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaagttc cccaaactat 240  
 aggcaagtat gtgacaaaca tagacttgtc agacaatgcc attacacata taacgaaaga 300  
 gtcctttcaa aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaaacaaca 360  
 gcacccaaat gaaaataaaa atgggtatgaa tattacagaa ggggcacttc tcagcctaag 420  
 aaatctaaca gttttactgc tggaagacaa ccagttatat actatacctg ctgggttgcc 480  
 tgagtctttg aaagaactta gcctaattca aaacaatata tttcaggtaa ctaaaaacaa 540  
 cacttttggg cttaggaact tggaagact ctatttgggc tggaactgct attttaaagt 600  
 taatcaaacc ttttaaggtag aagatggggc atttaaaaat cttatacact tgaaggtact 660  
 ctcatatct ttcaataacc ttttctatgt gcccccaaa ctaccaagtt ctctaaggaa 720  
 actttttctg agtaatgcc aatcatgaa catcactcag gaagacttca aaggactgga 780  
 aaatttaaca ttactagatc tgagtggaaa ctgtccaagg tgttacaatg ctccatttcc 840  
 ttgcacacct tgcaaggaaa actcatccat ccacatacat cctctggctt ttcaaagtct 900  
 cacccaactt ctctatctaa acctttccag cacttcctc aggacgattc cttctacctg 960  
 gtttgaaaat ctgtcaaact tgaaggaact ccactctgaa ttcaactatt tagttcaaga 1020

aattgcctcg ggggcatttt taacaaaact acccagttta caaatccttg atttgtcctt	1080
caactttcaa tataaggaat atttacaatt tattaatatt tcctcaaatt tctctaagct	1140
tcgttctctc aagaagttgc acttaagagg ctatgtgttc cgagaactta aaaagaagca	1200
tttcgagcat ctccagagtc ttccaaactt ggcaaccatc aacttgggca ttaactttat	1260
tgagaaaatt gatttcaaag ctttccagaa tttttccaaa ctgcacgtta tctatttatc	1320
aggaaatcgc atagcatctg tattagatgg tacagattat tcctcttggc gaaatcgtct	1380
tcggaaacct ctctcaacag acgatgatga gtttgatcca cagtggaatt tttaccatag	1440
caccaaacct ttaataaagc cacagtgtac tgcttatggc aaggccttgg atttaagttt	1500
gaacaatatt ttcatatttg ggaaaagcca atttgaaggt tttcaggata tcgcctgctt	1560
aaatctgtcc ttcaatgcc aatactcaagt gtttaaatggc acagaattct cctccatgcc	1620
ccacattaaa tatttggtt taaccaacaa cagactagac tttgatgata acaatgcttt	1680
cagtgatctt cagcatctag aagtgtctga cctgagccac aatgcacact atttcagtat	1740
agcaggggta acgcaccgtc taggatttat ccagaactta ataaacctca ggggtgttaa	1800
cctgagccac aatggcatth acaccctcac agaggaaagt gagctgaaaa gcatctcact	1860
gaaagaattg gttttcagt gaaatcgtct tgaccatttg tggaatgcaa atgatggcaa	1920
atactgggtcc atttttaaaa gtctccagaa tttgatacgc ctggacttat catacaataa	1980
ccttcaacaa atcccaaatg gagcattcct caatttgcct cagagcctcc aagagttact	2040
tatcagtggg aacaaattac gtttctttaa ttggacatta ctccagtatt ttcctcacct	2100
tcacttgctg gatttatcga gaaatgagct gtattttcta cccaattgcc tatctaagtt	2160
tgcacattcc ctggagacac tgctactgag ccataatcat ttctctcacc taccctctgg	2220
cttcctctcc gaagccagga atctggtgca cctggatcta agtttcaaca caataaagat	2280
gatcaataaa tcctccctgc aaaccaagat gaaaacgaac ttgtctattc tggagctaca	2340
tgggaactat tttgactgca cgtgtgacat aagtgatttt cgaagctggc tagatgaaaa	2400
tctgaatata acaattccta aattggtaaa tggtatatgt tccaatctg gggatcaaaa	2460
atcaaagagt atcatgagcc tagatctcac gacttgtgta tcggatacca ctgcagctgt	2520
cctgtttttc ctacattcc ttaccacctc catgggtatg ttggctgctc tggttcacca	2580
cctgttttac tgggatgttt ggtttatcta tcacatgtgc tctgctaagt taaaaggcta	2640
caggacttca tccacatccc aaactttcta tgatgcttat atttcttatg acaccaaaga	2700
tgcattctgt actgactggg taatcaatga actgcgctac caccttgaag agagtgaaga	2760
caaaagtgtc ctcttttgt tagaggagag ggattgggat ccaggattac ccatcattga	2820
taacctcatg cagagcataa accagagcaa gaaaacaatc tttgttttaa ccaagaaata	2880

tgccaagagc tggaacttta aaacagcttt ctacttggcc ttgcagagggc taatggatga 2940  
gaacatggat gtgattatatt tcatcctcct ggaaccagtg ttacagtact cacagtacct 3000  
gaggcttcgg cagaggatct gtaagagctc catcctccag tggcccaaca atcccaaagc 3060  
agaaaacttg ttttggcaaa gtctgaaaaa tgtggtcttg actgaaaatg attcacggta 3120  
tgacgatttg tacattgatt ccattaggca atactagtga tgggaagtca cgactctgcc 3180  
atcataaaaa cacacagctt ctccttacia tgaaccgaat 3220

<210> 56  
<211> 3220  
<212> DNA  
<213> murine

<400> 56  
attcagagtt ggatgttaag agagaaacaa acgttttacc ttcctttgtc tatagaacat 60  
ggaaaacatg cccctcagc catggattct gacgtgcttt tgtctgctgt cctctggaac 120  
cagtgccatc ttccataaag cgaactatc cagaagctat ccttgtgacg agataaggca 180  
caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaagtcc cccaaactat 240  
aggcaagtat gtgacaaaca tagacttgcc agacaatgcc attacacata taacgaaaga 300  
gtcctttcaa aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaaacaaca 360  
gcacccaaat gaaaataaaa atggtatgaa tattacagaa ggggcacttc tcagcctaag 420  
aaatctaaca gttttactgc tggaagacaa ccagttatat actatacctg ctgggttgcc 480  
tgagtctttg aaagaactta gcctaattca aaacaatata tttcaggtaa ctaaaaacaa 540  
cacttttggg cttaggaact tggaaagact ctatttgggc tggaaactgct attttaaatg 600  
taatcaaacc ttttaaggtag aagatggggc atttaaaaat cttatacact tgaaggtact 660  
ctcattatct ttcaataacc ttttctatgt gcccccaaa ctaccaagtt ctctaaggaa 720  
actttttctg agtaatgcc aaatcatgaa catcactcag gaagacttca aaggactgga 780  
aaatttaaca ttactagatc tgagtggaaa ctgtccaagg tgttacaatg ctccatttcc 840  
ttgcacacct tgcaaggaaa actcatccat ccacatacat cctctggcct ttcaaagtct 900  
cacccaactt ctctatctaa acctttccag cacttccctc aggacgattc cttctacctg 960  
gtttgaaaat ctgtcaaacc tgaaggaaact ccatcttgaa ttcaactatt tagttcaaga 1020  
aattgcctcg ggggcatttt taacaaaact acccagttta caaatccttg atttgtcctt 1080  
caactttcaa tataaggaaat atttacaatt tattaatatt tcctcaaatt tctctaagct 1140  
tcgttctctc aagaagttgc acttaagagg ctatgtgttc cgagaactta aaaagaagca 1200  
tttcgagcat ctccagagtc ttccaaactt ggcaaccatc aacttgggca ttaactttat 1260

tgagaaaatt gatttcaaag ctttccagaa tttttccaaa ctgcacgtta tctatattatc	1320
aggaaatcgc atagcatctg tattagatgg tacagattat tcctcttggc gaaatcgtct	1380
tcggaaacct ctctcaacag acgatgatga gtttgatcca cacgtgaatt tttaccatag	1440
caccaaacct ttaataaagc cacagtgtac tgcttatggc aaggccttgg atttaagttt	1500
gaacaatatt ttcattattg ggaaaagcca atttgaaggt tttcaggata tcgcctgctt	1560
aaatctgtcc ttcaatgcc aactcaagt gttaaatggc acagaattct cctccatgcc	1620
ccacattaaa tatttggatt taaccaacaa cagactagac tttgatgata acaatgcttt	1680
cagtgatctt cagcatctag aagtgtgga cctgagccac aatgcacact atttcagtat	1740
agcaggggta acgcaccgtc taggatttat ccagaactta ataaacctca ggggtgttaa	1800
cctgagccac aatggcattt acaccctcac agaggaaagt gagctgaaaa gcatctcact	1860
gaaagaattg gttttcagtg gaaatcgtct tgaccatttg tggaatgcaa atgatggcaa	1920
atactgggtc atttttaaaa gtctccagaa tttgatacgc ctggacttat catacaataa	1980
ccttcaacaa atcccaaatg gagcattcct caatttgcct cagagcctcc aagagttact	2040
tatcagtggg aacaaattac gtttctttaa ttggacatta ctccagtatt ttcctcacct	2100
tcacttgtcg gatttatcga gaaatgagct gtattttcta cccaattgcc tatctaagtt	2160
tgacatttcc ctggagacac tgctactgag ccataatcat ttctctcacc taccctctgg	2220
cttctctccc gaagccagga atctgggtgca cctggatcta agtttcaaca caataaagat	2280
gatcaataaa tcctccctgc aaaccaagat gaaaacgaac ttgtctattc tggagctaca	2340
tggaacttat tttgactgca cgtgtgacat aagtgatttt cgaagctggc tagatgaaaa	2400
tctgaatatc acaattccta aattggtaaa tggtatatgt tccaatcctg gggatcaaaa	2460
atcaaagagt atcatgagcc tagatctcac gacttgtgta tcggatacca ctgcagctgt	2520
cctgtttttc ctacatttcc ttaccacctc catgggtatg ttggctgctc tggttcacca	2580
cctgtttttac tgggatgttt gggttatcta tcacatgtgc tctgctaagt taaaaggcta	2640
caggacttca tcacatccc aaactttcta tgatgcttat atttcttatg acaccaaaaga	2700
tgcatctgtt actgactggg taatcaatga actgcgctac caccttgaag agagtgaaga	2760
caaaagtgtc ctcttttgtt tagaggagag ggattgggat ccaggattac ccatcattga	2820
taacctcatg cagagcataa accagagcaa gaaaacaatc tttgttttaa ccaagaaata	2880
tgccaagagc tggaacttta aaacagcttt ctacttggcc ttgcagaggc taatggatga	2940
gaacatggat gtgattatct tcactctcct ggaaccagtg ttacagtact cacagtacct	3000
gaggcttcgg cagaggatct gtaagagctc catcctccag tggccaaca atcccaaagc	3060
agaaaacttg ttttggcaaa gtctgaaaaa tgtggtcttg actgaaaatg attcacggta	3120
tgacgatttg tacattgatt ccattaggca atactagtga tgggaagtca cgactctgcc	3180

atcataaaaa cacacagctt ctccttataa tgaaccgaat

3220

&lt;210&gt; 57

&lt;211&gt; 1032

&lt;212&gt; PRT

&lt;213&gt; murine

&lt;400&gt; 57

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
1 5 10 15

Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
20 25 30

Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
35 40 45

Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
50 55 60

Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
65 70 75 80

Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
85 90 95

Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
100 105 110

Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
115 120 125

Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
130 135 140

Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
145 150 155 160

Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
165 170 175

Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
180 185 190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
195 200 205

Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
210 215 220

Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
225 230 235 240

Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
245 250 255

Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
260 265 270

Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
 275 280 285  
 Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
 290 295 300  
 Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
 305 310 315 320  
 Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
 325 330 335  
 Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
 340 345 350  
 Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
 355 360 365  
 Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
 370 375 380  
 Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
 385 390 395 400  
 Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
 405 410 415  
 Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
 420 425 430  
 Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp  
 435 440 445  
 Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
 450 455 460  
 Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
 465 470 475 480  
 Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
 485 490 495  
 Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
 500 505 510  
 Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu  
 515 520 525  
 Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu  
 530 535 540  
 His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
 545 550 555 560  
 Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
 565 570 575  
 Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
 580 585 590  
 Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly



	595					600					605				
Asn	Arg	Leu	Asp	His	Leu	Trp	Asn	Ala	Asn	Asp	Gly	Lys	Tyr	Trp	Ser
610						615				620					
Ile	Phe	Lys	Ser	Leu	Gln	Asn	Leu	Ile	Arg	Leu	Asp	Leu	Ser	Tyr	Asn
625				630						635				640	
Asn	Leu	Gln	Gln	Ile	Pro	Asn	Gly	Ala	Phe	Leu	Asn	Leu	Pro	Gln	Ser
				645				650						655	
Leu	Gln	Glu	Leu	Leu	Ile	Ser	Gly	Asn	Lys	Leu	Arg	Phe	Phe	Asn	Trp
		660						665				670			
Thr	Leu	Leu	Gln	Tyr	Phe	Pro	His	Leu	His	Leu	Leu	Asp	Leu	Ser	Arg
675						680						685			
Asn	Glu	Leu	Tyr	Phe	Leu	Pro	Asn	Cys	Leu	Ser	Lys	Phe	Ala	His	Ser
690						695				700					
Leu	Glu	Thr	Leu	Leu	Leu	Ser	His	Asn	His	Phe	Ser	His	Leu	Pro	Ser
705				710						715				720	
Gly	Phe	Leu	Ser	Glu	Ala	Arg	Asn	Leu	Val	His	Leu	Asp	Leu	Ser	Phe
				725				730						735	
Asn	Thr	Ile	Lys	Met	Ile	Asn	Lys	Ser	Ser	Leu	Gln	Thr	Lys	Met	Lys
		740				745						750			
Thr	Asn	Leu	Ser	Ile	Leu	Glu	Leu	His	Gly	Asn	Tyr	Phe	Asp	Cys	Thr
755						760						765			
Cys	Asp	Ile	Ser	Asp	Phe	Arg	Ser	Trp	Leu	Asp	Glu	Asn	Leu	Asn	Ile
770						775				780					
Thr	Ile	Pro	Lys	Leu	Val	Asn	Val	Ile	Cys	Ser	Asn	Pro	Gly	Asp	Gln
785				790						795				800	
Lys	Ser	Lys	Ser	Ile	Met	Ser	Leu	Asp	Leu	Thr	Thr	Cys	Val	Ser	Asp
				805				810						815	
Thr	Thr	Ala	Ala	Val	Leu	Phe	Phe	Leu	Thr	Phe	Leu	Thr	Thr	Ser	Met
		820				825						830			
Val	Met	Leu	Ala	Ala	Leu	Val	His	His	Leu	Phe	Tyr	Trp	Asp	Val	Trp
835						840				845					
Phe	Ile	Tyr	His	Met	Cys	Ser	Ala	Lys	Leu	Lys	Gly	Tyr	Arg	Thr	Ser
850						855				860					
Ser	Thr	Ser	Gln	Thr	Phe	Tyr	Asp	Ala	Tyr	Ile	Ser	Tyr	Asp	Thr	Lys
865				870						875				880	
Asp	Ala	Ser	Val	Thr	Asp	Trp	Val	Ile	Asn	Glu	Leu	Arg	Tyr	His	Leu
				885				890						895	
Glu	Glu	Ser	Glu	Asp	Lys	Ser	Val	Leu	Leu	Cys	Leu	Glu	Glu	Arg	Asp
		900				905						910			
Trp	Asp	Pro	Gly	Leu	Pro	Ile	Ile	Asp	Asn	Leu	Met	Gln	Ser	Ile	Asn
915						920						925			
Gln	Ser	Lys	Lys	Thr	Ile	Phe	Val	Leu	Thr	Lys	Lys	Tyr	Ala	Lys	Ser

930                      935                      940  
 Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp  
 945                      950                      955                      960  
 Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln  
                          965                      970                      975  
 Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile  
                          980                      985                      990  
 Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser  
                          995                      1000                      1005  
 Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp  
                          1010                      1015                      1020  
 Leu Tyr Ile Asp Ser Ile Arg Gln Tyr  
                          1025                      1030

<210> 58  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 58

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
 1                      5                      10                      15  
 Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
                          20                      25                      30  
 Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
                          35                      40                      45  
 Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
                          50                      55                      60  
 Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
 65                      70                      75                      80  
 Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
                          85                      90                      95  
 Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
                          100                      105                      110  
 Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
                          115                      120                      125  
 Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
                          130                      135                      140  
 Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
 145                      150                      155                      160  
 Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
                          165                      170                      175  
 Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
                          180                      185                      190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
 195 200 205  
 Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
 210 215 220  
 Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
 225 230 235 240  
 Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
 245 250 255  
 Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
 260 265 270  
 Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
 275 280 285  
 Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
 290 295 300  
 Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
 305 310 315 320  
 Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
 325 330 335  
 Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
 340 345 350  
 Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
 355 360 365  
 Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
 370 375 380  
 Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
 385 390 395 400  
 Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
 405 410 415  
 Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
 420 425 430  
 Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp  
 435 440 445  
 Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
 450 455 460  
 Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
 465 470 475 480  
 Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
 485 490 495  
 Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
 500 505 510  
 Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu

515	520	525
Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu		
530	535	540
His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser		
545	550	555
Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn		
565	570	575
Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu		
580	585	590
Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly		
595	600	605
Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser		
610	615	620
Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn		
625	630	635
Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser		
645	650	655
Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp		
660	665	670
Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg		
675	680	685
Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser		
690	695	700
Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser		
705	710	715
Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe		
725	730	735
Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys		
740	745	750
Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr		
755	760	765
Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile		
770	775	780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln		
785	790	795
Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp		
805	810	815
Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met		
820	825	830
Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp		
835	840	845
Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser		

850                      855                      860  
 Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys  
 865                      870                      875                      880  
 Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu  
                          885                      890                      895  
 Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp  
                          900                      905                      910  
 Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn  
                          915                      920                      925  
 Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser  
                          930                      935                      940  
 Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp  
 945                      950                      955                      960  
 Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln  
                          965                      970                      975  
 Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile  
                          980                      985                      990  
 Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser  
                          995                      1000                      1005  
 Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp  
                          1010                      1015                      1020  
 Leu Tyr Ile Asp Ser Ile Arg Gln Tyr  
                          1025                      1030

<210> 59  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 59

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
 1                      5                      10                      15  
 Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
                          20                      25                      30  
 Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
                          35                      40                      45  
 Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
                          50                      55                      60  
 Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
 65                      70                      75                      80  
 Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
                          85                      90                      95  
 Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
                          100                      105                      110

Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
 115 120 125  
 Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
 130 135 140  
 Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
 145 150 155 160  
 Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
 165 170 175  
 Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
 180 185 190  
 Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
 195 200 205  
 Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
 210 215 220  
 Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
 225 230 235 240  
 Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
 245 250 255  
 Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
 260 265 270  
 Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
 275 280 285  
 Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
 290 295 300  
 Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
 305 310 315 320  
 Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
 325 330 335  
 Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
 340 345 350  
 Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
 355 360 365  
 Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
 370 375 380  
 Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
 385 390 395 400  
 Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
 405 410 415  
 Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
 420 425 430  
 Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp

435 440 445  
 Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
 450 455 460  
 Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
 465 470 475 480  
 Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
 485 490 495  
 Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
 500 505 510  
 Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu  
 515 520 525  
 Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu  
 530 535 540  
 His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
 545 550 555 560  
 Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
 565 570 575  
 Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
 580 585 590  
 Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly  
 595 600 605  
 Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser  
 610 615 620  
 Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn  
 625 630 635 640  
 Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser  
 645 650 655  
 Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp  
 660 665 670  
 Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg  
 675 680 685  
 Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser  
 690 695 700  
 Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser  
 705 710 715 720  
 Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe  
 725 730 735  
 Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys  
 740 745 750  
 Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr  
 755 760 765  
 Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile

770 775 780  
 Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln  
 785 790 795 800  
 Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp  
 805 810 815  
 Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met  
 820 825 830  
 Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp  
 835 840 845  
 Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser  
 850 855 860  
 Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys  
 865 870 875 880  
 Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu  
 885 890 895  
 Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp  
 900 905 910  
 Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn  
 915 920 925  
 Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser  
 930 935 940  
 Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp  
 945 950 955 960  
 Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln  
 965 970 975  
 Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile  
 980 985 990  
 Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser  
 995 1000 1005  
 Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp  
 1010 1015 1020  
 Leu Tyr Ile Asp Ser Ile Arg Gln Tyr  
 1025 1030

&lt;210&gt; 60

&lt;211&gt; 3352

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

aggctggtat aaaaatctta ctctctctat tctctgagcc gctgctgccc ctgtgggaag 60  
 ggacctcgag tgtgaagcat ccttcctgt agctgctgtc cagtctgccc gccagaccct 120  
 ctggagaagc ccctgcccc cagcatgggt ttctgccgca gcgcctgca cccgctgtct 180



ctcctgggtgc	aggccatcat	gctggccatg	accctggccc	tgggtacctt	gcctgccttc	240
ctaccctgtg	agctccagcc	ccacggcctg	gtgaactgca	actggctgtt	cctgaagtct	300
gtgccccact	tctccatggc	agcaccctgt	ggcaatgtca	ccagcctttc	cttgtcctcc	360
aaccgcatcc	accacctcca	tgattctgac	tttggccacc	tgcccagcct	gcggcatctc	420
aacctcaagt	ggaactgccc	gccggttggc	ctcagcccca	tgcacttccc	ctgccacatg	480
accatcgagc	ccagcacctt	cttggtctgt	cccaccctgg	aagagctaaa	cctgagctac	540
aacaacatca	tgactgtgcc	tgcgctgccc	aaatccctca	tatccctgtc	cctcagccat	600
accaacatcc	tgatgctaga	ctctgccagc	ctcgccggcc	tgcatgccct	gcgcttccta	660
ttcatggacg	gcaactgtta	ttacaagaac	ccctgcaggc	aggcactgga	ggtggccccg	720
ggtgccctcc	ttggcctggg	caacctcacc	cacctgtcac	tcaagtacaa	caacctcact	780
gtggtgcccc	gcaacctgcc	ttccagcctg	gagtatctgc	tgttgtccta	caaccgcata	840
gtcaaactgg	cgcctgagga	cctggccaat	ctgaccgccc	tgcgtgtgct	cgatgtgggc	900
ggaaattgcc	gccgctgcga	ccacgctccc	aacctctgca	tggagtgccc	tcgtcacttc	960
ccccagctac	atcccgatac	cttcagccac	ctgagccgtc	ttgaaggcct	ggtgttgaag	1020
gacagttctc	tctcctggct	gaatgccagt	tggttccgtg	ggctgggaaa	cctccgagtg	1080
ctggacctga	gtgagaactt	cctctacaaa	tgcatcacta	aaaccaaggc	cttccagggc	1140
ctaacacagc	tgcgcaagct	taacctgtcc	ttcaattacc	aaaagagggt	gtcctttgcc	1200
cacctgtctc	tggccccctc	cttcgggagc	ctggtcgccc	tgaaggagct	ggacatgcac	1260
ggcatcttct	tccgctcact	cgatgagacc	acgctccggc	cactggcccc	cctgcccattg	1320
ctccagactc	tgcgctctgca	gatgaacttc	atcaaccagg	cccagctcgg	catcttcagg	1380
gccttccctg	gcctgcgcta	cgtggacctg	tgggacaacc	gcatcagcgg	agcttcggag	1440
ctgacagcca	ccatggggga	ggcagatgga	ggggagaagg	tctggctgca	gcctggggac	1500
cttgctccgg	ccccagtgga	cactcccagc	tctgaagact	tcaggcccaa	ctgcagcacc	1560
ctcaacttca	ccttggtatct	gtcacggaac	aacctgggtga	ccgtgcagcc	ggagatgttt	1620
gcccagctct	cgcacctgca	gtgcctgcgc	ctgagccaca	actgcatctc	gcaggcagtc	1680
aatggctccc	agttcctgcc	gctgaccggc	ctgcaggtgc	tagacctgtc	ccgcaataag	1740
ctggacctct	accacgagca	ctcattcacg	gagctaccgc	gactggaggc	cctggacctc	1800
agctacaaca	gccagccctt	tggcatgcag	ggcgtggggc	acaacttcag	cttcgtggct	1860
cacctgcgca	ccctgcgcca	cctcagcctg	gcccacaaca	acatccacag	ccaagtgtcc	1920
cagcagctct	gcagtacgtc	gctgcggggc	ctggacttca	gcggcaatgc	actgggcat	1980
atgtggggccg	aggagacct	ctatctgcac	ttcttccaag	gcctgagcgg	tttgatctgg	2040
ctggacttgt	cccagaaccg	cctgcacacc	ctcctgcccc	aaacctgcg	caacctcccc	2100

aagagcctac aggtgctgcg tctccgtgac aattacctgg cttcttttaa gtggtggagc 2160  
ctccacttcc tgcccaaact ggaagtctc gacctggcag gaaaccggct gaaggccctg 2220  
accaatggca gcctgcctgc tggcaccggtg ctccggaggc tggatgtcag ctgcaacagc 2280  
atcagcttcg tggcccccg cttcttttcc aaggccaagg agctgcgaga gctcaacctt 2340  
agcgccaacg ccctcaagac agtggaccac tcctggtttg gggccctggc gagtgccttg 2400  
caaatactag atgtaagcgc caaccctctg cactgcgcct gtggggcggc ctttatggac 2460  
ttcctgctgg aggtgcaggc tgccgtgccc ggtctgccc gccgggtgaa gtgtggcagt 2520  
ccggggcagc tccagggcct cagcatcttt gcacaggacc tgcgcctctg cctggatgag 2580  
gccctctcct gggactgttt cgcctctctg ctgctggctg tggctctggg cctgggtgtg 2640  
cccatgctgc atcacctctg tggctgggac ctctgggtact gcttccacct gtgcctggcc 2700  
tggcttccct ggcggggggcg gcaaagtggg cgagatgagg atgccctgcc ctacgatgcc 2760  
ttcgtggtct tcgacaaaac gcagagcgca gtggcagact ggggtgtacaa cgagcttcgg 2820  
gggcagctgg aggagtgcg tgggcgctgg gcaactccgc tgtgcctgga ggaacgcgac 2880  
tggctgcctg gcaaaacctt ctttgagaac ctgtgggcct cggctctatg cagccgcaag 2940  
acgtgtttg tgctggccc caccgaccgg gtcagtggc tcttgccgc cagcttctctg 3000  
ctggcccagc agcgctgct ggaggaccgc aaggacgtcg tgggtctggt gatcctgagc 3060  
cctgacggcc gccgctccc ctacgtgcgg ctgcgccagc gcctctgcc ccagagtgtc 3120  
ctcctctgga cccaccagcc cagtggctcag cgcagcttct gggcccagct gggcatggcc 3180  
ctgaccaggg acaaccacca cttctataac cggaacttct gccagggacc caccggcgaa 3240  
tagccgtgag ccggaatcct gcacggtgcc acctccacac tcacctcacc tctgcctgcc 3300  
tggtctgacc ctccctgct cgcctccctc accccacacc tgacacagag ca 3352

<210> 61  
<211> 3257  
<212> DNA  
<213> Homo sapiens

<400> 61  
ccgctgctgc ccctgtggga agggacctcg agtgtgaagc atccttccct gtagctgctg 60  
tccagtctgc ccgccagacc ctctggagaa gccctgccc cccagcatgg gtttctgccg 120  
cagcgccctg caccgctgt ctctcctggt gcaggccatc atgctggcca tgacctggc 180  
cctgggtacc ttgctgcct tcctacctg tgagctccag cccacggcc tggatgaactg 240  
caactggctg ttctgaagt ctgtgcccc cttctccatg gcagcaccgc gtggcaatgt 300  
caccagcctt tccttgctct ccaaccgcat ccaccacctc catgattctg actttgcccc 360

cctgcccagc	ctgcggcatc	tcaacctcaa	gtggaactgc	ccgccggttg	gcctcagccc	420
catgcacttc	ccctgcccaca	tgaccatcga	gcccagcacc	ttcttggttg	tgcccaccct	480
ggaagagcta	aacctgagct	acaacaacat	catgactgtg	cctgcgctgc	ccaaatccct	540
catatccctg	tccctcagcc	ataccaacat	cctgatgcta	gactctgcca	gcctcgccgg	600
cctgcatgcc	ctgcgcttcc	tattcatgga	cggcaactgt	tattacaaga	accctgcag	660
gcaggcactg	gaggtggccc	cgggtgccct	ccttgccctg	ggcaacctca	cccacctgtc	720
actcaagtac	aacaacctca	ctgtggtgcc	ccgcaacctg	ccttccagcc	tggagtatct	780
gctgttgctc	tacaacogca	tcgtcaaact	ggcgctgag	gacctggcca	atctgaccgc	840
cctgcgtgtg	ctcgatgtgg	gcggaaattg	ccgccgctgc	gaccacgctc	ccaaccctg	900
catggagtgc	cctcgtcact	ttccccagct	acatcccgat	accttcagcc	acctgagccg	960
tcttgaaggc	ctggtgttga	aggacagttc	tctctcctgg	ctgaatgcca	gttggttccg	1020
tgggctggga	aacctccgag	tgctggacct	gagtgagaac	ttcctctaca	aatgcatcac	1080
taaaaccaag	gccttccagg	gcctaacaca	gctgcgcaag	cttaacctgt	ccttcaatta	1140
ccaaaagagg	gtgtcctttg	cccacctgtc	tctggcccct	tccttcggga	gcctggctgc	1200
cctgaaggag	ctggacatgc	acggcatctt	cttccgctca	ctcgatgaga	ccacgctccg	1260
gccactggcc	cgcctgccc	tgctccagac	tctgcgtctg	cagatgaact	tcacaaacca	1320
ggcccagctc	ggcatcttca	gggccttccc	tggcctgcgc	tacgtggacc	tgtcggacaa	1380
ccgcatcagc	ggagcttcgg	agctgacagc	caccatgggg	gaggcagatg	gaggggagaa	1440
ggctctggctg	cagcctgggg	accttgctcc	ggccccagtg	gacactccca	gctctgaaga	1500
cttcaggccc	aactgcagca	ccctcaactt	caccttggtg	ctgtcacgga	acaacctggt	1560
gacctgtcag	ccggagatgt	ttgcccagct	ctcgcacctg	cagtgcctgc	gcctgagcca	1620
caactgcata	tcgcaggcag	tcaatggctc	ccagttcctg	ccgtgacccg	gtctgcagggt	1680
gctagacctg	ttccacaata	agctggacct	ctaccacgag	cactcattca	cggagctacc	1740
acgactggag	gccctggacc	tcagctacaa	cagccagccc	tttgccatgc	agggcgtggg	1800
ccacaacttc	agcttcgtgg	ctcacctgcg	cacctgcgc	cacctcagcc	tggcccacaa	1860
caacatccac	agccaagtgt	cccagcagct	ctgcagtacg	tcgctgcggg	ccctggactt	1920
cagcggcaat	gactggggcc	atatgtgggc	caggggagac	ctctatctgc	acttcttcca	1980
aggcctgagc	ggtttgatct	ggctggactt	gtcccagaac	cgcctgcaca	ccctcctgcc	2040
ccaaaccttg	cgaacctcc	ccaagagcct	acaggtgctg	cgtctccgtg	acaattacct	2100
ggccttcttt	aagtgggtga	gcctccactt	cctgccccaa	ctggaagtcc	tcgacctggc	2160
aggaaaccag	ctgaaggccc	tgaccaatgg	cagcctgcct	gctggcacc	ggctccggag	2220
gctggatgtc	agctgcaaca	gcatacagctt	cgtggccccc	ggcttctttt	ccaaggccaa	2280

ggagctgcga gagctcaacc ttagcgccaa cgccctcaag acagtggacc actcctgggt 2340  
 tggggccctg gcgagtgcc tgcaataact agatgtaagc gccaaacctc tgcactgcgc 2400  
 ctgtggggcg gcctttatgg acttctctgt ggaggtgcag gctgccgtgc ccggtctgcc 2460  
 cagccgggtg aagtgtggca gtccgggcca gctccagggc ctcagcatct ttgcacagga 2520  
 cctgcgcctc tgctggatg aggcctctc ctgggactgt ttgcctctc cgctgctggc 2580  
 tgtggctctg ggctgggtg tgcccatgct gcatcacctc tgtggctggg acctctggta 2640  
 ctgcttcac ctgtgcctgg cctggcttcc ctggcggggg cggcaaagtg ggcgagatga 2700  
 ggatgccctg ccctacgatg ccttcgtggt cttcgacaaa acgcagagcg cagtggcaga 2760  
 ctgggtgtac aacgagcttc gggggcagct ggaggagtgc cgtgggcgct gggcactccg 2820  
 cctgtgcctg gaggaacgcg actggctgcc tggcaaaacc ctctttgaga acctgtgggc 2880  
 ctcggtctat ggagccgca agacgctgtt tgtgctggcc cacacggacc gggtcagtgg 2940  
 tctcttgccg gccagcttcc tgctggccca gcagcgctg ctggaggacc gcaaggacgt 3000  
 cgtggtgctg gtgatcctga gccctgacgg ccgcccctcc cgctacgtgc ggctgcgcca 3060  
 gcgcctctgc cgccagagtg tctcctctg gcccaccag ccagtggtc agcgcagctt 3120  
 ctggggccag ctgggcatgg ccctgaccag ggacaaccac cacttctata accggaactt 3180  
 ctgccaggga ccacggccg aatagccgtg agccggaatc ctgcacggtg ccacctccac 3240  
 actcacctca cctctgc 3257

<210> 62  
 <211> 1032  
 <212> PRT  
 <213> Homo sapiens

<400> 62

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln  
 1 5 10 15  
 Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20 25 30  
 Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
 35 40 45  
 Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
 50 55 60  
 Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp  
 65 70 75 80  
 Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp  
 85 90 95  
 Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met

Thr	Ile	Glu	Pro	Ser	Thr	Phe	Leu	Ala	Val	Pro	Thr	Leu	Glu	Glu	Leu
		100					105					110			
		115					120					125			
Asn	Leu	Ser	Tyr	Asn	Asn	Ile	Met	Thr	Val	Pro	Ala	Leu	Pro	Lys	Ser
		130				135					140				
Leu	Ile	Ser	Leu	Ser	Leu	Ser	His	Thr	Asn	Ile	Leu	Met	Leu	Asp	Ser
		145				150				155					160
Ala	Ser	Leu	Ala	Gly	Leu	His	Ala	Leu	Arg	Phe	Leu	Phe	Met	Asp	Gly
				165					170					175	
Asn	Cys	Tyr	Tyr	Lys	Asn	Pro	Cys	Arg	Gln	Ala	Leu	Glu	Val	Ala	Pro
			180					185					190		
Gly	Ala	Leu	Leu	Gly	Leu	Gly	Asn	Leu	Thr	His	Leu	Ser	Leu	Lys	Tyr
		195					200					205			
Asn	Asn	Leu	Thr	Val	Val	Pro	Arg	Asn	Leu	Pro	Ser	Ser	Leu	Glu	Tyr
		210				215					220				
Leu	Leu	Leu	Ser	Tyr	Asn	Arg	Ile	Val	Lys	Leu	Ala	Pro	Glu	Asp	Leu
		225			230					235					240
Ala	Asn	Leu	Thr	Ala	Leu	Arg	Val	Leu	Asp	Val	Gly	Gly	Asn	Cys	Arg
				245					250					255	
Arg	Cys	Asp	His	Ala	Pro	Asn	Pro	Cys	Met	Glu	Cys	Pro	Arg	His	Phe
			260					265					270		
Pro	Gln	Leu	His	Pro	Asp	Thr	Phe	Ser	His	Leu	Ser	Arg	Leu	Glu	Gly
		275					280					285			
Leu	Val	Leu	Lys	Asp	Ser	Ser	Leu	Ser	Trp	Leu	Asn	Ala	Ser	Trp	Phe
		290				295					300				
Arg	Gly	Leu	Gly	Asn	Leu	Arg	Val	Leu	Asp	Leu	Ser	Glu	Asn	Phe	Leu
		305			310					315					320
Tyr	Lys	Cys	Ile	Thr	Lys	Thr	Lys	Ala	Phe	Gln	Gly	Leu	Thr	Gln	Leu
			325						330					335	
Arg	Lys	Leu	Asn	Leu	Ser	Phe	Asn	Tyr	Gln	Lys	Arg	Val	Ser	Phe	Ala
			340					345					350		
His	Leu	Ser	Leu	Ala	Pro	Ser	Phe	Gly	Ser	Leu	Val	Ala	Leu	Lys	Glu
			355				360					365			
Leu	Asp	Met	His	Gly	Ile	Phe	Phe	Arg	Ser	Leu	Asp	Glu	Thr	Thr	Leu
		370				375					380				
Arg	Pro	Leu	Ala	Arg	Leu	Pro	Met	Leu	Gln	Thr	Leu	Arg	Leu	Gln	Met
		385			390					395					400
Asn	Phe	Ile	Asn	Gln	Ala	Gln	Leu	Gly	Ile	Phe	Arg	Ala	Phe	Pro	Gly
			405						410					415	
Leu	Arg	Tyr	Val	Asp	Leu	Ser	Asp	Asn	Arg	Ile	Ser	Gly	Ala	Ser	Glu
			420					425					430		
Leu	Thr	Ala	Thr	Met	Gly	Glu	Ala	Asp	Gly	Gly	Glu	Lys	Val	Trp	Leu

435 440 445  
 Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu  
 450 455 460  
 Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser  
 465 470 475 480  
 Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser  
 485 490 495  
 His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val  
 500 505 510  
 Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu  
 515 520 525  
 Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu  
 530 535 540  
 Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly  
 545 550 555 560  
 Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr  
 565 570 575  
 Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser  
 580 585 590  
 Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn  
 595 600 605  
 Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe  
 610 615 620  
 Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu  
 625 630 635 640  
 His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln  
 645 650 655  
 Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser  
 660 665 670  
 Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg  
 675 680 685  
 Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg  
 690 695 700  
 Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe  
 705 710 715 720  
 Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala  
 725 730 735  
 Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu  
 740 745 750  
 Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala  
 755 760 765  
 Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu

770                      775                      780  
 Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser  
 785                      790                      795                      800  
  
 Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp  
                                  805                      810                      815  
  
 Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val  
                                  820                      825                      830  
  
 Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His  
                                  835                      840                      845  
  
 Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp  
                                  850                      855                      860  
  
 Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln  
 865                      870                      875                      880  
  
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu  
                                  885                      890                      895  
  
 Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp  
                                  900                      905                      910  
  
 Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr  
                                  915                      920                      925  
  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
                                  930                      935                      940  
  
 Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
 945                      950                      955                      960  
  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg  
                                  965                      970                      975  
  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val  
                                  980                      985                      990  
  
 Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln  
                                  995                      1000                      1005  
  
 Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg  
 1010                      1015                      1020  
  
 Asn Phe Cys Gln Gly Pro Thr Ala Glu  
                                  1025                      1030

<210> 63  
 <211> 1032  
 <212> PRT  
 <213> Homo sapiens

<400> 63

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln  
 1                      5                      10                      15  
  
 Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
                                  20                      25                      30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
 35 40 45  
 Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
 50 55 60  
 Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp  
 65 70 75 80  
 Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp  
 85 90 95  
 Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met  
 100 105 110  
 Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu  
 115 120 125  
 Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser  
 130 135 140  
 Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser  
 145 150 155 160  
 Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu  
 225 230 235 240  
 Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe  
 260 265 270  
 Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe  
 290 295 300  
 Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala  
 340 345 350  
 His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu



355 360 365  
 Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu  
 370 375 380  
 Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly  
 405 410 415  
 Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu  
 420 425 430  
 Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu  
 435 440 445  
 Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu  
 450 455 460  
 Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser  
 465 470 475 480  
 Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser  
 485 490 495  
 His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val  
 500 505 510  
 Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu  
 515 520 525  
 Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu  
 530 535 540  
 Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly  
 545 550 555 560  
 Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr  
 565 570 575  
 Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser  
 580 585 590  
 Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn  
 595 600 605  
 Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe  
 610 615 620  
 Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu  
 625 630 635 640  
 His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln  
 645 650 655  
 Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser  
 660 665 670  
 Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln  
 675 680 685  
 Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg

690 695 700  
 Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe  
 705 710 715 720  
 Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala  
 725 730 735  
 Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu  
 740 745 750  
 Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala  
 755 760 765  
 Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu  
 770 775 780  
 Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser  
 785 790 795 800  
 Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp  
 805 810 815  
 Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val  
 820 825 830  
 Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His  
 835 840 845  
 Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp  
 850 855 860  
 Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln  
 865 870 875 880  
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu  
 885 890 895  
 Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp  
 900 905 910  
 Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr  
 915 920 925  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
 930 935 940  
 Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
 945 950 955 960  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg  
 965 970 975  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val  
 980 985 990  
 Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln  
 995 1000 1005  
 Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg  
 1010 1015 1020  
 Asn Phe Cys Gln Gly Pro Thr Ala Glu

1025                      1030  
 <210> 64  
 <211> 333  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 64  
  
 Met Pro Met Lys Trp Ser Gly Trp Arg Trp Ser Trp Gly Pro Ala Thr  
 1                      5                      10                      15  
  
 His Thr Ala Leu Pro Pro Pro Gln Gly Phe Cys Arg Ser Ala Leu His  
                     20                      25                      30  
  
 Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu Ala  
                     35                      40                      45  
  
 Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His Gly  
                     50                      55                      60  
  
 Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe Ser  
 65                      70                      75                      80  
  
 Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser Asn  
                     85                      90                      95  
  
 Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser Leu  
                     100                      105                      110  
  
 Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser Pro  
                     115                      120                      125  
  
 Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu Ala  
                     130                      135                      140  
  
 Val Pro Thr Leu Glu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met Thr  
 145                      150                      155                      160  
  
 Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His Thr  
                     165                      170                      175  
  
 Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala Leu  
                     180                      185                      190  
  
 Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys Arg  
                     195                      200                      205  
  
 Gln Ala Leu Glu Val Ala Pro Gly Ala Leu Leu Gly Leu Gly Asn Leu  
                     210                      215                      220  
  
 Thr His Leu Ser Leu Lys Tyr Asn Asn Leu Thr Val Val Pro Arg Asn  
 225                      230                      235                      240  
  
 Leu Pro Ser Ser Leu Glu Tyr Leu Leu Leu Ser Tyr Asn Arg Ile Val  
                     245                      250                      255  
  
 Lys Leu Ala Pro Glu Asp Leu Ala Asn Leu Thr Ala Leu Arg Val Leu  
                     260                      265                      270  
  
 Asp Val Gly Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys  
                     275                      280                      285

Met Glu Cys Pro Arg His Phe Pro Gln Leu His Pro Asp Thr Phe Ser  
 290 295 300

His Leu Ser Arg Leu Glu Gly Leu Val Leu Lys Asp Ser Ser Leu Ser  
 305 310 315 320

Trp Leu Asn Ala Ser Trp Phe Arg Gly Leu Gly Asn Leu  
 325 330

<210> 65

<211> 216

<212> PRT

<213> Homo sapiens

<400> 65

Met Leu Tyr Ser Ser Cys Lys Ser Arg Leu Leu Asp Ser Val Glu Gln  
 1 5 10 15

Asp Phe His Leu Glu Ile Ala Lys Lys Gly Phe Cys Arg Ser Ala Leu  
 20 25 30

His Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu  
 35 40 45

Ala Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His  
 50 55 60

Gly Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe  
 65 70 75 80

Ser Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser  
 85 90 95

Asn Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser  
 100 105 110

Leu Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser  
 115 120 125

Pro Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu  
 130 135 140

Ala Val Pro Thr Leu Glu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met  
 145 150 155 160

Thr Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His  
 165 170 175

Thr Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala  
 180 185 190

Leu Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys  
 195 200 205

Arg Gln Ala Leu Glu Val Ala Pro  
 210 215

<210> 66

<211> 117  
 <212> PRT  
 <213> Homo sapiens

<400> 66

```

Met Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala
1          5          10          15

Phe Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp
          20          25          30

Leu Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly
          35          40          45

Asn Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His
          50          55          60

Asp Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys
65          70          75          80

Trp Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His
          85          90          95

Met Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu
          100          105          110

Leu Asn Leu Ser Tyr
          115

```

<210> 67  
 <211> 1032  
 <212> PRT  
 <213> Homo sapiens

<400> 67

```

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
1          5          10          15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
          20          25          30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
          35          40          45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn
          50          55          60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp
65          70          75          80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
          85          90          95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met
          100          105          110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
          115          120          125

```

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser  
 130 135 140  
 Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser  
 145 150 155 160  
 Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu  
 225 230 235 240  
 Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe  
 260 265 270  
 Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe  
 290 295 300  
 Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala  
 340 345 350  
 His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu  
 355 360 365  
 Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu  
 370 375 380  
 Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly  
 405 410 415  
 Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu  
 420 425 430  
 Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu  
 435 440 445  
 Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu

```

      450              455              460
Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser
465              470              475              480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser
      485              490              495

His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val
      500              505              510

Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu
      515              520              525

Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu
      530              535              540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly
545              550              555              560

Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr
      565              570              575

Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser
      580              585              590

Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
      595              600              605

Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe
      610              615              620

Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu
625              630              635              640

His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln
      645              650              655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser
      660              665              670

Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln
      675              680              685

Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg
      690              695              700

Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe
705              710              715              720

Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
      725              730              735

Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu
      740              745              750

Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
      755              760              765

Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu
      770              775              780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser

```

785                      790                      795                      800  
 Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp  
                                  805                                   810                                   815  
 Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val  
                                  820                                   825                                   830  
 Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His  
                                  835                                   840                                   845  
 Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp  
                                  850                                   855                                   860  
 Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln  
                                  865                                   870                                   875                                   880  
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu  
                                  885                                   890                                   895  
 Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp  
                                  900                                   905                                   910  
 Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr  
                                  915                                   920                                   925  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
                                  930                                   935                                   940  
 Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
                                  945                                   950                                   955                                   960  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg  
                                  965                                   970                                   975  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val  
                                  980                                   985                                   990  
 Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln  
                                  995                                   1000                                   1005  
 Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg  
                                  1010                                   1015                                   1020  
 Asn Phe Cys Gln Gly Pro Thr Ala Glu  
                                  1025                                   1030

<210> 68  
 <211> 3200  
 <212> DNA  
 <213> murine

<400> 68  
 tgtcagaggg agcctcggga gaatcctcca tctcccaaca tggttctccg tcgaaggact 60  
 ctgcaccctt tgtccctcct ggtacaggct gcagtgtctg ctgagactct ggccctgggt 120  
 accctgcctg ccttcctacc ctgtgagctg aagcctcatg gcctgggtgga ctgcaattgg 180  
 ctgttcctga agtctgtacc ccgtttctct gcggcagcat cctgtctcaa catcacccgc 240  
 ctctccttga tctccaaccg tatccaccac ctgcacaact ccgacttcgt ccacctgtcc 300



aacctgcggc agctgaacct caagtggaaac tgtccaccca ctggccttag cccctgcac	360
ttctcttgcc acatgacat tgagcccaga accttctggt ctatgcgtac actggaggag	420
ctgaacctga gctataatgg tatcaccact gtgccccgac tgcccagctc cctggtgaat	480
ctgagcctga gccacaccaa catcctgggt ctagatgcta acagcctgc cggcctatac	540
agcctgcggg ttctcttcat ggacgggaac tgctactaca agaaccctg cacaggagcg	600
gtgaagggtga cccagggcgc cctcctgggc ctgagcaatc tcacccatct gtctctgaag	660
tataacaacc tcacaaagggt gcccgcgcaa ctgccccca gcctggagta cctcctgggtg	720
tcctataacc tcattgtcaa gctggggcct gaagacctgg ccaatctgac ctcccttoga	780
gtacttgatg tgggtgggaa ttgccgtgcg tgcgacctg ccccaatcc ctgtatagaa	840
tgtggccaaa agtccctcca cctgcacct gagaccttcc atcacctgag ccatctggaa	900
ggcctgggtgc tgaaggacag ctctctccat aactgaact cttcctgggt ccaaggctctg	960
gtcaacctct cgggtgctga cctaagcgag aactttctct atgaaagcat caaccacacc	1020
aatgcctttc agaacctaac ccgctgcgc aagctcaacc tgccttcaa ttaccgcaag	1080
aaggatatct ttgcccgcct ccacctggca agttccttca agaacctgggt gtcactgcag	1140
gagctgaaca tgaacggcat cttcttccgc tcgctcaaca agtacacgct cagatggctg	1200
gccgatctgc ccaactcca cactctgcat cttcaaatga acttcatcaa ccaggcacag	1260
ctcagcatct ttggtacctt ccgagccctt cgctttgtgg acttgtcaga caatcgcatc	1320
agtgggcctt caacgctgtc agaagccacc cctgaagagg cagatgatgc agagcaggag	1380
gagctgttgt ctgcgatcc tcacccagct cactgagca cccctgcttc taagaacttc	1440
atggacaggt gtaagaactt caagttcacc atggacctgt ctcggaacaa cctgggtgact	1500
atcaagccag agatgtttgt caatctctca cgctccagt gtcttagcct gagccacaac	1560
tccattgcac aggctgtcaa tggctctcag ttctgcccgc tgactaatct gcagggtgctg	1620
gacctgtccc ataacaaact ggacttgtag cactggaaat cgttcagtga gctaccacag	1680
ttgcaggccc tggacctgag ctacaacagc cagcccttta gcatgaaggg tataggccac	1740
aatttcagtt ttgtggccca tctgtccatg ctacacagcc ttagcctggc acacaatgac	1800
attcataccc gtgtgtcttc acatctcaac agcaactcag tgaggtttct tgacttcagc	1860
ggcaacggta tgggccgcat gtgggatgag gggggccttt atctccattt cttccaaggc	1920
ctgagtggcc tgctgaagct ggacctgtct caaaataacc tgcatatcct ccggccccag	1980
aaccttgaca acctcccaa gagcctgaag ctgctgagcc tccgagacaa ctacctatct	2040
ttctttaact ggaccagtct gtccttctg cccaacctgg aagtcctaga cctggcaggc	2100
aaccagctaa aggcctgac caatggcacc ctgcctaag gcacctcct ccagaaactg	2160

gatgtcagca gcaacagtat cgtctctgtg gtcccagcct tcttcgctct ggcggtcgag 2220  
 ctgaaagagg tcaacctcag ccacaacatt ctcaagacgg tggatcgctc ctggtttggg 2280  
 cccattgtga tgaacctgac agttctagac gtgagaagca accctctgca ctgtgcctgt 2340  
 ggggcagcct tcgtagactt actgttggag gtgcagacca aggtgcctgg cctggctaata 2400  
 ggtgtgaagt gtggcagccc cggccagctg cagggccgta gcatcttcgc acaggacctg 2460  
 cggctgtgcc tggatgaggt cctctcttgg gactgctttg gcctttcact cttggctgtg 2520  
 gccgtgggca tgggtgtgcc tatactgcac catctctgcg gctgggacgt ctgggtactgt 2580  
 tttcatctgt gcctggcatg gctacctttg ctggcccgcga gccgacgcag cgcccaagct 2640  
 ctcccctatg atgccttcgt ggtgttcgat aaggcacaga gcgcagttgc ggactgggtg 2700  
 tataacgagc tgcgggtgcg gctggaggag cggcgcggtc gccgagccct acgcttgtgt 2760  
 ctggaggacc gagattggct gcctggccag acgctcttcg agaacctctg ggcttccatc 2820  
 tatgggagcc gcaagactct atttgtgctg gccacacgg accgcgtcag tggcctcctg 2880  
 cgcaccagct tcctgctggc tcagcagcgc ctgttggaa accgcaagga cgtggtggtg 2940  
 ttggtgatcc tgcgtccgga tgcccaccgc tcccgctatg tgcgactgcg ccagcgtctc 3000  
 tgccgccaga gtgtgctctt ctggccccag cagcccaacg ggcagggggg cttctgggcc 3060  
 cagctgagta cagccctgac tagggacaac cgccacttct ataaccagaa cttctgccgg 3120  
 ggacctacag cagaatagct cagagcaaca gctggaaaca gctgcatctt catgcctggt 3180  
 tcccgagttg ctctgcctgc 3200

&lt;210&gt; 69

&lt;211&gt; 3471

&lt;212&gt; DNA

&lt;213&gt; murine

&lt;400&gt; 69

tgaaagtgtc acttcctcaa ttctctgaga gacctggtg tggaacatca ttctctgccg 60  
 cccagtttgt cagaggagc ctggggagaa tctccatct cccaacatgg ttctccgtcg 120  
 aaggactctg cacccttgt cctcctggt acaggctgca gtgctggctg agactctggc 180  
 cctgggtacc ctgcctgcct tctaccctg tgagctgaag cctcatggcc tgggtgactg 240  
 caattggctg ttctgaagt ctgtacccg tttctctgcg gcagcatcct gctccaacat 300  
 caccgcctc tccttgatct ccaaccgtat ccaccacctg cacaactccg acttcgtcca 360  
 cctgtccaac ctgcggcagc tgaacctcaa gtggaactgt ccaccactg gccttagccc 420  
 cctgcacttc tcttgccaca tgaccattga gccagaacc ttcctggcta tgcgtacact 480  
 ggaggagctg aacctgagct ataatggtat caccactgtg ccccgactgc ccagctccct 540

ggtgaatctg agcctgagcc acaccaacat cctgggttcta gatgctaaca gcctcgccgg	600
cctatacagc ctgcgcgttc tcttcatgga cgggaactgc tactacaaga acccctgcac	660
aggagcgggtg aaggtgaccc caggcgcctt cctggggctg agcaatctca cccatctgtc	720
tctgaagtat aacaacctca caaaggtgcc ccgccaactg cccccagcc tggagtacct	780
cctgggtgtcc tataacctca ttgtcaagct ggggcctgaa gacctggcca atctgacctc	840
ccttcgagta cttgatgtgg gtgggaattg ccgtcgctgc gaccatgccc ccaatccctg	900
tatagaatgt ggccaaaagt ccctccacct gcacctgag accttccatc acctgagcca	960
tctggaaggc ctggtgctga aggacagctc tctccataca ctgaactctt cctggttcca	1020
aggtctggtc aacctctcgg tgctggacct aagcgagaac tttctctatg aaagcatcaa	1080
ccacaccaat gcctttcaga acctaaccgg cctgcgcaag ctcaacctgt ccttcaatta	1140
ccgcaagaag gtatcctttg cccgcctcca cctggcaagt tccttcaaga acctggtgtc	1200
actgcaggag ctgaacatga acggcatctt cttccgctcg ctcaacaagt acacgctcag	1260
atggetggcc gatctgcccc aactccacac tctgcatctt caaatgaact tcatcaacca	1320
ggcacagctc agcatctttg gtaccttcgg agcccttcgc tttgtggact tgtcagacaa	1380
tcgcatcagt gggccttcaa cgctgtcaga agccaccct gaagaggcag atgatgcaga	1440
gcaggaggag ctgttgtctg cggatcctca ccagctcca ctgagcacc ctgctttctaa	1500
gaacttcatg gacaggtgta agaacttcaa gttcaccatg gacctgtctc ggaacaacct	1560
ggtgactatc aagccagaga tgtttgtcaa tctctcacgc ctccagtgtc ttagcctgag	1620
ccacaactcc attgcacagg ctgtcaatgg ctctcagttc ctgccgctga ctaatctgca	1680
ggtgctggac ctgtcccata acaaactgga cttgtaccac tggaaatcgt tcagttagct	1740
accacagttg caggccctgg acctgagcta caacagccag cccttttagca tgaagggtat	1800
aggccacaat ttcagttttg tgacctatct gtccatgcta cagagcctta gcctggcaca	1860
caatgacatt cataccctg tgctctcaca tctcaacagc aactcagtga ggttttctga	1920
cttcagcggc aacgggtatg gccgcatgtg ggatgagggg ggcctttatc tccatttctt	1980
ccaaggcctg agtggcctgc tgaagctgga cctgtctcaa aataacctgc atatcctccg	2040
gccccagaac cttgacaacc tccccagag cctgaagctg ctgagcctcc gagacaacta	2100
cctatctttc tttaactgga ccagtctgtc cttcctacct aacctggaag tcctagacct	2160
ggcaggcaac cagctaaagg ccctgaccaa tggcaccctg cctaattgga ccctcctcca	2220
gaaactcgat gtcagtagca acagtatcgt ctctgtggtc ccagccttct tcgctctggc	2280
ggtcgagctg aaagaggtca acctcagcca caacattctc aagacgggtg atcgctcctg	2340
gtttggggcc atttgtatga acctgacagt tctagacgtg agaagcaacc ctctgcactg	2400
tgctgtggg gcagccttcg tagacttact gttggagggtg cagaccaagg tgctggcct	2460

ggctaattggt gtgaagtgtg gcagccccgg ccagctgcag ggccgtagca tcttcgcgca 2520  
 ggacctgcgg ctgtgcctgg atgaggtcct ctcttgggac tgctttggcc tttcactctt 2580  
 ggctgtggcc gtgggcatgg tggcgcctat actgcacat ctctgcggct gggacgtctg 2640  
 gtactgtttt catctgtgcc tggcatggct acctttgctg gcccgagcc gacgcagcgc 2700  
 ccaaactctc ccttatgatg ccttcgtggt gttcgataag gcacagagcg cagttgccga 2760  
 ctgggtgtat aacgagctgc gggcgcggct ggaggagcgg cgcggtcgcc gagccctacg 2820  
 cttgtgtctg gaggaccgag attggctgcc tggccagacg ctcttcgaga acctctgggc 2880  
 ttccatctat gggagccgca agactctatt tgtgctggcc cacacggacc gcgtcagtgg 2940  
 cctcctgcgc accagcttcc tgctggctca gcagcgcctg ttggaagacc gcaaggacgt 3000  
 ggtggtgttg gtgacccctg gtccggatgc ccaccgctcc cgctatgtgc gactgcgcca 3060  
 gcgtctctgc cgccagagtg tgctcttctg gcccagcag cccaacgggc aggggggctt 3120  
 ctggggccag ctgagtacag ccctgactag ggacaaccgc cacttctata accagaactt 3180  
 ctgccgggga cctacagcag aatagctcag agcaacagct ggaaacagct gcattctcat 3240  
 gcctgggtcc cgagttgtgc tgctgcctt gctctgtctt actacaccgc tatttgga 3300  
 gtgcgcaata tatgtacca agccaccagg ccacggagc aaagggtggc agtaaagggt 3360  
 agttttcttc ccatgcatct ttcaggagag tgaagataga caccagacc acacagaaca 3420  
 ggactggagt tcattctctg ccctccacc ccactttgcc tgtctctgta t 3471

<210> 70  
 <211> 3340  
 <212> DNA  
 <213> murine

<400> 70  
 tctctgagag accctgggtg ggaacatcat tctctgccgc ccagtttgtc agagggagcc 60  
 tcgggagaat cctccatctc ccaacatggt tctccgtcga aggactctgc accccttgtc 120  
 cctcctggta caggctgcag tgctggctga gactctggcc ctgggtaccc tgcctgcctt 180  
 cctaccctgt gagctgaagc ctcattggct ggtggactgc aattggctgt tctgaagtc 240  
 tgtacccctg ttctctgcgg cagcatcctg ctccaacatc accgcctct cttgatctc 300  
 caaccgtatc caccacctgc acaactccga cttcgtccac ctgtccaacc tgccggcagct 360  
 gaacctcaag tggaactgtc caccactgg ccttagcccc ctgcacttct cttgccacat 420  
 gaccattgag ccagaaacct tctggctat gcgtacactg gaggagctga acctgagcta 480  
 taatggatc accactgtgc ccgactgcc cagctccctg gtgaatctga gcctgagcca 540  
 caccaacatc ctggttctag atgctaacag cctcgcgggc ctatacagcc tgcgcgttct 600

cttcatggac	gggaactgct	actacaagaa	cccctgcaca	ggagcgggtga	aggtgacccc	660
aggcgccctc	ctgggcctga	gcaatctcac	ccatctgtct	ctgaagtata	acaacctcac	720
aaaggtgccc	cgccaactgc	ccccagcct	ggagtacctc	ctggtgtcct	ataacctcat	780
tgtcaagctg	gggcctgaag	acctggccaa	tctgacctcc	cttcgagtac	ttgatgtggg	840
tgggaattgc	cgtcgtgcg	accatgcccc	caatccctgt	atagaatgtg	gccaaaagtc	900
cctccacctg	cacctgaga	ccttccatca	cctgagccat	ctggaaggcc	tggtgctgaa	960
ggacagctct	ctccatacac	tgaactcttc	ctggttccaa	ggtctggtca	acctctcggt	1020
gctggacctt	agcgagaact	ttctctatga	aagcatcaac	cacaccaatg	cctttcagaa	1080
cctaaccgcg	ctgcgcaagc	tcaacctgtc	cttcaattac	cgcaagaagg	tatcctttgc	1140
ccgcctccac	ctggcaagtt	ccttcaagaa	cctggtgtca	ctgcaggagc	tgaacatgaa	1200
cggcattctc	ttccgctcgc	tcaacaagta	cacgctcaga	tggttgccg	atctgcccaa	1260
actccacact	ctgcatcttc	aatgaactt	catcaaccag	gcacagctca	gcatctttgg	1320
taccttcoga	gcccttogct	ttgtggactt	gtcagacaat	cgcattcagt	ggccttcaac	1380
gctgtcagaa	gccaccctg	aagaggcaga	tgatgcagag	caggaggagc	tgttgtctgc	1440
ggatcctcac	ccagctccac	tgagcacccc	tgcttctaag	aacttcatgg	acaggtgtaa	1500
gaacttcaag	ttcaccatgg	acctgtctcg	gaacaacctg	gtgactatca	agccagagat	1560
gtttgtcaat	ctctcacgcc	tccagtgtct	tagcctgagc	cacaactcca	ttgcacaggc	1620
tgtcaatggc	tctcagttcc	tgccgtgac	taatctgcag	gtgctggacc	tgtcccataa	1680
caaactggac	ttgtaccact	ggaaatcggt	cagtgcagta	ccacagttgc	aggccctgga	1740
cctgggctac	aacagccagc	cctttagcat	aaagggata	ggccacaatt	tcagttttgt	1800
ggcccatctg	tccatgctac	acagccttag	cctggcacac	aatgacattc	ataccctgtg	1860
gtcctcacat	ctcaacagca	actcagtgcg	gtttcttgac	ttcagcggca	acggtatggg	1920
ccgcatgtgg	gatgaggggg	gcctttatct	ccatttcttc	caaggcctga	gtggcctgct	1980
gaagctggac	ctgtctcaaa	ataacctgca	tatcctccgg	cccagaacc	ttgacaacct	2040
ccccaaagagc	ctgaagctgc	tgagcctccg	agacaactac	ctatctttct	ttaactggac	2100
cagtctgtcc	ttcctgcccc	acctggaagt	cctagacctg	gcaggcaacc	agctaaaggc	2160
cctgaccaat	ggcaccctgc	ctaatggcac	cctcctccag	aaactggatg	tcagcagcaa	2220
cagtatcgtc	tctgtgggtc	cagccttctt	cgtctggcg	gtcgagctga	aagaggtaa	2280
cctcagccac	aacattctca	agacggtgga	tcgtcctgg	tttgggcca	ttgtgatgaa	2340
cctgacagtt	ctagacgtga	gaagcaacct	tctgcactgt	gcctgtgggg	cagccttcgt	2400
agacttactg	ttggaggtgc	agaccaaggt	gcctggcctg	gctaattggtg	tgaagtgtgg	2460
cagccccggc	cagctgcagg	gccgtagcat	cttcgcacag	gacctgcggc	tgtgcctgga	2520

tgaggtcctc tcttgggact gctttggcct ttcactcttg gctgtggccg tgggcatggt 2580  
 ggtgcctata ctgcaccatc tctgcggctg ggacgtcttg tactgttttc atctgtgcct 2640  
 ggcattggcta cctttgctgg ccgcagccg acgcagccg caagctctcc cctatgatgc 2700  
 cttcgtggtg ttcgataagg cacagagcgc agttgcggac tgggtgtata acgagctgcg 2760  
 ggtgcggctg gaggggaggc gcggtcggc agccctacgc ttgtgtcttg aggaccgaga 2820  
 ttggctgcct ggccagacgc tcttcgagaa cctctgggct tccatctatg ggagccgcaa 2880  
 gactctatct gtgctggccc acacggaccg cgtcagtggc ctctcgcgca ccagcttcc 2940  
 gctggctcag cagcgcctgt tggaagaccg caaggacgtg gtggtgttg tgatcctgcg 3000  
 tccgatgcc caccgctccc gctatgtgcg actgcgccag cgtctctgcc gccagagtgt 3060  
 gctcttttg cccagcagc ccaacgggca ggggggcttc tgggcccagc tgagtacagc 3120  
 cctgactagg gacaaccgcc acttctataa ccagaacttc tgccggggac ctacagcaga 3180  
 atagctcaga gcaacagctg gaaacagctg catcttcatg cctggttccc gagttgctct 3240  
 gcctgccttg ctctgtctta ctacaccgct atttggaag tgcgcaatat atgctaccaa 3300  
 gccaccgggc ccacggagca aagggttggt gtaaagggtg 3340

<210> 71  
 <211> 3471  
 <212> DNA  
 <213> murine

<400> 71  
 tgaaagtgtc acttcctcaa ttctctgaga gaccctggtg tggaacatca ttctctgccg 60  
 cccagtttgt cagagggagc ctcgggagaa tctccatct cccaacatgg ttctccgtcg 120  
 aaggactctg cacccttgt cctcctggt acaggctgca gtgctggctg agactctggc 180  
 cctgggtacc ctgctgcct tctaccctg tgagctgaag cctcatggcc tgggtggactg 240  
 caattggctg ttctgaagt ctgtaccccg tttctctgcg gcagcatcct gctccaacat 300  
 caccgcctc tcttgatct ccaaccgat ccaccactg cacaactccg acttcgtcca 360  
 cctgtccaac ctgcccagc tgaacctcaa gtggaactgt ccaccactg gccttagccc 420  
 cctgcacttc tcttgccaca tgaccattga gcccagaacc ttctgggcta tgcgtacact 480  
 ggaggagctg aacctgagct ataatggtat caccactgtg cccgactgc ccagctccct 540  
 ggtgaatctg agcctgagcc acaccaacat cctggttcta gatgctaaca gcctcgccgg 600  
 cctatacagc ctgcgcgttc tcttcattga cgggaactgc tactacaaga acccctgcac 660  
 aggagcgggtg aaggtagccc caggcgcct cctgggcctg agcaatctca cccatctgtc 720  
 tctgaagtat aacaacctca caaagggtgcc ccgccaactg ccccccagcc tggagtacct 780

cctggtgtcc tataacctca ttgtcaagct ggggcctgaa gacctggcca atctgacctc	840
ccttcgagta cttgatgtgg gtgggaattg ccgtcgtgc gaccatgccc ccaatccctg	900
tatagaatgt ggccaaaagt ccctccacct gcacctgag accttccatc acctgagcca	960
tctggaaggc ctggtgctga aggacagctc tctccataca ctgaactctt cctggttcca	1020
aggctctggtc aacctctcgg tgctggacct aagcgagaac tttctctatg aaagcatcaa	1080
ccacaccaat gcctttcaga acctaaccgg cctgogcaag ctcaacctgt ccttcaatta	1140
ccgcaagaag gtatcctttg ccgcctcca cctggcaagt tccttcaaga acctggtgtc	1200
actgcaggag ctgaacatga acggcatctt cttccgctcg ctcaacaagt acacgctcag	1260
atggttgccc gatctgccc aactccacac tctgcatctt caaatgaact tcatcaacca	1320
ggcacagctc agcatctttg gtaccttcgg agcccttcgc tttgtggact tgtcagacaa	1380
tcgcatcagt gggccttcaa cgctgtcaga agccaccct gaagaggcag atgatgcaga	1440
gcaggaggag ctgttgtctg cggatcctca ccagctcca ctgagcacc ctgcttctaa	1500
gaacttcatg gacaggtgta agaacttcaa gttcaccatg gacctgtctc ggaacaacct	1560
ggtgactatc aagccagaga tgtttgtcaa tctctcacgc ctccagtgtc ttagcctgag	1620
ccacaactcc attgcacagg ctgtcaatgg ctctcagttc ctgccgtga ctaatctgca	1680
ggtgctggac ctgtcccata acaaactgga cttgtaccac tggaaatcgt tcagtgaagt	1740
accacagttg cagggcctgg acctgagcta caacagccag cccttttagca tgaagggtat	1800
aggccacaat tttagttttg tgacctctc gtccatgcta cagagcctta gcctggcaca	1860
caatgacatt cataccctg tgctctcaca tctcaacagc aactcagtga gggttcttga	1920
cttcagcggc aacggtatgg gccgcatgtg ggatgagggg ggcctttatc tccatttctt	1980
ccaaggcctg agtggcctgc tgaagctgga cctgtctcaa aataacctgc atatcctccg	2040
gccccagAAC cttgacaacc tccccagag cctgaagctg ctgagcctcc gagacaacta	2100
cctatctttc ttttaactgga ccagtctgtc cttctacccc aacctggaag tcctagacct	2160
ggcaggcaac cagctaaagg ccctgaccaa tggcaccctg cctaattggca ccctcctcca	2220
gaaactcgat gtcagtagca acagtatcgt ctctgtgggc ccagccttct tcgctctggc	2280
ggtcgagctg aaagaggtca acctcagcca caacattctc aagacggtgg atcgctcctg	2340
gtttggggcc attgtgatga acctgacagt tctagacgtg agaagcaacc ctctgcactg	2400
tgctgtggg gcagccttcg tagacttact gttggaggtg cagaccaagg tgcttggcct	2460
ggctaagtgt gtgaagtgtg gcagccccgg ccagctgcag ggccgtagca tcttcgcgca	2520
ggacctgcgg ctgtgcctgg atgaggtcct ctcttgggac tgctttggcc tttcactctt	2580
ggctgtggcc gtgggcatgg tgggtgcctat actgcacat ctctgcggct gggacgtctg	2640
gtactgtttt catctgtgcc tggcatggct acctttgtg gcccgagcc gacgcagcgc	2700

ccaaactctc ccttatgatg ccttcgtggt gttcgataag gcacagagcg cagttgccga 2760  
 ctgggtgtat aacgagctgc ggggtgcggct ggaggagcgg cgcggtcgcc gagccctacg 2820  
 cttgtgtctg gaggaccgag attggctgcc tggccagacg ctcttcgaga acctctgggc 2880  
 ttccatctat gggagccgca agactctatt tgtgctggcc cacacggacc gcgtcagtgg 2940  
 cctcctgcgc accagcttcc tgetggctca gcagcgctg ttggaagacc gcaaggacgt 3000  
 ggtggtgttg gtgatcctgc gtccggatgc ccaccgctcc cgctatgtgc gactgcgcca 3060  
 gcgtctctgc cgccagagtg tgetcttctg gcccagcag cccaacgggc aggggggctt 3120  
 ctggggccag ctgagtacag ccctgactag ggacaaccgc cacttctata accagaactt 3180  
 ctgccgggga cctacagcag aatagctcag agcaacagct ggaaacagct gcattctcat 3240  
 gcctggttcc cgagttgctc tgctgcctt gctctgtctt actacaccgc tatttggcaa 3300  
 gtgcgcaata tatgtacca agccaccagg cccacggagc aaaggttggc agtaaaggtt 3360  
 agttttcttc ccatgcatct ttcaggagag tgaagataga caccagacc acacagaaca 3420  
 ggactggagt tcattctctg cccctccacc ccactttgcc tgtctctgta t 3471

<210> 72  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 72

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
 1 5 10 15  
 Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20 25 30  
 Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
 35 40 45  
 Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn  
 50 55 60  
 Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
 65 70 75 80  
 Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
 85 90 95  
 Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
 100 105 110  
 Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
 115 120 125  
 Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
 130 135 140



Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
 145 150 155 160  
 Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
 225 230 235 240  
 Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
 260 265 270  
 Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
 290 295 300  
 Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
 340 345 350  
 Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
 355 360 365  
 Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
 370 375 380  
 Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
 405 410 415  
 Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
 420 425 430  
 Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
 435 440 445  
 Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
 450 455 460  
 Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu

169/231

805 810 815  
 Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val  
 820 825 830  
 Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe  
 835 840 845  
 His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser  
 850 855 860  
 Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln  
 865 870 875 880  
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu  
 885 890 895  
 Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp  
 900 905 910  
 Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr  
 915 920 925  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
 930 935 940  
 Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
 945 950 955 960  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His  
 965 970 975  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val  
 980 985 990  
 Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln  
 995 1000 1005  
 Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln  
 1010 1015 1020  
 Asn Phe Cys Arg Gly Pro Thr Ala Glu  
 1025 1030

<210> 73  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 73

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
 1 5 10 15  
 Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20 25 30  
 Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
 35 40 45  
 Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn  
 50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
 65 70 75 80  
 Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
 85 90 95  
 Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
 100 105 110  
 Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
 115 120 125  
 Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
 130 135 140  
 Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
 145 150 155 160  
 Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
 225 230 235 240  
 Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
 260 265 270  
 Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
 290 295 300  
 Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
 340 345 350  
 Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
 355 360 365  
 Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
 370 375 380  
 Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met

```

385          390          395          400
Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala
          405          410          415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr
          420          425          430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu
          435          440          445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser
          450          455          460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu
465          470          475          480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu
          485          490          495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala
          500          505          510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp
          515          520          525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu
          530          535          540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Gly Tyr Asn Ser Gln Pro Phe
545          550          555          560

Ser Ile Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser
          565          570          575

Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val
          580          585          590

Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly
          595          600          605

Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe
610          615          620

Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn
625          630          635          640

Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu
          645          650          655

Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr
          660          665          670

Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn
          675          680          685

Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu
690          695          700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala
705          710          715          720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn

```

```

      725      730      735
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn
      740      745      750

Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly
      755      760      765

Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly
      770      775      780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg
785      790      795      800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser
      805      810      815

Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val
      820      825      830

Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe
      835      840      845

His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser
      850      855      860

Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln
865      870      875      880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu
      885      890      895

Gly Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp
      900      905      910

Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr
      915      920      925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
      930      935      940

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945      950      955      960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His
      965      970      975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
      980      985      990

Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln
      995      1000      1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln
1010      1015      1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu
1025      1030

```

&lt;210&gt; 74

&lt;211&gt; 1032

&lt;212&gt; PRT

&lt;213&gt; murine

&lt;400&gt; 74

```

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1           5           10           15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
          20           25           30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
          35           40           45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn
50           55           60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn
65           70           75           80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
          85           90           95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met
          100          105          110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu
          115          120          125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130           135           140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145           150           155          160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly
          165          170          175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro
          180          185          190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
          195          200          205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210           215           220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu
225           230           235          240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
          245          250          255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser
260           265           270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly
275           280           285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe
290           295           300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305           310           315          320

```

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
 340 345 350  
 Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
 355 360 365  
 Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
 370 375 380  
 Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
 405 410 415  
 Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
 420 425 430  
 Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
 435 440 445  
 Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
 450 455 460  
 Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu  
 465 470 475 480  
 Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
 485 490 495  
 Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
 500 505 510  
 Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
 515 520 525  
 Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
 530 535 540  
 Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
 545 550 555 560  
 Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser  
 565 570 575  
 Met Leu Gln Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val  
 580 585 590  
 Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly  
 595 600 605  
 Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe  
 610 615 620  
 Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn  
 625 630 635 640  
 Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu



Lys	Leu	Leu	Ser	645	Leu	Arg	Asp	Asn	Tyr	650	Leu	Ser	Phe	Phe	Asn	655	Trp	Thr
			660						665							670		
Ser	Leu	Ser	Phe	Leu	Pro	Asn	Leu	Glu	Val	Leu	Asp	Leu	Ala	Gly	Asn			
		675					680						685					
Gln	Leu	Lys	Ala	Leu	Thr	Asn	Gly	Thr	Leu	Pro	Asn	Gly	Thr	Leu	Leu			
	690						695					700						
Gln	Lys	Leu	Asp	Val	Ser	Ser	Asn	Ser	Ile	Val	Ser	Val	Val	Pro	Ala			
705						710				715					720			
Phe	Phe	Ala	Leu	Ala	Val	Glu	Leu	Lys	Glu	Val	Asn	Leu	Ser	His	Asn			
				725					730						735			
Ile	Leu	Lys	Thr	Val	Asp	Arg	Ser	Trp	Phe	Gly	Pro	Ile	Val	Met	Asn			
			740					745						750				
Leu	Thr	Val	Leu	Asp	Val	Arg	Ser	Asn	Pro	Leu	His	Cys	Ala	Cys	Gly			
	755						760					765						
Ala	Ala	Phe	Val	Asp	Leu	Leu	Leu	Glu	Val	Gln	Thr	Lys	Val	Pro	Gly			
	770						775					780						
Leu	Ala	Asn	Gly	Val	Lys	Cys	Gly	Ser	Pro	Gly	Gln	Leu	Gln	Gly	Arg			
785					790					795					800			
Ser	Ile	Phe	Ala	Gln	Asp	Leu	Arg	Leu	Cys	Leu	Asp	Glu	Val	Leu	Ser			
				805					810						815			
Trp	Asp	Cys	Phe	Gly	Leu	Ser	Leu	Leu	Ala	Val	Ala	Val	Gly	Met	Val			
			820					825						830				
Val	Pro	Ile	Leu	His	His	Leu	Cys	Gly	Trp	Asp	Val	Trp	Tyr	Cys	Phe			
		835					840						845					
His	Leu	Cys	Leu	Ala	Trp	Leu	Pro	Leu	Leu	Ala	Arg	Ser	Arg	Arg	Ser			
	850					855					860							
Ala	Gln	Thr	Leu	Pro	Tyr	Asp	Ala	Phe	Val	Val	Phe	Asp	Lys	Ala	Gln			
865					870					875					880			
Ser	Ala	Val	Ala	Asp	Trp	Val	Tyr	Asn	Glu	Leu	Arg	Val	Arg	Leu	Glu			
				885					890						895			
Glu	Arg	Arg	Gly	Arg	Arg	Ala	Leu	Arg	Leu	Cys	Leu	Glu	Asp	Arg	Asp			
			900					905					910					
Trp	Leu	Pro	Gly	Gln	Thr	Leu	Phe	Glu	Asn	Leu	Trp	Ala	Ser	Ile	Tyr			
		915					920						925					
Gly	Ser	Arg	Lys	Thr	Leu	Phe	Val	Leu	Ala	His	Thr	Asp	Arg	Val	Ser			
	930					935						940						
Gly	Leu	Leu	Arg	Thr	Ser	Phe	Leu	Leu	Ala	Gln	Gln	Arg	Leu	Leu	Glu			
945					950					955					960			
Asp	Arg	Lys	Asp	Val	Val	Val	Leu	Val	Ile	Leu	Arg	Pro	Asp	Ala	His			
				965					970						975			
Arg	Ser	Arg	Tyr	Val	Arg	Leu	Arg	Gln	Arg	Leu	Cys	Arg	Gln	Ser	Val			

980                      985                      990  
 Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln  
           995                      1000                      1005  
  
 Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln  
           1010                      1015                      1020  
  
 Asn Phe Cys Arg Gly Pro Thr Ala Glu  
           1025                      1030

<210> 75  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 75

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
 1                      5                      10                      15  
  
 Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
           20                      25                      30  
  
 Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
           35                      40                      45  
  
 Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn  
           50                      55                      60  
  
 Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
 65                      70                      75                      80  
  
 Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
           85                      90                      95  
  
 Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
           100                      105                      110  
  
 Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
           115                      120                      125  
  
 Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
           130                      135                      140  
  
 Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
 145                      150                      155                      160  
  
 Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
           165                      170                      175  
  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
           180                      185                      190  
  
 Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
           195                      200                      205  
  
 Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
           210                      215                      220  
  
 Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
 225                      230                      235                      240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
 260 265 270  
 Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
 290 295 300  
 Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
 340 345 350  
 Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
 355 360 365  
 Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
 370 375 380  
 Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
 405 410 415  
 Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
 420 425 430  
 Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
 435 440 445  
 Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
 450 455 460  
 Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu  
 465 470 475 480  
 Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
 485 490 495  
 Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
 500 505 510  
 Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
 515 520 525  
 Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
 530 535 540  
 Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
 545 550 555 560  
 Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser

Met	Leu	Gln	Ser	Leu	Ser	Leu	Ala	His	Asn	Asp	Ile	His	Thr	Arg	Val
			580					585					590		
Ser	Ser	His	Leu	Asn	Ser	Asn	Ser	Val	Arg	Phe	Leu	Asp	Phe	Ser	Gly
		595					600					605			
Asn	Gly	Met	Gly	Arg	Met	Trp	Asp	Glu	Gly	Gly	Leu	Tyr	Leu	His	Phe
	610					615					620				
Phe	Gln	Gly	Leu	Ser	Gly	Leu	Leu	Lys	Leu	Asp	Leu	Ser	Gln	Asn	Asn
625					630					635					640
Leu	His	Ile	Leu	Arg	Pro	Gln	Asn	Leu	Asp	Asn	Leu	Pro	Lys	Ser	Leu
				645					650					655	
Lys	Leu	Leu	Ser	Leu	Arg	Asp	Asn	Tyr	Leu	Ser	Phe	Phe	Asn	Trp	Thr
			660					665					670		
Ser	Leu	Ser	Phe	Leu	Pro	Asn	Leu	Glu	Val	Leu	Asp	Leu	Ala	Gly	Asn
		675					680					685			
Gln	Leu	Lys	Ala	Leu	Thr	Asn	Gly	Thr	Leu	Pro	Asn	Gly	Thr	Leu	Leu
	690					695					700				
Gln	Lys	Leu	Asp	Val	Ser	Ser	Asn	Ser	Ile	Val	Ser	Val	Val	Pro	Ala
705					710					715					720
Phe	Phe	Ala	Leu	Ala	Val	Glu	Leu	Lys	Glu	Val	Asn	Leu	Ser	His	Asn
				725					730					735	
Ile	Leu	Lys	Thr	Val	Asp	Arg	Ser	Trp	Phe	Gly	Pro	Ile	Val	Met	Asn
			740					745					750		
Leu	Thr	Val	Leu	Asp	Val	Arg	Ser	Asn	Pro	Leu	His	Cys	Ala	Cys	Gly
	755						760					765			
Ala	Ala	Phe	Val	Asp	Leu	Leu	Leu	Glu	Val	Gln	Thr	Lys	Val	Pro	Gly
	770					775					780				
Leu	Ala	Asn	Gly	Val	Lys	Cys	Gly	Ser	Pro	Gly	Gln	Leu	Gln	Gly	Arg
785					790					795					800
Ser	Ile	Phe	Ala	Gln	Asp	Leu	Arg	Leu	Cys	Leu	Asp	Glu	Val	Leu	Ser
			805						810					815	
Trp	Asp	Cys	Phe	Gly	Leu	Ser	Leu	Leu	Ala	Val	Ala	Val	Gly	Met	Val
			820					825					830		
Val	Pro	Ile	Leu	His	His	Leu	Cys	Gly	Trp	Asp	Val	Trp	Tyr	Cys	Phe
		835					840					845			
His	Leu	Cys	Leu	Ala	Trp	Leu	Pro	Leu	Leu	Ala	Arg	Ser	Arg	Arg	Ser
	850					855					860				
Ala	Gln	Thr	Leu	Pro	Tyr	Asp	Ala	Phe	Val	Val	Phe	Asp	Lys	Ala	Gln
865					870					875					880
Ser	Ala	Val	Ala	Asp	Trp	Val	Tyr	Asn	Glu	Leu	Arg	Val	Arg	Leu	Glu
			885						890					895	
Glu	Arg	Arg	Gly	Arg	Arg	Ala	Leu	Arg	Leu	Cys	Leu	Glu	Asp	Arg	Asp

900 905 910  
 Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr  
 915 920 925  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
 930 935 940  
 Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
 945 950 955 960  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His  
 965 970 975  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val  
 980 985 990  
 Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln  
 995 1000 1005  
 Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln  
 1010 1015 1020  
 Asn Phe Cys Arg Gly Pro Thr Ala Glu  
 1025 1030

<210> 76  
 <211> 3002  
 <212> DNA  
 <213> Homo sapiens

<400> 76  
 gtggccttgggt attcactggc aggtttcaga catttagatc tttcttttaa tgactaacac 60  
 catgcctatc tgtggagaag ctggcaacat gtcacacctg gaaattgttt ttcaacatta 120  
 atactattat ttggcagtaa tccagattgc ttttgccacc aacctgaaga catatagagg 180  
 cagaaggaca ggaataattc tatttgtttc ctgttttgaa acttccatct gtaaggctat 240  
 caaaaggaga tgtgagagag ggtattgagt ctggcctgac aatgcagttc ttaaaccaaa 300  
 ggtccattat gcttctcctc tctgagaatc ctgacttacc tcaacaacgg agacatggca 360  
 cagtagccag cttggagact tctcagccaa tgctctgaga tcaagtcgaa gaccaatat 420  
 acagggtttt gagctcatct tcatcattca tatgaggaaa taagtggtaa aatccttgga 480  
 aatacaatga gactcatcag aaacatttac atattttgta gtattgttat gacagcagag 540  
 ggtgatgctc cagagctgcc agaagaaagg gaactgatga ccaactgctc caacatgtct 600  
 ctaagaaagg ttcccgaga cttgacccca gccacaacga cactggattt atcctataac 660  
 ctcctttttc aactccagag ttcagatttt cattctgtct ccaaactgag agttttgatt 720  
 ctatgccata acagaattca acagctggat ctcaaaacct ttgaattcaa caaggagtta 780  
 agatatttag atttgtctaa taacagactg aagagtgtaa cttggtattt actggcaggt 840  
 ctcagggtatt tagatctttc ttttaatgac tttgacacca tgctatctg tgaggaagct 900

ggcaacatgt	cacacctgga	aatcctaggt	ttgagtgggg	caaaaataca	aaaatcagat	960
ttccagaaaa	ttgctcatct	gcattctaaat	actgtcttct	taggattcag	aactcttctt	1020
cattatgaag	aaggtagcct	gccccatctta	aacacaacaa	aactgcacat	tgttttacca	1080
atggacacaa	atctctgggt	tcttttgcgt	gatggaatca	agacttcaaa	aatattagaa	1140
atgacaaaata	tagatggcaa	aagccaattt	gtaagttatg	aaatgcaacg	aaatcttagt	1200
ttagaaaaatg	ctaagacatc	ggttctattg	cttaataaaag	ttgatttact	ctgggacgac	1260
cttttctcta	tcttacaatt	tgtttgcat	acatcagtgg	aacactttca	gatccgaaat	1320
gtgacttttg	gtggaaggg	ttatcttgac	cacaattcat	ttgactactc	aaatactgta	1380
atgagaacta	taaaattgga	gcattgtacat	ttcagagtgt	tttacattca	acaggataaa	1440
atctattttgc	ttttgaccaa	aatggacata	gaaaacctga	caatatcaaa	tgacacaaatg	1500
ccacacatgc	ttttcccgaa	ttatctctag	aaattccaat	atttaaattt	tgccaataat	1560
atcttaacag	acgagttgtt	taaaagaact	atccaactgc	ctcacttgaa	aactctcatt	1620
ttgaatggca	ataaactgga	gacactttct	ttagtaagtt	gctttgctaa	caacacaccc	1680
ttggaacact	tggtctgag	tcaaaatcta	ttacaacata	aaaatgatga	aaattgctca	1740
tgccagaaa	ctgtgggtcaa	tatgaatctg	tcatacaata	aattgtctga	ttctgtcttc	1800
aggtgcttgc	ccaaaagtat	tcaaaactct	gacctaaata	ataaccaa	ccaaactgta	1860
cctaaagaga	ctattcatct	gatggcctta	cgagaactaa	atattgcatt	taattttcta	1920
actgatctcc	ctggatgcag	tcatttcagt	agactttcag	ttctgaacat	tgaaatgaac	1980
ttcattctca	gccccatctt	ggattttgtt	cagagctgcc	aggaagttaa	aactctaaat	2040
gcggaagaa	atccattccg	gtgtacctgt	gaattaaaaa	atttcattca	gcttgaaaca	2100
tattcagagg	tcattgatgt	tggtgggtca	gattcataca	cctgtgaata	ccctttaaac	2160
ctaaggggaa	ttagggttaa	agacgttcat	ctccacgaat	tatcttgcaa	cacagctctg	2220
ttgattgtca	ccattgtggg	tattatgcta	gttctggggg	tggtgtggc	cttctgtgtg	2280
ctccactttg	atctgccctg	gtatctcagg	atgctaggtc	aatgcacaca	aacatggcac	2340
agggttagga	aaacaacca	agaacaactc	aagagaaatg	tccgattcca	cgcatttatt	2400
tcatacagt	aacatgattc	tctgtgggtg	agaatgaat	tgatcccaa	tctagagaag	2460
gaagatgggt	ctatcttgat	ttgcctttat	gaaagctact	ttgacctgg	caaaagcatt	2520
agtgaaaata	ttgtaagctt	cattgagaaa	agctataagt	ccatctttgt	ttgtctccc	2580
aactttgtcc	agaatgagtg	gtgccattat	gaattttact	ttgccacca	caatctcttc	2640
catgaaaatt	ctgatcatat	aattcttata	ttactggaac	ccattccatt	ctattgcatt	2700
cccaccaggt	atcataaact	gaaagctctc	ctggaaaaaa	aagcataact	ggaatggccc	2760
aaggataggg	gtaaatgtgg	gcttttctgg	gcaaaccttc	gagctgctat	taatgttaat	2820

gtattagcca ccagagaaat gtatgaactg cagacattca cagagttaaa tgaagagtct 2880  
 cgagggttcta caatctctct gatgagaaca gattgtctat aaaatcccac agtccttggg 2940  
 aagttggggga ccacatacac tgttgggatg tacattgata caacctttat gatggcaatt 3000  
 tg 3002

<210> 77  
 <211> 811  
 <212> PRT  
 <213> Homo sapiens

<400> 77

Met Arg Leu Ile Arg Asn Ile Tyr Ile Phe Cys Ser Ile Val Met Thr  
 1 5 10 15  
 Ala Glu Gly Asp Ala Pro Glu Leu Pro Glu Glu Arg Glu Leu Met Thr  
 20 25 30  
 Asn Cys Ser Asn Met Ser Leu Arg Lys Val Pro Ala Asp Leu Thr Pro  
 35 40 45  
 Ala Thr Thr Thr Leu Asp Leu Ser Tyr Asn Leu Leu Phe Gln Leu Gln  
 50 55 60  
 Ser Ser Asp Phe His Ser Val Ser Lys Leu Arg Val Leu Ile Leu Cys  
 65 70 75 80  
 His Asn Arg Ile Gln Gln Leu Asp Leu Lys Thr Phe Glu Phe Asn Lys  
 85 90 95  
 Glu Leu Arg Tyr Leu Asp Leu Ser Asn Asn Arg Leu Lys Ser Val Thr  
 100 105 110  
 Trp Tyr Leu Leu Ala Gly Leu Arg Tyr Leu Asp Leu Ser Phe Asn Asp  
 115 120 125  
 Phe Asp Thr Met Pro Ile Cys Glu Glu Ala Gly Asn Met Ser His Leu  
 130 135 140  
 Glu Ile Leu Gly Leu Ser Gly Ala Lys Ile Gln Lys Ser Asp Phe Gln  
 145 150 155 160  
 Lys Ile Ala His Leu His Leu Asn Thr Val Phe Leu Gly Phe Arg Thr  
 165 170 175  
 Leu Pro His Tyr Glu Glu Gly Ser Leu Pro Ile Leu Asn Thr Thr Lys  
 180 185 190  
 Leu His Ile Val Leu Pro Met Asp Thr Asn Phe Trp Val Leu Leu Arg  
 195 200 205  
 Asp Gly Ile Lys Thr Ser Lys Ile Leu Glu Met Thr Asn Ile Asp Gly  
 210 215 220  
 Lys Ser Gln Phe Val Ser Tyr Glu Met Gln Arg Asn Leu Ser Leu Glu  
 225 230 235 240

Asn Ala Lys Thr Ser Val Leu Leu Leu Asn Lys Val Asp Leu Leu Trp  
 245 250 255  
 Asp Asp Leu Phe Leu Ile Leu Gln Phe Val Trp His Thr Ser Val Glu  
 260 265 270  
 His Phe Gln Ile Arg Asn Val Thr Phe Gly Gly Lys Ala Tyr Leu Asp  
 275 280 285  
 His Asn Ser Phe Asp Tyr Ser Asn Thr Val Met Arg Thr Ile Lys Leu  
 290 295 300  
 Glu His Val His Phe Arg Val Phe Tyr Ile Gln Gln Asp Lys Ile Tyr  
 305 310 315 320  
 Leu Leu Leu Thr Lys Met Asp Ile Glu Asn Leu Thr Ile Ser Asn Ala  
 325 330 335  
 Gln Met Pro His Met Leu Phe Pro Asn Tyr Pro Thr Lys Phe Gln Tyr  
 340 345 350  
 Leu Asn Phe Ala Asn Asn Ile Leu Thr Asp Glu Leu Phe Lys Arg Thr  
 355 360 365  
 Ile Gln Leu Pro His Leu Lys Thr Leu Ile Leu Asn Gly Asn Lys Leu  
 370 375 380  
 Glu Thr Leu Ser Leu Val Ser Cys Phe Ala Asn Asn Thr Pro Leu Glu  
 385 390 395 400  
 His Leu Asp Leu Ser Gln Asn Leu Leu Gln His Lys Asn Asp Glu Asn  
 405 410 415  
 Cys Ser Trp Pro Glu Thr Val Val Asn Met Asn Leu Ser Tyr Asn Lys  
 420 425 430  
 Leu Ser Asp Ser Val Phe Arg Cys Leu Pro Lys Ser Ile Gln Ile Leu  
 435 440 445  
 Asp Leu Asn Asn Asn Gln Ile Gln Thr Val Pro Lys Glu Thr Ile His  
 450 455 460  
 Leu Met Ala Leu Arg Glu Leu Asn Ile Ala Phe Asn Phe Leu Thr Asp  
 465 470 475 480  
 Leu Pro Gly Cys Ser His Phe Ser Arg Leu Ser Val Leu Asn Ile Glu  
 485 490 495  
 Met Asn Phe Ile Leu Ser Pro Ser Leu Asp Phe Val Gln Ser Cys Gln  
 500 505 510  
 Glu Val Lys Thr Leu Asn Ala Gly Arg Asn Pro Phe Arg Cys Thr Cys  
 515 520 525  
 Glu Leu Lys Asn Phe Ile Gln Leu Glu Thr Tyr Ser Glu Val Met Met  
 530 535 540  
 Val Gly Trp Ser Asp Ser Tyr Thr Cys Glu Tyr Pro Leu Asn Leu Arg  
 545 550 555 560  
 Gly Ile Arg Leu Lys Asp Val His Leu His Glu Leu Ser Cys Asn Thr



565 570 575  
 Ala Leu Leu Ile Val Thr Ile Val Val Ile Met Leu Val Leu Gly Leu  
 580 585 590  
 Ala Val Ala Phe Cys Cys Leu His Phe Asp Leu Pro Trp Tyr Leu Arg  
 595 600 605  
 Met Leu Gly Gln Cys Thr Gln Thr Trp His Arg Val Arg Lys Thr Thr  
 610 615 620  
 Gln Glu Gln Leu Lys Arg Asn Val Arg Phe His Ala Phe Ile Ser Tyr  
 625 630 635 640  
 Ser Glu His Asp Ser Leu Trp Val Lys Asn Glu Leu Ile Pro Asn Leu  
 645 650 655  
 Glu Lys Glu Asp Gly Ser Ile Leu Ile Cys Leu Tyr Glu Ser Tyr Phe  
 660 665 670  
 Asp Pro Gly Lys Ser Ile Ser Glu Asn Ile Val Ser Phe Ile Glu Lys  
 675 680 685  
 Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Asn Glu  
 690 695 700  
 Trp Cys His Tyr Glu Phe Tyr Phe Ala His His Asn Leu Phe His Glu  
 705 710 715 720  
 Asn Ser Asp His Ile Ile Leu Ile Leu Leu Glu Pro Ile Pro Phe Tyr  
 725 730 735  
 Cys Ile Pro Thr Arg Tyr His Lys Leu Lys Ala Leu Leu Glu Lys Lys  
 740 745 750  
 Ala Tyr Leu Glu Trp Pro Lys Asp Arg Arg Lys Cys Gly Leu Phe Trp  
 755 760 765  
 Ala Asn Leu Arg Ala Ala Ile Asn Val Asn Val Leu Ala Thr Arg Glu  
 770 775 780  
 Met Tyr Glu Leu Gln Thr Phe Thr Glu Leu Asn Glu Glu Ser Arg Gly  
 785 790 795 800  
 Ser Thr Ile Ser Leu Met Arg Thr Asp Cys Leu  
 805 810

<210> 78  
 <211> 2760  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (2529)..(2529)  
 <223> n is a, c, g, or t

<400> 78  
 aagaatttgg actcatatca agatgctctg aagaagaaca accctttagg atagccactg 60  
 caacatcatg accaaagaca aagaacctat tgttaaaagc ttccattttg ttgccttat 120

gatcataata gttggaacca gaatccagtt ctccgacgga aatgaatttg cagtagacaa	180
gtcaaaaaga ggtcttatto atgttccaaa agacctaccg ctgaaaacca aagtcttaga	240
tatgtctcag aactacatcg ctgagcttca ggtctctgac atgagctttc tatcagagtt	300
gacagttttg agactttccc ataacagaat ccagctactt gatttaagtg ttttcaagtt	360
caaccaggat ttagaatatt tggatttatc tcataatcag ttgcaaaaaga tctcctgcca	420
tcctattgtg agtttcaggc atttagatct ctcatcatt gatttcaagg ccctgccccat	480
ctgtaaggaa tttggcaact tatcacaact gaatttcttg ggattgagtg ctatgaagct	540
gcaaaaatta gatttgctgc caattgctca cttgcatcta agttatatcc ttctggattt	600
aagaaattat tatataaaag aaaatgagac agaaagtcta caaattctga atgcaaaaac	660
ccttcacctt gtttttcacc caactagttt attcgctatc caagtgaaca tatcagttaa	720
tacttttaggg tgcttacaac tgactaatat taaattgaat gatgacaact gtcaagtttt	780
cattaaattt ttatcagaac tcaccagagg tccaacctta ctgaatttta ccctcaacca	840
catagaaacg acttggaat gcctggtcag agtctttcaa tttctttggc ccaaacctgt	900
ggaatatctc aatatattaca atttaacaat aattgaaagc attcgtgaag aagattttac	960
ttattctaaa acgacattga aagcattgac aatagaacat atcacgaacc aagtttttct	1020
gttttcacag acagctttgt acaccgtgtt ttctgagatg aacattatga tgtaaacat	1080
ttcagatata ccttttatat acatgctgtg tcctcatgca ccaagcacat tcaagttttt	1140
gaactttacc cagaacgttt tcacagatag tatttttgaa aaatgttcca cgtagtttaa	1200
attggagaca cttatcttac aaaagaatgg attaaaagac cttttcaaag taggtctcat	1260
gacgaaggat atgccttctt tggaaatact ggatgttagc tggaattctt tggaatctgg	1320
tagacataaa gaaaactgca cttgggttga gagtatagtg gtgttaaatt tgtcttcaaa	1380
tatgcttact gactctgttt tcagatgttt acctcccagg atcaaggtag ttgatcttca	1440
cagcaataaa ataaagagcg ttcttaaaca agtcgtaaaa ctggaagctt tgcaagaact	1500
caatgttgct ttcaattctt taactgacct tcctggatgt ggcagcttta gcagcctttc	1560
tgtattgatc attgatcaca attcagtttc ccacccatcg gctgatttct tccagagctg	1620
ccagaagatg aggtcaataa aagcagggga caatccattc caatgtacct gtgagctaag	1680
agaatttgct aaaaatatag accaagtatc aagtgaagtg ttagagggct ggcctgattc	1740
ttataagtgt gactaccag aaagttatag aggaagccca ctaaaggact ttcacatgct	1800
tgaattatcc tgcaacataa ctctgctgat cgtcaccatc ggtgccacca tgctgggtgt	1860
ggctgtgact gtgacctccc tctgcatcta cttggatctg ccctgggtatc tcaggatggt	1920
gtgccagtgg acccagactc ggcgcagggc caggaacata cccttagaag aactccaaag	1980
aaacctccag tttcatgctt ttatttcata tagtgaacat gattctgcct gggtgaaaag	2040

tgaattggta ccttacctag aaaaagaaga tatacagatt tgtcttcattg agaggaactt 2100  
 tgtccctggc aagagcattg tggaaaatat catcaactgc attgagaaga gttacaagtc 2160  
 catctttgtt ttgtctccca actttgtcca gagtgagtgg tgccattacg aactctattt 2220  
 tgcccatcac aatctctttc atgaaggatc taataactta atcctcatct tactggaacc 2280  
 cattccacag aacagcattc ccaacaagta ccacaagctg aaggctctca tgacgcagcg 2340  
 gacttatttg cagtggccca aggagaaaag caaacgtggg ctcttttggg ctaacattag 2400  
 agccgctttt aatatgaaat taacactagt cactgaaaac aatgatgtga aatcttaaaa 2460  
 aaatttagga aattcaactt aagaaaccat tatttacttg gatgatgggtg aatagtacag 2520  
 tcgtaagtna ctgtctggag gtgcctccat tatcctcatg ccttcaggaa agacttaaca 2580  
 aaaacaatgt ttcattctggg gaactgagct aggcggtgag gttagcctgc cagttagaga 2640  
 cagcccagtc tcttctgggt taatcattat gtttcaaatt gaaacagtct cttttgagta 2700  
 aatgctcagt ttttcagctc ctctccactc tgctttccca aatggattct gttggtgaag 2760

<210> 79

<211> 2753

<212> DNA

<213> Homo sapiens

<400> 79

agaattttgga ctcatatcaa gatgctctga agaagaacaa cccttttagga tagccactgc 60  
 aacatcatga ccaaagacaa agaacctatt gttaaaagct tccattttgt ttgccttatg 120  
 atcataatag ttggaaccag aatccagttc tccgacggaa atgaatttgc agtagacaag 180  
 tcaaaaagag gtcttattca tgttccaaaa gacctaccgc tgaaaaccaa agtcttagat 240  
 atgtctcaga actacatcgc tgagcttcag gtctctgaca tgagctttct atcagagtgt 300  
 acagttttga gactttccca taacagaatc cagctacttg atttaagtgt tttcaagttc 360  
 aaccaggatt tagaatatct ggatttatct cataatcagt tgcaaaagat atcctgccat 420  
 cctattgtga gtttcaggca ttttagatctc tcattcaatg atttcaaggc cctgcccac 480  
 tgtaaggaat ttggcaactt atcacaactg aatttcttgg gattgagtgc tatgaagctg 540  
 caaaaattag atttgctgcc aattgctcac ttgcatctaa gttatatcct tctggattta 600  
 agaaattatt atataaaaga aaatgagaca gaaagtctac aaattctgaa tgcaaaaacc 660  
 cttcaccttg tttttcacc aactagttta ttgctatcc aagtgaacat atcagttaat 720  
 actttagggg gcttacaact gactaatatt aaattgaatg atgacaactg tcaagttttc 780  
 attaaatctt tatcagaact caccagaggt tcaaccttac tgaattttac cctcaaccac 840  
 atagaaacga cttggaaatg cctggtcaga gtctttcaat ttctttggcc caaacctgtg 900

gaatatctca atattttacaa ttttaacaata attgaaagca ttcgtgaaga agatttttact	960
tatttctaaaa cgacattgaa agcattgaca atagaacata tcacgaacca agttttttctg	1020
ttttcacaga cagctttgta caccgtgttt tctgagatga acattatgat gttaaccatt	1080
tcagatacac cttttataca catgctgtgt cctcatgcac caagcacatt caagtttttg	1140
aactttaccc agaacgtttt cacagatagt atttttgaaa aatgttccac gttagttaaa	1200
ttggagacac ttatcttaca aaaaaatgga ttaaaagacc ttttcaaagt aggtctcatg	1260
acgaaggata tgccttcttt ggaaatactg gatgttagct ggaattcttt ggaatctggg	1320
agacataaag aaaactgcac ttgggttgag agtatagtgg tgttaaattt gtcttcaa	1380
atgcttactg actctgtttt cagatgttta cctcccagga tcaaggtagt tgatcttcac	1440
agcaataaaa taaagagcgt tcctaaacaa gtcgtaaaac tggaagcttt gcaagaactc	1500
aatgttgctt tcaattcttt aactgacctt cctggatgtg gcagctttag cagcctttct	1560
gtattgatca ttgatcacia ttcagtttcc caccatcgg ctgatttctt ccagagctgc	1620
cagaagatga ggtcaataaa agcaggggac aatccattcc aatgtacctg tgagctaaga	1680
gaatttgta aaaatataga ccaagtatca agtgaagtgt tagagggtg gcctgattct	1740
tataagtgtg actaccaga aagttataga ggaagccac taaaggactt tcacatgtct	1800
gaattatcct gcaacataac tctgtgatc gtcaccatcg gtgccaccat gctgggtgtg	1860
gctgtgactg tgacctccct ctgcatctac ttggatctgc cctgggtatct caggatggg	1920
tgccagtga cccagactcg gcgcagggcc aggaacatac ccttagaaga actccaaaga	1980
aacctccagt ttcattgctt tatttcatat agtgaacatg attctgcctg ggtgaaaagt	2040
gaattggtag cttacctaga aaaagaagat atacagattt gtcttcatga gaggaacttt	2100
gtccctggca agagcattgt ggaaaatata atcaactgca ttgagaagag ttacaagtcc	2160
atctttgttt tgtctcccaa ctttgtccag agtgagtggt gccattacga actctat	2220
gccatcaca atctctttca tgaaggatct aataacttaa tcctcatctt actggaaccc	2280
attccacaga acagcattcc caacaagtac cacaagctga aggtctctcat gacgcagcgg	2340
acttatttgc agtggcccaa ggagaaaagc aaacgtgggc tcttttgggc taacattaga	2400
gccgctttta atatgaaatt aacactagtc actgaaaaca atgatgtgaa atcttaaaaa	2460
aatttaggaa attcaactta aagaaccatt atttacttgg atgatggtga atagtacagt	2520
cgtaagtaac tgtctggagg tgccctcatt atcctcatgc cttcaggaaa gacttaacaa	2580
aaacaatgtt tcatctgggg aactgagcta ggcggtgagg ttagcctgcc agttagagac	2640
agcccagtct cttctggttt aatcattatg tttcaaattg aaacagtctc ttttgagtaa	2700
atgctcagtt tttcagctcc tctocactct gctttcccaa atggattctg ttg	2753

<210> 80  
 <211> 796  
 <212> PRT  
 <213> Homo sapiens

<400> 80

```

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys
1           5           10           15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn
          20           25           30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys
          35           40           45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile
          50           55           60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val
65           70           75           80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe
          85           90           95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu
          100          105          110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu
          115          120          125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn
          130          135          140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys
          145          150          155          160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu
          165          170          175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln
          180          185          190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu
          195          200          205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln
          210          215          220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys
          225          230          235          240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu
          245          250          255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe
          260          265          270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile
          275          280          285

```

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
 290 295 300  
 Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
 305 310 315 320  
 Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
 325 330 335  
 Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
 340 345 350  
 Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
 355 360 365  
 Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
 370 375 380  
 Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
 385 390 395 400  
 Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
 405 410 415  
 Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
 420 425 430  
 Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu  
 435 440 445  
 Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
 450 455 460  
 Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
 465 470 475 480  
 Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
 485 490 495  
 Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
 500 505 510  
 Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
 515 520 525  
 Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
 530 535 540  
 Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
 545 550 555 560  
 Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
 565 570 575  
 Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
 580 585 590  
 Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr  
 595 600 605  
 Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr

610 615 620  
 Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
 625 630 635 640  
 Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
 645 650 655  
 Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
 660 665 670  
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
 675 680 685  
 Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
 690 695 700  
 Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
 705 710 715 720  
 His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu  
 725 730 735  
 Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
 740 745 750  
 Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
 755 760 765  
 Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys  
 770 775 780  
 Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
 785 790 795  
  
 <210> 81  
 <211> 796  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 81  
 Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
 1 5 10 15  
 Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
 20 25 30  
 Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
 35 40 45  
 Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
 50 55 60  
 Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
 65 70 75 80  
 Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
 85 90 95  
 Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
 100 105 110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
 115 120 125  
 Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
 130 135 140  
 Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
 145 150 155 160  
 Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
 165 170 175  
 Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
 180 185 190  
 Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
 195 200 205  
 Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
 210 215 220  
 Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
 225 230 235 240  
 Phe Leu Ser Glu Leu Thr Arg Gly Ser Thr Leu Leu Asn Phe Thr Leu  
 245 250 255  
 Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
 260 265 270  
 Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
 275 280 285  
 Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
 290 295 300  
 Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
 305 310 315 320  
 Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
 325 330 335  
 Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
 340 345 350  
 Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
 355 360 365  
 Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
 370 375 380  
 Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
 385 390 395 400  
 Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
 405 410 415  
 Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
 420 425 430  
 Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu



435 440 445  
 Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
 450 455 460  
 Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
 465 470 475 480  
 Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
 485 490 495  
 Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
 500 505 510  
 Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
 515 520 525  
 Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
 530 535 540  
 Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
 545 550 555 560  
 Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
 565 570 575  
 Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
 580 585 590  
 Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr  
 595 600 605  
 Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr  
 610 615 620  
 Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
 625 630 635 640  
 Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
 645 650 655  
 Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
 660 665 670  
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
 675 680 685  
 Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
 690 695 700  
 Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
 705 710 715 720  
 His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu  
 725 730 735  
 Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
 740 745 750  
 Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
 755 760 765  
 Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys

770                      775                      780  
 Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
 785                      790                      795

<210> 82  
 <211> 796  
 <212> PRT  
 <213> Homo sapiens

<400> 82

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
 1                      5                      10                      15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
                     20                      25                      30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
                     35                      40                      45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
                     50                      55                      60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
 65                      70                      75                      80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
                     85                      90                      95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
                     100                      105                      110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
                     115                      120                      125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
                     130                      135                      140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
 145                      150                      155                      160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
                     165                      170                      175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
                     180                      185                      190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
                     195                      200                      205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
                     210                      215                      220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
 225                      230                      235                      240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu  
                     245                      250                      255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
                     260                      265                      270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
 275 280 285  
 Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
 290 295 300  
 Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
 305 310 315 320  
 Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
 325 330 335  
 Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
 340 345 350  
 Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
 355 360 365  
 Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
 370 375 380  
 Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
 385 390 395 400  
 Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
 405 410 415  
 Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
 420 425 430  
 Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu  
 435 440 445  
 Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
 450 455 460  
 Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
 465 470 475 480  
 Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
 485 490 495  
 Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
 500 505 510  
 Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
 515 520 525  
 Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
 530 535 540  
 Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
 545 550 555 560  
 Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
 565 570 575  
 Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
 580 585 590  
 Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr

595                      600                      605  
 Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr  
 610                      615                      620  
 Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
 625                      630                      635                      640  
 Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
 645                      650                      655  
 Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
 660                      665                      670  
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
 675                      680                      685  
 Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
 690                      695                      700  
 Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
 705                      710                      715                      720  
 His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu  
 725                      730                      735  
 Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
 740                      745                      750  
 Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
 755                      760                      765  
 Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys  
 770                      775                      780  
 Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
 785                      790                      795

<210> 83  
 <211> 2604  
 <212> DNA  
 <213> murine

<400> 83  
 aagtaaaaat gctgtgaaga atggtaaagt ccctctggga tagcctctgc aacatgagcc 60  
 aagacagaaa acccatcgtg gggagtttcc actttgtttg cgccctggcc ttaatagtcg 120  
 gaagcatgac cccgttctct aatgaacttg agtctatggg agactattca aacaggaacc 180  
 ttactcatgt ccccaaagac ctgccaccaa gaacaaaagc cctgagtctg tctcaaaact 240  
 ctatatctga gcttcggatg cctgatatca gctttctgtc agagctgaga gttctgagac 300  
 tctccacaaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag 360  
 aatacctgga tgtctcacac aatcggttgc aaaacatctc ttgctgcct atggcgagcc 420  
 tgaggcatct agacctctca ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg 480  
 gcaacctgac gaagctgact ttcctgggat taagtgtgc caagttccga caactggatc 540

tgctcccagt tgctcacttg catctaagct gcattcttct ggacttagtg agtcatcata	600
taaaaggcgg ggaacagaa agtcttcaga ttcccaatac caccgttctc catttggctc	660
ttcatccaaa tagcttggtc tctgttcaag tgaacatgtc tgtaaacgct ttaggacatt	720
tacaactgag taatattaaa ttgaatgatg aaaactgtca aaggttaatg acatttttat	780
cagaactcac cagaggcca accttattga atgtgaccct ccagcacata gaaacaacct	840
ggaagtgtc ggttaaactt ttccaattct tttggccccg accggtggag tacctcaata	900
tttacaactt aacgataact gagagaatcg acaggaaga atttacttac tcggagacag	960
cactgaagtc actgatgata gagcacgtca aaaaccaagt gttcctcttt tcaaaggagg	1020
cgctatactc ggtgtttgct gagatgaaca tcaagatgct ctctatctca gacaccctt	1080
tcatccacat ggtgtgcccc ccatcccaa gctcatttac atttctgaac tttaaccaga	1140
atgtttttac tgacagtgtt tttcaaggct gttccacctt aaagagattg cagacactta	1200
tcttaciaaag gaatggtttg aagaactttt ttaaagtagc tctcatgact aagaatatgt	1260
cctctctgga aactttggat gttagtttga attctttgaa ctctcatgca tatgacagga	1320
catgcgcctg ggctgagagc atattggtgt tgaatttgc ttcgaatatg cttacaggct	1380
ctgtcttcag atgcttacct cccaaggcca aggtccttga ccttcacaac aacaggataa	1440
tgagcatccc taaagatgtc acccacctgc aggtcttgca ggaactcaat gtagcatcca	1500
actccttaac tgaccttcct ggggtgtggg ccttcagcag cttttctgtg ctggtcatcg	1560
accataactc agtttcccat ccctctgagg atttcttcca gagctgtcag aatattagat	1620
ccctaacagc gggaaacaac ccattccaat gcacatgtga gctgagggac tttgtcaaga	1680
acataggctg ggtagcaaga gaagtgggtg agggctggcc tgactcttac aggtgtgact	1740
accagaaaag ctctaaggga actgcactga gggacttcca catgtctcca ctgtcctgtg	1800
atactgttct gctgactgtc accatcgggg ccactatgct ggtgctggct gtcactgggg	1860
ctttcctctg tctctacttt gacctgccct ggtatgtgag gatgctgtgt cagtggacac	1920
agaccaggca cagggccagg cacatccct tagaggaaact ccagagaaac ctccagttcc	1980
atgcttttgt ctcatacagt gagcatgatt ctgcctgggt gaagaacgaa ttactacca	2040
acctagagaa agatgacatc cgggtttgcc tccatgagag gaactttgtc cctggcaaga	2100
gcattgtgga gaacatcatc aatttcattg agaagagtta caaggccatc tttgtgctgt	2160
ctccccactt catccagagt gagtgggtgcc attatgaact ctattttgcc catcataatc	2220
tcttccatga aggctctgat aacttaatcc tcatcttgct ggaaccatt ctacagaaca	2280
acattcccag tagataccac aagctgcggg ctctcatggc acagcggact tacttggaat	2340
ggcctactga gaagggcaaa cgtgggctgt tttgggcaa ccttagagct tcatttatta	2400
tgaagttagc ctagtcaat gaggatgatg tgaaaacttg aaacttgggt ttctaactta	2460

ataaactgtc aacctgggct ctcatgaaca ctgtggtttt cagttcctac ctggaggtag 2520  
 ttctgttctg gtgtcttagt ttgtctctgtg cttatgataa ataacatgtt tagaagtagt 2580  
 ttatgaagggt gctaagttca ttaa 2604

<210> 84  
 <211> 2604  
 <212> DNA  
 <213> murine

<400> 84  
 aagtaaaaat gctgtgaaga atggtaaagt ccctctggga tagcctctgc aacatgagcc 60  
 aagacagaaa acccatcgtg gggagtttcc actttgtttg cgccctggcc ttaatagtcg 120  
 gaagcatgac cccgttctct aatgaacttg agtctatggg agactattca aacaggaacc 180  
 ttactcatgt ccccaaagac ctgccacca gaacaaaagc cctgagtctg tctcaaaact 240  
 ctatatctga gcttcggatg cctgatatca gctttctgtc agagctgaga gttctgagac 300  
 tctcccacaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag 360  
 aatacctgga tgtctcacac aatcggttgc aaaacatctc ttgctgccct atggcgagcc 420  
 tgaggcatct agacctctca ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg 480  
 gcaacctgac gaagctgact ttctctggat taagtgtgc caagttccga caactggatc 540  
 tgctcccagt tgctcacttg catctaagct gcattcttct ggacttagtg agtcatcata 600  
 taaaaggcgg ggaaacagaa agtcttcaga ttcccaatac caccgttctc catttggtct 660  
 ttcatccaaa tagcttgttc tctgttcaag tgaacatgtc tgtaaacgct ttaggacatt 720  
 tacaactgag taatattaaa ttgaatgatg aaaactgtca aagggttaatg acatttttat 780  
 cagaactcac cagaggtcca accttattga atgtgaccct ccagcacata gaaacaacct 840  
 ggaagtgtc gggttaactt ttccaattct tttggccccg accggtggag tacctcaata 900  
 tttacaactt aacgataact gagagaatcg acagggaaga atttacttac tcggagacag 960  
 cactgaagtc actgatgata gagcacgtca aaaaccaagt gttctctttt tcaaaggagg 1020  
 cgctatactc ggtgtttgct gagatgaaca tcaagatgct ctctatctca gacaccctt 1080  
 tcatccacat ggtgtgcccc ccattcccaa gctcatttac atttctgaac tttaccaga 1140  
 atgtttttac tgacagtgtt tttcaaggct gttccacctt aaagagattg cagacactta 1200  
 tcttacaag gaatggtttg aagaactttt ttaaagtagc tctcatgact aagaatatgt 1260  
 cctctctgga aactttggat gttagtttga attctttgaa ctctcatgca tatgacagga 1320  
 catgcgcctg ggctgagagc atattgggtg tgaatttgtc ttcgaatatg cttacaggct 1380  
 ctgtcttcag atgcttacct cccaagggtca aggtccttga ccttcacaac aacaggataa 1440

tgagcatccc taaagatgtc acccacctgc aggcctttgca ggaactcaat gtagcatcca	1500
actccttaac tgaccttcct ggggtgtggg ccttcagcag cctttctgtg ctgggtcatcg	1560
accataactc agtttcccat ccctctgagg atttcttcca gagctgtcag aatattagat	1620
ccctaacagc gggaaacaac ccattccaat gcacatgtga gctgagggaac tttgtcaaga	1680
acataggctg ggtagcaaga gaagtgggtg agggctggcc tgactcttac aggtgtgact	1740
accagaaaag ctctaaggga actgcactga gggacttcca catgtctcca ctgtcctgtg	1800
atactgttct gctgactgtc accatcgggg ccactatgct ggtgctggct gtcactgggg	1860
ctttcctctg tctctacttt gacctgccct ggtatgtgag gatgctgtgt cagtggacac	1920
agaccaggca cagggccagg cacatcccct tagaggaact ccagagaaaac ctccagttcc	1980
atgcttttgt ctcatacagt gagcatgatt ctgcctgggt gaagaacgaa ttactacca	2040
acctagagaa agatgacatc cgggtttgcc tccatgagag gaactttgtc cctggcaaga	2100
gcattgtgga gaacatcatc aatttcattg agaagagtta caaggccatc tttgtgctgt	2160
ctccccactt catccagagt gagtgggtgcc attatgaact ctattttgcc catcataatc	2220
tcttccatga aggtctgat aacttaatcc tcatcttgct ggaaccatt ctacagaaca	2280
acattcccag tagataccac aagctgcggg ctctcatggc acagcggact tacttggaat	2340
ggcctactga gaagggcaaa cgtgggctgt tttgggcca ccttagagct tcatttatta	2400
tgaagttagc cttagtcaat gaggatgatg tgaaaacttg aaacttgggt ttctaactta	2460
ataaactgtc aacctgggct ctcatgaaca ctgtggtttt cagttcctac ctggaggtag	2520
ttctgttggtg gtgtcttagt ttgctctgtg cttatgataa ataacatgtt tagaagtagt	2580
ttatgaagggt gctaagttca ttaa	2604

<210> 85  
 <211> 2421  
 <212> DNA  
 <213> murine

<400> 85	
atggtaaagt ccctctggga tagcctctgc aacatgagcc aagacagaaa acccatcgtg	60
gggagtttcc actttgtttg cgccctggcc ttaatagtcg gaagcatgac ccggttctct	120
aatgaacttg agtctatggt agactattca aacaggaacc ttactcatgt ccccaaagac	180
ctgccaccaa gaacaaaagc cctgagtctg tctcaaaact ctatatctga gcttcggatg	240
cctgatataca gctttctgtc agagctgaga gttctgagac tctcccacaa caggatacgg	300
agccttgatt tccatgtatt cttgttcaat caggacttag aatacctgga tgtctcacac	360
aatcggttgc aaaacatctc ttgctgccct atggcgagcc tgaggcatct agacctctca	420
ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg gcaacctgac gaagctgact	480

ttcctgggat taagtgtgc aaagttccga caactggatc tgctcccagt tgctcacttg	540
catctaagct gcattcttct ggacttagtg agttatcata taaaaggcgg ggaaacagaa	600
agtcttcaga ttcccaatac caccgttctc catttggtct ttcattccaaa tagcttggtc	660
tctgttcaag tgaacatgtc tgtaaagct ttaggacatt tacaactgag taatattaaa	720
ttgaatgatg aaaactgtca aagggttaatg acatttttat cagaactcac cagaggcca	780
accttattga atgtgaccct ccagcacata gaaacaacct ggaagtgtc ggtaaactt	840
ttccaattct tttggccccg accggtggag tacctcaata ttacaactt aacgataact	900
gagagaatcg acaggaaga atttacttac tcggagacag cactgaagtc actgatgata	960
gagcacgtca aaaaccaagt gtccctctt tcaaaggagg cgctatactc ggtgtttgct	1020
gagatgaaca tcaagatgct ctctatctca gacacctt tcatccacat ggtgtgcccc	1080
ccatcccaa gctcatttac atttctgaac ttaccacaga atgtttttac tgacagtgtt	1140
tttcaaggct gttccacct aaagagattg cagacactta tcttacaag gaatggttg	1200
aagaactttt ttaaagtagc tctcatgact aagaatatgt cctctctgga aactttggat	1260
gttagtttga attctttgaa ctctcatgca tatgacagga catgcgctg ggctgagagc	1320
atattggtgt tgaatttgtc ttogaatatg cttacaggct ctgtcttcag atgcttacct	1380
cccaaggtea aggtccttga ccttcacaac aacaggataa tgagcatccc taaagatgtc	1440
accacctgc aggttttga ggaactcaat gtagcatcca actccttaac tgaccttct	1500
gggtgtggg ccttcagcag ctttctgtg ctggtcatcg accataactc agtttcccat	1560
ccctctgagg atttcttcca gagctgtcag aatattagat ccctaacagc gggaaacaac	1620
ccattccaat gcacatgtga gctgaggac tttgtcaaga acataggctg ggtagcaaga	1680
gaagtgttg agggctggc tgactcttac aggtgtgact acccagaaag ctctaaggga	1740
actgcactga gggacttcca catgtctcca ctgtcctgtg atactgttct gctgactgtc	1800
accatcgggg ccactatgct ggtgctggct gtcactgggg ctttctctg tctctacttt	1860
gacctgccct ggtatgtgag gatgctgtgt cagtggacac agaccaggca cagggccagg	1920
cacatccct tagaggaact ccagagaaac ctccagttcc atgcttttgt ctcatagct	1980
gagcatgatt ctgcctgggt gaagaacgaa ttactacca acctagagaa agatgacatc	2040
ggggtttgcc tccatgagag gaactttgtc cctggcaaga gcattgtgga gaacatcatc	2100
aatttcattg agaagagtta caaggccatc tttgtgctgt cccccactt catccagagt	2160
gagtgggtgcc attatgaact ctattttgcc catcataatc tcttccatga aggctctgat	2220
aacttaatcc tcatcttgt ggaacctt ctacagaaca acattcccag tagataccac	2280
aagctcgggg ctctcatggc acagcggact tacttggaaat ggcctactga gaagggcaaa	2340
cgtgggctgt tttgggcaa ccttagagct tcatttatta tgaagttagc cttagtcaat	2400



gaggatgatg tgaaaacttg a

2421

<210> 86  
 <211> 806  
 <212> PRT  
 <213> murine

<400> 86

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
 1 5 10 15  
 Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
 20 25 30  
 Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
 35 40 45  
 Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
 50 55 60  
 Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
 65 70 75 80  
 Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His  
 85 90 95  
 Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
 100 105 110  
 Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
 115 120 125  
 Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
 130 135 140  
 Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
 145 150 155 160  
 Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
 165 170 175  
 Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser His  
 180 185 190  
 His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
 195 200 205  
 Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
 210 215 220  
 Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
 225 230 235 240  
 Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
 245 250 255  
 Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
 260 265 270

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
 275 280 285  
 Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
 290 295 300  
 Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
 305 310 315 320  
 Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
 325 330 335  
 Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
 340 345 350  
 Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
 355 360 365  
 Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
 370 375 380  
 Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
 385 390 395 400  
 Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu  
 405 410 415  
 Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
 420 425 430  
 Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
 435 440 445  
 Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
 450 455 460  
 Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
 465 470 475 480  
 Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
 485 490 495  
 Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
 500 505 510  
 Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
 515 520 525  
 Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
 530 535 540  
 Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg  
 545 550 555 560  
 Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu  
 565 570 575  
 Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser  
 580 585 590  
 Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val

595 600 605  
 Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp  
 610 615 620  
 Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg  
 625 630 635 640  
 His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe  
 645 650 655  
 Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu  
 660 665 670  
 Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn  
 675 680 685  
 Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu  
 690 695 700  
 Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser  
 705 710 715 720  
 Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His  
 725 730 735  
 Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu Glu Pro Ile Leu Gln  
 740 745 750  
 Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln  
 755 760 765  
 Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe  
 770 775 780  
 Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn  
 785 790 795 800  
 Glu Asp Asp Val Lys Thr  
 805

<210> 87  
 <211> 806  
 <212> PRT  
 <213> murine

<400> 87

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
 1 5 10 15  
 Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
 20 25 30  
 Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
 35 40 45  
 Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
 50 55 60  
 Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
 65 70 75 80

Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His  
 85 90 95  
 Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
 100 105 110  
 Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
 115 120 125  
 Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
 130 135 140  
 Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
 145 150 155 160  
 Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
 165 170 175  
 Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser Tyr  
 180 185 190  
 His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
 195 200 205  
 Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
 210 215 220  
 Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
 225 230 235 240  
 Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
 245 250 255  
 Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
 260 265 270  
 Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
 275 280 285  
 Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
 290 295 300  
 Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
 305 310 315 320  
 Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
 325 330 335  
 Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
 340 345 350  
 Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
 355 360 365  
 Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
 370 375 380  
 Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
 385 390 395 400  
 Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu

405 410 415  
 Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
 420 425 430  
 Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
 435 440 445  
 Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
 450 455 460  
 Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
 465 470 475 480  
 Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
 485 490 495  
 Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
 500 505 510  
 Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
 515 520 525  
 Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
 530 535 540  
 Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg  
 545 550 555 560  
 Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu  
 565 570 575  
 Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser  
 580 585 590  
 Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val  
 595 600 605  
 Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp  
 610 615 620  
 Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg  
 625 630 635 640  
 His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe  
 645 650 655  
 Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu  
 660 665 670  
 Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn  
 675 680 685  
 Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu  
 690 695 700  
 Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser  
 705 710 715 720  
 Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His  
 725 730 735  
 Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu Glu Pro Ile Leu Gln

740 745 750  
 Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln  
 755 760 765  
 Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe  
 770 775 780  
 Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn  
 785 790 795 800  
 Glu Asp Asp Val Lys Thr  
 805  
 <210> 88  
 <211> 806  
 <212> PRT  
 <213> murine  
 <400> 88  
 Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
 1 5 10 15  
 Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
 20 25 30  
 Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
 35 40 45  
 Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
 50 55 60  
 Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
 65 70 75 80  
 Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His  
 85 90 95  
 Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
 100 105 110  
 Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
 115 120 125  
 Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
 130 135 140  
 Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
 145 150 155 160  
 Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
 165 170 175  
 Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser His  
 180 185 190  
 His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
 195 200 205  
 Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
 210 215 220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
 225 230 235 240  
 Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
 245 250 255  
 Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
 260 265 270  
 Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
 275 280 285  
 Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
 290 295 300  
 Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
 305 310 315 320  
 Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
 325 330 335  
 Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
 340 345 350  
 Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
 355 360 365  
 Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
 370 375 380  
 Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
 385 390 395 400  
 Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu  
 405 410 415  
 Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
 420 425 430  
 Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
 435 440 445  
 Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
 450 455 460  
 Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
 465 470 475 480  
 Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
 485 490 495  
 Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
 500 505 510  
 Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
 515 520 525  
 Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
 530 535 540  
 Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg





Glu Ser Met Val Asp Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys  
                   35                                  40                                  45  
 Asp Leu Pro Pro Arg Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile  
           50                                  55                                  60  
 Ser Glu Leu Arg Met Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val  
   65                                  70                                  75                                  80  
 Leu Arg Leu Ser His Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe  
                                   85                                  90                                  95  
 Leu Phe Asn Gln Asp Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu  
                                   100                                  105                                  110  
 Gln Asn Ile Ser Cys Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu  
                                   115                                  120                                  125  
 Ser Phe Asn Asp Phe Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn  
           130                                  135                                  140  
 Leu Thr Lys Leu Thr Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln  
   145                                  150                                  155                                  160  
 Leu Asp Leu Leu Pro Val Ala His Leu His Leu Ser Cys Ile Leu Leu  
                                   165                                  170                                  175  
 Asp Leu Val Ser Tyr His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln  
                                   180                                  185                                  190  
 Ile Pro Asn Thr Thr Val Leu His Leu Val Phe His Pro Asn Ser Leu  
                                   195                                  200                                  205  
 Phe Ser Val Gln Val Asn Met Ser Val Asn Ala Leu Gly His Leu Gln  
           210                                  215                                  220  
 Leu Ser Asn Ile Lys Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr  
   225                                  230                                  235                                  240  
 Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu  
                                   245                                  250                                  255  
 Gln His Ile Glu Thr Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe  
                                   260                                  265                                  270  
 Phe Trp Pro Arg Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
                                   275                                  280                                  285  
 Thr Glu Arg Ile Asp Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu  
   290                                  295                                  300  
 Lys Ser Leu Met Ile Glu His Val Lys Asn Gln Val Phe Leu Phe Ser  
   305                                  310                                  315                                  320  
 Lys Glu Ala Leu Tyr Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu  
                                   325                                  330                                  335  
 Ser Ile Ser Asp Thr Pro Phe Ile His Met Val Cys Pro Pro Ser Pro  
                                   340                                  345                                  350  
 Ser Ser Phe Thr Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser

355 360 365  
 Val Phe Gln Gly Cys Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu  
 370 375 380  
 Gln Arg Asn Gly Leu Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys  
 385 390 395 400  
 Asn Met Ser Ser Leu Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn  
 405 410 415  
 Ser His Ala Tyr Asp Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val  
 420 425 430  
 Leu Asn Leu Ser Ser Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu  
 435 440 445  
 Pro Pro Lys Val Lys Val Leu Asp Leu His Asn Asn Arg Ile Met Ser  
 450 455 460  
 Ile Pro Lys Asp Val Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val  
 465 470 475 480  
 Ala Ser Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser  
 485 490 495  
 Leu Ser Val Leu Val Ile Asp His Asn Ser Val Ser His Pro Ser Glu  
 500 505 510  
 Asp Phe Phe Gln Ser Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn  
 515 520 525  
 Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile  
 530 535 540  
 Gly Trp Val Ala Arg Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg  
 545 550 555 560  
 Cys Asp Tyr Pro Glu Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His  
 565 570 575  
 Met Ser Pro Leu Ser Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly  
 580 585 590  
 Ala Thr Met Leu Val Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr  
 595 600 605  
 Phe Asp Leu Pro Trp Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr  
 610 615 620  
 Arg His Arg Ala Arg His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
 625 630 635 640  
 Gln Phe His Ala Phe Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
 645 650 655  
 Lys Asn Glu Leu Leu Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys  
 660 665 670  
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
 675 680 685  
 Ile Asn Phe Ile Glu Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro



<211> 22  
<212> DNA  
<213> artificial sequence

<220>

<223> consensus subunit

<400> 92  
agttgagggg actttcccag gc

22

<210> 93  
<211> 27  
<212> DNA  
<213> artificial sequence

<220>

<223> CREB binding site

<400> 93  
agagattgcc tgacgtcaga gagctag

27

<210> 94  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>

<223> AP-1 binding site

<400> 94  
cgcttgatga gtcagccgga a

21

<210> 95  
<211> 15  
<212> DNA  
<213> artificial sequence

<220>

<223> AP-1 binding site

<400> 95  
cgcatgagtc agaca

15

<210> 96  
<211> 19  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 96

19  
tgcagaagtg aaactgagg  
<210> 97  
<211> 11  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> ISRE  
  
<400> 97  
agaacgaaac a 11  
  
<210> 98  
<211> 15  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> ISRE  
  
<400> 98  
gagaagtgaa agtgg 15  
  
<210> 99  
<211> 18  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> ISRE  
  
<400> 99  
taagaacatg aaactgaa 18  
  
<210> 100  
<211> 15  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> ISRE  
  
<400> 100  
atgaaactga aagta 15  
  
<210> 101  
<211> 16  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> ISRE

<400> 101  
tgaaaaccga aagcgc

16

<210> 102  
<211> 13  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 102  
agaaatggaa agt

13

<210> 103  
<211> 9  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 103  
tcacccac

9

<210> 104  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 104  
ctcacccac

10

<210> 105  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 105  
gccaccctac

10

<210> 106  
<211> 17  
<212> DNA  
<213> artificial sequence

<220>

<223> NFAT

<400> 106

tatgaaacag tttttcc

17

<210> 107

<211> 9

<212> DNA

<213> artificial sequence

<220>

<223> NFAT

<400> 107

aggaaactc

9

<210> 108

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> NFAT

<220>

<221> misc\_feature

<222> (2)..(2)

<223> N = a or g

<220>

<221> misc\_feature

<222> (5)..(5)

<223> N = a or g

<400> 108

anganattcc

10

<210> 109

<211> 16

<212> DNA

<213> artificial sequence

<220>

<223> NFAT

<400> 109

ccagttgagc cagaga

16

<210> 110

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> GAS

<400> 110  
ctttcagttt catattactc taaatccatt

30

<210> 111  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<220>  
<221> misc\_feature  
<222> (1)..(3)  
<223> N = a or g

<220>  
<221> misc\_feature  
<222> (5)..(6)  
<223> N = a or t

<220>  
<221> misc\_feature  
<222> (8)..(10)  
<223> N = c or t

<400> 111  
nnncnngnnn

10

<210> 112  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 112  
aggcatgcct

10

<210> 113  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 113  
gggcttgccc

10

<210> 114



<211> 10  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 114  
gggcttgctt 10  
  
<210> 115  
<211> 13  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 115  
gcctggactt gcc 13  
  
<210> 116  
<211> 20  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 116  
ggacatgccc gggcatgtcc 20  
  
<210> 117  
<211> 23  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 117  
gtagcattag cccagacatg tcc 23  
  
<210> 118  
<211> 36  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> TARE  
  
<400> 118  
gaggtatgca gacaagagtc agagtttccc cttgaa 36

<210> 119  
 <211> 10  
 <212> DNA  
 <213> artificial sequence

<220>

<223> SRF

<220>

<221> misc\_feature

<222> (3)..(8)

<223> N = a or t

<400> 119

ccnnnnnnngg

10

<210> 120

<211> 11

<212> DNA

<213> artificial sequence

<220>

<223> SRF

<400> 120

ccaaataagg c

11

<210> 121

<211> 670

<212> DNA

<213> Homo sapiens

<400> 121

agaaaaattt taaaaaatta ttcattcata tttttaggag ttttgaatga ttggatatgt 60  
 aatttatattc atattattaa tgtgtatcta tatagatttt tattttgcat atgtactttg 120  
 atacaaaatt tacatgaaca aattacacta aaagttattc cacaaatata cttatcaaat 180  
 taagttaaatt gtcaatagct tttaaactta aatttttagtt taacttttct gtcattcttt 240  
 actttgaata aaaagagcaa actttgtagt ttttatctgt gaagtagagg tatacgtaat 300  
 atacataaat agatatgcc aatctgtgtt attaaaattt catgaagatt tcaattagaa 360  
 aaaaataacca taaaaggctt tgagtgcagg tgaaaaatag gcaatgatga aaaaaaatga 420  
 aaaacttttt aaacacatgt agagagtgcg taaagaaagc aaaaacagag atagaaagta 480  
 caactaggga atttagaaaa tggaaattag tatgttcact atttaagacc tatgcacaga 540  
 gcaaagtctt cagaaaacct agaggccgaa gttcaagggt atccatctca agtagcctag 600  
 caatatttgc aacatcccaa tggccctgtc cttttcttta ctgatggccg tgctgggtgt 660  
 cagctacaaa 670

<210> 122  
 <211> 207  
 <212> DNA  
 <213> Homo sapiens

<400> 122  
 aggttctctg aaggccttgc ttcctgcaga tgccttaa at agggaaacata ctgatttcca 60  
 ctttctta at gcttctggac catttccatt tctgtttttg ctttccttct taactcttta 120  
 catgagttta gagccgtgtt tctcaa atga tgggctagca cgcgtaagag ctcggtacct 180  
 atcgatagag aaatgttctg gcacctg 207

<210> 123  
 <211> 161  
 <212> DNA  
 <213> Homo sapiens

<400> 123  
 aggttctctg aaggctttgc ttcctgcaga tgccttaa at agggaaacata ctgatttcca 60  
 ctttctta at gcttctggac cactttccat ttctgttttt gctttccttc ttgaactctt 120  
 tacatgagtt tagagccgtg tttctcaacc atttgtttt t 161

<210> 124  
 <211> 300  
 <212> DNA  
 <213> Homo sapiens

<400> 124  
 ttctcaggtc gtttgctttc ctttgctttc tcccaagtct tgttttacaa tttgcttttag 60  
 tcattcactg aaactttaaa aaacattaga aaacctcaca gtttgtaaat ctttttccct 120  
 attatatata tcataagata ggagcttaaa taaagagttt tagaaactac taaaatgtaa 180  
 atgacatagg aaaactgaaa gggagaagtg aaagtgggaa attcctctga atagagagag 240  
 gaccatctca tataaatagg ccataccac ggagaaagga cattctaact gcaaccttct 300

<210> 125  
 <211> 401  
 <212> DNA  
 <213> Homo sapiens

<400> 125  
 gatctgta at gaataagcag gaactttgaa gactcagtga ctcagtgagt aataaagact 60  
 cagtgacttc tgatcctgtc ctaactgcc a ctccttggtg tcccaagaaa gcggcttccct 120  
 gctctctgag gaggaccct tccctggaag gtaaaactaa ggatgtcagc agagaaattt 180  
 ttccaccatt ggtgcttggc caaagaggaa actgatgagc tcaactctaga tgagagagca 240  
 gtgagggaga gacagagact cgaatttccg gagctatttc agttttcttt tccgttttgt 300

gcaatttcac ttatgatacc ggccaatgct tggttgctat tttggaaact ccccttaggg 360  
gatgcccctc aactggccct ataaagggcc agcctgagct g 401

<210> 126  
<211> 781  
<212> DNA  
<213> Homo sapiens

<400> 126  
ggttgtctgt atgcctccct gagggatatt cactttctgc tcccatccgc ccctatgagc 60  
gagtacctat gagcacagga tgtgcacata tttgagtctt attagtggta cacgcagttt 120  
tatcatctcc ccaggtctgt gtctgtatga aatgtgcatg ggtgtgtgtg tgcacgcgtg 180  
tgttcccact cggggaatgt ggggagaggt gcatggagcc aagatgggtg gtaaatagta 240  
tgtttctgaa attaaaggac taatgtggag gaaggcgccc cagatgtact aaaccctttg 300  
ccttcactct atcctctctg acttgggaag aaccaggatt ttgtttttaa gcccttgggc 360  
atacagttgt tccatcccga catgaactca gcctcccgtc tgaccgcccc ttggccttcc 420  
ttcttcctcg atctgtggaa cccagggaa ctgcctagt ctgtctccaa gcaccttggc 480  
catgatgtaa acccagagaa attagcatct ccatctcctt ccttattccc caccctaaag 540  
tcatttcctc ttagttcatt acctgggatt ttgatgtcta tgttccctcc tcgttattga 600  
tacacacaca gagagagaca aacaaaaaag gaacttcttg aaattccccc agaaggtttt 660  
gagagttgtt ttcaatgttg caacaagtca gtttctagtt taagtttcca tcagaaagga 720  
gtagagtata taagttccag taccagcaac agcagcagaa gaaacaacat ctgtttcagg 780  
g 781

<210> 127  
<211> 277  
<212> DNA  
<213> Homo sapiens

<400> 127  
gcatctccat ctccctcctt attccccacc caaaagtcac ttctcttag ttcattacct 60  
gggattttga tgtctatggt ccttcctcgt tattgataca cacacagaga gagacaaaca 120  
aaaaaggaac ttcttgaaat tccccagaa ggttttgaga gttgttttca atgttgcaac 180  
aagtcagttt ctagtttaag ttccatcag aaaggagtag agtatataag ttccagtacc 240  
agcaacagca gcagaagaaa caacatctgt ttcaggg 277

<210> 128  
<211> 305  
<212> DNA  
<213> Homo sapiens

<400> 128

```

caagacatgc caagtgtctga gtcactaata aagaaaaaag aagtaaagga agagtgggtc   60
tgcttcttag cgctagcctc aatgacgacc taagctgcac ttttccccct agttgtgtct   120

tgcgatgcta aaggacgtca ttgcacaatc ttaataaggt ttccaatcag cccacccgc   180
tctggcccca ccctcaccct ccaacaaaga tttatcaaat gtgggatttt cccatgagtc   240
tcaatattag agtctcaacc cccaataaat ataggactgg agatgtctct gaggetcatt   300
ctgcc                                           305

```

```

<210> 129
<211> 1181
<212> DNA
<213> Homo sapiens

```

```

<400> 129
cctgcaagag acaccatcct gaggggaaga gggcttctga accagcttga cccaataaga   60
aattcttggg tgccgacggg gacagcagat tcagagccta gagccgtgcc tgcgtccgta   120
gtttccttct agcttctttt tgatttcaaa tcaagactta caggagagg gagcgataaa   180
cacaaactct gcaagatgcc acaaggctct cctttgacat cccaacaaa gaaggtagt   240
agtaatctcc ccctttctgc cctgaaccaa gtggcttcag taagtttcag ggctccagga   300
gacctgggca tgcaggtgcc gatgaaacag tggatgaagag actcagtggc agtggcagtg   360
gggagagcac tcgcagcaca ggcaaacctc tggcacaaga gcaaagtcct cactggagga   420
ttccaaggg tcacttggga gagggcaggc agcagccaac ctctcttaag tgggctgaag   480
cagggtgaaga aatggcagaa gacgcggtgg tggcaaaaag gagtacaca ctccacctgg   540
agacgccttg aagtaactgc acgaaatttg aggggtggcca ggcagttcta caacagccgc   600
ctcacaggga gagccagaac acagcaagaa ctcatatgac tggtagtatt accttcttca   660
taatcccagg cttggggggc tgcgatggag tcagaggaaa ctcatgtcag aacatctttg   720
gtttttacaa tacaaattaa ctggaacgct aaattctagc ctgttaatct ggtcactgaa   780
aaaaaaaaa tttttttttt ttcaaaaaac atagcttttag cttatttttt ttttctcttt   840
gtaaaacttc gtgcatgact tcagctttac tcttgtcaag acatgccaaag tgctgagtca   900
ctaataaaga aaaaagaagt aaaggaagag tggttctgct tcttagcgct agcctcaatg   960
acgacctaag ctgcactttt cccctagtt gtgtcttgcg atgctaaagg acgtcattgc   1020
acaatcttaa taaggtttcc aatcagcccc acccgctctg gccccaccct caccctccaa   1080
caaagattta tcaaatgtgg gatthtccca tgagtctcaa tattagagtc tcaaccccca   1140
ataaatatag gactggagat gtctctgagg ctcatctgc c                                           1181

```

```

<210> 130
<211> 778
<212> DNA

```

&lt;213&gt; Homo sapiens

&lt;400&gt; 130

```

ctaccacttg tctattctgc tatatagtca gtccttacat tgctttcttc ttctgataga      60
ccaaactctt taaggacaag tacctagtct tatctatttc tagatcccc acattactca      120
gaaagttact ccataaatgt ttgtggaact gatttctatg tgaagacatg tgccccctca      180
ctctgttaac tagcattaga aaaacaaatc ttttgaaaag ttgtagtatg cccctaagag      240
cagtaacagt tcctagaaac tctctaaaat gcttagaaaa agatttattt taaattacct      300
cccccaataa atgattggct ggcttatctt caccatcatg atagcatctg taattaactg      360
aaaaaaaaata attatgccat taaaagaaaa tcatccatga tcttgttcta acacctgcca      420
ctctagtact atatctgtca catgggtctat gataaagtta tctagaaata aaaaagcata      480
caattgataa ttcaccaaat tgtggagctt cagtatttta aatgtatatt aaaattaaat      540
tatttttaaag atcaaagaaa actttcgtca tactccgtat ttgataagga acaaatagga      600
agtgtgatga ctcaggtttg ccctgagggg atgggccatc agttgcaa at cgtggaattt      660
cctctgacat aatgaaaaga tgaggggtgca taagttctct agtaggggtga tgatataaaa      720
agccaccgga gcactccata aggcacaaac tttcagagac agcagagcac acaagctt      778

```

&lt;210&gt; 131

&lt;211&gt; 207

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 131

```

actccgtatt tgataaggaa caaataggaa gtgtgatgac tcaggtttgc cctgagggga      60
tgggccatca gttgcaa atc gtggaatttc ctctgacata atgaaaagat gaggggtgcat      120
aagttctcta gtaggggtgat gatataaaaa gccaccggag cactccataa ggcacaaact      180
ttcagagaca gcagagcaca caagctt      207

```

&lt;210&gt; 132

&lt;211&gt; 645

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 132

```

gggggtgatt tcaactcccc gggtgtgcc aggettgtcc ctgctaccg caccagcct      60
ttcctgaggc ctcaagcctg ccaccaagcc cccagctcct tctccccgca gggcccaaac      120
acaggcctca ggactcaaca cagcttttcc ctccaacccc gttttctctc cctcaacgga      180
ctcagctttc tgaagccct cccagttcta gttctatctt tttcctgcat cctgtctgga      240
agttagaagg aaacagacca cagacctggt ccccaaaaga aatggaggca ataggttttg      300
aggggcatgg ggacgggggt cagcctccag ggtcctacac acaaatcagt cagtggccca      360

```

gaagaccccc ctcggaatcg gagcagggag gatggggagt gtgaggggta tccttgatgc 420  
 ttgtgtgtcc ccaactttcc aaatccccgc ccccgcatg gagaagaaac cgagacagaa 480  
 ggtgcagggc ccactaccgc ttcctccaga tgagctcatg ggtttctcca ccaaggaagt 540  
 tttccgctgg ttgaatgatt ctttccccgc ctcctctcg ccccagggac atataaaggc 600  
 agttgttggc acaccagcc agcagacgct ccctcagcaa ggaca 645

<210> 133  
 <211> 457  
 <212> DNA  
 <213> Homo sapiens

<400> 133  
 gcctgtactc agccaagggt gcagagatgt tatatatgat tgctcttcag ggaaccgggc 60  
 ctccagctca caccacagct gctcaaccac ctctctctcg aattgactgt cccttctttg 120  
 gaactctagg cctgacccca ctccctggcc ctccagccc acgattcccc tgaccgact 180  
 ccctttccca gaactcagtc gcctgaaccc ccagcctgtg gttctctcct aggcctcagc 240  
 ctttctgccc tttgactgaa acagcagtat cttctaagcc ctgggggctt ccccgggccc 300  
 cagccccgac ctagaaccgg cccgctgcct gccacgtgc cactgccgct tcctctataa 360  
 aggacactga gcgtccgggc ccaggggctc cgcacagcag gtgaggctct cctgccccat 420  
 ctcttggggc tgcccgtgct tcgtgctttg gactacc 457

<210> 134  
 <211> 973  
 <212> DNA  
 <213> Homo sapiens

<400> 134  
 gcagcaaadc agaatggcag tttgattcat ggtgctgaga ctggagggtc ctctgctgta 60  
 ggctcagaat atgtctaagc aattgaggaa tgtctcagaa aacgtggggc tagtgtgcca 120  
 tatttatctg caaagccatt ttccctccct aattctgatt ggataagggc attacagttg 180  
 acttagcaaa acctgctggc tgttcctggg gaagtcccat gttgcagact cgaaggattt 240  
 atttattgta gcctccaagt tacggaattt ccctctgctc ctcttttttt ggtaatagtg 300  
 aattagggtt cactttccaa aacatgaact gtttcttgaa aaaaagaact tcattgcata 360  
 tagaaaaaaa caaagggtgc aatccattct aactataatg ctttttctca acacttaaac 420  
 ttttacagtt actttcagag gttatttttc aaaatatccc cagtaataga aatttttcat 480  
 cttttatagg taaacctaat tttttggtaa cagcaagttg tgctgatta ttagaacagt 540  
 gatttacctg gacagtcctc cttgatcaaa tactataaag taataggact ggctgcttt 600  
 gacagggcca aagatctgga actggcaagt tttaaataat tcaataaatg ctttgatcat 660  
 tcataaacacc attagattaa gtaaatagcc tccaacataa ctattttgag ggaaaacatt 720

gctcatttgg gtatctgatt tgtggtgtgt taaaacaagt ttcacgtctt atagcagtc 780  
 ctgaatgaaa acatcataag atggtatcta gaatggtgtg agaaaaggat tcatagctat 840  
 cctaggggta ttgtaaaaaa caaaggggtgc tttttgagga aatgaattta aaagcggggg 900  
 ggcacgcata gagacagacc ttgggaaagt agcttgagac agaagggaaa caggttgatt 960  
 tacgatgggg ttc 973

<210> 135  
 <211> 333  
 <212> DNA  
 <213> Homo sapiens

<400> 135  
 gctaccttaa gaaggctggt taccatctgg gttttcacag tgctttcaca ttcttatcac 60  
 tttcaacact actgcaaata ggaagggaca gtaacattta gaagagaaca aaacagaaac 120  
 tcttggaagc aggaaagggtg catgactcaa agagggaat tcctgtgcca taaaaggatt 180  
 gctggtgtat aaaatgctct atatatgcca attatcaatt tcctttcatg ttcagcattt 240  
 ctactccttc caagaagagc agcaaagctg aagttagcag cagcagcacc agcagcaaca 300  
 gcaaaaaaca aacatgagtg tgaagggcat ggc 333

<210> 136  
 <211> 1048  
 <212> DNA  
 <213> Homo sapiens

<400> 136  
 ggtgaccaag aatgtgagca agcccaggca cagccactgt gggcgctga ccaaacagca 60  
 ctaaatttgt gtgggacatg atcccagagg tgtgtggctt caccctcaa cgagtggcgt 120  
 ggcattggagt tactgaatct ccaagggtcaa acaggccctc aaattcatca agaaaagggt 180  
 agggacaaac atctgtacca agagaaggca ggaggagctg agcaacgtcc tgctgccatg 240  
 aggaaagcag ctgccaagaa ggactgagcc cctgccatct gcctataatg aaagctttgc 300  
 aaaataaaat aaatataaaa taaagtaata aaattaaatt aaatttaaaa ataaaataaa 360  
 gcaaaacaaa ataaaatata taaagtaaaa attgttaaaa tgcaaaacaa tatggacata 420  
 aatacagaaa cacagggaat cttctttagg cactcattta caggtaaaaa tatgaaattg 480  
 aataaagggtc atctggtgtc aaataatata ggccttatct attataagag tttggactga 540  
 aaagcaaaag tgagataaca aaaaaagct tttcagaata ttattttgta tagatatgtg 600  
 aaggatgaag ggtgggtgaa aggacaaaa acagaaacac agtcttctg aatgaatgac 660  
 aatcagaatt ccgctgcccc aagtagtccg acaattaaat ggattttctag gaaaagctac 720  
 cttagaagg ctggttacca tctgggtttt cacagtgtct tcacattctt atcactttca 780



aactactgc aaataggaag ggacagtaac atttagaaga gaacaaaaca gaaactcttg 840  
 gaagcaggaa aggtgcatga ctcaaagagg gaaattcctg tgccataaaa ggattgctgg 900  
 tgtataaaat gctctatata tgccaattat caatttcctt tcatgttcag catttctact 960  
 ccttccaaga agagcagcaa agctgaagtt agcagcagca gcaccagcag caacagcaaa 1020  
 aaacaaacat gagtgtgaag ggcatggc 1048

<210> 137  
 <211> 504  
 <212> DNA  
 <213> Homo sapiens

<400> 137  
 agggggcccc gcagcagccc cttggcttcc cttctccctt gcctcccctc cggggctccg 60  
 gttcagaggc actctgggcg cctgctacag cttccaaact gcgcgccttc cttcttcggc 120  
 agaaaaggac tttcagatgc ggcggcgggc gcggcggcga ctcaggacag cgccccctcc 180  
 cctaacggcc gcctctccct ctccccctcg ccgcgcccg ctcctccacc tctgggaagg 240  
 cgctgggggt gtggccaggg accggtataa agtcggggg agccgggtccc gggcagccgc 300  
 tcagccccct gccctcgcc gccgcgcgc tgccctgggc gggccgagga tgcggcgagc 360  
 cgccctcggc gccaggttg ctcctcccg cagcctgct aacttcccc gctacgtccc 420  
 cgctcgccc cgggcgccc ccgtctccc gcgcctccg ggtcggttc tccaggagcg 480  
 ccaggcgctg ccgcgtgtg ccct 504

<210> 138  
 <211> 1042  
 <212> DNA  
 <213> Homo sapiens

<400> 138  
 gatcacaaca gctctacaaa tacacaatga ttacaaggaa tggcgcccca ctggagttgt 60  
 tcaacgcaaa acttgacat tgcaagtggc aatctccag gcctgcctcc ctccacgagt 120  
 ggggtctgaat gggcctgaga ggcaaacatc caagaaggag gaagaggctc ggcggcacct 180  
 ccctccccgg gatttctgct gattccatct tggggaagca ggtggacca gggcccaaat 240  
 gcgcctggg gagattgagg gggcgaggaga ggttgcaagg ggcaagtggc aagagcctgt 300  
 taacgtctta gggcctccag gcctttctgt gccctagct gtgcctgtac gctttacccc 360  
 acctcaggag gcttgggtct cagcggttga ggctggaagc accgggggtgc ggtggaaagg 420  
 gctctgtcca ggaagaccgg atccgcagag ccgggagtc gggctaggaa gtccctttct 480  
 cggtgaggaga ctgaggccgc cttggcgagg cggaagaga ctcctccag gtcgggaaag 540  
 ggggccccgc agcagcccct tggcttccct tctcccttgc ctcctcccg gggctccggt 600

```

tcagaggcac tctgggcgcc tgctacagct tccaaactgc gccgttctct tcttcggcag      660
aaaaggactt tcagatgcgg cggcggcgcc ggcggcgact caggacagcg cccctcccc      720
taacggccgc ctctccctct cccctcgcc cgcccggt cccccacctc tgggaaggcg      780
ctgggggtgt ggccaggac cggtataaag tccgggggag ccggtcccgg gcagccgctc      840
agccccctgc ccctcgccgc ccgcgcctg cctggggcgg gccgaggatg cggcgcagcg      900
cctcgcgccg caggcttgct ccctccggca cgctgctaa cttccccgc tacgtccccg      960
ttcgcccgcc gggccgcccc gtctccccgc gccctccggg tcgggtcctc caggagcgcc     1020
aggcgctgcc gccgtgtgcc ct                                             1042

```

```

<210> 139
<211> 24
<212> DNA
<213> artificial sequence

```

```
<220>
```

```
<223> Immunostimulatory nucleic acid
```

```

<400> 139
tcgtcgtttt gacgttttgt cgtt                                             24

```

```

<210> 140
<211> 24
<212> DNA
<213> artificial sequence

```

```
<220>
```

```
<223> Immunostimulatory nucleic acid
```

```

<400> 140
tcgtcgtttt gtcgtttttt tcga                                             24

```

```

<210> 141
<211> 24
<212> DNA
<213> artificial sequence

```

```
<220>
```

```
<223> Immunostimulatory nucleic acid
```

```

<400> 141
tcgtcgtttc gtcgtttcgt cgtt                                             24

```

```

<210> 142
<211> 24
<212> DNA
<213> artificial sequence

```

<220>  
<223> Immunostimulatory nucleic acid

<400> 142  
tcgtcgttttc gtcgttttgt cgtt 24

<210> 143  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<400> 143  
tcgtcgtttt tcggtcgttt t 21

<210> 144  
<211> 22  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<400> 144  
tcgtcgtttt tcgtgcgttt tt 22

<210> 145  
<211> 22  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<400> 145  
tcgtcgtttt cggcggccgc cg 22

<210> 146  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<400> 146  
tcgtcgtttt acggcgccgt gccg 24

<210> 147  
<211> 24  
<212> DNA

<213> artificial sequence  
<220>

<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (13)..(13)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (21)..(21)  
<223> N = 5-methylcytosine

<400> 147  
tngtngtttt gtngttttgt ngtt

24

<210> 148  
<211> 27  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (7)..(7)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (11)..(11)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (13)..(14)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (16)..(16)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (19)..(19)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (22)..(22)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (26)..(27)  
<223> N = 5-methylcytosine  
  
<400> 148  
tngtngntgt ntngnttnt tnttggn

27

<210> 149  
<211> 21  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> Immunostimulatory nucleic acid  
  
<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (8)..(8)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (10)..(10)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (13)..(13)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (16)..(16)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (20)..(20)

<223> N = 5-methylcytosine  
<400> 149  
gngtttgntn ttntttnttgn g

21

<210> 150  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(4)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (8)..(8)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (12)..(12)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (15)..(16)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (19)..(19)  
<223> N = 5-methylcytosine

<400> 150  
gnnnaagntg gnatnngtna

20

<210> 151  
<211> 15  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 151  
tcctggcggg gaagt

15

<210> 152  
<211> 42  
<212> DNA  
<213> artificial sequence

<220>

<223> Oligonucleotide

<400> 152

gaaactcgag ccaccatgag acagactttg ccttgatatc ac

42

<210> 153

<211> 37

<212> DNA

<213> artificial sequence

<220>

<223> Oligonucleotide

<400> 153

gaaagaattc ttaatgtaca gagtttttgg atccaag

37

<210> 154

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 154

tgctgctttt gtgcttttgt gctt

24

<210> 155

<211> 20

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 155

tccatgacgt tcctgatgct

20

<210> 156

<211> 20

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 156

tccatgagct tcctgatgct

20

<210> 157

<211> 20

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<220>

<221> misc\_feature

<222> (8)..(8)

<223> N = 5-methylcytosine

<400> 157

tccatgangt tcctgatgct

20

<210> 158

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 158

tcgtcgtttt cggcgcgcgc cg

22

<210> 159

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 159

ggggacgacg tcgtgggggg g

21

<210> 160

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 160

tgctgctttt cggcggccgc cg

22

<210> 161

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 161

ggggagcagc tgctgggggg g

21



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**This Page Blank (uspto)**

---